Annual Review of Immunology Volume 26 2008

AR338-FM ARI 12 January 2008 18:11 Annual Review of Immunology Annu. Rev. Immunol. 2008.26:1-28. Downloaded from ar...

Author: Annual Reviews

36 downloads 2198 Views 13MB Size Report

This content was uploaded by our users and we assume good faith they have the permission to share this book. If you own the copyright to this book and it is wrongfully on our website, we offer a simple DMCA procedure to remove your content from our site. Start by pressing the button below!

Report copyright / DMCA form

DOWNLOAD PDF

AR338-FM

ARI

12 January 2008

18:11

Annual Review of Immunology

Annu. Rev. Immunol. 2008.26:1-28. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

Contents

Volume 26, 2008

Frontispiece K. Frank Austen p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p x Doing What I Like K. Frank Austen p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p1 Protein Tyrosine Phosphatases in Autoimmunity Torkel Vang, Ana V. Miletic, Yutaka Arimura, Lutz Tautz, Robert C. Rickert, and Tomas Mustelin p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p 29 Interleukin-21: Basic Biology and Implications for Cancer and Autoimmunity Rosanne Spolski and Warren J. Leonard p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p 57 Forward Genetic Dissection of Immunity to Infection in the Mouse S.M. Vidal, D. Malo, J.-F. Marquis, and P. Gros p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p 81 Regulation and Functions of Blimp-1 in T and B Lymphocytes Gislâine Martins and Kathryn Calame p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p133 Evolutionarily Conserved Amino Acids That Control TCR-MHC Interaction Philippa Marrack, James P. Scott-Browne, Shaodong Dai, Laurent Gapin, and John W. Kappler p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p171 T Cell Trafﬁcking in Allergic Asthma: The Ins and Outs Benjamin D. Medoff, Seddon Y. Thomas, and Andrew D. Luster p p p p p p p p p p p p p p p p p p p p p205 The Actin Cytoskeleton in T Cell Activation Janis K. Burkhardt, Esteban Carrizosa, and Meredith H. Shaffer p p p p p p p p p p p p p p p p p p p p233 Mechanism and Regulation of Class Switch Recombination Janet Stavnezer, Jeroen E.J. Guikema, and Carol E. Schrader p p p p p p p p p p p p p p p p p p p p p p p261 Migration of Dendritic Cell Subsets and their Precursors Gwendalyn J. Randolph, Jordi Ochando, and Santiago Partida-Sánchez p p p p p p p p p p p p p293

v

AR338-FM

ARI

12 January 2008

18:11

The APOBEC3 Cytidine Deaminases: An Innate Defensive Network Opposing Exogenous Retroviruses and Endogenous Retroelements Ya-Lin Chiu and Warner C. Greene p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p317 Thymus Organogenesis Hans-Reimer Rodewald p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p355 Death by a Thousand Cuts: Granzyme Pathways of Programmed Cell Death Dipanjan Chowdhury and Judy Lieberman p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p389 Annu. Rev. Immunol. 2008.26:1-28. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

Monocyte-Mediated Defense Against Microbial Pathogens Natalya V. Serbina, Ting Jia, Tobias M. Hohl, and Eric G. Pamer p p p p p p p p p p p p p p p p p p p421 The Biology of Interleukin-2 Thomas R. Malek p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p453 The Biochemistry of Somatic Hypermutation Jonathan U. Peled, Fei Li Kuang, Maria D. Iglesias-Ussel, Sergio Roa, Susan L. Kalis, Myron F. Goodman, and Matthew D. Scharff p p p p p p p p p p p p p p p p p p p p p481 Anti-Inﬂammatory Actions of Intravenous Immunoglobulin Falk Nimmerjahn and Jeffrey V. Ravetch p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p513 The IRF Family Transcription Factors in Immunity and Oncogenesis Tomohiko Tamura, Hideyuki Yanai, David Savitsky, and Tadatsugu Taniguchi p p p p p535 Choreography of Cell Motility and Interaction Dynamics Imaged by Two-Photon Microscopy in Lymphoid Organs Michael D. Cahalan and Ian Parker p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p585 Development of Secondary Lymphoid Organs Troy D. Randall, Damian M. Carragher, and Javier Rangel-Moreno p p p p p p p p p p p p p p p p627 Immunity to Citrullinated Proteins in Rheumatoid Arthritis Lars Klareskog, Johan Rönnelid, Karin Lundberg, Leonid Padyukov, and Lars Alfredsson p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p651 PD-1 and Its Ligands in Tolerance and Immunity Mary E. Keir, Manish J. Butte, Gordon J. Freeman, and Arlene H. Sharpe p p p p p p p p677 The Master Switch: The Role of Mast Cells in Autoimmunity and Tolerance Blayne A. Sayed, Alison Christy, Mary R. Quirion, and Melissa A. Brown p p p p p p p p p p705 T Follicular Helper (TFH ) Cells in Normal and Dysregulated Immune Responses Cecile King, Stuart G. Tangye, and Charles R. Mackay p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p741

vi

Contents

Annu. Rev. Immunol. 2008.26:1-28. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-01 ARI 9 March 2008 1:15

ANRV338-IY26-01

ARI

9 March 2008

1:15

Doing What I Like

Annu. Rev. Immunol. 2008.26:1-28. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

K. Frank Austen Department of Medicine, Harvard Medical School, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, Boston, Massachusetts 02115; email: [email protected]

Annu. Rev. Immunol. 2008. 26:1–28

Key Words

First published online as a Review in Advance on September 17, 2007

slow reacting substance of anaphylaxis, mast cell, alternative complement pathway, cysteinyl leukotrienes, mast cell progenitors

The Annual Review of Immunology is online at immunol.annualreviews.org This article’s doi: 10.1146/annurev.immunol.26.021607.090339 c 2008 by Annual Reviews. Copyright All rights reserved 0732-0582/08/0423-0001$20.00

Abstract I have spent my entire professional life at Harvard Medical School, beginning as a medical student. I have enjoyed each day of a diverse career in four medical subspecialties while following the same triad of preclinical areas of investigation—cysteinyl leukotrienes, mast cells, and complement—with occasional translational opportunities. I did not envision a career with a predominant preclinical component. Such a path simply evolved because I chose instinctively at multiple junctures to follow what proved to be propitious opportunities. My commentary notes some of the highlights for each area of interest and the mentors, collaborators, and trainees whose counsel has been immensely important at particular intervals or over an extended period.

1

ANRV338-IY26-01

ARI

9 March 2008

1:15

EARLY CAREER DETERMINANTS

Annu. Rev. Immunol. 2008.26:1-28. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

In 1946, after I graduated from high school, I was hospitalized with paralytic poliomyelitis. Although I was spared respiratory involvement, I experienced a loss and gradual recovery of strength in my extremities. I vividly recall the lumbar puncture on admission, the hospital-based management of the muscular discomfort with “hot packs,” and exercising with my mother’s cooking weights after discharge. The hospitalization prevented my entry into Amherst College with my class but did lead to one spring and three summer semesters at Akron University. I concentrated on the physical sciences at Akron University and ﬁnished Amherst College on schedule. It was this illness that prompted me to envision a career in medicine. Thus, I set serious academic goals for my Amherst years, whereas during high school, my studies had been secondary to sports. I majored in both chemistry and biology, as biochemistry did not have department status. My honors thesis, entitled “The Structure and Synthesis of Certain Uracil Analogs,” was directed to development of dietary inhibitors of Tetrahymena geleii. My remembrances of my student years at Harvard Medical School (HMS) are highlighted by three very different events. One was a contact from the Admissions Committee via a professor of gross anatomy to ask whether the selection of my brother, W. Gerald Austen, a senior at MIT majoring in mechanical engineering, for the next entering class would negatively affect my academic performance. Gerry and I shared a dormitory room for the next three years and pooled our advance yearly tuition to purchase a car in the fall, which we sold in a timely manner in the spring. Our competitive natures maximized our individual performances. The second event was a rather complex episode in which I and some old friends from Amherst College acquired a sheep from the Biophysics Department late one evening, which we then

2

Austen

slipped into the dormitory and introduced during intermission at the annual ﬁrst-year dance. At 3:00 am, a security ofﬁcer knocked on my door with an offer to forget what had occurred if I would quietly collect and return the sheep to its campus location. The third and most important remembrance relates to my exposure to Cliff Barger of the Physiology Department. He involved students in meaningful laboratory experimentation that required both technical skill and the ability to understand and analyze the observations being recorded. The experiments led students to an understanding of certain principles of renal physiology. Many years later, when I was preparing a presidential address to the American Association of Immunologists, I borrowed what I had learned from Dr. Barger about homeostasis. The talk, entitled “Homeostasis of Effector Systems Which Can Also Be Recruited for Immunologic Reactions,” noted the remarkable array of negative regulators for the inﬂammatory functions of the complement pathway as well as those for activated cell types in IgE-mediated reactions (1). In 1954, after completing medical school, I became one of 12 interns in internal medicine at the Massachusetts General Hospital (MGH). In contrast to my colleagues, I had never heard of the NIH, and thus, I was the only one to enter into the Berry Plan to meet my two years of obligated military service. At the end of my internship year, there was a major outbreak of poliomyelitis in the Boston area, and the two hospitals that conventionally accepted affected patients reached saturation. At that point, the MGH decided to ﬁll a major medical need by accepting these patients. As there was no one at the MGH with particular expertise in the management of patients with poliomyelitis, Dr. Walter Bauer, Chief of Medicine, asked two of the newly minted assistant residents, Jan Koch-Weser and me, to take responsibility for managing what he assumed would be a small polio service. In a relatively short time, the MGH had hundreds of admissions, and we became

Annu. Rev. Immunol. 2008.26:1-28. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-01

ARI

9 March 2008

1:15

responsible for those patients cared for in iron lungs. No one else was permitted to write orders for these patients. Patients and their families were somewhat encouraged by the fact that I had had polio, whereas I was most distressed by the substantial mortality rate of individuals approximately my own age. While using positive pressure to force the ﬂow of air into the lungs of a patient with poliomyelitis in the interval when the linens were being changed in the iron lung, I noted an improvement in his skin color and blood pressure, suggesting better oxygenation. By comparing an arterial oxygen determination made with the patient inside the machine, which applied negative pressure to suck air in versus that during a positive pressure period, I noted that the patient had marked hypoxia while in the iron lung. This condition had not been recognized owing to the limited facial exposure and congestion from the collar around the patient’s neck when in the iron lung. By removing patients from the iron lung and breathing them with a positive pressure method, we prevented any further deaths from vascular collapse. As a result, I published a paper in the New England Journal of Medicine (NEJM ) (2) while a house ofﬁcer and learned that dogma based on existing knowledge could be incorrect. The dogma was that these patients died of midbrain damage from the virus, whereas the real cause was inadequate lung function. The latter was correctly termed a ventilation-perfusion pulmonary mismatch many years later by Jeffrey Drazen when he presented me with the Kober Medal from the American Association of Physicians (3). A second NEJM paper with two microbiologists focused on the intercurrent respiratory infections in bulbospinal poliomyelitis (4). While on the neurology service later in the year, I recognized that individuals with pulmonary insufﬁciency and CO2 necrosis had not only a disorder of consciousness but also a tremor, termed asterixis, and papilledema. This insight arose from my reading about hypoxia while on the polio service and led to another publication in the NEJM (5).

Dr. Bauer had arranged for me to be assigned to direct a Rheumatology Service at Walter Reed Army Hospital during my obligated military service. However, during basic training, my credentials were reviewed, and the decision at Fort Sam Houston based on my three NEJM publications was that I should proceed to the Walter Reed Army Institute of Research. I was immensely fortunate to be assigned to Elmer L. Becker, MD, PhD, who had discovered that the ﬁrst component of guinea pig complement was an enzyme with esterase activity. He introduced me to the discipline of immunology and to the view that immunologic reactions initiate biochemical events. At the same time, I was required to meet my second set of orders to the hospitalbased Rheumatology Service and studied the effects on patients of aspirin at a dose that uncoupled oxidative phosphorylation and raised the metabolic rate (6, 7). On returning to the MGH as a medical resident in l958, I received my ﬁrst NIH grant, which provided me with technical support to shift the studies begun with Dr. Becker to human serum (8). Dr. Becker provided the recommendation essential for acceptance into the immunology laboratory directed by John Humphrey at the National Institute for Medical Research in Mill Hill, England, and the NIH provided a fellowship. I decided to join that laboratory because I hoped to develop a program to learn how immunologic reactions initiated biochemical events that, in turn, had biologic implications. It occurred to me that the immunologic release of histamine from mast cells (MCs) might afford the in vitro model that I sought. John Humphrey was isolating rat MCs from the peritoneal cavity with density gradients, and his colleague, Walter Brocklehurst, was studying the antigeninduced release of histamine and slow reacting substance of anaphylaxis (SRS-A) from sensitized guinea pig lung. That histamine release was a biochemical process rather than an exchange with external cations seemed likely based on the reported calcium and temperature dependence of this reaction. An www.annualreviews.org • Doing What I Like

MC: mast cell SRS-A: slow reacting substance of anaphylaxis

3

ANRV338-IY26-01

ARI

9 March 2008

1:15

unanticipated bonus was my introduction to SRS-A, a material that constricted guinea pig airways in an isolated heart-lung preparation and was not inhibited by antihistamines. I knew that antihistamines were efﬁcacious for treating allergic rhinitis but not bronchial asthma, and I had the instinctive feeling that SRS-A might be a mediator of airways constriction in bronchial asthma. Brocklehurst had developed the ﬁrst bioassay to measure both histamine and SRS-A in the diffusate of antigen-challenged guinea pig lung fragments. Histamine, which elicited distinct rapid contractions of guinea pig ileal smooth muscle in an organ bath, was measured ﬁrst. Then the ileal muscle was rendered unresponsive to histamine with an antihistamine, and the samples were reassessed for their content of SRS-A, which elicited a slow, progressive contraction. These studies led to three publications with Dr. Brocklehurst in the Journal of Experimental Medicine (9–11). The work with John Humphrey on isolated rat MCs resulted in a collaboration with another visitor, Herbert Rapp (12), who felt that I should have yet another fellowship to learn formal immunochemistry in the laboratory of Manfred Mayer at Johns Hopkins. In July 1961, I returned to the MGH to serve one year as Dr. Bauer’s chief medical resident. During that year, the physician responsible for the subspecialty of infectious diseases had a sabbatical, and Dr. Bauer assigned me the additional task of answering the consults in infectious diseases. He observed that I had had experience in managing microbial infections in patients with bulbospinal polio and understood the host through immunology. He added that Louis Weinstein, a distinguished infectious diseases clinician elsewhere in Boston, would make weekly rounds with me to facilitate my education and to advise on difﬁcult cases. After completing the chief residency, I had a period with Manfred Mayer and Herb Rapp in the Microbiology Department at Johns Hopkins during which we demonstrated the enzymatic activity of the ﬁrst complement component (C1) on one of its natu-

Annu. Rev. Immunol. 2008.26:1-28. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

C: complement (used only with numbers to indicate components)

4

Austen

ral substrates, the second component (C2), by immunochemical techniques (13). This work was particularly rewarding since during my time with Elmer Becker, the Mayer group had openly doubted the acetyltyrosine esterase activity Becker had reported for C1. My departure from Hopkins after only six months was somewhat precipitous. Walter Bauer had entered into pulmonary failure from emphysema, and he asked me to share the responsibility for his care with his personal physician. To the extent that Dr. Bauer could talk when we unplugged the tracheotomy, he focused on issues of academic medicine, my career development, and my family. He left me his desk, which I treasure in my home. After three years as a faculty member of the Infectious Disease group, I was asked by Robert Ebert, Chairman of Medicine, to become chief of the Pulmonary Unit. The rationale was that I was Board-certiﬁed in allergy and immunology, had experience in infectious diseases, had some knowledge of pulmonary function from my polio duties, and had a laboratory interest pertinent to bronchial asthma. The Pulmonary Unit was housed in new facilities and appreciably increased our laboratory space. The space contained a new cyclotron, a machine I did not understand and never used, for a physician-scientist who never appeared. My new responsibilities to pulmonary medicine energized my interest in one human disease, bronchial asthma, and reinforced my goal to study SRS-A.

BECOMING A DEPARTMENT In 1966, when Robert Ebert was appointed dean of HMS, he suggested that my immunology program would beneﬁt if I moved closer to the HMS campus as physician-inchief of the Robert B. Brigham Hospital (RBBH), a small institution entirely committed to the subspecialty of rheumatology. By now, I had been clinically active in infectious diseases and in pulmonary diseases at the MGH and in rheumatology during my service at the Walter Reed Army Hospital,

Annu. Rev. Immunol. 2008.26:1-28. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-01

ARI

9 March 2008

1:15

although my only subspecialty certiﬁcation was in allergy and immunology. I requested support to recruit two colleagues with different research backgrounds in immunology so that we could offer a coherent and broadly based training program. John R. David and I had been house ofﬁcers together at the MGH and had encountered each other again when we were postdoctoral fellows in England, albeit at different institutions. His expertise was in cell-mediated immunity, whereas mine was in antibody-mediated events. Peter Schur, who had also trained with Elmer Becker during his military service and then with Henry Kunkel, conducted clinical research, whereas John David and I were working with in vitro systems. The goal for the three of us in 1966 was to form a cohesive, yet technically diverse program through which to facilitate our individual research and improve our postdoctoral mentoring. The RBBH allocated all its research space to our program and had a patient base that allowed us to engage in clinical teaching as well as research. As John David, Peter Schur, and I not only shared common training experiences but also had the same goals for the department, its administrative structure was ﬂat. In the early 1970s, I was invited to take a chairmanship and historical chair of medicine at a school that at one time would have been my life’s goal. To my own astonishment, I made a decision that profoundly changed my career path. I found that my commitment to my personal research and my enjoyment of our developing department were so great that I preferred to remain at the RBBH. I would not again seriously consider becoming a chairman or accepting another major administrative task elsewhere. My decision to remain at the RBBH was driven by the knowledge that becoming a proper chairman would end my opportunity to unravel the aspects of the inﬂammatory response that seemed so intriguing and yet approachable. In 1974, our Rheumatology and Immunology program at the RBBH was granted departmental appointing status at HMS for ap-

proximately 20 years. This decision meant that promotions and appointments could be discussed directly with the HMS dean and further assured the development of our enterprise. Although we had signiﬁcant clinical and teaching responsibilities, they were elective. Thus, we had an optimal amount of time for research. However, as we were not a line department within the structure of HMS, we also had no budget from the school and were almost entirely responsible for our own funding. Thus, the department was dynamic and was supported almost entirely by the peer review process. We enjoyed a continued inﬂux of outstanding trainees, who progressed to faculty rank and then were recruited away at higher rank to ﬁne schools and teaching hospitals. We began to attract individuals with PhDs who were interested in the integrated biology of the inﬂammatory response. Over time, the MD faculty was enriched with fulltime clinical scholars and the laboratory faculty with PhD-trained investigators who often had received their postdoctoral training in the department. This combination of faculty improved our shared and ever-evolving technology and added to the quality of the training program. While at the MGH, I had begun to collaborate with Albert L. Sheffer in the study of patients with hereditary angioedema (HAE) due to a lack of a functional inhibitor of the ﬁrst component of complement (ClINH). After my appointment to the RBBH, we continued to study the roles of the complement system in HAE and the MC in patients with physical allergies. Indeed, the triad of complement, MC, and SRS-A research favored translational research in allergy and asthma over other medical applications. Thus, we added a training program in allergy and immunology and, in 1971, were funded as one of the seven initial Asthma and Allergic Diseases Centers conceived by the NIAID. At the same time, with the history and focus of the RBBH on the medical and surgical care of patients with arthritic diseases, we had a training grant in rheumatology www.annualreviews.org • Doing What I Like

HAE: hereditary angioedema

5

ARI

9 March 2008

1:15

and a Clinical Research Center supported by the NIAMD. HMS appointed me the ﬁrst incumbent of the Theodore Bevier Bayles Professorship in 1972; and in 1974, I was elected to the National Academy of Sciences and the American Academy of Arts and Sciences. In the background during the 1970s was the merger of the RBBH with the Peter B. Brigham Hospital (PBBH) and the Boston Hospital for Women (BHW). I chaired a committee composed of two physicians and one administrator from each of the hospitals to work out the new bylaws. There was also much to do in the community to acquire a Certiﬁcate of Need so that construction could proceed for what is now known as the Brigham and Women’s Hospital (BWH). Although our department beneﬁted greatly from being the focus of the RBBH, we sought the merger because of concern that a subspecialty hospital built on the need for in-patient care would not thrive with the changing paradigms and increasing complexity of medical and surgical care. As our three laboratories continued to expand, we began to appreciate that the beneﬁts from the cohesion of our setting were perhaps mitigated by its off-site location. Again, Dean Ebert played a key role in my life. He suggested that the RBBH and the BHW gift HMS the matching funds needed to build the Seeley G. Mudd Building on the HMS campus. The cost of our space would be discounted, and we would have state-of-theart new laboratories on the quadrangle adjacent to the new medical center encompassing the merged hospitals. Hence, in 1977, after 11 years at the RBBH, we moved to the campus of HMS. With the transfer of our clinical activities to the BWH, we retained our status as a separate appointing Department of Medicine at HMS, but for clarity we were designated as the Department of Rheumatology and Immunology within the BWH. In 1987, Dean Dan Tosteson funded the K. Frank Austen Professorship of Medicine with a gift from David A. Jones and the Humana Foundation. After a typical, somewhat

Annu. Rev. Immunol. 2008.26:1-28. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-01

6

Austen

long HMS search, Michael Brenner, MD, was appointed to the K. Frank Austen Professorship in 1991. In 1995, our department became a division of the Department of Medicine of HMS at the BWH with Dr. Brenner as chair. Over three decades, our program had grown from four full-time and seven parttime faculty members with ﬁve postdoctoral fellows to 55 full-time and 6 part-time faculty members with 45 fellows. Two years later, we moved from the Seeley G. Mudd Building to an expanded site in the Dana-Farber Cancer Institute. Michael Brenner added “Allergy” to the name of the division, and from 1995 onward I have focused on the formal development of that program with Al Sheffer. As I did previously for rheumatology, this effort has meant developing the needed laboratory-based and clinically oriented faculty directly from our training program. As the Bayles Chair was named for a distinguished RBBH rheumatologist, it was appropriate to transfer that chair to Dr. Brenner and for me to take a new chair directed to inﬂammation and respiratory diseases.

THE LABORATORY TRIAD: SRS-A/CYSTEINYL LEUKOTRIENES, MAST CELLS, AND COMPLEMENT As I was learning about SRS-A from Walter Brocklehurst and MCs from John Humphrey, Rodney Porter and others were unraveling the structure of antibody through protein chemistry. Perhaps because of my four years of training in internal medicine, I believed that interventions for the outcome or inﬂammatory side of immune injury would precede any development of therapies for the recognition side. As I also wished to maintain a clinical life, I felt that it would be best to work in areas relevant to a clinical question. Only later did I recognize the additional requirement that these questions needed to be addressed with state-of-the-art technology. Happily, because I entered these research areas at such an

Annu. Rev. Immunol. 2008.26:1-28. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-01

ARI

9 March 2008

1:15

early point, I could add the needed technology in a workable time frame that also allowed for a clinical life. Indeed, the latter stimulated my bench research. The three inﬂammatory components—mast cells, cysteinyl leukotrienes, and complement—that retained my interest all intersect with one another, providing occasional insights into parts of an integrated host inﬂammatory response. Nonetheless, the Study Section that awarded me a 10-year merit-based grant included the message that I could not in the future aggregate three strong areas into a single RO1. Below are my observations on each area, from the early years to the present.

THE CYSTEINYL LEUKOTRIENES (SRS-A) We now know that SRS-A, an antihistamineresistant constrictor of smooth muscle that is released from antigen-challenged guinea pig and human lung, is a mediator of bronchial asthma. We also know that the substance originally termed SRS-A was in fact composed of three cysteinyl leukotrienes (cysLTs): the biosynthetic intracellular product, leukotriene C4 (LTC4 ), and its extracellular metabolites, LTD4 and LTE4 . A limited number of cell types including MCs, eosinophils, basophils, and monocyte/macrophages possess the full biosynthetic pathway for LTC4 . Arachidonic acid released from the outer nuclear membrane by cytosolic phospholipase A2 (cPLA2 /type IV PLA2 ) in the presence of 5-lipoxygenase (5-LO) activating protein (FLAP) is converted sequentially by 5LO into 5-hydroperoxy-eicosatetraenoic acid (5HPETE) and LTA4 . LTA4 is then conjugated to reduced glutathione (GSH) to form LTC4 by LTC4 synthase (LTC4 S), an integral outer nuclear membrane protein. After carrier-mediated export of LTC4 , the cleavage removal of glutamic acid and then glycine from the GSH moiety provides the metabolites, LTD4 and LTE4 . The functions of the cys-LTs, which extend well beyond their historical smooth muscle–constricting action on

airways and microvasculature to include a range of leukocyte responses, are mediated by two known receptors, the CysLT1 and CysLT2 receptors. The structural deﬁnition of SRS-A as a conjugate of a cysteine-containing peptide and a metabolite of arachidonic acid, termed LTC4 , by Robert (Bob) Murphy with Sven Hammarstrom and Bengt Samuelsson (14) in 1979 profoundly changed the direction of my work. Through collaboration with E.J. Corey of the Chemistry Department of Harvard University, we immediately had synthetic LTC4 and then its metabolites, LTD4 and LTE4 , for pharmacologic studies in animals and humans. The use of these products to standardize an analytic reverse phase–high performance liquid chromatography (RP-HPLC) system allowed the identiﬁcation of LTC4 , LTD4 , and LTE4 in complex biologic mixtures; the characterization of their extracellular inactivation; the puriﬁcation of native human LTC4 S from lung; and, most important, the construction of a novel assay for expression cloning of human LTC4 S. As we had previously addressed such areas as the cell sources and immunoglobulin (Ig) classes involved in SRS-A generation and the physicochemical characteristics (with Robert Murphy) and pharmacologic actions (with Jeffrey Drazen) of SRS-A, our studies with SRSA/cys-LTs can be divided into those before and those after the structure was known.

cys-LT: cysteinyl leukotriene LTC4 S: leukotriene C4 synthase CysLT1 and CysLT2 receptors: receptors for the cysteinyl leukotrienes PCA: passive cutaneous anaphylaxis

SRS-A My initial studies with Brocklehurst demonstrating various common biochemical requirements for the antigen-induced release of SRS-A and histamine from actively sensitized guinea pig lung (9–11) did not reveal the responsible Ig class or cellular source. With Kurt Bloch, we found that haptenspeciﬁc guinea pig IgG1, but not IgG2, sensitized guinea pig lung fragments for DNPBSA-elicited histamine and SRS-A release and also mediated a passive cutaneous anaphylaxis (PCA) reaction implicating the MC www.annualreviews.org • Doing What I Like

7

ARI

9 March 2008

1:15

(15). A second Ig class, rat IgE, was shown to passively sensitize the rat peritoneal cavity for DNP-BSA-elicited histamine and SRSA release, and that response was lost with MC depletion (16). Deﬁnitive studies linking MCs and IgE to SRS-A generation were conducted in monkey lung fragments, with Teruko and Kimishige Ishizaka, using isolated IgE myeloma or atopic serum for passive sensitization followed by challenge with anti-IgE (17). Rat IgGa, which also prepared the peritoneal cavity for antigen-induced SRS-A generation and was produced more easily than IgE, was used routinely to generate product for characterization (18). As agonists other than SRS-A contracted the guinea pig ileum in an antihistamine-resistant manner, we considered it critical to produce the material immunologically. Because solubility studies revealed SRS-A to have both polar and nonpolar characteristics, we recruited Bob Murphy from the Department of Chemistry at MIT to help with a structural analysis. Robert (Bob) Orange produced heroic amounts of SRS-A from hundreds of rats and conducted the chromatography, while Bob Murphy used gas chromatography, gas chromatographymass spectroscopy, and high-resolution mass spectroscopy to identify the contaminants remaining after each puriﬁcation step and to assess the ﬁnal product from their combination. Rat and human SRS-A behaved in an identical fashion, with the ﬁnal product being an acidic, low-molecular-weight (400–1400 MW) moiety bioactive at a nanogram level or less (19). Although the moiety was not suitable for conventional mass spectrometric analyses, spark source mass spectroscopy demonstrated the sulfur atom to be more abundant in the bioactive samples, a ﬁnding conﬁrmed by electron probe analysis (20). The inactivation of SRS-A by arylsulfatases but not by a range of other enzymes and the ability of SRS-A to inhibit the cleavage of synthetic substrates of the enzyme were puzzling since the electrophoretic mobility and isoelectric point of SRS-A did not suggest a sulfate residue. In

Annu. Rev. Immunol. 2008.26:1-28. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-01

8

Austen

retrospect, the triene structure of the cys-LTs was read as an aromatic ring in the inhibition studies of arylsulfatases by SRS-A, and a contaminant was responsible for the inactivation (21). Nonetheless, the partial puriﬁcation and characterization of SRS-A as a sulfur-enriched substance and the ﬁnding of Charles Parker’s group that labeled arachidonic acid could be incorporated into SRS-A (22) provided background for the generation of double-labeled SRS from mastocytoma cells stimulated with calcium ionophore. Indeed, Murphy and colleagues needed to break the sulfur bridge between the lipid backbone and peptide adduct to characterize the lipid component as a triene (14). In a study with Robert Lewis, another long-time colleague, we used the puriﬁcation scheme to identify the cellular biosynthesis of bioactive SRS-A before its release from human MCs (23). These ﬁndings predicted the export pathway for newly synthesized LTC4 described 15 years later. Human eosinophils loaded with LTA4 at 4◦ C formed but did not release LTC4 until the temperature was raised, thereby demonstrating an energy-dependent export pathway (24). When the effects of intravenously administered SRS-A, histamine, prostaglandin (PG) F2α, and bradykinin on lung function in guinea pigs were compared, SRS-A markedly reduced dynamic compliance with minimal effect on pulmonary resistance, whereas the reverse was true for the other agonists (25). These ﬁndings, which indicated that SRS-A had a unique preference for peripheral airways, were further examined by comparing the in vitro contractile activity of SRS-A with histamine for guinea pig tracheal spirals and parenchymal strips. Whereas the effect of histamine concentration was equal for contractions of both smooth muscle preparations, the sensitivity of the tracheal spirals to SRS-A was 100-fold less than that of the parenchymal strips. These ﬁndings with puriﬁed SRS-A predicted the novel selectivity of LTC4 and the other cys-LTs for peripheral airways when inhaled by human volunteers.

ANRV338-IY26-01

ARI

9 March 2008

1:15

Annu. Rev. Immunol. 2008.26:1-28. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

Cysteinyl Leukotrienes LTC4 , LTD4 , and LTE4 On the basis of the composition of the SRS activity released by ionophore stimulation of mouse mastocytoma cells (14), E.J. Corey synthesized candidate stereoisomers with various sulfur-linked peptide adducts. In parallel bioassays of chemical moieties and the MCgenerated product by the Samuelsson group, LTC4 was established as 5(S)-hydroxy-6(R) glutathionyl-7, 9-trans, 11, 14-cis eicosatetraenoic acid (26). Corey provided our group with authentic LTC4 and related structures so that we could characterize biologic SRS-A generated from the rat peritoneal cavity and from human lung fragments. After a ﬁnal RPHPLC step (19, 25), the SRS-A prepared from both sources had two activity peaks for contraction of the guinea pig ileum in units/pmol that were equivalent to LTC4 and LTD4 (27). LTD4 had been identiﬁed as the product of cleavage removal of glutamic acid from the glutathionyl adduct of LTC4 by Piper and colleagues (28). Two of ﬁve puriﬁed rat SRS-A preparations contained a previously undescribed activity peak by RP-HPLC that eluted after LTC4 and LTD4 and also exhibited a triene UV absorbance spectrum at 280 nm. The elution time corresponded to a candidate structure in which the glycine had been cleaved from LTD4 and left only the cysteinyl adduct, which we termed LTE4 . Synthetic and biologic LTE4 had the same speciﬁc contractile activity for guinea pig ileum and parenchymal strips (29). However, LTE4 was a log more potent than LTD4 in contracting tracheal spirals and a log less potent in contracting parenchymal strips (30). The possibility of two separate cys-LT receptors had already arisen because an antagonist, FPL 55712, blocked the low-dose, high-afﬁnity parenchymal strip contractions produced by LTD4 but not the contractions initiated by LTC4 or high-dose LTD4 (31). Furthermore, after a contraction of parenchymal strips elicited by LTE4 but not LTC4 or LTD4 , followed by full relaxation, the response of the strip to

histamine was augmented due to the induced generation of a prostanoid (30), suggesting even a third response pathway. Because the cys-LTs are mediators generated during a local inﬂammatory response, we assessed the impact of the respiratory burst elicited in polymorphonuclear leukocytes (PMN) by phorbol myristate acetate (PMA) on their function, immunoreactivity, and integrity. By RP-HPLC with synthetic standards, each cys-LT was converted to a subclass-speciﬁc S-diastereoisomeric sulfoxide without function but with retained immunoreactivity and then, with disruption of the sulfur bridge, to an unreactive common end product, 6-trans-LTB4 . The metabolic inactivation was replicated with hydrogen peroxide, myeloperoxidase, and chloride anion, indicating an attack on the sulfur moiety by hypochlorous acid. Dose-response studies revealed LTE4 to be the most stable cys-LT in the presence of this inactivating pathway (32). Thus, in an integrated setting, the aggregate cellular effects of the cys-LTs reﬂect their relative individual stability and differential potency for expressed receptors on target cells.

LTC4 Synthase and the cys-LT Receptors With deﬁnition of LTC4 as the only biosynthetic intracellular cys-LT, we turned to isolation of the responsible enzyme, LTC4 S. Partial puriﬁcation of LTC4 S solubilized from rat basophilic leukemia-1 cells or guinea pig lung revealed that it was an integral membrane protein that lacked the substrate speciﬁcity for xenobiotics characteristic of the glutathione S-transferases (GSTs) (33, 34). Homogeneous 18-kDa human LTC4 S was solubilized and isolated from 60 billion KG-1 cells, and an Nterminal sequence of 22 amino acids and an internal sequence of 14 residues were obtained (35, 36). For expression cloning, Bing Lam developed a high-throughput ﬂuorescencelinked competitive immunoassay for detection of LTC4 generation by Cos cells www.annualreviews.org • Doing What I Like

9

ANRV338-IY26-01

ARI

9 March 2008

1:15

transfected with a cDNA library from KG-1 cells. The full-length cDNA that encoded the LTC4 S activity included the residues identiﬁed by amino acid sequencing of the puriﬁed protein (36). The N-terminal two-thirds of LTC4 S was 44% identical to FLAP at the protein level and 52% identical for the corresponding nucleotides. Both are integral perinuclear membrane proteins, and genomic cloning revealed that their intron/exon junctions align identically, suggesting their evolution by gene duplication (37). By ﬂuorescence in situ hybridization, the gene for human LTC4 S is on chromosome 5q35 distal to the gene cluster for the cytokines that are central to the Th2 phenotype implicated in asthmatic and allergic inﬂammation. The cDNA for mouse LTC4 S is 87% homologous to the human cDNA (38), and genomic cloning revealed identical intron/exon boundaries. The mouse LTC4 S gene is located in a region syntenic to human 5q35 on chromosome 11 near to the Th2 gene cluster (39). The LTC4 S gene is the only one among the recently deﬁned superfamily of membraneassociated proteins involved in eicosanoid and glutathione metabolism located on a chromosome with a Th2 gene cluster. That Th2 cytokines can regulate the pathway for cys-LT generation was recognized using human MCs derived from cord blood by culture in stem cell factor (SCF), interleukin (IL)-6, and IL-10 in studies with Joshua Boyce. Such MCs are deﬁcient in LTC4 S, and priming them with IL-4 induced steady-state transcripts, protein, and function for LTC4 S but did not increase transcripts or protein for other pathway components such as cPLA2 , FLAP, or 5-LO (40). In addition, priming these MCs with IL-3 or IL-5 translocated 5LO to the outer nuclear membrane for FLAPdependent generation of LTA4 , thereby optimizing LTC4 generation when IL-4 was also present. IL-4 priming also enhanced the capacity of the cys-LTs to induce chemokine and cytokine expression by culture-derived human MCs. The cys-LTs did not cause exocytosis, and their action involved two receptors

Annu. Rev. Immunol. 2008.26:1-28. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

IL: interleukin

10

Austen

inasmuch as a CysLT1 receptor antagonist blocked induction of IL-5 but not IL-8 (41). Although site-directed mutagenesis of human LTC4 S has identiﬁed residues for substrate binding and the integrated conjugation function for GSH and LTA4 (42), crystallography is critical for a mechanistic model. Thus, human LTC4 S was overexpressed in ﬁssion yeast, puriﬁed to apparent homogeneity, and grown in 2D crystals in sheets and vesicles for electron crystallography. Projection maps at 4.5 and 7.5 A˚ show that the enzyme is a trimer and that each monomer contains at least four alpha helices that insert into the membrane (43). Analysis of the atomic structure of LTC4 S at 3.3-A˚ resolution by X-ray crystallography has revealed that the monomer has four transmembrane alpha helices and forms threefold symmetric trimers as a unit with functional domains across each interface. The residues conjugating GSH at C6 and generating a hydroxyl group at C5 are on opposing monomers (44). To examine the functions of the cys-LTs in complex models of inﬂammation, mouse strains with targeted disruption of LTC4 S and each of the known cys-LT receptors, CysLT1 and CysLT2 , were developed and extensively backcrossed by Yoshihide Kanaoka. Disruption of the LTC4 S gene abrogated the capacity of tissues to conjugate LTA4 methyl ester with GSH, establishing the dominant role of this enzyme rather than GSTs in LTC4 biosynthesis (45). IgE-dependent PCA in the ear of the LTC4 S-deﬁcient and the CysLT1 and CysLT2 receptor–deﬁcient strains was reduced by more than one-half, thereby revealing a role for cys-LTs at least equal to that of the MC secretory granule amines in eliciting the plasma leakage at this site. The plasma leak in the LTC4 S-deﬁcient and CysLT1 receptor–deﬁcient strains, but not the CysLT2 receptor–deﬁcient strain, was also reduced by more than 50% after intraperitoneal injection of the microbial cell wall carbohydrate, zymosan (46–48). These studies reveal heterogeneity of the receptor expression of the microvasculature.

Annu. Rev. Immunol. 2008.26:1-28. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-01

ARI

9 March 2008

1:15

In turning to more complex models, we began with bleomycin-induced pulmonary ﬁbrosis for which the C57B/6 strain is optimal. Twelve days after intratracheal administration of bleomycin, the extent of macrophage and ﬁbroblast accumulation with deposition of extracellular matrix proteins, including collagen, was much less in the LTC4 S-deﬁcient strain. By digital image analysis, the septal thickening of the lower lobes was reduced to one-half that observed in wild-type (WT) littermates. The cys-LTs were absent from the bronchoalveolar lavage (BAL) ﬂuid of the deﬁcient strain and abundant in the BAL ﬂuid of the WT littermates, while the quantities of LTB4 and PGE2 were similar. The CysLT2 receptor–deﬁcient strain was as protected against bleomycin-induced pulmonary ﬁbrosis as the LTC4 S-deﬁcient strain but accumulated the same cys-LT content in the BAL ﬂuid as the WT littermates (48). In contrast, the CysLT1 receptor–deﬁcient strain had greater septal thickening than sufﬁcient controls (49). That ﬁbrosis is prevented by disruption of the pathway at different points, biosynthesis and receptor-mediated function, encoded by genes on different chromosomes, is strong evidence for the role of cys-LTs in this form of chronic inﬂammation.

THE MAST CELL The MC, which is derived from a hematopoietic stem cell, circulates as an immature monocyte-like progenitor (MCp) lacking cytoplasmic granules, is distributed to tissues as an immature progenitor, and matures and differentiates in a tissue-determined fashion. The major phenotypes of tissue MCs in mouse, rat, and human are the constitutive connective tissue type that surrounds microvasculature, often in proximity to nerve endings, and the T cell–dependent mucosal type at intraepithelial locations such as intestine and airways. In the rat and mouse, these MC phenotypes are distinguished by differences in their secretory granule proteoglycans, their proﬁle of secretory granule pro-

teases, and their expression of eicosanoids with activation. These phenotypic distinctions are less perceptible in humans, although the T cell–dependence of the mucosal population is evident from their absence in patients with impaired T cell functions. In initial in vitro studies, we used MCs harvested from the rat peritoneal cavity and isolated on density gradients or human lung MCs obtained from surgical specimens. The MC numbers were limited and the preparation time was excessive. Thus, when knowledge of growth factors evolved through the studies of Ehud Razin and others, we changed to culturederived mouse bone marrow–derived MCs (BMMCs), which are abundant but immature, and human cord blood–derived MCs, which, although quite mature, are of limited number. We initially focused on the nature and number of the secretory granule neutral proteases and proteoglycans. With these markers for cell development, we moved in vivo to characterize the transendothelial migration of MCp to peripheral tissues, the phenotypic plasticity of tissue MCs with location and superimposed inﬂammation, and the tissue-based control of MC activation.

MCp: mast cell progenitor

Secretory Granule Proteases and Proteoglycans The secretory granule is best known as a source of histamine, a mediator of the nasal coryza and ocular/cutaneous pruritus in allergic disease. Both histamine and the neutral proteases bear positive charges, which interact with the anionic glycosaminoglycans polymerized onto a peptide core of the proteoglycan(s) in the secretory granule. An electron microscopic study of human lung MCs revealed that the secretory granules had a crystalline structure of deﬁned periodicity with a lattice- or scroll-like distribution. With IgEdependent activation, the granules swelled, their crystalline structure dissolved, and in association with contractile elements they moved to the membrane for fusion and extracellular release of contents (50). The ionic www.annualreviews.org • Doing What I Like

11

ARI

9 March 2008

1:15

interactions of the released complex were disrupted at physiologic pH, and many of the cationic moieties including histamine diffused away, leaving a “ghost” composed of the proteoglycans and highly cationic proteases (51). We were surprised that the dominant human MC protease, which we termed tryptase, was a tetramer with four active sites (52). Although some considered the tetramer presentation to be a consequence of our protein isolation, the ﬁndings were conﬁrmed by others with X-ray crystallography. Tryptase is the dominant neutral protease in both human MC phenotypes and can cleave human C3 to release the C3a anaphylatoxin (53). MC-carboxypeptidase A (MC-CPA) is a speciﬁc marker for connective tissue MCs in both mice and humans. MC-CPA is unique among carboxypeptidases in having a CPAlike substrate-binding pocket and enzymatic activity but an overall protein and gene structure more similar to carboxypeptidase B (54, 55). Recently, Rodewald and colleagues (56) reported that MC-CPA protected mice against snake venom sarafotoxin, identifying the speciﬁc protease responsible for a host defense MC function reported by others. On two occasions, transformed mouse cell lines developed in other laboratories profoundly advanced our program by solving a technical issue. The ﬁrst was the derivation of connective tissue–like MC lines (KiSV-MC) by coculture of mouse splenocytes with ﬁbroblasts that produce the Kirsten murine sarcoma virus. In contrast to earlier lines, some of the KiSV-MC lines exhibited maturation indistinguishable from that of mouse peritoneal MCs and provided enough secretory granule protein for isolation of the proteases (57). MC-CPA from KiSV-MCs and from peritoneal MCs were both 36 kDa and had identical N-terminal amino acid sequences; these cells, along with BMMCs, expressed the same transcript encoded by a single gene for MCCPA (58). The four other proteins obtained from KiSV-MCs, ranging from 28 to 32 kDa, were serine proteases based on [3 H]DFP binding (59). Their cDNAs indicated that

Annu. Rev. Immunol. 2008.26:1-28. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-01

12

Austen

mouse MC protease (mMCP)-2 (60), -4 (61), and -5 (62) were in the chymase gene family, whereas mMCP-6 was a tryptase (63). The tissue distribution of their mRNA indicated that mMCP-2 was prominent in mouse mucosal MCs, while mMCP-4, -5, and -6 and CPA characterized the connective tissue MC phenotype. We subsequently recognized a second secretory granule tryptase, mMCP-7, in the BALB/c but not the C57B/6 strain (64) and another chymase, mMCP-9, selectively expressed in mouse uterine MCs (65). The chymases are differently regulated in BMMCs, with mMCP-5 being induced by SCF (66) and the mucosal mMCP-1 and mMCP-2 by IL9 or IL-10 (67). By nuclear run-on analysis, all the beta chymases were being transcribed in the BMMCs, and the cytokines were simply stabilizing the transcripts to allow translation (68). Such a mechanism of transcript stabilization could account for the phenotypic diversity of the protease proﬁle in different tissue MCs and for the further changes with inﬂammation by Trichinella spiralis infection (69). These seminal studies involved postdoctoral fellows Bill Seraﬁn, Dale Reynolds, Patrick McNeil, and John Hunt and depended on a long-time colleague, Richard Stevens. The second transformed MC line from another laboratory that was essential to our progress was the v-abl immortalized MC line (V3-MC). Unlike the KiSV-MC, these cells did not shed virus and could be used to follow lineage maturation after adoptive transfer to a BALB/c recipient (70). The clonal line was immature and expressed protein for mMCP-5, mMCP-7, and mMC-CPA but not mMCP-2 or mMCP-6. After adoptive transfer and residence in the liver or spleen, the line expressed all proteases, as did the resident MCs. In contrast, the V3-MCs identiﬁed in the small intestine by the abl marker were agranular at day 6 after adaptive transfer and without detectable proteases, and by 14 days expressed only abundant mMCP-2, a marker for mucosal MCs. The distinct protease phenotypes of the V3-MCs in the two

Annu. Rev. Immunol. 2008.26:1-28. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-01

ARI

9 March 2008

1:15

tissues reﬂecting additions and/or deletions elegantly demonstrated that protease expression was regulated by local factors. Because the proteases were bound in an active form in the secretory granule, we characterized the heparin moiety in rat peritoneal (71) and human lung MCs (72) after radiolabeling in vitro with [35 S]sulfate and [3 H]serine. This early work by Dean Metcalfe and Jerry Silbert showed that the rat proteoglycan was ten times larger than the human proteoglycan owing to the number and size of the glycosaminoglycans polymerized onto a glycine-/serine-rich small-core polypeptide (73). The proteoglycans in the BMMCs included heparin but were predominantly composed of chondroitin sulfate E glycosaminoglycans rich in Nacetylgalactosamine-4,6-disulfate sequences (74, 75). Irrespective of the size or nature of the glycosaminoglycans, the segment of the core polypeptide to which the glycosaminoglycans were attached was protease resistant. Cloning of the cDNA and gene that encode this peptide core in rat basophilic leukemia-1 cells (76), human promyelocytic HL-60 cells (77), and mouse BMMCs (78) revealed coding for a highly conserved N-terminal amino acid sequence and a stretch of alternating serine and glycine residues. Serglycin is the single peptide core for hematopoietic secretory granule proteoglycans, the selection of the types of glycosaminoglycan to be synthesized onto this peptide core is cell speciﬁc, and the protease resistance of serglycin allows storage association of active proteases to the glycosaminoglycans.

Development and Transendothelial Distribution of Mast Cell Progenitors (MCp) Investigations in the laboratories of Kitamura (79), Rodewald (80), and Schrader (81) indicated that MCp arise from bone marrow (BM) stem cells, circulate as agranular lineage progenitors, and settle into the small intestine at concentrations per million mononu-

clear cells (MNCs) that exceed the concentrations in other peripheral tissues. We assumed intestinal MCp to be the source of the Th2 cell–dependent MC hyperplasia that cleared adult worms (69), and Michael Gurish deﬁned the MCp integrins that sustained the intestinal reservoir. MNCs were harvested from the small intestine, BM, spleen, and lung, and the MCp per million MNCs was determined by limiting dilution and clonal expansion. The absence of β7 (CD49d) but not αE (CD103) or β2 (CD18) integrins resulted in a marked reduction of MCp in the small intestine but not in the lung, spleen, or BM of naive mice. To conﬁrm these ﬁndings, we eliminated MCp from WT mice by sublethal irradiation and introduced various monoclonal antibodies (mAbs) just after adoptive transfer of syngeneic BM. The administration of mAb to α4β7, α4, or β7 integrins and to their counterligands on the microvasculature, mucosal addressin cell adhesion molecule1 (MAdCAM-1) and vascular cell adhesion molecule-1 (VCAM-1), blocked reconstitution of the intestinal MCp, whereas mAb to αE or β1 integrins had no effect. The ﬁnding that blocking mAb to α4β7 was fully inhibitory even if administered four days after the syngeneic BM implied a priming phase for MC lineage development in recipient BM (82). This dynamic relationship between BM and the intestinal reservoir of MCp was conﬁrmed by showing that administration of blocking mAb every other day for one week to nonirradiated naive mice profoundly depleted the intestinal pool of MCp by blocking the regular inﬂux of new MCp (83). Furthermore, that the MCp reservoir was intact in mice null for the recombination activating (RAG)-2 and IL receptor common gamma chain genes indicated that this constitutive α4β7-dependent homing of MCp is independent of the Th2 cytokines needed to elicit mucosal MC hyperplasia (82). Finally, both mucosal and connective tissue MCs were deﬁcient in the β7 integrin-null mouse, indicating that a single lineage of MCp gives rise to both tissue phenotypes. www.annualreviews.org • Doing What I Like

13

ARI

9 March 2008

1:15

Mouse lung has minimal numbers of baseline MCp, and their recruitment with sensitization and inhalation antigen challenge depends partially on α4β7 but also involves α4β1. As lung lacks MAdCAM-1, adhesion with pulmonary inﬂammation is entirely through upregulated VCAM-1, likely accounting for the role of both α4-based integrins (84). The fact that blocking mAb to integrins of MCp prevents the accumulation of MCp in lung indicates that even with inﬂammation the initial host response is recruitment, not proliferation. The appreciation that β7-integrin expression is a requirement for transendothelial migration by MCp led to the discovery of a new bifunctional progenitor for both the MC and the basophil lineages. Candidate MCp progenitors in BM, spleen, and small intestine were depleted of irrelevant lineages, sorted by membrane phenotype, and characterized by growth in a cytokine mixture suitable for all hematopoietic lineages. In the C57B/6 strain, the spleen contained a population of bipotent β7+ /c-Kit+ /FcεR1+ basophil/MC progenitors (BaMCp) that gave rise in single-cell culture to colonies of either MCp or basophil progenitors (Bap). MCp but not Bap retained and increased β7 integrin expression. BaMCp administered intravenously to genetically MC-deﬁcient W/Wv mice reconstituted mature MCs in both spleen and stomach. The small intestine contained only MCp, suggesting that BaMCp do not leave the spleen. The granulocyte-related transcription factor CCAAT/enhancer-binding protein alpha (C/EBPα) played the major role in the fate decision of BaMCp, being retained by Bap and absent in MCp (85).

Annu. Rev. Immunol. 2008.26:1-28. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-01

Counterregulatory Signals Howard Katz, a new PhD in the laboratory of Steve Russell, had recognized that several mAbs obtained by immunizing Lewis rats with mononuclear phagocytes derived from BALB/c BM cultures in medium containing CSF-1 also bound BMMCs developed with 14

Austen

IL-3. He entered our postdoctoral program for the purpose of unraveling the epitopes for these mAbs, of which one, gp49B1, has proven to be of particular interest as a constitutively expressed negative regulatory receptor. Immunoprecipitation of a membrane epitope on both BMMCs and peritoneal MCs by the IgM mAb/B23.1 revealed a heterogeneous protein with a mean molecular mass of 49 kDa (86). Puriﬁcation of gp49 from a KiSV-MC clone provided the N-terminal amino acid sequence used to prepare oligonucleotides for screening a KiSV-MC library. Two of the fulllength cDNAs obtained, gp49A and gp49B1, were 97% homologous and encoded members of the Ig superfamily with two type 2 Ig-like extracellular domains, whereas the third, gp49B2, was identical to gp49B1 except for the lack of the entire transmembrane domain encoded by exon 6 (87, 88). That the putative tandem immunoreceptor tyrosine-based inhibition motifs (ITIMs) recognized in the cytosolic domain of gp49B1 were functional was established in vitro (89). Mice lacking the gp49B gene but not the g49A gene were generated and assessed for MC function by PCA (90). The net ear swelling of the sensitized ear due to MC activation and plasma extravasation was twofold greater in the gp49B1-deﬁcient strain than in the sufﬁcient WT littermates, and the number of MCs degranulated per unit area was also twofold greater. When the sensitizing dose of mAb IgE was reduced by one log, the net swelling of the sensitized ear in the deﬁcient strain was equal to that obtained in the WT strain with the standard tenfold greater sensitizing dose. In active cutaneous anaphylaxis of mice systemically sensitized to OVA and showing similar levels of speciﬁc IgE, an intradermal dose of OVA that elicited a robust vascular leak in the gp49B1-deﬁcient strain caused no measurable ear swelling in the WT mice. These studies not only uncovered a control receptor of IgE-dependent MC activation but, most important, recognized that such inﬂammation was normally dampened in situ by

Annu. Rev. Immunol. 2008.26:1-28. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-01

ARI

9 March 2008

1:15

an innate constitutive mechanism. That the activation of ear MCs by SCF also led to a signiﬁcantly greater vascular leak and MC degranulation in the gp49B1-deﬁcient mice as compared to the sufﬁcient littermates showed that regulation was not limited to adaptive immunity (91). There was yet a surprise. When lipopolysaccharide (LPS) was injected intradermally into the mouse ear to see if the gp49B1-null strain would have an exaggerated Toll-like receptor (TLR)-initiated MC-dependent swelling response, there was no early difference between the deﬁcient and sufﬁcient strains. Instead, by 24 h there was gross hemorrhage in the LPS-injected ear of the gp49B1-deﬁcient strain but none in the ear of the sufﬁcient littermates. The macroscopic bleeding visually apparent against the white fur of the gp49B1-deﬁcient BALB/c strain was reminiscent (to someone who had been working in immunology in the late 1950s) of a Schwartzman reaction. The microangiopathy of a Schwartzman reaction is due to a coagulopathy, not a vasculitis. On microscopic analysis, we saw venules occluded by thrombi composed of neutrophils, platelets, and ﬁbrin accompanied by a vascular margination and tissue inﬁltration by PMNs. The MCs were intact and not different in the deﬁcient strain. The lesion was prevented by administration of mAbs that depleted PMNs or blocked the interaction of their β2 integrin with the intercellular adhesion molecule 1 (ICAM-1) or by therapeutic inhibition of coagulation. Unexpectedly, the PMN expressed gp49B1, which is upregulated by LPS in WT mice (92). The “one-shot” Schwartzman reaction occurred in the deﬁcient strain owing to the absence of an innate control, gp49B1, of a TLR response on their PMNs. A member of the human leukocyte Ig-like receptor family (LIR-5) homologous to gp49B1 has been cloned (93) and renamed human LILRB4 to correspond to mouse LILRB4/gp49B1.

THE ALTERNATIVE COMPLEMENT PATHWAY In the 1950s, Pillemer and colleagues recognized that a plasma protein, designated properdin (P), was required for complementmediated bactericidal and hemolytic activity that was not antibody dependent (94). The properdin system/alternate complement pathway is composed of six proteins, of which four are speciﬁc to this pathway (P, factor B, factor D, and factor H) and two [C3 and C3b inactivator (C3bINA)] are shared with the classical antibody-dependent pathway. The most critical step in both activating pathways is the proteolytic cleavage of C3 to provide C3b for assembly of the ampliﬁcation C3 convertase, C3bBb. The same alternative pathway proteins are used for formation of a weak alternative pathway-initiating C3 convertase built with uncleaved C3. Unraveling the relationship of the initiation and ampliﬁcation phases of alternative pathway C3 cleavage followed the introduction of a quantitative, sensitive hemolytic assay for the assembly of C3bBb by my colleagues, Douglas Fearon and Shaun Ruddy (95). Sheep erythrocytes with afﬁxed C3b interacted with B in the presence of D to generate C3bBb sites, and the number of these sites could be calculated by lysis with additional C3 and C5-9. The cell-based assay had linear stoichiometry for generation of the C3bBb sites with incremental inputs of B and a ﬁxed dose of D, and a hemolytic efﬁciency comparable to cells bearing the classical C3 convertase. Our use of this assay included characterization of the proteins involved in the assembly, stabilization, and inactivation of C3bBb; recognition of the initiating alternative pathway C3 convertase, C3Bb; and demonstration of the integrated activation and ampliﬁcation of the alternative pathway on an activating particle or cell. Most important to the understanding of the alternative pathway was our discovery of the stabilizing function of P and of the destabilizing protein H for C3bBb. Properdin

www.annualreviews.org • Doing What I Like

15

ARI

9 March 2008

1:15

bound to C3b to form a trimolecular complex from which the decay of Bb was markedly retarded (96). Conversely, H terminated C3bBb function by dissociation-decay of Bb even in the presence of P (97, 98). This counterregulatory action allowed inactivation of C3b by C3bINA to prevent regeneration of the hemolytic site. With these insights into ampliﬁcation, we used the same proteins to seek the initiating alternative pathway C3 convertase, C3Bb, in the ﬂuid phase by comparing the dose-response effects of C3 and C3b for D-mediated cleavage inactivation of B. The time-dependent sigmoidal inactivation curve for B with C3 and D was delayed relative to that with C3b and was not inhibited by addition of C3bINA, indicating that C3Bb provided the C3b for subsequent formation of the ampliﬁcation convertase (99). Properdin dose-dependently augmented B inactivation with C3 and D, indicating stabilization of C3Bb. That D was a constitutively active serine protease (100) suggested a continuous low-grade cleavage of C3 in the presence of B and P and circumvention of the regulatory controls when C3b was deposited on an activating particle. To prove this mechanism, we used zymosan, the same insoluble polysaccharide derivative from yeast cell walls that Pillemer had used in recognizing the alternative complement-activating pathway (94). When zymosan was added to a mixture of C3, B, D, P, C3bINA, and H, an initial low-grade cleavage of C3 was followed by ampliﬁed cleavage that suggested a two-step process. Moreover, C3b bound to zymosan was relatively resistant to inactivation by C3bINA, and the hemolytic site, PC3bBb, assembled on zymosan was protected against H dissociation-decay, demonstrating that regulation of the ampliﬁcation site was retarded by the character of an activating particle (101). In a parallel study with the same six proteins, the addition of rabbit, but not sheep, erythrocytes initiated consumption of B and C3 in the ﬂuid phase and formation of lytic sites on the cell (102). Fearon then showed that enzymatic or chemical removal

Annu. Rev. Immunol. 2008.26:1-28. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-01

16

Austen

of membrane sialic acid groups from sheep erythrocytes converted these cells to activators of the alternative complement pathway while reducing the regulatory efﬁciency of C3bINA and H (103). Thus, the constitutive action of D to form C3Bb provides the C3b that, when afﬁxed to a protective nonself surface, forms a stabilized ampliﬁcation C3 convertase, PC3bBb, that provides diverse proinﬂammatory or host protective functions. The pattern recognition activation of the alternative complement pathway is a prime example of innate immunity. Our seminal insight that unraveled the activation and ampliﬁcation of the alternative pathway was that it might not begin with recruitment of a proenzyme but rather that nonself might be recognized by circumvention of surveillance mechanisms, H and C3bINA, that protect self.

TRANSLATIONAL INVESTIGATIONS The linkage of our bench research in our three focal areas to the clinic was most dynamic in the early years, when less was known, and continued at a reduced level until the early 1990s. Each clinical application of an insight gained at the bench involved a critical collaboration with either an astute full-time clinician or an established clinical investigator.

The cys-LTs After toiling with SRS-A for two decades, I was immensely curious about whether the cys-LTs provided by E.J. Corey would have the smooth muscle actions in humans that we had observed in animals. My equally curious colleagues, Bob Lewis and Nick Soter, joined me in an initial dose-response study in ourselves to intradermal LTD4 . The magnitude and persistence of the elicited wheal and ﬂare responses were so compelling that we initiated a second study with biopsies in which our cutaneous responses to the cys-LTs were compared with those to the other MCderived eicosanoids, LTB4 and PGD2 , and to

Annu. Rev. Immunol. 2008.26:1-28. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-01

ARI

9 March 2008

1:15

buffer. Equimolar amounts of LTC4 , LTD4 , and LTE4 elicited a local erythema and wheal of 6 h and 2 h duration, respectively, whereas the similar response to a higher dose of PGD2 was less sustained. The tissue showed dermal edema with marked and uniform dilation of capillaries, superﬁcial and deep venules, and arterioles as well as activation-related changes in the endothelium. There was no cellular inﬁltration in the cys-LT-injected sites. In contrast, LTB4 elicited a transient wheal and ﬂare followed 3–4 h later by induration that was characterized by a dermal inﬁltration composed almost solely of neutrophils. The combination of LTB4 and PGD2 intensiﬁed the cellular inﬁltrate. The ﬁndings that nanomole amounts of leukotrienes were active in human skin and that each subclass gave the expected biology were immensely rewarding to us (104). The Human Studies Committee delayed our planned investigation of the airway smooth muscle actions of aerosolized cysLTs to be certain that the skin exposure had no adverse effects. The concentrations of aerosolized LTC4 that reduced by 30% the maximum expiratory ﬂow rate (measured at 30% of vital capacity above residual volume) were in ug/ml, whereas those for histamine were in mg/ml, revealing a more than 1000fold greater potency for LTC4 in normal volunteers (105). LTC4 induced a fall in airﬂow that was slow in onset, prolonged, and associated with audible wheezing without a cough, whereas histamine acted rapidly and elicited a cough but not a wheeze. LTD4 was also three logs more potent than histamine, and the more biologically stable LTE4 was one log more potent as a bronchoconstrictor in normal human subjects. In contrast, in patients with bronchial asthma, the respective potencies of LTD4 and LTE4 relative to histamine were less than a log (106, 107). Although this ﬁnding would still classify the cys-LTs as potent bronchoconstrictors in individuals with bronchial asthma, it also suggests that their chronic overproduction somehow ameliorates receptor responses.

The Mast Cell In studies initiated in the clinic, a distinct form of physical allergy, exercise-induced anaphylaxis (EIA), was identiﬁed. When Al Sheffer described a number of patients “allergic to exercise” to the point of vascular collapse with jogging/running, indoor/outdoor team sports, tennis, and dancing, but without occurrence with every repetition of the exercise, it seemed reasonable to further expand the series. When the number reached 16, it was obviously a syndrome. EIA was deﬁned by a premonitory feeling of body warmth and itching unrelated to ambient temperature and progression to cutaneous erythema, conﬂuent hives, laryngeal edema with stridor or hoarseness, gastrointestinal cramps/colic, and frequently culmination in vascular collapse (108). Of seven patients with EIA who exercised on a treadmill with a moving grade while wearing an occlusive suit, four developed erythema and conventional-sized hives and two of these manifested laryngeal hoarseness. The four with symptoms showed a rise in blood histamine concentration, implicating MC activation (109), whereas the blood histamine concentration did not change in the subjects with EIA who did not respond to this challenge. In a repeat study, cutaneous biopsies of the patients with EIA with symptoms and signs showed classical MC degranulation that was absent in the nonresponders (110). In contrast to patients with cholinergic urticaria, who experienced punctate hives, elevations in blood histamine, and pulmonary symptoms with signiﬁcantly altered pulmonary function with the exercise protocol (111), pulmonary mechanics were not altered in the challenged patients with EIA. Patients with EIA can abort an episode by stopping the exercise with the onset of premonitory symptoms and can ameliorate/prevent attacks by allowing a suitable interval after a meal and/or by using various MC-directed interventions before exercise. Studies from the bench to the clinic identiﬁed a new MC-derived mediator, PGD2 , that accounted for intractable hypotension in

www.annualreviews.org • Doing What I Like

17

ARI

9 March 2008

1:15

occasional patients with systemic mastocytosis. In collaboration with John Oates and Jack Roberts, we assessed the eicosanoid products of MC activation. Gas chromatography-mass spectroscopy (GC-MS) analysis of calcium ionophore-stimulated or anti-IgE-activated puriﬁed rat peritoneal MCs revealed net generation of PGD2 with only minimal quantities of other eicosanoids. Similarly, activation of dispersed human lung MCs by anti-IgE showed selective PGD2 generation relative to other prostanoids and a linear relationship to histamine release (112, 113). The failure of H1 and H2 antagonists to control the severe body ﬂushing and hypotension in two patients with systemic mastocytosis led to a GC-MS analysis of urine and the structural identiﬁcation of a metabolite of PGD2 that was not present in more than 200 urine samples from normal subjects or patients with other diseases (114). The hypotension in one of these patients was controlled by treatment with highdose aspirin in combination with H1 and H2 antagonists. The evidence that MCs in patients with systemic mastocytosis can spontaneously release more than preformed secretory granule mediators accounts for our use of cromolyn sodium, a MC-stabilizing agent, along with H1 and H2 antagonists and, when indicated by severe ﬂushing, aspirin in their management (115).

Annu. Rev. Immunol. 2008.26:1-28. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-01

The Complement Pathways Disordered regulation of the complement system became a clinical focus because of our preclinical studies and ability to develop sensitive stoichiometric hemolytic assays for proteins whose absence or sustained presence deﬁned the syndrome. Such studies included patients with inborn deﬁciency of C1INH and bouts of HAE and others with autoantibody-mediated C1INH deﬁciency; patients with autoantibody-mediated stabilization of the ampliﬁcation C3 convertase by nephritic factor (NEF) and membranoproliferative glomerulonephritis; and patients with acquired clonal loss of decay18

Austen

accelerating factor (DAF) and paroxysmal nocturnal hemoglobinuria (PNH). Once Al Sheffer learned that Donaldson & Evans (116) had recognized a C1INH deﬁciency in patients with HAE by screening serum for lack of ability to inhibit C1 esterase activity, he appeared in my laboratory to request a suitable assay for this potentially fatal disease among his patients. Stoichiometric hemolytic assays for C2 and C4, substrates of C1, showed their concentrations in HAE to be two standard deviations below the mean for normal in kindreds lacking the protein or those with a nonfunctional protein and to be further reduced by consumption with a clinical episode (117, 118). The ﬁnding by Spaulding (119) that androgen treatment could prevent attacks of angioedema in patients with HAE led us to use attenuated androgens, which reduced but did not eliminate the risk of androgen-related side effects (120). The concentrations of C1INH in untreated HAE patients during asymptomatic periods were less than one quarter normal even though inheritance is autosomal dominant, suggesting consumption of the product of the good gene by the uninhibited C1. Reasonable prevention or amelioration of attacks was achieved with a dose of attenuated androgen that increased the mean functional concentrations of C1INH and C4 to less than one-half of the lower limit of normal, demonstrating a modest dose threshold for clinical beneﬁt (121). Acquired C1INH deﬁciency with clinical angioedema in patients with B cell proliferative disorders was recognized to be distinct from HAE because there was depletion of functional C1 and its binding subunit, C1q, as well as C4 and C2 (122). Analysis of three such patients showed circulating anti-idiotypes directed to the monoclonal Ig expressed on the surface of their lymph node B cells and on circulating B cells with ﬁxed C1q (123). Patients with PNH have erythrocytes with an acquired abnormal membrane sensitivity to complement-mediated lysis (PNH-E) and experience spontaneous episodes of intravascular hemolysis, often at night. Two membrane

Annu. Rev. Immunol. 2008.26:1-28. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-01

ARI

9 March 2008

1:15

control proteins, C3b receptor (CR1) and DAF, extracted and puriﬁed from human erythrocytes, can act exogenously to destabilize both the ampliﬁcation (C3bBb) and classical (C4b2a) C3 convertases (124, 125). We found that speciﬁc immunoprecipitates of surfacelabeled PNH-E lacked a 70 MW DAF but expressed a 250 MW CR1. Further, PNH-E, unlike normal erythrocytes, failed to absorb the DAF-neutralizing activity of speciﬁc rabbit IgG (126). These ﬁndings provided the ﬁrst in situ evidence that an endogenous membrane protein can downregulate the potential pathobiologic effects of ampliﬁcation resulting from the low-grade turnover of C3 by identifying an acquired clonal deletion of DAF in PNH-E. Patients with chronic glomerulonephritis and a reduced serum C3 concentration have normal concentrations of C4 and reduced concentrations of B, implicating the alternative complement pathway, while patients with systemic lupus erythematosus and reduced C3 concentrations have reduced concentrations of C4 with or without reduced concentrations of B, implicating classical immune complex activation with or without ampliﬁcation (127). C3 nephritic factor (C3 NeF) in serum of patients with low C3 concentrations and membranoproliferative glomerulonephritis was known to augment C3 consumption. Mohamed Daha and Doug Fearon found that chromatographically puriﬁed C3 NeF stabilized the hemolytic function of C3bBb on erythrocytes and interacted with C3, B, and D in the ﬂuid phase to form a trimolecular 10S complex of C3bBb/C3NeF (128). The C3NeF recovered chromatographically after decay of the 10S convertase was highly puriﬁed, fully functional (129), and composed of heavy and light chains (130). Others had recognized that C3 NeF was an Ig by depletion of the activity from serum with particle-bound anti-IgG. We provided direct evidence that it was an autoantibody with speciﬁcity that stabilized the ampliﬁcation convertase without a role for P and with resistance to induced decay by H (97).

EPILOGUE As physicians have entered my laboratory after experiencing a daily sense of accomplishment as house ofﬁcers, it was critical that I help them endure the initial difﬁculties inherent to bench research. Most important, I have tried to convey that advice is not criticism and that failure is predictable if the projects chosen have merit. Over the years, postdoctoral fellows have been routinely designated as ﬁrst author on manuscripts when a project reached fruition and as last author when they became faculty with mentoring responsibilities. I edited and rewrote many drafts of each manuscript, making sure that the literature was fully recognized and sometimes laying out an urgent set of additional experiments that we had not identiﬁed in laboratory meetings. Since 1966, the “ﬁnal” text has been edited by Arlene Stolper Simon. She has edited every manuscript of which I am an author, the sections of every volume for which I served as an editor, and every grant application that I submitted. Colleagues often mention that they can recognize faculty who trained here by a certain consistency in their oral and written presentations. A few years ago, I titled my acceptance of the Kober medal “It Only Gets Better” (131) to convey that experience with focus provides insights and an inclination for measured risk that is productive for research in a setting with talented trainees and wise colleagues. Those individuals noted in this document have generally progressed to faculty level, thereby extending our period of collaboration. I have concentrated on areas with a longitudinal span and have not included descriptions for our studies of chemotaxis (Edward Goetzl, Stephen Wasserman), kinin generation (Allen Kaplan, Jocelyn Spragg), classical complement pathway (Irma Gigli, Michel Kazatchkine), eosinophils (Barry Kay, Marc Rothenberg), ﬁsh oil–derived leukotrienes (Tak Lee), and some of our early work on SRSA biology by Daniel Stechschulte and Martin Valentine, my ﬁrst postdoctoral fellows. By being an administrative minimalist with an www.annualreviews.org • Doing What I Like

19

ANRV338-IY26-01

ARI

9 March 2008

1:15

Annu. Rev. Immunol. 2008.26:1-28. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

open door and much sharing of tasks, I have been able to concentrate on my triad of interests with results beyond my expectations. The respect for each other’s laboratories that grew between Bengt Samuelsson, E.J. Corey, Jeffrey Drazen, and me enhanced progress in the SRS-A/cys-LT ﬁeld and built long-term friendships. In the complement ﬁeld, there were times when the laboratories of Fred Rosen, Hans Muller-Eberhard, and my own were in competition, but we managed those

occasions so as to sustain our collaborations and friendships. My wife, Joycelyn Chapman Austen, has been especially generous in tolerating my avocation, in indulging the intensity of the ﬁveyear grant renewals, and in meeting every responsibility to our four wonderful children in a manner that reﬂected our joint interests. These children, and now our eight grandchildren, take my efforts to provide guidance with humor and tolerance.

DISCLOSURE STATEMENT The author is not aware of any biases that might be perceived as affecting the objectivity of this review.

LITERATURE CITED 1. Austen KF. 1978. Homeostasis of effector systems which can also be recruited for immunologic reactions. Pres. Address Am. Assoc. Immunol. J. Immunol. 121:793–805 2. Austen KF, Koch-Weser J, Field RA. 1956. Cardiorespiratory problems in severe poliomyelitis observed during the recent epidemic. N. Engl. J. Med. 254:790–93 3. Drazen JM. 2004. Presentation of the Kober Medal to K. Frank Austen. J. Clin. Invest. 114:1174–76 4. Livingstone JB, Austen KF, Kunz LJ. 1957. A study of intercurrent bacterial respiratory infections in bulbospinal poliomyelitis. N. Engl. J. Med. 257:861–66 5. Austen KF, Carmichael MW, Adams RD. 1957. Neurologic manifestations of chronic pulmonary insufﬁciency. N. Engl. J. Med. 257:579–90 6. Austen KF, Rubini ME, Meroney WH, Wolff J. 1958. Salicylates and thyroid function. I. Depression of thyroid function. J. Clin. Invest. 37:1131–43 7. Wolff J, Austen KF. 1958. Salicylates and thyroid function. II. The effect on the thyroidpituitary interrelation. J. Clin. Invest. 37:1144–52 8. Austen KF. 1960. The differentiation of the chloroform, peptone and antigen antibody inducible esterase activities of human serum from plasmin. Immunology 3:152–73 9. Austen KF, Brocklehurst WE. 1961. Anaphylaxis in chopped guinea pig lung. I. Effect of peptidase substrates and inhibitors. J. Exp. Med. 113:521–39 10. Austen KF, Brocklehurst WE. 1961. Anaphylaxis in chopped guinea pig lung. II. Enhancement of the anaphylactic release of histamine and slow reacting substance by certain dibasic aliphatic acids and inhibition by monobasic fatty acids. J. Exp. Med. 113:541–57 11. Austen KF, Brocklehurst WE. 1961. Anaphylaxis in chopped guinea pig lung. III. Effect of carbon monoxide, cyanide, salicylaldoxine, and ionic strength. J. Exp. Med. 114:29– 42 12. Humphrey JH, Austen KF, Rapp HJ. 1963. In vitro studies of reversed anaphylaxis with rat cells. Immunology 6:226–45 13. Stroud RM, Austen KF, Mayer MM. 1965. Catalysis of C’2 ﬁxation by C’1a: reaction kinetics, competitive inhibition by TAMe, and transferase hypothesis of the enzymatic action of C’1a on C’2, one of its natural substrates. Immunochemistry 2:219–34 20

Austen

Annu. Rev. Immunol. 2008.26:1-28. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-01

ARI

9 March 2008

1:15

14. Murphy RC, Hammarstrom S, Samuelsson B. 1979. Leukotriene C: a slow-reacting substance from murine mastocytoma cells. Proc. Natl. Acad. Sci. USA 76:4275– 79 15. Stechschulte DJ, Austen KF, Bloch KJ. 1967. Antibodies involved in antigen-induced release of slow reacting substance of anaphylaxis (SRS-A) in the guinea pig and rat. J. Exp. Med. 125:127–47 16. Orange RP, Stechschulte DJ, Austen KF. 1970. Immunochemical and biologic properties of rat IgE. II. Capacity to mediate the immunologic release of histamine and slow reacting substance of anaphylaxis (SRS-A). J. Immunol. 105:1087–95 17. Ishizaka T, Ishizaka K, Orange RP, Austen KF. 1970. The capacity of human immunoglobulin E to mediate the release of histamine and slow reacting substance of anaphylaxis (SRS-A) from monkey lung. J. Immunol. 104:335–43 18. Morse HC, Bloch KJ, Austen KF. 1968. Biologic properties of rat antibodies. II. Timecourse of appearance of antibodies involved in antigen-induced release of slow reacting substance of anaphylaxis (SRS-arat ): association of this activity with rat IgGa. J. Immunol. 101:658–63 19. Orange RP, Murphy RC, Karnovsky ML, Austen KF. 1973. The physicochemical characteristics and puriﬁcation of slow reacting substance of anaphylaxis. J. Immunol. 110:760– 70 20. Orange RP, Murphy RC, Austen KF. 1974. Inactivation of slow reacting substance of anaphylaxis (SRS-A) by arylsulfatases. J. Immunol. 113:316–22 21. Weller PF, Corey EJ, Austen KF, Lewis RA. 1986. Inhibition of homogeneous human eosinophil arylsulfatase B by sulﬁdopeptide leukotrienes. J. Biol. Chem. 261:1737–44 22. Jakschik BA, Falkenhein S, Parker CW. 1977. Precursor role of arachidonic acid in release of slow reacting substance from rat basophilic leukemia cells. Proc. Natl. Acad. Sci. USA 74:4577–81 23. Lewis RA, Wasserman SI, Goetzl EJ, Austen KF. 1974. Formation of slow-reacting substance of anaphylaxis in human lung tissue and cells before release. J. Exp. Med. 140:1133–46 24. Lam BK, Owen WF Jr, Austen KF, Soberman RJ. 1989. The identiﬁcation of a distinct export step following the biosynthesis of leukotriene C4 by human eosinophils. J. Biol. Chem. 264:12885–89 25. Drazen JM, Austen KF. 1974. Effects of intravenous administration of slow reacting substance of anaphylaxis, histamine, bradykinin, and prostaglandin F2 on pulmonary mechanics in the guinea pig. J. Clin. Invest. 53:1679–85 26. Marfat A, Corey EJ. 1985. Synthesis and structure elucidation of leukotrienes. In Advances in Prostaglandin, Thromboxane, and Leukotriene Research, ed. JE Pike, DR Morton Jr, 14:155–228. New York: Raven 27. Lewis RA, Austen KF, Drazen JM, Clark DA, Marfat A, Corey EJ. 1980. Slow reacting substances of anaphylaxis: identiﬁcation of leukotrienes C-1 and D from human and rat sources. Proc. Natl. Acad. Sci. USA 77:3710–14 28. Morris HR, Taylor GW, Piper PJ, Samhoun MN, Tippins JR. 1980. Slow reacting substances (SRSs); the structure identiﬁcation of SRSs from rat basophil leukemia (RBL-1) cells. Prostaglandins 19:185–201 29. Lewis RA, Drazen JM, Austen KF, Clark DA, Corey EJ. 1980. Identiﬁcation of the C(6)S-conjugate of leukotriene A with cysteine as a naturally occurring slow reacting substance of anaphylaxis (SRS-A). Importance of the 11-cis-geometry for biological activity. Biochem. Biophys. Res. Commun. 96:271–77 www.annualreviews.org • Doing What I Like

21

ARI

9 March 2008

1:15

30. Lee TH, Austen KF, Corey EJ, Drazen JM. 1984. Leukotriene E4 -induced airway hyperresponsiveness of guinea pig tracheal smooth muscle to histamine and evidence for three separate sulﬁdopeptide leukotriene receptors. Proc. Natl. Acad. Sci. USA 81:4922– 25 31. Drazen JM, Austen KF, Lewis RA, Clark DA, Goto G, et al. 1980. Comparative airway and vascular activities of leukotrienes C-1 and D in vivo and in vitro. Proc. Natl. Acad. Sci. USA 77:4354–58 32. Lee CW, Lewis RA, Tauber AI, Mehrotra M, Corey EJ, Austen KF. 1983. The myeloperoxidase-dependent metabolism of leukotrienes C4 , D4 and E4 to 6-transleukotriene B4 diastereoisomers and the subclass-speciﬁc S-diastereoisomeric sulfoxides. J. Biol. Chem. 258:15004–10 33. Yoshimoto T, Soberman RJ, Lewis RA, Austen KF. 1985. Isolation and characterization of leukotriene C4 synthetase of rat basophilic leukemia cells. Proc. Natl. Acad. Sci. USA 82:8399–403 34. Yoshimoto T, Soberman RJ, Spur B, Austen KF. 1988. Properties of highly puriﬁed leukotriene C4 synthase of guinea pig lung. J. Clin. Invest. 81:866–71 35. Penrose JF, Gagnon L, Goppelt-Struebe M, Myers P, Lam BK, et al. 1992. Puriﬁcation of human leukotriene C4 synthase. Proc. Natl. Acad. Sci. USA 89:11603–6 36. Lam BK, Penrose JF, Freeman GJ, Austen KF. 1994. Expression cloning of a cDNA for human leukotriene C4 synthase, a novel integral membrane protein conjugating reduced glutathione to leukotriene A4 . Proc. Natl. Acad. Sci. USA 91:7663–67 37. Penrose JF, Spector J, Baldasaro M, Xu K, Boyce J, et al. 1996. Molecular cloning of the gene for human leukotriene C4 synthase: organization, nucleotide sequence, and chromosomal localization to 5q35. J. Biol. Chem. 271:11356–61 38. Lam BK, Penrose JF, Rokach J, Xu K, Baldasaro MH, Austen KF. 1996. Molecular cloning, expression, and characterization of mouse leukotriene C4 synthase. Eur. J. Biochem. 238:606–12 39. Penrose JF, Baldasaro MH, Webster M, Xu K, Austen KF, Lam BK. 1997. Molecular cloning of the gene for mouse leukotriene C4 synthase. Eur. J. Biochem. 248:807– 13 40. Hsieh FH, Lam BK, Penrose JF, Austen KF, Boyce JA. 2001. T helper cell type 2 cytokines coordinately regulate immunoglobulin E-dependent cysteinyl leukotriene production by human cord blood–derived mast cells: profound induction of leukotriene C4 synthase expression by interleukin 4. J. Exp. Med. 193:123–33 41. Mellor EA, Frank N, Soler D, Hodge MR, Lora JM, et al. 2003. Expression of the type 2 receptor for cysteinyl leukotrienes (CysLT2 R) by human mast cells: functional distinction from CysLT1 R. Proc. Natl. Acad. Sci. USA 100:11589–93 42. Lam BK, Penrose JF, Xu K, Baldasaro MH, Austen KF. 1997. Site-directed mutagenesis of human leukotriene C4 synthase. J. Biol. Chem. 272:13923–28 43. Schmidt-Krey I, Kanaoka Y, Mills DJ, Irikura D, Haase W, et al. 2004. Human leukotriene C4 synthase at 4.5 A˚ resolution in projection. Structure 12:2009– 14 44. Ago H, Kanaoka Y, Irikura D, Lam BK, Shimamura T, et al. 2007. Crystal structure of LTC4 synthase, the membrane protein for cysteinyl leukotriene biosynthesis. Nature 448:609–12 45. Kanaoka Y, Maekawa A, Penrose JF, Austen KF, Lam BK. 2001. Attenuated zymosaninduced peritoneal vascular permeability and IgE-dependent passive cutaneous anaphylaxis in mice lacking leukotriene C4 synthase. J. Biol. Chem. 276:22608–13

Annu. Rev. Immunol. 2008.26:1-28. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-01

22

Austen

Annu. Rev. Immunol. 2008.26:1-28. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-01

ARI

9 March 2008

1:15

46. Maekawa A, Kanaoka Y, Lam BK, Austen KF. 2001. Identiﬁcation in mice of two isoforms of the cysteinyl leukotriene 1 receptor that result from alternative splicing. Proc. Natl. Acad. Sci. USA 98:2256–61 47. Maekawa A, Austen KF, Kanaoka Y. 2002. Targeted gene disruption reveals the role of cysteinyl leukotriene 1 receptor in the enhanced vascular permeability of mice undergoing acute inﬂammatory responses. J. Biol. Chem. 277:20820–24 48. Beller TC, Maekawa A, Friend DS, Austen KF, Kanaoka Y. 2004. Targeted gene disruption reveals the role of the cysteinyl leukotriene 2 receptor in increased vascular permeability and in bleomycin-induced pulmonary ﬁbrosis in mice. J. Biol. Chem. 44:46129– 34 49. Beller TC, Friend DS, Maekawa A, Lam BK, Austen KF, Kanaoka Y. 2004. Cysteinyl leukotriene 1 receptor controls the severity of chronic pulmonary inﬂammation and ﬁbrosis. Proc. Natl. Acad. Sci. USA 101:3047–52 50. Caulﬁeld JP, Lewis RA, Hein A, Austen KF. 1980. Secretion in dissociated human pulmonary mast cells: evidence for solubilization of granule contents before discharge. J. Cell Biol. 85:299–312 51. Schwartz LB, Riedel C, Caulﬁeld JP, Wasserman SI, Austen KF. 1981. Cell association of complexes of chymase, heparin proteoglycan, and protein after degranulation by rat mast cells. J. Immunol. 126:2071–78 52. Schwartz LB, Lewis RA, Austen KF. 1981. Tryptase from human pulmonary mast cells. Puriﬁcation and characterization. J. Biol. Chem. 256:11939–43 53. Schwartz LB, Kawahara MS, Hugli TE, Vik D, Fearon DT, Austen KF. 1983. Generation of C3a anaphylatoxin from human C3 by human mast cell tryptase. J. Immunol. 130:1891– 95 54. Reynolds DS, Gurley DS, Stevens RL, Sugarbaker DJ, Austen KF, Seraﬁn WE. 1989. Cloning of cDNAs that encode human mast cell carboxypeptidase A, and comparison of the protein with mouse mast cell carboxypeptidase A and rat pancreatic carboxypeptidases. Proc. Natl. Acad. Sci. USA 86:9480–84 55. Reynolds DS, Gurley DS, Austen KF. 1992. Cloning and characterization of the novel gene for mast cell carboxypeptidase A. J. Clin. Invest. 89:273–82 56. Schneider LA, Schlenner SM, Feyerabend TB, Wunderlin M, Rodewald H-R. 2007. Molecular mechanism of mast cell-mediated defense against endothelial and snake venom sarafotoxin. J. Exp. Med. 204:2629–39 57. Reynolds DS, Seraﬁn WE, Faller DV, Wall DA, Abbas AK, et al. 1988. Immortalization of murine connective tissue-type mast cells at multiple stages of their differentiation by coculture of splenocytes with ﬁbroblasts that produce Kirsten sarcoma virus. J. Biol. Chem. 263:12783–91 58. Reynolds DS, Stevens RL, Gurley DS, Lane WS, Austen KF, Seraﬁn WE. 1989. Isolation and molecular cloning of mast cell carboxypeptidase A. J. Biol. Chem. 264:20094– 99 59. Reynolds DS, Stevens RL, Lane WS, Carr MH, Austen KF, Seraﬁn WE. 1990. Different mouse mast cell populations express various combinations of at least six distinct mast cell serine proteases. Proc. Natl. Acad. Sci. USA 87:3230–34 60. Seraﬁn WE, Reynolds DS, Rogelj S, Lane WS, Conder GA, et al. 1990. Identiﬁcation and molecular cloning of a novel mouse mucosal mast cell serine protease. J. Biol. Chem. 265:423–29 61. Seraﬁn WE, Sullivan TP, Conder GA, Ebrahimi A, Marcham P, et al. 1991. Cloning of the cDNA and gene for mouse mast cell protease 4: demonstration of its late transcription www.annualreviews.org • Doing What I Like

23

ANRV338-IY26-01

ARI

9 March 2008

62.

63.

64.

Annu. Rev. Immunol. 2008.26:1-28. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

65.

66.

67.

68.

69.

70.

71. 72. 73. 74.

75.

76.

24

Austen

1:15

in mast cell subclasses and analysis of its homology to subclass-speciﬁc neutral proteases of the mouse and rat. J. Biol. Chem. 266:1934–41 McNeil HP, Austen KF, Somerville LL, Gurish MF, Stevens RL. 1991. Molecular cloning of the mouse mast cell protease-5 gene: a novel secretory granule protease expressed early in the differentiation of serosal mast cells. J. Biol. Chem. 266:20316–22 Reynolds DS, Gurley DS, Austen KF, Seraﬁn WE. 1991. Cloning of the cDNA and gene of mouse mast cell protease-6: transcription by progenitor mast cells and mast cells of the connective tissue subclass. J. Biol. Chem. 266:3847–53 Hunt JE, Stevens RL, Austen KF, Zhang J, Xia Z, Ghildyal N. 1996. Natural disruption of the mouse mast cell protease 7 gene in the C57BL/6 mouse. J. Biol. Chem. 271:2851–55 Hunt JE, Friend DS, Gurish MF, Feyfant E, Sali A, et al. 1997. Mouse mast cell protease 9, a novel member of the chromosome 14 family of serine proteases that is selectively expressed in uterine mast cells. J. Biol. Chem. 272:29158–66 Gurish MF, Ghildyal N, McNeil HP, Austen KF, Gillis S, Stevens RL. 1992. Differential expression of secretory granule proteases in mouse mast cells exposed to interleukin 3 and c-kit ligand. J. Exp. Med. 175:1003–12 Ghildyal N, Friend DS, Nicodemus CF, Austen KF, Stevens RL. 1993. Reversible expression of mouse mast cell protease 2 mRNA and protein in cultured mast cells exposed to interleukin-10. J. Immunol. 151:3206–14 Xia Z, Ghildyal N, Austen KF, Stevens RL. 1996. Post-transcriptional regulation of chymase expression in mast cells: a cytokine-dependent mechanism for controlling the expression of granule neutral proteases of hematopoietic cells. J. Biol. Chem. 271:8747– 53 Friend DS, Ghildyal N, Austen KF, Gurish MF, Matsumoto R, Stevens RL. 1996. Mast cells that reside at different locations in the jejunum of mice infected with Trichinella spiralis exhibit sequential changes in their granule ultrastructure and chymase phenotype. J. Cell Biol. 135:279–90 Gurish MF, Pear WS, Stevens RL, Scott ML, Sokol K, et al. 1995. Tissue-regulated differentiation and maturation of a v-abl-immortalized mast cell-committed progenitor. Immunity 3:175–86 Yurt RW, Leid RW Jr, Austen KF, Silbert JE. 1977. Native heparin from rat peritoneal mast cells. J. Biol. Chem. 252:518 Metcalfe DD, Lewis RA, Silbert JE, Rosenberg RD, Wasserman SI, Austen KF. 1979. Isolation and characterization of heparin from human lung. J. Clin. Invest. 64:1537–43 Metcalfe DD, Smith JA, Austen KF, Silbert JA. 1980. Polydispersity of rat mast cell heparin. Implications for proteoglycan assembly. J. Biol. Chem. 255:11753–58 Razin E, Stevens RL, Akiyama F, Schmid K, Austen KF. 1982. Culture from mouse bone marrow of a subclass of mast cells possessing a distinct chondroitin sulfate proteoglycan with glycosaminoglycans rich in N-acetylgalactosamine-4,6-disulfate. J. Biol. Chem. 257:7229–36 Seraﬁn WE, Katz HR, Austen KF, Stevens RL. 1986. Complexes of heparin proteoglycans, chondroitin sulfate E proteoglycans, and [3 H]diisopropyl ﬂuorophosphate-binding proteins are exocytosed from activated mouse bone marrow-derived mast cells. J. Biol. Chem. 261:15017–21 Avraham S, Stevens RL, Gartner MC, Austen KF, Lalley PA, Weis JH. 1988. Isolation of a cDNA that encodes the peptide core of the secretory granule proteoglycan of rat basophilic leukemia-1 cells and assessment of its homology to the human analogue. J. Biol. Chem. 263:7292–96

Annu. Rev. Immunol. 2008.26:1-28. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-01

ARI

9 March 2008

1:15

77. Stevens RL, Avraham S, Gartner MC, Bruns GAP, Austen KF, Weis JH. 1988. Isolation and characterization of a cDNA that encodes the peptide core of the secretory granule proteoglycan of human promyelocytic leukemia HL-60 cells. J. Biol. Chem. 263:7287– 91 78. Avraham S, Austen KF, Nicodemus CF, Gartner MC, Stevens RL. 1989. Cloning and characterization of the mouse gene that encodes the peptide core of secretory granule proteoglycans and expression of this gene in transfected rat-1 ﬁbroblasts. J. Biol. Chem. 264:16719–26 79. Kitamura Y, Go S, Hatanaka K. 1978. Decrease of mast cells in W/Wv mice and their increase by bone marrow transplantation. Blood 52:447–52 80. Rodewald HR, Dessing M, Dvorak AM, Galli SJ. 1996. Identiﬁcation of a committed precursor for the mast cell lineage. Science 271:818–22 81. Crapper RM, Schrader JW. 1983. Frequency of mast cell precursors in normal tissues determined by an in vitro assay: antigen induces parallel increases in the frequency of P cell precursors and mast cells. J. Immunol. 131:923–28 82. Gurish MF, Tao H, Abonia JP, Arya A, Friend DS, et al. 2001. Intestinal mast cell progenitors require CD49dβ7 (α4β7 integrin) for tissue-speciﬁc homing. J. Exp. Med. 194:1243–52 83. Abonia JP, Austen KF, Rollins BJ, Joshi SK, Flavell RA, et al. 2005. Constitutive homing of mast cell progenitors to the intestine depends on autologous expression of the chemokine receptor CXCR2. Blood 105:4308–13 84. Abonia JP, Hallgren J, Jones T, Shi R, Xu Y, et al. 2006. Alpha-4 integrins and VCAM-1, but not MAdCAM-1, are essential for recruitment of mast cell progenitors to the inﬂamed lung. Blood 108:1588–94 85. Arinobu Y, Iwasaki H, Gurish MF, Mizuno S, Shigematsu H, et al. 2005. Developmental checkpoints of the basophil/mast cell lineages in adult murine hematopoiesis. Proc. Natl. Acad. Sci. USA 102:18105–10 86. Katz HR, Benson AC, Austen KF. 1989. Activation and phorbol ester-stimulated phosphorylation of a plasma membrane glycoprotein antigen expressed on mouse IL-3dependent mast cells and serosal mast cells. J. Immunol. 142:919–26 87. Arm JP, Gurish MF, Reynolds DS, Scott HC, Gartner CS, et al. 1991. Molecular cloning of gp49, a cell surface antigen that is preferentially expressed by mouse mast cell progenitors and is a new member of the immunoglobulin superfamily. J. Biol. Chem. 266:15966– 73 88. Castells MC, Wu X, Arm JP, Austen KF, Katz HR. 1994. Cloning of the gp49B gene of the immunoglobulin superfamily and demonstration that one of its two products is an early-expressed mast cell surface protein originally described as gp49. J. Biol. Chem. 269:8393–401 89. Katz HR, Vivier E, Castells MC, McCormick MJ, Chambers JM, Austen KF. 1996. Mouse mast cell gp49B1 contains two immunoreceptor tyrosine-based inhibition motifs and suppresses mast cell activation when coligated with the high afﬁnity Fc receptor for IgE. Proc. Natl. Acad. Sci. USA 93:10809–14 90. Daheshia M, Friend DS, Grusby MJ, Austen KF, Katz HR. 2001. Increased severity of local and systemic anaphylactic reactions in gp49B1-deﬁcient mice. J. Exp. Med. 194:227– 33 91. Feldweg AM, Friend DS, Zhou JS, Kanaoka Y, Daheshia M, et al. 2003. gp49B1 suppresses stem cell factor-induced mast cell activation-secretion and attendant inﬂammation in vivo. Eur. J. Immunol. 33:2262–68 www.annualreviews.org • Doing What I Like

25

ARI

9 March 2008

1:15

92. Zhou JS, Friend DS, Feldweg AM, Daheshia M, Li L, et al. 2003. Prevention of lipopolysaccharide-induced microangiopathy by gp49B1: evidence for an important role for gp49B1 expression on neutrophils. J. Exp. Med. 198:1243–51 93. Arm JP, Nwankwo C, Austen KF. 1997. Molecular identiﬁcation of a novel family of human Ig superfamily members that possess immunoreceptor tyrosine-based inhibition motifs and homology to the mouse gp49B1 inhibitory receptor. J. Immunol. 159:2342–49 94. Pillemer L, Blum L, Lepow IH, Ross OA, Todd EW, Wardlaw AC. 1954. The properdin system and immunity. I. Demonstration and isolation of a new serum protein, properdin, and its role in immune phenomena. Science 120:279–85 95. Fearon DT, Austen KF, Ruddy S. 1973. Formation of a hemolytically active cellular intermediate by the interaction between properdin factors B and D and the activated third component of complement. J. Exp. Med. 138:1305–13 96. Fearon DT, Austen KF. 1975. Properdin: binding to C3b and stabilization of the C3bdependent convertase. J. Exp. Med. 142:856–63 97. Weiler JM, Daha MR, Austen KF, Fearon DT. 1976. Control of the ampliﬁcation convertase of complement by the plasma protein β1H. Proc. Natl. Acad. Sci. USA 73:3268–72 98. Whaley K, Ruddy S. 1976. Modulation of the alternative complement pathways by beta 1H globulin. J. Exp. Med. 144:1147–63 99. Fearon DT, Austen KF. 1975. Initiation of C3 cleavage in the alternative complement pathway. J. Immunol. 115:1357–61 100. Fearon DT, Austen KF, Ruddy S. 1974. Properdin factor D: characterization of its active site and isolation of the precursor form. J. Exp. Med. 139:355–66 101. Fearon DT, Austen KF. 1977. Activation of the alternative complement pathway due to resistance of zymosan-bound ampliﬁcation convertase to endogenous regulatory mechanisms. Proc. Natl. Acad. Sci. USA 74:1683–87 102. Fearon DT, Austen KF. 1977. Activation of the alternative complement pathway with rabbit erythrocytes by circumvention of the regulatory action of endogenous control proteins. J. Exp. Med. l46:22–33 103. Fearon DT. 1978. Regulation by membrane sialic acid of beta 1H-dependent decaydissociation of ampliﬁcation C3 convertase of the alternative complement pathway. Proc. Natl. Acad. Sci. USA 75:1971–75 104. Soter NA, Lewis RA, Corey EJ, Austen KF. 1983. Local effects of synthetic leukotrienes (LTC4 , LTD4 , LTE4 and LTB4 ) in human skin. J. Invest. Dermatol. 80:115– 19 105. Weiss JW, Drazen JM, Coles N, McFadden ER Jr, Weller PF, et al. 1982. Bronchoconstrictor effects of leukotriene C in humans. Science 216:196–98 106. Grifﬁn M, Weiss JW, Leitch AG, McFadden ER Jr, Corey EJ, et al. 1983. Effects of leukotriene D on the airways in asthma. N. Engl. J. Med. 308:436–39 107. Davidson AB, Lee TH, Scanlon PD, Solway J, McFadden ER Jr, et al. 1987. Bronchoconstrictor effects of leukotriene E4 in normal and asthmatic individuals. Am. Rev. Respir. Dis. 135:333–37 108. Sheffer AL, Austen KF. 1980. Exercise-induced anaphylaxis. J. Allergy Clin. Immunol. 66:106–11 109. Sheffer AL, Soter NA, McFadden ER Jr, Austen KF. 1983. Exercise-induced anaphylaxis: a distinct form of physical allergy. J. Allergy Clin. Immunol. 71:311–l6 110. Sheffer AL, Tong AKF, Murphy GF, Lewis RA, McFadden ER Jr, Austen KF. 1985. Exercise-induced anaphylaxis: a serious form of physical allergy associated with mast cell degranulation. J. Allergy Clin. Immunol. 75:479–84

Annu. Rev. Immunol. 2008.26:1-28. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-01

26

Austen

Annu. Rev. Immunol. 2008.26:1-28. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-01

ARI

9 March 2008

1:15

111. Soter NA, Wasserman SI, Austen KF, McFadden ER Jr. 1980. Release of mast cell mediators and alterations in lung function in patients with cholinergic urticaria. N. Engl. J. Med. 302:604–8 112. Roberts LJ II, Lewis RA, Oates JA, Austen KF. 1979. Prostaglandin, thromboxane, and 12-hydroxy-5,8,10,14-eicosatetraenoic acid production by ionophore-stimulated rat serosal mast cells. Biochim. Biophys. Acta 575:185–92 113. Lewis RA, Soter NA, Diamond PT, Austen KF, Oates JA, Roberts LJ II. 1982. Prostaglandin D2 generation after activation of rat and human mast cells with anti-IgE. J. Immunol. 129:1627–31 114. Roberts LJ II, Sweetman BJ, Lewis RA, Austen KF, Oates JA. 1980. Increased production of prostaglandin D2 in patients with systemic mastocytosis. N. Engl. J. Med. 303:1400–4 115. Soter NA, Austen KF, Wasserman SI. 1979. Oral disodium cromoglycate in the treatment of systemic mastocytosis. N. Engl. J. Med. 301:465–69 116. Donaldson VH, Evans RR. 1963. A biochemical abnormality in hereditary angioneurotic edema: absence of serum inhibitor of C’1-esterase. Am. J. Med. 35:37–44 117. Austen KF, Sheffer AL. 1965. Detection of hereditary angioneurotic edema by demonstration of a profound reduction in the second component of human complement. N. Engl. J. Med. 272:649–56 118. Ruddy S, Austen KF. 1967. A stoichiometric assay for the fourth component of complement in whole human serum using EAC’1agp and functionally pure human second component. J. Immunol. 99:1162–72 119. Spaulding WB. 1955. Hereditary angioneurotic oedema in two families. Can. Med. Assoc. J. 73:181–87 120. Sheffer AL, Fearon DT, Austen KF. 1979. Clinical and biochemical effects of impeded androgen (oxymethalone) therapy of hereditary angioedema (HAE). J. Allergy Clin. Immunol. 64:275–80 121. Sheffer AL, Fearon DT, Austen KF. 1981. Clinical and biochemical effects of stanozolol therapy for hereditary angioedema. J. Allergy Clin. Immunol. 68:181–87 122. Caldwell JR, Ruddy S, Schur PH, Austen KF. 1972. Acquired C1 inhibitor deﬁciency in lymphosarcoma. Clin. Immunol. Immunopathol. 1:39 123. Geha RS, Quinti I, Austen KF, Cicardi M, Sheffer A, Rosen FS. 1985. Acquired C1inhibitor deﬁciency associated with antiidiotypic antibody to monoclonal immunoglobulins. N. Engl. J. Med. 312:534–40 124. Fearon DT. 1980. Identiﬁcation of the membrane glycoprotein that is the C3b receptor of the human erythrocyte, polymorphonuclear leukocyte, B lymphocyte, and monocyte. J. Exp. Med. 152:20–30 125. Nicholson-Weller A, Burge J, Fearon DT, Weller PF, Austen KF. 1982. Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system. J. Immunol. 129:184–89 126. Nicholson-Weller A, March JP, Rosenfeld SI, Austen KF. 1983. Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deﬁcient in the complement regulatory protein, decay accelerating factor. Proc. Natl. Acad. Sci. USA 80:5066– 70 127. Hunsicker LG, Ruddy S, Carpenter CB, Schur PH, Merrill JP, et al. 1972. Metabolism of third complement component (C3) in nephritis: role of the classical and alternate (properdin) pathways for complement activation. N. Engl. J. Med. 287:835–40 128. Daha MR, Fearon DT, Austen KF. 1976. C3 nephritic factor (C3NeF): stabilization of ﬂuid phase and cell-bound alternative pathway convertase. J. Immunol. 116:1–7 www.annualreviews.org • Doing What I Like

27

ANRV338-IY26-01

ARI

9 March 2008

1:15

Annu. Rev. Immunol. 2008.26:1-28. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

129. Daha MR, Austen KF, Fearon DT. 1977. The incorporation of C3 nephritic factor (C3NeF) into a stabilized C3 convertase, C3b, Bb (C3NeF) and its release after decay of convertase function. J. Immunol. 19:812–17 130. Daha MR, Austen KF, Fearon DT. 1978. Heterogeneity, polypeptide composition and antigenic reactivity of C3NeF. J. Immunol. 120:1389–94 131. Austen KF. 2004. Acceptance of the Kober Medal: It only gets better. J. Clin. Invest. 114:1177

28

Austen

ANRV338-IY26-02

ARI

16 February 2008

11:8

Annu. Rev. Immunol. 2008.26:29-55. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

Protein Tyrosine Phosphatases in Autoimmunity Torkel Vang, Ana V. Miletic, Yutaka Arimura, Lutz Tautz, Robert C. Rickert, and Tomas Mustelin Burnham Institute for Medical Research, La Jolla, California 92037; email: [email protected], [email protected], [email protected], [email protected], [email protected], [email protected]

Annu. Rev. Immunol. 2008. 26:29–55

Key Words

First published online as a Review in Advance on October 11, 2007

LYP, PTPN22, CD45

The Annual Review of Immunology is online at immunol.annualreviews.org This article’s doi: 10.1146/annurev.immunol.26.021607.090418 c 2008 by Annual Reviews. Copyright All rights reserved 0732-0582/08/0423-0029$20.00

Abstract Protein tyrosine phosphatases (PTPs) are important regulators of many cellular functions and a growing number of PTPs have been implicated in human disease conditions, such as developmental defects, neoplastic disorders, and immunodeﬁciency. Here, we review the involvement of PTPs in human autoimmunity. The leading examples include the allelic variant of the lymphoid tyrosine phosphatase (PTPN22), which is associated with multiple autoimmune diseases, and mutations that affect the exon-intron splicing of CD45 (PTPRC). We also ﬁnd it likely that additional PTPs are involved in susceptibility to autoimmune and inﬂammatory diseases. Finally, we discuss the possibility that PTPs regulating the immune system may serve as therapeutic targets.

29

ANRV338-IY26-02

ARI

16 February 2008

11:8

INTRODUCTION

Annu. Rev. Immunol. 2008.26:29-55. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

T regulatory (Treg) cells: specialized T cells (CD4+ CD25+ Foxp3+ ) that suppress activation of the adaptive immune system, contributing to self-tolerance and immune system homeostasis Tolerance: a state of unresponsiveness of cells of the adaptive immune system to self-antigens TCR: T cell antigen receptor

30

Over 100 years ago Paul Ehrlich ﬁrst proposed the concept of horror autotoxicus, the unthinkable possibility that an organism’s immune system would mount a response against itself. Today, we know that breakdown of self-tolerance is not uncommon and can result in serious immune-mediated damage and destruction of an individual’s own cells and tissues. There are currently over 80 diseases classiﬁed as autoimmune, affecting approximately 5% of the human population. Moreover, autoimmune disorders are among the top 10 leading causes of death and affect at least 10 million individuals in the United States alone. Autoimmunity develops through a combination of environmental and genetic factors resulting in a broad spectrum of human illnesses. Many genes identiﬁed as causing or predisposing to autoimmunity encode proteins that are involved in lymphocyte, macrophage, or dendritic cell signal transduction (1–7). Studies conducted with patient samples and with numerous animal models of autoimmune disease have demonstrated that subtle imbalances in the regulation of the activation and/or function of immune cells can precipitate the development of autoimmunity. Although several autoimmune diseases are characterized by the presence of autoantibodies produced by autoreactive B cells, genetic evidence [e.g., major histocompatibility complex (MHC) association] and animal models point to a central role of autoreactive T cells as the primary mediators of autoimmune disease. More recently, T cell subsets, such as CD4+ CD25+ Foxp3+ T regulatory (Treg) cells and T helper 17 (Th17) cells, have been implicated in the maintenance of peripheral tolerance (discussed below) and in promoting inﬂammation and tissue destruction (8, 9), respectively. Even though the etiology of each autoimmune disease is different (and often poorly understood), it appears that a common theme is a failure of immunologic tolerance, presumably by one or more lymphocyte subsets. Central tolerance is generated through mechanisms of Vang et al.

thymic negative selection wherein developing T cells with medium to high afﬁnity for tissuespeciﬁc self-antigens are deleted, thereby eliminating putative autoreactive T cells from the peripheral T cell repertoire. Alternatively, thymocytes with T cell antigen receptors (TCRs) recognizing self-antigens can develop into Treg cells, which then function in the periphery to control self-reactive T cells that have escaped clonal deletion (10). Autoimmunity may develop if TCR signal strength is altered, for example by mutations in signaling proteins, leading to decreased effectiveness of negative selection allowing for the “escape” of autoreactive T cells and/or altering the development of Treg cells in the thymus. Analogous mechanisms are operative in B cells where high-afﬁnity/avidity self-antigens induce rapid elimination (clonal deletion) of newly formed B cells in the bone marrow. Low-afﬁnity/avidity interactions, by contrast, induce an anergic state where B cells are short lived and will succumb to apoptosis in the sustained presence of self-antigen (11, 12). Peripheral tolerance encompasses a myriad of mechanisms that include clonal anergy via activation by immature dendritic cells, clonal ignorance (13), clonal exhaustion, immune privilege, and regulation by Treg cells (14–16). Of note, Treg cells generated in the periphery, so-called adaptive Tregs, through the concerted actions of autoantigen and transforming growth factor-β (TGF-β), also function to suppress T cell activation. B cells can acquire self-reactivity as a consequence of V gene hypermutation during T cell–dependent differentiation in the germinal center. In such a case, altered antigen receptor speciﬁcity could lead to the efﬁcient uptake and presentation of autoantigens as well as the generation of plasma cells producing autoantibodies. Together, the mechanisms of peripheral tolerance are aimed at preventing activation of autoreactive T cells, thereby avoiding immune responses against self and, ultimately, tissue damage. Because of the increasing prevalence of autoimmune diseases, particularly in the

ANRV338-IY26-02

ARI

16 February 2008

11:8

Annu. Rev. Immunol. 2008.26:29-55. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

industrialized world, a better understanding of the molecular mechanisms of autoimmunity would be helpful for the development of more effective and speciﬁc treatments. Signaling molecules in immune cells are promising targets for such treatments. Protein tyrosine phosphatases (PTPs) constitute a group of signaling mediators playing important regulatory roles in immune cells and may prove useful as targets for medical treatment of autoimmune disorders. This review focuses on the known roles of PTPs in autoimmunity.

PROTEIN TYROSINE PHOSPHATASES The human genome contains a total of 107 genes encoding either experimentally veriﬁed PTPs or proteins with a domain homologous to the catalytic domain of these PTPs, i.e., probable PTPs (17). The corresponding gene products of 81 of these genes are predicted to be active protein phosphatases; 13 dephosphorylate inositol phospholipids, 2 dephosphorylate mRNA, and 11 are catalytically inactive. On the basis of the primary structure of the catalytic domains, PTPs can be divided into four evolutionarily distinct classes. Class I PTPs constitute the largest group with 99 members, including 38 classical PTPs and 61 VH1-like (dual-speciﬁc) phosphatases (DSPs). The classical PTPs can further be divided into receptor and nonreceptor PTPs. There are seven different subgroups of DSPs [MAPK phosphatases (MKPs), atypical DSPs, slingshots, PRLs, CDC14s, phosphatase and tensin homologs (PTENs), and myotubularins]. Class II contains only one member [low-molecular-weight phosphotyrosine phosphatase (LMPTP)], whereas class III has three members (CDC25 A, B, and C). All the members of these three classes of PTPs use a cysteine-based catalytic mechanism. In contrast, class IV PTPs are aspartate based and are currently represented by the four Eya genes. The expression patterns of individual PTPs vary from ubiquitous to strictly tissue

speciﬁc. Most cells express 30% to 60% of the entire complement of PTPs. Neuronal and hematopoietic cells tend to express a relatively high number of PTPs. T cells, for instance, contain between 60 and 70 different PTPs, and a similar set is found in B cells (18). Several PTPs are restricted to hematopoietic cells, for example LYP (lymphoid tyrosine phosphatase, also known as PTPN22); the mouse ortholog is called PEP [proline-, glutamicacid-, serine-, and threonine-rich (PEST)domain-enriched PTP)], SHP1 (Src homology 2-domain-containing PTP 1), CD45, and HePTP (hematopoietic PTP). Of the 60–70 PTPs expressed in T cells, approximately 20 regulate signaling events between the TCR and transactivation of the interleukin-2 (IL-2) gene (18). Most of these PTPs affect TCR signaling in an inhibitory manner, but a few (such as CD45, LMPTP, and SHP2) have a positive regulatory role. The importance of PTPs in immune cell signaling has recently been extensively reviewed (18, 19), and here we focus only on the involvement of PTPs in autoimmune disease (Table 1).

PTP: protein tyrosine phosphatase LYP: lymphoid tyrosine phosphatase Proline-rich motif/domain: a motif/domain that contains the proline-rich sequence PxxP and is found in numerous signaling proteins

LYMPHOID TYROSINE PHOSPHATASE (LYP; PTPN22) AND AUTOIMMUNITY Structure and Function of LYP The human PTPN22 gene is located on chromosome 1p13.3–13.1. It encodes an 807amino acid residue protein, LYP (20), which belongs to the PEST group of nonreceptor classical class I PTPs. The two other members of this family are PTP-PEST (PTP with PEST domain, genomic designation PTPN12) and PTP-HSCF (PTP hematopoietic stem-cell fraction, genomic designation PTPN18). LYP contains an N-terminal PTP domain, a central region of unknown function, and a C-terminal portion of approximately 200 amino acids containing four proline-rich motifs termed P1-P4. P4 is part of the so-called www.annualreviews.org • Phosphatases and Autoimmunity

31

ANRV338-IY26-02

Table 1

ARI

11:8

List of PTPs involved in autoimmunity, their mechanisms and phenotypesa

Common name

Annu. Rev. Immunol. 2008.26:29-55. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

16 February 2008

Genomic designation

Synonyms

Molecular mechanism(s) for disease development

Cellular mechanism(s) for disease development

Phenotype(s)b

Gain-of-function mutation, reduced TCR signaling

Reduced negative selection in thymus? Reduced activity of Treg cells? Altered activity of other hematopoietic cells?

Associated with T1D, RA, JIA, SLE, Graves’ disease, myasthenia gravis, generalized vitiligo, Wegener’s granulomatosis

LYP (PEP in mouse)

PTPN22

PTP-PEST

PTPN12

PTPG1, PTP-P19

Mutations in CD2BP1 cause loss of PTP-PEST binding. Altered spatial regulation of PTP-PEST?

Exaggerated proliferation and inﬁltration of neutrophils. Altered activities of B or T cells?

Indirectly associated with the autoinﬂammatory condition FRA/PAPA syndrome

CD45

PTPRC

B220, Gp180, LCA, Ly5, T220

Aberrant CD45 activity due to abnormal splicing, the produced CD45RA isoforms are less likely to dimerize and hence are less likely to be autoinhibited

Altered B and/or T cell function? In mice with aberrant CD45 activity, B cells are hyperresponsive and hyperproliferative

Associated with autoimmune hepatitis and systemic sclerosis, and perhaps MS. In mice with aberrant CD45 activity, SLE-like disease and lymphoproliferative disorder are observed

IA-2

PTPRN

Islet cell antigen 512

The normal protein serves as autoantigen

Serves as autoantigen in pancreatic β-cells in T1D

T1D

Ia-2β

PTPRN2

Phogrin, PTPRP, RPTPπ

The normal protein serves as autoantigen

Serves as autoantigen in pancreatic β-cells in T1D

T1D

SHP1

PTPN6

HCP, Hcph, PTP1C, SH-PTP1

In mice, loss of expression or loss of function

In mice, inﬂammation caused by aberrant myeloid cells, B cell abnormalities

In mice, motheaten phenotype; B cells alone cause SLE-like disease

a The list includes the most relevant PTPs with regard to autoimmunity. The PTPs are listed in the order they appear in the text. Unless otherwise stated, the information given applies for humans. b Abbreviations: T1D, type 1 diabetes; RA, rheumatoid arthritis; JIA, juvenile idiopathic arthritis; SLE, systemic lupus erythematosus; FRA/PAPA, familial recurrent arthritis/pyogenic sterile arthritis, pyoderma gangrenosum, and acne syndrome; MS, multiple sclerosis.

C-terminal homology (CTH) domain, which is found in all members of the PEST group of PTPs (21, 22). LYP may also exist as an alternatively spliced form called LYP2, which has a shorter C terminus, resulting in the absence of P2, P3, and P4 (CTH domain) (20), 32

Vang et al.

although this form has not been detected by others. The mouse ortholog of LYP is called PEP (23), and it was given the genomic designation PTPN8 because initially it was not clear that LYP and PEP were species orthologs. Both LYP and PEP are expressed exclusively

Annu. Rev. Immunol. 2008.26:29-55. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-02

ARI

16 February 2008

11:8

in hematopoietic cells and share 89% identity between their PTP domains and 61% identity for their noncatalytic portions. Much of the current knowledge regarding LYP/PEP is derived from studies of PEP, and it should be stressed that data obtained with PEP may not necessarily apply completely to LYP, as these two PTPs show subtle biochemical differences in some assays (T. Vang & T. Mustelin, unpublished observations). The subcellular localization of LYP is mainly cytoplasmic, but some PEP can also be found in the nucleus (20, 24). Factors determining the localization of LYP/PEP in cells are poorly understood, but several binding partners have been identiﬁed. The best characterized is C-terminal Src kinase (Csk), which through its Src homology 3 (SH3) domain binds to the P1 region in LYP/PEP (25–27). This interaction is of relatively high stoichiometry: In mouse T cells, approximately 5% of total cellular Csk associates with 25% to 50% of total cellular PEP (25); the corresponding numbers for LYP in human cells are not known. Like other PEST group PTPs, both LYP and PEP contain a CTH domain at their C termini to which the coiled-coil domain of the cytoskeletalassociated protein proline-serine-threonine PTP-associated protein (PSTPIP) can bind (T. Vang, A.V. Miletic & T. Mustelin, unpublished observations). The human ortholog of PSTPIP is called CD2-binding protein 1 (CD2BP1). There are also reports that LYP can interact with the adaptor molecule Grb2 (28) as well as the adaptor molecule and the E3 ligase c-Cbl (20). Both PEP and LYP inhibit TCR signaling by acting immediately downstream of the TCR. Speciﬁcally, PEP has been implicated in the dephosphorylation of the positive regulatory tyrosine residue in the activation loop of the Src family kinases (SFKs) FynT (Y417) and Lck (Y394), as well as ZAP-70 (29, 30). PEP also negatively impacts TCR-induced phosphorylation of the tyrosines within the immunoreceptor tyrosinebased activation motifs (ITAMs) in CD3/ζ-

chains, but these effects may be indirect because SFKs (particularly Lck) are responsible for phosphorylation of ITAMs (29). A recent study using a substrate-trapping mutant version of LYP combined with mass spectrometry identiﬁed the following substrates: Lck (Y394), the ITAMs of CD3/ζ-chains, ZAP-70 (Y493), Vav, and valosin-containing protein (31). The ability of LYP/PEP to bind Csk may be important. Although PEP dephosphorylates the positive regulatory tyrosine in the activation loop of Lck (Y394) and FynT (Y417), Csk phosphorylates the C-terminal negative regulatory tyrosine in Lck (Y505) and FynT (Y528) (29, 30). However, recent data contradict the notion that Csk association promotes LYP/PEP function in TCR signaling. First, PEP cannot bind Csk when the latter interacts with the membrane protein Cbp/PAG (Csk-binding protein/phosphoprotein associated with glycosphingolipid-enriched membrane domains), which exclusively partitions into lipid rafts and contributes to raft targeting of Csk (32). Second, PEP is in fact not found in lipid rafts (32). Therefore, at present it is unclear how PEP targets lipid raft–resident proteins such as Lck and FynT. In comparison, in human T cells, a small fraction of LYP partitions into lipid rafts, but this partitioning is independent of Csk binding, highlighting interesting differences between PEP and LYP (T. Vang, A.V. Miletic & T. Mustelin, unpublished observations). Mice deﬁcient in PEP have normal resting T cell numbers and subpopulations but exhibit enhanced memory T cell responses (33). Furthermore, restimulation of T cells from these animals is associated with elevated and sustained TCR-induced phosphorylation of both Lck-Y394 and of ZAP-70, as well as augmented proliferation. The lack of a noticeable phenotype in naive T cells from PEP−/− mice may be due to redundancy with PTP-PEST (Y. Arimura & T. Mustelin, unpublished observations). A recent study found that microRNA-181a targets and downregulates PEP expression, resulting in elevated www.annualreviews.org • Phosphatases and Autoimmunity

C-terminal homology (CTH) domain: a proline-rich sequence found at the C terminus of PEST group PTPs Csk: C-terminal Src kinase Src homology 3 (SH3) domain: a protein domain of approximately 60 amino acids capable of binding proline-rich motifs SFK: Src family kinase

33

ANRV338-IY26-02

ARI

16 February 2008

Annu. Rev. Immunol. 2008.26:29-55. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

Single-nucleotide polymorphism (SNP): one nucleotide in a gene differs between members of a species or between paired chromosomes in an individual causing a DNA sequence variation T1D: type 1 diabetes RA: rheumatoid arthritis

11:8

Lck-Y394 phosphorylation in resting T cells and rendering the cells hyperresponsive to TCR stimulation (34). In addition to PEP, microRNA-181a also targets DUSP6, a MAP kinase-speciﬁc phosphatase, which may contribute to the downstream response (34). In accordance with these observations for PEP, acute elimination of LYP in Jurkat T cells using RNA interference resulted in increased TCR-mediated activation of nuclear factor κB (35). Although most of our knowledge about LYP/PEP is derived from studies on T cells, LYP/PEP is also expressed in all other leukocyte lineages. In PEP-deﬁcient mice, the germinal center B cell population and IgG production are elevated, but it remains to be determined whether these effects are B cell intrinsic or secondary to defects in the T cell compartment (33).

Association of the C1858T Polymorphism in PTPN22 with Autoimmune Diseases In 2004, we reported that the C1858T single-nucleotide polymorphism (SNP) in the PTPN22 gene was associated with increased risk of type 1 diabetes (T1D) in two independent populations (6). The following year, association of T1D with the T1858 allele was conﬁrmed in additional large population samples (36–38). Furthermore, the same association was found for rheumatoid arthritis (RA) (35, 39–42), juvenile idiopathic arthritis ( JIA) (42, 43), systemic lupus erythematosus (SLE) (39, 41, 44), Graves’ disease (36, 45), myasthenia gravis (46), generalized vitiligo (47), and Wegener’s granulomatosis (48). Interestingly, some diseases were demonstrated not to be associated with the T1858 allele, including multiple sclerosis (MS) (41, 43, 49), inﬂammatory bowel diseases such as Crohn’s disease (50– 52) and ulcerative colitis (52, 53), celiac disease (42, 54), primary sclerosing cholangitis (42), primary biliary cirrhosis (55), psoriasis (43), and psoriatic arthritis (43). In addition, several other disorders (such as Hashimoto’s 34

Vang et al.

thyroiditis, primary Sjogren’s syndrome, and systemic sclerosis) have been investigated with regard to involvement of the C1858T SNP, but these data are somewhat conﬂicting, and more studies are required. A recent metaanalysis conﬁrmed the association between the T1858 allele and the diseases T1D, RA, JIA, SLE, and Graves’ disease, while there was no association with MS, inﬂammatory bowel disease, psoriasis, or Addison’s disease (56). In general, PTPN22 appears to be coupled to the collection of autoimmune diseases that typically are characterized by circulating autoantibodies. On the basis of many genetic studies conducted with different populations, there is a clear geographic gradient with regard to the frequency of the disease-associated T1858 allele in Europe. Even though this allele is relatively rare in southern European populations (2% in Italy, 6% in Spain), the frequency increases northward through Europe (8% in the United Kingdom, 12% in Sweden, 15.5% in Finland). Interestingly, in African American and Asian populations, the T1858 allele is virtually absent, suggesting a northern European origin and/or selective advantage for the T1858 allele in this region. Nevertheless, an adequate number of studies have now been conducted to demonstrate that the autoimmune disease association with the T1858 allele is population independent. In addition to the C1858T SNP (rs2476601), there are numerous other SNPs in the human PTPN22 gene. An initial investigation of the role of these other SNPs in RA patients conﬁrmed that C1858T is the major disease-associated SNP in PTPN22, but also suggested minor involvement of at least one other SNP (rs3789604) (57). Subsequent studies have supported the notion that C1858T is the only SNP in PTPN22 associated with RA (58–60). Similarly, T1D patients have also been investigated with regard to other SNPs in PTPN22. Whereas one report suggested that a promoter SNP in PTPN22 (-G1123C, rs2488457) confers increased risk

Annu. Rev. Immunol. 2008.26:29-55. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-02

ARI

16 February 2008

11:8

of T1D (61), a later study could not conﬁrm this connection (62), again supporting a role for C1858T as the major T1D-associated SNP in PTPN22 (63). However, it is still possible that additional polymorphisms may be discovered for PTPN22 and that these are independently related to different and/or overlapping groups of autoimmune disorders. For instance, one recent study suggested that the C1858T SNP was not associated with psoriasis but that there was evidence for a susceptibility locus for this disease somewhere else in PTPN22 or in its vicinity (64). The involvement of PTPN22 in multiple human autoimmune disorders places this gene in company of general autoimmunity genes (such as MHC and CTLA4) that increase the risk for numerous autoimmune diseases. The MHC locus (HLA variants) has the greatest impact among these genes, followed by PTPN22 and CTLA4 susceptibility variants. For T1D, HLA contributes approximately 40% to the familial clustering, while the corresponding number for PTPN22 is about 2% (65). Even so, the odds ratio is typically ∼1.5 for the T1858 allele in T1D, and that is substantially greater than the 1.1 value calculated for the CTLA4 variant predisposing for T1D (66). Obviously, the presence of many susceptibility loci and other factors, although of little impact on their own, can add up and contribute a signiﬁcant portion to the genetic predisposition for T1D. To better predict the risk for autoimmune disorders, MHC haplotype could perhaps be combined with PTPN22 genotype and an additional set of nongenetic factors. Studies published so far have not revealed ﬁrm genetic interactions between PTPN22 and MHC in RA or T1D, but two recent reports demonstrated a strong connection between the disease-associated T1858 allele and the occurrence of anticyclic citrullinated peptide antibodies in RA (67, 68). When combined, these two factors led to an up to 350-fold increased risk of developing RA (67, 68). The concurrent presence of these two factors also predicted

the later development of RA with extremely high accuracy (68). Similarly, the T1858 allele confers increased risk for development of insulin autoantibodies (as well as of other autoantibodies) and progression from insulitis to clinical T1D (69). For other autoimmune diseases, additional factors may likewise enhance the predictive power of PTPN22 C1858T. The C1858T SNP may also potentially serve as a prognostic factor. A link between the T1858 allele and the course of disease or other variables of autoimmune disorders has been reported. For instance, the T allele is preferentially associated with rheumatoid factor (RF)-positive RA and probably not with RFnegative disease (35, 40, 70), although there are some conﬂicting results (43, 50). There also seems to be a dose-dependent effect of the T allele because two copies of this allele give a much higher risk for RF-positive RA compared with one copy alone (40). Furthermore, a recent study demonstrated that RA disease progression rate (evaluated as tissue damage) was increased in patients carrying the T allele (71). The C1858T SNP is also associated with an earlier age at RA onset (67). A similar pattern is observed for other diseases. For example, Graves’ disease will debut at a younger age in T1858/T1858 homozygous patients compared with patients with C1858/C1858 genotype, whereas heterozygous patients develop the disease at an intermediate age (72). In contrast, no correlation between the T allele and severity of Graves’ disease has been demonstrated (72). Likewise, the age at onset for T1D is lower for patients with the T1858/T1858 genotype compared with the C1858/C1858 genotype, but no difference has been seen with regard to autoantibodies (38, 73). Clearly, more work is required to clarify whether and how the C1858T SNP is associated with the clinical course and severity of autoimmune diseases. Such studies will also answer the question of whether determination of a patient’s PTPN22 genotype will be useful for evaluation of disease prognosis and treatment. www.annualreviews.org • Phosphatases and Autoimmunity

35

ANRV338-IY26-02

ARI

16 February 2008

11:8

Effects of the Disease-Associated LYP∗ W620 Allele at the Molecular Level

Annu. Rev. Immunol. 2008.26:29-55. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

The C1858T SNP changes amino acid 620 in LYP from an arginine to a tryptophan (6). We refer to the two forms as LYP∗ R620 (encoded by the C1858 allele) and LYP∗ W620 (encoded by the T1858 allele). Residue 620 is located within the P1 region, which interacts with the SH3 domain of Csk. The structure of the Csk SH3 domain with a bound peptide, including the P1 region from PEP (this peptide sequence differs only by one amino acid residue from the corresponding human sequence), was solved by NMR (27). Interestingly, the Csk SH3 domain contains two peptide recognition surfaces: the usual polyproline helix-binding surface of SH3 domains as well as a hydrophobic patch that interacts with hydrophobic residues C-terminal to the polyproline helix of the PEP P1 region. In the P1 sequence PPLPERTPESFIV, the underlined residues are responsible for the binding to the polyproline helix-binding surface, and the two C-terminal residues (I and V) mediate the interaction with the hydrophobic patch. Both of these sets of interactions contribute to the binding afﬁnity. The P1 region in the human LYP∗ R620 (PPLPVRTPESFIV, R620 in bold) differs from the mouse sequence only in residue V619, which corresponds to a glutamic acid in the mouse. However, this residue is not involved in SH3 binding, and because the amino acid sequences of the Csk SH3 domain in humans and mice are identical, it is likely that the PEP-P1/Csk-SH3 and LYP∗ R620P1/Csk-SH3 interactions are virtually identical. These structures also strongly predict that the R620W change in LYP will severely impair the formation of the LYP-Csk complex. This model was conﬁrmed experimentally, both with recombinant and endogenous proteins. Thus, although LYP∗ R620 bound strongly to the SH3 domain of Csk, the corresponding interaction between LYP∗ W620 and Csk was undetectable (5, 6, 35).

36

Vang et al.

Because of earlier reports that PEP and Csk in complex downmodulate TCR signaling in a cooperative manner (29, 30), we and others expected that the inability of LYP∗ W620 to bind Csk would result in less efﬁcient inhibition of TCR signaling by LYP∗ W620 compared with LYP∗ R620. However, all experimental data clearly demonstrated that the opposite was the case. When expressed in either Jurkat T cells or in primary human T cells, both LYP∗ R620 and LYP∗ W620 reduced TCR signaling in a dosedependent manner, but at equivalent expression levels LYP∗ W620 was consistently more potent (5). This was observed for all TCRsignaling parameters tested, including LckY394 phosphorylation, ζ-chain phosphorylation, LAT phosphorylation, intracellular calcium ﬂux, Erk1/2 phosphorylation, activation of the proximal IL-2 promoter (containing NFAT and AP1 sites), as well as IL-2 secretion. Furthermore, T cells from the peripheral blood of T1D patients with LYP∗ W620 (heterozygous T1858/C1858 genotype) secreted less IL-2 in response to TCR/CD28 costimulation than T cells from patients homozygous for LYP∗ R620. All T cell subsets were similar between the two groups, excluding the possibility that the reduced IL-2 secretion levels were due to a skewing in T cell subsets. Importantly, when T cells from the two patient groups were stimulated with a combination of phorbol ester and ionomycin to bypass proximal TCR signaling, IL-2 secretion levels were indistinguishable, demonstrating that the only differences between the two groups were present in signaling events immediately downstream of the TCR. These ﬁndings raise the question: What is/are the mechanism(s) by which LYP∗ W620 is a stronger inhibitor of TCR signaling? There are several possibilities. Although residue 620 is more than 300 amino acid residues C-terminal to the PTP domain, LYP∗ W620 is approximately 1.5-fold more active a PTP than LYP∗ R620 (5). Although this increase in activity may not seem signiﬁcant, it is consistent with our observation that

Annu. Rev. Immunol. 2008.26:29-55. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-02

ARI

16 February 2008

11:8

even a modest overexpression of LYP in T cells has a profound inhibitory effect on TCR signaling. It remains unclear, however, how a mutation so far away from the PTP domain can affect the PTP activity. In the absence of crystal structures of the two LYP variants, one can only speculate that the noncatalytic portion of LYP may play a regulatory role in the function of the catalytic domain. In support of this notion, we found that deletion of the C-terminal half of PEP resulted in a ﬁvefold increase in its PTP activity (30), suggesting an interaction between the N and C termini of PEP. Thus, it is possible that binding of ligands to the C-terminal part of LYP may affect the catalytic activity of LYP/PEP, perhaps in a manner reminiscent of the way SH2 domain ligands activate SHP1 or SHP2. Even though Csk coimmunoprecipitated with LYP∗ R620 in the above-mentioned PTP assays, no coimmunoprecipitation was seen between LYP∗ W620 and Csk (5). Theoretically, the absence of Csk binding per se could enhance the catalytic activity of LYP (in what would be the opposite type of regulation compared with SHP1). However, such a model is less likely because the two LYP variants expressed and puriﬁed from a Csk-deﬁcient system did not exhibit changes in PTP activities when increasing amounts of Csk were added (T. Vang & T. Mustelin, unpublished observations). Another possibility is that the R620W mutant confers upon the P1 region of LYP the capacity to interact more strongly with other proteins and that these proteins can induce a more catalytically preferable conformation of the LYP PTP domain. However, in the absence of any experimental evidence, all of these possibilities remain completely speculative. It is reasonable to assume that there is an equilibrium between free LYP and LYP bound to known (Csk, Grb-2, c-Cbl, PSTPIP) or unknown proteins. Any skewing of this equilibrium may have profound cellular effects. In murine T cells, 25% to 50% of total cellular PEP are bound to Csk (25) in what appears to be a high-afﬁnity interaction with a Kd =

0.8 μM (27). This is probably also true for human LYP∗ R620 and Csk. In comparison, most SH3 domain-mediated interactions have a Kd ≥ 10 μM. Thus, a disruption of the LYPCsk interaction, as is the case for LYP∗ W620, may result in a more than 1.5-fold increase in the pool of free LYP (i.e., not bound to Csk), which may bind other proteins. Such a mechanism, combined with altered ligand properties for the P1 region of LYP∗ W620, may contribute to make LYP∗ W620 a stronger inhibitor of TCR signaling compared with LYP∗ R620. We currently have some experimental evidence in support for this model (T. Vang & T. Mustelin, unpublished data). Another explanation for the augmented inhibitory effect of LYP∗ W620 on TCR signaling is altered subcellular localization, which may be tightly connected with a new set of interacting partners for LYP∗ W620 compared with LYP∗ R620. There appear to be subtle differences between the two LYP variants as evaluated by subcellular localization analyses and biochemical fractionation studies (T. Vang, A.V. Miletic & T. Mustelin, unpublished data), but more studies are required to clarify these issues. A ﬁnal explanation for the increased inhibitory potential of LYP∗ W620 is an alteration in the substrate speciﬁcities and/or substrate afﬁnities compared with LYP∗ R620, although this has yet to be experimentally tested.

Src homology 2 (SH2) domain: a protein domain of approximately 100 amino acids capable of binding tyrosine phosphorylated proteins

Effects of the Disease-Associated LYP∗ W620 at the Cellular and Systemic Level A simplistic model of autoimmunity would predict that T cells with abnormalities augmenting TCR signaling would be likely to cause disease. However, there is emerging evidence that the picture is much more complex. For instance, peripheral T cells from T1D patients are hyporesponsive rather than hyperresponsive to TCR stimulation in vitro (74). Furthermore, thymocytes from nonobese diabetic mice are also hyporesponsive with regard to TCR-mediated activation www.annualreviews.org • Phosphatases and Autoimmunity

37

ARI

16 February 2008

11:8

and proliferation (75–77). Indirect evidence also suggests that thymocyte hyporesponsiveness because of abnormalities in early TCR signaling can play a causative role in autoimmune disorders (2). Together, these ﬁndings may explain why LYP∗ W620 as a more potent inhibitor of TCR signaling can still enhance the risk for a variety of autoimmune diseases. This also explains why patients with the T1858/T1858 genotype are at a higher risk for autoimmune diseases than heterozygotes (T1858/C1858), because there is a dosedependent effect of LYP∗ W620. Another question is how LYP∗ W620 affects T cells so that autoimmunity develops. At present, there is a lack of experimental data covering this ﬁeld. However, one can envision two possibilities, and they are not mutually exclusive. First, the reduced signal transduction ability downstream of the TCR, caused by LYP∗ W620, may result in a skewing of the TCR repertoire toward generation of more autoreactive TCRs in the thymus. The resulting failure in deleting these autoreactive thymocytes by negative selection gives rise to a peripheral T cell population with enhanced ability for self-recognition. Second, the presence of LYP∗ W620 in Treg cells may inhibit signaling in these cells so that they become insufﬁcient in their ability to control the activity of autoreactive T cells in peripheral blood and tissues. Interestingly, a recent report demonstrated that PTPN22 is a direct Foxp3 target gene and that, although stimulation of Foxp3− hybridoma cells resulted in upregulation of PTPN22, this increase was not observed in Foxp3+ hybridoma cells or in ex vivo Treg cells (78). There are still several unanswered questions. All our knowledge about the cellular effects of LYP∗ W620 comes from studies on Jurkat T cells or on primary T cells (mainly CD4+ T helper cells). It is possible that LYP∗ W620 affects the development of autoimmunity through more complex mechanisms involving other immune cell lineages. The potential role for Treg cells has already been mentioned. Furthermore, some of the

Annu. Rev. Immunol. 2008.26:29-55. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-02

38

Vang et al.

autoimmune disorders associated with the T1858 allele of PTPN22 are not regarded as primarily T cell mediated. A possible role in B cell biology has been suggested by the association of the T allele with RF-positive RA but not with RF-negative RA (35, 40, 70). In contrast, in T1D, there is no signiﬁcant correlation between the T allele and the appearance or levels of autoantibodies. Also, the role of LYP in the autoantibody response may not necessarily be intrinsic to B cells but rather a consequence of altered T cell help. The uncertainty regarding which cells are phenotypically affected by LYP∗ W620 in different disease settings is further exempliﬁed by a recent study demonstrating that carriers of the T1858 allele are more prone to certain infectious diseases, such as invasive pneumococcal infections and Gram-positive empyema (79). These ﬁndings may reﬂect reduced antibody responses owing to the presence of LYP∗ W620 in B cells, or they may even be caused by the effects of LYP∗ W620 in neutrophils. To make the picture even more complex, T cells have also been shown to play an important protective role in the early phase of the immune response toward pneumococcal lung infection (80). LYP∗ W620 may also simultaneously exert effects in all these cell lineages. Moreover, because LYP is found in all leukocytes, it may play a role in the function of dendritic cells, macrophages, and natural killer cells. Certainly, more studies are required to clarify which hematopoietic cells are responsible for the different effects of LYP∗ W620. On the basis of current knowledge, we favor a model wherein LYP∗ W620 functions primarily in T cell–mediated autoimmunity by reducing TCR signaling in the thymus and/or periphery, although we are aware that effects in other immune cell lineages are likely. Our model is supported by the role T cells play during the initiation phase of the autoimmune diseases associated with the C1858T SNP. In addition, altered TCR signaling has been reported in both T1D and RA as well as in animal models of these diseases, for

ANRV338-IY26-02

ARI

16 February 2008

11:8

Annu. Rev. Immunol. 2008.26:29-55. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

instance the nonobese diabetic mouse model in which peripheral T cells exhibit hyporesponsiveness to TCR engagement in the early phase of the autoimmune disease (75, 77). Interestingly, diminished TCR signaling in developing thymocytes owing to a mutation in ZAP-70 (which serves as a substrate for LYP) also results in autoimmune disease in mice (2). Finally, the two other shared autoimmunity genes, MHC and CTLA4, play a role in antigen recognition by T cells and in negative regulation of TCR signaling, respectively.

Why Has Evolution Kept the C1858T SNP? A fascinating question is why evolution has kept the C1858T SNP. From a historical perspective, the relatively high prevalence of autoimmune disorders currently seen is a characteristic trait of modern society. Although it is evident that the T1858 allele is tightly associated with several autoimmune disorders, some of which have a relatively poor prognosis, the negative effects of the C1858T SNP on the immune system of the modern human being may have been beneﬁcial in ancient times. Interestingly, a recent report demonstrated that the T allele is associated with increased risk of atherosclerosis in men as evaluated by intima-media thickness of the carotid artery (81). A corresponding association was not found in women, but here there was an association between the T1858 allele and several risk factors for atherosclerosis, including body mass index (BMI), waist circumference, waist-to-hip ratio, and elevated serum levels of triglycerides and C-reactive protein. Like autoimmunity, atherosclerosis is a disease that has reached epidemic levels in the modern world. However, individuals with typical syndrome X characteristics (high BMI, elevated hip-to-waist ratio, big waist circumference, and elevated serum lipids) probably had a survival advantage in ancient times because they could easily gain weight when food supplies were adequate and survive for longer periods of times when food supplies were low. It was

also recently reported that carriers of the T allele are less susceptible to developing clinically signiﬁcant tuberculosis (82). Given the worldwide epidemic of tuberculosis in historical times, individuals with protection against this disease may have had a survival advantage. However, carriers of the T allele have not always had an advantage in ﬁghting infections, as carriers of the T allele are at higher risk for certain infectious diseases, such as invasive pneumococcal infections and Gram-positive empyema (79). Taken together, the data suggest that the T1858 allele has been a selection factor. Because the T allele is found in Europeans but is virtually absent in Africans and Asians, there may have been a regional advantage of the T allele. Alternatively, the T allele may have originated in northern Europe, but did not provide sufﬁcient advantage to spread worldwide.

INVOLVEMENT OF OTHER PEST GROUP PTPs IN AUTOIMMUNITY In addition to LYP, there are two other PEST group PTPs in humans, namely PTPPEST (PTPN12) and PTP-HSCF (PTPN18) (19). These PTPs share certain structural features, including an N-terminal PTP domain and a noncatalytic C-terminal portion containing different sequence motifs. All PEST group PTPs also contain a proline-rich CTH domain. However, the sequence motifs within the noncatalytic parts of the three family members differ to a certain degree, thereby providing a basis for shared as well as unique interaction partners. PTP-PEST is ubiquitously expressed, whereas PTP-HSCF is primarily found in brain, stem cells, and hematopoietic cells where expression tends to be higher in primitive cells compared with mature cells. In immune cells, there may be a certain degree of redundancy between the different PEST group PTPs ( Y. Arimura & T. Mustelin, unpublished observations), and this can explain the seemingly mild phenotype observed in PEP-deﬁcient mice (33). That www.annualreviews.org • Phosphatases and Autoimmunity

39

ANRV338-IY26-02

ARI

16 February 2008

11:8

LYP/PEP act primarily on SFKs and their substrates (CD3/ζ-chain ITAMs and ZAP70) suggests that PTP-PEST and/or PTPHSCF may target the same proteins. However, these two PTPs also seem to have unique functions. For instance, PTP-PEST dephosphorylates several cytoskeletal and focal adhesion proteins (83, 84), and PTP-HSCF may play a role in regulation of the Tec family protein tyrosine kinases (PTKs) (85). To date, there are no reports of a direct involvement of PTP-PEST or PTP-HSCF in autoimmune disease. Because LYP∗ W620 is a gain-of-function variant and there are likely redundant functions between LYP and at least PTP-PEST, one could envision that activating mutations in the PTPN12 gene could also be associated with autoimmunity. Indeed, there are several SNPs in PTPN12, but no disease association with one or more of these SNPs has been published. It is also worth mentioning that the PTPN12 gene is located on chromosome 7q in a region that exhibits evidence of linkage to inﬂammatory bowel disease (86). PTP-PEST, LYP, and PTP-HSCF may be indirectly involved in an autoimmunityrelated group of disorders called autoinﬂammatory diseases, which are conditions involving inﬂammation due to breakdown in self-tolerance but where detection of antigenspeciﬁc T cells and/or autoantibodies fails (87). The autoinﬂammatory condition familial recurrent arthritis (FRA)/PAPA syndrome (pyogenic sterile arthritis, pyoderma gangrenosum, and acne) is caused by mutations in the coiled-coil domain of a cytoskeletalassociated protein called CD2BP1 (in humans) or PSTPIP (in mice) (88). All PEST group PTPs can normally through their CTH domain bind the coiled-coil domain of CD2BP1/PSTPIP (19) (T. Vang, A.V. Miletic & T. Mustelin, unpublished data), but the disease-associated mutated form of CD2BP1 exhibits more than 90% reduction in its ability to interact with PTP-PEST (88). Most likely, the binding between disease-associated CD2BP1 and LYP/PTP-HSCF is affected

Annu. Rev. Immunol. 2008.26:29-55. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

PTK: protein tyrosine kinase

40

Vang et al.

in a similar way. C-terminal to the coiledcoil domain, CD2BP1 contains an SH3 domain that interacts with CD2, Abl, and WASP (Wiskott-Aldrich syndrome protein). Notably, the CD2/CD2BP1/PTP-PEST complex negatively affects T cell responses (89). Similarly, the CD2BP1/PTP-PEST complex also exists in other hematopoietic cells, and the disruption of this complex in neutrophils from FRA/PAPA syndrome patients is most likely the underlying cause for the accumulation of dysfunctional neutrophils in the affected organs in this disease (88). Furthermore, CD2BP1 can also bind to pyrin, which is primarily expressed in myeloid cells and is mutated in familial Mediterranean fever, another autoinﬂammatory disease (90).

CD45 AND AUTOIMMUNITY CD45 (PTPRC ) is expressed in all nucleated hematopoietic cells and consists of a highly glycosylated extracellular part, a single transmembrane domain, and a cytoplasmic portion containing two consecutive PTP domains (called D1 and D2) (91). The membrane distal D2 is catalytically inactive but necessary to support the PTP activity of the membrane proximal D1. Different isoforms of CD45 are expressed owing to alternative splicing of exons 4 (gives rise to CD45RA), 5 (gives CD45RB), and 6 (gives CD45RC); CD45RABC includes all three exons. The isoform CD45RO is a result of exons 4–6 spliced out. Different CD45 isoforms are expressed during the life span of immune cells. For instance, naive peripheral T cells primarily express CD45RB, and memory T cells predominantly express CD45RO. CD45 is extremely abundant in T cells. In fact, it constitutes 10% of all surface protein. With regard to TCR signaling, CD45 has a nonredundant positive regulatory role, which involves activation of the SFKs Lck and FynT through dephosphorylation of the C-terminal tyrosine residues Y505 and Y528, respectively (18). Consistent with this function, patients lacking CD45 suffer from severe combined immunodeﬁciency

Annu. Rev. Immunol. 2008.26:29-55. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-02

ARI

16 February 2008

11:8

(92). In the peripheral blood of these patients, B cell numbers are normal, but the T cell population is greatly diminished, and these few T cells are unresponsive to mitogenic stimulation (92). CD45-deﬁcient mice exhibit similar B and T cell phenotypes to that which is observed in patients lacking CD45 (93). Interestingly, although B cells are generated in CD45−/− mice, BCR-mediated positive and negative selection events are impaired (94). With respect to autoimmunity, autoreactive B cells are generated in CD45−/− mice as a consequence of altered threshold signaling by self-antigen, but autoantibodies are not generated because of impairments in late B cell differentiation (95). In T cells, CD45 activity is regulated at several levels, including spatiotemporal mechanisms, phosphorylation, and autoinhibition by dimerization (18) (Figure 1). Notably, CD45 splice variants with a smaller extracellular portion (CD45RO) homodimerize more easily compared with those with a larger extracellular domain (CD45RA, CD45RAB, and CD45RABC) (96). Because naive and memory T cells express different repertoires of CD45 isoforms, such a mechanism may allow differential regulation of CD45 between subsets of T cells. The molecular basis for autoinhibition by dimerization was proposed to involve a wedge-like structure in CD45, blocking the catalytic site in the other CD45 molecule of the dimer (97). This model was supported by the ﬁnding that disruption of the function of the putative wedge by mutating a key residue (from glutamic acid to arginine at position 624) abolished dimerizationinduced inhibition of CD45 (97). Moreover, knockin mice with a corresponding mutation (from glutamic acid to arginine at position 613, hereafter called CD45-E613R) in CD45 developed a phenotype characterized by a lymphoproliferative syndrome as well as autoimmune disease (such as lupus nephritis), suggesting aberrant CD45 activity in these animals (98). However, the authors found no evidence for activation of Lck in CD45E613R knockin T cells, and these cells exhib-

ited the same proliferative responses in vitro compared with wild-type T cells, indicating that the wedge model cannot explain important features of CD45 regulation in T cell biology (98). Furthermore, the crystal structure of CD45 is incompatible with the wedge model for several reasons (99). First, even when highly concentrated, the CD45 cytoplasmic region does not dimerize. Second, the intramolecular D1-D2 interaction appeared very tight and may not allow the deformation needed for an intermolecular D1-D1 interaction. And ﬁnally, the wedge region is not involved in any intermolecular interactions. At present, there is some debate regarding the role of the CD45 wedge. On the basis of the published coordinates for the CD45 structure, the researchers behind the CD45E613R knockin mice conducted a re-analysis of the CD45 structure (100). They conﬁrmed the existence of the wedge, but its involvement in CD45 regulation is still an open question. The latter study also encompassed a more thorough investigation of the CD45E613R knockin mice, demonstrating that the observed phenotype in these mice (lymphoproliferative disorder) is due to hyperresponsive B cells, whereas T cells do not play any role (100). CD45 has also been linked to several autoimmune disorders in humans. The C77G SNP in PTPRC (the gene encoding CD45) was initially reported to associate with MS (101). This mutation disrupts an exonic splicing silencer for exon 4 in the PTPRC gene, with the consequence that high levels of exon 4–encoded CD45 isoforms are produced (i.e., CD45RA) in all cell lineages (102). As already mentioned, CD45RA isoforms do not dimerize as easily as CD45RO. Therefore, according to the model for autoinhibition by dimerization, patients with the C77G mutation should have aberrant CD45 activity in cells that normally only would express CD45RO, thereby suggesting a mechanism for disease development. However, subsequent studies have not been able to conﬁrm the association between the C77G SNP and MS (103, 104). www.annualreviews.org • Phosphatases and Autoimmunity

41

ANRV338-IY26-02

ARI

16 February 2008

11:8

a Lipid raft

FN SH3

D1 SH2

Lck

D2 Phosphorylated Y505

b

CD45RABC

Annu. Rev. Immunol. 2008.26:29-55. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

CD45R0

More active

Less active

More active

CD45RABC

c

Less active

d

CD45R0

CD45AP

Fodrin

CK2, PKC, Csk

Figure 1 CD45 activity in T cells is regulated at several levels. (a) While Lck preferentially partitions into lipid rafts, approximately 95% of all CD45 molecules are excluded from rafts. Therefore, it remains controversial whether CD45-mediated activation of Lck (through dephosphorylation of Y505 in Lck) occurs within lipid rafts or outside. (b) CD45 activity is inhibited by homodimerization. Because CD45 isoforms with smaller extracellular portions (such as CD45RO) tend to homodimerize more easily compared with isoforms with larger extracellular parts (such as CD45RABC), the PTP activity of the former will be lower. (c) CD45 isoform–speciﬁc interactions with other transmembrane proteins may affect the juxtapositioning of CD45 with its substrates (such as Lck). (d ) CD45 may be regulated by numerous other proteins, for instance by binding CD45-associated protein (CD45AP) or fodrin (a cytoskeletal protein). CD45 can also be phosphorylated by casein kinase 2 (CK2), protein kinase C (PKC), and Csk. FN, ﬁbronectin-like; SH, Src homology.

Nevertheless, there seems to be a connection between the C77G mutation and increased risk for systemic sclerosis (105) and autoimmune hepatitis (106), but not with T1D or 42

Vang et al.

Graves’ disease (107). Another mutation in PTPRC, C59A, has also been reported to interfere with alternative splicing in several members of a MS multiplex family (i.e., a large

ANRV338-IY26-02

ARI

16 February 2008

11:8

family in which several members have MS), leading to CD45RA expression on memory T cells (108).

Annu. Rev. Immunol. 2008.26:29-55. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

INVOLVEMENT OF OTHER TRANSMEMBRANE PTPs IN AUTOIMMUNITY In addition to CD45, there are 20 other transmembrane (or receptor-like) PTPs in humans. A large number of these are found in leukocytes, and there is currently limited evidence for an involvement of these PTPs in autoimmune diseases. Because LYP most likely is associated with autoimmunity through regulation of SFKs, we can speculate that transmembrane PTPs acting on SFKs are connected as well; in addition to CD45, those would include PTPα and PTPε. Interestingly, two other transmembrane PTPs have been implicated as major autoantigens in pancreatic β-cells in connection with T1D, namely PTPRN (IA-2) and PTPRN2 (IA-2β, phogrin) (109, 110).

SHP1 AND SHP2 IN AUTOIMMUNITY SHP1 (PTPN6 ) consists of two N-terminal SH2 domains, a PTP domain, and a Cterminal tail. It is expressed in hematopoietic cells and is a well-characterized PTP that negatively regulates immune cell activation through recruitment to immunoreceptor tyrosine-based inhibition motifs (ITIMs) in signaling molecules. SHP1 catalyzes dephosphorylation of ITAMs, the Syk family kinases Syk and ZAP-70, SLP-76, PI3 kinase, and Vav, to name a few. The association of SHP1 with autoimmunity was ﬁrst revealed in motheaten and viable motheaten mice in which mutations cause abnormal splicing of SHP1 transcripts. As a result, motheaten mice lack SHP1 protein, while viable motheaten mice express catalytically defective protein (111, 112). Motheaten and viable motheaten mice (hereafter referred to as motheaten mice) display aggressive hyperinﬂammation characterized by hyperactive T

and B cells, as well as myeloid and phagocytic cells. Moreover, motheathen mice express autoantibodies and display glomerulonephritis (113). Notably, SHP1-deﬁcient mice show a two- to threefold increase in the percentage of Treg cells, potentially explaining the minimal contribution of T cells compared with myeloid cells in the inﬂammation displayed by motheaten mice (114). Importantly, conditional deletion of SHP1 in B cells causes autoantibody production and glomerulonephritis, demonstrating that these hallmarks of the motheaten phenotype are B cell intrinsic and not secondary to dysregulated macrophage activity (19). Polymorphisms in the gene encoding SHP1 (PTPN6 ) have been found in humans, but unlike PTPN22, no association with autoimmune disease has been found. Of note, it has been reported that some SLE patients express lower levels of SHP1 as well as of CD45 (115). It is also worth mentioning that SHP1 mutations have been demonstrated in numerous hematological diseases, including myelodysplastic syndrome (116), and in certain types of lymphoma (117). SHP2 (PTPN11) is widely expressed and, similar to SHP1, contains two SH2 domains, a PTP domain, and a C-terminal tail. SHP2 is generally a positive regulator of signaling through receptor tyrosine kinases and cytokine receptors as well as of integrin signaling. TCR signaling is also positively regulated by SHP2 (118). Our preliminary ﬁndings from the analysis of mice lacking SHP2 in B cells indicates that it has a minimal role in BCR signaling but negatively regulates germinal center formation (R.V. Kolla, F. Princen, D. Ostertag, G.S. Feng & R.C. Rickert, in preparation). Although there are no reports of involvement of SHP2 in autoimmune diseases, mutations in the gene encoding SHP2 (PTPN11) are associated with Noonan syndrome (NS), a disorder characterized by multiple developmental defects, and LEOPARD (multiple lentigines, electrocardiographic-conduction abnormalities, ocular hypertelorism, pulmonary stenosis, abnormal genitalia, retardation of growth, www.annualreviews.org • Phosphatases and Autoimmunity

43

ANRV338-IY26-02

ARI

16 February 2008

11:8

and sensorineural deafness) syndrome, a rare, autosomal dominant disorder that shares many of the clinical features of NS. Interestingly, mutations in NS code for gainof-function proteins, whereas LEOPARD syndrome is characterized by a dominantnegative, loss-of-function SHP2 protein (119). Mutations in PTPN11 have also been associated with Helicobacter pylori-induced gastric atrophy/cancer (120) and in numerous myeloid leukemias and lymphomas (121, 122). Annu. Rev. Immunol. 2008.26:29-55. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

OTHER NONRECEPTOR PTPs IN AUTOIMMUNITY Although no PTPs aside from the aforementioned PTPs have been linked to autoimmunity, it is conceivable that mutations altering the function of other PTPs, perhaps combined with genetic or environmental factors, may precipitate autoimmune disease. Gene knockout studies are beginning to reveal the roles of many nonreceptor PTPs in lymphocyte development and activation. Mice lacking expression of TCPTP (PTPN2) show defects in T and B cell development and activation (123), which may be caused by its function in regulation of STAT1 signaling in the nucleus (124). In contrast, PTPH1 (PTPN3)deﬁcient mice displayed no discernible defects in TCR signaling despite a proposed function of PTPH1 in the dephosphorylation of ITAMs (125). Like PTPH1, PTPMEG1 (PTPN4) and HePTP (PTPN7) have been implicated in negative regulation of TCR signaling (126). Although HePTP expression is induced by IL-2, suggesting that it may be involved in contraction of T cell responses following activation (127–129), and HePTP functions to regulate Erk and p38, the knockout mice displayed no noticeable phenotype aside from a two- to ﬁvefold increase in Erk1/2 and p38 activation. PTPD1 (PTPN21) reportedly associates with Tec kinases and functions to activate Tec and Itk (130). The precise function of PTP-BAS (FAP-1, PTPN13) in T lymphocytes is unknown; however, it may function to regulate 44

Vang et al.

apoptosis of developing or activated T cells as it associates with, and inhibits, cell surface expression of FAS (131). Future studies, including SNP analysis, may reveal roles for these and other PTPs in human autoimmunity.

DUSPs IN AUTOIMMUNITY—FOCUS ON MAPK PHOSPHATASES MAPK (mitogen-activated protein kinase) phosphatases (MKPs, a subgroup of the DUSPs) are important for regulation of MAPKs, which can function either to amplify or to attenuate innate immune responses and are essential for lymphocyte development, activation, and homeostasis (132). In this regard, at least 10 MKPs are expressed in developing thymocytes, and MKP expression levels vary at different stages of T cell development and can be modulated by TCR signaling (133). Together, these data suggest that MKPs potentially play an important role in thymic selection and/or Treg cell development. Gene-targeting studies have revealed the speciﬁcity, redundancy, and cross talk between MKPs in both innate and adaptive immunity (134). MKP-1 (DUSP1) is a phosphatase that primarily regulates activation of p38 and JNK1/2, with little effect on Erk1/2 activation (135). Mice lacking MKP-1 revealed a critical function for MKP-1 in regulation of innate immune responses to microbial components via a negative-feedback loop that includes p38 and JNK. Moreover, compared with wild-type controls, MKP-1-deﬁcient mice showed increased severity of collagen-induced arthritis resulting from increased levels of systemic TNF-α and IL-6, as well as high levels of antitype II collagen antibodies, suggesting that in addition to an important function in innate immune cells, MKP-1 may also be critical in regulation of T and/or B lymphocytes. Although a MKP-1 SNP has been identiﬁed in ovarian cancer to date, no associations have been made between MKP-1 and autoimmune disease (136).

Annu. Rev. Immunol. 2008.26:29-55. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-02

ARI

16 February 2008

11:8

PAC-1 (DUSP2) expression is induced in T cells in response to antigen receptor stimulation and functions to negatively regulate JNK activation but augments both p38 and ERK1/2 activation. Unlike MKP-1−/− mice, PAC-1-deﬁcient mice show decreased inﬂammatory cytokine production by myeloid cells following stimulation with Toll-like receptor ligands (137). PAC-1−/− CD4+ T cells have diminished proliferation and cytokine production, indicating that PAC-1 is a positive regulator of both innate and adaptive immune cell signaling. In addition, PAC-1 is a direct transcriptional target of p53 in response to cell stress, suggesting that PAC-1 may be important in cellular apoptosis and growth suppression, both of which are critical in contraction of immune responses and are aberrant in many autoimmune disorders (138). MKP-5 (DUSP10) is constitutively expressed in naive CD4+ T cells and is downregulated following TCR activation (139). Following mitogenic stimulation, MKP-5deﬁcient T cells display diminished proliferation but increased cytokine production by both Th1 and Th2 cells, as well as increased IFN-γ and TNF-α production by cytolytic CD8+ T cells in vitro. Notably, although primary responses to lymphocytic choriomeningitis virus infection were similar between wild-type and MKP-5−/− mice, upon secondary infection, MKP-5−/− CD4+ and CD8+ T cells had increased cytokine production. Thus, MKP5 functions to diminish T cell responses, thereby preventing excessive, and potentially harmful, T cell activation during an immune response. Several other MKPs have been implicated in regulation of T cell activation and homeostasis; however, the precise function and association with autoimmunity of these MKPs are not yet established. For example, MKP-2 (DUSP4), MKP-3 (DUSP6 ), hVH3 (DUSP5), MKP-7 (DUSP16 ), and LMWDSP20 (DUSP18) are all implicated in regulation of ERK1/2 and/or JNK1/2 activation (140–143). VHR (DUSP3) is a negative regulator of TCR signaling whose activation is,

in part, mediated by ZAP-70 phosphorylation (144), and expression of VHR controls cell cycle, differentiation, or senescence through regulation of ERK1/2 and JNK1/2 MAPKs (145). VHX (DUSP22), like VHR, is implicated in negative regulation of TCR signaling (146), whereas MKP-6 (DUSP14) associates with CD28 and negatively regulates CD28 signals (147). Interestingly, MGC1136 (DUSP24) is upregulated in tolerant T cells and thus could function in induction or maintenance of lymphocyte tolerance (148).

POTENTIAL FOR TREATMENT OF AUTOIMMUNE DISORDERS USING PTP INHIBITORS? PTPs have recently been implicated in an increasing number of human diseases. That, in turn, has begun to elicit a growing interest in PTPs as drug targets and the development of potent and selective PTP inhibitors (149). The spark that truly ignited the quest for PTP inhibitors with great market potential was the paper reporting the PTP1B knockout mouse, which indicated that PTP1B acts as a negative regulator of insulin signaling (123). Inhibition of PTP1B would conceivably alleviate insulin resistance in type 2 diabetes and would improve the effects of insulin on both glucose balance and fatty acid metabolism. Although the enthusiasm for PTP inhibitors was initially dampened by the notions that PTPs were less speciﬁc than, for example, PTKs and that the structure of the active site of PTPs did not allow for the generation of selective inhibitors, it has now become increasingly clear that PTPs indeed have unique, nonredundant, important functions and a great deal of speciﬁcity in vivo. The question of how selective small-molecule inhibitors can be developed is perhaps not quite resolved, but many promising examples have been published. The crystallization of many PTPs has revealed that the surface topology surrounding the catalytic pocket of each PTP has numerous unique features that can be utilized for the rational structure-based design of highly selective www.annualreviews.org • Phosphatases and Autoimmunity

45

ARI

16 February 2008

11:8

compounds (149). The highest afﬁnity and the most selective inhibitors reported so far have been those that interact with several such distinct surface features. These features together with new techniques in PTP inhibitor design (150) provide great opportunities for the development of sufﬁciently selective and efﬁcient PTP inhibitors. In our view, speciﬁc criteria have to be fulﬁlled for selecting a particular PTP as a drug target for the treatment of autoimmune disease. First, the target enzyme should have higher activity in autoimmunity than in healthy subjects. Second, the protein should be expressed mostly in immune cells. Third, the biological function of the PTP should be reasonably well known. At this point, only LYP fulﬁlls these criteria, although the biology of this PTP is only partially understood. Most importantly, the activity of the disease-associated LYP∗ W620 enzyme is

Annu. Rev. Immunol. 2008.26:29-55. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-02

about 50% higher than the nonmutated form (LYP∗ R620) (5), and the protein is found only in hematopoietic cells (20). Thus, in theory, a selective small-molecule LYP inhibitor could eliminate the effects of LYP∗ W620 on TCR signaling. Such an inhibitor would need to reduce the activity of LYP∗ W620 only to a certain extent. Under these conditions, TCR signaling should be corrected to normal levels, and the autoimmunity-inducing process precipitated by LYP∗ W620 would be neutralized. However, because of the complexity and plasticity of the immune system and the many different roles that signaling molecules can have, the timing and strategy of such a treatment would need to be carefully evaluated. Once suitable small-molecule PTP inhibitors with viable pharmacological properties have been developed, their potential for treatment of autoimmune disorders can be experimentally evaluated.

DISCLOSURE STATEMENT The authors are not aware of any biases that might be perceived as affecting the objectivity of this review.

ACKNOWLEDGMENTS This work was supported by grants from the U.S. National Institutes of Health (AI53585 to T.M.), the Oxnard Foundation (to T.M.), and the Norwegian Cancer Society (to T.V.). We apologize to all colleagues whose papers we could not cite owing to space constraints.

NOTE ADDED IN PROOF A recent study demonstrated no association between Graves’ disease and individual SNPs in PTPN12, but some of these SNPs were associated with ophthalmopathy and/or interacted with a previously associated thyrotropin hormone receptor SNP (151). Another study has shown that mice with speciﬁc deletion of SHP1 in B cells develop an SLE-like condition, suggesting that SHP1 deﬁciency in B cells alone is sufﬁcient to cause autoimmune disease (152).

LITERATURE CITED 1. Rose NR, Mackay IR. 1999. The Autoimmune Diseases. London: Academic 2. Sakaguchi N, Takahashi T, Hata H, Nomura T, Tagami T, et al. 2003. Altered thymic T-cell selection due to a mutation of the ZAP-70 gene causes autoimmune arthritis in mice. Nature 426:454–60 3. Sakaguchi S, Sakaguchi N, Yoshitomi H, Hata H, Takahashi T, Nomura T. 2006. Spontaneous development of autoimmune arthritis due to genetic anomaly of T cell signal transduction: Part 1. Semin. Immunol. 18:199–206 46

Vang et al.

Annu. Rev. Immunol. 2008.26:29-55. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-02

ARI

16 February 2008

11:8

4. Chang TT, Kuchroo VK, Sharpe AH. 2002. Role of the B7-CD28/CTLA-4 pathway in autoimmune disease. Curr. Dir. Autoimmun. 5:113–30 5. Vang T, Congia M, Macis MD, Musumeci L, Orru V, et al. 2005. Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. Nat. Genet. 37:1317–19 6. Bottini N, Musumeci L, Alonso A, Rahmouni S, Nika K, et al. 2004. A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat. Genet. 36:337–38 7. Bottini N, Vang T, Cucca F, Mustelin T. 2006. Role of PTPN22 in type 1 diabetes and other autoimmune diseases. Semin. Immunol. 18:207–13 8. Nomura T, Sakaguchi S. 2007. Foxp3 and Aire in thymus-generated Treg cells: a link in self-tolerance. Nat. Immunol. 8:333–34 9. Zheng Y, Danilenko DM, Valdez P, Kasman I, Eastham-Anderson J, et al. 2007. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inﬂammation and acanthosis. Nature 445:648–51 10. Jordan MS, Boesteanu A, Reed AJ, Petrone AL, Holenbeck AE, et al. 2001. Thymic selection of CD4+ CD25+ regulatory T cells induced by an agonist self-peptide. Nat. Immunol. 2:301–6 11. Gauld SB, Benschop RJ, Merrell KT, Cambier JC. 2005. Maintenance of B cell anergy requires constant antigen receptor occupancy and signaling. Nat. Immunol. 6:1160–67 12. Grimaldi CM, Hicks R, Diamond B. 2005. B cell selection and susceptibility to autoimmunity. J. Immunol. 174:1775–81 13. Stockinger B. 1999. T lymphocyte tolerance: from thymic deletion to peripheral control mechanisms. Adv. Immunol. 71:229–65 14. Fontenot JD, Gavin MA, Rudensky AY. 2003. Foxp3 programs the development and function of CD4+ CD25+ regulatory T cells. Nat. Immunol. 4:330–36 15. Fontenot JD, Rasmussen JP, Williams LM, Dooley JL, Farr AG, Rudensky AY. 2005. Regulatory T cell lineage speciﬁcation by the forkhead transcription factor foxp3. Immunity 22:329–41 16. Kim JM, Rasmussen JP, Rudensky AY. 2007. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat. Immunol. 8:191–97 17. Alonso A, Sasin J, Bottini N, Friedberg I, Friedberg I, et al. 2004. Protein tyrosine phosphatases in the human genome. Cell 117:699–711 18. Mustelin T, Vang T, Bottini N. 2005. Protein tyrosine phosphatases and the immune response. Nat. Rev. Immunol. 5:43–57 19. Pao LI, Badour K, Siminovitch KA, Neel BG. 2007. Nonreceptor protein-tyrosine phosphatases in immune cell signaling. Annu. Rev. Immunol. 25:473–523 20. Cohen S, Dadi H, Shaoul E, Sharfe N, Roifman CM. 1999. Cloning and characterization of a lymphoid-speciﬁc, inducible human protein tyrosine phosphatase, Lyp. Blood 93:2013–24 21. Spencer S, Dowbenko D, Cheng J, Li W, Brush J, et al. 1997. PSTPIP: a tyrosine phosphorylated cleavage furrow-associated protein that is a substrate for a PEST tyrosine phosphatase. J. Cell Biol. 138:845–60 22. Cote JF, Chung PL, Theberge JF, Halle M, Spencer S, et al. 2002. PSTPIP is a substrate of PTP-PEST and serves as a scaffold guiding PTP-PEST toward a speciﬁc dephosphorylation of WASP. J. Biol. Chem. 277:2973–86 23. Matthews RJ, Bowne DB, Flores E, Thomas ML. 1992. Characterization of hematopoietic intracellular protein tyrosine phosphatases: description of a phosphatase containing an SH2 domain and another enriched in proline-, glutamic acid-, serine-, and threoninerich sequences. Mol. Cell. Biol. 12:2396–405 www.annualreviews.org • Phosphatases and Autoimmunity

47

ARI

16 February 2008

11:8

24. Gjorloff-Wingren A, Saxena M, Han S, Wang X, Alonso A, et al. 2000. Subcellular localization of intracellular protein tyrosine phosphatases in T cells. Eur. J. Immunol. 30:2412–21 25. Cloutier JF, Veillette A. 1996. Association of inhibitory tyrosine protein kinase p50csk with protein tyrosine phosphatase PEP in T cells and other hemopoietic cells. EMBO J. 15:4909–18 26. Gregorieff A, Cloutier JF, Veillette A. 1998. Sequence requirements for association of protein-tyrosine phosphatase PEP with the Src homology 3 domain of inhibitory tyrosine protein kinase p50(csk). J. Biol. Chem. 273:13217–22 27. Ghose R, Shekhtman A, Goger MJ, Ji H, Cowburn D. 2001. A novel, speciﬁc interaction involving the Csk SH3 domain and its natural ligand. Nat. Struct. Biol. 8:998–1004 28. Hill RJ, Zozulya S, Lu YL, Ward K, Gishizky M, Jallal B. 2002. The lymphoid protein tyrosine phosphatase Lyp interacts with the adaptor molecule Grb2 and functions as a negative regulator of T-cell activation. Exp. Hematol. 30:237–44 29. Cloutier JF, Veillette A. 1999. Cooperative inhibition of T-cell antigen receptor signaling by a complex between a kinase and a phosphatase. J. Exp. Med. 189:111–21 30. Gjorloff-Wingren A, Saxena M, Williams S, Hammi D, Mustelin T. 1999. Characterization of TCR-induced receptor-proximal signaling events negatively regulated by the protein tyrosine phosphatase PEP. Eur. J. Immunol. 29:3845–54 31. Wu J, Katrekar A, Honigberg LA, Smith AM, Conn MT, et al. 2006. Identiﬁcation of substrates of human protein-tyrosine phosphatase PTPN22. J. Biol. Chem. 281:11002–10 32. Davidson D, Bakinowski M, Thomas ML, Horejsi V, Veillette A. 2003. Phosphorylationdependent regulation of T-cell activation by PAG/Cbp, a lipid raft-associated transmembrane adaptor. Mol. Cell. Biol. 23:2017–28 33. Hasegawa K, Martin F, Huang G, Tumas D, Diehl L, Chan AC. 2004. PEST domainenriched tyrosine phosphatase (PEP) regulation of effector/memory T cells. Science 303:685–89 34. Li QJ, Chau J, Ebert PJ, Sylvester G, Min H, et al. 2007. miR-181a is an intrinsic modulator of T cell sensitivity and selection. Cell 129:147–61 35. Begovich AB, Carlton VE, Honigberg LA, Schrodi SJ, Chokkalingam AP, et al. 2004. A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am. J. Hum. Genet. 75:330–37 36. Smyth D, Cooper JD, Collins JE, Heward JM, Franklyn JA, et al. 2004. Replication of an association between the lymphoid tyrosine phosphatase locus (LYP/PTPN22) with type 1 diabetes, and evidence for its role as a general autoimmunity locus. Diabetes 53:3020–23 37. Onengut-Gumuscu S, Ewens KG, Spielman RS, Concannon P. 2004. A functional polymorphism (1858C/T) in the PTPN22 gene is linked and associated with type I diabetes in multiplex families. Genes Immun. 5:678–80 38. Ladner MB, Bottini N, Valdes AM, Noble JA. 2005. Association of the single nucleotide polymorphism C1858T of the PTPN22 gene with type 1 diabetes. Hum. Immunol. 66:60– 64 39. Orozco G, Eerligh P, Sanchez E, Zhernakova S, Roep BO, et al. 2005. Analysis of a functional BTNL2 polymorphism in type 1 diabetes, rheumatoid arthritis, and systemic lupus erythematosus. Hum. Immunol. 66:1235–41 40. Lee AT, Li W, Liew A, Bombardier C, Weisman M, et al. 2005. The PTPN22 R620W polymorphism associates with RF positive rheumatoid arthritis in a dose-dependent manner but not with HLA-SE status. Genes Immun. 6:129–33

Annu. Rev. Immunol. 2008.26:29-55. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-02

48

Vang et al.

Annu. Rev. Immunol. 2008.26:29-55. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-02

ARI

16 February 2008

11:8

41. Criswell LA, Pfeiffer KA, Lum RF, Gonzales B, Novitzke J, et al. 2005. Analysis of families in the multiple autoimmune disease genetics consortium (MADGC) collection: the PTPN22 620W allele associates with multiple autoimmune phenotypes. Am. J. Hum. Genet. 76:561–71 42. Viken MK, Amundsen SS, Kvien TK, Boberg KM, Gilboe IM, et al. 2005. Association analysis of the 1858C>T polymorphism in the PTPN22 gene in juvenile idiopathic arthritis and other autoimmune diseases. Genes Immun. 6:271–73 43. Hinks A, Barton A, John S, Bruce I, Hawkins C, et al. 2005. Association between the PTPN22 gene and rheumatoid arthritis and juvenile idiopathic arthritis in a UK population: further support that PTPN22 is an autoimmunity gene. Arthritis Rheum. 52:1694–99 44. Kyogoku C, Langefeld CD, Ortmann WA, Lee A, Selby S, et al. 2004. Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE. Am. J. Hum. Genet. 75:504–7 45. Velaga MR, Wilson V, Jennings CE, Owen CJ, Herington S, et al. 2004. The codon 620 tryptophan allele of the lymphoid tyrosine phosphatase (LYP) gene is a major determinant of Graves’ disease. J. Clin. Endocrinol. Metab. 89:5862–65 46. Vandiedonck C, Capdevielle C, Giraud M, Krumeich S, Jais JP, et al. 2006. Association of the PTPN22∗ R620W polymorphism with autoimmune myasthenia gravis. Ann. Neurol. 59:404–7 47. Canton I, Akhtar S, Gavalas NG, Gawkrodger DJ, Blomhoff A, et al. 2005. A singlenucleotide polymorphism in the gene encoding lymphoid protein tyrosine phosphatase (PTPN22) confers susceptibility to generalised vitiligo. Genes Immun. 6:584–87 48. Jagiello P, Aries P, Arning L, Wagenleiter SE, Csernok E, et al. 2005. The PTPN22 620W allele is a risk factor for Wegener’s granulomatosis. Arthritis Rheum. 52:4039–43 49. Begovich AB, Caillier SJ, Alexander HC, Penko JM, Hauser SL, et al. 2005. The R620W polymorphism of the protein tyrosine phosphatase PTPN22 is not associated with multiple sclerosis. Am. J. Hum. Genet. 76:184–87 50. van Oene M, Wintle RF, Liu X, Yazdanpanah M, Gu X, et al. 2005. Association of the lymphoid tyrosine phosphatase R620W variant with rheumatoid arthritis, but not Crohn’s disease, in Canadian populations. Arthritis Rheum. 52:1993–98 51. Wagenleiter SE, Klein W, Griga T, Schmiegel W, Epplen JT, Jagiello P. 2005. A casecontrol study of tyrosine phosphatase (PTPN22) conﬁrms the lack of association with Crohn’s disease. Int. J. Immunogenet. 32:323–24 52. Martin MC, Oliver J, Urcelay E, Orozco G, Gomez-Garcia M, et al. 2005. The functional genetic variation in the PTPN22 gene has a negligible effect on the susceptibility to develop inﬂammatory bowel disease. Tissue Antigens 66:314–17 53. Prescott NJ, Fisher SA, Onnie C, Pattni R, Steer S, et al. 2005. A general autoimmunity gene (PTPN22) is not associated with inﬂammatory bowel disease in a British population. Tissue Antigens 66:318–20 54. Rueda B, Nunez C, Orozco G, Lopez-Nevot MA, de la Concha EG, et al. 2005. C1858T functional variant of PTPN22 gene is not associated with celiac disease genetic predisposition. Hum. Immunol. 66:848–52 55. Milkiewicz P, Pache I, Buwaneswaran H, Liu X, Coltescu C, et al. 2006. The PTPN22 1858T variant is not associated with primary biliary cirrhosis. Tissue Antigens 67:434–37 56. Lee YH, Rho YH, Choi SJ, Ji JD, Song GG, et al. 2007. The PTPN22 C1858T functional polymorphism and autoimmune diseases—a meta-analysis. Rheumatology 46:49–56 57. Carlton VE, Hu X, Chokkalingam AP, Schrodi SJ, Brandon R, et al. 2005. PTPN22 genetic variation: evidence for multiple variants associated with rheumatoid arthritis. Am. J. Hum. Genet. 77:567–81 www.annualreviews.org • Phosphatases and Autoimmunity

49

ARI

16 February 2008

11:8

58. Wesoly J, Hu X, Thabet MM, Chang M, Uh H, et al. 2007. The 620W allele is the PTPN22 genetic variant conferring susceptibility to RA in a Dutch population. Rheumatology 46:617–21 59. Ikari K, Momohara S, Inoue E, Tomatsu T, Hara M, et al. 2006. Haplotype analysis revealed no association between the PTPN22 gene and RA in a Japanese population. Rheumatology 45:1345–48 60. Hinks A, Eyre S, Barton A, Thomson W, Worthington J. 2007. Investigation of genetic variation across the protein tyrosine phosphatase gene in patients with rheumatoid arthritis in the UK. Ann. Rheum. Dis. 66:683–86 61. Kawasaki E, Awata T, Ikegami H, Kobayashi T, Maruyama T, et al. 2006. Systematic search for single nucleotide polymorphisms in a lymphoid tyrosine phosphatase gene (PTPN22): association between a promoter polymorphism and type 1 diabetes in Asian populations. Am. J. Med. Genet. Part A 140:586–93 62. Cinek O, Hradsky O, Ahmedov G, Slavcev A, Kolouskova S, et al. 2007. No independent role of the –1123 G>C and +2740 A>G variants in the association of PTPN22 with type 1 diabetes and juvenile idiopathic arthritis in two Caucasian populations. Diabetes Res. Clin. Pract. 76:297–303 63. Onengut-Gumuscu S, Buckner JH, Concannon P. 2006. A haplotype-based analysis of the PTPN22 locus in type 1 diabetes. Diabetes 55:2883–89 64. Huffmeier U, Steffens M, Burkhardt H, Lascorz J, Schurmeier-Horst F, et al. 2006. Evidence for susceptibility determinant(s) to psoriasis vulgaris in or near PTPN22 in German patients. J. Med. Genet. 43:517–22 65. Concannon P, Erlich HA, Julier C, Morahan G, Nerup J, et al. 2005. Type 1 diabetes: evidence for susceptibility loci from four genome-wide linkage scans in 1435 multiplex families. Diabetes 54:2995–3001 66. Ueda H, Howson JM, Esposito L, Heward J, Snook H, et al. 2003. Association of the Tcell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423:506–11 67. Plenge RM, Padyukov L, Remmers EF, Purcell S, Lee AT, et al. 2005. Replication of putative candidate-gene associations with rheumatoid arthritis in >4000 samples from North America and Sweden: association of susceptibility with PTPN22, CTLA4, and PADI4. Am. J. Hum. Genet. 77:1044–60 68. Johansson M, Arlestig L, Hallmans G, Rantapaa-Dahlqvist S. 2006. PTPN22 polymorphism and anticyclic citrullinated peptide antibodies in combination strongly predicts future onset of rheumatoid arthritis and has a speciﬁcity of 100% for the disease. Arthritis Res. Ther. 8:R19 69. Hermann R, Lipponen K, Kiviniemi M, Kakko T, Veijola R, et al. 2006. Lymphoid tyrosine phosphatase (LYP/PTPN22) Arg620Trp variant regulates insulin autoimmunity and progression to type 1 diabetes. Diabetologia 49:1198–208 70. Dieude P, Garnier S, Michou L, Petit-Teixeira E, Glikmans E, et al. 2005. Rheumatoid arthritis seropositive for the rheumatoid factor is linked to the protein tyrosine phosphatase nonreceptor 22-620W allele. Arthritis Res. Ther. 7:R1200–7 71. Lie BA, Viken MK, Odegard S, van der Heijden D, Landewe R, et al. 2007. Associations between the PTPN22 1858C>T polymorphism and radiographic joint destruction in patients with rheumatoid arthritis: results from a 10-year longitudinal study. Ann. Rheum. Dis. 66:1604–9 72. Skorka A, Bednarczuk T, Bar-Andziak E, Nauman J, Ploski R. 2005. Lymphoid tyrosine phosphatase (PTPN22/LYP) variant and Graves’ disease in a Polish population: association and gene dose-dependent correlation with age of onset. Clin. Endocrinol. 62:679–82

Annu. Rev. Immunol. 2008.26:29-55. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-02

50

Vang et al.

Annu. Rev. Immunol. 2008.26:29-55. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-02

ARI

16 February 2008

11:8

73. Fedetz M, Matesanz F, Caro-Maldonado A, Smirnov II, Chvorostinka VN, et al. 2006. The 1858T PTPN22 gene variant contributes to a genetic risk of type 1 diabetes in a Ukrainian population. Tissue Antigens 67:430–33 74. Salojin KV, Zhang J, Madrenas J, Delovitch TL. 1998. T-cell anergy and altered T-cell receptor signaling: effects on autoimmune disease. Immunol. Today 19:468–73 75. Salojin K, Zhang J, Cameron M, Gill B, Arreaza G, et al. 1997. Impaired plasma membrane targeting of Grb2-murine son of sevenless (mSOS) complex and differential activation of the Fyn-T cell receptor (TCR)-zeta-Cbl pathway mediate T cell hyporesponsiveness in autoimmune nonobese diabetic mice. J. Exp. Med. 186:887–97 76. Delovitch TL, Singh B. 1997 . The nonobese diabetic mouse as a model of autoimmune diabetes: immune dysregulation gets the NOD. Immunity 7:727–38. Erratum. 1998. Immunity 8(4):531 77. Rapoport MJ, Lazarus AH, Jaramillo A, Speck E, Delovitch TL. 1993. Thymic T cell anergy in autoimmune nonobese diabetic mice is mediated by deﬁcient T cell receptor regulation of the pathway of p21ras activation. J. Exp. Med. 177:1221–26 78. Marson A, Kretschmer K, Frampton GM, Jacobsen ES, Polansky JK, et al. 2007. Foxp3 occupancy and regulation of key target genes during T-cell stimulation. Nature 445:931– 35 79. Chapman SJ, Khor CC, Vannberg FO, Maskell NA, Davies CW, et al. 2006. PTPN22 and invasive bacterial disease. Nat. Genet. 38:499–500 80. Kadioglu A, Andrew PW. 2004. The innate immune response to pneumococcal lung infection: the untold story. Trends Immunol. 25:143–49 81. Pertovaara M, Raitala A, Juonala M, Kahonen M, Lehtimaki T, et al. 2007. Autoimmunity and atherosclerosis: functional polymorphism of PTPN22 is associated with phenotypes related to the risk of atherosclerosis. The Cardiovascular Risk in Young Finns Study. Clin. Exp. Immunol. 147:265–69 82. Gomez LM, Anaya JM, Martin J. 2005. Genetic inﬂuence of PTPN22 R620W polymorphism in tuberculosis. Hum. Immunol. 66:1242–47 83. Cote JF, Charest A, Wagner J, Tremblay ML. 1998. Combination of gene targeting and substrate trapping to identify substrates of protein tyrosine phosphatases using PTPPEST as a model. Biochemistry 37:13128–37 84. Garton AJ, Flint AJ, Tonks NK. 1996. Identiﬁcation of p130(cas) as a substrate for the cytosolic protein tyrosine phosphatase PTP-PEST. Mol. Cell. Biol. 16:6408–18 85. Aoki N, Ueno S, Mano H, Yamasaki S, Shiota M, et al. 2004. Mutual regulation of protein-tyrosine phosphatase 20 and protein-tyrosine kinase Tec activities by tyrosine phosphorylation and dephosphorylation. J. Biol. Chem. 279:10765–75 86. Satsangi J, Parkes M, Louis E, Hashimoto L, Kato N, et al. 1996. Two stage genomewide search in inﬂammatory bowel disease provides evidence for susceptibility loci on chromosomes 3, 7 and 12. Nat. Genet. 14:199–202 87. Galon J, Aksentijevich I, McDermott MF, O’Shea JJ, Kastner DL. 2000. TNFRSF1A mutations and autoinﬂammatory syndromes. Curr. Opin. Immunol. 12:479–86 88. Wise CA, Gillum JD, Seidman CE, Lindor NM, Veile R, et al. 2002. Mutations in CD2BP1 disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinﬂammatory disorder. Hum. Mol. Genet. 11:961–69 89. Yang H, Reinherz EL. 2006. CD2BP1 modulates CD2-dependent T cell activation via linkage to protein tyrosine phosphatase (PTP)-PEST. J. Immunol. 176:5898–907 90. Shoham NG, Centola M, Mansﬁeld E, Hull KM, Wood G, et al. 2003. Pyrin binds the PSTPIP1/CD2BP1 protein, deﬁning familial Mediterranean fever and PAPA syndrome as disorders in the same pathway. Proc. Natl. Acad. Sci. USA 100:13501–6 www.annualreviews.org • Phosphatases and Autoimmunity

51

ARI

16 February 2008

11:8

91. Hermiston ML, Xu Z, Weiss A. 2003. CD45: a critical regulator of signaling thresholds in immune cells. Annu. Rev. Immunol. 21:107–37 92. Kung C, Pingel JT, Heikinheimo M, Klemola T, Varkila K, et al. 2000. Mutations in the tyrosine phosphatase CD45 gene in a child with severe combined immunodeﬁciency disease. Nat. Med. 6:343–45 93. Kishihara K, Penninger J, Wallace VA, Kundig TM, Kawai K, et al. 1993. Normal B lymphocyte development but impaired T cell maturation in CD45-exon6 protein tyrosine phosphatase-deﬁcient mice. Cell 74:143–56 94. Cyster JG, Healy JI, Kishihara K, Mak TW, Thomas ML, Goodnow CC. 1996. Regulation of B-lymphocyte negative and positive selection by tyrosine phosphatase CD45. Nature 381:325–28 95. Huntington ND, Xu Y, Puthalakath H, Light A, Willis SN, et al. 2006. CD45 links the B cell receptor with cell survival and is required for the persistence of germinal centers. Nat. Immunol. 7:190–98 96. Xu Z, Weiss A. 2002. Negative regulation of CD45 by differential homodimerization of the alternatively spliced isoforms. Nat. Immunol. 3:764–71 97. Majeti R, Bilwes AM, Noel JP, Hunter T, Weiss A. 1998. Dimerization-induced inhibition of receptor protein tyrosine phosphatase function through an inhibitory wedge. Science 279:88–91 98. Majeti R, Xu Z, Parslow TG, Olson JL, Daikh DI, et al. 2000. An inactivating point mutation in the inhibitory wedge of CD45 causes lymphoproliferation and autoimmunity. Cell 103:1059–70 99. Nam HJ, Poy F, Saito H, Frederick CA. 2005. Structural basis for the function and regulation of the receptor protein tyrosine phosphatase CD45. J. Exp. Med. 201:441–52. Erratum. 2005. J. Exp. Med. 201(6):1019 100. Hermiston ML, Tan AL, Gupta VA, Majeti R, Weiss A. 2005. The juxtamembrane wedge negatively regulates CD45 function in B cells. Immunity 23:635–47 101. Jacobsen M, Schweer D, Ziegler A, Gaber R, Schock S, et al. 2000. A point mutation in PTPRC is associated with the development of multiple sclerosis. Nat. Genet. 26:495–99 102. Lynch KW, Weiss A. 2001. A CD45 polymorphism associated with multiple sclerosis disrupts an exonic splicing silencer. J. Biol. Chem. 276:24341–47 103. Barcellos LF, Caillier S, Dragone L, Elder M, Vittinghoff E, et al. 2001. PTPRC (CD45) is not associated with the development of multiple sclerosis in U.S. patients. Nat. Genet. 29:23–24 104. Vorechovsky I, Kralovicova J, Tchilian E, Masterman T, Zhang Z, et al. 2001. Does 77C–>G in PTPRC modify autoimmune disorders linked to the major histocompatibility locus? Nat. Genet. 29:22–23 105. Schwinzer R, Witte T, Hundrieser J, Ehlers S, Momot T, et al. 2003. Enhanced frequency of a PTPRC (CD45) exon A mutation (77C–>G) in systemic sclerosis. Genes Immun. 4:168–69 106. Vogel A, Strassburg CP, Manns MP. 2003. 77 C/G mutation in the tyrosine phosphatase CD45 gene and autoimmune hepatitis: evidence for a genetic link. Genes Immun. 4:79–81 107. Wood JP, Pani MA, Bieda K, Meyer G, Usadel KH, Badenhoop K. 2002. A recently described polymorphism in the CD28 gene on chromosome 2q33 is not associated with susceptibility to type 1 diabetes. Eur. J. Immunogenet. 29:347–49 108. Jacobsen M, Hoffmann S, Cepok S, Stei S, Ziegler A, et al. 2002. A novel mutation in PTPRC interferes with splicing and alters the structure of the human CD45 molecule. Immunogenetics 54:158–63

Annu. Rev. Immunol. 2008.26:29-55. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-02

52

Vang et al.

Annu. Rev. Immunol. 2008.26:29-55. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-02

ARI

16 February 2008

11:8

109. Passini N, Larigan JD, Genovese S, Appella E, Sinigaglia F, Rogge L. 1995. The 37/40kDa autoantigen in insulin-dependent diabetes mellitus is the putative tyrosine phosphatase IA-2. Proc. Natl. Acad. Sci. USA 92:9412–16 110. Lu J, Li Q, Xie H, Chen ZJ, Borovitskaya AE, et al. 1996. Identiﬁcation of a second transmembrane protein tyrosine phosphatase, IA-2beta, as an autoantigen in insulindependent diabetes mellitus: precursor of the 37-kDa tryptic fragment. Proc. Natl. Acad. Sci. USA 93:2307–11 111. Shultz LD, Schweitzer PA, Rajan TV, Yi T, Ihle JN, et al. 1993. Mutations at the murine motheaten locus are within the hematopoietic cell protein-tyrosine phosphatase (Hcph) gene. Cell 73:1445–54 112. Tsui HW, Siminovitch KA, de Souza L, Tsui FW. 1993. Motheaten and viable motheaten mice have mutations in the haematopoietic cell phosphatase gene. Nat. Genet. 4:124–29 113. Westhoff CM, Whittier A, Kathol S, McHugh J, Zajicek C, et al. 1997. DNA-binding antibodies from viable motheaten mutant mice: implications for B cell tolerance. J. Immunol. 159:3024–33 114. Carter JD, Calabrese GM, Naganuma M, Lorenz U. 2005. Deﬁciency of the Src homology region 2 domain-containing phosphatase 1 (SHP-1) causes enrichment of CD4+ CD25+ regulatory T cells. J. Immunol. 174:6627–38 115. Huck S, Le Corre R, Youinou P, Zouali M. 2001. Expression of B cell receptor-associated signaling molecules in human lupus. Autoimmunity 33:213–24 116. Mena-Duran AV, Togo SH, Bazhenova L, Cervera J, Bethel K, et al. 2005. SHP1 expression in bone marrow biopsies of myelodysplastic syndrome patients: a new prognostic factor. Br. J. Haematol. 129:791–94 117. Zhang Q, Wang HY, Marzec M, Raghunath PN, Nagasawa T, Wasik MA. 2005. STAT3and DNA methyltransferase 1-mediated epigenetic silencing of SHP-1 tyrosine phosphatase tumor suppressor gene in malignant T lymphocytes. Proc. Natl. Acad. Sci. USA 102:6948–53 118. Nguyen TV, Ke Y, Zhang EE, Feng GS. 2006. Conditional deletion of Shp2 tyrosine phosphatase in thymocytes suppresses both pre-TCR and TCR signals. J. Immunol. 177:5990–96 119. Kontaridis MI, Swanson KD, David FS, Barford D, Neel BG. 2006. PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects. J. Biol. Chem. 281:6785–92 120. Kawai S, Goto Y, Ito LS, Oba-Shinjo SM, Uno M, et al. 2006. Signiﬁcant association between PTPN11 polymorphism and gastric atrophy among Japanese Brazilians. Gastric Cancer 9:277–83 121. Chan RJ, Feng GS. 2007. PTPN11 is the ﬁrst identiﬁed proto-oncogene that encodes a tyrosine phosphatase. Blood 109:862–67 122. Mohi MG, Neel BG. 2007. The role of Shp2 (PTPN11) in cancer. Curr. Opin. Genet. Dev. 17:23–30 123. You-Ten KE, Muise ES, Itie A, Michaliszyn E, Wagner J, et al. 1997. Impaired bone marrow microenvironment and immune function in T cell protein tyrosine phosphatasedeﬁcient mice. J. Exp. Med. 186:683–93 124. Zhu W, Mustelin T, David M. 2002. Arginine methylation of STAT1 regulates its dephosphorylation by T cell protein tyrosine phosphatase. J. Biol. Chem. 277:35787–90 125. Bauler TJ, Hughes ED, Arimura Y, Mustelin T, Saunders TL, King PD. 2007. Normal TCR signal transduction in mice that lack catalytically active PTPN3 protein tyrosine phosphatase. J. Immunol. 178:3680–87 www.annualreviews.org • Phosphatases and Autoimmunity

53

ARI

16 February 2008

11:8

126. Han S, Williams S, Mustelin T. 2000. Cytoskeletal protein tyrosine phosphatase PTPH1 reduces T cell antigen receptor signaling. Eur. J. Immunol. 30:1318–25 127. Saxena M, Williams S, Brockdorff J, Gilman J, Mustelin T. 1999. Inhibition of T cell signaling by mitogen-activated protein kinase-targeted hematopoietic tyrosine phosphatase (HePTP). J. Biol. Chem. 274:11693–700 128. Saxena M, Williams S, Gilman J, Mustelin T. 1998. Negative regulation of T cell antigen receptor signal transduction by hematopoietic tyrosine phosphatase (HePTP). J. Biol. Chem. 273:15340–44 129. Adachi M, Torigoe T, Sekiya M, Minami Y, Taniguchi T, et al. 1995. IL-2-induced gene expression of protein-tyrosine phosphatase LC-PTP requires acidic and serine-rich regions within IL-2 receptor beta chain. FEBS Lett. 372:113–18 130. Jui HY, Tseng RJ, Wen X, Fang HI, Huang LM, et al. 2000. Protein-tyrosine phosphatase D1, a potential regulator and effector for Tec family kinases. J. Biol. Chem. 275:41124–32 131. Ivanov VN, Lopez Bergami P, Maulit G, Sato TA, Sassoon D, Ronai Z. 2003. FAP-1 association with Fas (Apo-1) inhibits Fas expression on the cell surface. Mol. Cell. Biol. 23:3623–35 132. Liu Y, Shepherd EG, Nelin LD. 2007. MAPK phosphatases—regulating the immune response. Nat. Rev. Immunol. 7:202–12 133. Tanzola MB, Kersh GJ. 2006. The dual speciﬁcity phosphatase transcriptome of the murine thymus. Mol. Immunol. 43:754–62 134. Owens DM, Keyse SM. 2007. Differential regulation of MAP kinase signalling by dualspeciﬁcity protein phosphatases. Oncogene 26:3203–13 135. Abraham SM, Clark AR. 2006. Dual-speciﬁcity phosphatase 1: a critical regulator of innate immune responses. Biochem. Soc. Trans. 34:1018–23 136. Suzuki C, Unoki M, Nakamura Y. 2001. Identiﬁcation and allelic frequencies of novel single-nucleotide polymorphisms in the DUSP1 and BTG1 genes. J. Hum. Genet. 46:155– 57 137. Jeffrey KL, Brummer T, Rolph MS, Liu SM, Callejas NA, et al. 2006. Positive regulation of immune cell function and inﬂammatory responses by phosphatase PAC-1. Nat. Immunol. 7:274–83 138. Yin Y, Liu YX, Jin YJ, Hall EJ, Barrett JC. 2003. PAC1 phosphatase is a transcription target of p53 in signalling apoptosis and growth suppression. Nature 422:527–31 139. Zhang Y, Blattman JN, Kennedy NJ, Duong J, Nguyen T, et al. 2004. Regulation of innate and adaptive immune responses by MAP kinase phosphatase 5. Nature 430:793–97 140. Kovanen PE, Rosenwald A, Fu J, Hurt EM, Lam LT, et al. 2003. Analysis of gamma c-family cytokine target genes. Identiﬁcation of dual-speciﬁcity phosphatase 5 (DUSP5) as a regulator of mitogen-activated protein kinase activity in interleukin-2 signaling. J. Biol. Chem. 278:5205–13 141. Mandl M, Slack DN, Keyse SM. 2005. Speciﬁc inactivation and nuclear anchoring of extracellular signal-regulated kinase 2 by the inducible dual-speciﬁcity protein phosphatase DUSP5. Mol. Cell. Biol. 25:1830–45 142. Masuda K, Shima H, Katagiri C, Kikuchi K. 2003. Activation of ERK induces phosphorylation of MAPK phosphatase-7, a JNK speciﬁc phosphatase, at Ser-446. J. Biol. Chem. 278:32448–56 143. Wu Q, Huang S, Sun Y, Gu S, Lu F, et al. 2006. Dual speciﬁcity phosphatase 18, interacting with SAPK, dephosphorylates SAPK and inhibits SAPK/JNK signal pathway in vivo. Front. Biosci. 11:2714–24 144. Alonso A, Rahmouni S, Williams S, van Stipdonk M, Jaroszewski L, et al. 2003. Tyrosine phosphorylation of VHR phosphatase by ZAP-70. Nat. Immunol. 4:44–48

Annu. Rev. Immunol. 2008.26:29-55. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-02

54

Vang et al.

Annu. Rev. Immunol. 2008.26:29-55. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-02

ARI

16 February 2008

11:8

145. Cerignoli F, Rahmouni S, Ronai Z, Mustelin T. 2006. Regulation of MAP kinases by the VHR dual-speciﬁc phosphatase: implications for cell growth and differentiation. Cell Cycle 5:2210–15 146. Alonso A, Merlo JJ, Na S, Kholod N, Jaroszewski L, et al. 2002. Inhibition of T cell antigen receptor signaling by VHR-related MKPX (VHX), a new dual speciﬁcity phosphatase related to VH1 related (VHR). J. Biol. Chem. 277:5524–28 147. Marti F, Krause A, Post NH, Lyddane C, Dupont B, et al. 2001. Negative-feedback regulation of CD28 costimulation by a novel mitogen-activated protein kinase phosphatase, MKP6. J. Immunol. 166:197–206 148. Perco P, Blaha P, Kainz A, Mayer B, Hauser P, et al. 2006. Molecular signature of mice T lymphocytes following tolerance induction by allogeneic BMT and CD40-CD40L costimulation blockade. Transpl. Int. 19:146–57 149. Tautz L, Pellecchia M, Mustelin T. 2006. Targeting the PTPome in human disease. Expert Opin. Ther. Targets 10:157–77 150. Pellecchia M, Becattini B, Crowell KJ, Fattorusso R, Forino M, et al. 2004. NMR-based techniques in the hit identiﬁcation and optimisation processes. Expert Opin. Ther. Targets 8:597–611 151. Syed AA, Simmonds MJ, Brand OJ, Franklyn JA, Gough SC, Heward JM. 2007. Preliminary evidence for interaction of PTPN12 polymorphism with TSHR genotype and association with Graves’ ophthalmopathy. Clin. Endocrinol. In press 152. Pao LI, Lam KP, Henderson JM, Kutok JL, Alimzhanov M, et al. 2007. B cell-speciﬁc deletion of protein-tyrosine phosphatase Shp1 promotes B-1a cell development and causes systemic autoimmunity. Immunity 27:35–48

www.annualreviews.org • Phosphatases and Autoimmunity

55

AR338-FM

ARI

12 January 2008

18:11

Annual Review of Immunology

Annu. Rev. Immunol. 2008.26:29-55. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

Contents

Volume 26, 2008

Frontispiece K. Frank Austen p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p x Doing What I Like K. Frank Austen p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p1 Protein Tyrosine Phosphatases in Autoimmunity Torkel Vang, Ana V. Miletic, Yutaka Arimura, Lutz Tautz, Robert C. Rickert, and Tomas Mustelin p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p 29 Interleukin-21: Basic Biology and Implications for Cancer and Autoimmunity Rosanne Spolski and Warren J. Leonard p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p 57 Forward Genetic Dissection of Immunity to Infection in the Mouse S.M. Vidal, D. Malo, J.-F. Marquis, and P. Gros p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p 81 Regulation and Functions of Blimp-1 in T and B Lymphocytes Gislâine Martins and Kathryn Calame p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p133 Evolutionarily Conserved Amino Acids That Control TCR-MHC Interaction Philippa Marrack, James P. Scott-Browne, Shaodong Dai, Laurent Gapin, and John W. Kappler p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p171 T Cell Trafﬁcking in Allergic Asthma: The Ins and Outs Benjamin D. Medoff, Seddon Y. Thomas, and Andrew D. Luster p p p p p p p p p p p p p p p p p p p p p205 The Actin Cytoskeleton in T Cell Activation Janis K. Burkhardt, Esteban Carrizosa, and Meredith H. Shaffer p p p p p p p p p p p p p p p p p p p p233 Mechanism and Regulation of Class Switch Recombination Janet Stavnezer, Jeroen E.J. Guikema, and Carol E. Schrader p p p p p p p p p p p p p p p p p p p p p p p261 Migration of Dendritic Cell Subsets and their Precursors Gwendalyn J. Randolph, Jordi Ochando, and Santiago Partida-Sánchez p p p p p p p p p p p p p293

v

AR338-FM

ARI

12 January 2008

18:11

The APOBEC3 Cytidine Deaminases: An Innate Defensive Network Opposing Exogenous Retroviruses and Endogenous Retroelements Ya-Lin Chiu and Warner C. Greene p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p317 Thymus Organogenesis Hans-Reimer Rodewald p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p355 Death by a Thousand Cuts: Granzyme Pathways of Programmed Cell Death Dipanjan Chowdhury and Judy Lieberman p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p389 Annu. Rev. Immunol. 2008.26:29-55. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

Monocyte-Mediated Defense Against Microbial Pathogens Natalya V. Serbina, Ting Jia, Tobias M. Hohl, and Eric G. Pamer p p p p p p p p p p p p p p p p p p p421 The Biology of Interleukin-2 Thomas R. Malek p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p453 The Biochemistry of Somatic Hypermutation Jonathan U. Peled, Fei Li Kuang, Maria D. Iglesias-Ussel, Sergio Roa, Susan L. Kalis, Myron F. Goodman, and Matthew D. Scharff p p p p p p p p p p p p p p p p p p p p p481 Anti-Inﬂammatory Actions of Intravenous Immunoglobulin Falk Nimmerjahn and Jeffrey V. Ravetch p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p513 The IRF Family Transcription Factors in Immunity and Oncogenesis Tomohiko Tamura, Hideyuki Yanai, David Savitsky, and Tadatsugu Taniguchi p p p p p535 Choreography of Cell Motility and Interaction Dynamics Imaged by Two-Photon Microscopy in Lymphoid Organs Michael D. Cahalan and Ian Parker p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p585 Development of Secondary Lymphoid Organs Troy D. Randall, Damian M. Carragher, and Javier Rangel-Moreno p p p p p p p p p p p p p p p p627 Immunity to Citrullinated Proteins in Rheumatoid Arthritis Lars Klareskog, Johan Rönnelid, Karin Lundberg, Leonid Padyukov, and Lars Alfredsson p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p651 PD-1 and Its Ligands in Tolerance and Immunity Mary E. Keir, Manish J. Butte, Gordon J. Freeman, and Arlene H. Sharpe p p p p p p p p677 The Master Switch: The Role of Mast Cells in Autoimmunity and Tolerance Blayne A. Sayed, Alison Christy, Mary R. Quirion, and Melissa A. Brown p p p p p p p p p p705 T Follicular Helper (TFH ) Cells in Normal and Dysregulated Immune Responses Cecile King, Stuart G. Tangye, and Charles R. Mackay p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p741

vi

Contents

ANRV338-IY26-03

ARI

16 February 2008

11:18

Annu. Rev. Immunol. 2008.26:57-79. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

Interleukin-21: Basic Biology and Implications for Cancer and Autoimmunity∗ Rosanne Spolski and Warren J. Leonard Laboratory of Molecular Immunology, National Heart, Lung, and Blood Institute, Bethesda, Maryland 20892-1674; email: [email protected], [email protected]

Annu. Rev. Immunol. 2008. 26:57–79

Key Words

First published online as a Review in Advance on November 8, 2007

cytokine, Blimp-1, plasma cell differentiation, Stat3, antitumor, adaptive immunity, innate immunity

The Annual Review of Immunology is online at immunol.annualreviews.org This article’s doi: 10.1146/annurev.immunol.26.021607.090316 c 2008 by Annual Reviews. Copyright All rights reserved 0732-0582/08/0423-0057$20.00 ∗ The U.S. Government has the right to retain a nonexclusive, royalty-free license in and to any copyright covering this paper.

Abstract Interleukin-21 (IL-21), a potent immunomodulatory four-α-helicalbundle type I cytokine, is produced by NKT and CD4+ T cells and has pleiotropic effects on both innate and adaptive immune responses. These actions include positive effects such as enhanced proliferation of lymphoid cells, increased cytotoxicity of CD8+ T cells and natural killer (NK) cells, and differentiation of B cells into plasma cells. Conversely, IL-21 also has direct inhibitory effects on the antigen-presenting function of dendritic cells and can be proapoptotic for B cells and NK cells. IL-21 is also produced by Th17 cells and is a critical regulator of Th17 development. The regulatory activity of IL-21 is modulated by the differentiation state of its target cells as well as by other cytokines or costimulatory molecules. IL-21 has potent antitumor activity but is also associated with the development of autoimmune disease. IL-21 transcription is dependent on a calcium signal and NFAT sites, and IL-21 requires Stat3 for its signaling. The key to harnessing the power of IL-21 will depend on better understanding its range of biological actions, its mechanism of action, and the molecular basis of regulation of expression of IL-21 and its receptor.

57

ANRV338-IY26-03

ARI

16 February 2008

11:18

INTRODUCTION

Annu. Rev. Immunol. 2008.26:57-79. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

Immune responses to foreign antigens have evolved to comprise the two interacting arms of cellular and humoral responses: the innate and adaptive immune systems. The cellular components of the innate immune system, including dendritic cells (DCs), natural killer (NK) cells, macrophages, and granulocytes, possess pattern recognition receptors capable of detecting conserved structural components of pathogens whose recognition then initiates immediate responses. One of the key responses of the innate immune system is the production of cytokines that then regulate the antigen-driven differentiation of the adaptive immune system, composed of naive lymphoid B and T cells, which then results in the development of antigen-speciﬁc effector responses. Cytokines produced by the innate immune system as well as cytokines produced by activated T cells drive the expansion and effector functions of the adaptive immune response as well as the downregulation of responses once the offending agent has been eradicated. Much attention has been paid over the past several decades to the array of cytokines that are produced by these immune cells and play such an important role in the ampliﬁcation and control of responses to pathogens. Understanding the mechanisms involved in the production and function of these cytokines is key to predicting and employing clinical strategies for controlling these responses. One of the most important families of cytokines includes the type I four-α-helicalbundle cytokines, which comprise many of the interleukins and colony-stimulating factors as well as a range of other molecules such as erythropoietin, growth hormone, and prolactin. In one subfamily of this set of cytokines, the receptors share the common cytokine receptor γ chain, γc , which is mutated in humans with X-linked severe combined immunodeﬁciency (XSCID) (1), a disease characterized by the absence of T and NK cells but the presence of nonfunctional B cells. This set of cytokines includes IL-2, IL-4, IL-7, IL-9, IL-

58

Spolski

·

Leonard

15, and IL-21, the most recently discovered member (2, 3) (see Figure 1). The IL-21 receptor was discovered in 2000 as an orphan receptor, ﬁrst denoted as NILR for novel interleukin receptor and now as IL21R (4, 5). IL-21 was cloned as the ligand for this novel receptor (5) and was ﬁrst observed to be produced by CD4+ T cells and to modulate the proliferation and effector function of other lymphoid cells. Subsequently, however, IL-21 was observed to act on multiple nonlymphoid lineages as well and to be produced by innate immune natural killer T (NKT) cells and the more recently identiﬁed Th17 lineage. This has expanded our understanding of the broad potential roles for this cytokine in the development and control of immune responses. Moreover, IL-21 has been shown to have strong antitumor action via its effects on both NK and CD8+ T cells and also has been identiﬁed as a key component in the development of autoimmune disease. The dissection of these beneﬁcial and pathogenic effects of IL-21 has begun to offer a new appreciation of the complexity of the interaction between the innate and adaptive immune responses.

IL-21 Receptor and Ligand Structure The IL-21 receptor (IL-21R) was ﬁrst discovered by genomic and cDNA sequencing projects as an open reading frame that putatively encoded a type I cytokine receptor (4, 5). Its predicted amino acid sequence was most related to the IL-2 receptor β chain, and like IL-2Rβ, IL-21R appeared to be lymphohematopoietic restricted. Moreover, IL-21R was located immediately downstream of IL4Rα on human chromosome 16 (4). Thus, IL-21R was clearly related to the γc family of cytokines. Indeed, when identiﬁed, the ligand for this novel type I receptor was most similar to IL-2, IL-4, and IL-15 (5). The functional receptor for IL-21 is IL-21R + γc (6, 7). IL-21R was observed initially to be expressed on T, B, and NK cells (4, 8).

ANRV338-IY26-03

ARI

16 February 2008

11:18

IL-2Rα α

IL-15Rα IL-4

IL-2 Mutant

γc

IL-2Rβ

γc

IL-4R

IL-7

IL-21

γc

IL-21R

γc

IL-7R

IL-9

γc

IL-9R

IL-15

γc

IL-2Rβ

γc

XSCID

• B cell proliferation • Th2 T cell development

• B cell development in mice

Annu. Rev. Immunol. 2008.26:57-79. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

• Ig class switch • T cell proliferation • Antigen-induced cell death • Boosting of cytolitic activity of NK cells • Development of Treg cells

• NK cell development • CD8+ memory T cell homeostasis

• T cell development in humans and mice

• Memory T cell development

• Mucus production • Mast cell proliferation

• Comitogen for T cell proliferation • Cooperative expansion of CD8+ T cells • Antitumor agent • Plasma cell differentiation • Implicated in autoimmunity (see Fig. 4)

Figure 1 Cytokine receptors containing the common cytokine receptor γ chain (γc ). The IL-21 receptor is a member of a family of receptors that share γc . In addition to γc , each of these receptors has one or more distinctive receptor components. Mutations in γc result in X-linked severe combined immunodeﬁciency (XSCID); the severity of this disease results from defective signaling through all these receptors.

Expression on B cells was the highest, even on resting cells, with constitutive expression in a number of cell lines (4, 8). Low-level IL-21R expression on T cells was also observed but was signiﬁcantly increased following T cell receptor (TCR) stimulation (4, 8). Interestingly, like that of IL-2Rβ, expression of IL21R was also augmented in cells transformed with HTLV-I (4). Recently, the three-dimensional structure of human IL-21 has been solved by heteronuclear NMR spectroscopy (9). As anticipated, it is a typical up-up-down-down four-α-helicalbundle cytokine. A segment of the molecule involving helix C that is important for receptor binding is relatively unstable, and stabilization of this region in a human IL-21 analog results in a tenfold increase in biological potency (9).

The Molecular Basis for IL-21 Signaling Like other type I cytokines, IL-21 signals via the Jak-STAT pathway (see Figure 2). Analogous to IL-2, IL-4, IL-7, IL-9, and IL-15, Jak1 and Jak3 are the Janus family tyrosine kinases that are activated by IL-21 (4, 6, 7). IL21 can activate Stat1, Stat3, and both Stat5a and Stat5b (10, 11). However, the activation of Stat5a and Stat5b is relatively weak and transient, whereas the activation of Stat3 is the most sustained. Stat3 appears to be the most important STAT protein for IL-21 signaling. Indeed, there is defective signaling to IL-21 in T cells that lack expression of Stat3 (11). The IL-21R cytoplasmic domain contains six tyrosine residues. One of these, Tyr 510, is phosphorylated and serves as a critical docking site for both Stat1 and Stat3. On the basis

www.annualreviews.org • Interleukin-21

59

ANRV338-IY26-03

ARI

16 February 2008

11:18

IL-21

IL-21

Ras SOS Grb2

γc

Pl 3-K

SOCS 1+3

Raf

Y510

Akt

Jak3 Jak1

Stat3

IL-21R

Annu. Rev. Immunol. 2008.26:57-79. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

MEK

Stat3

p70S6K

Stat3

CYTOPLASM

MAPK

Gene expression NUCLEUS

Co

Co TF

TF

Basal POL complex TATA

Stat3

TF

GAS

Basal complex TATA

POL

IL-21 target genes Granzyme A, Bcl-3, Jak3, granzyme B

Figure 2 Signaling pathways for the IL-21 receptor (IL-21R). Upon IL-21 binding, Jak1 and Jak3, which interact with IL-21R and γc , respectively, are activated and then phosphorylate Stat3 and Stat1 and weakly phosphorylate Stat5 proteins. This leads to STAT dimerization and translocation to the nucleus, with subsequent binding to target gene regulatory elements. A critical tyrosine in the IL-21R cytoplasmic domain (Y510) is primarily responsible for the docking of Stat1 and Stat3. Five other cytoplasmic tyrosines are not shown. Additionally, ligand binding to the IL-21R can lead to activation of the MAP kinase (MAPK) and the PI 3-kinase (PI 3-K) pathways. Target genes activated by IL-21 have been identiﬁed, but the involvement of each of these signaling pathways in the regulation of these genes remains to be determined. Co, co-activator; POL, RNA polymerase; TF, transcription factor.

of analysis using the chemical inhibitors wortmannin and PD98059, we can conclude that PI 3-kinase and MAP kinase pathways also contribute to IL-21 signaling. These different signaling pathways may function in distinct phases of lineage development and function.

IL-21 Ligand and Receptor Regulation IL-21 is produced by CD4+ T cells (5) as well as by NKT cells (13). Although the genes encoding IL-21 and IL-2 are adjacent to each other, the regulation of these genes is signiﬁ60

Spolski

·

Leonard

cantly distinct. Both cytokines can be induced in CD4+ T cells by signaling via the TCR, but IL-21 mRNA can be induced by a calcium signal alone in preactivated T cells, whereas IL-2 mRNA induction requires both a calcium signal and protein kinase C (14). Nuclear factor of activated T cells (NFAT) binding sites in the IL-21 promoter region contribute to the regulation of IL-21 transcription (14, 15). Interestingly, NFATC2 binds in vivo, but mice lacking NFATC2 still express IL-21, indicating functional redundancy with other NFAT family proteins (14). Mycobacterial antigens

Annu. Rev. Immunol. 2008.26:57-79. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-03

ARI

16 February 2008

11:18

(BCG) upregulate levels of IL-21 in NKT cells in both mouse and human systems (16), revealing that innate immune signals can also induce IL-21 production. IL-21 receptor expression has been detected on CD4+ T cells, CD8+ T cells, B cells, NK cells, DCs, macrophages, and keratinocytes (4, 5, 8, 17–19), suggesting that IL21 has a broad range of actions. Although IL-21 is not required for hematopoiesis, as demonstrated by analysis of IL-21R knockout (KO) mice (20), IL-21R mRNA has also been detected on a population of bone marrow progenitors, and IL-21 can expand hematopoietic progenitor cells both in vivo and in vitro (20a). Within the T cell lineage, IL-21R expression is induced as cells differentiate from double negative (CD4− CD8− ) thymocytes to double positive (CD4+ CD8+ ) thymocytes (8), but this expression may not be absolutely essential for thymocyte differentiation because there is normal thymic development in IL-21R KO mice (20). Low but detectable levels of IL21R are found on mature CD4+ and CD8+ T cells (8), and these levels are upregulated in response to either TCR or IL-21 (8, 21). TCRmediated IL-21R expression is regulated in part by the induction and dephosphorylation of the transcription factor Sp1 (21). Within the B cell lineage, IL-21R is expressed at a low level at the pre–B cell stage of development; this level persists through the ﬁrst transitional (T1) stage but then increases at the second transitional (T2) stage (22). Mature follicular B cells express higher basal levels of IL-21R than are found on mature T cells (8), and these levels are further increased by signals either through the B cell receptor (BCR) or through CD40 (23). Marginal zone B cells respond to IL-21 but have lower IL-21R expression than do follicular B cells (22). Plasma cells have no detectable surface IL-21R (23), in keeping with their terminally differentiated and nonproliferative state. Interestingly, however, myeloma plasmacytoma cells do express surface IL-21R (24), which may provide a distinct survival advantage for these cells in vivo.

IL-21 AND B CELL FUNCTION IL-21 Plays a Critical Role in Immunoglobulin Production The role of IL-21 in B cell function has been investigated in both in vitro studies and in vivo systems employing IL-21R KO and IL-21 transgenic mice. IL-21 is not essential for B cell development; no defects in B cell subsets within bone marrow or periphery have been observed in IL-21R KO mice (20). B cells from IL-21R KO mice normally proliferate in response to lipopolysaccharide (LPS), anti-CD40, or the combination of IL4 plus anti-IgM (20). The most striking defect in naive IL-21R KO mice is a reduced level of serum IgG1, yet an increased level of IgE (20). Upon immunization with T cell– dependent antigens, IL-21R KO mice have strikingly impaired production of antigenspeciﬁc IgG1 and signiﬁcantly higher levels of antigen-speciﬁc IgE (20), an unexpected result given that IgG1 and IgE are usually coordinately regulated. These elevated levels of IgE in IL-21R KO mice were consistent with experiments demonstrating that IL-21 administered to wild-type (WT) mice at the time of immunization can lead to reduced IgE responses, as well as with in vitro experiments showing that IL-21 can reduce levels of germline Cε transcripts, leading to reduced IgEspeciﬁc switching (25). Interestingly, in vitro experiments using human peripheral blood B cells revealed that IL-21 can both positively and negatively regulate IgE production, depending on the context. For example, IL-21 in combination with PHA and IL-4 inhibited IgE, whereas IL-21 in combination with anti-CD40 plus IL-4 led to increased IgE levels (26). The precise molecular mechanism(s) by which IL-21 regulates IgE production remains to be fully delineated, particularly because IL-21 can also be proapoptotic for B cells (see below). IL-4 is required for IgE production, and as expected, IL-4/IL-21R double-knockout (DKO) mice could not produce IgE,

www.annualreviews.org • Interleukin-21

61

ARI

16 February 2008

11:18

conﬁrming that IL-4 is indeed necessary for the enhanced levels of IgE seen in the IL-21R KO mice. But surprisingly, the DKO mice exhibited a pan-hypogammaglobulinemia, with essentially absent levels of IgG1, IgG2a, IgG2b, and IgG3 and greatly reduced levels of IgM (20). Thus, IL-21 and IL-4 cooperatively regulate immunoglobulin (Ig) production. These observations may also explain the B cell phenotype in humans with XSCID (2, 20). In this severe immunodeﬁciency, B cells develop normally but are nonfunctional; patients exhibit a severe pan-hypogammaglobulinemia. In the mouse, elimination of γc results in a loss not only of T cells but also of B cells, given a critical role in the mouse, but not human, for IL-7 signaling in B cell development (27). By keeping IL-7 signaling intact and thus allowing B cells to develop but by eliminating signaling by IL-4 and IL-21, we apparently have mimicked in mice the human XSCID B cell phenotype (20).

Annu. Rev. Immunol. 2008.26:57-79. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-03

IL-21 Induces B Cell Apoptosis in a Context-Dependent Manner One of the most puzzling aspects of IL-21 biology is that, in contrast to other members of the γc -dependent cytokines, IL-21 can be potently proapoptotic for B cells. Initially, IL21 was found to augment anti-CD40-induced human B cell proliferation but inhibit proliferation to anti-IgM and IL-4 (5). The inhibition of LPS-induced proliferation by IL-21 results at least in part from a strong proapoptotic signal from IL-21 (8, 28, 29). The degree of IL-21-induced apoptosis is dependent on the context of B cell activation: Apoptosis dominates when B cells are activated with Toll-like receptor (TLR) signals such as LPS or CpG but augments proliferation when B cells are activated with BCR signals (antiIgM) plus T cell–derived costimulatory signals such as those provided by anti-CD40 (8, 28, 29). The apoptotic signal is caspase dependent because it can be inhibited with caspase inhibitors (28). Although apoptosis can

62

Spolski

·

Leonard

be prevented by the overexpression of the antiapoptotic Bcl-2 protein (28, 29), IL-21 has no effect on Bcl-2 protein levels in B cells (29). Analysis of genes involved in apoptosis revealed that IL-21 increases mRNA and protein levels of the proapoptotic mitochondrial protein Bim and decreases levels of Bcl-xL (8). IL-21-induced apoptosis was eliminated in B cells from Bim KO mice, conﬁrming that Bim-1 plays a role in the IL-21-mediated death of B cells. Other antiapoptotic proteins may be involved in the rescue from IL-21mediated apoptosis. For example, IL-4 can rescue B cells from LPS + IL-21-induced cell death through upregulation of Bcl-xL, and this rescue is dependent on the presence of Bcl-6 (30). IL-21-mediated induction of apoptosis may in part also account for the inhibitory effects of IL-21 on IgE production. Vaccination with Mycobacterium bovis bacillus (BCG) activated Vα14 NKT cells to express high levels of IL-21, which in turn preferentially induced apoptosis of IgE-expressing B cells but not apoptosis of other Ig-isotypeexpressing B cells (16). The mechanism for this speciﬁc apoptosis seems to involve IL21-induced formation of a complex between Bcl-2 and the proapoptotic molecule Bcl-2modifying factor (Bmf), which is speciﬁcally expressed in the IgE-expressing population of B cells. Bmf thereby inhibits the usual antiapoptotic activity of Bcl-2, leading to speciﬁc apoptosis of IgE-producing B cells and the subsequent loss of IgE production. The above results indicate that IL-21 can differentially inﬂuence the outcome of an antibody response, depending on the costimulatory signals present at the time that B cells encounter antigen (see Figure 3). B cells receiving a polyclonal, nonspeciﬁc signal such as those mediated by the TLRs would thus potentially produce nonantigen-speciﬁc Igs, including autoreactive Igs. Expansion of this potentially deleterious population would be prevented by the presence of IL-21 at the time of encounter. In contrast, a B cell that interacts speciﬁcally via its BCR and receives speciﬁc

ANRV338-IY26-03

ARI

16 February 2008

11:18

Without BCR signal or T cell interaction

With BCR signal and/or T cell interaction IL-21

LPS IL-21

Ag

TLR BCR

IL-21R

IL-21R

BCR

Naive B

TLR

CD4+ T

Naive B CD40

Proliferation, isotype switching, antibody production

Apoptosis Ag

Annu. Rev. Immunol. 2008.26:57-79. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

IL-4

Memory B cell

IL-21R

IL-21

Plasma cell

Pathology and immune disorders

Figure 3 Effects of IL-21 on B cell differentiation and survival. Signaling through the IL-21 receptor (IL-21R) has two potential outcomes for naive B cells. (Left) In the absence of a B cell receptor (BCR) or T cell interaction signal or in the presence of a Toll-like receptor (TLR)-dependent signal, IL-21 induces apoptosis of a naive B cell. (Right) In the presence of a BCR signal and/or costimulatory interactions with T cells, IL-21 induces proliferation, isotype class switching, and differentiation to either memory B cells or terminally differentiated plasma cells. Memory B cells maintain IL-21R and respond to IL-21 plus antigen signals to differentiate into plasma cells, with subsequent downregulation of IL-21R expression.

T cell help would receive a positive costimulatory signal from IL-21.

IL-21 Drives Terminal Differentiation of B Cells to Plasma Cells The analysis of IL-21R KO mice had indicated a critical role for IL-21 in Ig production. The role of IL-21 in antibody responses was further investigated through the use of IL-21 transgenic mice as well as through hydrodynamic transfection of mice with an IL21 expression plasmid (29). In both systems, IL-21-induced apoptosis could be detected by annexin V staining of naive B cells ex vivo. Surprisingly, in both mouse models, there

were increased numbers of total splenic B cells rather than the expected decrease resulting from IL-21-induced apoptosis. Most of the increase in B cell numbers resulted from increases in the number of immature B cells and in the number of postswitch B cells and plasma cells. However, there was no change in the number of mature B cells. This was consistent with the increased concentrations of serum IgM and IgG1. In vitro experiments using murine splenic B cells showed that IL-21 in combination with anti-IgM could directly induce the differentiation and accumulation of Syndecan-1+ plasma cells in these cultures (29). The ability of IL-21 to promote differentiation to plasma cells was explained by its potent induction of B lymphocyte–induced www.annualreviews.org • Interleukin-21

63

ARI

16 February 2008

11:18

maturation protein-1 (Blimp-1) (29), a transcription factor that acts as a master switch for the program of transcriptional changes involved in terminal differentiation of B cells to plasma cells (31). Surprisingly, in both primary splenic B cells as well as in a B cell line, IL-21 also induced the production of the transcription factor Bcl-6 (29). Blimp-1 and Bcl-6 function as mutually exclusive transcription factors that negatively regulate the expression of each other and correlate with the plasma cell and the memory cell phenotype, respectively (31, 32). It is not yet clear whether both transcription factors are induced by IL21 within the same individual cells; if so, their coinduction by IL-21 may be limited to a speciﬁc stage of B cell development prior to the commitment to either memory cell or plasma cell lineages. Corresponding to its effects on mouse B cells, IL-21 also plays a major role in stimulating the differentiation of human B cells. Naive cord blood B cells as well as postswitch memory B cells can be driven to differentiate to plasma cells by IL-21 in combination with either BCR and/or CD40 signals (33). IL-21 costimulation of human B cells also induced high levels of Blimp-1 as well as activation-induced cytidine deaminase (AID), but surprisingly this did not induce somatic hypermutation (33). Although IL-21 acted as a switch factor for production of both IgG1 and IgG3 by human peripheral B cells (34), costimulation of naive cord blood B cells with IL-21 plus anti-CD40 induced predominantly the IgG3 isotype (33), suggesting that molecular differences in the responding populations can account for switch preferences. Interestingly, although IL-21 and IL-4 cooperate in the production of Ig, as seen in the absence of Ig responses in IL-4/IL-21R DKO mice (20), these two cytokines appear antagonistic in their effects in both murine and human B cell differentiation into plasma cells: IL-4 inhibited IL-21-mediated plasma cell differentiation by B cells stimulated with either anti-IgM or anti-IgM plus anti-CD40 but did not inhibit B cells stimulated with anti-

Annu. Rev. Immunol. 2008.26:57-79. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-03

64

Spolski

·

Leonard

CD40 alone (29, 33). The functional interaction between IL-4 and IL-21 is thus complex and dependent on the nature of costimulatory signals as well as the developmental stage of the target B cell. Although IL-21R levels are higher on naive than on memory B cells (23), IL-21 can also induce rapid plasma cell differentiation in a population of human marginal zone memory B cells (35). This differentiation occurs in response to the combination of IL21 plus BAFF/BLyS, a TNF family cytokine produced by the local DC population (36). The combination of IL-21 with BAFF leads to the synergistic induction of both Blimp-1 and AID, providing a possible mechanism for rapid upregulation of IgG-secreting plasma cells in an antigen-independent manner (35).

IL-21 EFFECTS ON CD4+ T CELL FUNCTION IL-21 Is Produced by Multiple T Helper Populations The functional capacity of CD4+ T cell populations is highly dependent on the cytokines that are available in the environment at the time of TCR priming. Th1 cells arise in response to DC-derived IL-12, produce IFNγ and TNF-α, and are involved in mediating strong inﬂammatory responses to intracellular pathogens. IL-4-mediated Th2 cell differentiation results in cells that produce cytokines, including IL-4, IL-5, and IL-13, which mediate antibody responses to extracellular pathogens. Th17 cells, the most recently identiﬁed CD4+ T cell subset, differentiate in response to TGF-β and IL-6 signals and produce IL-17, which mediates neutrophil differentiation and inﬁltration during various infections (37). Each of these CD4+ T cell populations can produce IL-21, although to different extents, and can respond to IL-21 with distinct differentiative responses. Nevertheless, the subset(s) of cells responsible for IL-21 production at speciﬁc phases of various in vivo immune responses is not yet fully clear.

Annu. Rev. Immunol. 2008.26:57-79. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-03

ARI

16 February 2008

11:18

Several laboratories originally examined the Th subset expression of IL-21 and obtained ostensibly inconsistent results. One study reported that IL-21 mRNA and protein are produced by Th2-polarized cells but not by Th1polarized cells (38), but another used a DNA array analysis of expression in human Th1and Th2-polarized CD4 T cells and showed that IL-21 mRNA was expressed predominantly in Th1 cells (39). Furthermore, IL-21 mRNA expression was highest in a population of follicular Th cells that could augment B cell antibody responses to antigen (39). Recent work has identiﬁed Th17 cells as producing signiﬁcantly higher levels of IL-21 mRNA and protein than either Th1 or Th2 cells do (40, 41). IL-21 itself and IL-6 were identiﬁed as essential for the upregulation of IL-21 in this lineage (40–42); Stat3 signaling was essential (41, 42). In the committed Th17 cell, TCR signaling can further upregulate IL21 production. The functional signiﬁcance of Th17 expression of IL-21 is further discussed below.

Regulation of Th1 versus Th2 Differentiation In Vitro by IL-21 Although both Th1 and Th2 cells produce IL-21, the effects of IL-21 on differentiation within these subsets are only beginning to be delineated. Analogous to effects of IL-21 on B cell proliferation and function, the end result may depend on other cytokines or immune populations as well as on the developmental stage of the target cell. The initial observation that IL-21 can function as a Th2 cytokine was based in part on in vitro experiments showing that IL-21 could inhibit IFN-γ expression only when IL-21 was present at the time of naive CD4+ T cell priming under Th1 conditions (38). There was not, however, a general downregulation of the Th1 program in that IL-21 had no effect on T-bet or IL-12Rβ2 expression, both of which are induced in Th1 cells even when Th1 cells are primed in the presence of IL-21. The speciﬁc decrease of IFN-γ by IL-21 was mediated by the direct

repression of Eomesodermin, a T-box transcription factor important for IFN-γ induction (43). Moreover, in populations of human peripheral blood T cells that were preactivated with TCR, IL-21 could induce the expression of a panel of Th1 genes, including those encoding IFN-γ, T-bet, and IL-12Rβ2, suggesting that the effects of IL-21 on already activated cells may be distinct from those on naive T cells (44).

Regulation of Th1 versus Th2 Responses In Vivo by IL-21 The role that IL-21 plays in the in vivo regulation of Th1 versus Th2 polarization has been studied via the use of IL-21R KO mice in a number of immunization and infection models. IL-21R KO mice exhibit normal development of CD4+ T cells both in the thymus and in the periphery (20). Additionally, in vitro stimulation of naive CD4+ T cells under Th1- or Th2-polarized conditions showed no differences in WT versus IL-21R KO levels of IFN-γ or IL-4, suggesting that IL-21 is not essential for the normal differentiation of these two subsets (20). When IL21R KO mice were examined in a delayedtype hypersensitivity model in which footpad swelling was measured after an antigenic challenge, these KO mice had higher inﬂammatory responses than did WT mice (38). Ex vivo antigen-speciﬁc challenge of CD4+ T cells in these challenged mice revealed higher production of IFN-γ by KO than by WT cells. Another group examined the expression of IL-21 during the time course of infection with Schistosoma mansoni, a parasite that induces a Th2-dependent granuloma formation (45). IL-21 levels were measured in strains of mice that developed massive Th1 (IL-4/IL-10 DKO) or Th2 (IL-12/IL-10 DKO) responses to the parasite. Although infection of these mice with schistosome eggs induced highly polarized responses in the lungs, as evaluated by the production of IL-13 and IFN-γ, IL21 was produced during the infection in both strains of mice, indicating that IL-21 does not www.annualreviews.org • Interleukin-21

65

ARI

16 February 2008

11:18

behave as a classical Th1 or Th2 cytokine (45). When IL-21R KO mice were infected with S. mansoni, there was not a corresponding increase in Th1 cytokine production, despite a reduced Th2 response (i.e., decreased production of IL-4, IL-10, and IL-13) to the parasite in the granulomatous tissues of the lungs. Consistent with the decreased Th2 response in the IL-21R KO mice, there was more rapid resolution of the lung granulomas in these mice, indicating that IL-21 plays a role in the initiation and maintenance of a granulomatous inﬂammatory response. In spite of the reduced Th2 responses in the S. mansoni– infected mice, there was no difference in the cytokine proﬁle of CD4+ T cells stimulated ex vivo with antigen, suggesting that in vivo IL21 deﬁciency may not alter the Th priming of CD4+ T cells per se but rather may lead to a depressed Th2 response through mechanisms that are not yet clear. In a separate study, IL21R KO mice that were infected with Heligmosomoides polygyrus intestinal parasites developed fewer and smaller granulomas and had a reduced eosinophilia in the blood, suggesting a defective Th2 type response (46). However, analysis of ex vivo cytokine production from infected mice revealed no differences in levels of IFN-γ or IL-4 (46).

Annu. Rev. Immunol. 2008.26:57-79. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-03

IL-21 Critically Regulates Th17 Development IL-17-producing Th17 cells have distinctive developmental and functional properties that differ from those ascribed to Th1 and Th2 CD4+ effector T cells (47, 48). TGF-β, an immunosuppressive cytokine with a role in the generation of T regulatory (Treg) cells (49), also plays a key role in the induction of the Th17 differentiation pathway (50). However, Treg and Th17 cells are induced by TGF-β in a mutually exclusive manner; IL-6 shifts the balance in favor of Th17 cells and decreases the development of Treg cells (51). An analysis of TCR-stimulated CD4+ T cells revealed that the IL-21 gene was one of the genes most highly induced by IL-6 (42). 66

Spolski

·

Leonard

Indeed, IL-21 mRNA and protein are very highly expressed in Th17 cells, at levels approximately ﬁvefold higher than in Th1- and Th2-polarized cells (40, 41). The induction of IL-21 leads to a further autocrine upregulation of IL-21 (42). Interestingly, IL-21 induced IL-23R expression on these CD4+ T cells (41, 42). IL-23R forms dimers with the IL-12Rβ1 subunit, which is shared by both IL-12R and IL-23R (52). Although IL-23 is an important factor in inﬂammatory disease in both mice and humans, its receptor is not present on naive T cells, and IL-23 may play a role in the expansion of already differentiated Th17 cells (53). The induction of IL-23R by IL-21 in naive CD4+ T cells is therefore a critical step in the differentiation and possibly in the expansion of Th17 cells in vivo. IL-21 and IL-23 both upregulated expression of the orphan nuclear receptor RORγt, which is essential for Th17 differentiation (54) and which leads to further upregulation of IL-21 (42). IL-17 production was signiﬁcantly lower in CD4+ T cells from IL-21R KO mice that were induced in vitro with TGF-β and IL-6, demonstrating that the induction of IL-21 by IL-6 leads to an ampliﬁcation of this differentiation pathway (41, 42). In fact, no IL-23R was induced by TGF-β + IL-6 in CD4+ T cells from IL-21 KO or IL-21R KO mice, indicating a critical role for IL-21 in controlling IL-23R expression (41, 42). The initial induction of IL-21 in Th17 cells therefore is critical for the establishment of an autocrine ampliﬁcation pathway for maximal IL-17 production.

IL-21 and Treg Induction IL-21 also plays an indirect role in the regulation of Treg differentiation. Interestingly, IL6 is critical in the inhibition of Treg differentiation by TGF-β and in the induction of Th17 differentiation (51). Indeed, IL-6 KO mice do not produce Th17 cells but produce a dominant FoxP3+ Treg population (40). However, in mice that are deﬁcient in both IL-6 and FoxP3+ Treg cells, Th17 cells are once again

ANRV338-IY26-03

ARI

16 February 2008

11:18

present, and these cells are produced in response to IL-21 in combination with TGFβ, demonstrating the presence of an IL-6independent pathway for Th17 production. The negative effects of IL-21 on Treg production are further demonstrated by the presence of a three- to fourfold increased FoxP3+ CD4+ T cell population in IL-21 KO mice (41).

Annu. Rev. Immunol. 2008.26:57-79. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

IL-21 Regulates Proliferation and Effector Function of CD8+ T Cells IL-21 is produced by CD4+ T cells and, as indicated above, inﬂuences the development of speciﬁc functional subsets within this lineage; however, the CD8+ T cell lineage is perhaps the primary target of the proliferative effects of IL-21. Nevertheless, CD8+ T cell development appears normal in the IL21R KO mice (20), indicating compensatory redundancy of these proliferative effects. In vitro experiments demonstrate that IL-21 by itself has very little if any effect on naive or memory phenotype CD8+ T cell proliferation and expansion but that it has a profound synergistic effect on proliferation in combination with either IL-7 or IL-15 (55), cytokines previously identiﬁed as playing major roles in homeostatic expansion of naive or memory CD8+ T cells (56, 57). This synergistic effect is especially evident when CD8+ T cells are stimulated in the absence of TCR signals (55), suggesting that IL-21 may play a role in antigen-independent expansion of this lineage in vivo. Gene expression analysis by DNA microarrays reveals that subsets of mRNAs are regulated individually by IL-21 or IL-15, but an additional set of mRNAs are cooperatively or distinctively regulated by the combination of IL-21 and IL-15, including granzyme B, which is important in cytolytic function of CD8+ T cells, as well as c-jun, which plays a role in the control of proliferative responses (55). The molecular mechanism of this synergistic transcriptional activity by these two cytokines remains to be determined. It is interesting that IL-21 activates Stat1 and Stat3

whereas IL-15 activates Stat5; however, differential STAT protein activation alone cannot be the full explanation given that the cooperative effect of IL-15 with IL-21 cannot be mimicked by IL-2, even though, like IL15, IL-2 is an activator of Stat5 proteins. Despite the ability of IL-21 to synergistically upregulate proliferation in combination with either IL-7 or IL-15, IL-21 has distinct effects on the differentiation of CD8+ T cells. IL-15 treatment of naive CD8+ T cells induces an effector phenotype in CD8+ T cells characterized by reduced CD28 and CD62L surface proteins, but IL-21 acts to prevent the downregulation of these proteins and potentially serves to maintain the important costimulatory function mediated by them (58). Although IL-21 alone can lead to the downregulation of CD44 expression on CD8+ T cells, the combination of IL-21 with IL-15 enhanced the accumulation of CD44high CD8+ T cells (55). With regard to cytokine production by naive CD8+ T cells, IL-21 alone induced no accumulation of IFN-γ-producing cells, and IL-15 alone could induce these cells, but the combination led to a further increase in the number of IFN-γ-producing cells (55). The effects of IL-21 on antigen-speciﬁc CD8+ T cell proliferation and effector function have been examined in several experimental systems. Primary immunization of mice with vaccinia virus expressing HIV gp160 antigen induced signiﬁcantly lower expansion and cytolytic activity in IL-21R KO mice than in WT mice (55), indicating a role for IL-21 in antigen-speciﬁc expansion and functional differentiation of naive CD8+ T cells in vivo. When naive human CD8+ T cells were stimulated in vitro with mature DCs presenting a tumor-associated peptide, there was a greatly augmented proliferation when IL-21 was added, leading to the accumulation of a population of cytotoxic cells characterized by a CD28high surface phenotype and a tenfold higher afﬁnity for antigen and a signiﬁcantly increased production of IL-2, as compared with cells stimulated in the absence of IL21 (59). In contrast to the ability of IL-21 to www.annualreviews.org • Interleukin-21

67

ARI

16 February 2008

11:18

augment the antigen-independent proliferation of both naive and memory CD8+ T cells, IL-21 augmented proliferative and differentiative effects of antigen-dependent stimulation with naive but not with memory CD8+ T cells. The basis for this difference is not yet known. A study of the effects of IL-21 on CD8+ effector T cells in HIV-infected patients revealed that IL-21 could upregulate perforin production in the absence of cell activation or proliferation, whereas IL15-mediated upregulation of perforin was less substantial and occurred only in the presence of proliferation (60). This induction of perforin by IL-21 in memory T cells was greater in cells from HIV patients than from normal controls. Thus, the proliferative and functional effects of IL-21 differ for naive and memory CD8+ T cells.

Annu. Rev. Immunol. 2008.26:57-79. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-03

Actions of IL-21 on Natural Killer Cells NK cell development depends on the function of γc cytokines; γc KO mice are devoid of mature NK cells (61, 62). IL-21R KO mice have normal numbers of fully functional NK cells (20, 63), indicating that IL21 is not required for NK cell development, but it has become clear that IL-21 plays a role in NK cell maturation and functional development and that the actions of IL-21 on this lineage are stage speciﬁc. The original observation of an effect of IL-21 on NK cells was that IL-21 enhanced in vitro generation of NK cells from bone marrow precursors (5). Although γc KO mice lack mature NK cells, bone marrow NK cell precursors (CD122+ NK1.1− CD49b− ) develop even in the absence of γc -mediated signals, and a small subset of these precursors expresses IL21R (64). Increases in IL-21R levels on these precursors depended on IL-15, suggesting that IL-15 may regulate the ability of NK precursors to respond to IL-21 (64). Although IL-21 has not been found to affect NK cell generation, experiments using human cord blood NK cell precursors showed that these 68

Spolski

·

Leonard

cells progressed further along the maturation pathway if IL-21 was added to the combination of IL-15, Flt3, stem cell factor, and IL-7, a set of cytokines required for in vitro generation of NK cells (65). Once committed immature NK cells are generated, IL-21 can also enhance their proliferative response to suboptimal IL-2 or IL-15 concentrations while having no effect on proliferation by itself (66). Interestingly, IL-21 had a biphasic effect on the growth of immature NK cells: Low doses of IL-21 enhance proliferation and high doses inhibit proliferation, even in the presence of IL-2 or IL-15 (66). IL-21 also has effects on mature NK cells, including effects on both proliferation and survival as well as on NK cell–speciﬁc cell surface receptors. IL-21 had a negative effect on the proliferation of NK cells that had been activated by IL-15, either inhibiting proliferation or increasing their apoptosis (67). In spite of the reduced proliferative and survival effects of IL-21 on NK cells, these cells exhibited enhanced cytolytic function, increased IFN-γ production, and conversion to a large granular phenotype, all indicative of enhanced effector function of these cells (63, 67). In addition, IL-21 inclusion in the in vitro–generated NK cell cultures resulted in changes in the expression of several NK cell inhibitory and activating receptors. For example, IL-2 and IL-15 could induce inhibitory Ly49 receptors on mature NK cells, but the inclusion of IL-21 downregulated these receptors (68). The NKG2D receptor was similarly downregulated by IL21 in cultures of human NK cells (69). This decreased expression was mediated by transcriptional repression of the DAP10 adaptor through which NKG2D signals. Consistent with these changes in NK receptor expression, IL-21 modestly inhibited NK cell lysis of NKG2D-sensitive targets (69). Although IL21 repressed NKG2D expression on mature peripheral blood NK cells, IL-21 enhanced NKG2D expression on murine bone marrow– derived NK cells, which represent a less mature population of NK cells. This underscores

ANRV338-IY26-03

ARI

16 February 2008

11:18

the stage-speciﬁc effects of IL-21 on NK cells (67). Thus, although IL-21 is not required for NK cell development, it inﬂuences the proliferation and functional activity of this lineage.

Annu. Rev. Immunol. 2008.26:57-79. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

IL-21 Effects on Natural Killer T Cells NKT cells are a population of T cells expressing a restricted TCR repertoire; they recognize glycolipids presented by CD1d as well as inhibitory and activating NK receptors (70). NKT cells have immunoregulatory activity on other subsets that is related to their secretion of cytokines and their potent cytotoxic activity. Similar to its effect on NK cells, IL-21 can increase the proliferation of NKT cells in response to in vitro stimulation with antiCD3 but only when combined with either IL2 or IL-15 (13). IL-21 can also stimulate the in vitro release of increased levels of IL-4 and IL13 by NKT cells. In addition, IL-21 upregulated effector function in NKT cells through the induction of granzyme B and conversion to a large granular cell morphology similar to what was found for NK cells (13). Interestingly, NKT cells are also potent producers of IL-21 when stimulated in vitro with anti-CD3 or in vivo with α-GalCer, a stimulatory glycolipid speciﬁc for NKT cells (13). Levels of IL-21 protein secreted by NKT were signiﬁcantly higher than those produced by splenic CD4+ T cells in response to anti-CD3 stimulation. The ability of NKT cells to produce large amounts of IL-21 in response to microbial stimuli opens the possibility that these innate immune cells can regulate the initial steps in the formation of an adaptive immune response by B and T cells.

IL-21 Inhibits Dendritic Cell Maturation and Function DCs are peripheral myeloid cells that have the capacity to recognize microbial components via surface receptors, endocytose these microbes, and then undergo maturation in response to some of these microbial compo-

nents. Subsequent to this maturation, DCs migrate to lymphoid organs, where they function as antigen-presenting cells for T cells. The initial evidence that IL-21 can affect the proliferation or differentiation of myeloid cells came from the observation that injection of an IL-21-encoding plasmid into WT mice led to increases in the numbers of both CD11b+ and Gr1+ cells in the periphery (71). Although most of the effects of IL-21 on lymphoid cells are stimulatory, involving enhanced proliferation or effector function, effects of IL-21 on DCs are largely inhibitory. DCs can be generated and expanded in vitro by culturing bone marrow precursor cells with GM-CSF. When DC cultures were expanded in this manner in the presence of either IL21 or IL-15, differences in their phenotype and function were evident (17). Although IL15-treated DCs behaved as mature DCs and could present antigen in both in vivo and in vitro assays, IL-21-treated DCs maintained an immature phenotype that was characterized by low MHC class II expression accompanied by increased uptake of antigen and lowlevel expression of CC-chemokine receptor 7 (CCR7) (17). When IL-21-primed DCs were stimulated with LPS, there was no upregulation of MHC class II, CD86, or CD80 costimulatory proteins, in contrast to the upregulation that is seen with IL-15-primed DCs, and the IL-21-primed DCs had inhibitory effects on T cell responses. Even when DCs were treated for only 2 h in vitro with IL-21 plus ovalbumin antigen and then adoptively transferred in vivo, they could inhibit T cell– mediated contact hypersensitivity responses (17). IL-21 can also exert proinﬂammatory effects on immune responses through the induction of the neutrophil chemoattractant CXCchemokine ligand 8 (CXCL8) in macrophages (72). Neutrophils apparently lack IL-21R but can be recruited to sites of inﬂammation indirectly through IL-21-mediated CXCL8 induction on macrophages. Additionally, the critical role played by IL-21 in the differentiation and expansion of Th17 cells leads to the www.annualreviews.org • Interleukin-21

69

ANRV338-IY26-03

ARI

16 February 2008

11:18

production of IL-17 family cytokines that affect neutrophil recruitment and function (40– 42). Thus, IL-21 can either dampen immune responses or exacerbate them, depending on the myeloid population that is targeted and the timing of exposure to IL-21 during the course of an immune response.

IL-21 Mediates Potent Antitumor Responses

Annu. Rev. Immunol. 2008.26:57-79. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

The ability of IL-21 to regulate both T cell– mediated and NK cell–mediated immune responses suggested possible antitumor effects. Indeed, IL-21 has been examined in a number of in vivo tumor models, and these studies have conﬁrmed the potent effects of IL21 as an antitumor agent in animal models. The success in these models has led to the use of IL-21 in several phase I clinical trials in advanced-stage melanoma patients. The mechanisms of the antitumor action of IL-21 involve augmented NK cell and CD8+ T cell cytotoxicity. Systemic expression of IL-21 by plasmidmediated in vivo delivery led to an inhibition of the growth of large preestablished melanomas and ﬁbrosarcomas (71). These effects were mediated predominantly by NK cells; ablation of this population reduced the antitumor effect, with only minimal effects seen by ablation of the CD8+ T cell population. Signiﬁcantly, there were no major in vivo toxic effects, even at high doses of IL-21 (71), unlike the severe toxicity observed with similar doses of IL-2 or IFN-α. In another study that used a different approach to achieve high systemic levels of cytokine, IL-21 and IL23 were constitutively expressed in pancreatic carcinomas, leading to retarded tumor growth in nude mice, an effect that was again predominantly mediated by NK cells (73). IL-21 overexpression in mammary adenocarcinoma cells also led to the prevention of tumor initiation, although in this system there was no role for NK cells, and the tumor prevention was completely dependent on CD8+ T cells (74). 70

Spolski

·

Leonard

NK cell–mediated killing of tumors after treatment with IL-21 appears to depend on the presence of NKG2D ligands on the tumor target because there was no IL-21-mediated enhancement of rejection of tumors that did not express these ligands and killing could be blocked by antibodies to NKG2D (75). IL-21 could enhance killing of ligand-positive tumors even in Rag2 KO mice, demonstrating that this is an NK cell–mediated event not requiring an adaptive immune response. These experiments suggest that the action of IL-21 on NK cells may be limited to tumors involving the NKG2D recognition system. Although this study found no effects of IL-21 on NK cell expression of this receptor, other studies did ﬁnd either positive or negative effects of IL-21 on NKG2D expression (67, 69). Other tumor systems have allowed the delineation of IL-21-induced CD8+ T cell– mediated killing mechanisms. One study compared the antitumor activity of intraperitoneally delivered IL-2, IL-15, and IL-21 with syngeneic E.G7 thymomas. This study found that, although all three cytokines could induce greater survival than PBS, IL-21 was the most potent, and the administration of IL21 resulted in a doubling of the 50% survival time, with 20–30% of the mice surviving for more than four months after IL-21 was administered (76). When these long-term survivors were rechallenged with thymoma, all the mice survived for more than 100 days, and this survival was dependent on the presence of a persistent CD8+ T cell memory population that was less susceptible to apoptosis than were CD8+ T cells induced by treatment with IL-2 (76). In another study, mice with large, established melanomas were treated by adoptive transfer of in vitro expanded tumor-speciﬁc CD8+ T cells plus peptide vaccine, followed by intraperitoneal administration of either IL2, IL-15, or IL-21 or the combination of IL-15 plus IL-21 (55). Treatment with either IL-15 or IL-21 led to partial tumor regression, but consistent with the synergistic effects of these two cytokines on CD8+ T cell

Annu. Rev. Immunol. 2008.26:57-79. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-03

ARI

16 February 2008

11:18

proliferation, the combination of IL-15 and IL-21 led to complete regression of a subset of these melanomas and long-term survival of the majority of the treated mice (55). Although treatment with IL-2 alone was less effective therapy than treatment with either IL-15 or IL-21, IL-21 acted synergistically with low-dose IL-2 after the adoptive transfer of naive tumor-speciﬁc CD8+ T cells into mice with preestablished melanomas (77). Nearly half of these treated mice survived for more than 150 days. When these long-term survivors were rechallenged with melanoma, all were protected, indicating the induction of long-term immunity as a result of the combination of IL-2 with IL-21. Although IL-21 has shown great potential as a cancer chemotherapeutic agent either alone or in combination with other cytokines, it also has potential for being used with other forms of therapy. The TRAIL/DR5 ligand/receptor pair controls apoptosis and has been the target for monoclonal antibody therapy in some tumors (78). AntiDR5 mAb can inhibit tumor growth in an FcR-dependent fashion mediated by NK cell antibody-dependent cellular cytotoxicity (79). IL-21 can enhance the ability of NK cells to lyse antibody-coated cancer cells (80). After anti-DR5 treatment of tumor-bearing mice, some tumor cells die, and these apoptotic tumor cells prime CTL to respond to tumorspeciﬁc antigens. When tumor-bearing mice were treated with anti-DR5, followed by IL21, there was enhanced suppression of metastasis of small, preestablished tumors as well as an enhanced CD8+ memory T cell response to secondary tumor challenge. In contrast, similar treatment did not eradicate large, established tumors (81). Another method for enhancing the innate immune response involves the use of the CD1d-reactive glycolipid α-GalCer. In vivo treatment of mice with α-GalCer potently activates NKT cells that then stimulate the activation and proliferation of other lymphoid populations (82). The combination of α-GalCer treatment and IL-21 administra-

tion resulted in synergistically enhanced prevention of tumor metastasis (83). Transfer of DCs pulsed with α-GalCer, followed by IL21, reduced already established metastatic tumors (83). Overall, these results suggest that the ability of IL-21 to enhance NK, NKT, and CD8+ T cell function can potentially be used in combination with numerous chemotherapeutic protocols to lead to further advances in the eradication of tumors. These preclinical studies have shown that IL-21 has signiﬁcant antitumor activity against a variety of tumors that is mediated by multiple mechanisms involving both the innate and adaptive immune systems. IL-21 has entered human clinical trials, and phase I results in patients with metastatic melanoma have been reported (84). Consistent with the animal models, IL-21 was well tolerated, and there were few adverse effects, unlike the capillary leak syndrome or neurotoxicity resulting from IL-2 and IFN-α therapy. IL-21 potently upregulated perforin and granzyme B mRNA in patients, at all except the lowest dose tested. One patient in the phase I trial achieved complete remission, and 9 of 29 had stable disease at the end of the study.

Role of IL-21 in Autoimmune Disease In light of the pleiotropic effects of IL-21 on the function of different components of the innate and adaptive immune systems, it was difﬁcult to predict the role that IL-21 would play in the various autoimmune diseases. The initial observation that suggested that IL-21 might play a role in the progression of B cell–mediated autoimmune disease was that, in the BXSB.B6-Yaa+ mouse model of systemic lupus erythematosus (SLE), the development of disease correlated with an increased serum expression of IL-21 (29). This was consistent with the increased serum Igs in these mice and the role for IL-21 in plasma cell differentiation. Another autoimmune mouse strain, the sanroque mutant, has a defect in the function www.annualreviews.org • Interleukin-21

71

Annu. Rev. Immunol. 2008.26:57-79. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-03

ARI

16 February 2008

11:18

of a protein, Roquin, which is a negative regulator of the production of a unique population of follicular T helper (TFH) cells (85). These TFH cells produce high levels of IL-21, and sanroque mutant mice have increased levels of these TFH cells as well as increased production of IL-21 accompanied by augmented levels of antinuclear antibodies, glomerulonephritis, and peripheral lymphadenopathy (85). The hypothesis is that the increased levels of IL-21 lead to increased formation of high-afﬁnity autoreactive antibodies by follicular B cells. That these autoimmune phenotypes were accompanied by high levels of IL-21 suggested that blocking the IL-21 signal might ameliorate autoimmune symptoms. Such a study was performed in the lupus-prone MRL-Fas/lpr mouse model through the use of IL-21R-Fc fusion proteins as blocking agents (86). Analogous to the Yaa mice results, lpr CD4+ T cells produced higher levels of IL-21. IL-17 IL-21

Th17

Th2 IFN-γ

Cytotoxicity, proliferation, antitumor activity

NKT

Th1

Cytotoxicity, proliferation, antitumor activity

IL-21 DC

NK

APC function

CD8

B Proliferation/apoptosis, plasma cell differentiation, Ig production

Cytotoxicity, proliferation/survival, antitumor activity

Figure 4 IL-21 has pleiotropic effects on multiple target cells. IL-21 is produced by multiple subpopulations of CD4+ T cells and by natural killer T (NKT) cells (indicated by the red arrows), although the amounts secreted by T helper (Th) 17 and NKT cells are signiﬁcantly higher than those secreted by Th1 and Th2 cells. IL-21 can then function as an autocrine factor for these populations, with the indicated effects, or can then exert varied positive or negative effects on lineages that do not themselves produce IL-21. 72

Spolski

·

Leonard

Treatment of these mice with the IL-21Rblocking agent led to a partial reduction of lymphadenopathy, morphological changes in kidney glomeruli, and slightly reduced levels of IgG1 and IgG2a. In a mouse model of collagen-induced arthritis, the IL-21Rblocking agent also slightly reduced inﬂammation (87), suggesting that interruption of the IL-21 signaling pathway may be beneﬁcial in several autoimmune diseases. One of the genetic loci that are associated with the autoimmune diabetic phenotype in the nonobese diabetic mouse (NOD) is the insulin-dependent diabetes susceptibility 3 locus (Idd3). This locus contains the genes encoding both IL-21 and IL-2 (88). Because these cytokines are known to play roles in the proliferation and function of CD8+ T cells and Treg cells, attempts have been made to identify mutations within this region that associate with diabetes prevalence in the population. One study in the NOD mouse found increased levels of IL-21 mRNA in T cells and suggested that high levels of IL-21 protein may promote homeostatic proliferation of the autoreactive CD8+ T cells that mediate destruction of the pancreatic islet β cells (89). However, a recent study has ruled out the possibility that IL-21 is the genetic determinant of Idd3 that predisposes one to the development of diabetes (90). IL-21 also has disease-promoting effects in experimental allergic encephalitis (EAE) (91), an experimental model of human multiple sclerosis, which is induced by immunization of mice with myelin antigen in the presence of adjuvants. When IL-21 is administered to mice before induction of disease, there is increased severity of disease characterized by increased numbers of inﬂammatory cells in the central nervous system. However, if IL-21 is administered after disease has been initiated, there is no effect on the disease severity. The ability of IL-21 to exacerbate disease is totally dependent on the presence of NK cells because depletion of these cells before disease induction abrogates the effect of IL-21 (91). Although these effects were

Annu. Rev. Immunol. 2008.26:57-79. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-03

ARI

16 February 2008

11:18

attributed to the ability of IL-21 to activate NK cell–mediated inﬂammatory responses, recent studies have pointed to the role that IL-21 plays in the induction and expansion of the Th17 population in this EAE model (40, 41). IL-21 or IL-21R KO mice have a tenfold reduction in the number of IL-17-producing cells and greatly reduced EAE disease progression (40, 41), as do mice deﬁcient in IL17 (92). Interestingly, IL-21 KO mice have increased numbers of Treg cells (41). The enhanced autoimmune symptoms in the mice injected with IL-21 before the initiation of EAE may be the result of increased numbers of Th17 cells and reduced numbers of Treg cells (40).

CONCLUDING REMARKS Since the discovery of IL-21 and IL-21R in 2000, this γc family cytokine system has been demonstrated to have effects on an extremely broad set of target cells, including T cells, B cells, NK cells, NKT cells, and DCs (see Figure 4). The actions of IL-21 on each of these target cells can be either stimulatory

or suppressive, and the ultimate outcome depends on the manner by which the IL-21 signal is integrated with other signals received by a target cell. Although IL-21 was initially thought to be produced solely by antigenstimulated CD4+ T cells, the discovery that IL-21 is produced by NKT cells implies that it is a key player in early innate immune responses as well. The recent discovery that IL21 is produced by and plays a major role in the differentiation of the Th17 lineage has expanded our understanding of the ways that IL21 may contribute to inﬂammatory responses. Moreover, studies of cancer and autoimmune models suggest that administering IL-21 or blocking the action of IL-21 holds promise in a number of disease settings. IL-21 is thus an exciting cytokine with pleiotropic actions on multiple lineages whose modulation has clear therapeutic beneﬁts in animal models. Understanding how and when it exerts various effects in vivo are some of the major basic science challenges, with the goal that future studies will both advance our scientiﬁc knowledge and contribute to moving IL-21 into the therapeutic setting.

FUTURE ISSUES 1. To be able to speciﬁcally amplify or neutralize the effects of IL-21 in pathological situations, investigators will require an understanding of the stage-speciﬁc and context-speciﬁc signaling events involved in the response to IL-21. 2. The in vivo sites where IL-21-producing cells are found are not yet deﬁned. This awaits the construction of reporter mice, with the hope that mRNA expression will correlate with protein expression. The availability of these mice will allow an understanding of the physiological expression of IL-21 as well as mechanisms for controlling levels of IL-21. 3. An in-depth understanding of the molecular basis of IL-21 and IL-21R gene expression will be important to better understand and develop ways of controlling the expression of this cytokine and its receptor. Analogously, a more detailed understanding of IL-21-induced signaling pathways is also important. 4. A major clinical issue will be balancing the immunostimulatory effects of IL-21 on lymphoid lineages with the largely immunosuppressive actions on DCs and the apoptotic effects on inappropriately stimulated B cells.

www.annualreviews.org • Interleukin-21

73

ANRV338-IY26-03

ARI

16 February 2008

11:18

5. The effects of IL-21 on CD8+ T cell phenotype and function suggest that IL-21 will have an impact on immunological memory, with potential ramiﬁcations for vaccination strategies.

DISCLOSURE STATEMENT The authors have issued patents and/or patent applications related to IL-21.

ACKNOWLEDGMENT Annu. Rev. Immunol. 2008.26:57-79. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

This work was supported by the Intramural Research Program, National Heart, Lung, and Blood Institute, NIH.

LITERATURE CITED 1. Noguchi M, Yi H, Rosenblatt HM, Filipovich AH, Adelstein S, et al. 1993. Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeﬁciency in humans. Cell 73:147–57 2. Leonard WJ. 2001. Cytokines and immunodeﬁciency diseases. Nat. Rev. Immunol. 1:200– 8 3. Leonard WJ, Spolski R. 2005. Interleukin-21: a modulator of lymphoid proliferation, apoptosis and differentiation. Nat. Rev. Immunol. 5:688–98 4. Ozaki K, Kikly K, Michalovich D, Young PR, Leonard WJ. 2000. Cloning of a type I cytokine receptor most related to the IL-2 receptor beta chain. Proc. Natl. Acad. Sci. USA 97:11439–44 5. Parrish-Novak J, Dillon SR, Nelson A, Hammond A, Sprecher C, et al. 2000. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 408:57–63 6. Habib T, Senadheera S, Weinberg K, Kaushansky K. 2002. The common γ chain (γc) is a required signaling component of the IL-21 receptor and supports IL-21-induced cell proliferation via JAK3. Biochemistry 41:8725–31 7. Asao H, Okuyama C, Kumaki S, Ishii N, Tsuchiya S, et al. 2001. Cutting edge: the common γ-chain is an indispensable subunit of the IL-21 receptor complex. J. Immunol. 167:1–5 8. Jin H, Carrio R, Yu A, Malek TR. 2004. Distinct activation signals determine whether IL21 induces B cell costimulation, growth arrest, or Bim-dependent apoptosis. J. Immunol. 173:657–65 9. Bondensgaard K, Breinholt J, Madsen D, Omkvist DH, Kang L, et al. 2007. The existence of multiple conformers of interleukin-21 directs engineering of a superpotent analogue. J. Biol. Chem. 282:23326–36 10. Konforte D, Paige CJ. 2006. Identiﬁcation of cellular intermediates and molecular pathways induced by IL-21 in human B cells. J. Immunol. 177:8381–92 11. Zeng R, Spolski R, Casas E, Zhu W, Levy DE, Leonard WJ. 2007. The molecular basis of IL-21-mediated proliferation. Blood 109:4135–42 12. Deleted in proof 74

Spolski

·

Leonard

Annu. Rev. Immunol. 2008.26:57-79. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-03

ARI

16 February 2008

11:18

13. Coquet JM, Kyparissoudis K, Pellicci DG, Besra G, Berzins SP, et al. 2007. IL-21 is produced by NKT cells and modulates NKT cell activation and cytokine production. J. Immunol. 178:2827–34 14. Kim HP, Korn LL, Gamero AM, Leonard WJ. 2005. Calcium-dependent activation of interleukin-21 gene expression in T cells. J. Biol. Chem. 280:25291–97 15. Mehta DS, Wurster AL, Weinmann AS, Grusby MJ. 2005. NFATc2 and T-bet contribute to T-helper-cell-subset-speciﬁc regulation of IL-21 expression. Proc. Natl. Acad. Sci. USA 102:2016–21 16. Harada M, Magara-Koyanagi K, Watarai H, Nagata Y, Ishii Y, et al. 2006. IL-21-induced Bε cell apoptosis mediated by natural killer T cells suppresses IgE responses. J. Exp. Med. 203:2929–37 17. Brandt K, Bulfone-Paus S, Foster DC, Ruckert R. 2003. Interleukin-21 inhibits dendritic cell activation and maturation. Blood 102:4090–98 18. Distler JH, Jungel A, Kowal-Bielecka O, Michel BA, Gay RE, et al. 2005. Expression of interleukin-21 receptor in epidermis from patients with systemic sclerosis. Arthritis Rheum. 52:856–64 19. Caruso R, Fina D, Peluso I, Fantini MC, Tosti C, et al. 2007. IL-21 is highly produced in Helicobacter pylori-infected gastric mucosa and promotes gelatinases synthesis. J. Immunol. 178:5957–65 20. Ozaki K, Spolski R, Feng CG, Qi CF, Cheng J, et al. 2002. A critical role for IL-21 in regulating immunoglobulin production. Science 298:1630–34 20a. Ozaki K, Hishiya A, Hatanaka K, Nakajima H, Wang G, et al. 2006. Overexpression of interleukin 21 induces expansion of hematopoietic progenitor cells. Int. J. Hematol. 84:224–30 21. Wu Z, Kim HP, Xue HH, Liu H, Zhao K, Leonard WJ. 2005. Interleukin-21 receptor gene induction in human T cells is mediated by T-cell receptor-induced Sp1 activity. Mol. Cell Biol. 25:9741–52 22. Jin H, Malek TR. 2006. Redundant and unique regulation of activated mouse B lymphocytes by IL-4 and IL-21. J. Leukoc. Biol. 80:1416–23 23. Good KL, Bryant VL, Tangye SG. 2006. Kinetics of human B cell behavior and ampliﬁcation of proliferative responses following stimulation with IL-21. J. Immunol. 177:5236–47 24. Brenne AT, Baa de Ro T, Waage A, Sundan A, Borset M, Hjorth-Hansen H. 2002. Interleukin-21 is a growth and survival factor for human myeloma cells. Blood 99:3756– 62 25. Suto A, Nakajima H, Hirose K, Suzuki K, Kagami S, et al. 2002. Interleukin 21 prevents antigen-induced IgE production by inhibiting germ line Cε transcription of IL-4stimulated B cells. Blood 100:4565–73 26. Wood N, Bourque K, Donaldson DD, Collins M, Vercelli D, et al. 2004. IL-21 effects on human IgE production in response to IL-4 or IL-13. Cell Immunol. 231:133–45 27. Puel A, Ziegler SF, Buckley RH, Leonard WJ. 1998. Defective IL7R expression in T− B+ NK+ severe combined immunodeﬁciency. Nat. Genet. 20:394–97 28. Mehta DS, Wurster AL, Whitters MJ, Young DA, Collins M, Grusby MJ. 2003. IL-21 induces the apoptosis of resting and activated primary B cells. J. Immunol. 170:4111– 18 29. Ozaki K, Spolski R, Ettinger R, Kim HP, Wang G, et al. 2004. Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6. J. Immunol. 173:5361–71 www.annualreviews.org • Interleukin-21

75

ARI

16 February 2008

11:18

30. Tsuruoka N, Arima M, Arguni E, Saito T, Kitayama D, et al. 2007. Bcl6 is required for the IL-4-mediated rescue of the B cells from apoptosis induced by IL-21. Immunol. Lett. 110:145–51 31. Calame KL, Lin KI, Tunyaplin C. 2003. Regulatory mechanisms that determine the development and function of plasma cells. Annu. Rev. Immunol. 21:205–30 32. Shaffer AL, Lin KI, Kuo TC, Yu X, Hurt EM, et al. 2002. Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. Immunity 17:51–62 33. Ettinger R, Sims GP, Fairhurst AM, Robbins R, da Silva YS, et al. 2005. IL-21 induces differentiation of human naive and memory B cells into antibody-secreting plasma cells. J. Immunol. 175:7867–79 34. Pene J, Gauchat JF, Lecart S, Drouet E, Guglielmi P, et al. 2004. Cutting edge: IL-21 is a switch factor for the production of IgG1 and IgG3 by human B cells. J. Immunol. 172:5154–57 35. Ettinger R, Sims GP, Robbins R, Withers D, Fischer RT, et al. 2007. IL-21 and BAFF/BLyS synergize in stimulating plasma cell differentiation from a unique population of human splenic memory B cells. J. Immunol. 178:2872–82 36. Ng LG, Mackay CR, Mackay F. 2005. The BAFF/APRIL system: life beyond B lymphocytes. Mol. Immunol. 42:763–72 37. Weaver CT, Hatton RD, Mangan PR, Harrington LE. 2007. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu. Rev. Immunol. 25:821–52 38. Wurster AL, Rodgers VL, Satoskar AR, Whitters MJ, Young DA, et al. 2002. Interleukin 21 is a T helper (Th) cell 2 cytokine that speciﬁcally inhibits the differentiation of naive Th cells into interferon γ-producing Th1 cells. J. Exp. Med. 196:969–77 39. Chtanova T, Tangye SG, Newton R, Frank N, Hodge MR, et al. 2004. T follicular helper cells express a distinctive transcriptional proﬁle, reﬂecting their role as non-Th1/Th2 effector cells that provide help for B cells. J. Immunol. 173:68–78 40. Korn T, Bettelli E, Gao W, Awasthi A, J¨ager A, et al. 2007. IL-21 initiates an alternative pathway to induce proinﬂammatory TH 17 cells. Nature 448:484–87 41. Nurieva R, Yang XO, Martinez G, Zhang Y, Panopoulos AD, et al. 2007. Essential autocrine regulation by IL-21 in the generation of inﬂammatory T cells. Nature 448:480– 83 42. Zhou L, Ivanov II, Spolski R, Min R, Shenderov K, et al. 2007. IL-6 programs TH -17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat. Immunol. 8:967–74 43. Suto A, Wurster AL, Reiner SL, Grusby MJ. 2006. IL-21 inhibits IFN-γ production in developing Th1 cells through the repression of Eomesodermin expression. J. Immunol. 177:3721–27 44. Strengell M, Sareneva T, Foster D, Julkunen I, Matikainen S. 2002. IL-21 up-regulates the expression of genes associated with innate immunity and Th1 response. J. Immunol. 169:3600–5 45. Pesce J, Kaviratne M, Ramalingam TR, Thompson RW, Urban JF Jr, et al. 2006. The IL-21 receptor augments Th2 effector function and alternative macrophage activation. J. Clin. Invest. 116:2044–55 46. Frohlich A, Marsland BJ, Sonderegger I, Kurrer M, Hodge MR, et al. 2007. IL-21 receptor signaling is integral to the development of Th2 effector responses in vivo. Blood 109:2023–31

Annu. Rev. Immunol. 2008.26:57-79. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-03

76

Spolski

·

Leonard

Annu. Rev. Immunol. 2008.26:57-79. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-03

ARI

16 February 2008

11:18

47. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, et al. 2005. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat. Immunol. 6:1123–32 48. Park H, Li Z, Yang XO, Chang SH, Nurieva R, et al. 2005. A distinct lineage of CD4 T cells regulates tissue inﬂammation by producing interleukin 17. Nat. Immunol. 6:1133– 41 49. Li MO, Sanjabi S, Flavell RA. 2006. Transforming growth factor-β controls development, homeostasis, and tolerance of T cells by regulatory T cell-dependent and -independent mechanisms. Immunity 25:455–71 50. Mangan PR, Harrington LE, O’Quinn DB, Helms WS, Bullard DC, et al. 2006. Transforming growth factor-β induces development of the TH 17 lineage. Nature 441:231–34 51. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, et al. 2006. Reciprocal developmental pathways for the generation of pathogenic effector TH 17 and regulatory T cells. Nature 441:235–38 52. Kastelein RA, Hunter CA, Cua DJ. 2007. Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inﬂammation. Annu. Rev. Immunol. 25:221– 42 53. Bettelli E, Oukka M, Kuchroo VK. 2007. TH -17 cells in the circle of immunity and autoimmunity. Nat. Immunol. 8:345–50 54. Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, et al. 2006. The orphan nuclear receptor RORγt directs the differentiation program of proinﬂammatory IL-17+ T helper cells. Cell 126:1121–33 55. Zeng R, Spolski R, Finkelstein SE, Oh S, Kovanen PE, et al. 2005. Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. J. Exp. Med. 201:139–48 56. Schluns KS, Kieper WC, Jameson SC, Lefrancois L. 2000. Interleukin-7 mediates the homeostasis of na¨ıve and memory CD8 T cells in vivo. Nat. Immunol. 1:426–32 57. Zhang X, Sun S, Hwang I, Tough DF, Sprent J. 1998. Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15. Immunity 8:591–99 58. Alves NL, Arosa FA, van Lier RA. 2005. IL-21 sustains CD28 expression on IL-15activated human naive CD8+ T cells. J. Immunol. 175:755–62 59. Li Y, Bleakley M, Yee C. 2005. IL-21 inﬂuences the frequency, phenotype, and afﬁnity of the antigen-speciﬁc CD8 T cell response. J. Immunol. 175:2261–69 60. White L, Krishnan S, Strbo N, Liu H, Kolber MA, et al. 2007. Differential effects of IL-21 and IL-15 on perforin expression, lysosomal degranulation, and proliferation in CD8 T cells of patients with human immunodeﬁciency virus-1 (HIV). Blood 109:3873–80 61. Cao X, Shores EW, Hu-Li J, Anver MR, Kelsall BL, et al. 1995. Defective lymphoid development in mice lacking expression of the common cytokine receptor γ chain. Immunity 2:223–38 62. DiSanto JP, Muller W, Guy-Grand D, Fischer A, Rajewsky K. 1995. Lymphoid development in mice with a targeted deletion of the interleukin 2 receptor γ chain. Proc. Natl. Acad. Sci. USA 92:377–81 63. Kasaian MT, Whitters MJ, Carter LL, Lowe LD, Jussif JM, et al. 2002. IL-21 limits NK cell responses and promotes antigen-speciﬁc T cell activation: a mediator of the transition from innate to adaptive immunity. Immunity 16:559–69 64. Vosshenrich CA, Ranson T, Samson SI, Corcuff E, Colucci F, et al. 2005. Roles for common cytokine receptor γ-chain-dependent cytokines in the generation, differentiation, and maturation of NK cell precursors and peripheral NK cells in vivo. J. Immunol. 174:1213–21 www.annualreviews.org • Interleukin-21

77

ARI

16 February 2008

11:18

65. Sivori S, Cantoni C, Parolini S, Marcenaro E, Conte R, et al. 2003. IL-21 induces both rapid maturation of human CD34+ cell precursors towards NK cells and acquisition of surface killer Ig-like receptors. Eur. J. Immunol. 33:3439–47 66. Toomey JA, Gays F, Foster D, Brooks CG. 2003. Cytokine requirements for the growth and development of mouse NK cells in vitro. J. Leukoc. Biol. 74:233–42 67. Brady J, Hayakawa Y, Smyth MJ, Nutt SL. 2004. IL-21 induces the functional maturation of murine NK cells. J. Immunol. 172:2048–58 68. Gays F, Martin K, Kenefeck R, Aust JG, Brooks CG. 2005. Multiple cytokines regulate the NK gene complex-encoded receptor repertoire of mature NK cells and T cells. J. Immunol. 175:2938–47 69. Burgess SJ, Marusina AI, Pathmanathan I, Borrego F, Coligan JE. 2006. IL-21 downregulates NKG2D/DAP10 expression on human NK and CD8+ T cells. J. Immunol. 176:1490–97 70. Godfrey DI, Kronenberg M. 2004. Going both ways: immune regulation via CD1ddependent NKT cells. J. Clin. Invest. 114:1379–88 71. Wang G, Tschoi M, Spolski R, Lou Y, Ozaki K, et al. 2003. In vivo antitumor activity of interleukin 21 mediated by natural killer cells. Cancer Res. 63:9016–22 72. Pelletier M, Bouchard A, Girard D. 2004. In vivo and in vitro roles of IL-21 in inﬂammation. J. Immunol. 173:7521–30 73. Ugai S, Shimozato O, Yu L, Wang YQ, Kawamura K, et al. 2003. Transduction of the IL-21 and IL-23 genes in human pancreatic carcinoma cells produces natural killer celldependent and -independent antitumor effects. Cancer Gene Ther. 10:771–78 74. Di Carlo E, Comes A, Orengo AM, Rosso O, Meazza R, et al. 2004. IL-21 induces tumor rejection by speciﬁc CTL and IFN-γ-dependent CXC chemokines in syngeneic mice. J. Immunol. 172:1540–47 75. Takaki R, Hayakawa Y, Nelson A, Sivakumar PV, Hughes S, et al. 2005. IL-21 enhances tumor rejection through a NKG2D-dependent mechanism. J. Immunol. 175:2167–73 76. Moroz A, Eppolito C, Li Q, Tao J, Clegg CH, Shrikant PA. 2004. IL-21 enhances and sustains CD8+ T cell responses to achieve durable tumor immunity: comparative evaluation of IL-2, IL-15, and IL-21. J. Immunol. 173:900–9 77. He H, Wisner P, Yang G, Hu HM, Haley D, et al. 2006. Combined IL-21 and low-dose IL-2 therapy induces antitumor immunity and long-term curative effects in a murine melanoma tumor model. J. Transl. Med. 4:24 78. Takeda K, Stagg J, Yagita H, Okumura K, Smyth MJ. 2007. Targeting death-inducing receptors in cancer therapy. Oncogene 26:3745–57 79. Takeda K, Yamaguchi N, Akiba H, Kojima Y, Hayakawa Y, et al. 2004. Induction of tumor-speciﬁc T cell immunity by anti-DR5 antibody therapy. J. Exp. Med. 199:437– 48 80. Roda JM, Parihar R, Lehman A, Mani A, Tridandapani S, Carson WE 3rd. 2006. Interleukin-21 enhances NK cell activation in response to antibody-coated targets. J. Immunol. 177:120–29 81. Smyth MJ, Hayakawa Y, Cretney E, Zerafa N, Sivakumar P, et al. 2006. IL-21 enhances tumor-speciﬁc CTL induction by anti-DR5 antibody therapy. J. Immunol. 176:6347–55 82. Smyth MJ, Crowe NY, Pellicci DG, Kyparissoudis K, Kelly JM, et al. 2002. Sequential production of interferon-γ by NK1.1+ T cells and natural killer cells is essential for the antimetastatic effect of α-galactosylceramide. Blood 99:1259–66 83. Smyth MJ, Wallace ME, Nutt SL, Yagita H, Godfrey DI, Hayakawa Y. 2005. Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer. J. Exp. Med. 201:1973–85

Annu. Rev. Immunol. 2008.26:57-79. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-03

78

Spolski

·

Leonard

Annu. Rev. Immunol. 2008.26:57-79. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-03

ARI

16 February 2008

11:18

84. Davis ID, Skrumsager BK, Cebon J, Nicholaou T, Barlow JW, et al. 2007. An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma. Clin. Cancer Res. 13:3630–36 85. Vinuesa CG, Cook MC, Angelucci C, Athanasopoulos V, Rui L, et al. 2005. A RINGtype ubiquitin ligase family member required to repress follicular helper T cells and autoimmunity. Nature 435:452–58 86. Herber D, Brown TP, Liang S, Young DA, Collins M, Dunussi-Joannopoulos K. 2007. IL-21 has a pathogenic role in a lupus-prone mouse model and its blockade with IL21R.Fc reduces disease progression. J. Immunol. 178:3822–30 87. Young DA, Hegen M, Ma HL, Whitters MJ, Albert LM, et al. 2007. Blockade of the interleukin-21/interleukin-21 receptor pathway ameliorates disease in animal models of rheumatoid arthritis. Arthritis Rheum. 56:1152–63 88. Denny P, Lord CJ, Hill NJ, Goy JV, Levy ER, et al. 1997. Mapping of the IDDM locus Idd3 to a 0. 35-cM interval containing the interleukin-2 gene. Diabetes 46:695–700 89. King C, Ilic A, Koelsch K, Sarvetnick N. 2004. Homeostatic expansion of T cells during immune insufﬁciency generates autoimmunity. Cell 117:265–77 90. Yamanouchi J, Rainbow D, Serra P, Howlett S, Hunter K, et al. 2007. Interleukin-2 gene variation impairs regulatory T cell function and causes autoimmunity. Nat. Genet. 39:329–37 91. Vollmer TL, Liu R, Price M, Rhodes S, La Cava A, Shi FD. 2005. Differential effects of IL-21 during initiation and progression of autoimmunity against neuroantigen. J. Immunol. 174:2696–701 92. Komiyama Y, Nakae S, Matsuki T, Nambu A, Ishigame H, et al. 2006. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J. Immunol. 177:566–73

www.annualreviews.org • Interleukin-21

79

AR338-FM

ARI

12 January 2008

18:11

Annual Review of Immunology

Annu. Rev. Immunol. 2008.26:57-79. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

Contents

Volume 26, 2008

Frontispiece K. Frank Austen p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p x Doing What I Like K. Frank Austen p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p1 Protein Tyrosine Phosphatases in Autoimmunity Torkel Vang, Ana V. Miletic, Yutaka Arimura, Lutz Tautz, Robert C. Rickert, and Tomas Mustelin p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p 29 Interleukin-21: Basic Biology and Implications for Cancer and Autoimmunity Rosanne Spolski and Warren J. Leonard p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p 57 Forward Genetic Dissection of Immunity to Infection in the Mouse S.M. Vidal, D. Malo, J.-F. Marquis, and P. Gros p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p 81 Regulation and Functions of Blimp-1 in T and B Lymphocytes Gislâine Martins and Kathryn Calame p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p133 Evolutionarily Conserved Amino Acids That Control TCR-MHC Interaction Philippa Marrack, James P. Scott-Browne, Shaodong Dai, Laurent Gapin, and John W. Kappler p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p171 T Cell Trafﬁcking in Allergic Asthma: The Ins and Outs Benjamin D. Medoff, Seddon Y. Thomas, and Andrew D. Luster p p p p p p p p p p p p p p p p p p p p p205 The Actin Cytoskeleton in T Cell Activation Janis K. Burkhardt, Esteban Carrizosa, and Meredith H. Shaffer p p p p p p p p p p p p p p p p p p p p233 Mechanism and Regulation of Class Switch Recombination Janet Stavnezer, Jeroen E.J. Guikema, and Carol E. Schrader p p p p p p p p p p p p p p p p p p p p p p p261 Migration of Dendritic Cell Subsets and their Precursors Gwendalyn J. Randolph, Jordi Ochando, and Santiago Partida-Sánchez p p p p p p p p p p p p p293

v

AR338-FM

ARI

12 January 2008

18:11

The APOBEC3 Cytidine Deaminases: An Innate Defensive Network Opposing Exogenous Retroviruses and Endogenous Retroelements Ya-Lin Chiu and Warner C. Greene p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p317 Thymus Organogenesis Hans-Reimer Rodewald p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p355 Death by a Thousand Cuts: Granzyme Pathways of Programmed Cell Death Dipanjan Chowdhury and Judy Lieberman p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p389 Annu. Rev. Immunol. 2008.26:57-79. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

Monocyte-Mediated Defense Against Microbial Pathogens Natalya V. Serbina, Ting Jia, Tobias M. Hohl, and Eric G. Pamer p p p p p p p p p p p p p p p p p p p421 The Biology of Interleukin-2 Thomas R. Malek p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p453 The Biochemistry of Somatic Hypermutation Jonathan U. Peled, Fei Li Kuang, Maria D. Iglesias-Ussel, Sergio Roa, Susan L. Kalis, Myron F. Goodman, and Matthew D. Scharff p p p p p p p p p p p p p p p p p p p p p481 Anti-Inﬂammatory Actions of Intravenous Immunoglobulin Falk Nimmerjahn and Jeffrey V. Ravetch p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p513 The IRF Family Transcription Factors in Immunity and Oncogenesis Tomohiko Tamura, Hideyuki Yanai, David Savitsky, and Tadatsugu Taniguchi p p p p p535 Choreography of Cell Motility and Interaction Dynamics Imaged by Two-Photon Microscopy in Lymphoid Organs Michael D. Cahalan and Ian Parker p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p585 Development of Secondary Lymphoid Organs Troy D. Randall, Damian M. Carragher, and Javier Rangel-Moreno p p p p p p p p p p p p p p p p627 Immunity to Citrullinated Proteins in Rheumatoid Arthritis Lars Klareskog, Johan Rönnelid, Karin Lundberg, Leonid Padyukov, and Lars Alfredsson p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p651 PD-1 and Its Ligands in Tolerance and Immunity Mary E. Keir, Manish J. Butte, Gordon J. Freeman, and Arlene H. Sharpe p p p p p p p p677 The Master Switch: The Role of Mast Cells in Autoimmunity and Tolerance Blayne A. Sayed, Alison Christy, Mary R. Quirion, and Melissa A. Brown p p p p p p p p p p705 T Follicular Helper (TFH ) Cells in Normal and Dysregulated Immune Responses Cecile King, Stuart G. Tangye, and Charles R. Mackay p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p741

vi

Contents

Annu. Rev. Immunol. 2008.26:81-132. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-04

ARI

16 February 2008

11:22

Forward Genetic Dissection of Immunity to Infection in the Mouse S.M. Vidal,1,∗ D. Malo,2,∗ J.-F. Marquis,3 and P. Gros3,∗ 1

Department of Microbiology and Immunology, 2 Research Institute of the McGill University Health Center and Department of Human Genetics, and 3 Department of Biochemistry, McGill University, Montreal, Quebec, Canada H3G 1Y6; email: [email protected]

Annu. Rev. Immunol. 2008. 26:81–132

Key Words

First published online as a Review in Advance on October 22, 2007

forward genetics, positional cloning, macrophage, NK cell, innate immunity

The Annual Review of Immunology is online at immunol.annualreviews.org This article’s doi: 10.1146/annurev.immunol.26.021607.090304 c 2008 by Annual Reviews. Copyright All rights reserved 0732-0582/08/0423-0081$20.00 ∗

Authors contributed equally to this review.

Abstract Forward genetics is an experimental approach in which gene mapping and positional cloning are used to elucidate the molecular mechanisms underlying phenotypic differences between two individuals for a given trait. This strategy has been highly successful for the study of inbred mouse strains that show differences in innate susceptibility to bacterial, parasitic, fungal, and viral infections. Over the past 20 years, these studies have led to the identiﬁcation of a number of cell populations and critical biochemical pathways and proteins that are essential for the early detection of and response to invading pathogens. Strikingly, the macrophage is the point of convergence for many of these genetic studies. This has led to the identiﬁcation of diverse pathways involved in extracellular and intracellular pathogen recognition, modiﬁcation of the properties and content of phagosomes, transcriptional response, and signal transduction for activation of adaptive immune mechanisms. In models of viral infections, elegant genetic studies highlighted the pivotal role of natural killer cells in the detection and destruction of infected cells.

81

ANRV338-IY26-04

ARI

16 February 2008

11:22

INTRODUCTION

Annu. Rev. Immunol. 2008.26:81-132. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

Infectious diseases continue to be a major determinant of global health, exacerbated by recent factors, such as global population growth, an increase in the number and size of vulnerable populations, limited access to medical care in areas of endemic disease, and the human immunodeﬁciency virus (HIV) pandemic. Increased worldwide travel has further facilitated the export of several diseases to nonendemic areas. The impact of infectious diseases has been most severe in the developing world owing to the degradation of socioeconomic conditions, movement to new habitats, and, importantly, emergence of drug resistance and the lack of efﬁcacious vaccines leading to the remarkable resurgence of old foes, such as malaria and tuberculosis (TB) (1) (http://www.who.int). In addition to environmental factors, the health status of the host, and virulence determinants of the pathogen, clinical epidemiology and population studies as well as studies in twins have shown that host genetic factors play an important role, particularly in the onset but also in the progression of infection, the type of disease developed, and the ultimate outcome of infection with many pathogens (2, 3). In fact, infectious agents may have exerted the single most powerful evolutionary pressure on the human genome. Spectacular examples of the effect of infectious agents on the human genome include the protective effects of CCR5 mutations against HIV/AIDS (4) and the malaria-protective effect of heterozygosity at otherwise diseasecausing hemoglobinopathies, such as sickle cell anemia and thalassemias (5). Researchers have identiﬁed additional single-gene effects in humans that cause either selective or generalized immunodeﬁciencies, phenotypically expressed as an innate susceptibility to certain types of bacterial and viral infections (6). The study of these infrequent single-gene effects in humans is useful for better understanding the molecular pathogenesis of infection, but it also reveals normal host defense mechanisms that can potentially be used as novel targets for 82

Vidal et al.

drug discovery and therapeutic intervention in these diseases (7). However, linkage and association studies show that the genetic component of susceptibility to infection is usually complex and multigenic, which reﬂects the plurality of cell types and physiological and biochemical pathways involved in both the initial sensing of and the dynamic response to a pathogen (2). This complex host:microbe interaction interface gives rise to apparent genetic heterogeneity, incomplete penetrance, and variable expressivity that together reduce the power of standard genetic association or linkage studies. The laboratory mouse has proven to be extremely useful in the dissection of the genetic architecture of host defenses against many infectious diseases (8–11). Indeed, there exist excellent mouse models of experimental infection with many human pathogens, in which several aspects of the human disease are accurately reproduced: These include pathogenesis (tissues and cells involved, types and progression of lesions developed) and physiological responses (inﬂammation, immunity, etc.). These physiological responses can be studied in an environment in which pathogenassociated variables such as strain, virulence, dose, and route of infection can be carefully controlled. In addition, excellent immunological and biochemical reagents in the form of assays, markers, and antibodies are available to characterize innate and adaptive immune responses in these infection models. From a genetic standpoint, a number of inbred, recombinant, and naturally occurring or experimentally induced mutants [such as N-ethyl-N-nitrosourea (ENU)-induced mutants] exist that can be used to search for polymorphic alleles and major gene effects that affect onset, progression, host response, and ultimate outcome of infection. Additional mapping stocks such as recombinant inbred, recombinant congenic, and large multistrain intercross can sometimes be used to deconvolute multigenic effects into monogenic traits. With the sequencing and annotation of the mouse genome, good mapping tools are now

Annu. Rev. Immunol. 2008.26:81-132. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-04

ARI

16 February 2008

11:22

available in the form of haplotype maps and informative markers, such as single nucleotide polymorphisms (SNPs) and simple sequence length polymorphisms (SSLPs). In addition, mRNA expression data are available for most genes, which facilitates the prioritization of candidate genes for positional cloning. Finally, germ line modiﬁcation in transgenic mice can be used to generate gain- or lossof-function alleles for validation of the role of individual genes. Generally, two major genetic approaches in the mouse have been used to identify host proteins and biochemical pathways that affect host response to infection with viral, parasitic, fungal, and bacterial pathogens. The ﬁrst is the reverse genetics approach in which the role of an individual gene is tested by directly infecting mice carrying a loss-of-function mutation (usually a deletion) at the corresponding locus. Usually, a possible role for a gene of interest is based on prior direct or indirect evidence that links the gene to pathogenesis or response to infection; researchers then examine the mutant for evidence supporting such a role. The second approach, which is the focus of this review, is the study of differential susceptibility of inbred mouse strains to infection with bacterial, parasitic, and viral pathogens. The major advantage of this socalled forward genetics approach is that the effect of the gene(s) on susceptibility is already validated in vivo. An obvious disadvantage of this approach is that the genetic effect may be complex, with individual monogenic contributions possibly difﬁcult to delineate. Nevertheless, this approach has been extremely successful in the study of infectious diseases and has revealed a treasure trove of genes, proteins, and signaling pathways that play critical roles in the immune response to a large number of infectious agents. We describe some of the most informative examples of such discoveries (summarized in Table 1 and Figure 1), with an emphasis on the implications of the discovered genes and proteins for our evolving understanding of innate or acquired immune defenses.

THE Ity-Lsh-Bcg LOCUS: REGULATION OF MACROPHAGE INTRACELLULAR IRON BY Nramp1/Slc11a1 Speciﬁc groups of pathogens penetrate host cells and proliferate, sheltered in the intracellular milieu. Certain microbes enter different cell types via an active microbe-driven invasion process, whereas others can survive and replicate after engulfment by professional phagocytes (macrophages, monocytes, and neutrophils). The intracellular environment provides a replicative niche rich in nutrients and sheltered from attacks by the host immune system. In the case of engulfment by professional phagocytes, intracellular pathogens have evolved mechanisms to escape or resist the microbicidal arsenal of these cells: These mechanisms include escape from the phagosome (Listeria), modulation of phagosome maturation (Mycobacterium, Legionella, Salmonella), and survival in fully mature phagolysosomes (Leishmania) (12–15). Understanding the genetic basis of differential susceptibility to infection with intracellular pathogens in inbred mouse strains has proven extremely informative for understanding the interface of host:pathogen interaction and identifying normal defense mechanisms of phagocytes that may fail in permissive hosts. The Ity-Lsh-Bcg locus constitutes one of the oldest and best studied examples of a single mutation in mouse with pleiotropic consequences on host defenses against unrelated intracellular pathogens (for historical reviews, please see References 16 and 17). Thirty years ago, several groups independently noted interstrain differences in susceptibility to infection with Salmonella enterica serovar Typhimurium (S. Typhimurium), Leishmania donovani, and Mycobacterium bovis (BCG). Segregation analyses showed that differences in susceptibility were controlled by a single gene, which was given the appellation Ity, Lsh, and Bcg. Concordance in differential www.annualreviews.org • Immunity to Infection in the Mouse

83

ANRV338-IY26-04

Table 1

ARI

16 February 2008

Host resistance loci revealed by forward genetics approachesa

Pathogen(s)

Annu. Rev. Immunol. 2008.26:81-132. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

11:22

Locus (Gene)

Main cell type(s)

Protein function or biological process/mechanism of action

Reference(s)

Salmonella Typhimurium Leishmania donovani Mycobacterium bovis (BCG)

Ity-Lsh-Bcg (Nramp1)

M

Iron transporter/regulation of intraphagosomal iron

16, 17, 20

Salmonella Typhimurium

Lps (Tlr4)

M

Surface receptor for bacterial LPS/cellular recognition of LPS

63, 64, 70, 75

Salmonella Typhimurium

xid (btk)

B

Tyrosine kinase/tegulation of B cell development

60, 65, 66

Legionella pneumophila

Lgn1 (Birc1e)

M

NLR protein/intracellular antigen recognition

113, 114

Bacillus anthracis

Ltsx1 (Nalp1b)

M

NLR protein/sensing of anthrax toxin

125, 126, 128

Mycobacterium bovis (BCG) Salmonella Typhimurium Plasmodium chabaudi AS Mycobacterium tuberculosis

Myls (Icsbp/IRF8)

M

Transcriptional regulator/regulation of the IL-12 and IFN-γ pathway

130, 134, 135

Mycobacterium tuberculosis Listeria monocytogenes

sst1 (Ipr1)

M

Transcriptional regulator/transcriptional activation in response to intracellular pathogens

139, 144–146

Candida albicans Listeria monocytogenes

C5 (C5a)

unknown

Component of complement cascade/proinﬂammatory activity

156–158, 161, 162

Plasmodium chabaudi AS

Char4 (Pklr)

E

Pyruvate kinase/glycolysis in erythrocytes (role for ATP production)

167–170

Plasmodium chabaudi AS

Char9 (Vnn1/Vnn3)

E

Pantetheinases/production of the antioxidant cysteamine

167, 171

Toxoplasma gondii

Tyk2 (Tyk2)

M

Jak kinase/cellular signaling by cytokine receptors

180, 181

Orientia tsutsugamushi

Ric (Spp1)

M, T, NK

Phosphoprotein/recruitment of leukocytes and T cell polarization

187, 189, 190, 192, 193

Chlamydia trachomatis

Ctrq3 (Irgb10)

M and others

p47GTPase/mediator of the inhibitory effect of IFN-γ

197, 199

Orthomyxovirus (inﬂuenza)

Mx (Mx1)

M

GTPase/inhibition of viral genome transcription

206–209

Coronavirus (MHV)

Hv2 (Ceacam1)

EP

Transmembrane glycoprotein (with Ig domains)/adhesion molecule, signal regulatory protein

236–239

West Nile Virus (WNV)

Flv (Oas1b)

M

Oligoadenylate synthetase/part of the OAS/RNase L system of RNA decay pathway stimulated by type I IFN

257–259

Cytomegalovirus (MCMV)

Cmv1 (Ly49h)

NK

MHC class I receptor/recognition of infected cells by NK cell receptors

272, 274–276, 277–280

Staphylococcus aureus

Obl (Cd36 )

M

Scavenger receptor type B/regulation of the Tlr2/6-dependent signaling pathway

299

Vesicular stomatitis virus (VSV) Vaccinia virus

Lps2 (Trif )

M

Toll-receptor–associated activator of IFN/regulation of the Tlr3- and Tlr4-dependent signaling pathway

300, 305–308

Cytomegalovirus (MCMV)

Cpg1 (Tlr9)

M

Transmembrane receptor/recognition of pathogen-derived molecules

301, 309

84

Vidal et al.

ANRV338-IY26-04

Table 1

ARI

16 February 2008

(Continued )

Pathogen(s)

Annu. Rev. Immunol. 2008.26:81-132. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

11:22

Locus (Gene)

Main cell type(s)

Protein function or biological process/mechanism of action

Reference(s)

Cytomegalovirus (MCMV) Staphylococcus aureus Listeria monocytogenes

3d (Unc93b)

M

Molecular mechanism unknown/regulation of the Tlr3, Tlr7 and Tlr9-dependent signaling pathway

295, 302, 310

Cytomegalovirus (MCMV) Listeria monocytogenes Vesicular stomatitis virus (VSV)

Domino (Stat1)

M

Transcription factor/activated by IFN

313, 315

Cytomegalovirus (MCMV)

Jinx (Unc13d)

NK, CTL

Membrane trafﬁcking/priming (fusion) of cytoplasmic vesicles

314, 316

a M, macrophages; E, erythrocytes; NK, natural killer cells; CTL, cytotoxic T lymphocytes; T, T cells; EP, epithelial cells; LPS, lipopolysaccharide; NLR, nucleotide-binding oligomerization domain (NOD)-like receptor; IL-12, interleukin-12; IFN-γ, interferon-γ; Jak, Janus kinase; p47GTPase, p47 family of IFN-γ-inducible GTPases; OAS, oligoadenylate synthetase; MHC, major histocompatibility complex; TLR, Toll-like receptor.

susceptibility to the three pathogens among inbred strains and in recombinant inbred strains (RIS) (bred from resistant and susceptible parents), together with cosegregation in progeny-testing experiments and colocalization of the three loci to the same proximal chromosome 1 domain, strongly suggested that Ity, Lsh, and Bcg were in fact the same locus (18, 19). In the three infection models, phenotypic expression of the locus is characterized by differential growth of the three pathogens in the spleen and liver, a phenomenon that can be reproduced in explanted macrophage populations ex vivo, which identiﬁed macrophages as responsible for the gene effect (17). The gene responsible for the ItyLsh-Bcg effect was one of the earliest genes to be isolated by positional cloning, which was in those days a laborious approach based on high-resolution linkage mapping, physical mapping by restriction enzyme analysis using pulsed-ﬁeld gel electrophoresis, and the creation of a transcript map of the minimal physical interval via delineation of CpG islands and isolation of splicing-competent exons (20). Based on its tissue speciﬁc expression in liver, spleen, and macrophages, a positional candidate, Nramp1 [natural resistance–associated macrophage protein 1, now annotated as so-

lute carrier family 11 member 1 (Slc11a1)] was selected from ﬁve candidates for further study. Nramp1 encodes a membrane phosphoglycoprotein with 12 putative transmembrane domains. Studies in inbred strains of mice showed that susceptibility to infections was associated with a single Gly169Asp (G169D) mutation in predicted TM4 of the protein (20). The G169D mutation impairs protein folding and processing, which results in the absence of mature Nramp1 polypeptide in the membrane compartment of susceptible cells (21). Researchers validated Nramp1 as the gene underlying Ity-Lsh-Bcg by creating a null mutation (knockout) and demonstrating that this otherwise resistant 129Sv mouse stock becomes susceptible to S. Typhimurium, L. donovani, and M. bovis (BCG) infections when Nramp1 is deleted (22). Also, transfer of the Nramp1G169 allele onto the C57BL/6J (Nramp1D169 ) background restores resistance to infection (23). Finally, the human gene, NRAMP1, was cloned and studied for a possible role in resistance and susceptibility to mycobacterial infections in humans (24). Brieﬂy, NRAMP1 maps on human chromosome 2q35, and researchers used numerous polymorphic variants within or outside the gene, including functional promotor www.annualreviews.org • Immunity to Infection in the Mouse

85

ANRV338-IY26-04

ARI

16 February 2008

11:22

during a TB outbreak in a Canadian Aboriginal family (26) and in pediatric TB cases from South Africa (27). Additional studies have shown that NRAMP1 is involved in susceptibility to two other common mycobacterial diseases, leprosy (28, 29) and Buruli ulcer (30).

polymorphisms, in case-control and familybased studies. NRAMP1 variants were consistently found to be associated with susceptibility to pulmonary TB in African and Asian populations but not in populations of European descent (25). In addition, direct genetic linkage data were obtained for NRAMP1

Chr. 1

A3

A5

B

C1

C2 C3

Stat1

Annu. Rev. Immunol. 2008.26:81-132. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

Chr. 2

A2 A3

A1

C5

E1 E2

D

Nramp1 B

C1

C3

E2

F

H1 H2 H3 H4

H6

H1 H2

H4

Ipr1 E1

D

E2 E3

E5 F2 F3

H3

C5a Chr. 3

A1 A2

A3

B

C

E1

D

E3

F1

F2

G1 G2 G3 H1

F3

H2

H3

H4

Pklr Chr. 4

A1 A2

A3

B2 B3

A5

C1 C2

C3

C5 C6

C7

D1

E1 E2

D3

Tlr4 Chr. 5

A1 A2

B1 B2 B3 C1

A3

D

Chr. 6

A2

A1

A3

B1

E2 E3 E4 E5

E1

Cd36

F

B3

B2

C1

Oas1b

D1 D2 D3 E1 E2 E3 F1 F2 F3

C3

Ly49p Chr. 7

A1

A2

C

A3 B1 B2 B3 B4 B5

D2

G2 G3

G1

Spp1

E1

E3 F1

F2

G3

G1

Ly49h F3

F4

F5

Ceacam1 Chr. 8

A2

A3

Chr. 9

A1 A2 A3

A4

B2 B3.1 B3.2 B3.3 C1 C2

C3 C4 C5

D1

D3

E1

E2

Icsbp/IRF8 B

C

D

E4

E1

F2 F3 F4

F1

Tyk2 Chr. 10

A1

A2

A3 A4

Tlr9

B1

B3

B2

B4

C1

C2

C3

D1

D2

D3

Vnn1/Vnn3 Chr. 11

A1 A2

A4

A5

B1.1 B1.2 B1.3 B2

Irgb10 Chr. 13

A2 A3.1

A1

A5

A3.3 A4

B1

B3

B4

C

B5

Nalp1b B2

B3

D

E1

E2

Unc13d

C1

C3

D1

Birc1e Chr. 16

A2 A3

B1

B2

B3

B4

B5

C1.1 C1.2 C1.3 C2 C3.1

C3.2

C3.3

C4

Mx1 Chr. 17

A2

A1

B1

B2

B3

C

D

E1.1 E1.2 E1.3 E2

A

B

E4

E5

Trif

H2-D Chr. 19

E3

C1

C2

C3

D1

D2

D3

Unc93b Chr. X

A2

A4

A5

A6

B

C1 C2 C3

D

E1 E2 E3 F1

F2 F3 F4 F5

Btk 86

Vidal et al.

Annu. Rev. Immunol. 2008.26:81-132. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-04

ARI

16 February 2008

11:22

The Slc11a1 protein is present in the membrane of (a) Lamp-1+ lysosomes of macrophages and monocytes and (b) gelatinase+ tertiary granules of neutrophils (31, 32). Upon phagocytosis of inert particles or live microbes, Slc11a1 is rapidly recruited to the membrane of the maturing phagosome (31, 32). Clues about the function of Slc11a1 at the phagosomal membrane came from the discovery that the close mammalian relative Slc11a2 (Nramp2, DCT1, DMT1; ∼75% similarity to Slc11a1) functions as a pH-dependent iron (Fe2+ ) transport system (33, 34). Slc11a2 is required for the acquisition of nutritional iron at the duodenum brush border and acts as a transporter of transferrin-associated iron across the membrane of recycling endosomes in many cell types. Mutations in mouse and human (35) Slc11a2/Nramp2 cause a severe form of microcytic anemia (35, 36). Subsequently, microﬂuorescence imaging studies in live macrophages using inert particles labeled with metal-sensitive ﬂuorophores, together with studies in transfected CHO cells, showed that Slc11a1 (Nramp1) similarly functions as a metal efﬂux pump for Mn2+ and Fe2+ ions at the phagosomal membrane (37, 38). Transport occurs down a pro-

ton gradient generated by the concanamycinsensitive vacuolar H+ /ATPase. Therefore, Nramp1 and Nramp2 transport metal ions by the same mechanism but individually perform this activity in a cell type– and subcellular compartment–speciﬁc fashion. Consequently, the antimicrobial effect of Nramp1/Slc11a1 against different infectious agents can be explained by its capacity to restrict metal ions from the phagosomal space. The mechanism by which Nramp1mediated iron restriction negatively affects intracellular microbial survival/growth was investigated using phagosomes containing Mycobacterium, Salmonella, and Leishmania. Using M. bovis (BCG) and Mycobacterium avium as test pathogens, investigators showed that Nramp1 recruitment to the phagosomal membrane abrogates the ability of mycobacteria to block phagosome maturation, which causes increased acidiﬁcation, enhanced fusion to lysosomes, augmented mycobacterial cell damage, and reduced intracellular replication (39, 40). In the case of Salmonellacontaining vacuoles (SCV), recruitment of Nramp1 similarly antagonizes the ability of Salmonella to modulate phagosome maturation, which causes enhanced association

←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−− Figure 1 Chromosomal location of mouse genes affecting susceptibility to infections and identiﬁed by forward genetics. The chromosomal position of host resistance-associated genes affecting susceptibility to infection with bacterial, viral, and parasitic pathogens is identiﬁed with respect to relevant mouse chromosomes. Map positions have been determined using the Mouse Ensembl annotation (www.ensembl.org/Mus musculus/index.html). The position of cytogenetically identiﬁable chromosomal bands is indicated. The chromosomes are not drawn to scale, and the exact position for each gene may differ slightly depending on the source of information. See text for details. [Abbreviations: Stat1, signal transducer and activator of transcription 1; Nramp1, natural-resistance-associated macrophage protein 1; Ipr1, intracellular pathogen resistance 1; C5a, complement component 5a; Pklr, pyruvate kinase liver and red blood cell; TLR, Toll-like receptor; Cd36, Cd36 antigen; Spp1, secreted phosphoprotein 1; Oas1b, 2 -5 oligoadenylate synthetase 1B; Ly49p, killer cell lectin-like receptor, subfamily A, member 16; Ly49h, killer cell lectin-like receptor, subfamily A, member 8; Ceacam1, CEA-related cell adhesion molecule 1; Icsbp, interferon (IFN) consensus sequence-binding protein; IRF8, IFN regulatory factor 8; Tyk2, tyrosine kinase 2; Vnn1/Vnn3, vanin 1 and 3; Irgb10, iron-regulated virulence protein 10; Nalp1b, NACHT, LRR, and Pyrin domain–containing 1b; Unc13d, unc-13 homolog D; Birc1e, baculoviral IAP repeat-containing 1e; Mx1, myxovirus resistance 1; H2-D, histocompatibility 2, D region; Trif, Toll receptor–associated activator of IFN; Unc93b, unc-93 homolog B; Btk, Bruton agammaglobulinemia tyrosine kinase.] www.annualreviews.org • Immunity to Infection in the Mouse

87

ARI

16 February 2008

11:22

of early endosomal proteins (e.g., EEA1, a ﬂuid phase marker) and the late endosomal protein, the mannose-6-phosphate receptor (M6PR) (41). Furthermore, the addition of membrane-permeant iron chelators to Nramp1-negative macrophages can recapitulate the Nramp1 effect and stimulate recruitment of M6PR and EEA1 to SCVs (42). Salmonella responds to Nramp1-mediated iron depletion by activating transcription of several virulence genes that map within the Salmonella pathogenicity island 2 (SPI2) region, including ssrA and sseJ (43). An adequate supply of iron is essential for intracellular survival of Salmonella, and iron stimulates intracellular growth of this bacterium (44). The Salmonella genome encodes several high- and low-afﬁnity transporters for ferric and ferrous iron ( fepBCDG, sitA-D, FeoABC, CorAD, and the Nramp homolog MntH ), and several of these transporters are essential for Salmonella virulence in vivo and for replication in Nramp1-negative macrophages (45, 46). Conversely, the presence of intracellular Salmonella is sensed by macrophages, which respond by activating an iron-restriction/extrusion pathway with enhanced expression of ferroportin (iron exporter), lipocalin 2, and heme oxygenase mRNAs (44). On a related note, Huynh and coworkers (47) recently identiﬁed the LIT1 protein as the major Fe2+ import system of Leishmania; LIT1 is uniquely expressed at the plasma membrane of the intracellular form of the parasite (amastigote), and it is essential for virulence in vivo and in macrophages ex vivo. LIT1 expression is induced in response to low iron levels, and LIT1 is differentially expressed in Nramp1positive (higher expression) and Nramp1negative (lower expression) macrophages (47). These studies highlight the critical role that iron plays at the interface of host:pathogen interaction, where metal transporters such as Nramp1 and ferroportin act as major defenses to restrict intracellular access to this essential nutrient.

Annu. Rev. Immunol. 2008.26:81-132. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-04

88

Vidal et al.

THE Lps LOCUS: CELLULAR RECOGNITION OF BACTERIAL LIPOPOLYSACCHARIDE BY TOLL-LIKE RECEPTOR 4 AND INNATE IMMUNITY TO SALMONELLA INFECTION Salmonella is a ubiquitous, facultative intracellular, Gram-negative bacterium that causes two major diseases in developed and developing countries: typhoid fever and salmonellosis. Salmonella enterica serovar Typhi (S. Typhi) is the causative agent of typhoid fever and affects 17 million people annually, with 200,000 associated deaths. Salmonellosis is one of the most common and widely distributed food-borne diseases (http://www.cdc.gov). The frequency of multidrug-resistant nontyphoidal Salmonella (NTS) is increasing in developing countries; the disease presents as bacteremia (invasive NTS) often without diarrhea (48). Several speciﬁc human populations are at increased risk of Salmonella infection, including patients with sickle cell anemia (49), chronic granulomatous disease (50), and Plasmodium falciparum infection (51). In addition, humans who harbor mutations in genes that regulate the activation of phagocytes (IFNGR1, IFNGR2, IL12B, IL12RB1, and STAT1) are highly susceptible to recurrent Salmonella infections (reviewed in 52). Increased incidence of Salmonella infections also occurs in individuals with immunodeﬁciencies such as common variable immunodeﬁcieny (CVID), X-linked agammaglobulinemia (XLA), major histocompatibility complex (MHC) class II deﬁciency, HIV infection, and ectodermal dysplasia with immunodeﬁciency (reviewed in 53). Several mouse models of Salmonella infection have been used for the study of host:pathogen interactions (54–57). The most widely used model is intravenous infection with S. Typhimurium, which causes systemic disease resembling typhoid fever. Response to this infection involves the activation of both the innate and adaptive immune responses of the host; genetic analysis in the

Annu. Rev. Immunol. 2008.26:81-132. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-04

ARI

16 February 2008

11:22

Salmonella model has successfully identiﬁed key host genes and proteins participating in these two pathways. Sublethal systemic infection with S. Typhimurium is characterized by four distinct phases of infection: rapid clearance of the bacteria from the bloodstream (phase 1), which requires complement and the production of reactive oxygen species (ROS); sheltering of some bacteria in macrophages and polymorphonuclear leukocytes from the spleen and the liver where the bacteria initiate a replicative phase (phase 2); stimulation of the innate immune response pathways by Salmonella products, such as lipopolysaccharide (LPS), and priming of the adaptive innate immune response [by tumor necrosis factor α (TNF-α), IFN-γ, interleukin (IL)-12, IL-18, and Toll-like receptor 4 (Tlr4)], resulting in dampening of the infection (phase 3); and activation of antigen-speciﬁc immunity and clearance of the infection (phase 4) (53). Inbred strains of mice show differential susceptibility to infection with Salmonella (reviewed in 58). Strains such as C57BL/6J, C57BL/10J, BALB/cJ, FVB, and DBA/1J are extremely susceptible and succumb within 5– 6 days post infection owing to their inability to suppress bacterial growth during the early innate immune response phase (phase 2) (22; D. Malo, unpublished data). C3H/HeJ mice show a similar degree of susceptibility, although they are able to survive the second phase of infection. However, C3H/HeJ mice present with high bacterial load in spleen and liver later during infection because of an inadequate adaptive innate immune response. Strains A/J, DBA/2J, and C3H/HeN present an intermediate susceptibility phenotype and show increased survival time (most noticeable with lower infectious inoculum) but cannot survive beyond the transition of innate to acquired immune defenses (phase 3). CBA/J mice show increased survival times and are able to survive the ﬁrst three phases of infection but ultimately succumb to infection because of their inability to mount an appropriate antigen-speciﬁc immunity. Finally, substrains of 129 inbred mice are ex-

tremely resistant, although they are unable to clear the infection, and they develop a chronic carrier state (56, 58). Investigators studying the natural variation of the host response to Salmonella infection in spontaneous mouse mutants (Ity, xid, Lps, and Ity4) (59–62) identiﬁed major novel host response pathways (Nramp1Ity , btkxid , Tlr4Lps , and PklrIty4 ) (20, 62– 66). The classical inbred strains, C57BL/6J, C57BL/10J, BALB/cJ, FVB, and DBA/1J, are all extremely susceptible to infection because of a loss-of-function mutation in the Nramp1/Slc11a1 gene (see the section on ItyLsh-Bcg), a major regulator of Salmonella susceptibility in mice. Mice carrying a mutant allele at Nramp1 all die early independently of their genetic background; the Nramp1 effect can be worsened in some cases by the presence of other Salmonella susceptibility alleles such as Tlr4Lps or PklrIty4 (see below) (62, 67, 68). The C3H/HeJ strain is exquisitely susceptible to infection with S. Typhimurium and other Gram-negative bacteria (59, 69, 70). This susceptibility is independent of Nramp1 alleles (C3H/HeJ has a resistance Nramp1G169 allele) but is linked to an aberrant response to the immunostimulatory properties of LPS. Sultzer (71) ﬁrst described the Lps (lipopolysaccharide response) locus in C3H/HeJ mice in 1968, and observed that C3H/HeJ mice are 20 to 38 times more resistant than A/HeJ mice to the toxic effects of systemic administration of LPS. A defective LPS response in C3H/HeJ mice affects several cell types, including B cells, T cells, macrophages, and ﬁbroblasts. Two allelic forms were recognized for Lps: a normal allele, Lpsn , and a defective allele, Lpsd (72). Other strains of mice (C57BL/10ScNCr and C57BL/6J.KB2mnd ) present LPS hyporesponsiveness as well (73, 74). F1 progeny from crosses between C3H/HeJ and C57BL/10ScNCr or between C3H/HeJ and C57BL/6J.KB2-mnd were also LPS hyporesponsive, which indicates that the three parental strains harbor a genetic defect in the same gene or in the same pathway. www.annualreviews.org • Immunity to Infection in the Mouse

89

ARI

16 February 2008

11:22

LPS hyporesponsiveness of C3H/HeJ mice is inherited as an autosomal codominant trait, whereas the LPS-hyporesponsive phenotype of C57BL/10ScCr mice is fully recessive (reviewed in 75). The response to Salmonella infection was inherited as a single dominant trait in all crosses performed between Lpsd and Lpsn mice. Using a variety of RIS, segregating backcrosses and congenic mice, the Lps locus was mapped to mouse chromosome 4 (reviewed in 75). A positional cloning approach was used by two research groups to identify the gene underlying the Lps phenotype (63, 64). Different subphenotypes were used to clone the Lps locus: the LPS-mitogenic response of splenocytes (63, 64), the response to Salmonella infection (64), and TNF production by macrophages (63). High-resolution linkage and physical mapping narrowed the Lps interval to 1.8 Mb (70; Ensembl mouse m36) that harbored an excellent positional candidate, Tlr4, an important component of the signal transduction initiated by LPS in humans in vitro (76). Support for Tlr4 underlying Lps came from the identiﬁcation of independent mutant alleles at Tlr4 in mouse strains defective in LPS response: C3H/HeJ mice present a single missense mutation resulting in a proline to histidine substitution at codon 712 within the signaling domain of Tlr4 (63, 64); C57BL/10ScCr mice have no Tlr4 transcripts (63, 64), as a consequence of a 75-kb chromosomal deletion encompassing the whole Tlr4 gene (77); and the mutation identiﬁed in C57BL/6.KB2-mnd Tlr4 mice consists of a complete deletion of exon II owing to a splicing defect, which results in a mutant variant consisting of only the ﬁrst 31 N-terminal residues of the protein (wildtype Tlr4 contains 835 residues) (74). Conﬁrmation of the role of Tlr4 in LPS hyporesponsiveness and Salmonella susceptibility was obtained through the creation and study of Tlr4-deﬁcient mice and Tlr4 transgenic mice (67, 68, 78, 79). TLR family members are evolutionarily conserved, type 1 transmembrane receptors

Annu. Rev. Immunol. 2008.26:81-132. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-04

90

Vidal et al.

characterized by an extracellular leucine-rich repeat (LRR) domain and an intracellular domain similar to the intracellular domain of the IL-1 receptor, the TIR (Toll/IL-1 receptor) domain. The ﬁrst identiﬁed member of this family, Drosophila Toll, is involved with innate immunity to fungal infection through the induction of an antifungal peptide. In mammals, 12 TLRs have been identiﬁed and classiﬁed by their ability to sense speciﬁc pathogen-associated molecular patterns (PAMPs) in vitro (reviewed in 80). Several TLRs are essential for defense against different pathogens, as shown by studies in TLR-deﬁcient mice. Tlr4 recognizes LPS with the cooperation of LPS-binding protein and coreceptors CD14 and MD2 (now annotated Ly96, lymphocyte antigen 96). Tlr4 triggers innate immunity through the activation of two signaling pathways: (a) nuclear factor-κB (NF-κB) signaling via the TIR domain–containing adapter protein (TIRAP) and myeloid differentiation primary response gene 88 (MyD88), which results in the activation of IL-1 receptor–associated kinases (IRAKs) and further recruitment of TNF receptor–associated factor 6 (TRAF6), and (b) a MyD88-independent pathway involving adapter proteins TRIF (Toll receptor– associated activator of IFN) and TRAM (TRIF-related adapter molecule), which results in the activation of IFN regulatory factor 3 (IRF3), the induction of type I IFNs, and a delayed NF-κB response (80). Recognition of LPS by TLR4 leads to the induction by macrophages of several proinﬂammatory cytokines, including IL-1, IL-6, IL-8, IL-12, chemokines, costimulatory molecules (CD80 and CD86), MHC class II, and nitric oxide synthase 2 (NOS2). Induction of CD80/CD86 and IL-12 by TLRs contributes to the initiation of adaptive immunity and the induction of T helper 1 (Th1) effector responses (81). TLR4 gene polymorphisms are associated with susceptibility to various infectious and noninfectious diseases (reviewed in 82, 83). Two polymorphisms, Asp299Gly and Thr399Ile, were originally associated with

Annu. Rev. Immunol. 2008.26:81-132. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-04

ARI

16 February 2008

11:22

the lung response to inhaled LPS in healthy human volunteers (84). The Asp299Gly and Thr399Ile TLR4 alleles are associated with an increased risk of Gram-negative infection (85), sepsis (86, 87), severe inﬂammatory response syndrome (88), severe malaria (89), brucellosis (90), and respiratory syncytial virus disease (91). The same TLR4 alleles are protective against Legionnaire’s disease (92). Studies in mice bearing inactivating mutations for individual members of the TLR family have shown that other members of the TLR family likewise play a critical role in the host response to a broad range of bacterial, viral, fungal, and parasitic infections in TLRdeﬁcient mice (reviewed in 80, 93) and in speciﬁc human populations (reviewed in 82, 83). In humans, genetic variants in TLR2 are associated with susceptibility to TB (94) and the clinical manifestations (paucibacillary versus multibacillary) of leprosy (95, 96). A common mutation within TLR5 is associated with an increased susceptibility to Legionella pneumophila, the causative agent of Legionnaire’s disease (97). Heritable defects of the human TLR signaling pathway have been identiﬁed in patients suffering from recurrent infection and carrying mutations within the genes NEMO (now annotated IκBkγ, inhibitor of kappaB kinase gamma), IKBA (now annotated NFκBiα, nuclear factor of kappa light chain gene enhancer in B-cells inhibitor, alpha), and IRAK4 (6).

THE X-LINKED IMMUNODEFICIENCY LOCUS: B CELL DEVELOPMENT AND HOST RESPONSE TO SALMONELLA INFECTION CBA/N mice do not survive the late phase of Salmonella infection because they are defective in the humoral immune response against bacterial antigens (60). CBA/N mice carry the xid mutation (x-linked immunodeﬁciency), which is phenotypically expressed as a reduced number of B cells (50% of the normal B cell num-

ber), decreased serum IgM and IgG3 levels, normal levels of IgG1, IgG2a, and IgG2b, and a compromised T cell–independent immune response (98). The susceptibility of xid mice is recessive and maps to the X-chromosome; hemizygous males and homozygous females (for the xid locus) are susceptible to Salmonella infection whereas heterozygous females are fully resistant (60). The transfer of speciﬁc anti-Salmonella antibodies restores resistance to infection in affected xid males, which shows the importance of circulating antibodies in resistance to S. Typhimurium during the late phase of infection (99). The xid mutation of CBA/N mice was cloned via a positional candidate approach several years after it was ﬁrst described (65, 66). The xid mutation maps to a region of mouse chromosome X that is homologous to the human chromosomal region carrying the gene involved in XLA or Bruton’s agammaglobulinemia. Patients with XLA suffer from recurrent and persistent bacterial infections caused by Pseudomonas spp., Staphylococcus aureus, Streptococcus pneumoniae, and Haemophilus inﬂuenzae early in life. Lessfrequent intestinal infections with Salmonella spp. also occur in XLA patients. Male patients with XLA present a more severe immunodeﬁciency compared with the xid mouse, have less than 1% of the normal number of B cells, present panhypogammaglobulinemia [absence of immunoglobulins (Igs) of all classes], and fail to make antibody to all antigens (reviewed in 100). The gene responsible for the human disease, Bruton’s tyrosine kinase (BTK), was identiﬁed by positional cloning as a tyrosine kinase expressed during B cell development (101, 102). In humans, mutations within BTK occur in XLA families (101, 102). Soon after the human discovery, a mutation within the gene encoding btk was shown to be responsible for the xid phenotype in CBA/N mice (65, 66). The role of btk in xid was validated in vivo through the creation of a deletion allele; this allele causes a phenotype similar to xid and less severe than XLA in humans, possibly owing to www.annualreviews.org • Immunity to Infection in the Mouse

91

ARI

16 February 2008

11:22

the presence in the mouse of a btk-related kinase, Tec, that may compensate for the loss of btk function (103). Btk is a member of the Tec family of nonreceptor cytoplasmic tyrosine kinases that are highly expressed in most cells of the hematopoietic lineage (104). btk is expressed at all stages of B cell differentiation from pro to mature B cells, with the exception of plasma cells. Btk is also expressed in erythroid precursors, myeloid cells, mast cells, and megakaryocytes, but not in T or natural killer (NK) cells (101, 102). btk encodes a tyrosine kinase that possesses ﬁve different domains; these include the pleckstrinhomology (PH), the Tec-homology (TH), the Src homology 1 (SH1, known as the kinase domain), SH2, and SH3 domains (105). The expression of btk is critical for the proliferation, differentiation, survival, and apoptosis of B-lineage cells and is a major component of the B cell receptor (BCR) signalosome (105, 106). All domains of the btk protein bind a variety of interacting partners, which suggests its involvement in multiple signaling pathways (reviewed in 105). Notably, btk is involved in the activation of the transcription factor NFκB through the phosphorylation of the p65 subunit of the NF-κB complex in response to BCR engagement and to LPS (107, 108). Btk is also involved in the negative regulation of TLR signaling and, more speciﬁcally, in the phosphorylation of the adapter protein TIRAP after TLR2 and TLR4 stimulation (109, 110), which allows the interaction of TIRAP with SOCS-1 (suppressor of cytokine signaling 1). The interaction of TIRAP with SOCS-1 results in TIRAP polyubiquitination and subsequent degradation (110). Lindvall and colleagues (105) reported 554 different mutations in XLA patients that involve all domains of the BTK gene as well as noncoding sequences (http:// bioinf.uta.fi/BTKbase). In xid mice, a missense mutation at a conserved arginine residue (R28C) within the PH domain of btk prevents its ability to translocate to the plasma membrane and trigger signaling that regulates B cell survival and growth (111).

Annu. Rev. Immunol. 2008.26:81-132. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-04

92

Vidal et al.

THE LGN1 LOCUS: INTRACELLULAR RECOGNITION OF LEGIONELLA BY BIRC1E, A MEMBER OF THE NOD-LIKE RECEPTOR FAMILY Legionella pneumophila is a Gram-negative bacterium that causes a severe form of pneumonia called Legionnaire’s disease. L. pneumophila is a strict intracellular pathogen that survives and replicates in human macrophages, residing in a replicative phagosome that does not mature into a phagolysosome but rather acquires functional and biochemical characteristics of the endoplasmic reticulum (ER). These characteristics include the presence of ribosomes at the phagosomal membrane, retention of the ER markers calnexin and glucose-6-phosphatase, and the absence of lysosomal markers (e.g., Lamp1) (112). Macrophages from most inbred strains of mouse are resistant to infection with L. pneumophila (Philadelphia 1), with the exception of thioglycolate-elicited A/J macrophages that are permissive to the replication of L. pneumophila ex vivo (reviewed in 113). Studies in informative crosses between A/J and other inbred strains showed that susceptibility in A/J is controlled by a single locus on mouse chromosome 13, designated Lgn1. The minimal genetic interval (0.32 cM) is a highly complex and duplicated region containing several intact and rearranged copies of the Birc1 gene (113). Birc1 proteins are expressed in macrophages and are upregulated following macrophage phagocytosis of inert particles or live Legionella or Salmonella. Two intact gene copies, Birc1b and Birc1e, are contained within the minimal physical interval of Lgn1 (113). Functional complementation studies in transgenic mice, using large overlapping cloned segments from the region [bacterial artiﬁcial chromosome (BAC) clones], showed that Birc1e gene transfer to otherwise permissive A/J mice and overexpression of the Birc1e gene was sufﬁcient to restore resistance and restrict L. pneumophila replication in macrophages derived from the transgenic mice. Parallel

Annu. Rev. Immunol. 2008.26:81-132. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-04

ARI

16 February 2008

11:22

studies showed that morpholino-based antisense inhibition of Birc1e can partially reverse the nonpermissiveness of macrophages from mouse strains containing a transgenic copy of Birc1e (114, 115). Together, these results strongly suggested that Birc1e is the gene underlying the Lgn1 defect. The complexity of the genomic region overlapping Lgn1 has so far precluded the creation and testing of a lossof-function mutant at Birc1e or at other Birc1 family members. The Birc1 gene family was initially annotated as neuronal apoptosis inhibitory protein (Naip) on the basis of (a) a possible implication of Naip in spinal muscular atrophy as a regulator of neuronal apoptosis and (b) the presence of baculovirus inhibitor of apoptosis protein (IAP) repeat (BIR) domains in the predicted Naip polypeptide, which interact with cellular caspases (116). The role of Naip5 in macrophage function remained unknown for many years. The recent reclassiﬁcation of Naip/Birc proteins as part of the nucleotidebinding oligomerization domain (NOD)-like receptor (NLR) family provided important clues to the possible function of Birc1e in macrophage defenses against infections. NLRs are a group of 23 structurally related cytosolic proteins (117, 118) that have several features in common: (a) a nucleotide binding domain (for oligomerization), (b) LRRs that act as recognition motifs for PAMPs in other proteins such as TLRs, and (c) a protein:protein interaction module that is speciﬁc for each member or subgroup of this family (e.g., BIR domains in Birc1). The NLR family [also known as the nucleotide binding site (NBS)-LRR or CATERPILLAR family] includes NOD1/NOD2 [also known as CARD (caspase recruitment domain)4/CARD15], which sense bacterial peptidoglycan; IL-1βconverting enzyme (ICE)-protease-activating factor (Ipaf ) (also known as CARD12), which interacts with intracellular ﬂagellin from certain Gram-negative bacteria; cryopyrin [also known as NALP3 (nacht, LRR, and Pyrin domain–containing 3), which binds bacterial RNA; and others that function as intracellu-

lar sensors of bacterial products (117, 118). Mutations in NLR family members are associated with dysregulated inﬂammation in certain chronic conditions such as Crohn’s disease (NOD2), Blau syndrome (NOD2), atopic eczema and asthma (NOD1), familial cold inﬂammatory syndrome [cold autoinﬂammatory syndrome 1 (CIAS1)], and bare lymphocyte syndrome [MHC class II transactivator (CIITA)] (117, 118). Recent studies have shed considerable light on the mechanism of action (the ligand and cellular signaling pathways) of Birc1e in macrophage defenses against Legionella. Infection of macrophages with Legionella pneumophila induces caspase-1-dependent cell death, a protective mechanism that restricts intracellular replication and requires a functional copy of Birc1e (Birc1e is seemingly impaired in A/J cells) (119). Additional studies by Nunez and colleagues (120) pointed to further complexity in the activation of caspase-1 in macrophages following infection with L. pneumophila (in addition to Birc1e). Activation of caspase-1 is dependent on the transfer of Legionella products to the cytosol via a functional type IV secretion system, and macrophages deﬁcient in caspase-1 (Casp1−/− ) or deﬁcient in Ipaf (Card12−/− ) are more permissive to L. pneumophila infection than control C57BL/6J (B6) macrophages (119). These observations support a model in which recognition of Legionella products by the LRR domain of Birc1e causes activation of the Ipaf-containing inﬂammasome, which results in bacteriostatic activity and ultimately cell death. Recent genetic analyses of L. pneumophila mutants strongly suggest that ﬂagellin may be the bacterial protein recognized by Birc1e: Bacterial ﬂagellin mutants grow in otherwise nonpermissive B6 macrophages and do not induce cell death (121, 122). Finally, results from studies of L. pneumophila– containing phagosomes formed in wild-type and Birc1e-deﬁcient macrophages suggest even more complexity in the mechanism of action of Birc1e. Indeed, the presence of Birc1e is associated with a reduced acquisition of ER www.annualreviews.org • Immunity to Infection in the Mouse

93

ANRV338-IY26-04

ARI

16 February 2008

11:22

Annu. Rev. Immunol. 2008.26:81-132. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

markers (calnexin) and an enhanced acquisition of lysosomal markers (Lamp1, Cathepsin D) in primary macrophages (123). The Birc1e effect on phagosome maturation is very rapid, occurring within the ﬁrst hour of infection, which raises the possibility that, in addition to caspase-1, the sensing of bacterial products by Birc1e may affect other early protein targets important in antagonizing the intracellular survival strategy of L. pneumophila. The identity of such targets is unknown but of great interest.

LTXS1: SENSING OF ANTHRAX TOXIN BY THE NOD-LIKE RECEPTOR PROTEIN NALP1B Bacillus anthracis is a Gram-positive bacterium that causes anthrax. Pathogenesis of B. anthracis infection involves the production of several soluble factors by the bacterium; these include the protective antigen (PA), the edema factor (EF), and the lethal factor (LF), which assemble to form the edema toxin (ET) (PA + EF) and the lethal toxin (LeTx) (PA + LF). LeTx causes necrosis, is highly toxic for macrophages, and induces rapid death in systemic anthrax infection (124). Inbred mouse strains differ in their degree of susceptibility to LeTx-induced macrophage necrosis: Strains such as AKR/J, C57BL/6J, A/J, P/J, NOD/LtJ, and SJL/J are resistant, and strains such as BALB/cJ, C3H/HeJ, CBA/J, FVB/NJ, SWR/J, and NON/LtJ are susceptible (125). Typically, C3H macrophages are lysed by LeTx concentrations 100,000 times lower than those required to lyse A/J macrophages, and it was therefore suggested that A/J cells lack the LeTx target (124). Initial mapping studies in informative BXH and AKXL RIS and in [B6 × C3H] F1 × B6 backcross mice showed that the differential response to LeTx is controlled by a single gene, designated Ltxs1, that was regionally assigned to the central portion of mouse chromosome 11 (HSA17) (126). Additional high-resolution linkage and physical mapping 94

Vidal et al.

studies delineated the Ltxs1 interval to a 0.51 cM segment that contained 14 known genes and 5 unannotated sequences (125). Dietrich and coworkers (127) initially identiﬁed the kinesin-like motor protein Kif1C as responsible for the Ltxs1 gene effect on the basis that (a) Kif1C was the only gene in the minimal interval that showed polymorphic differences between responsive and unresponsive mouse strains, (b) alteration of the subcellular distribution of the Kif1C protein by brefeldin A increased susceptibility to LeTx, and (c) ectopic expression of the resistance allele of Kif1C in susceptible macrophages increased survival following LeTx exposure. Additional recent studies by Dietrich and coworkers (128) excluded Kif1C as a candidate and provided convincing evidence that an adjacent positional candidate, the NLR protein–encoding gene Nalp1b, is in fact responsible for the Ltxs1 effect. Nalp1b is part of a cluster of three adjacent paralogs (with Nalp1a and Nalp1c), and studies in macrophages from the susceptible strain 129S1 showed that of the three only Nalp1b was transcribed in that strain. Sequencing the Nalp1b gene in 18 mouse strains revealed a complex pattern of coding polymorphisms in the Nalp1b protein that can be grouped into four major alleles (128). LeTx-susceptible strains uniformly harbored the same allele (allele 1), whereas resistant strains carried either alleles 2, 3, or 4. Validation of the Nalp1b gene as responsible for Ltxs1 came from (a) the demonstration that transgenic mice from a B6 background (resistant) carrying a BAC clone containing the susceptible allele from 129S1 became susceptible to LeTx, whereas (b) treatment of 129S1 macrophages with antisense morpholino oligonucleotides against Nalp1b increased resistance to LeTx (128). Generating a death signal through Nalp1b in response to LeTx appears to involve caspase-1. Indeed, treatment of macrophages from susceptible strains but not resistant strains activates caspase-1, and macrophages from 129S1 (susceptible) mice carrying a null mutation at caspase-1 (Casp1−/− ) become resistant to

ANRV338-IY26-04

ARI

16 February 2008

11:22

Annu. Rev. Immunol. 2008.26:81-132. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

cell lysis by LeTx. These results suggest a model for the cytoxicity of LeTx in susceptible strains in which the intracellular toxin interacts with Nalp1b, which results in the activation of caspase-1 and the induction of cell death. Although the mechanism by which LeTx activates Nalp1b remains unknown (PAMP emulation, direct proteolytic processing by the toxin, etc.), these studies provide another clear illustration of the role of NLR proteins as cytoplasmic sensors of bacterial products.

MYLS: PLEIOTROPIC EFFECTS OF ICSBP/IRF8 MUTATION ON MYELOPROLIFERATION AND SUSCEPTIBILITY TO INTRACELLULAR INFECTIONS As described above, susceptibility to infection with low doses of M. bovis (BCG) is determined in inbred mouse strains by alleles at the Nramp1 (Slc11a1) locus; Nramp1G169 is associated with resistance and Nramp1D169 with susceptibility (16). Notable exceptions include (a) the wild-derived strain Mus spretus, whose intermediate level of resistance (despite a Nramp1G169 haplotype) is caused by a complex set of modiﬁers (129), and (b) the BXH2 strain (130). BXH-2 is a RIS derived from C3H/HeJ and C57BL/6J parents, known to develop a chronic myelogenous leukemia by a two-step mutagenesis process (131). The ﬁrst hit is an inherited, predisposing mutation speciﬁc to BXH-2 that causes myeloproliferation, whereas the second hit results from retroviral-mediated insertional mutagenesis that causes the expansion of clonal tumors (132). The second hit has been well characterized, including the nature of the replicationcompetent B-ecotropic virus, the multiple sites of integration, the study of which has unveiled a number of novel tumor suppressors and oncogenes altered by the virus (133). By monitoring splenomegaly and the inﬁltration of GR1+ /Mac1+ neutrophil precursors in spleen, liver, and lymph nodes as phenotypic markers, investigators showed that the BXH-

2-speciﬁc myeloproliferation trait is inherited as a single recessive trait (designated Myls) that maps to the distal portion of chromosome 8 (130). Additional genetic and physical mapping experiments identiﬁed IFN consensus sequence-binding protein 1 (Icsbp1), also known as IRF8, as a strong positional candidate. Icsbp1 is a transcriptional regulator that heterodimerizes with other members of the IRF family and plays an important role in activation of IFN-γ-responsive genes that bear internal ribosome entry site (IRES) regulatory sequence elements. BXH-2 mice carry a R294C mutation within the predicted IRFassociation domain of the protein. On the basis of previous reverse genetics studies showing that Icsbp1 acts as a negative regulator of the granulocyte lineage, investigators proposed that the R294C mutation is pathogenic. Subsequently, Turcotte and coworkers found the R294C allele to be associated with a failure of BXH-2 splenocytes to produce IL-12 and IFN-γ in response to activating stimuli (134). Despite a C3H/HeJ-derived Nramp1G169 allele, BXH-2 mice are susceptible to M. bovis (BCG) infection, and experiments in informative F2 crosses derived from BXH-2 showed that homozygosity for the mutant Irf8C294 allele is associated with increased BCG replication early in infection (130, 134). Strikingly, BXH-2 cannot resolve M. bovis (BCG) infection in spleen and liver late in infection. The associated uncontrolled replication of the otherwise avirulent M. bovis (BCG) is associated with the complete absence of granuloma formation in infected BXH-2 tissues (135). Additional preliminary data also indicate that BXH-2 mice are extremely susceptible to pulmonary TB following an intravenous challenge with highly virulent Mycobacterium tuberculosis H37Rv (J.F. Marquis and P. Gros, unpublished data). The effect of the Irf8C294 mutation is pleiotropic because BXH-2 mice show collateral susceptibility to infection with the unrelated pathogens S. Typhimurium and Plasmodium chabaudi (135). In the case of P. chabaudi, although BXH-2 mice can clear www.annualreviews.org • Immunity to Infection in the Mouse

95

ANRV338-IY26-04

ARI

16 February 2008

11:22

the initial burst of parasitemia, they fail to mount a long-term protective immune response as the animals develop multiple waves of recurring parasitemia late in the infection. These ﬁndings together suggest that Icsbp1 plays a critical role in both innate and acquired immune responses to intracellular pathogens.

Annu. Rev. Immunol. 2008.26:81-132. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

SUSCEPTIBILITY TO PULMONARY TUBERCULOSIS (SST1): ROLE OF THE IPR1 GENE IN MACROPHAGE RESPONSE TO MYCOBACTERIUM TUBERCULOSIS TB is caused by pulmonary infection with the bacterial pathogen Mycobacterium tuberculosis. TB remains a major global health issue, with an estimated 32% of the world’s population currently or previously infected (136), 8 million new cases per year (137), and 1–1.5 million deaths annually. Despite high infection rates, only 5%–10% of infected individuals have a lifetime risk of developing active disease, which suggests a possible role for genetic factors in human susceptibility to TB. Direct evidence for a genetic component includes the following: (a) epidemiological data indicating sex and racial differences in susceptibility, (b) geographical distribution and familial aggregation of disease, (c) population studies in endemic areas of disease and during ﬁrst contact epidemics, and (d ) concordance rates in mono- and dizygotic twins (for a comprehensive review, see 138). Numerous case control studies pointed to several gene variants that contribute to the risk of TB, and whole-genome scans identiﬁed suggestive linkages on several chromosomes, including 8, 11, 15, 20, and X (138). The complex genetic component of susceptibility to TB has been extensively studied in mouse models of infection for the past 60 years. Brieﬂy, the efﬁcacy of the host response to pulmonary TB is under complex genetic control in the mouse, with a broad spectrum of disease severity observed among different strains (138). Genetic 96

Vidal et al.

studies by whole-genome scanning have located a number of TB susceptibility loci, but so far only a single locus (Ipr1) has been identiﬁed (139) and is reviewed herein. There is an additional enormous body of published work on the effect of individual gene knockouts on the susceptibility to pulmonary infection with M. tuberculosis, using a reverse genetics approach (140–142); this work is not discussed here. Surveys of inbred strains for susceptibility to M. tuberculosis (H37Rv), as measured by the extent of pulmonary replication and overall survival following intravenous or aerosol infections, classiﬁed the CBA, DBA/2, C3H, and 129/Sv strains as susceptible and the C57BL/10, C57BL/6, and BALB/c strains as more resistant (143). In a number of F1 hybrids tested (B6D2, CD2, CB6, and B6129), resistance is inherited in a dominant fashion. Susceptibility is generally associated with a failure to contain bacterial growth in the lungs, an inﬂammatory reaction causing consolidation of the lungs, and ultimately death. Resistant strains limit bacterial growth and can prevent massive tissue injury (142). Kramnik and colleagues (144) recently characterized the unique supersusceptibility of the C3HeB/FeJ strains to infection with M. tuberculosis Erdman (106 bacilli, i.v.). Studies in informative C3HeB/FeJ × C57BL/6J F1 and F2 mice led to the localization of a major gene effect on central chromosome 1 [(LOD) = 10.4], designated sst1. Studies in congenic C3HeB/FeJ mice with B6 sst1r alleles (C3H.B6-sst1) showed that sst1 exerts pleiotropic effects on other intracellular pathogens and also confers increased protection in vivo against Listeria monocytogenes, and explanted sst1 congenic macrophages show increased IFN-γ-dependent listericidal activity in vitro (145). Resistance is associated with an increased capacity of macrophages to restrict replication of M. tuberculosis in vitro, linked to an induction of apoptosis in M. tuberculosis– infected resistant macrophages. Scrutiny of the sst1 genetic interval for positional candidates expressed in macrophages identiﬁed a

Annu. Rev. Immunol. 2008.26:81-132. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-04

ARI

16 February 2008

11:22

transcript, designated intracellular pathogen resistance 1 (Ipr1), which is present in resistant macrophages and whose expression is induced upon M. tuberculosis infection but is absent from susceptible cells (139). The sst1 genetic interval includes part of a large unstable repeat of ampliﬁed DNA that contains several rearranged copies of Ipr1-related sequences. In C3HeB/FeJ, this ampliﬁcation may have caused rearrangement(s) of the Ipr1 gene, leading to the absence of mRNA expression. The Ipr1 candidacy for sst1 was validated by showing that expression of the full-length Ipr1 transcript in transgenic C3HeB/FeJ mice can partially suppress M. tuberculosis replication in the lungs in vivo, and in macrophages in vitro (139). Ipr1 codes for IFN-induced protein 75 (Iﬁ75), a protein with several sequence motifs that indicate a nuclear localization and transcriptional regulatory activity. Iﬁ75 is a relative of the human protein SP110, a transcription factor regulated by IFN that interacts with certain viral proteins, including proteins from hepatitis C virus (HCV) and Epstein-Barr virus (146). These ﬁndings suggest that Iﬁ75 participates in transcriptional activation in macrophages in response to intracellular pathogens. In humans, loss-of-function mutations in SP110 cause veno-occlusive disease with immunodeﬁciency (VODI), an autosomal recessive disorder characterized by severe hypogammaglobulinemia, combined B cell and T cell immunodeﬁciency, absent lymph node germinal centers, absent tissue plasma cells, and hepatic vascular occlusion and ﬁbrosis (147). Evidence for an association of SP110 alleles with susceptibility to TB has been obtained from studies of families from different areas of Western Africa, including Gambia, Guinea-Bissau, and the Republic of Guinea (148). Additional case-control studies with populations from West Africa (149), Russia (150), and South Africa (151) have failed to provide evidence for an association of Sp110 variants with susceptibility to TB.

DEFICIENCY IN THE C5 COMPONENT OF COMPLEMENT AND SUSCEPTIBILITY TO SYSTEMIC INFECTION WITH CANDIDA ALBICANS In humans, Candida albicans exists as a harmless commensal organism in the gastrointestinal and genitourinary tracts. However, C. albicans can also cause infections in immunocompromised individuals. Such infections can be superﬁcial and limited to mucocutaneous candidiasis or can take the form of severe acute invasive candidiasis after bloodstream dissemination of the organism (152, 153). Researchers have described mouse models of mucocutaneous and acute infections and conducted genetic studies in inbred mouse strains in each model. The LD50 (lethal dose, 50%) for most C. albicans isolates introduced intravenously in immunocompetent mice is between 104 and 106 blastospores, depending on the strain of C. albicans, the growth conditions used to prepare the inoculum, and the genetic makeup of the murine host (154, 155). Candida albicans introduced by the intravenous route replicates in the spleen, liver, kidneys, and brain; inbred mouse strains are either resistant (C57BL/6J, BALB/cJ, CBA/J, and DBA/1) or susceptible (A/J, DBA/2J, NZB/J, and AKR/J) to infection, as measured by the extent of fungal replication, type and extent of tissue damage, and overall survival time (156). These studies further identiﬁed a partial correlation between the complement competence status (C5a) and susceptibility to infection (156). Recent genetic studies in A/J and C57BL/6J mice showed that extreme susceptibility in A/J mice is associated with the absence of an inﬂammatory response in infected tissues and very early death. Interestingly, A/J mice succumb to the acute infection within 48 h but display fungal loads in infected tissues that are considerably lower than those detected in moribund, resistant B6 mice three weeks after infection. In informative (A/J × B6) F2 mice, susceptibility is www.annualreviews.org • Immunity to Infection in the Mouse

97

ARI

16 February 2008

11:22

recessive and inherited as a monogenic trait that was mapped by whole-genome scan to the proximal part of chromosome 2 (157) in the vicinity of the structural gene for the C5 component of complement. Up to 40% of inbred strains carry an ancestral mutation consisting of a 2-bp deletion near the 5 end of the mRNA, which introduces a premature stop codon 4 bp downstream of the deletion (158). This mutation leads to the production of a truncated and nonfunctional 216 amino acid translation product. This truncated protein is not secreted. Thus, C5 deﬁciency in mice is associated with severe susceptibility to acute C. albicans infection. C5 is proteolytically processed to C5a, b, and c, which react with opsonized microbes to form a membrane attack complex that creates pores in the membrane of invading microbes following the binding of antibodies. In addition, C5a acts as a major chemoattractant to recruit neutrophils and macrophages to the site of infection, a response that is impaired in C5-deﬁcient mice (157, 159). Analysis of the proﬁle of cytokines during infection of A/J and B6 mice shows a pattern of extreme inﬂammatory and allergic response, which suggests unregulated production of proinﬂammatory molecules including TNF-α, IL-6, monocyte chemotactic protein 1 (MCP1), macrophage inﬂammatory protein 2 (MIP2), tissue inhibitor of metalloproteinase 1 (TIMP1), and KC. Transcript-proﬁling studies showed that this dysregulated inﬂammatory response is associated with severe cardiomyopathy (elevated creatine kinase and cardiac troponin I), hypoglycemia, and rapid death (160). In addition, C5 deﬁciency is associated with susceptibility to other types of infections, including infection by the intracellular pathogen L. monocytogenes. Indeed, the Lr1 locus previously shown to control interstrain difference in susceptibility to L. monocytogenes in A/J, C57BL/6J, and AXB/BXA recombinant inbred mice (161) was attributed to C5 deﬁciency (162). Finally, we observed that C5 deﬁciency in A/J mice and related strains has a positive effect on susceptibility to cerebral

Annu. Rev. Immunol. 2008.26:81-132. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-04

98

Vidal et al.

malaria caused by Plasmodium berghei (K. Kain and P. Gros, unpublished data), highlighting the detrimental impact of the host inﬂammatory response on the pathogenesis of cerebral malaria.

BLOOD-STAGE REPLICATION OF THE MALARIA PARASITE PLASMODIUM CHABAUDI: POSITIONAL CLONING OF THE CHAR4 AND CHAR9 RESISTANCE LOCI Malaria is caused by infection with members of the protozoan parasite family Plasmodium. Close to half a billion cases of malaria are believed to occur each year, with one million reported fatalities, mostly in young children from countries in sub-Saharan Africa. Severe anemia and cerebral malaria are major disease manifestations of blood-stage malaria, especially in Africa, where transmission rates are high. There is no effective vaccine against malaria, a problem exacerbated by the appearance of drug resistance in the Plasmodium parasite and insecticide resistance in the insect vector (163). Malaria is one of the clearest manifestations of host genetic factors inﬂuencing disease pathogenesis, with important threeway interactions between host genes, the environment, and the malaria parasite. Wellknown normal or disease-associated alterations in certain erythrocyte proteins can protect against malaria in humans, and positive selection by the parasite for heterozygosity at these variants occurs in endemic areas (coevolution). Celebrated examples include disease-causing alleles of thalassemias, sickle cell anemia, glucose-6-phosphate dehydrogenase (G6PD) deﬁciency, and a few others. For a more comprehensive description of the genetic component of susceptibility to malaria in humans, the reader is referred to recent comprehensive reviews on this subject (5, 164). The genetic control of susceptibility to malaria has been studied in mouse via the use of two infection models: P. chabaudi

Annu. Rev. Immunol. 2008.26:81-132. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-04

ARI

16 February 2008

11:22

AS and P. berghei, which respectively mimic the blood-stage and cerebral phases of the disease. Although linkage mapping studies have detected multiple loci that affect susceptibility to either type of infection (165), the genes underlying these effects have been identiﬁed in only two cases, which are reviewed below. Infection of mice with P. chabaudi– parasitized erythrocytes mimics several pathophysiological aspects of the blood-stage infection in humans, including host response, genetic control of parasitemia, and ultimate outcome of infection. Using levels of parasitemia at the peak of infection, investigators have classiﬁed inbred strains of mice as either resistant (C57BL/6J) or susceptible (A/J, C3H/HeJ, SJL) to blood-stage replication of P. chabaudi (165). Susceptibility is associated with muted inﬂammatory and erythropoietic responses and a decreased survival time. Whole-genome scans conducted in backcross and F2 mice bred from resistant and susceptible parents, using peak parasitemia and mortality as quantitative phenotypes, showed that the genetic control of interstrain differences is extremely complex, with as many as nine detected Chabaudi resistance loci (Char), including major contributions from distal chromosome 9 (Char1), central chromosome 8 (Char2), and chromosome 17 (Char3, H-2 locus) (165). This complex genetic trait has been studied in a set of AcB/BcA reciprocal recombinant congenic strains (derived from A/J and B6 mice by systematic inbreeding of a second backcross) (166). By virtue of the breeding scheme used in their derivation, individual AcB/BcA strains carry a small portion (12.5%) of one parental genome ﬁxed as a set of congenic segments on the genetic background (87.5%) of the other parental strain. Of a subset of 18 AcB/BcA strains tested for susceptibility to infection with P. chabaudi AS, AcB55 and AcB61 mice showed a discordant phenotype; these mice were very resistant to P. chabaudi infection despite carrying A/J-derived susceptibility alleles at Char1 and Char2 (165). Linkage studies in informative

[AcB55 X A/J] F2 mice localized a strong gene effect (Char4) on chromosome 3 (LOD = 6.57) that regulates peak parasitemia following infection (167). Phenotypic characterization of AcB55 and AcB61 strains showed that resistance to malaria in these strains is associated with splenomegaly, elevated reticulocyte numbers in peripheral blood, and an elevated number of Ter119+ cells in the bone marrow, which suggests enhanced constitutive erythropoietic activity in both strains (168). Combined analysis of the level of blood stage parasitemia at the peak of infection and reticulocyte numbers showed that both traits are regulated by the same locus (Char4), which suggests that the two traits are physiologically related. The transcript map on the chromosomal region contained a strong positional candidate, liver- and red cell–speciﬁc pyruvate kinase (Pklr), on the basis of both its essential role for ATP production in erythrocytes and the fact that mutations in PKLR cause hemolytic anemia in humans. Sequencing revealed the presence of an isoleucine to asparagine substitution at residue 90 (I90N) of the Pklr protein in malaria-resistant AcB55 and AcB61 strains; this is a mutation that was previously described in a human case of pyruvate kinase (PK) deﬁciency (169). Recently, a second mutant allele was identiﬁed at the pklr locus in a CBA/N mouse genetic background (CBA/N-Pkslc ), G338D. Similar to the I90N allele, the G338D allele not only abrogates PK enzymatic activity and causes severe hemolytic anemia, but also confers dramatic protection against P. chabaudi infection (170). These ﬁndings show that deﬁciency in the erythrocyte PK protects against malaria. The mechanistic basis of the protective effect is related to (a) a reduced half-life of PK-deﬁcient erythrocytes in vivo and (b) increased phagocytosis of uninfected and Plasmodium-infected erythrocytes in an Fc receptor–independent fashion (170). Therefore, the protective effect of PK deﬁciency is mechanistically related to the effect previously proposed for G6PD deﬁciency and β-thalassemias. Interestingly, the malaria-protective effect of the www.annualreviews.org • Immunity to Infection in the Mouse

99

ARI

16 February 2008

11:22

PK deﬁciency–induced hemolytic anemia has the opposite effect on susceptibility to acute infection with S. Typhimurium (170a). In this case, perturbations in either homeostasis of iron stores or hemopoietic cell composition (constitutive erythropoiesis) or both contribute to reduce host defenses or enhance replication of this unrelated pathogen. During the positional cloning of the Char4 locus, linkage analysis in [AcB55 × A/J] F2 mice revealed a second, albeit more modest, genetic contribution of chromosome 10 (D10Mit189) that is localized to a 14-Mb C57BL/6J-derived congenic segment ﬁxed in the AcB55 strain (167). C57BL/6J alleles at this locus are protective (reduced peak parasitemia), are inherited in a codominant fashion, and show an additive effect with Char4. This locus was given the designation Char9 and was recently identiﬁed by positional cloning (171). The B6-derived 14-Mb Char9 congenic segment contains 77 predicted genes that were characterized with respect to (a) tissue-speciﬁc expression, (b) the presence of strain-speciﬁc alterations in the level of gene expression, and (c) strain-speciﬁc polymorphic variants in coding and regulatory regions of positional candidates. Vanin 1 (Vnn1) and Vnn3 were identiﬁed as the likely candidates responsible for Char9. Vnn1/Vnn3 map within a conserved haplotype block, and their expression is strictly cis-regulated by this haplotype. The absence of Vnn messenger RNA expression and the lack of pantetheinase protein activity in tissues are associated with susceptibility to malaria and are linked to a complex rearrangement in the Vnn3 promoter region (171). Vanin genes code for pantetheinases, a group of enzymes involved in the production of cysteamine, a key regulator of host responses to inﬂammatory stimuli. Passive administration of cysteamine in vivo partially corrects susceptibility to malaria in A/J mice, as measured by reduced blood parasitemia and decreased mortality (171). These studies suggest that pantetheinase is critical for the host response to malaria. Indeed, pantetheinase activity and cystamine production

Annu. Rev. Immunol. 2008.26:81-132. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-04

100

Vidal et al.

may be required to mount an early and beneﬁcial inﬂammatory response against the infectious agent, which includes the production of protective type I cytokines such as IL-12. Conversely, elimination of pantetheinase activity in Vnn1−/− mice protects against the pathogenic inﬂammatory response in the gut caused by either chronic exposure to nonsteroid anti-inﬂammatory drugs or infection with Schistosoma mansoni (172). Finally, these results raise the possibility that cysteamine may be a valid, hostbased molecule for therapeutic intervention in malaria, either alone or in combination with current parasite-based antimalarial drugs such as meﬂoquine.

THE JANUS KINASE TYROSINE KINASE 2 AND ITS ROLE IN RESISTANCE TO TOXOPLASMA GONDII INFECTION Toxoplasma gondii is an obligate intracellular protozoan. Toxoplasmosis is an important opportunistic infection in pregnant women (causing abortion and fetal abnormalities) and immunocompromised individuals (causing ocular and brain necrosis during reactivation of toxoplasmosis). In immunocompetent hosts, toxoplasmosis is the most common cause of infection-associated eye disease worldwide (173). Domestic cats are the host and the main reservoir of the parasite, although most warm-blooded animals as well as ﬁsh and reptiles can be carriers of Toxoplasma. Human contaminations occur principally through ingestion of contaminated food and fecal contamination of hands or congenitally by transplacental transmission (reviewed in 174). During the acute phase of infection, Toxoplasma tachyzoites replicate in macrophages and dendritic cells (DCs). During this early phase of infection, the cytokine IL-12 is essential to trigger IFN-γ-dependent immune responses and for the development of a parasite-speciﬁc Th1 response (175–177). The mouse strain B10.Q-H2q/SgJ is extremely susceptible to infection with T. gondii,

Annu. Rev. Immunol. 2008.26:81-132. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-04

ARI

16 February 2008

11:22

and these mice succumb within two weeks after systemic infection owing to an inability to control parasite replication in macrophages (178, 179). In B10.Q-H2q/SgJ, susceptibility is associated with a general defect in the production of IFN-γ early during infection in vivo and with the hyporesponsiveness of splenocytes to IL-12 in vitro with respect to IFN-γ production (178). An F1 cross between susceptible B10.Q-H2q/SgJ and the related but resistant substrain B10.QH2q/Ai demonstrated that the susceptible phenotype is recessive (179). Linkage mapping in (B10.Q-H2q/SgJ × C57BL/6J)F1 × B10.Q-H2q/SgJ backcrossed mice conﬁrmed that susceptibility to infection with Toxoplasma is recessive and controlled by a single gene located on the centromeric part of chromosome 9 (HSA19) (180). Yap and colleagues (180) used a positional-candidate approach to identify tyrosine kinase 2 (Tyk2), a Janus kinase involved in cellular signaling by cytokine receptors as a strong candidate for the chromosome 9 locus (181). Sequencing of the Tyk2 gene led to the identiﬁcation of a strain-speciﬁc missense mutation (E775K) in B10.Q-H2q/SgJ mice. The E775K mutation results in the complete loss of Tyk2 function, most likely owing to instability of the E775K Tyk2 protein variant. The mutation in Tyk2 was used for mapping in the segregating backcross panel with the mutation in Tyk2 and showed tight linkage to the disease phenotype (LOD score of 53.3). Tyk2-deﬁcient mice were subsequently created and shown to be susceptible to infection with Toxoplasma; their response is characterized by impaired IFN-γ production and high parasite replication. More importantly, mice issued from a cross between B10.Q-H2q/SgJ and Tyk2-deﬁcient mice remained susceptible to infection, which conﬁrms that Tyk2 is the gene underlying the immune defect of B10.Q-H2q/SgJ mice (180). The family of Janus kinases consists of four members: Jak1, Jak2, Jak3, and Tyk2. Mutations in Jak3 cause severe combined immunodeﬁciency (SCID) in humans (182). Different Jak kinases associate constitutively with

the cytoplasmic domain of speciﬁc cytokine receptors (reviewed in 183). After activation of the receptor by ligand binding, Jak kinases phosphorylate the receptor and trigger the recruitment of signal transducer and activator of transcription proteins (STATs) and other adapter molecules. Activation of Tyk2 is involved in the signaling of several cytokines, including IL-12, IL-23, and type 1 IFNs (184). The critical role of TYK2 in humans was established by studies of a rare case of TYK2 deﬁciency in a patient presenting unusual susceptibility to various bacterial (S. aureus, atypic mycobacteria, nontyphi Salmonella), viral (herpes simplex infection), and fungal (oral candidasis) infections (185). The patient also suffered from atopic dermatitis with elevated levels of IgE. This patient displayed several cellular defects in cytokine signaling pathways, which explains his susceptibility to different classes of pathogens; the defects included alterations in signaling through type 1 IFN, IL-6, IL-10, IL-12, and IL-23. These studies in mouse and human demonstrated the pleiotropic role of Tyk2 in the innate and acquired immune responses to a variety of pathogens.

THE RIC LOCUS: RESISTANCE TO ORIENTIA TSUTSUGAMUSHI Orientia (formerly Rickettsia) tsutsugamushi is an obligate intracellular Gram-negative bacterium causing Scrub typhus, an acute, febrile, infectious disease zoonotic across southeast Asia and the western Paciﬁc region (186). Approximately one million cases of Scrub typhus occur annually (http://www.cdc.gov). Humans acquire the disease when O. tsutsugamushi is transmitted by feeding trombiculid mites. The bacteria multiply at the inoculation site, causing local inﬂammation and eschars with regional lymphadenopathy, before progressing within a few days to cause a systemic disease involving the lungs, heart, liver, spleen, and CNS. Resistance to the lethal effects of acute systemic infection with O. tsutsugamushi was www.annualreviews.org • Immunity to Infection in the Mouse

101

ARI

16 February 2008

11:22

studied in inbred mouse strains. Groves & Osterman (187) classiﬁed mice as resistant (AKR/J, BALB/c, C57BL/6J, C57L/J, and SWR/J) or susceptible (A/HeJ, CBA/J, DBA/1J, DBA/2J, SJL/J, and several C3H substrains) to infection on the basis of LD50 after intraperitoneal infection. Susceptible mice develop local and systemic bacterial growth during the ﬁrst week of O. tsutsugamushi infection and die within 10–12 days, whereas resistant mice show low microbial replication and complete survival after infection. Macrophage-mediated cellular immunity is essential for the resolution of infection in resistant strains (188). Genetic analyses in F1 and F2 crosses between resistant BALB/c and susceptible C3H/He progenitors showed that resistance to infection is determined by a single dominant gene, designated Ric (187, 189). Groves and colleagues mapped the Ric locus to a 45-Mb region of chromosome 5 using RIS of the BXH and CXS series (189). During the study of the molecular defect underlying Ric, a positional candidate, Eta1 (early T lymphocyte activation 1; also known as osteopontin and renamed Spp1 for secreted phosphoprotein 1), was identiﬁed. Eta1 expression is strongly induced during O. tsutsugamushi infection in vivo and is associated with inhibition of bacterial replication (190). Eta1 is a secreted, integrin-binding glycophosphoprotein with multiple functions that is expressed in several tissues during inﬂammation. Eta1 is produced by activated macrophages, T cells, and NK cells (191). More recent work using mice deﬁcient in Eta1 indicated that Eta1 contributes to host resistance to virus (rotavirus and herpes simplex virus 1) and bacteria (L. monocytogenes) (192, 193) and correlates with the clinical outcome of mycobacterial infection in humans (194). The proinﬂammatory functions of Eta1 include recruitment of leukocytes to sites of inﬂammation and polarization of T cells (195). Although these studies clearly identiﬁed a critical role for Eta1 in the host response to certain intracellular pathogens, whether it is the primary molecular defect underlying the

Annu. Rev. Immunol. 2008.26:81-132. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-04

102

Vidal et al.

Ric mutation remains to be established. Additional high-resolution linkage studies, mutational analysis in O. tsutsugamushi permissive strains, and complementation testing with Eta1-deﬁcient mice are required to clarify this point.

THE CTRQ3 LOCUS: ROLE OF THE P47GTPases IN SUSCEPTIBILITY TO CHLAMYDIA TRACHOMATIS Chlamydia trachomatis is an obligate intracellular pathogen that causes a variety of diseases in humans; different serotypes infect the ocular or genital mucosa. Chlamydia has a dual life cycle that involves an extracellular elementary body, a metabolically quiescent but infectious form, and a reticular body that replicates inside host cells. In host cells, Chlamydia replicates inside a specialized vacuole known as the inclusion (196). The variability in disease frequency and disease severity in people infected with Chlamydia suggested a possible contribution of genetic factors. Several infection models were developed in mice using either C. trachomatis (muco/cutaneous or systemic model) or C. pneumoniae (pulmonary model) (197, 198). In an intravenous infection with high doses of C. trachomatis, inbred mouse strains show different levels of susceptibility as determined by the extent of transient replication in the spleen (197). Typically, C57Bl/6J mice support 10-fold less replication than C3H mice, as measured by the amount of Chlamydia DNA (determined by PCR-based methods). The different degree of susceptibility to C. trachomatis infection in vivo can be partially reproduced ex vivo using mouse primary ﬁbroblasts (MEFs), which suggests the involvement of a cell-autonomous mechanism of defense. Whole-genome scan experiments in F2 mice derived from C57BL/6J and C3H/HeJ, using spleen chlamydial load 29 h postinfection, suggested a multigenic control with three quantitative trait loci (QTLs). These QTL reach signiﬁcance on chromosomes 2 (Ctrq1), 3 (Ctrq2), and 11 (Ctrq3) (197). A

Annu. Rev. Immunol. 2008.26:81-132. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-04

ARI

16 February 2008

11:22

congenic mouse line carrying a 30 Mb chromosome 11 segment harboring Ctrq3 from C3H/HeJ (susceptible), transferred onto the resistant genetic background of C57BL/6J, was more permissive to C. trachomatis replication than were B6 controls. Therefore, the Ctrq3 locus can contribute to susceptibility independently of the Ctrq1 and Ctrq2 QTLs (197). Subsequent studies in subcongenic lines narrowed the Ctrq3 interval down to a 1.2 Mb segment (199). This segment contains 18 annotated genes, including two members of the p47 family of IFN-γinducible GTPases (p47GTPases), IFN-γinduced GTPase (Igtp), and iron-regulated virulence protein 10 (Irgb10). p47GTPases comprise a group of 23 related proteins that play an important role in the innate defense repertoire of macrophages and other cell types. p47GTPases are structurally deﬁned by the presence of a nucleotidebinding domain (G domain) that confers GTP binding and hydrolysis properties on these proteins. The expression of p47GTPases is inducible (50- to 100-fold) by IFN-γ through STAT1-mediated transcriptional activation. P47GTPases bind to different endomembrane compartments and quickly relocalize to pathogen-containing vacuoles in macrophages and other cells upon infection (200). Recent reverse genetics studies showed that mice lacking members of this family become dramatically susceptible to infection with certain intracellular bacteria, including Mycobacterium, Salmonella, and Listeria, as well as protozoans such as T. gondii and Leishmania major, and viruses such as Coxsackie B3 and vesicular stomatostatis virus (VSV) (200). Expression studies showed that although constitutive and IFN-γ-inducible mRNA expression of Igtp is similar in both B6 and C3H mice, Igrb10 expression in response to IFN-γ was 20-fold higher in B6 than in C3H mice, which suggests that diminished expression of Igrb10 may be responsible for C. trachomatis susceptibility in C3H/HeJ mice (199). Addi-

tional experiments showed that overexpression of Irgb10 in MEFs from C3H/HeJ mice in the presence of IFN-γ caused increased resistance to C. trachomatis, whereas RNAimediated inhibition of Irgb10 in C57BL/6J cells rendered them more permissive to C. trachomatis replication (199). These results are supported by recent RNAi studies showing that another p47GTPase, IFN-inducible GTPase 1 (Iigp1), is a critical component of the inhibitory effect of IFN-γ on the growth of human C. trachomatis L2 in murine epithelial cells in vitro (201). Together, these results highlight the role of IFN-γ and p47GTPase signaling in effective host defenses against Chlamydia (see Figure 2).

THE MYXOVIRUS RESISTANCE (MX) LOCUS: IFN-INDUCIBLE GTPases OF THE DYNAMIN SUPERFAMILY AND RESISTANCE TO ORTHOMIXOVIRUS (INFLUENZA) INFECTION Inﬂuenza viruses (members of the orthomyxovirus family) cause upper respiratory tract infections in humans and various domestic animals; these include chickens (fowl plague), horses (equine inﬂuenza), and pigs (swine inﬂuenza). In nature, wildfowl and shorebirds may form the virus reservoir. According to the World Health Organization (WHO) (http://www.who.int/en/), in an inﬂuenza epidemic 5% to 15% of the population is affected, including 3–5 million cases of severe illness and between 250,000 to 500,000 deaths every year. The elderly, young children, and people with compromised health status are at high risk for serious complications. Highly pathogenic inﬂuenza of certain subtypes can cause global outbreaks. Three inﬂuenza pandemics have occurred in the twentieth century: the Spanish ﬂu in 1918 resulted in approximately 50 million deaths worldwide, the Asian inﬂuenza in 1957 resulted in more than 1 million deaths, and the Hong Kong inﬂuenza in 1968 www.annualreviews.org • Immunity to Infection in the Mouse

103

ANRV338-IY26-04

ARI

16 February 2008

11:22

S. aureus?

LRR TLR4

MyD88 Tirap TIR Tram Trif

LRR TLR6 TIR

1 Early response (inflammatory cytokines) 2 Late response (lFN-β)

2

1

Pathogen

NK cells T cells

Irgb10 NF-κB

Igtp

IRF-3 Igtp Icsbp /IRF8

Irgb10

P47GTPases

IFN-γ

IL-12

IFN-γR

IFN-αβR

Ipr1/Ifi75 Jak1

STAT2

Cytokines

Tyk2

Ipaf

Anthrax toxin

pro-IL-1β

?

IL-1β

STAT1 STAT2

Legionellacontaining vacuole

Nalp1b Bacterial growth restriction Caspase 1

IFN-β STAT1

Flagellin

Birc1e

STAT1 STAT1

-β IFN

Annu. Rev. Immunol. 2008.26:81-132. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

Nr

am

p1

Fe2+

CD36 TLR2 LRR Phagosome

MyD88 Tirap TIR

Lysosome

LPS

IFN-β ?

NUCLEUS

Mtb MACROPHAGE

Figure 2 Central role of the macrophage in genetic studies of infection susceptibility loci. Schematic representation of several major biochemical, physiological, and signaling pathways relevant to macrophage defenses against infectious agents. Genes and proteins involved play a key role in these pathways; mutations identiﬁed by forward genetics as causing alterations in resistance to infections are shown in red. See text for details. [Abbreviations: Nramp1, natural-resistance-associated macrophage protein 1; LRR, leucine-rich repeat; MyD88, myeloid differentiation primary response gene 88; Tirap, Toll receptor-associated activator of interferon; Trif, Toll/IL-1 receptor (TIR) domain–containing adapter-inducing interferon-β; Tram, TRIF-related adapter molecule; Icsbp, IFN consensus sequence-binding protein; IRF, IFN regulatory factor; Mtb, Mycobacterium tuberculosis; Nalp1b, nacht, LRR, and Pyrin domain–containing 1b; Birc1e, baculoviral IAP repeat-containing 1e; Ipaf, IL-1 β-converting enzyme–protease-activating factor; JAK, Janus kinase; STAT, signal transducer and activator of transcription; Tyk, tyrosine kinase; CD36, CD36 antigen; Irgb10, iron-regulated virulence protein 10; Igtp, IFN-γ-induced GTPase; Ipr1, intracellular pathogen resistance 1; Iﬁ75, IFN-induced protein 75.]

was responsible for approximately 700,000 deaths (202). More recently, the emergence of the highly pathogenic avian H5N1 inﬂuenza virus, which is transmitted directly from birds 104

Vidal et al.

to humans, highlights the threat of future inﬂuenza outbreaks and pandemics. Genetic studies in mouse models of inﬂuenza were used successfully to identify

Annu. Rev. Immunol. 2008.26:81-132. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-04

ARI

16 February 2008

11:22

major host determinants of susceptibility and resistance to infection. Most laboratory mouse strains (C57BL/6J, C3H/HeJ, BALB/cJ CBA/J, CE/J, I/LnJ, and PERA/Ei) are extremely susceptible to intranasal infection with mouse-adapted strains of inﬂuenza virus, with the exception of the A2G strain and several wild-derived inbred strains (SL/NiA, T9, and CAST/Ei) (203–205). Resistance of A2G mice is speciﬁc for inﬂuenza and is controlled by a single dominant gene named Mx (myxovirus resistance locus); the protective effect of Mx is mediated by type 1 IFNs (206). The Mx locus has two phenotypic alleles: Mx+ (resistant, dominant) and Mx− (susceptible, recessive) (207). A candidate gene for Mx was identiﬁed as a protein that was differentially expressed (determined by 2D-gel electrophoresis) in Mx+ and Mx− cells in response to stimulation with type 1 IFN (208). A nuclear protein of 72 kDa, named Mx1, was inducible by type 1 IFN and present only in cells carrying the wild-type allele at Mx but not in cells of the Mx− phenotype. Staeheli and colleagues (207) further cloned the Mx1 gene, mapped it to mouse chromosome 16, and showed that it belongs to the superfamily of dynamin-like large GTPases. Linkage studies in informative backcross progeny issued from crosses between different laboratory strains carrying the Mx− allele established that susceptibility to inﬂuenza maps to the 8 Mb at the distal end of chromosome 16 where the Mx1 gene was previously localized (209). Mutational analyses revealed that the Mx− defect in BALB/cJ, C57BL/6J, and C3H/HeJ mice is caused by deletion of exons 9–11 and some ﬂanking sequences, which results in a truncated, nonfunctional Mx1 protein. The Mx− phenotype of CBA/J, CE/J, I/LnJ, and PERA/Ei mice is caused by a nonsense mutation in exon 10 that converts codon 389 (Lys) to a termination codon, which prevents synthesis of functional Mxl (210). Mx1 is a nuclear protein whose expression is stimulated by IFN-α/β or by viral infection. Mx1 contributes to speciﬁc resistance against the inﬂuenza virus by acting at an early stage of the

viral infection cycle to inhibit primary transcription of the virus, probably through inhibition of the viral PB2 polymerase subunit (211, 212). Mx homologs are present in all eukaryotes examined, including humans, cattle, pigs, rats, horses, hamsters, chicken, ﬁsh, and yeast. In mice, a second Mx gene (Mx2), closely linked to Mx1 on chromosome 16, was identiﬁed and shown to be nonfunctional in classical inbred mouse strains (the Mx2 mRNA carries an insertion at position 1366, which causes a translational frameshift) (213). However, in wild-derived mice, Mx2 is expressed following exposure to type 1 IFN or viral infection and localizes to the cytoplasm, where it can inhibit VSV replication (214). In humans, two Mx proteins (MxA and MxB) were identiﬁed as GTPases and map to the region of chromosome 21 homologous to mouse chromosome 16. Only MxA has detectable antiviral activity and, in contrast to Mx1, inhibits replication of a spectrum of viruses, including members of the orthomyxoviruses (inﬂuenza and Thogoto virus), rhabdoviruses (VSV), paramyxoviruses (Measles virus), and picornaviruses (coxsackie virus), among others (reviewed in 215). The essential role of Mxl in inﬂuenza resistance has been demonstrated in vitro and in vivo. Transfection of the wild-type Mx1 allele into Mx− cells transforms them from a sensitive to a resistant phenotype (207). In addition, the resistant phenotype of Mx+ cells can be abolished by the use of an anti-Mxl antibody (216). In vivo, transgenic mice that express mouse Mx1 or human MxA are fully protected against inﬂuenza infection (217, 218).

THE HV2 LOCUS: CEACAM1B AND THE CONTROL OF CORONAVIRUS ENTRY INTO THE HOST CELL With a single-stranded positive-sense RNA genome of 30–32 kb (219), coronaviruses are the largest of all the RNA viruses. They have a broad host range and cause a variety of diseases. In humans, coronaviruses www.annualreviews.org • Immunity to Infection in the Mouse

105

ARI

16 February 2008

11:22

cause respiratory disease and, to a lesser extent, infections of the digestive tract and neurological syndromes. Human coronaviruses OC43 (HCoV-OC43) and HCoV-229E are the causative agents of the common cold (220); the more recently identiﬁed agents HCoV-HKU1 and HCoV-NL63 cause more severe, although rarely fatal, infections of the upper and lower respiratory tract (221–223). Severe acute respiratory syndrome (SARS)CoV causes a life-threatening pneumonia (224) and is the most pathogenic human coronavirus identiﬁed to date (225, 226). SARSCoV may reside in an animal reservoir (227, 228) and recently initiated an epidemic in humans through zoonotic transmission (228). Coronaviruses also cause economically important diseases of livestock, poultry, and laboratory animals (229). In mice, several strains of the prototype coronavirus, mouse hepatitis virus (MHV), with different degrees of pathogenicity and tissue tropism, have been used to study infection in vivo. For example, the A59 strain of MHV is hepatotropic (230), and the JMH strain induces encephalitis and sometimes demyelination (231). The MHV3 strain induces fatal hepatitis (232). More recently, researchers found that respiratory infection with the MHV1 strain produces severe pneumonia accompanied by tissue destruction, mainly in the lung (233). Several pathophysiological features are common between mice infected with MHV and patients infected with SARS-CoV and are consistent with immunopathological disease: These include the propensity of viruses to infect macrophages and DCs and an increased systemic concentration of chemokines and cytokines (234). In mice, activated macrophages are present at sites of inﬂammation and participate in tissue destruction (234). Inbred mouse strains are susceptible to experimental infection with MHV, although the SJ/L strain can sustain a 10,000-fold higher infectious dose (235). Examination and segregation analysis of several inbred strains showed that resistance is recessive and that expression of disease resistance is controlled by

Annu. Rev. Immunol. 2008.26:81-132. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-04

106

Vidal et al.

a single autosomal gene acting at the level of the infected cell (236). Following virus replication in macrophages, this resistance trait was mapped to mouse chromosome 7 at the Hv2 locus (237, 238), now designated carcinoembryonic antigen–related cell adhesion molecule 1 (Ceacam1). More recently, investigators showed that Ceacam1 controls survival differences between SJ/L and BALB/c mice (239). In the SJ/L strain, the inability of MHV to bind the host cell membrane suggested that resistance to infection is due to the absence of a functional receptor for the virus (240); the receptor was ﬁnally identiﬁed biochemically (241). CEACAM1 is a member of the carcinoembryonic antigen (CEA) family in the Ig superfamily (242). Mouse CEACAM1 isoforms are transmembrane glycoproteins with either two or four Ig domains that are produced by alternative splicing of the primary transcript (243). An immunoreceptor tyrosine-based inhibitory motif (ITIM) is present in the cytoplasmic domain of CEACAM1 and confers immunomodulatory function to this molecule (244). The expression of CEACAM1 glycoproteins is widespread not only on the apical membranes of epithelial cells in the gastrointestinal and respiratory tracts (245), which are the main targets of MHV replication, but also in small vascular endothelial cells, hematopoietic cells, and glial cells of the nervous system. In these tissues, CEACAM1 performs many important cellular functions. It may act as a cell adhesion molecule, an angiogenic factor, a tumor suppressor, and/or a signal regulatory protein (246). In inbred mice, there are two Ceacam1 alleles; susceptible strains carry the Ceacam1a allele. Expression of CEACAM1a in human and hamster cells is sufﬁcient to overcome the species barrier to MHV infection, which supports the role of CEACAM1a as a functional MHV receptor. Resistant SJ/L mice carry the Ceacam1b allele, which encodes a protein with a 27 amino acid substitution in the ﬁrst Ig domain of CEACAM1b. Extensive mutational and biochemical analysis showed that this region mediates CEACAM1

Annu. Rev. Immunol. 2008.26:81-132. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-04

ARI

16 February 2008

11:22

binding to the spike protein of the MHV envelope. Three mouse lines with genetically engineered mutations in Ceacam1a were produced (247, 248). Mice with complete abrogation of the CEACAM1a protein exhibited resistance to MHV infection via the intranasal and intracerebral route with no clinical signs of disease even at high doses, which demonstrates the critical role of a virus receptor in resistance to infection. Human CEACAM1a proteins do not recognize mouse or human coronaviruses but instead bind Gram-negative bacteria in the vicinity of the MHV binding site. In addition to CEACAM1, CEACAM3, CEACAM5, and CEACAM6 proteins allow bacterial anchoring or invasion of the host cell (246). Infection with Neisseria gonorrhoeae promotes CEACAM1-mediated inhibition of CD4+ T cell activation, which indicates an immunoregulatory role for the cytoplasmic ITIM-containing tail of CEACAM1. In stark contrast, the neutrophil-restricted CEACAM3 receptor possesses an immunotyrosine activating motif (ITAM) in its intracellular domain, which promotes ITAMdependent internalization of the CEACAM3 bacterial complex and neutrophil bactericidal activity via a Syk kinase–dependent pathway (249–251). Thus, particular species of bacteria seem to exploit adhesion to CEACAM1 to promote immunosuppression.

THE FLV LOCUS: SPECIFIC INHIBITION OF WEST NILE VIRUS REPLICATION BY 2 ,5 -OLIGOADENYLATE SYNTHASE 1B West Nile virus (WNV) is a re-emerging pathogen that cycles primarily between mosquitoes and birds; humans represent one of several incidental hosts (252). The virus is widely distributed throughout Africa, the Middle East, and India but was not detected in the Western Hemisphere before 1999, when it caused an outbreak of viral encephalitis in New York (252). Since then, the virus

has propagated rapidly throughout all North America, resulting in considerable acute morbidity and mortality. Epidemiologic studies indicate that although 80% of infections remain subclinical, 20% progress to a febrile illness. Of these, more than 30% of cases in the U.S. progress to neuroinvasive disease, causing meningitis, encephalitis, and/or ﬂaccid paralysis (253). WNV is a member of the genus Flavivirus (family Flaviviridae), which also contains the Yellow Fever, Dengue, and Japanese encephalitis viruses. Flaviviruses contain a positive-sense RNA genome of 10 kb. Viral replication in host cells generates negativestrand RNA intermediates that serve as templates for nascent positive-strand RNA synthesis. WNV replicates initially in Langerhans cells, a resident DC of the skin. Following peripheral replication, WNV spreads to the CNS, possibly through TNF-mediated changes in blood-brain barrier permeability. Neurons are the primary target of WNV in the brain and spinal cord. Although WNV can directly antagonize IFN-induced responses after infection, type I IFN is still required to restrict WNV replication and spread (254). The characterization of innate resistance to ﬂavivirus-induced morbidity and mortality started as early as 1929 (255). Selective breeding in mice led to the development of resistant and susceptible lines, followed by the demonstration that a single autosomal dominant locus, designated Flv, is responsible for the differences in the host response against several types of ﬂaviviruses (256). Following intracerebral infection, viral titers in the brain of resistant mice with the Flvr resistance allele are several orders of magnitude lower than in Flvs susceptible mice. Similarly, virus titer yields in cells cultured from resistant or susceptible animals are also dramatically different, which indicates that resistance to ﬂavivirus acts intracellularly on ﬂavivirus replication. Most common laboratory-inbred strains of mice are susceptible to experimental infection, whereas wild-derived strains (e.g., PR1, MBT/Pas, MAI/Pas) are not (257). The resistance www.annualreviews.org • Immunity to Infection in the Mouse

107

ARI

16 February 2008

11:22

allele from donor PR1 mice was introduced onto the susceptible C3H/He background to produce the congenic inbred C3H.PR1-Flvr . Using this strain in crosses with the susceptible C3H/He or BALB/c mouse strains, and following the load of Murray Valley encephalitis virus in brains of infected mice, Flv was mapped to chromosome 5 (258). Additional high-resolution linkage mapping experiments delineated a minimal interval for Flv of 0.45 cM (259). In a parallel study, an identical interval was deﬁned for resistance in terms of survival to a low intraperitoneal inoculum of the recent WNV variant ISr98/NY99 (from New York) and of a different set of wildderived mouse strains (257). Physical mapping in BAC clones, exon trapping, and cDNA selection techniques were used to identify positional candidates. A cluster of genes encoding the 2 ,5 -oligoadenylate synthetases (2 ,5 OAS) contained excellent candidates on the basis of their known (IFN-inducible) antiviral activity in response to double-stranded RNA (dsRNA). Of the ﬁve functional Oas genes found in mice (Oas1g, Oas1b, Oas1a, Oas2, Oas3), only Oas1b is important for the host response to WNV and plays a key role in WNV pathogenesis. All susceptible mice tested so far have a T-to-C transition that replaces an arginine residue with a premature stop codon, which probably results in a defective enzyme without nucleotidyl transferase activity (257, 259). This assumption was reinforced by the observation that replication of WNV is less efﬁcient in neuroblastoma cell clones that overexpress the normal copy of Oas1b than in those expressing the mutant variant (259). Moreover, upregulation of OAS1B (under the control of the Tet-Off expression system) in ﬁbroblasts efﬁciently inhibited WNV replication at the early stages of the virus life cycle by dramatically reducing the levels of positivestranded viral RNA. It remains unclear what provides speciﬁcity to OAS1B in this system (259). OAS proteins are part of the OAS/RNase L system of RNA decay stimulated by the type I IFN antiviral response. Transcrip-

Annu. Rev. Immunol. 2008.26:81-132. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-04

108

Vidal et al.

tion of OAS genes is upregulated by type I IFN, and expressed OAS proteins are activated by dsRNA. Activated OAS catalyzes the synthesis of 2 ,5 -oligoadenylates, which in turn activate RNase L, a latent endoribonuclease that degrades viral and cellular RNAs. RNase L−/− murine embryonic ﬁbroblasts and PKR−/− × RNase L−/− bone marrow–derived macrophages supported increased WNV replication in vitro (recently reviewed in 214). Moreover, mice deﬁcient in both PKR and RNase L showed increased lethality following WNV infection, with greater viral loads in peripheral tissues at early time points after infection. However, the mechanisms by which Oas gene alleles affect ﬂavivirus pathogenesis remain uncertain; recent reports suggest that Oas1b gene effects on WNV replication are independent of RNase L (253). A recent study of 33 WNV-infected patients showed a positive association between the nucleotide change T210C and susceptibility to WNV disease in humans (260). Their analysis predicted that the T210C nucleotide change creates a new OAS splice enhancer site that may result in production of a dominant-negative protein (260).

THE CMV1 LOCUS AND ITS RELATIVES: RECOGNITION OF THE CYTOMEGALOVIRUSINFECTED CELL BY NATURAL KILLER CELL RECEPTORS Most humans are infected by human cytomegalovirus (HCMV), a virus of the Herpesviridae family, characterized by a large double-stranded DNA genome (200 kb), wide tissue tropism, and the ability to establish latency in immunocompetent individuals. Primary infections are mostly subclinical or they may be associated with a selflimited mononucleosis-like syndrome. However, HCMV is the most common cause of virus-induced mental retardation and congenital deafness in the Western world. In addition, HCMV infections can cause serious

Annu. Rev. Immunol. 2008.26:81-132. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-04

ARI

16 February 2008

11:22

morbidity and mortality among immunocompromised subjects (recently reviewed in 261). Patients with congenital defects in NK cells are also particularly vulnerable to infection by herpesvirus (262–265). A central aspect of the pathogenesis of CMV is that many genes serve to evade or subvert mechanisms of host defense (266– 268). Infection of mice with the closely related mouse CMV (MCMV) has proven exceptionally useful for the study of the complex host:pathogen interactions (recently reviewed in 269). In mice, genetically determined resistance against MCMV is under multigenic control, with contributions from both H2 and non-H2 genes (270, 271). Inbred strains carrying the H2k haplotype, such as CBA, C3H/HeJ, or congenic BALB.K, are up to 10 times more resistant (measured as survival time) to MCMV than strains with H2b or H2d haplotypes (271). However, in strains with a C57BL background and the H2b haplotype, non-H2-linked effects override H2determined susceptibility. The Cmv1 locus is one of the best characterized loci in the C57BL/6 mouse strain that is responsible for non-H2 host resistance against MCMV infection (272). Through genetic analysis of progeny from MCMVresistant and MCMV-susceptible parents, Scalzo and coworkers (272) identiﬁed a single locus, Cmv1, as the major determinant of MCMV-resistance in the C57BL/6 mouse strain. Cmv1 is an autosomal (chromosome 6) dominant trait that restricts viral replication at the level of the spleen and other target organs such as liver and lung (272). Cmv1 function is mediated by NK cells (273). Researchers cloned the Cmv1 locus using a combination of high-resolution mapping, physical mapping, and detailed immunological characterization of C57BL/6 mice. The cloning was complicated by the fact that Cmv1 resides within an interval that contains 14 highly related genes of the Ly49 family of MHC class I receptors (277). Ly49h, a gene that encodes an activating NK cell receptor, was identiﬁed as the gene underlying the Cmv1 locus

(274–276). Ly49h is present in the MCMVresistant strain C57BL/6 but is absent in susceptible strains such as BALB/c, DBA/2, and 129Sv/J (278). In fact, a clonal expansion of Ly49H+ NK cells occurs following MCMV infection of C57BL/6 mice (279). The crucial role of Ly49H-bearing NK cells in host defense against viral infection was validated by restoring MCMV-resistance in genetically susceptible mice through transgenic expression of Ly49h (280). Ly49 molecules constitute an extended family of activating and inhibitory C-lectintype receptors that recognize MHC class I (277, 281). Activating LY49H, contrary to inhibitory ITIM-bearing Ly49 receptors, associates with the ITAM-containing DNAXactivating protein of 12 kD (DAP12) adapter protein, also known as killer cell activating receptor–associated protein (KARAP). The importance of the Ly49H/DAP12 receptor complex in NK cell–mediated resistance to MCMV infection is supported by the observation that DAP12 mutant mice present a considerable increase in MCMV titers in the spleen and liver following infection (282). Ly49H speciﬁcally recognizes MCMVinfected cells via a direct interaction with the m157 MCMV protein, which has structural homology to MHC class I molecules (283, 284). Deletion of the m157 gene is associated with gain of virulence in Ly49H+ mouse strains but not in Ly49H− strains, which indicates that m157 is the only MCMV-encoded protein that activates Ly49H+ NK cells (285). Arase et al. (283) demonstrated that m157 also binds to an inhibitory receptor, Ly49I, expressed on NK cells in 129 mice, which suggests that m157 may have evolved as a mechanism to escape NK cell killing by targeting inhibitory receptors in certain susceptible mice. These observations predicted a dynamic interaction between Ly49 receptors and MCMV evasion genes, which was recently conﬁrmed. In fact, several MCMV strains isolated from wild mice had variants of the m157 gene, many of which disrupted the open reading frame and inactivated the www.annualreviews.org • Immunity to Infection in the Mouse

109

ARI

16 February 2008

11:22

gene (286). In addition, sequential passage of the commonly used Smith strain of MCMV in Ly49H+ C57BL/6 mice (287) or in SCID mice (288) resulted in loss-of-function mutations in the m157 gene. This result demonstrates the ability of Ly49H+ NK cells to exert enough selective pressure to permit the speciﬁc outgrowth of MCMV escape mutants with alterations in m157. Further genetic analysis of MCMVresistant inbred strains demonstrated the presence of alternative NK cell–encoded resistance mechanisms, Cmv3 (289) and Cmv4 (290), which operate individually or in combination with speciﬁc H2 haplotypes. The Cmv4 locus is also tightly linked to the Ly49 cluster and presents a second example of a major locus effect in MCMV resistance present in a wild-derived inbred mouse strain, PWK/Pas. Although the Cmv4 effect is independent of Ly49H/m157, the most likely candidate remains another activating NK cell receptor that speciﬁcally recognizes MCMV-infected cells (290). Support for alternate activating Ly49 receptors determining MCMV resistance also comes from the study of the Cmv3 locus present in a resistant mouse strain, MA/My (289). This strain carries a Ly49 haplotype similar to that of the MCMV-susceptible 129 strain, which lacks Ly49h. MA/My mice also contain the protective H2k haplotype, whereas 129 (H2b ) present with susceptible haplotypes, which suggests a possible role of H2 in MA/My resistance. Linkage analyses suggested that MCMV resistance in MA/My is linked to the Ly49 gene cluster. However, only the speciﬁc combination of Ly49 (Ly49em ) with MHC (H2k ) alleles is associated with virus resistance. A model including contributions of Ly49 genes, H2-loci, and their interaction explained 40% of the phenotypic variance in this cross. A cell reporter assay, in which cells expressing the activating receptor Ly49P were responsive to challenge only with H2k target cells infected with MCMV, conﬁrmed a physical interaction between the Ly49 and H2 gene products. Blocking anti-

Annu. Rev. Immunol. 2008.26:81-132. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-04

110

Vidal et al.

bodies to class I H2k gene product, H2-Dk , directly implicated this molecule in stimulation of Ly49P (289). Thus, Ly49P recognition of MCMV infection in the context of H2Dk points to a novel mechanism of NK cell function, in which an activating Ly49P receptor mediates host resistance against MCMV through speciﬁc recognition of a virally altered MHC class I molecule. The discovery of Ly49H- and Ly49P-mediated recognition of MCMV-infected cells supports the hypothesis that activating receptors have evolved under evolutionary pressures from pathogens and has revealed an exceptional speciﬁcity of this arm of the innate immune system for unique viral determinants (Figure 3). Human killer cell Ig-like receptors (KIR) are the functional counterparts of murine Ly49s (291). Rigorous epidemiological studies based on very large patient cohorts demonstrated that combinations of KIR and HLA are associated with protection against infections by several viruses, including HIV and HCV [recently reviewed by Carrington & Martin (292)]. Remarkably, the ﬁndings suggest that these genetic interactions may manifest different mechanisms of protection. During HIV infection, speciﬁc receptor-ligand pairs may convey protection by directly increasing NK cell activation (293). In the case of protection against low inoculums of HCV, speciﬁc weakly inhibitory KIR/HLA pairs may afford protection by lowering the threshold of NK cell activation (294). By analogy with mouse models of MCMV resistance, direct NK cell killing of infected cells may reduce the risk or severity of infection with human viruses.

THE OBLIVIOUS, CPG1, LPS2, AND TRIPLE D PHENOTYPES: TOLL-LIKE RECEPTOR PATHWAYS AND THE CONTROL OF VIRAL PROLIFERATION New models of host susceptibility to infection have recently been identiﬁed in largescale mouse mutagenesis projects via the use

ANRV338-IY26-04

ARI

16 February 2008

11:22

CD4

MHC I

MHC II

Endoplasmic reticulum Endosome Unc93b

49

TLR3

Ly

?

dsRNA ssRNA

Viruses

TLR7 CpG DNA NK

INNATE IMMUNE CELL

MyD88

Inflammatory cytokines Trif

IFN-αβ IFN-αβ STAT1

NF-κB

Mx 2'-5' OAS

STAT2

STAT1

NUCLEUS

STAT2

Viruscontaining vacuole CD8

IRF-7

R

IRF-3 STAT1

STAT2

Jak1

Tyk2

TC

Annu. Rev. Immunol. 2008.26:81-132. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

TLR9

IFN-αβR IFN-αβ

Figure 3 Genetically identiﬁed molecular pathways activated in response to viral infections. Schematic representation of several major biochemical, physiological, and signaling pathways relevant to the response of cells of the immune system (CD4+ and CD8+ T cells, NK cells, and macrophages) against viral pathogens. Genes and proteins shown play a key role in these pathways; mutations identiﬁed by forward genetics as causing alterations in resistance to viruses are identiﬁed in red. (This ﬁgure is inspired by Reference 9.) See text for details. [Abbreviations: CpG DNA, DNA containing guanine–phosphate diester–cytosine dinucleotides; TRIF, Toll/IL-1 receptor (TIR) domain–containing adapter-inducing IFN-β; MyD88, myeloid differentiation primary response gene 88; STAT, signal transducer and activator of transcription; Mx, myxovirus resistance; 2 -5 OAS, 2 -5 -oligoadenylate synthetases; Ly49, killer cell lectin-like receptor; Jak1, Janus kinase 1; Tyk2, tyrosine kinase 2; Unc93b, unc-93 homolog B.]

of the chemical agent ENU (recently reviewed in 295). The technique can theoretically cause a mutation in any gene and is limited only by the ingenuity of the screening approach (recently reviewed in 296–298). In a typical whole-genome mutagenesis screen, inbred male mice are treated with ENU to

induce several hundred germ line mutations per mouse. The males are crossed to wildtype females of the same strain, and large cohorts of offspring are tested to identify the phenotypically distinct mice most likely to bear a large-effect mutation. ENU mutagenesis is a powerful tool to map novel www.annualreviews.org • Immunity to Infection in the Mouse

111

ARI

16 February 2008

11:22

biochemical and physiological pathways that play critical roles in host defenses against infections and aids in the establishment of new mouse models of human diseases. To explore TLR pathways, Beutler and coworkers (reviewed in 295) designed a genomewide screen for dominant and recessive ENUinduced mutations in C57BL/6 mice. In this experiment, thioglycolate-elicited peritoneal macrophages were collected from male mice, and researchers measured the TNF bioactivity of these cells in response to TLR agonists. Secondary screens of mice with unresponsive macrophages produced several new models of susceptibility to infection, including the Oblivious (299), Lps2 (300), CpG1 (301), and Triple D (3d ) (302) mutants that have been well characterized during in vivo infection. The Oblivious (Obl ) mutation causes a recessive immunodeﬁciency phenotype in which macrophages are insensitive to some [e.g., lipoteichoic acid, the diacylated bacterial macrophage-activating lipopeptide 2 (MALP2)] but not all (e.g., zymosan) TLR2/6-dependent microbial stimuli. Perhaps for this reason, Obl homozygous mutants are highly susceptible to Gram-positive S. aureus infections. Positional cloning of the Obl locus revealed a premature stop codon in the Cd36 gene (299). Macrophages from Obl mice have an identical phenotype to that of Cd36−/− mice, and macrophage function can be rescued by transfection of a wild-type version of Cd36, which provides convincing evidence that Cd36 is the gene responsible for the Obl phenotype (299). Unexpectedly, Obl mice permit MCMV to grow to high titers in vivo. CD36 is a member of the scavenger receptor type B family (303), previously implicated in the recognition of oxidized lowdensity lipoprotein (LDL) particles and the uptake of fatty acids (304), but unrelated to infection or TLR signaling. However, these experiments suggested that the TLR2/TLR6 complex uses CD36 as a coreceptor for some of its bacterial ligands and for a yet undeﬁned molecule derived or elicited from MCMV.

Annu. Rev. Immunol. 2008.26:81-132. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-04

112

Vidal et al.

The Lps2 mutant phenotype causes macrophages to lose their responsiveness to TLR4 and TLR3 ligands, which indicates that Lps2 may be a common intermediary of the TLR4 and TLR3 intracellular pathways (300). Of particular importance to viral pathogenesis, Lps2 macrophages also cannot generate an LPS- or dsRNA-induced type I IFN response and are highly susceptible to infection with VSV or Vaccinia virus (300). In correlation, the Lps2 mutation abolishes the activation of the gene transcription factor IRF3. As a result, Lps2 homozygotes are markedly resistant to the lethal effect of challenge with LPS, and their immune response to MCMV is compromised, which allows high viral titers in the spleen (305). The enhanced pathogenicity to MCMV is associated with a failure to produce adequate amounts of type 1 IFN, as measured in the serum early after infection. Following positional cloning, the Lps2 mutation was found to correspond to a single base pair deletion in the Trif gene (306, 307). In vitro rescue experiments with Trif again compensated for the Lps2 phenotype, and the knockout of Trif yielded a phenotype similar to that of the Lps2 allele. The identiﬁcation of Lps2 revealed the bipartite nature of LPS (which signals through MyD88 and Trif) and the role of this intracellular pathway in host resistance to virus infection (308). In parallel studies, the mouse phenotype CpG1 was ﬁrst characterized by the unresponsiveness of mutant macrophages to stimulation with a synthetic analog of CpG-DNA. This PAMP is recognized by TLR9. Accordingly, sequencing of the Tlr9 coding region indicated that the genetic defect was a nucleotide substitution that resulted in a nonconservative amino acid replacement (L499P) in a well-conserved region of the protein (301). The CpG1 mutation is associated with severe susceptibility to MCMV (301), as is a targeted mutation in the TLR9 receptor (309). These and other data suggest that the signaling pathways of both TLR9, via the adapter MyD88, and TLR3, via the adapter TRIF, are activated by viral infection and

Annu. Rev. Immunol. 2008.26:81-132. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-04

ARI

16 February 2008

11:22

contribute to innate defense in an additive and nonredundant manner by stimulating the production of type I IFN for activation of effector response by NK cells (295). Finally, the Triple D (3d ) mutant phenotype abrogates macrophage signaling via the RNA and DNA agonists of the intracellular receptors TLR3, TLR7, and TLR9 (302). 3d mice succumb early to a challenge with MCMV (most likely because nucleic acids are an important by-product of virus infection); however, these mice are also susceptible to other organisms such as S. aureus and L. monocytogenes (295). 3d mice are also deﬁcient in APC activity despite normal levels of MHC class I and MHC class II antigen presenting molecules (302). Using positional cloning, researchers found that the 3d mutation introduces a single H412R substitution in the polytopic ER-resident membrane protein UNC93B. Transfection of the wild-type allele into 3d mutant mice rescues TNF production, which shows that the speciﬁc H412R mutation is responsible for the signaling defect in DCs from homozygous Unc93b mutant mice (302). The precise function of the UNC93B protein remains unknown. The mutation does not affect the stability or localization of the protein but rather abolishes the interaction between UNC93B and the transmembrane domain of TLR3 and TLR9 (310), which suggests that this physical association is crucial for TLR signaling. A notable human study by Casanova and colleagues (311) linked a mutation in UNC93B to the etiology of herpes simplex encephalitis (HSE). Cells isolated from an HSE patient presented a selective lack of response to TLR7, -8, and -9 agonists, similar to the response of cells obtained from 3d mutant mice. In addition, the production of type 1 IFNs was selectively impaired in the patient’s cells in response to stimulation with several viruses. Pedigree analysis and candidate gene sequencing associated the phenotype with a homozygous four-nucleotide deletion that introduces a premature stop codon in the UNC93B1 cDNA. Moreover, transfection

of wild-type cDNA into these cells complements cytokine secretion in the patient’s cells, which indicates that UNC93B deﬁciency is the predisposing factor to HSE in this family. Remarkably, the addition of recombinant IFN prior to viral infection fully complements the cellular phenotype of UNC93B mutant cells, which suggests that IFN could be a possible treatment in certain HSE patients. These studies provided the ﬁrst description of the genetic etiology of HSE and validated the applicability of a chemical-mutagenesis approach to identify mechanisms of human susceptibility to infection.

DOMINO AND JINX: IN VIVO DISSECTION OF HOST RESISTANCE AGAINST MOUSE CYTOMEGALOVIRUS Beutler and colleagues (312) initiated a genome-wide screen of mice derived from ENU-progenitors for host susceptibility to infection against MCMV. In this experiment, mice were challenged with MCMV and observed for severe levels of morbidity or high viral counts in the spleen. Out of approximately 11,300 mutant mice derived from ENU-progenitors, they found 11 transmissible mutations (312), of which the Domino (313) and Jinx (314) mutant phenotypes were recently characterized. The Domino mutation manifests as a severe recessive phenotype that is associated with high MCMV load and mortality by day four postinfection (313). In addition, the in vivo response to L. monocytogenes and macrophage growth of VSV are also impaired (315). This latter phenotype is not corrected by administration of type I IFN. Candidate gene sequencing and in vivo crosses with Stat−/− mice demonstrated that Domino corresponds to a point mutation that alters the binding domain of STAT1, abolishing its activation (313). The study of the Jinx phenotype led to new insights into the pathogenesis of CMV infection (314). Despite high viral load in the spleen, Jinx mutants show robust cytokine www.annualreviews.org • Immunity to Infection in the Mouse

113

ARI

16 February 2008

11:22

production, which indicates adequate sensing of the infection. Detailed phenotypic characterization of Jinx mice showed defects in NK cell and cytotoxic T lymphocyte (CTL) granule exocytosis, which are speciﬁc to viral infection. Through mapping and sequencing, investigators attributed viral susceptibility to the creation of a novel donor splice site in Unc13d. This change is predicted to introduce a premature stop codon, thus eliminating one of the two Ca2+ binding domains of the 1085 amino acid protein (314). The precise function of the UNC13-D protein remains undeﬁned, although it is required for the fusion competence of cytoplasmic vesicles only in certain immune cells (316). UNC13D is conserved throughout evolution from C. elegans to humans (317). Remarkably, mutations in the human ortholog MUNC13-4 cause type 3 familial hemophagocytic lymphohistiocytosis (FHL3), a severe disease characterized by hepatosplenomegaly, anemia, and thrombocytopenia (318). However, FHL3 may require either a virus or bacteria as an infectious trigger for expression of the phenotype (319). Likewise, Jinx mice do not present hepatosplenomegaly in the absence of infection. However, hemophagocytic lymphohistiocytosis (HLH) can be induced by at least one virus, the arenavirus lymphocytic choriomeningitis virus (LCMV), which conﬁrms that UNC13-D is responsible for the Jinx phenotype (314). MUNC134/UNC13-D belongs to a large family of paralogous proteins, of which the closest relatives (MUNC13-1 to MUNC13-4) are expressed in the brain (320), where they serve partially redundant functions in the priming of synaptic vesicles (321, 322). This is clearly not the case for UNC13-D, whose role in NK function seems unique, and can now be explored in the Jinx model.

Annu. Rev. Immunol. 2008.26:81-132. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-04

CONCLUSIONS AND FUTURE PERSPECTIVES Over the past 75 years, the laboratory mouse has been the animal model of choice to study 114

Vidal et al.

many aspects of host defenses against infections, which has led to numerous seminal discoveries. These discoveries include the major histocompatibility locus (and the concept of self-recognition), the presence of discrete cell populations such as macrophages, DCs, and lymphocytes responsible for early antigen recognition, the orchestration of the adaptive immune response, and the resulting long-term protection against reinfecting pathogens. With the advent of laboratoryinbred mouse strains some 50 years ago, scientists began readily to report reproducible differences in the responses of different mouse stocks to different types of infections, and the ﬁeld of immunogenetics was born. Early segregation studies revealed that some of these strain-speciﬁc differences in susceptibility are inherited as monogenic traits, and scientists were prompt to realize that identiﬁcation of the gene involved may yield important insight into the mechanisms by which the host recognizes, interacts with, and ultimately eliminates infectious agents. However, the absence of adequate mapping tools, including a paucity of genetic markers, the resulting frail genetic map, and the lack of DNA analysis methods rendered the task of going from a chromosomal localization to identiﬁcation of the gene and protein involved largely impossible. The advent of interspeciﬁc mouse crosses, simple sequence length polymorphisms (dinucleotide repeats), ﬂuorescence in situ hybridization, long-range physical mapping by pulsed-ﬁeld gel electrophoresis, large insert libraries in artiﬁcial yeast and bacterial chromosomes, exon ampliﬁcation, and efﬁcient DNA sequencing technologies gave birth to the ﬁeld of genomics 20 years ago. The years that followed saw the positional cloning of some of the oldest and best known so-called host-resistance loci, such as Mx (p47GTPase), Ity/Lsh/Bcg (Nramp1), Lps (Tlr4), Cmv1 (Ly49h) and several others covered in this review. Some of these discoveries had a dramatic impact on our understanding of host:pathogen interactions and shed considerable light on the critical early steps of

Annu. Rev. Immunol. 2008.26:81-132. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-04

ARI

16 February 2008

11:22

this interaction. In particular, the discovery of LRRs as modular structures for the recognition of PAMPs and the critical role of LRRcontaining proteins (including the TLR and NLR families) uncovered a previously unknown pathway for extracellular and intracellular antigen recognition by macrophages and other cells. The next wave of innovation came in the form of a complete draft of the whole genome, an annotated transcript map together with powerful technologies such as high-throughput DNA sequencing and genotyping, and microarrays for whole-genome transcript proﬁling. These technologies have greatly facilitated the process of positional cloning, which has now become a fairly routine, albeit still laborious, endeavor, and have led to the discoveries of many other genes and

proteins important for the antimicrobial arsenal of the mammalian host. What is next? These new high-throughput technologies have opened the door to a more systematic sampling of the genetic diversity of inbred mouse stocks for differential response to infectious stimuli. Expanded genetic diversity may come not only from commercially available inbred mouse strains (Mouse Phenome Project), but also more importantly from ENU-mutagenized mouse stocks with the long-term potential to test the contribution of every gene in the genome to host response to infections. Although this is an enormous endeavor, several such large screens are currently underway. These screens will no doubt generate a wealth of additional information in this key area of immunology.

DISCLOSURE STATEMENT The authors are not aware of any biases that might be perceived as affecting the objectivity of this review.

LITERATURE CITED 1. Corbett EL, Steketee RW, ter Kuile FO, Latif AS, Kamali A, Hayes RJ. 2002. HIV1/AIDS and the control of other infectious diseases in Africa. Lancet 359:2177–87 2. Hill AV. 2006. Aspects of genetic susceptibility to human infectious diseases. Annu. Rev. Genet. 40:469–86 3. Clementi M, Di Gianantonio E. 2006. Genetic susceptibility to infectious diseases. Reprod. Toxicol. 21:345–49 4. Lederman MM, Penn-Nicholson A, Cho M, Mosier D. 2006. Biology of CCR5 and its role in HIV infection and treatment. JAMA 296:815–26 5. Min-Oo G, Gros P. 2005. Erythrocyte variants and the nature of their malaria protective effect. Cell. Microbiol. 7:753–63 6. Casanova JL, Abel L. 2007. Human genetics of infectious diseases: a uniﬁed theory. EMBO J. 26:915–22 7. Casanova JL, Abel L. 2004. Human mannose-binding lectin in immunity: friend, foe, or both? J. Exp. Med. 199:1295–99 8. Buer J, Balling R. 2003. Mice, microbes and models of infection. Nat. Rev. Genet. 4:195– 205 9. Kielczewska A, Vidal SM. 2006. Enemy at the gates: forward genetics of the mouse antiviral response. Curr. Opin. Immunol. 18:617–26 10. Lipoldova M, Demant P. 2006. Genetic susceptibility to infectious disease: lessons from mouse models of leishmaniasis. Nat. Rev. Genet. 7:294–305 11. Tuite A, Gros P. 2006. The impact of genomics on the analysis of host resistance to infectious disease. Microbes Infect. 8:1647–53 www.annualreviews.org • Immunity to Infection in the Mouse

115

ARI

16 February 2008

11:22

12. Amer AO, Swanson MS. 2002. A phagosome of one’s own: a microbial guide to life in the macrophage. Curr. Opin. Microbiol. 5:56–61 13. Bogdan C, Rollinghoff M. 1999. How do protozoan parasites survive inside macrophages? Parasitol. Today 15:22–28 14. Rosenberger CM, Finlay BB. 2003. Phagocyte sabotage: disruption of macrophage signalling by bacterial pathogens. Nat. Rev. Mol. Cell Biol. 4:385–96 15. Russell DG. 2001. Mycobacterium tuberculosis: here today, and here tomorrow. Nat. Rev. Mol. Cell Biol. 2:569–77 16. Skamene E, Schurr E, Gros P. 1998. Infection genomics: Nramp1 as a major determinant of natural resistance to intracellular infections. Annu. Rev. Med. 49:275–87 17. Forbes JR, Gros P. 2001. Divalent-metal transport by NRAMP proteins at the interface of host-pathogen interactions. Trends Microbiol. 9:397–403 18. O’Brien AD, Rosenstreich DL, Taylor BA. 1980. Control of natural resistance to Salmonella typhimurium and Leishmania donovani in mice by closely linked but distinct genetic loci. Nature 287:440–42 19. Skamene E, Gros P, Forget A, Kongshavn PA, St Charles C, Taylor BA. 1982. Genetic regulation of resistance to intracellular pathogens. Nature 297:506–9 20. Vidal SM, Malo D, Vogan K, Skamene E, Gros P. 1993. Natural resistance to infection with intracellular parasites: isolation of a candidate for Bcg. Cell 73:469–85 21. Vidal SM, Pinner E, Lepage P, Gauthier S, Gros P. 1996. Natural resistance to intracellular infections: Nramp1 encodes a membrane phosphoglycoprotein absent in macrophages from susceptible (Nramp1 D169) mouse strains. J. Immunol. 157:3559–68 22. Vidal S, Tremblay ML, Govoni G, Gauthier S, Sebastiani G, et al. 1995. The Ity/Lsh/Bcg locus: natural resistance to infection with intracellular parasites is abrogated by disruption of the Nramp1 gene. J. Exp. Med. 182:655–66 23. Govoni G, Vidal S, Gauthier S, Skamene E, Malo D, Gros P. 1996. The Bcg/Ity/Lsh locus: genetic transfer of resistance to infections in C57BL/6J mice transgenic for the Nramp1Gly169 allele. Infect. Immun. 64:2923–29 24. Poon A, Schurr E. 2004. The NRAMP genes and human susceptibility to common diseases. In The NRAMP Family, ed. M Cellier, P Gros, pp. 29–43. New York: Kluwer Acad./Plenum 25. Li HT, Zhang TT, Zhou YQ, Huang QH, Huang J. 2006. SLC11A1 (formerly NRAMP1) gene polymorphisms and tuberculosis susceptibility: a meta-analysis. Int. J. Tuberc. Lung Dis. 10:3–12 26. Greenwood CM, Fujiwara TM, Boothroyd LJ, Miller MA, Frappier D, et al. 2000. Linkage of tuberculosis to chromosome 2q35 loci, including NRAMP1, in a large aboriginal Canadian family. Am. J. Hum. Genet. 67:405–16 27. Malik S, Abel L, Tooker H, Poon A, Simkin L, et al. 2005. Alleles of the NRAMP1 gene are risk factors for pediatric tuberculosis disease. Proc. Natl. Acad. Sci. USA 102:12183–88 28. Abel L, Sanchez FO, Oberti J, Thuc NV, Hoa LV, et al. 1998. Susceptibility to leprosy is linked to the human NRAMP1 gene. J. Infect. Dis. 177:133–45 29. Alcais A, Sanchez FO, Thuc NV, Lap VD, Oberti J, et al. 2000. Granulomatous reaction to intradermal injection of lepromin (Mitsuda reaction) is linked to the human NRAMP1 gene in Vietnamese leprosy sibships. J. Infect. Dis. 181:302–8 30. Stienstra Y, van der Werf TS, Oosterom E, Nolte IM, van der Graaf WT, et al. 2006. Susceptibility to Buruli ulcer is associated with the SLC11A1 (NRAMP1) D543N polymorphism. Genes Immun. 7:185–89

Annu. Rev. Immunol. 2008.26:81-132. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-04

116

Vidal et al.

Annu. Rev. Immunol. 2008.26:81-132. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-04

ARI

16 February 2008

11:22

31. Canonne-Hergaux F, Calafat J, Richer E, Cellier M, Grinstein S, et al. 2002. Expression and subcellular localization of NRAMP1 in human neutrophil granules. Blood 100:268– 75 32. Gruenheid S, Pinner E, Desjardins M, Gros P. 1997. Natural resistance to infection with intracellular pathogens: the Nramp1 protein is recruited to the membrane of the phagosome. J. Exp. Med. 185:717–30 33. Gunshin H, Mackenzie B, Berger UV, Gunshin Y, Romero MF, et al. 1997. Cloning and characterization of a mammalian proton-coupled metal-ion transporter. Nature 388:482–88 34. Fleming MD, Romano MA, Su MA, Garrick LM, Garrick MD, Andrews NC. 1998. Nramp2 is mutated in the anemic Belgrade (b) rat: evidence of a role for Nramp2 in endosomal iron transport. Proc. Natl. Acad. Sci. USA 95:1148–53 35. Lam-Yuk-Tseung S, Camaschella C, Iolascon A, Gros P. 2006. A novel R416C mutation in human DMT1 (SLC11A2) displays pleiotropic effects on function and causes microcytic anemia and hepatic iron overload. Blood Cells Mol. Dis. 36:347–54 36. Fleming MD, Trenor CC 3rd, Su MA, Foernzler D, Beier DR, et al. 1997. Microcytic anaemia mice have a mutation in Nramp2, a candidate iron transporter gene. Nat. Genet. 16:383–86 37. Forbes JR, Gros P. 2003. Iron, manganese, and cobalt transport by Nramp1 (Slc11a1) and Nramp2 (Slc11a2) expressed at the plasma membrane. Blood 102:1884–92 38. Jabado N, Jankowski A, Dougaparsad S, Picard V, Grinstein S, Gros P. 2000. Natural resistance to intracellular infections: natural resistance-associated macrophage protein 1 (Nramp1) functions as a pH-dependent manganese transporter at the phagosomal membrane. J. Exp. Med. 192:1237–48 39. Hackam DJ, Rotstein OD, Zhang W, Gruenheid S, Gros P, Grinstein S. 1998. Host resistance to intracellular infection: mutation of natural resistance-associated macrophage protein 1 (Nramp1) impairs phagosomal acidiﬁcation. J. Exp. Med. 188:351–64 40. Frehel C, Canonne-Hergaux F, Gros P, De Chastellier C. 2002. Effect of Nramp1 on bacterial replication and on maturation of Mycobacterium avium-containing phagosomes in bone marrow-derived mouse macrophages. Cell. Microbiol. 4:541–56 41. Cuellar-Mata P, Jabado N, Liu J, Furuya W, Finlay BB, et al. 2002. Nramp1 modiﬁes the fusion of Salmonella typhimurium-containing vacuoles with cellular endomembranes in macrophages. J. Biol. Chem. 277:2258–65 42. Jabado N, Cuellar-Mata P, Grinstein S, Gros P. 2003. Iron chelators modulate the fusogenic properties of Salmonella-containing phagosomes. Proc. Natl. Acad. Sci. USA 100:6127–32 43. Zaharik ML, Vallance BA, Puente JL, Gros P, Finlay BB. 2002. Host-pathogen interactions: Host resistance factor Nramp1 up-regulates the expression of Salmonella pathogenicity island-2 virulence genes. Proc. Natl. Acad. Sci. USA 99:15705–10 44. Nairz M, Theurl I, Ludwiczek S, Theurl M, Mair SM, et al. 2007. The co-ordinated regulation of iron homeostasis in murine macrophages limits the availability of iron for intracellular Salmonella typhimurium. Cell. Microbiol. 9:2126–40 45. Boyer E, Bergevin I, Malo D, Gros P, Cellier MF. 2002. Acquisition of Mn(II) in addition to Fe(II) is required for full virulence of Salmonella enterica aerovar typhimurium. Infect. Immun. 70:6032–42 46. Kehres DG, Janakiraman A, Slauch JM, Maguire ME. 2002. SitABCD is the alkaline Mn2+ transporter of Salmonella enterica serovar Typhimurium. J. Bacteriol. 184:3159– 66 www.annualreviews.org • Immunity to Infection in the Mouse

117

ARI

16 February 2008

11:22

47. Huynh C, Sacks DL, Andrews NW. 2006. A Leishmania amazonensis ZIP family iron transporter is essential for parasite replication within macrophage phagolysosomes. J. Exp. Med. 203:2363–75 48. Kariuki S, Revathi G, Kariuki N, Muyodi J, Mwituria J, et al. 2005. Increasing prevalence of multidrug-resistant nontyphoidal salmonellae, Kenya, 1994–2003. Int. J. Antimicrob. Agents 25:38–43 49. Wong WY. 2001. Prevention and management of infection in children with sickle cell anaemia. Paediatr. Drugs 3:793–801 50. Mouy R, Fischer A, Vilmer E, Seger R, Griscelli C. 1989. Incidence, severity, and prevention of infections in chronic granulomatous disease. J. Pediatr. 114:555–60 51. Graham SM, Hart CA, Molyneux EM, Walsh AL, Molyneux ME. 2000. Malaria and Salmonella infections: cause or coincidence? Trans. R. Soc. Trop. Med. Hyg. 94:227 52. Casanova JL, Abel L. 2004. The human model: a genetic dissection of immunity to infection in natural conditions. Nat. Rev. Immunol. 4:55–66 53. Mastroeni P. 2006. Mechanisms of immunity to Salmonella infection. In Salmonella Infections: Clinical, Immunological and Molecular Aspects, ed. P Mastroeni, D Maskell, pp. 17–36. Cambridge, UK: Cambridge Univ. Press 54. Barthel M, Hapfelmeier S, Quintanilla-Martinez L, Kremer M, Rohde M, et al. 2003. Pretreatment of mice with streptomycin provides a Salmonella enterica serovar Typhimurium colitis model that allows analysis of both pathogen and host. Infect. Immun. 71:2839–58 55. Caron J, Loredo-Osti JC, Laroche L, Skamene E, Morgane K, Malo D. 2002. Identiﬁcation of genetic loci controlling bacterial clearance in experimental Salmonella enteritidis infection: an unexpected role of Nramp 1 (Slc11a1) in the persistence of infection in mice. Genes Immun. 3:196–204 56. Monack DM, Bouley DM, Falkow S. 2004. Salmonella typhimurium persists within macrophages in the mesenteric lymph nodes of chronically infected Nramp1+/+ mice and can be reactivated by IFNγ neutralization. J. Exp. Med. 199:231–41 57. Sukupolvi S, Edelstein A, Rhen M, Normark SJ, Pfeifer JD. 1997. Development of a murine model of chronic Salmonella infection. Infect. Immun. 65:838–42 58. Roy MF, Malo D. 2002. Genetic regulation of host responses to Salmonella infection in mice. Genes Immun. 3:381–93 59. O’Brien AD, Rosenstreich DL, Scher I, Campbell GH, MacDermott RP, Formal SB. 1980. Genetic control of susceptibility to Salmonella typhimurium in mice: role of the LPS gene. J. Immunol. 124:20–24 60. O’Brien AD, Scher I, Campbell GH, MacDermott RP, Formal SB. 1979. Susceptibility of CBA/N mice to infection with Salmonella typhimurium: inﬂuence of the X-linked gene controlling B lymphocyte function. J. Immunol. 123:720–24 61. Plant J, Glynn AA. 1976. Genetics of resistance to infection with Salmonella typhimurium in mice. J. Infect. Dis. 133:72–78 62. Roy MF, Riendeau N, Loredo-Osti JC, Malo D. 2006. Complexity in the host response to Salmonella Typhimurium infection in AcB and BcA recombinant congenic strains. Genes Immun. 7:655–66 63. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, et al. 1998. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282:2085–88 64. Qureshi ST, Lariviere L, Leveque G, Clermont S, Moore KJ, et al. 1999. Endotoxintolerant mice have mutations in Toll-like receptor 4 (Tlr4). J. Exp. Med. 189:615–25

Annu. Rev. Immunol. 2008.26:81-132. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-04

118

Vidal et al.

Annu. Rev. Immunol. 2008.26:81-132. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-04

ARI

16 February 2008

11:22

65. Rawlings DJ, Saffran DC, Tsukada S, Largaespada DA, Grimaldi JC, et al. 1993. Mutation of unique region of Bruton’s tyrosine kinase in immunodeﬁcient XID mice. Science 261:358–61 66. Thomas JD, Sideras P, Smith CI, Vorechovsky I, Chapman V, Paul WE. 1993. Colocalization of X-linked agammaglobulinemia and X-linked immunodeﬁciency genes. Science 261:355–58 67. Bihl F, Salez L, Beaubier M, Torres D, Lariviere L, et al. 2003. Overexpression of Tolllike receptor 4 ampliﬁes the host response to lipopolysaccharide and provides a survival advantage in transgenic mice. J. Immunol. 170:6141–50 68. Roy MF, Lariviere L, Wilkinson R, Tam M, Stevenson MM, Malo D. 2006. Incremental expression of Tlr4 correlates with mouse resistance to Salmonella infection and ﬁne regulation of relevant immune genes. Genes Immun. 7:372–83 69. Robson HG, Vas SI. 1972. Resistance of inbred mice to Salmonella typhimurium. J. Infect. Dis. 126:378–86 70. Qureshi ST, Lariviere L, Sebastiani G, Clermont S, Skamene E, et al. 1996. A highresolution map in the chromosomal region surrounding the Lps locus. Genomics 31:283– 94 71. Sultzer BM. 1968. Genetic control of leucocyte responses to endotoxin. Nature 219:1253–54 72. Watson J, Kelly K, Largen M, Taylor BA. 1978. The genetic mapping of a defective LPS response gene in C3H/HeJ mice. J. Immunol. 120:422–24 73. Coutinho A, Forni L, Melchers F, Watanabe T. 1977. Genetic defect in responsiveness to the B cell mitogen lipopolysaccharide. Eur. J. Immunol. 7:325–28 74. Bihl F, Lariviere L, Qureshi ST, Flaherty L, Malo D. 2001. LPS-hyporesponsiveness of mnd mice is associated with a mutation in Toll-like receptor 4. Genes Immun. 2:56–59 75. Qureshi ST, Gros P, Malo D. 1999. The Lps locus: genetic regulation of host responses to bacterial lipopolysaccharide. Inﬂamm. Res. 48:613–20 76. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. 1997. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388:394–97 77. Poltorak A, Smirnova I, Clisch R, Beutler B. 2000. Limits of a deletion spanning Tlr4 in C57BL/10ScCr mice. J. Endotoxin Res. 6:51–56 78. Hoshino K, Takeuchi O, Kawai T, Sanjo H, Ogawa T, et al. 1999. Cutting edge: Toll-like receptor 4 (TLR4)-deﬁcient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J. Immunol. 162:3749–52 79. Kalis C, Kanzler B, Lembo A, Poltorak A, Galanos C, Freudenberg MA. 2003. Toll-like receptor 4 expression levels determine the degree of LPS-susceptibility in mice. Eur. J. Immunol. 33:798–805 80. Akira S, Uematsu S, Takeuchi O. 2006. Pathogen recognition and innate immunity. Cell 124:783–801 81. Schnare M, Barton GM, Holt AC, Takeda K, Akira S, Medzhitov R. 2001. Toll-like receptors control activation of adaptive immune responses. Nat. Immunol. 2:947–50 82. Miller SI, Ernst RK, Bader MW. 2005. LPS, TLR4 and infectious disease diversity. Nat. Rev. Microbiol. 3:36–46 83. Verstak B, Hertzog P, Mansell A. 2007. Toll-like receptor signalling and the clinical beneﬁts that lie within. Inﬂamm. Res. 56:1–10 84. Arbour NC, Lorenz E, Schutte BC, Zabner J, Kline JN, et al. 2000. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat. Genet. 25:187–91 www.annualreviews.org • Immunity to Infection in the Mouse

119

ARI

16 February 2008

11:22

85. Agnese DM, Calvano JE, Hahm SJ, Coyle SM, Corbett SA, et al. 2002. Human Toll-like receptor 4 mutations but not CD14 polymorphisms are associated with an increased risk of gram-negative infections. J. Infect. Dis. 186:1522–25 86. Lorenz E, Mira JP, Frees KL, Schwartz DA. 2002. Relevance of mutations in the TLR4 receptor in patients with gram-negative septic shock. Arch. Intern. Med. 162:1028–32 87. Smirnova I, Mann N, Dols A, Derkx HH, Hibberd ML, et al. 2003. Assay of locusspeciﬁc genetic load implicates rare Toll-like receptor 4 mutations in meningococcal susceptibility. Proc. Natl. Acad. Sci. USA 100:6075–80 88. Child NJ, Yang IA, Pulletz MC, de Courcy-Golder K, Andrews AL, et al. 2003. Polymorphisms in Toll-like receptor 4 and the systemic inﬂammatory response syndrome. Biochem. Soc. Trans. 31:652–53 89. Mockenhaupt FP, Cramer JP, Hamann L, Stegemann MS, Eckert J, et al. 2006. Toll-like receptor (TLR) polymorphisms in African children: common TLR-4 variants predispose to severe malaria. J. Commun. Dis. 38:230–45 90. Rezazadeh M, Hajilooi M, Raﬁei A, Haidari M, Nikoopour E, et al. 2006. TLR4 polymorphism in Iranian patients with brucellosis. J. Infect. 53:206–10 91. Tal G, Mandelberg A, Dalal I, Cesar K, Somekh E, et al. 2004. Association between common Toll-like receptor 4 mutations and severe respiratory syncytial virus disease. J. Infect. Dis. 189:2057–63 92. Hawn TR, Verbon A, Janer M, Zhao LP, Beutler B, Aderem A. 2005. Toll-like receptor 4 polymorphisms are associated with resistance to Legionnaires’ disease. Proc. Natl. Acad. Sci. USA 102:2487–89 93. Trinchieri G, Sher A. 2007. Cooperation of Toll-like receptor signals in innate immune defence. Nat. Rev. Immunol. 7:179–90 94. Ben-Ali M, Barbouche MR, Bousnina S, Chabbou A, Dellagi K. 2004. Toll-like receptor 2 Arg677Trp polymorphism is associated with susceptibility to tuberculosis in Tunisian patients. Clin. Diagn. Lab. Immunol. 11:625–26 95. Bochud PY, Hawn TR, Aderem A. 2003. Cutting edge: a Toll-like receptor 2 polymorphism that is associated with lepromatous leprosy is unable to mediate mycobacterial signaling. J. Immunol. 170:3451–54 96. Kang TJ, Chae GT. 2001. Detection of Toll-like receptor 2 (TLR2) mutation in the lepromatous leprosy patients. FEMS Immunol. Med. Microbiol. 31:53–58 97. Hawn TR, Verbon A, Lettinga KD, Zhao LP, Li SS, et al. 2003. A common dominant TLR5 stop codon polymorphism abolishes ﬂagellin signaling and is associated with susceptibility to Legionnaires’ disease. J. Exp. Med. 198:1563–72 98. Wicker LS, Scher I. 1986. X-linked immune deﬁciency (xid) of CBA/N mice. Curr. Top. Microbiol. Immunol. 124:87–101 99. O’Brien AD, Scher I, Metcalf ES. 1981. Genetically conferred defect in anti-Salmonella antibody formation renders CBA/N mice innately susceptible to Salmonella typhimurium infection. J. Immunol. 126:1368–72 100. Conley ME, Broides A, Hernandez-Trujillo V, Howard V, Kanegane H, et al. 2005. Genetic analysis of patients with defects in early B-cell development. Immunol. Rev. 203:216–34 101. Vetrie D, Vorechovsky I, Sideras P, Holland J, Davies A, et al. 1993. The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature 361:226–33 102. Tsukada S, Saffran DC, Rawlings DJ, Parolini O, Allen RC, et al. 1993. Deﬁcient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell 72:279–90

Annu. Rev. Immunol. 2008.26:81-132. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-04

120

Vidal et al.

Annu. Rev. Immunol. 2008.26:81-132. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-04

ARI

16 February 2008

11:22

103. Ellmeier W, Jung S, Sunshine MJ, Hatam F, Xu Y, et al. 2000. Severe B cell deﬁciency in mice lacking the tec kinase family members Tec and Btk. J. Exp. Med. 192:1611–24 104. Smith CI, Baskin B, Humire-Greiff P, Zhou JN, Olsson PG, et al. 1994. Expression of Bruton’s agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells. J. Immunol. 152:557–65 105. Lindvall JM, Blomberg KE, Valiaho J, Vargas L, Heinonen JE, et al. 2005. Bruton’s tyrosine kinase: cell biology, sequence conservation, mutation spectrum, siRNA modiﬁcations, and expression proﬁling. Immunol. Rev. 203:200–15 106. Fruman DA, Satterthwaite AB, Witte ON. 2000. Xid-like phenotypes: a B cell signalosome takes shape. Immunity 13:1–3 107. Bajpai UD, Zhang K, Teutsch M, Sen R, Wortis HH. 2000. Bruton’s tyrosine kinase links the B cell receptor to nuclear factor κB activation. J. Exp. Med. 191:1735–44 108. Doyle SL, Jefferies CA, O’Neill LA. 2005. Bruton’s tyrosine kinase is involved in p65mediated transactivation and phosphorylation of p65 on serine 536 during NFκB activation by lipopolysaccharide. J. Biol. Chem. 280:23496–501 109. Gray P, Dunne A, Brikos C, Jefferies CA, Doyle SL, O’Neill LA. 2006. MyD88 adapterlike (Mal) is phosphorylated by Bruton’s tyrosine kinase during TLR2 and TLR4 signal transduction. J. Biol. Chem. 281:10489–95 110. Mansell A, Smith R, Doyle SL, Gray P, Fenner JE, et al. 2006. Suppressor of cytokine signaling 1 negatively regulates Toll-like receptor signaling by mediating Mal degradation. Nat. Immunol. 7:148–55 111. Kang SW, Wahl MI, Chu J, Kitaura J, Kawakami Y, et al. 2001. PKCβ modulates antigen receptor signaling via regulation of Btk membrane localization. EMBO J. 20:5692–702 112. Tilney LG, Harb OS, Connelly PS, Robinson CG, Roy CR. 2001. How the parasitic bacterium Legionella pneumophila modiﬁes its phagosome and transforms it into rough ER: implications for conversion of plasma membrane to the ER membrane. J. Cell Sci. 114:4637–50 113. Fortier A, Diez E, Gros P. 2005. Naip5/Birc1e and susceptibility to Legionella pneumophila. Trends Microbiol. 13:328–35 114. Diez E, Lee SH, Gauthier S, Yaraghi Z, Tremblay M, et al. 2003. Birc1e is the gene within the Lgn1 locus associated with resistance to Legionella pneumophila. Nat. Genet. 33:55–60 115. Wright EK, Goodart SA, Growney JD, Hadinoto V, Endrizzi MG, et al. 2003. Naip5 affects host susceptibility to the intracellular pathogen Legionella pneumophila. Curr. Biol. 13:27–36 116. Maier JK, Lahoua Z, Gendron NH, Fetni R, Johnston A, et al. 2002. The neuronal apoptosis inhibitory protein is a direct inhibitor of caspases 3 and 7. J. Neurosci. 22:2035– 43 ˜ G. 2005. NOD-LRR proteins: role 117. Inohara N, Chamaillard M, McDonald C, Nunez in host-microbial interactions and inﬂammatory disease. Annu. Rev. Biochem. 74:355–83 118. Fritz JH, Ferrero RL, Philpott DJ, Girardin SE. 2006. Nod-like proteins in immunity, inﬂammation and disease. Nat. Immunol. 7:1250–57 119. Zamboni DS, Kobayashi KS, Kohlsdorf T, Ogura Y, Long EM, et al. 2006. The Birc1e cytosolic pattern-recognition receptor contributes to the detection and control of Legionella pneumophila infection. Nat. Immunol. 7:318–25 ˜ 120. Lamkanﬁ M, Amer A, Kanneganti TD, Munoz-Planillo R, Chen G, et al. 2007. The Nod-like receptor family member Naip5/Birc1e restricts Legionella pneumophila growth independently of caspase-1 activation. J. Immunol. 178:8022–27 www.annualreviews.org • Immunity to Infection in the Mouse

121

ARI

16 February 2008

11:22

121. Molofsky AB, Byrne BG, Whitﬁeld NN, Madigan CA, Fuse ET, et al. 2006. Cytosolic recognition of ﬂagellin by mouse macrophages restricts Legionella pneumophila infection. J. Exp. Med. 203:1093–104 122. Ren T, Zamboni DS, Roy CR, Dietrich WF, Vance RE. 2006. Flagellin-deﬁcient Legionella mutants evade caspase-1- and Naip5-mediated macrophage immunity. PLoS Pathog. 2:e18 123. Fortier A, de Chastellier C, Balor S, Gros P. 2007. Birc1e/Naip5 rapidly antagonizes modulation of phagosome maturation by Legionella pneumophila. Cell. Microbiol. 9:910– 23 124. Friedlander AM, Bhatnagar R, Leppla SH, Johnson L, Singh Y. 1993. Characterization of macrophage sensitivity and resistance to anthrax lethal toxin. Infect. Immun. 61:245–52 125. Watters JW, Dietrich WF. 2001. Genetic, physical, and transcript map of the Ltxs1 region of mouse chromosome 11. Genomics 73:223–31 126. Roberts JE, Watters JW, Ballard JD, Dietrich WF. 1998. Ltx1, a mouse locus that inﬂuences the susceptibility of macrophages to cytolysis caused by intoxication with Bacillus anthracis lethal factor, maps to chromosome 11. Mol. Microbiol. 29:581–91 127. Watters JW, Dewar K, Lehoczky J, Boyartchuk V, Dietrich WF. 2001. Kif1C, a kinesinlike motor protein, mediates mouse macrophage resistance to anthrax lethal factor. Curr. Biol. 11:1503–11 128. Boyden ED, Dietrich WF. 2006. Nalp1b controls mouse macrophage susceptibility to anthrax lethal toxin. Nat. Genet. 38:240–44 129. Turcotte K, Loredo-Osti JC, Fortin P, Schurr E, Morgan K, Gros P. 2006. Complex genetic control of susceptibility to Mycobacterium bovis (Bacille Calmette-Guerin) infection in wild-derived Mus spretus mice. Genes. Immun. 7:684–87 130. Turcotte K, Gauthier S, Mitsos LM, Shustik C, Copeland NG, et al. 2004. Genetic control of myeloproliferation in BXH-2 mice. Blood 103:2343–50 131. Bedigian HG, Johnson DA, Jenkins NA, Copeland NG, Evans R. 1984. Spontaneous and induced leukemias of myeloid origin in recombinant inbred BXH mice. J. Virol. 51:586–94 132. Bedigian HG, Taylor BA, Meier H. 1981. Expression of murine leukemia viruses in the highly lymphomatous BXH-2 recombinant inbred mouse strain. J. Virol. 39:632–40 133. Li J, Shen H, Himmel KL, Dupuy AJ, Largaespada DA, et al. 1999. Leukaemia disease genes: large-scale cloning and pathway predictions. Nat. Genet. 23:348–53 134. Turcotte K, Gauthier S, Tuite A, Mullick A, Malo D, Gros P. 2005. A mutation in the Icsbp1 gene causes susceptibility to infection and a chronic myeloid leukemia-like syndrome in BXH-2 mice. J. Exp. Med. 201:881–90 135. Turcotte K, Gauthier S, Malo D, Tam M, Stevenson MM, Gros P. 2007. Icsbp1/IRF-8 is required for innate and adaptive immune responses against intracellular pathogens. J. Immunol. 179:2467–76 136. WHO. 2000. The World Health Report 2000: Health Systems Improving Performance. Geneva: WHO 137. WHO. 2002. The World Health Report 2002: Global Tuberculosis Control: Surveillance, Planning, Financing. Geneva: WHO 138. Fortin A, Abel L, Casanova JL, Gros P. 2007. Host genetics of Mycobacterial diseases in mice and men: Forward genetic studies of BCG-osis and tuberculosis. Annu. Rev. Genomics Hum. Genet. 8:163–92 139. Pan H, Yan BS, Rojas M, Shebzukhov YV, Zhou H, et al. 2005. Ipr1 gene mediates innate immunity to tuberculosis. Nature 434:767–72

Annu. Rev. Immunol. 2008.26:81-132. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-04

122

Vidal et al.

Annu. Rev. Immunol. 2008.26:81-132. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-04

ARI

16 February 2008

11:22

140. Kaufmann SH. 2003. Immune response to tuberculosis: experimental animal models. Tuberculosis 83:107–11 141. Kaufmann SH. 2001. How can immunology contribute to the control of tuberculosis? Nat. Rev. Immunol. 1:20–30 142. North RJ, Jung YJ. 2004. Immunity to tuberculosis. Annu. Rev. Immunol. 22:599–623 143. Medina E, North RJ. 1998. Resistance ranking of some common inbred mouse strains to Mycobacterium tuberculosis and relationship to major histocompatibility complex haplotype and Nramp1 genotype. Immunology 93:270–74 144. Kramnik I, Dietrich WF, Demant P, Bloom BR. 2000. Genetic control of resistance to experimental infection with virulent Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. USA 97:8560–65 145. Boyartchuk V, Rojas M, Yan BS, Jobe O, Hurt N, et al. 2004. The host resistance locus sst1 controls innate immunity to Listeria monocytogenes infection in immunodeﬁcient mice. J. Immunol. 173:5112–20 146. Nicewonger J, Suck G, Bloch D, Swaminathan S. 2004. Epstein-Barr virus (EBV) SM protein induces and recruits cellular Sp110b to stabilize mRNAs and enhance EBV lytic gene expression. J. Virol. 78:9412–22 147. Roscioli T, Cliffe ST, Bloch DB, Bell CG, Mullan G, et al. 2006. Mutations in the gene encoding the PML nuclear body protein Sp110 are associated with immunodeﬁciency and hepatic veno-occlusive disease. Nat. Genet. 38:620–22 148. Tosh K, Campbell SJ, Fielding K, Sillah J, Bah B, et al. 2006. Variants in the SP110 gene are associated with genetic susceptibility to tuberculosis in West Africa. Proc. Natl. Acad. Sci. USA 103:10364–68 149. Thye T, Browne EN, Chinbuah MA, Gyapong J, Osei I, et al. 2006. No associations of human pulmonary tuberculosis with Sp110 variants. J. Med. Genet. 43:e32 150. Szeszko JS, Healy B, Stevens H, Balabanova Y, Drobniewski F, et al. 2007. Resequencing and association analysis of the SP110 gene in adult pulmonary tuberculosis. Hum. Genet. 121:155–60 151. Babb C, Keet EH, van Helden PD, Hoal EG. 2007. SP110 polymorphisms are not associated with pulmonary tuberculosis in a South African population. Hum. Genet. 121:521–22 152. Kullberg BJ, Filler SG. 2002. Candidemia. In Candida and Candidiasis, ed. RA Calderone, pp. 327–40. Washington, DC: ASM Press 153. Eggimann P, Garbino J, Pittet D. 2003. Epidemiology of Candida species infections in critically ill nonimmunosuppressed patients. Lancet Infect. Dis. 3:685–702 154. Ashman RB. 1998. Candida albicans: pathogenesis, immunity and host defence. Res. Immunol. 149:281–88 155. Ashman RB, Fulurija A, Papadimitriou JM. 1996. Strain-dependent differences in host response to Candida albicans infection in mice are related to organ susceptibility and infectious load. Infect. Immun. 64:1866–69 156. Tuite A, Mullick A, Gros P. 2004. Genetic analysis of innate immunity in resistance to Candida albicans. Genes Immun. 5:576–87 157. Tuite A, Elias M, Picard S, Mullick A, Gros P. 2005. Genetic control of susceptibility to Candida albicans in susceptible A/J and resistant C57BL/6J mice. Genes Immun. 6:672–82 158. Wetsel RA, Fleischer DT, Haviland DL. 1990. Deﬁciency of the murine ﬁfth complement component (C5). A 2-base pair gene deletion in a 5 -exon. J. Biol. Chem. 265:2435– 40 www.annualreviews.org • Immunity to Infection in the Mouse

123

ARI

16 February 2008

11:22

159. Mullick A, Elias M, Picard S, Bourget L, Jovcevski O, et al. 2004. Dysregulated inﬂammatory response to Candida albicans in a C5-deﬁcient mouse strain. Infect. Immun. 72:5868–76 160. Mullick A, Leon Z, Min-Oo G, Berghout J, Lo R, et al. 2006. Cardiac failure in C5deﬁcient A/J mice after Candida albicans infection. Infect. Immun. 74:4439–51 161. Gervais F, Stevenson M, Skamene E. 1984. Genetic control of resistance to Listeria monocytogenes: regulation of leukocyte inﬂammatory responses by the Hc locus. J. Immunol. 132:2078–83 162. Gervais F, Desforges C, Skamene E. 1989. The C5-sufﬁcient A/J congenic mouse strain. Inﬂammatory response and resistance to Listeria monocytogenes. J. Immunol. 142:2057– 60 163. Good MF. 2005. Vaccine-induced immunity to malaria parasites and the need for novel strategies. Trends Parasitol. 21:29–34 164. Kwiatkowski DP. 2005. How malaria has affected the human genome and what human genetics can teach us about malaria. Am. J. Hum. Genet. 77:171–92 165. Fortin A, Stevenson MM, Gros P. 2002. Complex genetic control of susceptibility to malaria in mice. Genes Immun. 3:177–86 166. Fortin A, Diez E, Rochefort D, Laroche L, Malo D, et al. 2001. Recombinant congenic strains derived from A/J and C57BL/6J: a tool for genetic dissection of complex traits. Genomics 74:21–35 167. Fortin A, Cardon LR, Tam M, Skamene E, Stevenson MM, Gros P. 2001. Identiﬁcation of a new malaria susceptibility locus (Char4) in recombinant congenic strains of mice. Proc. Natl. Acad. Sci. USA 98:10793–98 168. Min-Oo G, Fortin A, Tam MF, Gros P, Stevenson MM. 2004. Phenotypic expression of pyruvate kinase deﬁciency and protection against malaria in a mouse model. Genes Immun. 5:168–75 169. Min-Oo G, Fortin A, Tam MF, Nantel A, Stevenson MM, Gros P. 2003. Pyruvate kinase deﬁciency in mice protects against malaria. Nat. Genet. 35:357–62 170. Min-Oo G, Tam M, Stevenson MM, Gros P. 2007. Pyruvate kinase deﬁciency: Correlation between enzyme activity, extent of hemolytic anemia and protection against malaria in independent mouse mutants. Blood Cells Mol. Dis. 39:63–69 170a. Roy M-F, Riendeau N, B´edard C, H´elie P, Min-Oo G, et al. 2007. Pyruvate kinase deﬁciency confers susceptibility to Salmonella typhimurium infection in mice. J. Exp. Med. 204:2949–61 171. Min-Oo G, Fortin A, Pitari G, Tam M, Stevenson MM, Gros P. 2007. Complex genetic control of susceptibility to malaria: positional cloning of the Char9 locus. J. Exp. Med. 204:511–24 172. Martin F, Penet MF, Malergue F, Lepidi H, Dessein A, et al. 2004. Vanin-1−/− mice show decreased NSAID- and Schistosoma-induced intestinal inﬂammation associated with higher glutathione stores. J. Clin. Invest. 113:591–97 173. Pavesio CE, Lightman S. 1996. Toxoplasma gondii and ocular toxoplasmosis: pathogenesis. Br. J. Ophthalmol. 80:1099–107 174. Aliberti J. 2005. Host persistence: exploitation of anti-inﬂammatory pathways by Toxoplasma gondii. Nat. Rev. Immunol. 5:162–70 175. Gazzinelli RT, Wysocka M, Hayashi S, Denkers EY, Hieny S, et al. 1994. Parasiteinduced IL-12 stimulates early IFN-γ synthesis and resistance during acute infection with Toxoplasma gondii. J. Immunol. 153:2533–43

Annu. Rev. Immunol. 2008.26:81-132. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-04

124

Vidal et al.

Annu. Rev. Immunol. 2008.26:81-132. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-04

ARI

16 February 2008

11:22

176. Scanga CA, Aliberti J, Jankovic D, Tilloy F, Bennouna S, et al. 2002. Cutting edge: MyD88 is required for resistance to Toxoplasma gondii infection and regulates parasiteinduced IL-12 production by dendritic cells. J. Immunol. 168:5997–6001 177. Gaddi PJ, Yap GS. 2007. Cytokine regulation of immunopathology in toxoplasmosis. Immunol. Cell Biol. 85:155–59 178. Ortmann R, Smeltz R, Yap G, Sher A, Shevach EM. 2001. A heritable defect in IL-12 signaling in B10.Q/J mice. I. In vitro analysis. J. Immunol. 166:5712–19 179. Yap GS, Ortmann R, Shevach E, Sher A. 2001. A heritable defect in IL-12 signaling in B10.Q/J mice. II. Effect on acute resistance to Toxoplasma gondii and rescue by IL-18 treatment. J. Immunol. 166:5720–25 180. Shaw MH, Boyartchuk V, Wong S, Karaghiosoff M, Ragimbeau J, et al. 2003. A natural mutation in the Tyk2 pseudokinase domain underlies altered susceptibility of B10.Q/J mice to infection and autoimmunity. Proc. Natl. Acad. Sci. USA 100:11594–99 181. Velazquez L, Fellous M, Stark GR, Pellegrini S. 1992. A protein tyrosine kinase in the interferon α/β signaling pathway. Cell 70:313–22 182. Macchi P, Villa A, Giliani S, Sacco MG, Frattini A, et al. 1995. Mutations of Jak-3 gene in patients with autosomal severe combined immune deﬁciency (SCID). Nature 377:65–68 183. Watford WT, O’Shea JJ. 2006. Human tyk2 kinase deﬁciency: another primary immunodeﬁciency syndrome. Immunity 25:695–97 184. Yap GS, Shaw MH, Ling Y, Sher A. 2006. Genetic analysis of host resistance to intracellular pathogens: lessons from studies of Toxoplasma gondii infection. Microbes Infect. 8:1174–78 185. Minegishi Y, Saito M, Morio T, Watanabe K, Agematsu K, et al. 2006. Human tyrosine kinase 2 deﬁciency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Immunity 25:745–55 186. Jeong YJ, Kim S, Wook YD, Lee JW, Kim KI, Lee SH. 2007. Scrub typhus: clinical, pathologic, and imaging ﬁndings. Radiographics 27:161–72 187. Groves MG, Osterman JV. 1978. Host defenses in experimental scrub typhus: genetics of natural resistance to infection. Infect. Immun. 19:583–88 188. Nacy CA, Groves MG. 1981. Macrophages in resistance to rickettsial infections: early host defense mechanisms in experimental scrub typhus. Infect. Immun. 31:1239–50 189. Groves MG, Rosenstreich DL, Taylor BA, Osterman JV. 1980. Host defenses in experimental scrub typhus: mapping the gene that controls natural resistance in mice. J. Immunol. 125:1395–99 190. Patarca R, Freeman GJ, Singh RP, Wei FY, Durfee T, et al. 1989. Structural and functional studies of the early T lymphocyte activation 1 (Eta-1) gene. Deﬁnition of a novel T cell-dependent response associated with genetic resistance to bacterial infection. J. Exp. Med. 170:145–61 191. O’Regan AW, Nau GJ, Chupp GL, Berman JS. 2000. Osteopontin (Eta-1) in cellmediated immunity: teaching an old dog new tricks. Immunol. Today 21:475–78 192. Ashkar S, Weber GF, Panoutsakopoulou V, Sanchirico ME, Jansson M, et al. 2000. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science 287:860–64 193. Rollo EE, Hempson SJ, Bansal A, Tsao E, Habib I, et al. 2005. The cytokine osteopontin modulates the severity of rotavirus diarrhea. J. Virol. 79:3509–16 194. Nau GJ, Chupp GL, Emile JF, Jouanguy E, Berman JS, et al. 2000. Osteopontin expression correlates with clinical outcome in patients with mycobacterial infection. Am. J. Pathol. 157:37–42 www.annualreviews.org • Immunity to Infection in the Mouse

125

ARI

16 February 2008

11:22

195. Shinohara ML, Jansson M, Hwang ES, Werneck MB, Glimcher LH, Cantor H. 2005. T-bet-dependent expression of osteopontin contributes to T cell polarization. Proc. Natl. Acad. Sci. USA 102:17101–6 196. Gambhir M, Basanez MG, Turner F, Kumaresan J, Grassly NC. 2007. Trachoma: transmission, infection, and control. Lancet Infect. Dis. 7:420–27 197. Bernstein-Hanley I, Balsara ZR, Ulmer W, Coers J, Starnbach MN, Dietrich WF. 2006. Genetic analysis of susceptibility to Chlamydia trachomatis in mouse. Genes Immun. 7:122–29 198. Li D, Borovkov A, Vaglenov A, Wang C, Kim T, et al. 2006. Mouse model of respiratory Chlamydia pneumoniae infection for a genomic screen of subunit vaccine candidates. Vaccine 24:2917–27 199. Bernstein-Hanley I, Coers J, Balsara ZR, Taylor GA, Starnbach MN, Dietrich WF. 2006. The p47 GTPases Igtp and Irgb10 map to the Chlamydia trachomatis susceptibility locus Ctrq-3 and mediate cellular resistance in mice. Proc. Natl. Acad. Sci. USA 103:14092–97 200. Taylor GA, Feng CG, Sher A. 2004. p47 GTPases: regulators of immunity to intracellular pathogens. Nat. Rev. Immunol. 4:100–9 201. Nelson DE, Virok DP, Wood H, Roshick C, Johnson RM, et al. 2005. Chlamydial IFN-γ immune evasion is linked to host infection tropism. Proc. Natl. Acad. Sci. USA 102:10658–63 202. Rajagopal S, Treanor J. 2007. Pandemic (avian) inﬂuenza. Semin. Respir. Crit. Care Med. 28:159–70 203. Lindenmann J. 1962. Resistance of mice to mouse-adapted inﬂuenza A virus. Virology 16:203–4 204. Lindenmann J. 1964. Inheritance of resistance to inﬂuenza virus in mice. Proc. Soc. Exp. Biol. Med. 116:506–9 205. Lindenmann J, Lane CA, Hobson D. 1963. The resistance of A2g mice to myxoviruses. J. Immunol. 90:942–51 206. Haller O, Arnheiter H, Gresser I, Lindenmann J. 1979. Genetically determined, interferon-dependent resistance to inﬂuenza virus in mice. J. Exp. Med. 149:601–12 207. Staeheli P, Haller O, Boll W, Lindenmann J, Weissmann C. 1986. Mx protein: constitutive expression in 3T3 cells transformed with cloned Mx cDNA confers selective resistance to inﬂuenza virus. Cell 44:147–58 208. Horisberger MA, Staeheli P, Haller O. 1983. Interferon induces a unique protein in mouse cells bearing a gene for resistance to inﬂuenza virus. Proc. Natl. Acad. Sci. USA 80:1910–14 209. Reeves RH, O’Hara BF, Pavan WJ, Gearhart JD, Haller O. 1988. Genetic mapping of the Mx inﬂuenza virus resistance gene within the region of mouse chromosome 16 that is homologous to human chromosome 21. J. Virol. 62:4372–75 210. Staeheli P, Sutcliffe JG. 1988. Identiﬁcation of a second interferon-regulated murine Mx gene. Mol. Cell. Biol. 8:4524–28 211. Pavlovic J, Haller O, Staeheli P. 1992. Human and mouse Mx proteins inhibit different steps of the inﬂuenza virus multiplication cycle. J. Virol. 66:2564–69 212. Stranden AM, Staeheli P, Pavlovic J. 1993. Function of the mouse Mx1 protein is inhibited by overexpression of the PB2 protein of inﬂuenza virus. Virology 197:642–51 213. Staeheli P, Grob R, Meier E, Sutcliffe JG, Haller O. 1988. Inﬂuenza virus-susceptible mice carry Mx genes with a large deletion or a nonsense mutation. Mol. Cell. Biol. 8:4518–23 214. Guenet JL. 2005. Assessing the genetic component of the susceptibility of mice to viral infections. Brief. Funct. Genomic Proteomics 4:225–40

Annu. Rev. Immunol. 2008.26:81-132. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-04

126

Vidal et al.

Annu. Rev. Immunol. 2008.26:81-132. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-04

ARI

16 February 2008

11:22

215. Haller O, Kochs G. 2002. Interferon-induced mx proteins: dynamin-like GTPases with antiviral activity. Trafﬁc 3:710–17 216. Arnheiter H, Haller O. 1988. Antiviral state against inﬂuenza virus neutralized by microinjection of antibodies to interferon-induced Mx proteins. EMBO J. 7:1315–20 217. Arnheiter H, Skuntz S, Noteborn M, Chang S, Meier E. 1990. Transgenic mice with intracellular immunity to inﬂuenza virus. Cell 62:51–61 218. Pavlovic J, Arzet HA, Hefti HP, Frese M, Rost D, et al. 1995. Enhanced virus resistance of transgenic mice expressing the human MxA protein. J. Virol. 69:4506–10 219. Lai MM, Cavanagh D. 1997. The molecular biology of coronaviruses. Adv. Virus Res. 48:1–100 220. Riski H, Hovi T. 1980. Coronavirus infections of man associated with diseases other than the common cold. J. Med. Virol. 6:259–65 221. van der Hoek L, Pyrc K, Jebbink MF, Vermeulen-Oost W, Berkhout RJ, et al. 2004. Identiﬁcation of a new human coronavirus. Nat. Med. 10:368–73 222. Fouchier RA, Schneeberger PM, Rozendaal FW, Broekman JM, Kemink SA, et al. 2004. Avian inﬂuenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome. Proc. Natl. Acad. Sci. USA 101:1356–61 223. Woo PC, Lau SK, Chu CM, Chan KH, Tsoi HW, et al. 2005. Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia. J. Virol. 79:884–95 224. Peiris JS, Lai ST, Poon LL, Guan Y, Yam LY, et al. 2003. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 361:1319–25 225. Marra MA, Jones SJ, Astell CR, Holt RA, Brooks-Wilson A, et al. 2003. The genome sequence of the SARS-associated coronavirus. Science 300:1399–404 226. Rota PA, Oberste MS, Monroe SS, Nix WA, Campagnoli R, et al. 2003. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 300:1394–99 227. Li W, Shi Z, Yu M, Ren W, Smith C, et al. 2005. Bats are natural reservoirs of SARS-like coronaviruses. Science 310:676–79 228. Lau SK, Woo PC, Li KS, Huang Y, Tsoi HW, et al. 2005. Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proc. Natl. Acad. Sci. USA 102:14040–45 229. Navas-Martin S, Weiss SR. 2003. SARS: lessons learned from other coronaviruses. Viral Immunol. 16:461–74 230. Navas S, Seo SH, Chua MM, Sarma JD, Lavi E, et al. 2001. Murine coronavirus spike protein determines the ability of the virus to replicate in the liver and cause hepatitis. J. Virol. 75:2452–57 231. Iacono KT, Kazi L, Weiss SR. 2006. Both spike and background genes contribute to murine coronavirus neurovirulence. J. Virol. 80:6834–43 232. Parr RL, Fung L, Reneker J, Myers-Mason N, Leibowitz JL, Levy G. 1995. Association of mouse ﬁbrinogen-like protein with murine hepatitis virus-induced prothrombinase activity. J. Virol. 69:5033–38 233. De Albuquerque N, Baig E, Ma X, Zhang J, He W, et al. 2006. Murine hepatitis virus strain 1 produces a clinically relevant model of severe acute respiratory syndrome in A/J mice. J. Virol. 80:10382–94 234. Perlman S, Dandekar AA. 2005. Immunopathogenesis of coronavirus infections: implications for SARS. Nat. Rev. Immunol. 5:917–27 www.annualreviews.org • Immunity to Infection in the Mouse

127

ARI

16 February 2008

11:22

235. Stohlman SA, Frelinger JA, Weiner LP. 1980. Resistance to fatal central nervous system disease by mouse hepatitis virus, strain JHM. II. Adherent cell-mediated protection. J. Immunol. 124:1733–39 236. Knobler RL, Haspel MV, Oldstone MB. 1981. Mouse hepatitis virus type 4 (JHM strains) induced fatal central nervous system disease. I. genetic control and murine neuron as the susceptible site of disease. J. Exp. Med. 153:832–43 237. Smith MS, Click RE, Plagemann PG. 1984. Control of mouse hepatitis virus replication in macrophages by a recessive gene on chromosome 7. J. Immunol. 133:428–32 238. Knobler RL, Taylor BA, Wooddell MK, Beamer WG, Oldstone MB. 1984. Host genetic control of mouse hepatitis virus type-4 (JHM strain) replication. II. The gene locus for susceptibility is linked to the Svp-2 locus on mouse chromosome 7. Exp. Clin. Immunogenet. 1:217–22 239. Ohtsuka N, Taguchi F. 1997. Mouse susceptibility to mouse hepatitis virus infection is linked to viral receptor genotype. J. Virol. 71:8860–63 240. Boyle JF, Weismiller DG, Holmes KV. 1987. Genetic resistance to mouse hepatitis virus correlates with absence of virus-binding activity on target tissues. J. Virol. 61:185–89 241. Williams RK, Jiang GS, Holmes KV. 1991. Receptor for mouse hepatitis virus is a member of the carcinoembryonic antigen family of glycoproteins. Proc. Natl. Acad. Sci. USA 88:5533–36 242. Thompson JA, Grunert F, Zimmermann W. 1991. Carcinoembryonic antigen gene family: molecular biology and clinical perspectives. J. Clin. Lab. Anal. 5:344–66 243. McCuaig K, Rosenberg M, N´edellec P, Turbide C, Beauchemin N. 1993. Expression of the Bgp gene and characterization of mouse colon biliary glycoprotein isoforms. Gene 127:173–83 244. Chen T, Zimmermann W, Parker J, Chen I, Maeda A, Bolland S. 2001. Biliary glycoprotein (BGPa, CD66a, CEACAM1) mediates inhibitory signals. J. Leukoc. Biol. 70:335–40 245. Beauchemin N, Draber P, Dveksler G, Gold P, Gray-Owen S, et al. 1999. Redeﬁned nomenclature for members of the carcinoembryonic antigen family. Exp. Cell Res. 252:243–49 246. Kuespert K, Pils S, Hauck CR. 2006. CEACAMs: their role in physiology and pathophysiology. Curr. Opin. Cell Biol. 18:565–71 247. Blau DM, Turbide C, Tremblay M, Olson M, Letourneau S, et al. 2001. Targeted disruption of the Ceacam1 (MHVR) gene leads to reduced susceptibility of mice to mouse hepatitis virus infection. J. Virol. 75:8173–86 248. Hemmila E, Turbide C, Olson M, Jothy S, Holmes KV, Beauchemin N. 2004. Ceacam1a−/− mice are completely resistant to infection by murine coronavirus mouse hepatitis virus A59. J. Virol. 78:10156–65 249. Schmitter T, Pils S, Sakk V, Frank R, Fischer KD, Hauck CR. 2007. The granulocyte receptor carcinoembryonic antigen-related cell adhesion molecule 3 (CEACAM3) directly associates with Vav to promote phagocytosis of human pathogens. J. Immunol. 178:3797–805 250. McCaw SE, Schneider J, Liao EH, Zimmermann W, Gray-Owen SD. 2003. Immunoreceptor tyrosine-based activation motif phosphorylation during engulfment of Neisseria gonorrhoeae by the neutrophil-restricted CEACAM3 (CD66d) receptor. Mol. Microbiol. 49:623–37 251. Schmitter T, Agerer F, Peterson L, Munzner P, Hauck CR. 2004. Granulocyte CEACAM3 is a phagocytic receptor of the innate immune system that mediates recognition and elimination of human-speciﬁc pathogens. J. Exp. Med. 199:35–46

Annu. Rev. Immunol. 2008.26:81-132. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-04

128

Vidal et al.

Annu. Rev. Immunol. 2008.26:81-132. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-04

ARI

16 February 2008

11:22

252. Mackenzie JS, Gubler DJ, Petersen LR. 2004. Emerging ﬂaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. Nat. Med. 10:S98– 109 253. Samuel MA, Diamond MS. 2006. Pathogenesis of West Nile Virus infection: a balance between virulence, innate and adaptive immunity, and viral evasion. J. Virol. 80:9349–60 254. King NJ, Getts DR, Getts MT, Rana S, Shrestha B, Kesson AM. 2007. Immunopathology of ﬂavivirus infections. Immunol. Cell Biol. 85:33–42 255. Webster L. 1936. Inheritance of resistance of mice to enteric bacterial and neurotropic virus infections. J. Exp. Med. 65:261–86 256. Sangster MY, Heliams DB, Mackenzie JS, Shellam GR. 1993. Genetic studies of ﬂavivirus resistance in inbred strains derived from wild mice: evidence for a new resistance allele at the ﬂavivirus resistance locus (Flv). J. Virol. 67:340–47 257. Mashimo T, Lucas M, Simon-Chazottes D, Frenkiel MP, Montagutelli X, et al. 2002. A nonsense mutation in the gene encoding 2 -5 -oligoadenylate synthetase/L1 isoform is associated with West Nile virus susceptibility in laboratory mice. Proc. Natl. Acad. Sci. USA 99:11311–16 258. Sangster MY, Urosevic N, Mansﬁeld JP, Mackenzie JS, Shellam GR. 1994. Mapping the Flv locus controlling resistance to ﬂaviviruses on mouse chromosome 5. J. Virol. 68:448–52 259. Perelygin AA, Scherbik SV, Zhulin IB, Stockman BM, Li Y, Brinton MA. 2002. Positional cloning of the murine ﬂavivirus resistance gene. Proc. Natl. Acad. Sci. USA 99:9322– 27 260. Yakub I, Lillibridge KM, Moran A, Gonzalez OY, Belmont J, et al. 2005. Single nucleotide polymorphisms in genes for 2 -5 -oligoadenylate synthetase and RNase L inpatients hospitalized with West Nile virus infection. J. Infect. Dis. 192:1741–48 261. Soderberg-Naucler C. 2006. Human cytomegalovirus persists in its host and attacks and avoids elimination by the immune system. Crit. Rev. Immunol. 26:231–64 262. Biron CA, Byron KS, Sullivan JL. 1989. Severe herpesvirus infections in an adolescent without natural killer cells. N. Engl. J. Med. 320:1731–35 263. Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP. 1999. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu. Rev. Immunol. 17:189–220 264. Etzioni A, Eidenschenk C, Katz R, Beck R, Casanova JL, Pollack S. 2005. Fatal varicella associated with selective natural killer cell deﬁciency. J. Pediatr. 146:423–25 265. Bernard F, Picard C, Cormier-Daire V, Eidenschenk C, Pinto G, et al. 2004. A novel developmental and immunodeﬁciency syndrome associated with intrauterine growth retardation and a lack of natural killer cells. Pediatrics 113:136–41 266. Lilley BN, Ploegh HL. 2005. Viral modulation of antigen presentation: manipulation of cellular targets in the ER and beyond. Immunol. Rev. 207:126–44 267. Mocarski ES Jr. 2002. Immunomodulation by cytomegaloviruses: manipulative strategies beyond evasion. Trends Microbiol. 10:332–39 268. Reddehase MJ. 2002. Antigens and immunoevasins: opponents in cytomegalovirus immune surveillance. Nat. Rev. Immunol. 2:831–44 269. Scalzo AA, Corbett AJ, Rawlinson WD, Scott GM, Degli-Esposti MA. 2007. The interplay between host and viral factors in shaping the outcome of cytomegalovirus infection. Immunol. Cell Biol. 85:46–54 270. Grundy JE, Mackenzie JS, Stanley NF. 1981. Inﬂuence of H-2 and non-H-2 genes on resistance to murine cytomegalovirus infection. Infect. Immun. 32:277–86 www.annualreviews.org • Immunity to Infection in the Mouse

129

ARI

16 February 2008

11:22

271. Chalmer JE, Mackenzie JS, Stanley NF. 1977. Resistance to murine cytomegalovirus linked to the major histocompatibility complex of the mouse. J. Gen. Virol. 37:107–14 272. Scalzo AA, Fitzgerald NA, Simmons A, La Vista AB, Shellam GR. 1990. Cmv-1, a genetic locus that controls murine cytomegalovirus replication in the spleen. J. Exp. Med. 171:1469–83 273. Scalzo AA, Fitzgerald NA, Wallace CR, Gibbons AE, Smart YC, et al. 1992. The effect of the Cmv-1 resistance gene, which is linked to the natural killer cell gene complex, is mediated by natural killer cells. J. Immunol. 149:581–89 274. Lee SH, Girard S, Macina D, Busa M, Zafer A, et al. 2001. Susceptibility to mouse cytomegalovirus is associated with deletion of an activating natural killer cell receptor of the C-type lectin superfamily. Nat. Genet. 28:42–45 275. Daniels KA, Devora G, Lai WC, O’Donnell CL, Bennett M, Welsh RM. 2001. Murine cytomegalovirus is regulated by a discrete subset of natural killer cells reactive with monoclonal antibody to Ly49H. J. Exp. Med. 194:29–44 276. Brown MG, Dokun AO, Heusel JW, Smith HR, Beckman DL, et al. 2001. Vital involvement of a natural killer cell activation receptor in resistance to viral infection. Science 292:934–37 277. Anderson SK, Ortaldo JR, McVicar DW. 2001. The ever-expanding Ly49 gene family: repertoire and signaling. Immunol. Rev. 181:79–89 278. Lee SH, Gitas J, Zafer A, Lepage P, Hudson TJ, et al. 2001. Haplotype mapping indicates two independent origins for the Cmv1s susceptibility allele to cytomegalovirus infection and reﬁnes its localization within the Ly49 cluster. Immunogenetics 53:501–5 279. Dokun AO, Kim S, Smith HR, Kang HS, Chu DT, Yokoyama WM. 2001. Speciﬁc and nonspeciﬁc NK cell activation during virus infection. Nat. Immunol. 2:951–56 280. Lee SH, Zafer A, de Repentigny Y, Kothary R, Tremblay ML, et al. 2003. Transgenic expression of the activating natural killer receptor Ly49H confers resistance to cytomegalovirus in genetically susceptible mice. J. Exp. Med. 197:515–26 281. Dimasi N, Biassoni R. 2005. Structural and functional aspects of the Ly49 natural killer cell receptors. Immunol. Cell Biol. 83:1–8 282. Sjolin H, Tomasello E, Mousavi-Jazi M, Bartolazzi A, Karre K, et al. 2002. Pivotal role of KARAP/DAP12 adaptor molecule in the natural killer cell-mediated resistance to murine cytomegalovirus infection. J. Exp. Med. 195:825–34 283. Arase H, Mocarski ES, Campbell AE, Hill AB, Lanier LL. 2002. Direct recognition of cytomegalovirus by activating and inhibitory NK cell receptors. Science 296:1323–26 284. Smith HR, Heusel JW, Mehta IK, Kim S, Dorner BG, et al. 2002. Recognition of a virus-encoded ligand by a natural killer cell activation receptor. Proc. Natl. Acad. Sci. USA 99:8826–31 285. Bubic I, Wagner M, Krmpotic A, Saulig T, Kim S, et al. 2004. Gain of virulence caused by loss of a gene in murine cytomegalovirus. J. Virol. 78:7536–44 286. Voigt V, Forbes CA, Tonkin JN, Degli-Esposti MA, Smith HR, et al. 2003. Murine cytomegalovirus m157 mutation and variation leads to immune evasion of natural killer cells. Proc. Natl. Acad. Sci. USA 100:13483–88 287. French AR, Pingel JT, Wagner M, Bubic I, Yang L, et al. 2004. Escape of mutant double-stranded DNA virus from innate immune control. Immunity 20:747–56 288. French AR, Pingel JT, Kim S, Yang L, Yokoyama WM. 2005. Rapid emergence of escape mutants following infection with murine cytomegalovirus in immunodeﬁcient mice. Clin. Immunol. 115:61–69

Annu. Rev. Immunol. 2008.26:81-132. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-04

130

Vidal et al.

Annu. Rev. Immunol. 2008.26:81-132. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-04

ARI

16 February 2008

11:22

289. Desrosiers MP, Kielczewska A, Loredo-Osti JC, Adam SG, Makrigiannis AP, et al. 2005. Epistasis between mouse Klra and major histocompatibility complex class I loci is associated with a new mechanism of natural killer cell-mediated innate resistance to cytomegalovirus infection. Nat. Genet. 37:593–99 290. Adam SG, Caraux A, Fodil-Cornu N, Loredo-Osti JC, Lesjean-Pottier S, et al. 2006. Cmv4, a new locus linked to the NK cell gene complex, controls innate resistance to cytomegalovirus in wild-derived mice. J. Immunol. 176:5478–85 291. Long EO, Burshtyn DN, Clark WP, Peruzzi M, Rajagopalan S, et al. 1997. Killer cell inhibitory receptors: diversity, speciﬁcity, and function. Immunol. Rev. 155:135–44 292. Carrington M, Martin MP. 2006. The impact of variation at the KIR gene cluster on human disease. Curr. Top. Microbiol. Immunol. 298:225–57 293. Martin MP, Nelson G, Lee JH, Pellett F, Gao X, et al. 2002. Cutting edge: susceptibility to psoriatic arthritis: inﬂuence of activating killer Ig-like receptor genes in the absence of speciﬁc HLA-C alleles. J. Immunol. 169:2818–22 294. Khakoo SI, Thio CL, Martin MP, Brooks CR, Gao X, et al. 2004. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 305:872–74 295. Beutler B, Jiang Z, Georgel P, Crozat K, Croker B, et al. 2006. Genetic analysis of host resistance: Toll-like receptor signaling and immunity at large. Annu. Rev. Immunol. 24:353–89 296. Papathanasiou P, Goodnow CC. 2005. Connecting mammalian genome with phenome by ENU mouse mutagenesis: gene combinations specifying the immune system. Annu. Rev. Genet. 39:241–62 297. Godinho SI, Nolan PM. 2006. The role of mutagenesis in deﬁning genes in behaviour. Eur. J. Hum. Genet. 14:651–59 298. Clark AT, Goldowitz D, Takahashi JS, Vitaterna MH, Siepka SM, et al. 2004. Implementing large-scale ENU mutagenesis screens in North America. Genetica 122:51–64 299. Hoebe K, Georgel P, Rutschmann S, Du X, Mudd S, et al. 2005. CD36 is a sensor of diacylglycerides. Nature 433:523–27 300. Hoebe K, Du X, Georgel P, Janssen E, Tabeta K, et al. 2003. Identiﬁcation of Lps2 as a key transducer of MyD88-independent TIR signalling. Nature 424:743–48 301. Tabeta K, Georgel P, Janssen E, Du X, Hoebe K, et al. 2004. Toll-like receptors 9 and 3 as essential components of innate immune defense against mouse cytomegalovirus infection. Proc. Natl. Acad. Sci. USA 101:3516–21 302. Tabeta K, Hoebe K, Janssen EM, Du X, Georgel P, et al. 2006. The Unc93b1 mutation 3d disrupts exogenous antigen presentation and signaling via Toll-like receptors 3, 7 and 9. Nat. Immunol. 7:156–64 303. Calvo D, Dopazo J, Vega MA. 1995. The CD36, CLA-1 (CD36L1), and LIMPII (CD36L2) gene family: cellular distribution, chromosomal location, and genetic evolution. Genomics 25:100–6 304. Endemann G, Stanton LW, Madden KS, Bryant CM, White RT, Protter AA. 1993. CD36 is a receptor for oxidized low density lipoprotein. J. Biol. Chem. 268:11811–16 305. Hoebe K, Du X, Goode J, Mann N, Beutler B. 2003. Lps2: a new locus required for responses to lipopolysaccharide, revealed by germline mutagenesis and phenotypic screening. J. Endotoxin Res. 9:250–55 306. Oshiumi H, Matsumoto M, Funami K, Akazawa T, Seya T. 2003. TICAM-1, an adaptor molecule that participates in Toll-like receptor 3-mediated interferon-β induction. Nat. Immunol. 4:161–67 www.annualreviews.org • Immunity to Infection in the Mouse

131

ARI

16 February 2008

11:22

307. Yamamoto M, Sato S, Mori K, Hoshino K, Takeuchi O, et al. 2002. Cutting edge: a novel Toll/IL-1 receptor domain-containing adapter that preferentially activates the IFN-β promoter in the Toll-like receptor signaling. J. Immunol. 169:6668–72 308. Yamamoto M, Sato S, Hemmi H, Hoshino K, Kaisho T, et al. 2003. Role of adaptor TRIF in the MyD88-independent Toll-like receptor signaling pathway. Science 301:640– 43 309. Krug A, French AR, Barchet W, Fischer JA, Dzionek A, et al. 2004. TLR9-dependent recognition of MCMV by IPC and DC generates coordinated cytokine responses that activate antiviral NK cell function. Immunity 21:107–19 310. Brinkmann MM, Spooner E, Hoebe K, Beutler B, Ploegh HL, Kim YM. 2007. The interaction between the ER membrane protein UNC93B and TLR3, 7, and 9 is crucial for TLR signaling. J. Cell Biol. 177:265–75 311. Casrouge A, Zhang SY, Eidenschenk C, Jouanguy E, Puel A, et al. 2006. Herpes simplex virus encephalitis in human UNC-93B deﬁciency. Science 314:308–12 312. Beutler B, Crozat K, Koziol JA, Georgel P. 2005. Genetic dissection of innate immunity to infection: the mouse cytomegalovirus model. Curr. Opin. Immunol. 17:36–43 313. Crozat K, Georgel P, Rutschmann S, Mann N, Du X, et al. 2006. Analysis of the MCMV resistome by ENU mutagenesis. Mamm. Genome 17:398–406 314. Crozat K, Hoebe K, Ugolini S, Hong NA, Janssen E, et al. 2007. Jinx, an MCMV susceptibility phenotype caused by disruption of Unc13d: a mouse model of type 3 familial hemophagocytic lymphohistiocytosis. J. Exp. Med. 204:853–63 315. Beutler B, Georgel P, Rutschmann S, Jiang Z, Croker B, Crozat K. 2005. Genetic analysis of innate resistance to mouse cytomegalovirus (MCMV). Brief. Funct. Genomic Proteomics 4:203–13 316. Neeft M, Wieffer M, de Jong AS, Negroiu G, Metz CH, et al. 2005. Munc13–4 is an effector of rab27a and controls secretion of lysosomes in hematopoietic cells. Mol. Biol. Cell 16:731–41 317. Brose N, Hofmann K, Hata Y, Sudhof TC. 1995. Mammalian homologues of Caenorhabditis elegans unc-13 gene deﬁne novel family of C2-domain proteins. J. Biol. Chem. 270:25273–80 318. Feldmann J, Callebaut I, Raposo G, Certain S, Bacq D, et al. 2003. Munc13–4 is essential for cytolytic granules fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (FHL3). Cell 115:461–73 319. Fisman DN. 2000. Hemophagocytic syndromes and infection. Emerg. Infect. Dis. 6:601– 8 320. Brose N, Rosenmund C, Rettig J. 2000. Regulation of transmitter release by Unc-13 and its homologues. Curr. Opin. Neurobiol. 10:303–11 321. Verhage M, Maia AS, Plomp JJ, Brussaard AB, Heeroma JH, et al. 2000. Synaptic assembly of the brain in the absence of neurotransmitter secretion. Science 287:864–69 322. Varoqueaux F, Sons MS, Plomp JJ, Brose N. 2005. Aberrant morphology and residual transmitter release at the Munc13-deﬁcient mouse neuromuscular synapse. Mol. Cell Biol. 25:5973–84

Annu. Rev. Immunol. 2008.26:81-132. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-04

132

Vidal et al.

AR338-FM

ARI

12 January 2008

18:11

Annual Review of Immunology

Annu. Rev. Immunol. 2008.26:81-132. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

Contents

Volume 26, 2008

Frontispiece K. Frank Austen p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p x Doing What I Like K. Frank Austen p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p1 Protein Tyrosine Phosphatases in Autoimmunity Torkel Vang, Ana V. Miletic, Yutaka Arimura, Lutz Tautz, Robert C. Rickert, and Tomas Mustelin p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p 29 Interleukin-21: Basic Biology and Implications for Cancer and Autoimmunity Rosanne Spolski and Warren J. Leonard p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p 57 Forward Genetic Dissection of Immunity to Infection in the Mouse S.M. Vidal, D. Malo, J.-F. Marquis, and P. Gros p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p 81 Regulation and Functions of Blimp-1 in T and B Lymphocytes Gislâine Martins and Kathryn Calame p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p133 Evolutionarily Conserved Amino Acids That Control TCR-MHC Interaction Philippa Marrack, James P. Scott-Browne, Shaodong Dai, Laurent Gapin, and John W. Kappler p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p171 T Cell Trafﬁcking in Allergic Asthma: The Ins and Outs Benjamin D. Medoff, Seddon Y. Thomas, and Andrew D. Luster p p p p p p p p p p p p p p p p p p p p p205 The Actin Cytoskeleton in T Cell Activation Janis K. Burkhardt, Esteban Carrizosa, and Meredith H. Shaffer p p p p p p p p p p p p p p p p p p p p233 Mechanism and Regulation of Class Switch Recombination Janet Stavnezer, Jeroen E.J. Guikema, and Carol E. Schrader p p p p p p p p p p p p p p p p p p p p p p p261 Migration of Dendritic Cell Subsets and their Precursors Gwendalyn J. Randolph, Jordi Ochando, and Santiago Partida-Sánchez p p p p p p p p p p p p p293

v

AR338-FM

ARI

12 January 2008

18:11

The APOBEC3 Cytidine Deaminases: An Innate Defensive Network Opposing Exogenous Retroviruses and Endogenous Retroelements Ya-Lin Chiu and Warner C. Greene p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p317 Thymus Organogenesis Hans-Reimer Rodewald p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p355 Death by a Thousand Cuts: Granzyme Pathways of Programmed Cell Death Dipanjan Chowdhury and Judy Lieberman p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p389 Annu. Rev. Immunol. 2008.26:81-132. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

Monocyte-Mediated Defense Against Microbial Pathogens Natalya V. Serbina, Ting Jia, Tobias M. Hohl, and Eric G. Pamer p p p p p p p p p p p p p p p p p p p421 The Biology of Interleukin-2 Thomas R. Malek p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p453 The Biochemistry of Somatic Hypermutation Jonathan U. Peled, Fei Li Kuang, Maria D. Iglesias-Ussel, Sergio Roa, Susan L. Kalis, Myron F. Goodman, and Matthew D. Scharff p p p p p p p p p p p p p p p p p p p p p481 Anti-Inﬂammatory Actions of Intravenous Immunoglobulin Falk Nimmerjahn and Jeffrey V. Ravetch p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p513 The IRF Family Transcription Factors in Immunity and Oncogenesis Tomohiko Tamura, Hideyuki Yanai, David Savitsky, and Tadatsugu Taniguchi p p p p p535 Choreography of Cell Motility and Interaction Dynamics Imaged by Two-Photon Microscopy in Lymphoid Organs Michael D. Cahalan and Ian Parker p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p585 Development of Secondary Lymphoid Organs Troy D. Randall, Damian M. Carragher, and Javier Rangel-Moreno p p p p p p p p p p p p p p p p627 Immunity to Citrullinated Proteins in Rheumatoid Arthritis Lars Klareskog, Johan Rönnelid, Karin Lundberg, Leonid Padyukov, and Lars Alfredsson p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p651 PD-1 and Its Ligands in Tolerance and Immunity Mary E. Keir, Manish J. Butte, Gordon J. Freeman, and Arlene H. Sharpe p p p p p p p p677 The Master Switch: The Role of Mast Cells in Autoimmunity and Tolerance Blayne A. Sayed, Alison Christy, Mary R. Quirion, and Melissa A. Brown p p p p p p p p p p705 T Follicular Helper (TFH ) Cells in Normal and Dysregulated Immune Responses Cecile King, Stuart G. Tangye, and Charles R. Mackay p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p741

vi

Contents

Annu. Rev. Immunol. 2008.26:133-169. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-05

ARI

24 February 2008

9:40

Regulation and Functions of Blimp-1 in T and B Lymphocytes Gislˆaine Martins and Kathryn Calame Department of Microbiology, Columbia University College of Physicians and Surgeons, New York, New York 10032; email: [email protected], [email protected]

Annu. Rev. Immunol. 2008. 26:133–69

Key Words

The Annual Review of Immunology is online at immunol.annualreviews.org

transcription, repressor, terminal differentiation, cytokines

This article’s doi: 10.1146/annurev.immunol.26.021607.090241

Abstract

c 2008 by Annual Reviews. Copyright All rights reserved 0732-0582/08/0423-0133$20.00

B lymphocyte–induced maturation protein-1 (Blimp-1), discovered 16 years ago as a transcriptional repressor of the IFNβ promoter, plays fundamentally important roles in many cell lineages and in early development. This review focuses on Blimp-1 in lymphocytes. In the B cell lineage, Blimp-1 is required for development of immunoglobulin-secreting cells and for maintenance of long-lived plasma cells (LLPCs). Direct targets of Blimp-1 and the transcriptional cascades Blimp-1 initiates to trigger plasmacytic differentiation are described. Blimp-1 also affects the homeostasis and function of CD4+ , CD8+ , and regulatory CD4+ T cells, and Blimp-1 levels are highest in antigen-experienced T cells. Blimp-1 attenuates T cell proliferation and survival and modulates differentiation. Roles for Blimp-1 in Th1/Th2 speciﬁcation, regulatory T cell function, and CD8 differentiation and function are under investigation. Signals that induce Blimp-1 in B cells include Toll-like receptor ligands and cytokines; in T cells, T cell receptors and cytokines induce Blimp-1. In spite of some commonalities, different targets and regulators of Blimp-1 in B and T cells suggest intriguing evolutionary divergence of this regulatory machinery.

133

ANRV338-IY26-05

ARI

24 February 2008

9:40

INTRODUCTION

Annu. Rev. Immunol. 2008.26:133-169. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

Zinc finger: the structural domain of a protein, composed of ∼30 amino acids binding a zinc ion, that mediates sequence-speciﬁc binding to DNA

Although transcription factors containing zinc ﬁnger DNA-binding domains constitute the largest family of transcription factors (1), a single zinc ﬁnger–containing transcriptional repressor, B lymphocyte–induced maturation protein-1 (Blimp-1, also called PRDIBF1) plays critical and nonredundant roles in both B and T lymphocytes. In addition, Blimp-1 plays important roles in certain nonlymphoid lineages in adults and in various aspects of embryonic development in many organisms. In this article, we review the role of Blimp-1 in B and T lymphocytes in detail, with an emphasis on recent ﬁndings. Other reviews including this topic have appeared recently (2–7).

BLIMP-1 BASICS Although there is nothing unusual about its structure, an unusual role for Blimp-1 in B cells was indicated in early work.

Discovery Blimp-1 cDNA was ﬁrst cloned by Maniatis and colleagues (8), who used expression cloning to identify a human cDNA encoding a zinc ﬁnger–containing protein that bound to the positive regulatory domain I (PRDI) of the human IFNβ promoter. They named the protein PRDIBF1 (positive regulatory domain I-binding factor 1) and, in addition to verifying its binding speciﬁcity, demonstrated that the protein was a transcriptional repressor, which was induced upon virus infection of the human osteosarcoma line U20S. Three years later, Davis and colleagues (9) isolated a murine cDNA from a subtractive screen of BCL1 lymphoma cells compared before and after induction of differentiation to Ig-secreting plasma cells by treatment with IL-2+IL-5. Because the message was induced following cytokine-dependent differentiation of the cells, they called it B lymphocyteinduced maturation protein-1, or Blimp-1 (9). Although they did not show directly that the zinc ﬁnger protein encoded by their cDNA 134

Martins

·

Calame

was a transcription factor or deﬁne a binding site, they made the critical observation that ectopic expression of the protein was sufﬁcient to drive the BCL1 cells to mature into Igsecreting plasmacytoid cells. Later that year, Huang (10) brought these two lines of study together by showing that Blimp-1 was the murine homolog of PRDIBF1, although the mouse protein had a slightly different N terminus from the human, containing 67 additional amino acids (10). Indeed, the human and mouse proteins are highly homologous and are interchangeable in functional assays. (For simplicity, we use the name Blimp-1 for both the human and mouse proteins in this review.) Huang’s recognition that PRDIBF1 and Blimp-1 were homologs identiﬁed this protein as a transcriptional repressor, with a deﬁned binding speciﬁcity, that was capable of driving BCL1 lymphoma cells to differentiate into Ig-secreting plasma cells. Subsequently the gene structure of prdm1 (11), encoding Blimp-1, as well as its location on human chromosome 6q21, and the syntenic region of mouse chromosome 10 (12) were deﬁned. The mouse gene extends over ∼23 kb and contains 8 exons. Exons 6, 7, and 8 encode the zinc ﬁnger domains (Figure 1a,b).

Protein Domains and Biochemical Mechanism of Action Murine Blimp-1 contains 856 amino acids and is predicted to be a 95,835-Da protein. Human Blimp-1 has 789 amino acids and a predicted molecular weight of 87,990 Da. The ﬁve C2 H2 zinc ﬁnger motifs in the C terminus of Blimp-1 were clearly implicated as the DNA-binding domain; however, further study showed that only the ﬁrst two ﬁnger motifs are necessary for recognition of the PRDI region in the IFNβ promoter (13). The consensus-binding site for Blimp-1 was determined and, consistent with the Maniatis papers (8, 13), was very similar to that of IFN regulatory factor (IRF)1 and IRF2 (14). In fact, Blimp-1 and IRF1/2 compete for binding to the site in the IFNβ promoter (14).

ANRV338-IY26-05

ARI

a

24 February 2008

Acidic PR

9:40

Proline

5 Zn fingers

Acidic

* Exon:

1 2 3

4 5

6

7

*

Blimp-1

*

8

* mRNA 500 bp

b prdm1 Exon:

1

2 3

4

5

6

7

8

Annu. Rev. Immunol. 2008.26:133-169. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

c prdm gfp

IRES

GFP pA

d

LoxP

LoxP

prdm flox Figure 1 Blimp-1 mRNA and the prdm1 gene. (a) Murine Blimp-1 mRNA showing which portions are encoded by each exon. 5 and 3 noncoding regions are white. Coding regions are colored, with acidic regions light blue, PR region orange, proline-rich region dark blue, and zinc ﬁngers dark green (11). (b–d ) Murine prdm1 gene with exons shown as raised boxes. Coding regions are blue, and noncoding are white. The approximate location of clustered transcription start sites is indicated by an arrow. The gene covers about 23 kb; in the ﬁgure, the scale for introns is 2 times less than the scale for exons. (c) Alterations in prdm1 to make the prdm1gfp knockin allele. A region containing a splice acceptor site followed by stop codons in all three frames ( yellow hexagon), an internal ribosome entry site (IRES), and cDNA encoding e-GFP (green ﬂuorescent protein) followed by a SV40 polyadenylation site (pA) was inserted into intron 6 (24). (d ) Structure of the prdm1ﬂox allele. LoxP sites (red bolts) were inserted in intron 5 and 3 to exon 8. Upon Cre-dependent deletion, exons 6–8, encoding the zinc ﬁnger domains, are deleted (34).

Other domains of the protein (Figure 1a) include a proline-rich region N-terminal to the zinc ﬁngers and a PR domain conserved between Blimp-1 and the Rb-binding protein RIZ1 (encoded by prdm2) (15, 16). The proline-rich region along with the zinc ﬁngers is required for transcriptional repression and has been shown to mediate association of Blimp-1 with transcriptional corepressor hGroucho (17) and histone deacetylases 1 and 2 (18). Deacetylation of histone lysine residues is associated with a repressive chromatin structure. The PR domain was named for the ﬁrst two proteins where it was discovered, PRDIBF1 and RIZ. PR domains in Blimp-1 and RIZ have similarity to SET domains found

in histone methyl transferases (HMT) (19), and the PR domain of RIZ1 does have HMT activity (20). Although the PR domain of Blimp-1 does not have demonstrable HMT activity, Blimp-1 recruits the G9a HMT to the IFNβ promoter (21). G9a methylates lysine 9 on histone 3, a repressive histone modiﬁcation. H3K9 methylation occurs in the IFN-β promoter upon ectopic expression of Blimp-1 (21). Finally, in primordial germ cells, Blimp-1 complexes with prmt5, an arginine HMT that catalyzes symmetrical dimethylation of arginine 3 on H2A and H4 (22). Thus, Blimp-1 appears to repress transcription by recruiting proteins or corepressor complexes that modify histones (by deacetylation, H3K9 methylation, and www.annualreviews.org • Blimp-1 in T and B Lymphocytes

135

ANRV338-IY26-05

ARI

24 February 2008

IHC: immunohistochemistry

Annu. Rev. Immunol. 2008.26:133-169. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

GC: germinal center Cre and “floxed” alleles: bacteriophage P1’s Cre recombinase excises DNA between two similarly oriented 34 bp loxP recombination sites, leaving a single loxP site. DNA ﬂanked by loxP sites is said to be “ﬂoxed” and is a target for Cre-dependent deletion

9:40

arginine methylation) to create a more closed or repressive chromatin structure. However, further work is necessary to learn exactly how chromatin is modiﬁed at speciﬁc Blimp1 target genes when Blimp-1 represses them and to learn if chromatin modiﬁcation is the only mechanism by which Blimp-1 represses transcription.

BLIMP-1 IN B CELL BIOLOGY Based on the demonstration by Davis and colleagues (9) that Blimp-1 was sufﬁcient to drive plasmacytic differentiation, much work has focused on the role of Blimp-1 in the B cell lineage. This work provides a paradigm for exploring its roles in other cell lineages.

Expression Pattern of Blimp-1 Blimp-1 expression in the B cell lineage has been studied by immunohistochemistry (IHC) in mice and humans and using a green ﬂuorescent protein (GFP) reporter gene knocked into one allele of the prdm1 locus in mice (Figure 1c). In mice, both IHC (23) and GFP (24) studies show that some plasmablasts and all plasma cells express Blimp-1. GFP analyses provide evidence that increasing levels of Blimp-1 correspond to stages of plasma cell differentiation from plasmablasts to long-lived plasma cells (LLPCs) in the bone marrow (24). Consistent with this idea, plasma cells resulting from a secondary response had higher levels of Blimp-1 compared with those formed in a primary response (25). No Blimp-1 expression has been observed in memory B cells in mouse (26) or human (27). Although peritoneal B-1 cells express low levels of Blimp-1 mRNA (28) and protein, indicated by the GFP reporter (29), Blimp1 mRNA is induced by lipopolysaccharide (LPS) upon Toll-like receptor (TLR) 4 signaling in B-1 cells (30), and the kinetics of induction, measured using the GFP reporter, are more rapid than that for B2 cells (29).

136

Martins

·

Calame

Although IHC is not quantitative, it is probably more sensitive than the GFP reporter. Furthermore, half-lives of Blimp-1 and GFP mRNA and protein are probably not exactly the same, introducing some doubt into using GFP as an absolute indicator of endogenous Blimp-1 expression. IHC for endogenous Blimp-1 has revealed that a small fraction (∼5%–15%) of cells in germinal centers (GCs) also express Blimp-1. (Blimp-1 has not been detected in B cells at earlier stages.) Blimp-1+ cells in GCs do not express Bcl-6 but do contain cytoplasmic Ig and probably represent centrocytes that are fated to leave the GC as plasmablasts (23). Blimp-1 appears in these GC cells before Syndecan-1 (CD138) (31). Blimp-1 expression patterns in humans are similar to those in mice (32, 33). The GC B cells that express Blimp-1 are Pax5+ Bcl-6− ; outside the GC, human plasma cells do not express Pax5 (32, 33). In an in vitro system in which human centrocytes were induced to become Ig-secreting plasma cells, high levels of Blimp-1 mRNA were not achieved until levels of Bcl-6, Pax5, and Bach2 had fallen signiﬁcantly (27).

Blimp-1 Is Required for Ig Secretion Mice with a conditional deletion of prdm1 in the B lineage were created by crossing mice with “ﬂoxed” prdm1 alleles to CD19Cre transgenic mice (34). In these mice, exons 6– 8, which encode all the zinc ﬁnger domains, are deleted in mature B cells in the presence of Cre recombinase (Figure 1d ). Consistent with Blimp-1’s expression pattern, these mice revealed that Blimp-1 is required for plasma cell formation and for normal Ig secretion in response to both T-independent (TI) and Tdependent (TD) antigens. In the B cell conditional knockout (CKO) mice, peripheral B cell subsets were normal, and GCs formed in response to the TD antigen. Class switch recombination (CSR) occurred normally, as evidenced by the appearance of switch circles (M. Shapiro-Shelef & K. Calame, unpublished),

Annu. Rev. Immunol. 2008.26:133-169. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-05

ARI

24 February 2008

9:40

but secretion of all isotypes was severely reduced. In addition, GCs were enlarged in CKO mice, suggesting a developmental block at the late/post-GC stage. Subsequent studies on the CD19Cre CKO mice revealed that, although B1 B cells were present in normal numbers and were capable of self-renewal, they failed to secrete Ig normally (30). Thus, Blimp-1 is required for normal Ig secretion in all B cell subsets. A recent report (110) has investigated in more detail the low Ig secretion observed in mice lacking Blimp-1 in the B cell lineage (34). Using reconstitution of Rag−/− mice with fetal liver cells from prdm1gfp/gpf mice, these researchers showed that there is an early phase in plasmacytic differentiation, which they call a “preplasmablast,” during which Pax5 activity is inhibited and genes repressed by Pax5 and other plasma cell genes, but not Blimp-1, are expressed. These cells secrete low amounts of Ig and provide evidence for an early phase of plasmacytic differentiation that is independent of Blimp-1 but requires inhibition of Pax5. Thus, these authors conclude that, although Blimp-1 is required for full plasmacytic differentiation and normal levels of Ig secretion, B cells can enter an initial phase of plasmacytic differentiation without Blimp1. One caveat regarding this work, however, is the question of whether the prdm1gfp allele used in this study is a true null allele or a hypomorphic allele, owing to the potential, via differential splicing, to form Blimp-1 mRNA (Figure 1c ). Embryos homozygous for the prdm1gfp allele live until at least E13 or E14, allowing transfer of fetal liver cells for reconstitution studies (35). In contrast, embryos homozygous for either of two different deletion alleles, including one generated from the prdm1ﬂox allele (Figure 1d ), die signiﬁcantly earlier at E10.5 (36). Blimp-1 is not required for formation of memory B cells because in the CKO mice there is an exaggerated GC response upon a secondary challenge even though these cells are unable to differentiate into plasma cells (34). This is consistent with the ﬁnding that

Blimp-1 mRNA is not present in human memory B cells formed in in vitro cultures (27) or in ex vivo puriﬁed human memory cells (26). Preplasma memory cells in the bone marrow, however, were dramatically reduced in the CKO mice, suggesting a requirement for Blimp-1 to form this interesting but controversial (26, 37, 38) subset. Using an inducible gene deletion system, investigators showed that LLPCs (see the Long-Lived Plasma Cells sidebar) in the bone marrow, formed in the presence of Blimp-1, require continued expression of Blimp-1 for their maintenance (39). LLPCs in the bone marrow provide a second form of humoral memory by providing continuous immunity to pathogens that have been previously encountered. They survive in the bone marrow without proliferation or antigen stimulation for long periods of time (40). The continued requirement for Blimp-1 shows that the repressive changes in chromatin that Blimp-1 facilitates must be labile on at least an important subset of its target genes, requiring continued activity of Blimp-1 to maintain repression. These studies showed that when prdm1 was deleted, CD138+ , Ig-secreting cells, resident in the bone marrow disappeared; however, whether they died or dedifferentiated was not established and requires further study. Thus, Blimp-1 is uniquely required for formation and maintenance of all Ig-secreting B cells, and interfering with its activity might be a way to target LLPC in autoimmunity or other pathological conditions.

Plasmacytic differentiation: terminal differentiation of an activated B cell to become an Ig-secreting plasma cell

Targets of Blimp-1 Not only is Blimp-1 necessary for plasma cell formation and function, it is also sufﬁcient. The striking ability of ectopically expressed Blimp-1 to drive plasmacytic development, originally demonstrated in 1994 by Davis and colleagues (9), was subsequently extended beyond BCL1 cells to normal splenic B cells (47, 48). Importantly, however, when Blimp-1 expression is forced in B cells at earlier developmental stages, it causes cell death (49). www.annualreviews.org • Blimp-1 in T and B Lymphocytes

137

ANRV338-IY26-05

ARI

24 February 2008

9:40

Annu. Rev. Immunol. 2008.26:133-169. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

LONG-LIVED PLASMA CELLS In a primary response, most plasma cells formed after a T cell–dependent GC reaction secrete antibodies with high afﬁnity and switched isotypes. Because of changes in chemokine receptors such as CXCR5, they exit the follicles, and some migrate to niches in the bone marrow. In the bone marrow niches, they receive survival signals that include IL-6, made by bone marrow stromal cells (41), and TNF family members BAFF (B cell-activating factor) or APRIL (a proliferation-inducing ligand) that signal through BCMA (B cell maturation antigen) (42). LLPCs have been shown to survive for months to years, sometimes for the lifetime of the organism (43) in the absence of an antigen (44) or cell division (45). Interestingly, when an organism mounts a new primary response, some previously formed LLPCs, resident in the bone marrow, are mobilized to leave the bone marrow survival niches, presumably providing space for newly formed plasma cells and ensuring a dynamic repertoire of LLPCs, reﬂecting the immunological experience of the organism (46). Because they provide constant immunological vigilance in the form of secreted antibodies, LLPCs are considered one form of humoral immunity. For more details on LLPCs, see a recent review (40).

XBP-1: X-box binding protein-1 Gene expression profile: the unique, global pattern of genes expressed as steady-state mRNA in a given cell type

138

Ig-secreting plasma cells differ signiﬁcantly, both morphologically and functionally, from activated B cells; they express neither BCR nor MHC class II on their surface, and they are postmitotic (6). The ability of a single transcription factor to trigger such a complex and dramatic developmental decision is unusual and was a driving force behind efforts to identify targets of Blimp-1-dependent repression in B cells. Gene expression analyses comparing Burkitt lymphoma lines with or without forced expression of Blimp-1 revealed more than 250 genes whose expression was altered by Blimp-1 (50). Obviously such experiments reveal both direct and indirect Blimp-1 targets (Figure 2). Three main programs of gene expression were altered by Blimp-1. (a) A proliferative program including cMYC, E2F1, and other genes required for entry into cycle and cell division was repressed. Myc had Martins

·

Calame

previously been shown to be a direct target of Blimp-1-dependent repression (51, 52). (b) A program involved in Ig secretion, including J chain, X-box binding protein-1 (XBP-1), as well as Ig heavy and Ig light chain genes, was induced. (c) An extensive program of gene expression characteristic of activated or GC B cells was repressed, including genes encoding the critical transcription factors Pax5 and Bcl-6. Pax5 was previously shown to be a direct target of Blimp-1 (53), and recent studies show that bcl6 is also directly repressed by Blimp-1 (L. Cimmino & K. Calame, unpublished). The “B cell program” repressed by Blimp-1 includes repression of genes involved in response to signals from the BCR; genes, notably AICDA, involved in CSR and somatic hypermutation (SHM); genes encoding costimulatory molecules for T cells; and genes for chemokine receptors (Figure 2). Direct targets among this group also include class II transactivator (CIITA) via promoter III, required for MHC class II expression in B cells (48, 54), ID3 and SPIB (50) (Figure 3, Table 1). Another gene expression study identiﬁed genes regulated by Blimp-1 in BCL1 and M12 cells (55). This study conﬁrmed much of the earlier work but also identiﬁed other interesting genes regulated by Blimp-1 in B cells, including induction of irf4 and repression of taci. Using mutant forms of Blimp-1, investigators also identiﬁed genes whose regulation depended on the PR domain of Blimp-1, including ell2 (55). XBP-1 is a transcriptional activator that is required for plasma cell development and function (56). When the gene expression proﬁles of splenic B cells lacking Blimp1 and XBP-1 were compared (57), it was clear that Blimp-1 expression is necessary for expression of XBP-1 and that XBP-1 is the proximate activator of multiple genes necessary for expanded endoplasmic reticulum and protein secretion as well as of genes causing increased cell size, lysosome content, mitochondrial mass and function, ribosome numbers, and total protein synthesis. In the

ANRV338-IY26-05

ARI

24 February 2008

9:40

a

Blimp-1 myc

Annu. Rev. Immunol. 2008.26:133-169. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

dhrf odc1 ldha cdc2a

gadd45a ddit3 cdkn1a cdkn2c

id3

pax5

aicda blnk cd19 cd79a ciita syk

igh igl igj xbp1

igl

Direct repression spi-b

ciita

bcl-6

btk

h2 cd74

cdkn1a trp53 prdm1

Secretory genes

Blimp-1 Direct?

b

Indirect?

e2f1

mybl1/ mybl2

ebf1

pou2f2/ pou2af1

tcfe2a

myc mcm7 dhfr cdc2a pcna myb2

sox-4 cdc2a

pax5 cd79a

cd79a h2 blr1

aicda

Figure 2 Transcription factors that are targets of Blimp-1 in B cells. Panel (a) indicates genes shown to be directly repressed by Blimp-1, and panel (b) indicates genes Blimp-1 represses by a currently unknown mechanism. In both cases, target genes that are known to be regulated by the indicated transcription factors and that had their expression altered by Blimp-1 (50) are shown. Green indicates genes involved in cell proliferation, purple, genes involved in B cell phenotype and function, and blue, genes involved in Ig secretion. All genes are given murine designations for clarity and consistency.

absence of Blimp-1, neither XBP-1 nor its target genes are expressed normally (57). The mechanism responsible for Blimp-1dependent induction of XBP-1 may be via repression of pax5 since Pax5 has been reported to repress xbp1 (59). However, a detailed gene expression study in B cells lacking Pax5 did not show that XBP-1 was elevated (60), suggesting another, currently unknown, mechanism may be responsible for Blimp-1-dependent expression of XBP-1. In chicken DT40 cells lacking Pax5, both Blimp-1 and XBP-1 were elevated (61), providing evidence that Pax5 does repress xbp1 in this setting. Thus, although it is established that Blimp-1 is necessary for XBP1 induction in B cells, the exact mechanism

by which Blimp-1 regulates XBP-1 remains uncertain.

Regulation of Blimp-1 and Plasmacytic Differentiation Plasmacytic differentiation must be strictly regulated. Failure to mount a humoral response in a timely fashion would clearly jeopardize the organism. However, if plasmacytic differentiation occurred too soon during a TD response, before germinal center reactions were completed, afﬁnity maturation and class switching would be compromised, and the strength and quality of both primary and secondary responses would be www.annualreviews.org • Blimp-1 in T and B Lymphocytes

Germinal center (GC) reaction: In response to T cell–dependent antigens and T cell help, B cells form GCs, where they undergo rapid proliferation, afﬁnity maturation, and CSR. Memory cells and plasmablasts result from the GC reaction

139

ANRV338-IY26-05

ARI

24 February 2008

MITF

Bach2

irf4

Naive B cell

Pax5

prdm1

MITF Annu. Rev. Immunol. 2008.26:133-169. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

9:40

Plasma cell

xbp1

GC B cell

Pax5

Bach2 Bcl-6

Figure 3 Inhibition of genes required for plasma cell differentiation in earlier naive follicular B cells and by germinal center (GC) B cells. Red bars indicate transcriptional repression, and the blue arrow indicates induction. Factors in naive B cells are shown in the yellow box; factors in GC B cells are shown in the blue box (59–61, 90, 95–97, 100, 103, 106).

diminished. In addition, peripheral tolerance requires B cells to selectively respond to signals from self-antigens by dying or becoming anergic rather than undergoing plasmacytic differentiation. Finally, it is important that memory B cells be poised to differentiate to Table 1

plasma cells rapidly in response to secondary antigenic challenge but also be regulated so that spontaneous differentiation does not occur in the absence of a stimulus. Expression of Blimp-1 sets plasmacytic differentiation into effect in what is normally an irreversible process. Thus, understanding the regulation of Blimp-1 expression is critical for understanding how appropriate primary humoral responses, peripheral B cell tolerance, and B cell memory are regulated. The data detailed below support a general model in which (a) the B cell developmental stage and (b) the nature, strength, and duration of signals that B cells receive from antigen, TLRs, and cytokines combine to determine Blimp-1 expression and plasmacytic development. In B cells, Blimp-1 expression is regulated primarily at the level of transcription initiation (11). Multiple, clustered transcription initiation sites have been mapped in the mouse gene that give rise to a full-length protein (11). An alternative transcription start site, located 5 of exon 4 in the human gene,

Direct targets of Blimp-1 repression in lymphocytes

Gene

Transcriptional regulator?

B cell target

T cell target

References

bcl6

Yes, repressor

Yes

Yes

L. Cimmino & K. Calame, unpublished

myc

Yes, activator and repressor

Yes

No

51; G. Martins, L. Cimmino & K. Calame, unpublished

ciita (promoter III)

Yes, coactivator

Yes

Not expressed

48, 54

fos

Yes, activator

n.d.

Yes

162a; E. Magnusdottis, G. Martins & K. Calame, unpublished

Id3

Yes, inhibitor of E proteins

Yes

n.d.

50

ifng

No

Not expressed

Yes

L. Cimmino & K. Calame, unpublished

il2

No

n.d.

Yes

62; G. Martins & K. Calame, unpublished

pax5

Yes, activator and repressor

Yes

Not expressed

53

spib

Yes, activator

Yes

n.d.

50

tbet

Yes, activator

n.d.

Yes

L. Cimmino & K. Calame, unpublished

n.d., not determined.

140

Martins

·

Calame

Annu. Rev. Immunol. 2008.26:133-169. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-05

ARI

24 February 2008

9:40

gives rise to a shorter protein known as the beta form, which lacks 101 N-terminal amino acids, contains only a partial PR domain, and has reduced transcription repression activity (62). This form is usually present in submolar amounts relative to the full-length form. Blimp-1 mRNA and protein are labile, with half-lives of less than 2 h (C. Tunyaplin & K. Calame, unpublished). Although phosphorylation of the protein has been observed ( J. Noronha & K. Calame, unpublished), there is no evidence that levels of phosphorylation are regulated, and the effect of phosphorylation on function has not been assessed. IHC shows Blimp-1 is localized entirely in the nucleus in mouse (23) and human (32) B cells. Activators of prdm1 transcription. Pattern-recognition receptors (63), including TLRs, RIG-I-like receptors, and possibly NOD-like receptors, induce Blimp-1 in many settings. This was ﬁrst demonstrated by induction of Blimp-1 by Sendai virus (double-stranded RNA) infection of U20S cells (8). In B cells treated in vitro, LPS, which activates TLR4, is a strong inducer of Blimp-1 mRNA for murine splenic B cells and for B-1 cells from the peritoneal cavity (30, 47). CpG, which activates TLR9, induces Blimp-1 in human tonsillar B cell cultures (T. Kuo & K. Calame, unpublished). Reishi polysaccharides, which activate TLR4/TLR2, also induce Blimp-1, apparently using different signaling pathways in human and murine B cells (64). These data are consistent with an analysis of TLR4−/− and MyD88−/− mice (65). [MyD88 is an obligate signal transducer for all TLRs except TLR3 and TLR4, which have both MyD88-dependent and MyD88independent pathways (63, 66).] B cells from these mice do not secrete IgM or IgG antibodies normally. Further analysis showed that for a TI-2 response to ﬂagellin, which activates TLR5, MyD88−/− B cells had a defective IgM and IgG1, but not IgG3, response. In a TD GC reaction, both TLR4−/− and MyD88−/− B cells were defective in formation of GC

B cells. GC B cells lacking MyD88 had decreased Blimp-1 mRNA and increased Bcl-6 mRNA. These data are consistent with the idea that TLR signals induce Blimp-1 in both TI and TD responses. However, a more recent paper (67) calls into question the role of TLR signals for B cell responses as it showed that mice lacking all TLR-dependent signaling mounted normal responses to TD antigens delivered in various adjuvants. Thus, the role of TLRs in B cell responses is unclear at present, although their ability to induce Blimp-1 is unquestioned. Pattern recognition receptors activate NF-κB (63), and NF-κB appears to be a direct activator of prdm1 transcription (Table 3), as evidenced by the failure of p65−/− p50−/− 3T3 cells to induce Blimp-1 in response to Sendai virus infection, failure of splenic B cells to induce Blimp-1 in response to LPS in the presence of NF-κB inhibitors, and the binding of p65 in vivo to multiple κB sites in the region 5 to transcription initiation on prdm1 (T. Kuo, E. Magnusdottir & K. Calame, unpublished). TLR or RIG-I activation of Blimp-1 mRNA is sufﬁcient to induce plasmacytic differentiation in activated B cells. However, activated NF-κB is apparently not sufﬁcient to induce Blimp-1 in all stages of B cell development because it plays important roles earlier in B cell development (68), yet Blimp1 is not expressed in these earlier B cells. Furthermore, BCR, CD40 ligation, and B cell–activating factor (BAFF)-dependent signaling also activate NF-κB but do not induce Blimp-1 mRNA (69). In fact, BCR, CD40, and IL-4 signals block LPS-dependent induction of Blimp-1 in murine splenic B cells (69), although in human B cells BCR and CD40 activation enhance IL-21’s ability to induce plasmacytic differentiation and Blimp-1 expression (70). There has, however, been a report that a stress response in macrophage and B cell lines induces Blimp-1 in a way that depends on NF-κB (71). Other transcription factors, including NF-IL6 and IRF1, IRF3, and IRF8 are also induced by TLR signaling (72) and may also induce Blimp-1, especially www.annualreviews.org • Blimp-1 in T and B Lymphocytes

BAFF: B cell activating factor

141

ANRV338-IY26-05

ARI

Table 2

24 February 2008

9:40

Signals that regulate Blimp-1 expression

Function

Signal

B cells

References

T cells

References

IL-2

Yes (BCL1 line)

9

Yes

74, 76

IL-4

n.d.

—

Yes

132

IL-5

Yes

9

n.d.

—

IL-6

Yes (lymphoma lines, bone marrow)

K.L. Lin & K. Calame, unpublished

n.d.

—

IL-10

Yes

27

n.d.

—

IL-21

Yes

77

n.d.

—

B/TCR

Indirect via Bcl-6 or others

78

Yes

76, 35

LPS

Yes

47

n.d.

—

CpG

Yes

29

n.d.

—

Cytokine

Annu. Rev. Immunol. 2008.26:133-169. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

Clonotypic receptor TLR ligand

n.d., not determined.

because IRF8 induces Blimp-1 in myeloid cells (73). Several cytokines, including IL-2, IL5, IL-6, IL-10, and IL-21, induce Blimp1 mRNA, as ﬁrst noted by Davis and colleagues (9) who showed that Blimp-1 mRNA was induced by IL-2+IL-5 in BCL1 cells (Table 2). Indeed, in T cells as well as B cells, IL-2 is a strong inducer of Blimp-1 mRNA (74). IL-6 induces plasmacytic differentiation of certain human B cell lines (75), and this is accompanied by induction of Blimp-1 mRNA (K.-I. Lin & K. Calame, unpublished). Although there is little evidence that IL-6 is important for driving plasmacytic differentiation during a primary response in vivo, IL-6, secreted by stromal cells, is critical for maintenance of LLPCs in the bone marrow (41). One of its important functions in this setting may be to induce Blimp-1, which is continuously required for the maintenance of these plasma cells (39), although this has not been directly demonstrated. Plasmacytic differentiation of human B cells can be induced by IL-10 following activation by BCR and CD40 signals (79–81). Indeed, if IL-10 is added to human memory cell cultures, rapid plasmacytic differentiation

STAT: signal transducer and activator of transcription

142

Martins

·

Calame

ensues (82) and is accompanied by induction of Blimp-1 mRNA (27). IL-21 is necessary for normal Ig secretion (83, 84) and induces differentiation of B cells to plasma cells in mice (77). Interestingly, IL21 induces both Blimp-1 and Bcl-6 mRNA (77). Similarly, when human B cells are stimulated via BCR and CD40, IL-21 is a strong inducer of both plasmacytic differentiation and Blimp-1 mRNA, and the effect of IL-21 is enhanced in combination with IL-2 (70). IL-2, IL-6, IL-10, and IL-21 all activate signal transducer and activator of transcription 3 (STAT3), strongly implicating STAT3 as a direct activator of prdm1 transcription. Although this has not been deﬁnitely demonstrated, forced expression of a dominantnegative form of STAT3 inhibited Blimp-1 mRNA induction in BCL1 cells (85), providing evidence that STAT3 does activate prdm1 transcription. In addition, and consistent with early observations in BCL1 cells, IL-5, which primarily activates STAT5 (86), induces Blimp-1 mRNA and, like IL-21, also induces genes involved in GC B cells such as bcl6 and aicda (87). IL-2 also activates STAT5 (88), and STAT5 may be important in the IL-2-dependent activation of Blimp-1. However, one study (89) has shown that activated

ANRV338-IY26-05

ARI

Annu. Rev. Immunol. 2008.26:133-169. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

Table 3

24 February 2008

9:40

Transcription factors that regulate prdm1 transcriptiona

Transcription factor

Activity

B cell

References

T cell

References

AP-1 (fos-Jun)

Activator

Yes

90

(Yes)

—

Bach2

Repressor

Yes

95

Not expressed

96

Bcl-6

Repressor

Yes

97

Yes

L. Cimmino & K. Calame, unpublished

Blimp-1

Autorepressor

n.d.

—

Yes

L. Cimmino & K. Calame, unpublished; 162a

IRF4

Activator

Yes

93

n.d.

—

Foxp3

Activator

Not expressed

—

Yes

98

NFAT

Activator

Yes

99

(Yes)

—

NF-κB

Activator

Yes

T. Kuo and K. Calame, unpublished

(Yes)

—

Pax5

Repressor

Yes

102a

(No)

—

STAT3

Activator

Yes

85

(Yes)

—

STAT5

Activator

n.d.

—

Yes

D. Gong & T. Malek, personal communication

a Parentheses indicate activities implied but not experimentally demonstrated. n.d., not determined.

STAT5 blocks plasmacytic differentiation, so the role of STAT5 in Blimp-1 regulation in B cells is currently unclear. In addition to Jak/STAT pathways, these cytokines also activate other signaling pathways, including the Ras-Raf-ERK, the phosphatidylinositol 3kinase (PI3K), the JNK/SAPK, and the p38 signaling pathways, and these may play a role in induction of Blimp-1 as well, although most of these possibilities remain unexplored. Two other transcriptional regulators, IRF4 and AP-1, bind prdm1 and directly activate its transcription (Table 3). AP-1 was ﬁrst implicated as an activator of the human gene when it was found that Bcl-6 repressed Blimp-1 transcription by associating with c-Jun and inhibiting the ability of AP-1 to activate PRDM1 (90). Evidence that AP-1 also induces murine prdm1 transcription comes from studies using c-Fos transgenic mice. Splenic B cells from these mice undergo more signiﬁcant plasmacytic differentiation in response to CD40 and IL-4 than do controls. Further studies on these mice also demonstrated binding of AP-1 to the prdm1 gene by chromatin

immunoprecipitation (ChIP) (91). Because Blimp-1 can be induced in mice lacking c-Fos, it seems that, although AP-1 activates Blimp-1 transcription, AP-1 is not essential (91). IRF4 is necessary for plasma cell formation (92) and more recently has also been shown as a requirement for CSR (93, 94). Mice lacking IRF4 in their B cells have been analyzed to determine if IRF4 might be upstream of Blimp-1 in a regulatory cascade. Two groups obtained different answers to this question. Klein et al. (94) created mice with a conditional deletion of irf4 in GC B cells. Upon LPS stimulation of splenic B cells in vitro, plasmacytic differentiation was blocked, but Blimp-1 mRNA was similarly induced in both wild-type and CKO, providing evidence that IRF4 does not act upstream of Blimp-1 and is not required for Blimp-1 induction. However, when Sciammas et al. (93) studied B cells from the original knockout mice (92), they also observed a failure in plasmacytic development after LPS stimulation, but in their studies, Blimp-1 mRNA failed to be induced. They went on to perform ChIP studies, which www.annualreviews.org • Blimp-1 in T and B Lymphocytes

ChIP: chromatin immunoprecipitation

143

ARI

24 February 2008

9:40

identiﬁed a site between exon 5 and 6 of prdm1 that was occupied by IRF4 in vivo in stimulated, but not in naive, B cells. They concluded that IRF4 is a direct transcriptional activator of prdm1. Although the discrepancy between the two studies remains unexplained, it may be that minor differences in activation conditions or the developmental stage of the cells studied altered the availability of IRF4 partners or other regulators of prdm1 in the two studies, accounting for different results. The ChIP studies (93), however, strongly suggest that IRF4 does indeed induce prdm1 transcription in at least some conditions.

Annu. Rev. Immunol. 2008.26:133-169. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-05

Repressors of prdm1 transcription. It is becoming increasingly clear that repression of Blimp-1 is important for its regulated expression in B cells. Bcl-6 was the ﬁrst repressor of Blimp-1 to be identiﬁed, based on microarray analyses of Burkitt cell lines expressing Bcl-6 or a dominant-negative Bcl-6 (97). Forced expression of Bcl-6 also inhibited plasmacytic differentiation and Blimp-1 expression in murine splenic B cells following activation (85). Bcl-6 represses prdm1 transcription by interfering with the AP-1 activator (90) and by binding directly to a conserved site in exon 5 of the murine gene (100). MTA3, a cell type-speciﬁc subunit of the corepressor complex Mi-2/NuRD, acts as a corepressor with Bcl-6, and when MTA3 and Bcl-6 expression is forced in myeloma cell lines, Ig secretion and Blimp-1 mRNA expression are inhibited, essentially causing dedifferentiation of these transformed plasma cells (101). Signals that lead to strong activation of PI3K in B cells favor plasmacytic differentiation and inhibit CSR (102). Part of this effect appears to depend on Blimp-1. The mechanism involves PI3K-dependent activation of Akt, which inhibits FoxO-dependent activation of Bcl-6, thus decreasing Bcl-6 and allowing derepression of prdm1 when PI3K is strongly activated (102). Loss of Pax5 in mature murine B cells leads to increased expression of Blimp-1 (60), 144

Martins

·

Calame

and similar results are observed in chicken DT40 cells (61). However, whether this effect is due to direct repression of prdm1 by Pax5 or to Pax5-dependent induction of Bcl-6, which then represses prdm1, or both was not clear in those studies. In mice, loss of Pax5 did not alter Bcl-6 mRNA levels, but in DT40 cells, Bcl-6 was diminished in the absence of Pax5, and induction of Blimp-1 in the absence of Pax5 could be blocked by Bcl-6 (61). A very recent report shows that Pax5 binds to prdm1 and directly represses it (102a). Another repressor of prdm1 transcription is Bach2, a repressor that interacts with small Maf proteins (95). Bach2 is speciﬁcally expressed in B cells and required for normal CSR and SHM. Bach2−/− mice have a hyperIgM syndrome and spontaneous plasmacytic differentiation of IgM-secreting cells (95). LPS treatment of Bach2−/− splenic B cells led to abnormally elevated Blimp-1 and XBP-1 mRNA and to repression of AID mRNA (95). Subsequently, a binding site for the Bach2MalK heterodimer in the prdm1 promoter region was identiﬁed, and binding of MalK in vivo was demonstrated by ChIP (103), providing additional evidence that Bach2 directly represses prdm1. Repression of plasmacytic differentiation and Blimp-1 expression. There are several mechanisms that prevent premature plasmacytic differentiation by repressing transcription factors required by plasma cells, and most of these mechanisms involve Blimp-1 (Figure 3). Of the three prdm1 repressors discussed above, Bach2 and Pax5 are expressed in preB and naive B cells (96), as well as in GC B cells. Additionally, Pax5 has been reported to repress xbp1 (59, 61), although there are data to the contrary (60). Finally, microphthalmiaassociated transcription factor MITF, which is most abundant in naive B cells, represses IRF4 mRNA by an undetermined mechanism. B cells lacking MITF have spontaneous plasmacytic differentiation (106), providing direct evidence that MITF is important for normal control of terminal differentiation.

Annu. Rev. Immunol. 2008.26:133-169. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-05

ARI

24 February 2008

9:40

Because IRF4 is a direct activator of prdm1 (93), its repression indirectly represses prdm1. Expression of Bcl-6 protein is highly restricted to GC B cells (33, 104, 105). Thus, Bcl-6 appears to add a second layer of prdm1 repression speciﬁcally at the GC stage. Thus, Bach2, MITF, and Pax5 repress plasmacytic differentiation in naive B cells and at developmental stages before and during the GC reaction; in the GC, Bcl-6 is present to further ensure that plasmacytic differentiation is inhibited. Interestingly, when human memory B cells develop in vitro from tonsillar centrocytes, Bach2, Pax5, and Bcl-6 mRNA levels decrease signiﬁcantly, suggesting that one reason memory cells can differentiate into plasma cells quickly is because they lack these repressors (27). Induction and establishment of plasmacytic differentiation. Current understanding of Blimp-1 regulators, as detailed above, shows that Blimp-1 expression and the plasmacytic differentiation that ensues require a combination of two kinds of events: (a) removal of inhibitors Bcl-6, Pax5, MITF, and Bach2 and (b) induction of activators including IRF4, AP-1, NF-κB, and STAT3 (Figure 4). Interestingly, all three general signals necessary for Ig secretion—antigen, TLR ligands, and cytokines—provide one or more of these signals. The requirement both to remove inhibitors and to supply activators may help explain why LPS is such a potent immunogen because TLR4 activates both MyD88-dependent and -independent pathways (107). The requirement may also explain why activated NF-κB present in B cells at earlier developmental stages or BCR signals alone are unable to induce Blimp-1 mRNA. How are the inhibitors removed? This is a critical question that relates directly to the question of how exit of plasmablasts from the GC is regulated. Unfortunately, information is far from complete, but dissecting the regulation of Blimp-1 in GC and post-GC B cells provides one way to ap-

B cell

Plasma cell

BCR PI3K

MITF

NFAT

irf4

IL-21 FoxO Mad1

Bcl-6

STAT3

prdm1

NF-κB TLR

Pax5

Bach2

xbp1

Provide activation

Remove inhibition Figure 4 Two signals necessary for plasma cell differentiation. Arrows and bars indicate positive or negative regulation, and the orange star indicates protein degradation (27, 29, 30, 47, 78, 93, 99, 100, 108–112).

proach the question. Recent studies establish that high-afﬁnity BCRs direct GC B cells to a plasmacytic fate (108, 109), so models must incorporate BCR signals. Studies using in vitro cultures of human tonsillar centrocytes that develop into plasma cells in response to IL-10 (27) show that levels of Bcl6, Pax5, and Bach2 mRNA drop signiﬁcantly before large increases in Blimp-1 mRNA occur. There is little information available concerning the mechanisms responsible for loss of Pax5 and Bach2 expression, although decreased Pax5 was observed in preplasmablasts prior to Blimp-1 induction (110). Several mechanisms remove Bcl-6 from GC B cells. BCR-dependent activation of mitogen-activated protein kinase (MAPK) leads to phosphorylation of Bcl-6, which targets Bcl-6 for ubiquitin-dependent degradation (78). Because Bcl-6 is abundant in GC B cells, this mechanism may only be operative in response to strong BCR signals or in combination with other signals, and it may initiate exit of B cells from the GC, as a decrease in Bcl-6 activity is required for both post-GC plasma cell and memory B cell differentiation www.annualreviews.org • Blimp-1 in T and B Lymphocytes

145

ARI

24 February 2008

9:40

(27). Acetylation inactivates the ability of Bcl6 to repress transcription, and Bcl-6 is acetylated in GC B cells, although there is no knowledge of if or how acetylation of Bcl-6 may be regulated in GC B cells (111). The E box factor Mad1 is elevated in plasma cells and directly represses Bcl-6 (112). Finally, because FoxO3A activates Bcl-6 (113) and Akt inactivates FoxO transcription factors (114), strong BCR signals, activating PI3K and Akt and inactivating FoxO, lead to a reduction in Bcl-6 and an increase in Blimp-1 in B cells (102). Interestingly, Bcl-6 is not abundant in marginal zone B cells or B1 B cells, and neither Bach2, Pax5, nor Bcl-6 mRNA are found in human memory B cells formed in vitro (27). Thus, in these settings, induction of Blimp-1 can occur more rapidly when appropriate activators are induced. Mice lacking OBF-1 have impaired plasmacytic differentiation in response to certain kinds of stimulation (115). Without OBF-1, bcl6 and pax5 are not repressed, and prdm1 is not induced when B cells are activated in vitro with CD40L and IL-4. However, stimulation by LPS is normal in the absence of OBF-1 (115). The mechanism requiring OBF-1 for induction of Blimp-1 is not clear, although ChIP assays provided no evidence for direct binding of octamer-OBF-1 complexes to prdm1. OBF-1 may indeed be needed to remove one or more repressors such as Bcl-6 in response to certain signals. Many mechanisms are likely to induce or activate activators of prdm1. TLR signals, activating NF-κB, induce Blimp-1 in GC B cells (27) and B-1 B cells (29, 30) and probably in naive and marginal zone B cells present in splenic B cell preparations following treatment with LPS (47). Vav signaling is required downstream of TLR signals to induce Blimp-1 mRNA and to form Igsecreting plasma cells (116). Mature marginal zone B cells, stimulated with TLR ligands, proliferate and express IRF4 but do not express Blimp-1 when they lack Vav proteins, demonstrating that IRF4 alone is not sufﬁ-

Annu. Rev. Immunol. 2008.26:133-169. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-05

146

Martins

·

Calame

cient to induce Blimp-1. NFAT (nuclear factor of activated T cells) factors are important in B cells, and calcineurin/NFAT-dependent induction of IRF4 is important for post-GC plasmacytic development (99). Because IRF4 is probably a direct activator of prdm1 (93), it follows that NFAT signaling indirectly induces Blimp-1 mRNA in post-GC plasma cells. The role of BCR in regulating prdm1 is interesting and, given rather fragmentary data, certainly deserves further study. There is no evidence that BCR signals alone are sufﬁcient to induce prdm1, and in combination with TLR signals, BCR signals actually block plasma cell formation in vitro (117) and Blimp-1 expression (47). However, NFAT, an indirect activator of prdm1 (99), and AP-1, a direct activator (90), are activated by BCR signals (118). Furthermore, in anergic B cells that do not induce Blimp-1 or develop into plasma cells, NFAT signaling downstream of BCR is uncoupled, whereas extracellular signal regulated kinase (ERK) signaling downstream of BCR is maintained (119). BCR signaling via Ras and MAPK kinase (MEK) to ERK integrates BCR and cytokine signals. ERK activation, via continuous BCR signaling, inhibits Blimp-1 induction, and IL-2 and IL-5 inactivate ERK via induction of the DUSP 5 phosphatase (120). The mechanism for ERK-dependent inhibition of Blimp-1 was not identiﬁed, but it might involve Bcl-6 or its cofactors. It is also interesting that in mice lacking Bruton’s tyrosine kinase, TI-2 activation of B cells initially induces Blimp-1, but this is not sustained, and the cells do not progress to become plasmablasts (121). Once Blimp-1 is expressed, it is sufﬁcient to cause plasmacytic differentiation. Blimp-1 also speciﬁcally represses genes encoding two critical transcription factors required for GC B cells—pax5 (53) and bcl6 (90, 100). Thus, the plasma cell program is enforced, and earlier stages of B cell development are inhibited by Blimp-1.

ANRV338-IY26-05

ARI

24 February 2008

9:40

Blimp-1 in B Cell Malignancies

Annu. Rev. Immunol. 2008.26:133-169. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

Recent studies provide evidence that abnormal regulation or abnormal activity of Blimp1 may be one causal event in some B cell malignancies. If Blimp-1 acts as a tumor suppressor, lack of its activity could be important in some forms of lymphoma. Alternatively, its ability to enforce a plasma cell phenotype may be important in plasma cell tumors.

Diffuse large B cell lymphoma. When an early study identiﬁed myc as a direct target of Blimp-1-dependent transcriptional repression (51), it was logical to speculate that Blimp-1 might function as a tumor suppressor, especially given the prominent role of dysregulated c-Myc expression in B cell tumors (122). Interestingly, however, aged mice with conditional deletion of prdm1 in the B cell lineage do not develop B cell tumors spontaneously (M. Shapiro-Shelef & K. Calame, unpublished), indicating that loss of Blimp-1 alone is not sufﬁcient for B lymphomagenesis. Nevertheless, there is growing evidence that deletion or mutation of PRDM1 is frequently found in a subset of diffuse large B cell lymphoma (DLBCL), providing evidence that it may indeed function as a tumor suppressor (123–125). Similar PRDM1 mutations were not found in B or T or myeloid leukemias or in the 467 common carcinomas examined (126). In the most thorough study on DLBCL, PRDM1 was inactivated by structural alterations in 24% (8 out of 34) activated B cell–like diffuse large cell lymphomas but not in GC B cell–like (n = 0/37) or unclassiﬁed (n = 0/21) DLBCLs (125). However, a subset of DLBCL, which expressed Blimp-1, lacked detectable plasmablastic or immunoblastic changes and displayed more aggressive behavior, with a shorter failure-free survival (127). Thus, further studies are warranted to determine how expression and lack of expression of Blimp-1 affect the formation and properties of different subsets of DLBCL.

Murine plasmacytoma and human multiple myeloma. Malignant plasma cells in both mice (plasmacytoma) and humans (multiple myeloma) express abundant levels of Blimp-1, which likely reﬂects their differentiated state as plasma cells and the fact that they usually secrete Ig. Blimp-1 is also present in a subset of DLBCL but not in marginal zone lymphomas or chronic lymphocytic leukemia (32), and abortive plasmacytic differentiation in some Hodgkin and Reed Sternberg cells is indicated by the presence of Blimp-1 (128). Apparently, the ability of Blimp-1 to repress myc is overcome in these tumors by oncogenic changes, such as chromosomal translocation, that activate and dysregulate myc transcription or the dominant activity of other oncoproteins. [However, Blimp-1 is apparently able to repress myc in other tumors, such as myeloid tumors, where it is induced by IRF8 (73).] There is active interest in determining how forcing expression of Blimp-1 or, alternatively, blocking its activity or knocking down its expression might affect the growth and phenotypic properties of myeloma or other B cell tumors. In a recent study, treatment of myeloma cell lines with 2-methoxyestradiol, which suppresses their growth and induces apoptosis, also led to an elevation of Blimp1 and XBP-1 and repressed MYC and PAX5 (129). In some myeloma cell lines, the proportion of the beta form of Blimp-1 is elevated in comparison with normal plasma cells (62, 130), which might decrease the overall activity of Blimp-1, but the functional consequences of elevated beta form have not been elucidated clearly. Assuming Blimp-1 is necessary for the Ig secretion program in myeloma, as it is in normal plasma cells, one reasonable prediction is that blocking Blimp-1 in the tumors might block Ig secretion. Whether this would cause apoptosis owing to endoplasmic reticulum stress as observed upon administration of protease inhibitors (131) or to failure of other survival mechanisms (39) or dedifferentiation (101) remains to be determined. www.annualreviews.org • Blimp-1 in T and B Lymphocytes

DLBCL: diffuse large B cell lymphoma

147

ANRV338-IY26-05

ARI

24 February 2008

9:40

BLIMP-1 IN T CELL BIOLOGY

LCMV: lymphocytic choriomeningitis virus

The understanding that Blimp-1 is also important in the T lymphocyte lineage emerged only within the past 2–3 years. Thus, this work is at an earlier stage. Although the overall effect of lacking Blimp-1 T cells is fatal, owing to spontaneous inﬂammatory disease, the cellular and molecular effects are more subtle and complex than the effects in B cells.

Expression of Blimp-1 in T Cells Blimp-1 protein is expressed in human (32, 132) and mouse (35, 74) T cells, and in both species Blimp-1 levels are signiﬁcantly higher in antigen-experienced cells. Indeed, the levels of Blimp-1 mRNA and protein in antigen-experienced murine and human T

Treg

Naive

Activated/effector

Memory

Naive

Activated/ effector

Memory

Blimp-1 transcripts

Annu. Rev. Immunol. 2008.26:133-169. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

Regulatory T (Treg) cells: those CD4+ CD25+ regulatory T cells, both constitutive and inducible, that express FoxP3 and suppress T cell responses

Activation and differentiation status Figure 5 Blimp-1 expression in T cells. Blimp-1 mRNA (represented by arbitrary units on the y-axis) is present in low levels in naive CD4+ and CD8+ T cells but is abundant in ex vivo isolated antigen-experienced (CD62LLo CD44Hi and CD62LHi CD44Hi ) cells. Memory CD8+ T cells and some of the memory CD4+ T cells are contained in the CD62LHi CD44Hi subpopulation, which expresses slightly lower levels of Blimp-1 mRNA than the CD62LLo CD44Hi cells. In vitro stimulation (not depicted) of the naive T cells results in a slow increase in Blimp-1 expression, reaching levels similar to that observed in the ex vivo isolated antigen-experienced cells. Ex vivo isolated CD4+ CD25+ naturally occurring, regulatory T (Treg) cells express Blimp-1 transcripts at the same levels as effector nonregulatory CD4+ T cells (35, 76, 132). 148

Martins

·

Calame

cells are similar to those observed in cultures where plasma cells are generated in vitro by LPS treatment of splenic B cells (76, 132). Although steady-state Blimp-1 mRNA is present in low levels in mouse thymocytes (76, 133) and naive CD4+ and CD8+ T cells (76, 132), levels increase 20–40 times upon stimulation with α-CD3, α-CD28, and IL-2 (35, 76, 132). Induction of Blimp-1 mRNA and protein in vitro is slow, with maximum levels achieved 3–5 days poststimulation (76, 132). T cell receptor (TCR) restimulation in the presence of α-CD28 leads to a further increase in Blimp-1 mRNA expression (132; L. Cimmino & K. Calame unpublished). Blimp-1 mRNA is also found in high levels in ex vivo puriﬁed CD4+ or CD8+ effector/memory (CD62LLo /CD44Hi ) and memory phenotype (CD62LHi /CD44Hi ) T cells, with the ﬁrst subpopulation showing slightly more abundant Blimp-1 transcripts (Figure 5) (76). Finally, Blimp-1 transcripts are observed in high levels in ex vivo puriﬁed CD4+ CD25+ CD62LHi , which are mostly composed of Foxp3+ cells, known as naturally occurring, regulatory T (Treg) cells (35, 76). Prdm1-GFP knockin (Figure 1c) reporter mice (24) have been used to monitor Blimp-1 expression in T cells (24). GFP expression is not detected in the thymus or in naive peripheral T cells, but it was observed in in vitro– activated T cells, in vivo antigen-experienced CD4+ and CD8+ peripheral T cells, and in CD4+ CD25+ CD62LHi cells, which are primarily Foxp3+ Treg cells (24). Thus, despite the limitations of using GFP as a reporter for Blimp-1 expression, these data are consistent with observations described above showing that within the T cell lineage Blimp-1 is found in highest levels in antigen-experienced cells and in naturally occurring Treg cells. In agreement with these patterns, Blimp-1 is upregulated in vivo in CD8+ antigen-speciﬁc T cells upon infection with herpes simplex virus (HSV) (35) and with lymphocytic choriomeningitis virus (LCMV) (R. Rutishauser & S. Kaech, unpublished).

Annu. Rev. Immunol. 2008.26:133-169. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-05

ARI

24 February 2008

9:40

Although Blimp-1 expression is consistently elevated in antigen-experienced CD4+ T cells, levels vary: Naive CD4+ T cells stimulated under Th2 conditions (IL-2, IL-4, and anti-IFN-γ) express higher levels of Blimp1 steady-state mRNA than do cells stimulated under Th1 (IL-2, IL-12, and anti-IL4) or nonpolarizing conditions (IL-2) (132; L. Cimmino & K. Calame, unpublished). Indeed, Blimp-1 mRNA expression seems to be repressed as cells differentiate under Th1 conditions because at the end of a 6-day culture, Th1 cells express less Blimp-1 steadystate mRNA than do cells stimulated under nonpolarizing conditions (L. Cimmino & K. Calame, unpublished). However, differential expression of Blimp-1 in Th subsets was not observed in the Blimp-1-GFP knockin reporter mice (35). Nonetheless, immunoblotting reveals that Blimp-1 protein is higher in Th2 than in Th1 cells after two rounds of polarization in vitro (L. Cimmino & K. Calame, unpublished). Importantly, these differences are observed before any restimulation at the end of the differentiation rounds, suggesting that the differential levels of Blimp-1 expression are maintained in resting Th1 and Th2 cells and might be related to the maintenance of the respective T helper phenotype.

Blimp-1 and T Cell Development The pattern of Blimp-1 mRNA expression in T cells—low in thymocytes and naive T cells, high in antigen-experienced T cells—is consistent with the idea that Blimp-1 is more important for T cell function than development; however, conditional deletion of Blimp1 in T cells (prdm1F/F Lck-Cre mice) resulted in signiﬁcant alterations in the thymus (76). The prdm1F/F Lck-Cre mice have a threefold decrease in the numbers of total thymocytes (76), which can be attributed to a marked reduction in the absolute numbers of CD4+ and CD8+ double-positive (DP) as well as singlepositive (SP) CD4+ or CD8+ thymocytes. This defect is observed as early as 4 weeks after birth and progresses with age. There

is no signiﬁcant alteration in the number of double-negative (DN) and γδ thymocytes and no signiﬁcant differences in the distribution of the various DN thymocyte subsets between control and prdm1F/F Lck-Cre mice, as determined by CD25 and CD44 expression. Also, developmental stage-speciﬁc surface markers (CD5, TCRβ, HSA, CD24, and CD69) and short-term BrdU incorporation are indistinguishable between control and prdm1F/F LckCre mice, suggesting that the maturation and proliferation of each subset are preserved in the absence of Blimp-1. However, DP thymocytes are more susceptible to cell death, suggesting that Blimp-1 may regulate survival during negative selection of DP thymocytes (76). Nevertheless, the possibility that decreased survival of the prdm1F/F Lck-Cre mice DP thymocytes is secondary to the immune activation in the periphery cannot be excluded, and more work is required to clarify the role of Blimp-1 in thymocyte development.

Functions of Blimp-1 in T Cells Mice lacking Blimp-1 in their T cells have provided valuable information about the role(s) of Blimp-1 in the T lineage. Although these CKO mice were created in different ways in two laboratories, most of the observations from the two groups were consistent. However, one key difference is the possible role Blimp-1 may play in CD4+ Treg cells. Spontaneous inflammatory disease in mice with T cells lacking Blimp-1. Two strategies were used to generate mice with Blimp1-deﬁcient T cells. One group crossed the prdm1F/F mice (Figure 1d ) with proximal Lck-Cre or CD4-Cre transgenic mice, generating mice in which Blimp-1 deletion was speciﬁcally restricted to T lymphocytes (76; G. Martins & K. Calame, unpublished). The other group used fetal liver cells from prdm1gfp/gfp (Figure 1c) embryos to reconstitute the hematopoietic compartment of Rag-1-deﬁcient mice, resulting in the www.annualreviews.org • Blimp-1 in T and B Lymphocytes

149

ARI

24 February 2008

9:40

generation of chimeric mice in which cells from the myeloid and lymphoid lineages were prdm1gfp/gfp and Blimp-1 deﬁcient (35). Despite the differences in the two approaches, both studies revealed that lack of Blimp-1 results in profound alterations of T cell function and homeostasis, culminating with the spontaneous development of inﬂammatory disease (35, 76). Whereas in the ﬁrst model (T cell–speciﬁc deletion of Blimp-1) the inﬂammatory disease was concentrated in the colon (35, 76), mice reconstituted with prdm1gfp/gfp fetal liver cells also had inﬂammation in other organs, including lungs and liver (35). Although the nature of this difference has not yet been systematically addressed, it may simply reﬂect the different approaches used (deletion of Blimp-1 in T cells only versus deletion of Blimp-1 in the lymphoid and myeloid compartments). If so, one would predict that Blimp-1 might be important for regulating the function of hematopoietic cells other than T and B lymphocytes, a possibility that remains to be investigated. It is also possible that the difference in severity of the inﬂammatory disease observed in the two models is related to differences in the genetic background: The prdm1F/F LckCre mice were of mixed 129xC57BL/6 background, whereas the prdm1gfp/gfp mice where backcrossed into C57BL/6. In other models of spontaneous development of inﬂammatory diseases (134) the severity and target organs might vary in different genetic backgrounds. Finally, differences in the animal facilities used to house the different Blimp-1 CKOs could also explain differences in the inﬂammatory phenotype. The cellular and molecular mechanisms associated with development of colitis in mice with Blimp-1-deﬁcient T cells are not completely understood. T cell dysfunction is associated with colitis in many murine models, which are generally characterized by deregulated activation of effector T cells with excessive production of IFN-γ and decreased production of IL-10 and/or defective devel-

Annu. Rev. Immunol. 2008.26:133-169. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-05

150

Martins

·

Calame

opment/function of Tregs (135, 136). Current data indicate several probable causes of colitis development in the prdm1F/F Lck-Cre mice. Blimp-1-deﬁcient CD4+ T cells produce increased amounts of IFN-γ, and their production of IL-10 is signiﬁcantly impaired (see below), indicating deregulated T cell activation and/or biased Th1 differentiation. There is also partial impairment of Treg function in the absence of Blimp-1, discussed below. Interestingly, a small population of CD4+ T cells with colitogenic potential can be found in normal mice (137). Apparently, these cells can be driven into the antigen-experienced pool by the presence of commensal bacteria but are normally kept under control by Treg cells in an IL-10-dependent manner (137). Hence, it would be interesting to know if the antigen-experienced cells that accumulate in mice with T cell–speciﬁc deletion of Blimp-1 contain these potentially colitogenic cells. If that is indeed the case, the defective production of IL-10 by Blimp-1-deﬁcient Treg cells (see below) could provide a mechanistic explanation for their accumulation. Nonetheless, direct evidence linking the accumulation of the antigen-experienced cells with the spontaneous development of colitis in the T cell– speciﬁc Blimp-deﬁcient mice is still lacking, and it is not known if the defect in IL-10 production is associated with colitis in these mice. T cell homeostasis and attenuation of IL2 production. The elevated expression of Blimp-1 in peripheral antigen-experienced T cells and the substantial accumulation of these cells in both prdm1F/F Lck-Cre and prdm1gfp/gfp mice, despite the different genetic backgrounds of the mice, provide strong evidence that Blimp-1 is important in T cell homeostasis. Evidence from studies in which Blimp-1 is ectopically expressed (74, 132) or deleted from T cells (35, 76) indicates that Blimp1 regulates responsiveness and homeostasis of peripheral T cells by attenuating both proliferation and survival. Blimp-1-deﬁcient antigen-experienced CD4+ T cells are less susceptible to apoptosis upon restimulation

Annu. Rev. Immunol. 2008.26:133-169. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-05

ARI

24 February 2008

9:40

in vitro (35; G. Martins & K. Calame, unpublished), and in vitro–differentiated Blimp1-deﬁcient Th1 cells are more resistant to cell death caused by cytokine withdrawal (35), suggesting that Blimp-1 normally promotes apoptosis of effector T cells. In addition, it appears that Blimp-1 attenuates proliferation induced upon TCR stimulation of naive T cells. Ectopic expression of Blimp-1 resulted in decreased proliferation of CD4+ T cells (132), and naive CD4+ T cells from the prdm1F/F Lck-Cre mice proliferate better than wild-type cells when stimulated in suboptimal conditions (76). Stimulation in optimal conditions, including CD28-mediated costimulation and addition of exogenous IL-2, abrogates the proliferation differences between Blimp-1-sufﬁcient and -deﬁcient cells (35, 76), suggesting that regulation of proliferation by Blimp-1 is limited to conditions in which costimulation is absent or weak, such as presentation of a self-antigen in the periphery where the normal result is anergy of the responder T cell (138, 139). Thus, lack of Blimp-1 may cause increased responsiveness to self-antigens. Furthermore, one may speculate that Blimp-1 normally attenuates tonic signaling through the TCR (140). Both possibilities remain to be experimentally evaluated. Blimp-1-deﬁcient CD8+ T cells seem to respond abnormally to exogenous antigens, as indicated by the increased accumulation of antigen-speciﬁc CD8+ T cells after infection of prdm1gfp/gfp mice with HSV (35). Also, in a system where P14 TCR transgenic, prdm1deﬁcient or control naive CD8+ T cells were transferred to wild-type recipient mice and the recipients infected with LCMV, there was signiﬁcantly more accumulation of Blimp-1deﬁcient cells (R. Rutishauser & S. Kaech, unpublished). One key mechanism by which Blimp-1 modulates T cell responsiveness is likely to be through repression of IL-2. IL-2, acting in both autocrine and paracrine manners, regulates the initial expansion of naive T cells upon TCR stimulation in vitro (141, 142) and

possibly in vivo. Paracrine IL-2 is also important for the in vivo survival of Tregs, which in turn regulate the proliferation of peripheral T cells (142, 143). Multiple observations support the idea that Blimp-1 represses IL-2. Production of IL-2 is elevated in naive Blimp1-deﬁcient CD4+ T cells following activation in vitro (76), and IL-2 steady-state mRNA levels in naive Blimp-1-deﬁcient CD4+ T cells are elevated relative to controls both before and following activation in vitro (G. Martins & K. Calame, unpublished). Ectopic expression of Blimp-1 signiﬁcantly decreases IL-2 production in wild-type CD4+ and CD8+ T cells, and IL-2 production declines when Blimp-1 levels are highest after TCR stimulation (74, 132). Moreover, ectopic expression of Blimp-1 inhibited the expression of an IL-2 promoter-GFP reporter (74) in vitro. However, the relationship between IL-2 and Blimp-1 is additionally complicated and interesting. As detailed below, IL-2 signaling strongly induces prdm1 transcription (74). Thus, T cell activation induces il2 transcription, IL-2 signaling induces prdm1 transcription, and Blimp-1 feeds back to repress il2 transcription (Figure 6). Blimp-1 therefore appears to be a key component of the pathway by which IL-2 downregulates its own expression during later phases of T cell activation (144) (Figure 6). Together these data suggest a model (Figure 7) in which Blimp-1 controls T cell function in two different stages: At the initial activation stage it may regulate responsiveness by attenuating IL-2 production and proliferation, and, subsequently, it may enhance the elimination of effector cells via apoptosis. Additionally, Blimp-1 might be required for the proper function of Treg cells, another pathway by which Blimp-1 regulates T cell responses. Thus, Blimp-1-deﬁcient T cells would proliferate more when differentiating into effectors, and the effectors would survive better. This could help to explain the abnormal accumulation of antigen-experienced cells observed in the Blimp-1-deﬁcient mice. www.annualreviews.org • Blimp-1 in T and B Lymphocytes

151

ANRV338-IY26-05

ARI

24 February 2008

9:40

2

Antigen and costimulation

1

IL-2R

TCR

NFAT Fos (AP-1) NF-κB

3 IL-2

il2 Annu. Rev. Immunol. 2008.26:133-169. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

IL-2

STAT3 or STAT5

prdm1

Blimp-1

4

Figure 6 The regulatory feedback loop involving Blimp-1 and IL-2 in T cells. (1) Antigen and costimulation induce il2 (pink rectangle) transcription via NFAT, AP-1, and NF-κB. (2) IL-2 secreted from the cell, in either an autocrine or paracrine manner, binds the IL-2 receptor. (3) IL-2 signaling, probably via activated STAT3 or STAT5, induces prdm1 transcription and Blimp-1 protein (74). Blimp-1 represses il2 directly and also represses fos, a component of AP-1 which activates il2 (4) (G. Martins & K. Calame, unpublished).

T helper differentiation. Blimp-1 appears to play a role in Th2 cells by repressing Th1 genes (Figure 8). Deletion of Blimp1 in T cells causes increased production of IFN-γ and decreased production of IL-10 (35, 76). Production of IL-4 was decreased in one model of T cell deletion of Blimp-1 (35) but not signiﬁcantly altered in another (76). The increased production of IFN-γ by Blimp-1-deﬁcient T cells suggests that Blimp1 may attenuate Th1 differentiation. Consistent with that, Blimp-1 transcripts and protein are more abundant in Th2 than in Th1 cells differentiated in vitro (132; L. Cimmino & K. Calame, unpublished). Despite these observations, Blimp-1-deﬁcient CD4+ T cells can be polarized into Th1 or Th2 cells in vitro, and IL-4 production seems unaffected, although IFN-γ production is slightly increased in both Th1 and Th2 cells derived from Blimp-1deﬁcient mice (L. Cimmino & K. Calame, unpublished). It will be important to determine if Blimp-1-deﬁcient Th cells can still 152

Martins

·

Calame

polarize normally in an in vivo immune response, where the factors directing Th polarization, such as strength of TCR stimulation and concentration of different cytokines, are more complex than in the in vitro cultures. Consistent with increased IFN-γ production, Blimp-1-deﬁcient T cells show increased levels of IFN-γ and Tbet steady-state mRNA (L. Cimmino & K. Calame, unpublished). Another important player in the regulation of Th differentiation by Blimp-1 appears to be Bcl-6. Blimp-1-deﬁcient T cells have increased Bcl-6 mRNA levels (L. Cimmino & K. Calame, unpublished), and Bcl-6 proteins can repress Th2 differentiation by interfering with the function of GATA-3 (145), a master regulator of Th2 differentiation (reviewed in 146), and by direct repression of il5 transcription (147). Thus, alleviating bcl6 repression could be one mechanism responsible for increased production of Th1 cytokines in Blimp-1-deﬁcient T cells. The idea that Blimp-1 might be required to inhibit Th1

ANRV338-IY26-05

ARI

24 February 2008

9:40

Antigen and costimulation IL-2 TCR IL-2R

1

AP-1 (cFos) NFAT NF-κB

Blimp-1

STAT3 or STAT5

2

Annu. Rev. Immunol. 2008.26:133-169. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

Other genes

+

il2

+

bcl2a1

pdrm1

NUCLEUS

Proliferation and survival Figure 7 A model for Blimp-1 attenuation of proliferation and survival in CD4+ T cells. TCR stimulation of naive T cells induces IL-2 production and Blimp-1 expression. Blimp-1 attenuates T cell proliferation and survival following primary activation in several ways. (1) Blimp-1 attenuates induction of the il2 gene indirectly by repressing fos and directly by repressing il2. (2) Blimp-1 also represses transcription of bcl2a1 (although it is not known if this occurs directly or indirectly). By interfering with pathways 1 and 2, Blimp-1 might regulate proliferation and survival upon primary TCR stimulation. Pathway 2 could also remain operative in antigen-experienced cells at later stages of differentiation because Blimp-1-deﬁcient Th1 effector cells seem more resistant to cytokine deprivation cell death (35). Additionally, Blimp-1 might repress genes related to activation-induced cell death (AICD) induction (not shown). This latter pathway is more likely to be operative in antigen-experienced cells, at later stages of differentiation, as indicated by the phenotype of mice with Blimp-1-deﬁcient T cells (35, 76).

Activation IL-12 AP-1 NFAT NF-κB

STAT4

ifng

bcl6

tbet

pdrm1

Blimp-1

Figure 8 A model for Blimp-1 attenuation of Th1 cell differentiation. Blimp-1 represses ifng directly and indirectly via repression of tbet. It also represses bcl6 and tbet directly and indirectly via repression of ifng (L. Cimmino and K. Calame, unpublished).

differentiation also ﬁts with the observation that ablation of Blimp-1 in T cells results in spontaneous development of colitis, which, in most of the cases, is mediated by IFNγ-producing cells (135, 136). However, to date there is no direct evidence that a biased Th1 response is a cause of the spontaneous colitis/inﬂammatory disease observed in mice with Blimp-1-deﬁcient T cells. Colitis development in the prdm1F/F LckCre mice might also be associated with the impaired production of IL-10. The decreased production of IL-10 by the Blimp1-deﬁcient cells is most likely a cell-intrinsic defect because it is observed in conditions in which IFN-γ is minimal or nonexistent, such as when puriﬁed CD4+ CD25+ Foxp3+ Treg cells are stimulated in vitro (G. Martins & K. Calame, unpublished). This ﬁnding also www.annualreviews.org • Blimp-1 in T and B Lymphocytes

153

ANRV338-IY26-05

ARI

24 February 2008

9:40

indicates that regulation of IL-10 production by Blimp-1 extends to the Treg cells, and this defect could be one of the triggers of the inﬂammatory disease observed in these mice, as discussed below.

Annu. Rev. Immunol. 2008.26:133-169. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

Differentiation of CD8+ T cells. The expression pattern of Blimp-1 is similar in CD4+ and CD8+ cells (35, 74, 76, 132), but little is known about the role of Blimp-1 in CD8 cells. As mentioned above, prdm1gfp/gfp mice are able to mount an efﬁcient CD8+ -mediated response to HSV infection, and in this model, Blimp-1-deﬁcient CD8+ T cells performed immediate effector functions, such as IFN-γ production and cytotoxicity, normally. Interestingly, there was signiﬁcant accumulation of antigen-speciﬁc CD8+ T cells by day 55 postinfection in the prdm1gfp/gfp mice. Kallies et al. (35) suggested that these were memory cells, but neither their phenotype nor function was evaluated. If these cells are indeed memory cells, these results would indicate that Blimp-1 attenuates the formation of memory cells or enhances their elimination. This would be consistent with the idea that Blimp-1 is important for the elimination of antigen-experienced cells and, in the CD8+ lineage, may limit the transition from effectors to memory cells. Blimp-1-deﬁcient antigen-speciﬁc cells also accumulate in vivo after infection with LCMV, in a transfer system where only the antigen-speciﬁc CD8+ T cells were Blimp-1 deﬁcient (R. Rutishauser & S. Kaech, personal communication). In this system, the accumulated cells have a memory precursor effectorlike phenotype (CD127Hi KLRG1Lo ) characterized by high levels of expression of the IL-7 receptor. Taken together, these results suggest that Blimp-1 might play an important role in the differentiation of CD8+ T cells, but this requires further investigation. It will be important to know if the memory cells that accumulate in the absence of Blimp-1 in both systems can actually provide protection upon infection when transferred to a naive recipient. Also, identiﬁcation of Blimp-1 154

Martins

·

Calame

target genes in these systems could provide important insights into the molecular mechanisms regulating the differentiation of memory cells in the CD8+ lineage. In this context, an important player could be Bcl-6, which is a target of Blimp-1 in B and T cells and is known to support the survival of memory CD8+ T cells (148, 149). Treg cell function in vivo. The expression of high levels of Blimp-1 in Treg cells and the inﬂammatory disease associated with Blimp-1 ablation in T cells suggest a role for Blimp-1 in Treg cell differentiation and/or function. However, CD4+ CD25+ Foxp3+ Treg cells develop normally in the absence of Blimp-1 (35, 76). Indeed, prdm1gfp/gfp mice show increased frequency of splenic CD4+ /FoxP3+ cells (35), and peripheral CD4+ /Foxp3+ cells numbers increase with age in the prdm1F/F Lck-Cre mice (G. Martins & K. Calame, unpublished observations). It is important to determine if this expansion is due to increased IL-2 in the mice. Blimp-1-deﬁcient Treg cells perform normally in in vitro suppression assays and are also able to suppress colitis caused by homeostatic expansion of naive CD4+ T cells in Rag1-deﬁcient mice (35, 76). Nevertheless, Blimp-1-deﬁcient Treg cells cannot suppress acute colitis induced by dextran sodium sulfate (DSS) administration (76) and do not prevent inﬂammatory disease in Blimp-1-deﬁcient mice (35, 76), demonstrating a functional impairment. The reason that Blimp-1-deﬁcient Tregs control colitis in the RAG reconstitution system but not in the DSS system is not clear but may be related to the differential requirement for IL-10. IL-10 is associated with resistance to DSS-induced colitis (150, 151) but may not be as critical for preventing colitis induced by homeostatic proliferation of naive CD4+ cells (137). Available data indicate that Blimp-1 is required for IL-10 production by Treg cells (G. Martins & K. Calame, unpublished observations) as well as for nonregulatory CD4+ T cells (35, 76). Because Blimp-1 is a repressor,

ANRV338-IY26-05

ARI

24 February 2008

9:40

it is likely that Blimp-1 represses a gene that negatively regulates IL-10 expression, but this remains to be determined.

Annu. Rev. Immunol. 2008.26:133-169. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

Targets of Blimp-1 in T Cells RNA microarray analyses and gene expression studies using a quantitative reverse transcriptase PCR (qRT-PCR) have begun to reveal genes that are targets of Blimp-1 repression in T cells. This list includes bcl2a1, bcl6, il2, erg2, ifng, prdm1, tbet, and fos. Some of these targets (bcl2a1 and bcl6 ) are in common with B cells; others seem to be unique to T cells (Table 1). qRT-PCR studies, showing higher levels of mRNA in Blimp-1-deﬁcient T cells compared with controls, combined with ChIP assays, demonstrating binding of endogenous Blimp-1 in primary T cells, have shown that il2, fos, ifng, tbet, and bcl6 are direct targets of Blimp-1-dependent repression in T cells (G. Martins, L. Cimmino & K. Calame, unpublished). The evidence that Blimp-1 represses IL-2 production was discussed above, and it makes sense that il2 is a direct target of Blimp-1 repression. It seems likely that, in addition to direct repression of il2, repression of fos is important for the Blimp-1-dependent attenuation of T cell activation and IL-2 production. mRNA encoding Fos, a member of the AP1 family of transcription factors, is elevated in Blimp-1-deﬁcient CD4+ T cells following TCR stimulation. Fos is an important activator of IL-2 production upon TCR stimulation in T cells (152, 153). Thus, repression of il2 transcription by Blimp-1 in T cells seems to occur both directly and indirectly. Although not yet directly tested, Blimp-1 may repress il2 in Treg as well as in nonregulatory CD4+ T cells (Figure 9). Repression of ifng, tbet, and bcl6 is very likely to be important for Blimp-1-dependent repression of Th1 differentiation. Ifng is not only directly repressed by Blimp-1 but may also be indirectly repressed by suppression of tbet. In turn, decreased IFN-γ production would decrease expression of both tbet

and bcl6. In yet another example of redundant regulation, Blimp-1 also directly represses both of these genes. Thus, Blimp-1 is part of a complicated network of regulation that inhibits Th1 differentiation (Figure 8). However, the functional importance of this aspect of Blimp-1’s activity remains largely untested. An interesting common target gene for Blimp-1 in both B and T cells is bcl2a1, encoding A1, an antiapoptotic member from the Bcl-2 family of proteins (reviewed in Reference 154). A1 (a and b) are highly expressed by Blimp-1-deﬁcient cells in microarray studies comparing in vitro stimulated CD4+ T cells from control and prdm1F/F Lck-Cre mice (G. Martins & K. Calame, unpublished). Accordingly, A1 transcripts, measured by qRTPCR, are more abundant in Blimp-1-deﬁcient CD4+ T cells stimulated in vitro. In B cells, bcl2a1 is repressed by Blimp-1 (50), and enforced expression of A1 rescued Blimp-1induced cell death (155). In T cells, A1 is expressed upon TCR stimulation (156), and it may play a role in protecting cells from cytokine deprivation–induced cell death (157). A CD2-driven bcl2a1 transgenic mouse showed an increased number of peripheral T cells, but their activation status was not evaluated. T cells from these transgenic mice also show decreased death upon stimulation with T cell mitogens (157). Similar to other Bcl-2 family members, A1 does not seem to play any nonredundant role in protecting T cells from activation-induced cell death (AICD) (157). This is consistent with the fact that AICD, as assayed following in vitro activation of naive CD4+ T cells, was unaltered in CD4+ T cells from the prdm1f /f mice (76). Nonetheless, Blimp-1-deﬁcient in vitro–generated CD4+ effector T cells are more resistant to cytokine withdrawal–induced cell death (76; G. Martins & K. Calame, unpublished). Thus, derepression of bcl2a1 in the Blimp-1deﬁcient T cells might contribute to the accumulation of the antigen-experienced cells in the periphery of the prdm1f /f LckCre mice. Sequence inspections reveal the www.annualreviews.org • Blimp-1 in T and B Lymphocytes

AICD: activation-induced cell death

155

ANRV338-IY26-05

ARI

24 February 2008

9:40

IL-2 IL-2 IL-2 IL-2R

Foxp3

Annu. Rev. Immunol. 2008.26:133-169. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

NFAT AP-1 (Fos)

Blimp-1

STAT3 and STAT5

pdrm1

il2 il10 Figure 9

A model for Blimp-1 in Treg cells. Blimp-1 is expressed in high levels in Treg cells, induced by Foxp3 directly and probably also by IL-2, to which Treg cells are highly responsive. Blimp-1 could promote IL-10 expression by repressing a factor that normally inhibits its expression. IL-2 production is normally repressed in Treg cells by Foxp3, which interferes with NFAT induction of the il2 gene. Direct or indirect repression of il2 by Blimp-1 may also occur, as discussed in the text. Dotted lines represent regulation that is predicted based on ﬁndings in nonregulatory T cells but not yet conﬁrmed in Treg cells.

presence of Blimp-1 putative-binding sites in the promoter region of the murine bcl2a1 gene (G. Martins & K. Calame, unpublished observations). ChIP studies are needed to clarify if A1 is a direct target of Blimp-1 in T cells.

Regulation of Blimp-1 Expression in T Cells While several aspects of transcriptional regulation of prdm1 appear to be conserved in T cells and B cells, the overall regulatory pathways in T cells are distinct, and in T cells there is a clear role for antigen receptor stimulation in Blimp-1 induction. TCR and IL-2. Blimp-1 mRNA and proteins are induced during T cell activation. In vitro stimulation of naive CD4+ T cells with α-CD3, or α-CD3 and α-CD28, results in Blimp-1 mRNA induction, but maximum levels are induced when exogenous IL2 is administered together with α-CD3 and α-CD28 (132; L. Cimmino & K. Calame unpublished), suggesting that IL-2 greatly po156

Martins

·

Calame

tentiates prdm1 induction upon TCR stimulation. Indeed, T cells lacking the β-chain of the IL-2 receptor (IL-2Rβ−/− ) express signiﬁcantly less Blimp-1 than wild-type cells upon TCR stimulation, and TCR stimulation in the presence of IL-2-neutralizing antibodies resulted in very low/undetectable Blimp1 protein (74). Therefore, a large portion, but not all, of prdm1 induction upon TCR stimulation seems to be secondary to induction of IL-2. Furthermore, IL-2 is required to maintain Blimp-1 expression after the initial in vitro activation of CD8+ T cells, a function that IL-15, another common gamma chain cytokine, was unable to perform (74). The importance of IL-2 for Blimp-1 expression is consistent with the late expression of Blimp-1 during T cell activation in vitro, and it is likely to have important regulatory functions because Blimp-1 represses il2, as discussed above. The components downstream of IL-2 signaling required for Blimp-1 induction remain to be identiﬁed, but STAT5 is probably an important element in this pathway.

Annu. Rev. Immunol. 2008.26:133-169. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-05

ARI

24 February 2008

9:40

Other regulators. High levels of Blimp-1 in naturally occurring Foxp3+ Treg cells are likely to be caused by IL-2 signaling, which is critical for maintenance and proliferation of Treg cells in the periphery (158) (Figure 9). In addition, a genome-wide analysis of Foxp3 targets showed that prdm1 is directly activated by Foxp3 (159), adding further support to the idea that Blimp-1 is required for proper function of Treg cells. Extrapolating from the data in nonregulatory cells, we can surmise that Blimp-1 likely represses il2 transcription in Treg cells. This would provide another mechanism, in addition to competition with NFAT (160), by which Foxp3 represses il2 in Treg cells (Figure 9). Comparative analysis of gene expression proﬁles in Blimp-1-sufﬁcient and -deﬁcient Treg cells will be necessary to further elucidate Blimp-1’s mechanisms of action in Treg cells. The fact that Blimp-1 transcripts can be induced, albeit to low levels, in the IL-2Rβ−/− T cells upon TCR stimulation, indicates the existence of IL-2-independent pathways for Blimp-1 induction. Blimp-1 protein levels were increased in these cells upon TCR stimulation in the presence of IL-4 or IL-12, suggesting that these cytokines can also induce Blimp-1 expression (74). Interestingly, in these studies IL-4 seems to be a stronger inducer of Blimp-1 protein than IL-12 (74). In wild-type naive CD4+ T cells, Blimp-1 mRNA is also induced more strongly by IL4 than by IL-12, and in this same system, administration of exogenous IFN-γ reduces the induction of Blimp-1 transcripts upon TCR stimulation (L. Cimmino & K. Calame, unpublished). Thus, consistent with the expression patterns discussed above, TCR stimulation in Th2-promoting conditions (IL4) results in strong induction of Blimp-1, whereas Th1-promoting conditions (IL-12 and IFN-γ) result in weak Blimp-1 induction. IL-21 is expressed in T cells as well as B cells (160a), and although IL-21 induces prdm1 in B cells, there is currently no information as to whether IL-21 induces prdm1 in T cells. IL21 is expressed at high levels in inﬂammatory

conditions (161, 162), and if it induces Blimp1 in T cells, this could be a mechanism for downregulation of T cell function and containment of inﬂammation. In addition to being regulated by TCR stimulation and cytokines, preliminary data indicate that prdm1 is autoregulated by Blimp1. This was ﬁrst discovered in epidermal keratinocytes, where a Blimp-1 deﬁciency results in elevated amounts of transcripts from the deleted allele relative to transcripts from the wild-type allele. In this same system, ChIP assays show that Blimp-1 directly binds the prdm1 gene (162a), thus indicating that lack of Blimp-1 results in increased transcription of Blimp-1 mRNA. Similarly, in vitro– stimulated CD4+ T cells from prdm1 CKO mice show an increase in Blimp-1 mRNA as detected by real-time PCR using primers for the region upstream of the deleted region (L. Cimmino & K. Calame, unpublished). CD4+ CD25+ T cells from prdm1gfp/gfp mice also seem to have increased amounts of prdm1 mRNA, as demonstrated by semiquantitative RT-PCR (35). The physiological relevance of Blimp-1 autoregulation in T lymphocytes still remains to be addressed, but given the general action of Blimp-1 in attenuating T cell responses, it might be that autoregulation was selected to avoid inappropriate termination of immune responses. In this context, it would be interesting to learn if Blimp-1 autoregulation only occurs when Blimp-1 is expressed in very high levels or, in other words, if prdm1 itself is among the set of Blimp-1 targets that are susceptible to regulation only when Blimp-1 is available at very high levels.

OVERVIEW Interestingly, although mice lacking Blimp1 in their B cells are deﬁcient in antibodies, they survive well in pathogen-free conditions. In contrast, mice lacking Blimp-1 in T cells die of inﬂammatory disease within a few months. In B cells, Blimp-1 is clearly required and sufﬁcient for terminal differentiation of plasma cells. In T cells, its roles www.annualreviews.org • Blimp-1 in T and B Lymphocytes

157

ARI

24 February 2008

Annu. Rev. Immunol. 2008.26:133-169. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-05

158

9:40

appear more complicated, probably reﬂecting the more complicated pathways of activation, effector and memory differentiation, and homeostatic maintenance in this lineage. Whereas a common role for Blimp-1 in both lineages may involve terminally differentiated functions, the apparent roles of Blimp-1 in memory T cells and in attenuating responses to activation appear to be unique and not found in the B lineage. While it is too early to understand fully how the molecular mechanisms of Blimp-1 action and regulation may differ in T and B cells, there appear to be interesting commonalities between the two lineages.

ﬁne-tuning of these regulatory networks. A ﬁnal common theme is that Blimp-1 is often involved in feedback loops. In both B and T cells, Blimp-1 represses bcl6, and Bcl-6 represses prdm1. Such mutual repression loops can help establish mutually exclusive states—a GC B cell versus a plasma cell in the B lineage and Th1 versus Th2 in the CD4+ T cell lineage. A different feedback loop is present in naive T cells where activation induces IL-2 (Figure 6), IL-2 in turn induces Blimp-1, and Blimp-1 then represses il2 itself as well as fos, and Fos is a mediator of activation. In this setting, Blimp-1 is apparently important in the attenuation of the immune response.

Common Themes

Remaining Questions

In spite of apparently serving quite different regulatory roles in the life of B and T lymphocytes, there are some aspects of Blimp-1-dependent regulation that are strikingly similar. First, the majority (8 of the 10) identiﬁed direct targets of Blimp-1 repression (Table 1) are themselves transcriptional regulators with their own, often extensive and important, sets of gene targets. Thus, Blimp-1 acts early in speciﬁc transcriptional regulatory cascades. For example, direct target Pax5 both activates genes required for B cell commitment (163) and function (164) and represses genes expressed in other hematopoietic lineages and genes expressed in plasma cells (60). A second common theme is the redundancy in how Blimp-1 regulates some genes. For example, in B cells, myc is repressed by Blimp-1 both directly and indirectly by repression of an important activator, E2F (50). AID mRNA is repressed indirectly by Blimp-1-dependent repression of two activators, Pax5 and E2A (50). In T cells, Blimp-1 represses il2 directly and indirectly by repressing an activator of IL2 transcription, fos. Tbet is repressed both directly and indirectly by repression of its strong inducer, IFN-γ. It seems reasonable to suggest that this redundancy reﬂects the importance of repressing given target genes and/or provides the possibility for multiple ways of

Important and interesting questions remain to be answered regarding Blimp-1’s role in lymphocytes in both a short-term and a longterm sense. In the short-term, a complete understanding of Blimp-1’s roles in various T cell subsets and in lymphoid malignancies remains to be established. It will be of interest to identify additional direct and indirect targets to understand more fully the regulatory pathways dependent on Blimp-1, especially in Treg cells and CD8+ T cells, which have not yet been studied in detail. Many groups are currently identifying various signals and transcriptional mechanisms that regulate Blimp-1, and given the importance of Blimp-1 action, understanding its regulation is a key issue. The functional importance of alternate promoter usage to generate the beta form needs further study, as does the possibility that Blimp-1 mRNA or protein may be regulated posttranscriptionally by degradation, covalent modiﬁcation or other mechanisms. The mechanism of action of Blimp-1 requires more study to identify corepressors that are required for its activity. Structural determination of a repressorcorepressor complex would provide molecular information that might aid in designing small-molecule inhibitors of Blimp-1. The possibility of competition between Blimp-1

Martins

·

Calame

Annu. Rev. Immunol. 2008.26:133-169. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-05

ARI

24 February 2008

9:40

and IRF1 or IRF2 also deserves additional study. Finally, it is intriguing to speculate that, although Blimp-1 appears normal in some forms of common variable immune deﬁciency (CVID) (165), there could be mutations in prdm1 in other forms of CVID. In a long-term sense, as more information is obtained on the role, regulation, and mechanism of action of Blimp-1 in both normal and abnormal or malignant lymphocytes, it can be compared with the growing understanding of the roles of Blimp-1 in early embryogenesis in many species including Drosophila

(166), Xenopus (167), Zebraﬁsh (168–172), Fugu (173), and mouse (22, 36, 174) as well as with results of studies showing roles for Blimp-1 in other adult murine cell lineages such as sebocytes (175) and epidermal keratinocytes (162a). Hopefully, when more data are available, such comparisons will reveal information about how transcriptional regulatory pathways involving Blimp-1 have evolved and may provide insight into the currently unanswered question of why this single transcription factor plays such important and varied roles in multiple cell lineages.

DISCLOSURE STATEMENT The authors are not aware of any biases that might be perceived as affecting the objectivity of this review.

ACKNOWLEDGMENTS We are grateful to members of the Calame laboratory and many colleagues for helpful discussions. This work was supported by RO1AI 50569 and RO1AI43576 to K.C.

LITERATURE CITED 1. Rousseau-Merck MF, Koczan D, Legrand I, Moller S, Autran S, Thiesen HJ. 2002. The KOX zinc ﬁnger genes: genome wide mapping of 368 ZNF PAC clones with zinc ﬁnger gene clusters predominantly in 23 chromosomal loci are conﬁrmed by human sequences annotated in EnsEMBL. Cytogenet. Genome Res. 98:147–53 2. Kallies A, Nutt SL. 2007. Terminal differentiation of lymphocytes depends on Blimp-1. Curr. Opin. Immunol. 19:156–62 3. Shaffer AL, Wright G, Yang L, Powell J, Ngo V, et al. 2006. A library of gene expression signatures to illuminate normal and pathological lymphoid biology. Immunol. Rev. 210:67–85 4. Sciammas R, Davis MM. 2005. Blimp-1; immunoglobulin secretion and the switch to plasma cells. Curr. Top. Microbiol. Immunol. 290:201–24 5. Johnson K, Shapiro-Shelef M, Tunyaplin C, Calame K. 2005. Regulatory events in early and late B-cell differentiation. Mol. Immunol. 42:749–61 6. Shapiro-Shelef M, Calame K. 2005. Regulation of plasma cell development. Nat. Rev. Immunol. 5:230–42 7. Calame K. 2006. Transcription factors that regulate memory in humoral responses. Immunol. Rev. 211:269–79 8. Keller AD, Maniatis T. 1991. Identiﬁcation and characterization of a novel repressor of beta-interferon gene expression. Genes Dev. 5:868–79 9. Turner CA Jr, Mack DH, Davis MM. 1994. Blimp-1, a novel zinc finger-containing protein that can drive the maturation of B lymphocytes into immunoglobulinsecreting cells. Cell 77:297–306 www.annualreviews.org • Blimp-1 in T and B Lymphocytes

9. Describes cloning of murine Blimp-1 cDNA. Shows that forced expression of Blimp-1 is sufficient to drive BCL1 lymphoma cells to secrete Ig.

159

ARI

24 February 2008

9:40

10. Huang S. 1994. Blimp-1 is the murine homolog of the human transcriptional repressor PRDI-BF1. Cell 78:9 11. Tunyaplin C, Shapiro MA, Calame KL. 2000. Characterization of the B lymphocyteinduced maturation protein-1 (Blimp-1) gene, mRNA isoforms and basal promoter. Nucleic Acids Res. 28:4846–55 12. Mock BA, Liu L, LePaslier D, Huang S. 1996. The B-lymphocyte maturation promoting transcription factor BLIMP1/PRDI-BF1 maps to D6S447 on human chromosome 6q21-q22.1 and the syntenic region of mouse chromosome 10. Genomics 37:24– 28 13. Keller AD, Maniatis T. 1992. Only two of the ﬁve zinc ﬁngers of the eukaryotic transcriptional repressor PRDI-BF1 are required for sequence-speciﬁc DNA binding. Mol. Cell. Biol. 12:1940–49 14. Kuo TC, Calame KL. 2004. B lymphocyte-induced maturation protein (Blimp)-1, IFN regulatory factor (IRF)-1, and IRF-2 can bind to the same regulatory sites. J. Immunol. 173:5556–63 15. Canote R, Du Y, Carling T, Tian F, Peng Z, Huang S. 2002. The tumor suppressor gene RIZ in cancer gene therapy (review). Oncol. Rep. 9:57–60 16. Huang S, Shao G, Liu L. 1998. The PR domain of the Rb-binding zinc ﬁnger protein RIZ1 is a protein binding interface and is related to the SET domain functioning in chromatin-mediated gene expression. J. Biol. Chem. 273:15933–39 17. Ren B, Chee KJ, Kim TH, Maniatis T. 1999. PRDI-BF1/Blimp-1 repression is mediated by corepressors of the Groucho family of proteins. Genes Dev. 13:125– 37 18. Yu J, Angelin-Duclos C, Greenwood J, Liao J, Calame K. 2000. Transcriptional repression by Blimp-1 (PRDI-BF1) involves recruitment of histone deacetylase. Mol. Cell. Biol. 20:2592–603 19. Dillon SC, Zhang X, Trievel RC, Cheng X. 2005. The SET-domain protein superfamily: protein lysine methyltransferases. Genome Biol. 6:227 20. Derunes C, Briknarova K, Geng L, Li S, Gessner CR, et al. 2005. Characterization of the PR domain of RIZ1 histone methyltransferase. Biochem. Biophys. Res. Commun. 333:925–34 21. Gyory I, Wu J, Fejer G, Seto E, Wright KL. 2004. PRDI-BF1 recruits the histone H3 methyltransferase G9a in transcriptional silencing. Nat. Immunol. 5:299– 308 22. Ancelin K, Lange UC, Hajkova P, Schneider R, Bannister AJ, et al. 2006. Blimp1 associates with Prmt5 and directs histone arginine methylation in mouse germ cells. Nat. Cell Biol. 8:623–30 23. Angelin-Duclos C, Cattoretti G, Lin KI, Calame K. 2000. Commitment of B lymphocytes to a plasma cell fate is associated with Blimp-1 expression in vivo. J. Immunol. 165:5462–71 24. Kallies A, Hasbold J, Tarlinton DM, Dietrich W, Corcoran LM, et al. 2004. Plasma cell ontogeny deﬁned by quantitative changes in Blimp-1 expression. J. Exp. Med. 200:967– 77 25. Gonzalez-Garcia I, Ocana E, Jimenez-Gomez G, Campos-Caro A, Brieva JA. 2006. Immunization-induced perturbation of human blood plasma cell pool: progressive maturation, IL-6 responsiveness, and high PRDI-BF1/BLIMP1 expression are critical distinctions between antigen-speciﬁc and nonspeciﬁc plasma cells. J. Immunol. 176:4042– 50

Annu. Rev. Immunol. 2008.26:133-169. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-05

160

Martins

·

Calame

Annu. Rev. Immunol. 2008.26:133-169. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-05

ARI

24 February 2008

9:40

26. Blink EJ, Light A, Kallies A, Nutt SL, Hodgkin PD, Tarlinton DM. 2005. Early appearance of germinal center-derived memory B cells and plasma cells in blood after primary immunization. J. Exp. Med. 201:545–54 27. Kuo TC, Shaffer AL, Haddad J Jr, Choi YS, Staudt LM, Calame K. 2007. Repression of BCL-6 is required for the formation of human memory B cells in vitro. J. Exp. Med. 204:819–30 28. Tumang JR, Frances R, Yeo SG, Rothstein TL. 2005. Spontaneously Ig-secreting B-1 cells violate the accepted paradigm for expression of differentiation-associated transcription factors. J. Immunol. 174:3173–77 29. Fairfax KA, Corcoran LM, Pridans C, Huntington ND, Kallies A, et al. 2007. Different kinetics of Blimp-1 induction in B cell subsets revealed by reporter gene. J. Immunol. 178:4104–11 30. Savitsky D, Calame K. 2006. B-1 B lymphocytes require Blimp-1 for immunoglobulin secretion. J. Exp. Med. 203:2305–14 31. Lampert IA, Van Noorden S, Wotherspoon AC. 2005. Centrocytoid plasma cells of the germinal center. Appl. Immunohistochem. Mol. Morphol. 13:124–31 32. Cattoretti G, Angelin-Duclos C, Shaknovich R, Zhou H, Wang D, Alobeid B. 2005. PRDM1/Blimp-1 is expressed in human B-lymphocytes committed to the plasma cell lineage. J. Pathol. 206:76–86 33. Cattoretti G, Shaknovich R, Smith PM, Jack HM, Murty VV, Alobeid B. 2006. Stages of germinal center transit are deﬁned by B cell transcription factor coexpression and relative abundance. J. Immunol. 177:6930–39 34. Shapiro-Shelef M, Lin KI, McHeyzer-Williams LJ, Liao J, McHeyzer-Williams MG, Calame K. 2003. Blimp-1 is required for the formation of immunoglobulin secreting plasma cells and preplasma memory B cells. Immunity 19:607– 20 35. Kallies A, Hawkins ED, Belz GT, Metcalf D, Hommel M, et al. 2006. Transcriptional repressor Blimp-1 is essential for T cell homeostasis and self-tolerance. Nat. Immunol. 7:466–74 36. Vincent SD, Dunn NR, Sciammas R, Shapiro-Shalef M, Davis MM, et al. 2005. The zinc ﬁnger transcriptional repressor Blimp1/Prdm1 is dispensable for early axis formation but is required for speciﬁcation of primordial germ cells in the mouse. Development 132:1315–25 37. Driver DJ, McHeyzer-Williams LJ, Cool M, Stetson DB, McHeyzer-Williams MG. 2001. Development and maintenance of a B220− memory B cell compartment. J. Immunol. 167:1393–405 38. Bell J, Gray D. 2003. Antigen-capturing cells can masquerade as memory B cells. J. Exp. Med. 197:1233–44 39. Shapiro-Shelef M, Lin KI, Savitsky D, Liao J, Calame K. 2005. Blimp-1 is required for maintenance of long-lived plasma cells in the bone marrow. J. Exp. Med. 202:1471– 76 40. Radbruch A, Muehlinghaus G, Luger EO, Inamine A, Smith KG, et al. 2006. Competence and competition: the challenge of becoming a long-lived plasma cell. Nat. Rev. Immunol. 6:741–50 41. Minges Wols HA, Underhill GH, Kansas GS, Witte PL. 2002. The role of bone marrowderived stromal cells in the maintenance of plasma cell longevity. J. Immunol. 169:4213– 21 42. O’Connor BP, Raman VS, Erickson LD, Cook WJ, Weaver LK, et al. 2004. BCMA is essential for the survival of long-lived bone marrow plasma cells. J. Exp. Med. 199:91–98 www.annualreviews.org • Blimp-1 in T and B Lymphocytes

34. Describes mice with B cells lacking prdm1 and shows that Blimp-1 is necessary for formation of plasma cells and for Ig secretion. 35. One of two independent studies that reported a nonredundant role for Blimp-1 in T cell homeostasis and function.

161

Annu. Rev. Immunol. 2008.26:133-169. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-05

ARI

24 February 2008

51. Identified myc as the first known target of Blimp-1dependent repression in B cells.

56. Showed that XBP-1 is required for plasma cell differentiation.

162

9:40

43. Slifka MK, Matloubian M, Ahmed R. 1995. Bone marrow is a major site of long-term antibody production after acute viral infection. J. Virol. 69:1895–902 44. Manz RA, Lohning M, Cassese G, Thiel A, Radbruch A. 1998. Survival of long-lived plasma cells is independent of antigen. Int. Immunol. 10:1703–11 45. Manz RA, Thiel A, Radbruch A. 1997. Lifetime of plasma cells in the bone marrow. Nature 388:133–34 46. Odendahl M, Mei H, Hoyer BF, Jacobi AM, Hansen A, et al. 2005. Generation of migratory antigen-speciﬁc plasma blasts and mobilization of resident plasma cells in a secondary immune response. Blood 105:1614–21 47. Schliephake DE, Schimpl A. 1996. Blimp-1 overcomes the block in IgM secretion in lipopolysaccharide/antimu F(ab’)2-costimulated B lymphocytes. Eur. J. Immunol. 26:268–71 48. Piskurich JF, Lin KI, Lin Y, Wang Y, Ting JP, Calame K. 2000. BLIMP-I mediates extinction of major histocompatibility class II transactivator expression in plasma cells. Nat. Immunol. 1:526–32 49. Messika EJ, Lu PS, Sung YJ, Yao T, Chi JT, et al. 1998. Differential effect of B lymphocyte-induced maturation protein (Blimp-1) expression on cell fate during B cell development. J. Exp. Med. 188:515–25 50. Shaffer AL, Lin KI, Kuo TC, Yu X, Hurt EM, et al. 2002. Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. Immunity 17:51–62 51. Lin Y, Wong K, Calame K. 1997. Repression of c-myc transcription by Blimp-1, an inducer of terminal B cell differentiation. Science 276:596–99 52. Lin KI, Lin Y, Calame K. 2000. Repression of c-myc is necessary but not sufﬁcient for terminal differentiation of B lymphocytes in vitro. Mol. Cell. Biol. 20:8684– 95 53. Lin KI, Angelin-Duclos C, Kuo TC, Calame K. 2002. Blimp-1-dependent repression of Pax-5 is required for differentiation of B cells to immunoglobulin M-secreting plasma cells. Mol. Cell. Biol. 22:4771–80 54. Ghosh N, Gyory I, Wright G, Wood J, Wright KL. 2001. Positive regulatory domain I binding factor 1 silences class II transactivator expression in multiple myeloma cells. J. Biol. Chem. 276:15264–68 55. Sciammas R, Davis MM. 2004. Modular nature of Blimp-1 in the regulation of gene expression during B cell maturation. J. Immunol. 172:5427–40 56. Reimold AM, Iwakoshi NN, Manis J, Vallabhajosyula P, Szomolanyi-Tsuda E, et al. 2001. Plasma cell differentiation requires the transcription factor XBP-1. Nature 412:300–7 57. Shaffer AL, Shapiro-Shelef M, Iwakoshi NN, Lee AH, Qian SB, et al. 2004. XBP1, downstream of Blimp-1, expands the secretory apparatus and other organelles, and increases protein synthesis in plasma cell differentiation. Immunity 21:81–93 58. Lin KI, Angelin-Duclos C, Kuo TC, Calame K. 2002. Blimp-1-dependent repression of Pax-5 is required for differentiation of B cells to immunoglobulin M-secreting plasma cells. Mol. Cell. Biol. 22:4771–80 59. Reimold AM, Ponath PD, Li YS, Hardy RR, David CS, et al. 1996. Transcription factor B cell lineage-speciﬁc activator protein regulates the gene for human X-box binding protein 1. J. Exp. Med. 183:393–401 60. Delogu A, Schebesta A, Sun Q, Aschenbrenner K, Perlot T, Busslinger M. 2006. Gene repression by Pax5 in B cells is essential for blood cell homeostasis and is reversed in plasma cells. Immunity 24:269–81 Martins

·

Calame

Annu. Rev. Immunol. 2008.26:133-169. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-05

ARI

24 February 2008

9:40

61. Nera KP, Kohonen P, Narvi E, Peippo A, Mustonen L, et al. 2006. Loss of Pax5 promotes plasma cell differentiation. Immunity 24:283–93 62. Gyory I, Fejer G, Ghosh N, Seto E, Wright KL. 2003. Identiﬁcation of a functionally impaired positive regulatory domain I binding factor 1 transcription repressor in myeloma cell lines. J. Immunol. 170:3125–33 63. Trinchieri G, Sher A. 2007. Cooperation of Toll-like receptor signals in innate immune defence. Nat. Rev. Immunol. 7:179–90 64. Lin KI, Kao YY, Kuo HK, Yang WB, Chou A, et al. 2006. Reishi polysaccharides induce immunoglobulin production through the TLR4/TLR2-mediated induction of transcription factor Blimp-1. J. Biol. Chem. 281:24111–23 65. Pasare C, Medzhitov R. 2005. Control of B-cell responses by Toll-like receptors. Nature 438:364–68 66. Yamamoto M, Sato S, Hemmi H, Hoshino K, Kaisho T, et al. 2003. Role of adaptor TRIF in the MyD88-independent Toll-like receptor signaling pathway. Science 301:640– 43 67. Gavin AL, Hoebe K, Duong B, Ota T, Martin C, et al. 2006. Adjuvant-enhanced antibody responses in the absence of Toll-like receptor signaling. Science 314:1936–38 68. Sen R. 2006. Control of B lymphocyte apoptosis by the transcription factor NF-κB. Immunity 25:871–83 69. Knodel M, Kuss AW, Berberich I, Schimpl A. 2001. Blimp-1 overexpression abrogates IL-4- and CD40-mediated suppression of terminal B cell differentiation but arrests isotype switching. Eur. J. Immunol. 31:1972–80 70. Ettinger R, Sims GP, Fairhurst AM, Robbins R, da Silva YS, et al. 2005. IL-21 induces differentiation of human naive and memory B cells into antibody-secreting plasma cells. J. Immunol. 175:7867–79 71. Doody GM, Stephenson S, Tooze RM. 2006. BLIMP-1 is a target of cellular stress and downstream of the unfolded protein response. Eur. J. Immunol. 36:1572–82 72. Takeda K, Kaisho T, Akira S. 2003. Toll-like receptors. Annu. Rev. Immunol. 21:335– 76 73. Tamura T, Kong HJ, Tunyaplin C, Tsujimura H, Calame K, Ozato K. 2003. ICSBP/IRF8 inhibits mitogenic activity of p210 Bcr/Abl in differentiating myeloid progenitor cells. Blood 102:4547–54 74. Gong D, Malek TR. 2007. Cytokine-dependent Blimp-1 expression in activated T cells inhibits IL-2 production. J. Immunol. 178:242–52 75. Chen-Kiang S. 1995. Regulation of terminal differentiation of human B-cells by IL-6. Curr. Top. Microbiol. Immunol. 194:189–98 76. Martins GA, Cimmino L, Shapiro-Shelef M, Szabolcs M, Herron A, et al. 2006. Transcriptional repressor Blimp-1 regulates T cell homeostasis and function. Nat. Immunol. 7:457–65 77. Ozaki K, Spolski R, Ettinger R, Kim HP, Wang G, et al. 2004. Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6. J. Immunol. 173:5361–71 78. Niu H, Ye BH, Dalla-Favera R. 1998. Antigen receptor signaling induces MAP kinasemediated phosphorylation and degradation of the BCL-6 transcription factor. Genes Dev. 12:1953–61 79. Rousset F, Garcia E, Defrance T, Peronne C, Vezzio N, et al. 1992. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc. Natl. Acad. Sci. USA 89:1890–93 www.annualreviews.org • Blimp-1 in T and B Lymphocytes

74. Shows that IL-2 induces prdm1 and shows that Blimp-1 downregulates IL-2 production upon T cell activation. 76. One of two independent studies that reported a nonredundant role for Blimp-1 in T cell homeostasis and function.

163

ARI

24 February 2008

9:40

80. Avery DT, Ellyard JI, Mackay F, Corcoran LM, Hodgkin PD, Tangye SG. 2005. Increased expression of CD27 on activated human memory B cells correlates with their commitment to the plasma cell lineage. J. Immunol. 174:4034–42 81. Choe J, Kim HS, Zhang X, Armitage RJ, Choi YS. 1996. Cellular and molecular factors that regulate the differentiation and apoptosis of germinal center B cells. Anti-Ig downregulates Fas expression of CD40 ligand-stimulated germinal center B cells and inhibits Fas-mediated apoptosis. J. Immunol. 157:1006–16 82. Choe J, Choi YS. 1998. IL-10 interrupts memory B cell expansion in the germinal center by inducing differentiation into plasma cells. Eur. J. Immunol. 28:508–15 83. Ozaki K, Spolski R, Feng CG, Qi CF, Cheng J, et al. 2002. A critical role for IL-21 in regulating immunoglobulin production. Science 298:1630–34 84. Leonard WJ, Spolski R. 2005. Interleukin-21: a modulator of lymphoid proliferation, apoptosis and differentiation. Nat. Rev. Immunol. 5:688–98 85. Reljic R, Wagner SD, Peakman LJ, Fearon DT. 2000. Suppression of signal transducer and activator of transcription 3-dependent B lymphocyte terminal differentiation by BCL-6. J. Exp. Med. 192:1841–48 86. de Groot RP, Coffer PJ, Koenderman L. 1998. Regulation of proliferation, differentiation and survival by the IL-3/IL-5/GM-CSF receptor family. Cell Signal. 10:619– 28 87. Horikawa K, Takatsu K. 2006. Interleukin-5 regulates genes involved in B-cell terminal maturation. Immunology 118:497–508 88. Moriggl R, Topham DJ, Teglund S, Sexl V, McKay C, et al. 1999. Stat5 is required for IL-2-induced cell cycle progression of peripheral T cells. Immunity 10:249– 59 89. Scheeren FA, Naspetti M, Diehl S, Schotte R, Nagasawa M, et al. 2005. STAT5 regulates the self-renewal capacity and differentiation of human memory B cells and controls Bcl-6 expression. Nat. Immunol. 6:303–13 90. Vasanwala FH, Kusam S, Toney LM, Dent AL. 2002. Repression of AP-1 function: a mechanism for the regulation of Blimp-1 expression and B lymphocyte differentiation by the B cell lymphoma-6 protooncogene. J. Immunol. 169:1922–29 91. Ohkubo Y, Arima M, Arguni E, Okada S, Yamashita K, et al. 2005. A role for cfos/activator protein 1 in B lymphocyte terminal differentiation. J. Immunol. 174:7703– 10 92. Mittrucker HW, Matsuyama T, Grossman A, Kundig TM, Potter J, et al. 1997. Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function. Science 275:540–43 93. Sciammas R, Shaffer AL, Schatz JH, Zhao H, Staudt LM, Singh H. 2006. Graded expression of interferon regulatory factor-4 coordinates isotype switching with plasma cell differentiation. Immunity 25:225–36 94. Klein U, Casola S, Cattoretti G, Shen Q, Lia M, et al. 2006. Transcription factor IRF4 controls plasma cell differentiation and class-switch recombination. Nat. Immunol. 7:773–82 95. Muto A, Tashiro S, Nakajima O, Hoshino H, Takahashi S, et al. 2004. The transcriptional programme of antibody class switching involves the repressor Bach2. Nature 429:566–71 96. Muto A, Hoshino H, Madisen L, Yanai N, Obinata M, et al. 1998. Identiﬁcation of Bach2 as a B-cell-speciﬁc partner for small maf proteins that negatively regulate the immunoglobulin heavy chain gene 3 enhancer. EMBO J. 17:5734–43

Annu. Rev. Immunol. 2008.26:133-169. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-05

164

Martins

·

Calame

Annu. Rev. Immunol. 2008.26:133-169. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-05

ARI

24 February 2008

9:40

97. Shaffer AL, Yu X, He Y, Boldrick J, Chan EP, Staudt LM. 2000. BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. Immunity 13:199–212 98. Zheng YJS, Kas A, Chu TT, Gavin MA, Rudensky AY. 2007. Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells. Nature 445:936–40 99. Winslow MM, Gallo EM, Neilson JR, Crabtree GR. 2006. The calcineurin phosphatase complex modulates immunogenic B cell responses. Immunity 24:141–52 100. Tunyaplin C, Shaffer AL, Angelin-Duclos CD, Yu X, Staudt LM, Calame KL. 2004. Direct repression of prdm1 by Bcl-6 inhibits plasmacytic differentiation. J. Immunol. 173:1158–65 101. Fujita N, Jaye DL, Geigerman C, Akyildiz A, Mooney MR, et al. 2004. MTA3 and the Mi-2/NuRD complex regulate cell fate during B lymphocyte differentiation. Cell 119:75–86 102. Omori SA, Cato MH, Anzelon-Mills A, Puri KD, Shapiro-Shelef M, et al. 2006. Regulation of class-switch recombination and plasma cell differentiation by phosphatidylinositol 3-kinase signaling. Immunity 25:545–57 102a. Mora-Lopez F, Reales E, Brieva JA, Campos-Caro A. 2007. Human B SAP and BLIMP1 conform an autoregulatory loop. Blood. In press 103. Ochiai K, Katoh Y, Ikura T, Hoshikawa Y, Noda T, et al. 2006. Plasmacytic transcription factor Blimp-1 is repressed by Bach2 in B cells. J. Biol. Chem. 281:38226–34 104. Cattoretti G, Chang CC, Cechova K, Zhang J, Ye BH, et al. 1995. BCL-6 protein is expressed in germinal-center B cells. Blood 86:45–53 105. Onizuka T, Moriyama M, Yamochi T, Kuroda T, Kazama A, et al. 1995. BCL-6 gene product, a 92- to 98-kD nuclear phosphoprotein, is highly expressed in germinal center B cells and their neoplastic counterparts. Blood 86:28–37 106. Lin L, Gerth AJ, Peng SL. 2004. Active inhibition of plasma cell development in resting B cells by microphthalmia-associated transcription factor. J. Exp. Med. 200:115– 22 107. O’Neill LA, Bowie AG. 2007. The family of ﬁve: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat. Rev. Immunol. 7:353–64 108. Paus D, Phan TG, Chan TD, Gardam S, Basten A, Brink R. 2006. Antigen recognition strength regulates the choice between extrafollicular plasma cell and germinal center B cell differentiation. J. Exp. Med. 203:1081–91 109. Phan TG, Paus D, Chan TD, Turner ML, Nutt SL, et al. 2006. High afﬁnity germinal center B cells are actively selected into the plasma cell compartment. J. Exp. Med. 203:2419–24 110. Kallies A, Hasbold J, Fairfax K, Pridans C, Emslie D, et al. 2007. Initiation of plasmacell differentiation is independent of the transcription factor Blimp-1. Immunity 26:555– 66 111. Bereshchenko OR, Gu W, Dalla-Favera R. 2002. Acetylation inactivates the transcriptional repressor BCL6. Nat. Genet. 32:606–13 112. Lee SC, Bottaro A, Chen L, Insel RA. 2006. Mad1 is a transcriptional repressor of Bcl-6. Mol. Immunol. 43:1965–71 113. Fernandez de Mattos S, Essaﬁ A, Soeiro I, Pietersen AM, Birkenkamp KU, et al. 2004. FoxO3a and BCR-ABL regulate cyclin D2 transcription through a STAT5/BCL6dependent mechanism. Mol. Cell. Biol. 24:10058–71 114. Okkenhaug K, Ali K, Vanhaesebroeck B. 2007. Antigen receptor signalling: a distinctive role for the p110delta isoform of PI3K. Trends Immunol. 28:80–87 www.annualreviews.org • Blimp-1 in T and B Lymphocytes

97. This paper used microarray analyses to identify direct targets of Bcl-6 and was the first to show that Bcl-6 directly represses prdm1.

165

Annu. Rev. Immunol. 2008.26:133-169. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-05

ARI

24 February 2008

125. The most complete study showing that PRDM1 is inactivated in one subset of DLBCL, implying a role for Blimp-1 as a tumor suppressor.

166

9:40

115. Corcoran LM, Hasbold J, Dietrich W, Hawkins E, Kallies A, et al. 2005. Differential requirement for OBF-1 during antibody-secreting cell differentiation. J. Exp. Med. 201:1385–96 116. Stephenson LM, Miletic AV, Kloeppel T, Kusin S, Swat W. 2006. Vav proteins regulate the plasma cell program and secretory Ig production. J. Immunol. 177:8620– 25 117. Kearney JF, Cooper MD, Lawton AR. 1976. B lymphocyte differentiation induced by lipopolysaccharide. III. Suppression of B cell maturation by antimouse immunoglobulin antibodies. J. Immunol. 116:1664–68 118. de Gorter DJ, Vos JC, Pals ST, Spaargaren M. 2007. The B cell antigen receptor controls AP-1 and NFAT activity through Ras-mediated activation of Ral. J. Immunol. 178:1405–14 119. Rui L, Vinuesa CG, Blasioli J, Goodnow CC. 2003. Resistance to CpG DNA-induced autoimmunity through tolerogenic B cell antigen receptor ERK signaling. Nat. Immunol. 4:594–600 120. Rui L, Healy JI, Blasioli J, Goodnow CC. 2006. ERK signaling is a molecular switch integrating opposing inputs from B cell receptor and T cell cytokines to control TLR4driven plasma cell differentiation. J. Immunol. 177:5337–46 121. Vinuesa CG, Sunners Y, Pongracz J, Ball J, Toellner KM, et al. 2001. Tracking the response of Xid B cells in vivo: TI-2 antigen induces migration and proliferation but Btk is essential for terminal differentiation. Eur. J. Immunol. 31:1340– 50 122. Hoffman B, Amanullah A, Shafarenko M, Liebermann DA. 2002. The protooncogene c-myc in hematopoietic development and leukemogenesis. Oncogene 21:3414– 21 123. Tam W, Gomez M, Chadburn A, Lee JW, Chan WC, Knowles DM. 2006. Mutational analysis of PRDM1 indicates a tumor-suppressor role in diffuse large B-cell lymphomas. Blood 107:4090–100 124. Tate G, Hirayama-Ohashi Y, Kishimoto K, Mitsuya T. 2007. Novel BLIMP1/PRDM1 gene mutations in B-cell lymphoma. Cancer Genet. Cytogenet. 172:151–53 125. Pasqualucci L, Compagno M, Houldsworth J, Monti S, Grunn A, et al. 2006. Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma. J. Exp. Med. 203:311–17 126. Yoo NJ, Jeong EG, Lee SH, Lee SH. 2007. Absence of PRDM1 exon 2 mutation in acute leukemia. Eur. J. Haematol. 78:171–72 127. Garcia JF, Roncador G, Garcia JF, Sanz AI, Maestre L, et al. 2006. PRDM1/BLIMP-1 expression in multiple B and T-cell lymphoma. Haematologica 91:467–74 128. Buettner M, Greiner A, Avramidou A, Jack HM, Niedobitek G. 2005. Evidence of abortive plasma cell differentiation in Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphoma. Hematol. Oncol. 23:127–32 129. Zhou X, Jiang H, Hou J. 2007. Coordination of upregulated XBP-1 and downregulated c-myc during myeloma cell differentiation induced by 2-methoxyestradiol. Leuk. Res. 31:1267–73 130. Ocana E, Gonzalez-Garcia I, Gutierrez NC, Mora-Lopez F, Brieva JA, Campos-Caro A. 2006. The expression of PRDI-BF1 beta isoform in multiple myeloma plasma cells. Haematologica 91:1579–80 131. Lee AH, Iwakoshi NN, Anderson KC, Glimcher LH. 2003. Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc. Natl. Acad. Sci. USA 100:9946– 51 Martins

·

Calame

Annu. Rev. Immunol. 2008.26:133-169. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-05

ARI

24 February 2008

9:40

132. Santner-Nanan BB-SF, Xiao Z, Poser N, Sennefelder H, Rauthe S, et al. 2006. Blimp-1 is expressed in human and mouse T cell subsets and leads to loss of IL-2 production and to defective proliferation. Signal Transduct. 6:268–79 133. Tabrizifard SOA, Plotkin J, Fallahi-Sichani M, Livak F, Petrie HT. 2004. Analysis of transcription factor expression during discrete stages of postnatal thymocyte differentiation. J. Immunol. 173:1094–102 134. Okazaki T, Honjo T. 2006. The PD-1-PD-L pathway in immunological tolerance. Trends Immunol. 27:195–201 135. Blumberg RSSL, Strober W. 1999. Animal models of mucosal inﬂammation and their relation to human inﬂammatory bowel disease. Curr. Opin. Immunol. 11:648–56 136. Bouma GSW. 2003. The immunological and genetic basis of inﬂammatory bowel disease. Nat. Rev. Immunol. 3:521–33 137. Asseman C, Read S, Powrie F. 2003. Colitogenic Th1 cells are present in the antigenexperienced T cell pool in normal mice: control by CD4+ regulatory T cells and IL-10. J. Immunol. 171:971–78 138. Walker LS, Abbas AK. 2002. The enemy within: keeping self-reactive T cells at bay in the periphery. Nat. Rev. Immunol. 2:11–19 139. Mathis DBC. 2004. Back to central tolerance. Immunity 20:509–16 140. Haks MCBS, Ciofani M, Rhodes M, Lefebvre JM, Trop S, et al. 2003. Low activation threshold as a mechanism for ligand-independent signaling in pre-T cells. J Immunol. 170:2853–61 141. Depper JM, Leonard WJ, Robb RJ, Waldmann TA, Greene WC. 1983. Blockade of the interleukin-2 receptor by anti-Tac antibody: inhibition of human lymphocyte activation. J. Immunol. 131:690–96 142. Malek TR, Bayer AL. 2004. Tolerance, not immunity, crucially depends on IL-2. Nat. Rev. Immunol. 4:665–74 143. Feh´ervari ZYT, Sakaguchi S. 2006. The dichotomous role of IL-2: tolerance vs immunity. Trends Immunol. 27:109–11 144. Villarino AV, Tato CM, Stumhofer JS, Yao Z, Cui YK, et al. 2007. Helper T cell IL2 production is limited by negative feedback and STAT-dependent cytokine signals. J. Exp. Med. 204:65–71 145. Kusam STL, Sato H, Dent AL. 2003. Inhibition of Th2 differentiation and GATA-3 expression by BCL-6. J. Immunol. 170:2435–41 146. Ansel KMLD, Rao A. 2003. An epigenetic view of helper T cell differentiation. Nat. Immunol. 4:616–23 147. Arima MTH, Ichii H, Kojima S, Okada S, Hatano M, et al. 2002. A putative silencer element in the IL-5 gene recognized by Bcl6. J. Immunol. 169:829–36 148. Ichii HSA, Hatano M, Okada S, Toyama H, Taki S, et al. 2002. Role for Bcl-6 in the generation and maintenance of memory CD8+ T cells. Nat. Immunol. 6:558–63 149. Ichii HSA, Kuroda Y, Tokuhisa T. 2004. Bcl6 acts as an ampliﬁer for the generation and proliferative capacity of central memory CD8+ T cells. J. Immunol. 173:883–91 150. Ramakers JDVM, Thuijls G, Te Velde AA, Mensink RP, Plat J. 2007. The PPARgamma agonist rosiglitazone impairs colonic inﬂammation in mice with experimental colitis. J. Clin. Immunol. 3:275–83 151. Smith PMN, Walsh CM, Fallon RE, McKenzie AN, van Rooijen N, Fallon PG. 2007. Infection with a helminth parasite prevents experimental colitis via a macrophagemediated mechanism. J. Immunol. 178:4557–66 152. Maci´an FL-RC, Rao A. 2001. Partners in transcription: NFAT and AP-1. Oncogene 20:2476–89 www.annualreviews.org • Blimp-1 in T and B Lymphocytes

167

ARI

24 February 2008

9:40

153. Shaulian E, Karin M. 2002. AP-1 as a regulator of cell life and death. Nat. Cell Biol. 4:E131–36 154. Marsden VSSA. 2003. Control of apoptosis in the immune system: Bcl-2, BH3-only proteins and more. Annu. Rev. Immunol. 21:71–105 155. Knodel M, Kuss AW, Lindemann D, Berberich I, Schimpl A. 1999. Reversal of Blimp1-mediated apoptosis by A1, a member of the Bcl-2 family. Eur. J. Immunol. 29:2988–98 156. Tomayko MMPJ, Bolcavage JM, Levy SL, Allman DM, Cancro MP. 1999. Expression of the Bcl-2 family member A1 is developmentally regulated in T cells. Int. Immunol. 11:1753–61 157. Gonzalez JOA, Prystowsky MB. 2003. A1 is a growth-permissive antiapoptotic factor mediating postactivation survival in T cells. Blood 101:2679–85 158. Fontenot JDRJ, Gavin MA, Rudensky AY. 2005. A function for interleukin 2 in Foxp3expressing regulatory T cells. Nat. Immunol. 6:1142–51 159. Zheng Y, Josefowicz SZ, Kas A, Chu TT, Gavin MA, Rudensky AY. 2007. Genomewide analysis of Foxp3 target genes in developing and mature regulatory T cells. Nature 445:936–40 160. Wu Y, Borde M, Heissmeyer V, Feuerer M, Lapan AD, et al. 2006. FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell 126:375–87 160a. Spolski R, Leonard WJ. 2008. Interleukin-21: basic biology and implications for cancer and autoimmunity. Annu. Rev. Immunology 26:57–79 161. Peluso IFM, Fina D, Caruso R, Boirivant M, MacDonald TT, et al. 2007. IL-21 counteracts the regulatory T cell-mediated suppression of human CD4+ T lymphocytes. J. Immunol. 178:732–39 162. Korn TBE, Gao W, Awasthi A, J¨ager A, Strom TB, et al. 2007. IL-21 initiates an alternative pathway to induce proinﬂammatory T(H)17 cells. Nature 448:484–87 162a. Magnusdottir E, Kalachikov S, Mizukoshi K, Savitsky D, Ishida-Yamamoto A, et al. 2007. Epidermal terminal differentiation depends on B lymphocyte induced maturation protein 1. Proc. Natl. Acad. Sci. USA 104:14988–93 163. Nutt SL, Heavey B, Rolink AG, Busslinger M. 1999. Commitment to the B-lymphoid lineage depends on the transcription factor Pax5. Nature 401:556–62 164. Horcher M, Souabni A, Busslinger M. 2001. Pax5/BSAP maintains the identity of B cells in late B lymphopoiesis. Immunity 14:779–90 165. Taubenheim N, von Hornung M, Durandy A, Warnatz K, Corcoran L, et al. 2005. Deﬁned blocks in terminal plasma cell differentiation of common variable immunodeﬁciency patients. J. Immunol. 175:5498–503 166. Ng T, Yu F, Roy S. 2006. A homologue of the vertebrate SET domain and zinc ﬁnger protein Blimp-1 regulates terminal differentiation of the tracheal system in the Drosophila embryo. Dev. Genes Evol. 216:243–52 167. de Souza FS, Gawantka V, Gomez AP, Delius H, Ang SL, Niehrs C. 1999. The zinc ﬁnger gene Xblimp1 controls anterior endomesodermal cell fate in Spemann’s organizer. EMBO J. 18:6062–72 168. Wilm TP, Solnica-Krezel L. 2005. Essential roles of a zebraﬁsh prdm1/blimp1 homolog in embryo patterning and organogenesis. Development 132:393–404 169. Lee BC, Roy S. 2006. Blimp-1 is an essential component of the genetic program controlling development of the pectoral limb bud. Dev. Biol. 300:623–34 170. Mercader N, Fischer S, Neumann CJ. 2006. Prdm1 acts downstream of a sequential RA, Wnt and Fgf signaling cascade during zebraﬁsh forelimb induction. Development 133:2805–15

Annu. Rev. Immunol. 2008.26:133-169. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-05

168

Martins

·

Calame

ANRV338-IY26-05

ARI

24 February 2008

9:40

Annu. Rev. Immunol. 2008.26:133-169. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

171. Baxendale S, Davison C, Muxworthy C, Wolff C, Ingham PW, Roy S. 2004. The Bcell maturation factor Blimp-1 speciﬁes vertebrate slow-twitch muscle ﬁber identity in response to Hedgehog signaling. Nat. Genet. 36:88–93 172. Roy S, Ng T. 2004. Blimp-1 speciﬁes neural crest and sensory neuron progenitors in the zebraﬁsh embryo. Curr. Biol. 14:1772–77 173. Ohtani M, Miyadai T, Hiroishi S. 2006. B-lymphocyte-induced maturation protein-1 (Blimp-1) gene of torafugu (Takifugu rubripes). Fish Shellﬁsh Immunol. 20:409–13 174. Ohinata Y, Payer B, O’Carroll D, Ancelin K, Ono Y, et al. 2005. Blimp1 is a critical determinant of the germ cell lineage in mice. Nature 436:207–13 175. Horsley V, O’Carroll D, Tooze R, Ohinata Y, Saitou M, et al. 2006. Blimp1 deﬁnes a progenitor population that governs cellular input to the sebaceous gland. Cell 126:597– 609

www.annualreviews.org • Blimp-1 in T and B Lymphocytes

169

AR338-FM

ARI

12 January 2008

18:11

Annual Review of Immunology

Annu. Rev. Immunol. 2008.26:133-169. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

Contents

Volume 26, 2008

Frontispiece K. Frank Austen p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p x Doing What I Like K. Frank Austen p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p1 Protein Tyrosine Phosphatases in Autoimmunity Torkel Vang, Ana V. Miletic, Yutaka Arimura, Lutz Tautz, Robert C. Rickert, and Tomas Mustelin p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p 29 Interleukin-21: Basic Biology and Implications for Cancer and Autoimmunity Rosanne Spolski and Warren J. Leonard p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p 57 Forward Genetic Dissection of Immunity to Infection in the Mouse S.M. Vidal, D. Malo, J.-F. Marquis, and P. Gros p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p 81 Regulation and Functions of Blimp-1 in T and B Lymphocytes Gislâine Martins and Kathryn Calame p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p133 Evolutionarily Conserved Amino Acids That Control TCR-MHC Interaction Philippa Marrack, James P. Scott-Browne, Shaodong Dai, Laurent Gapin, and John W. Kappler p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p171 T Cell Trafﬁcking in Allergic Asthma: The Ins and Outs Benjamin D. Medoff, Seddon Y. Thomas, and Andrew D. Luster p p p p p p p p p p p p p p p p p p p p p205 The Actin Cytoskeleton in T Cell Activation Janis K. Burkhardt, Esteban Carrizosa, and Meredith H. Shaffer p p p p p p p p p p p p p p p p p p p p233 Mechanism and Regulation of Class Switch Recombination Janet Stavnezer, Jeroen E.J. Guikema, and Carol E. Schrader p p p p p p p p p p p p p p p p p p p p p p p261 Migration of Dendritic Cell Subsets and their Precursors Gwendalyn J. Randolph, Jordi Ochando, and Santiago Partida-Sánchez p p p p p p p p p p p p p293

v

AR338-FM

ARI

12 January 2008

18:11

The APOBEC3 Cytidine Deaminases: An Innate Defensive Network Opposing Exogenous Retroviruses and Endogenous Retroelements Ya-Lin Chiu and Warner C. Greene p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p317 Thymus Organogenesis Hans-Reimer Rodewald p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p355 Death by a Thousand Cuts: Granzyme Pathways of Programmed Cell Death Dipanjan Chowdhury and Judy Lieberman p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p389 Annu. Rev. Immunol. 2008.26:133-169. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

Monocyte-Mediated Defense Against Microbial Pathogens Natalya V. Serbina, Ting Jia, Tobias M. Hohl, and Eric G. Pamer p p p p p p p p p p p p p p p p p p p421 The Biology of Interleukin-2 Thomas R. Malek p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p453 The Biochemistry of Somatic Hypermutation Jonathan U. Peled, Fei Li Kuang, Maria D. Iglesias-Ussel, Sergio Roa, Susan L. Kalis, Myron F. Goodman, and Matthew D. Scharff p p p p p p p p p p p p p p p p p p p p p481 Anti-Inﬂammatory Actions of Intravenous Immunoglobulin Falk Nimmerjahn and Jeffrey V. Ravetch p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p513 The IRF Family Transcription Factors in Immunity and Oncogenesis Tomohiko Tamura, Hideyuki Yanai, David Savitsky, and Tadatsugu Taniguchi p p p p p535 Choreography of Cell Motility and Interaction Dynamics Imaged by Two-Photon Microscopy in Lymphoid Organs Michael D. Cahalan and Ian Parker p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p585 Development of Secondary Lymphoid Organs Troy D. Randall, Damian M. Carragher, and Javier Rangel-Moreno p p p p p p p p p p p p p p p p627 Immunity to Citrullinated Proteins in Rheumatoid Arthritis Lars Klareskog, Johan Rönnelid, Karin Lundberg, Leonid Padyukov, and Lars Alfredsson p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p651 PD-1 and Its Ligands in Tolerance and Immunity Mary E. Keir, Manish J. Butte, Gordon J. Freeman, and Arlene H. Sharpe p p p p p p p p677 The Master Switch: The Role of Mast Cells in Autoimmunity and Tolerance Blayne A. Sayed, Alison Christy, Mary R. Quirion, and Melissa A. Brown p p p p p p p p p p705 T Follicular Helper (TFH ) Cells in Normal and Dysregulated Immune Responses Cecile King, Stuart G. Tangye, and Charles R. Mackay p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p741

vi

Contents

Annu. Rev. Immunol. 2008.26:171-203. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-06

ARI

26 February 2008

20:33

Evolutionarily Conserved Amino Acids That Control TCR-MHC Interaction Philippa Marrack,1,2,3,4 James P. Scott-Browne,2 Shaodong Dai,1,2 Laurent Gapin,2 and John W. Kappler1,2,4,5,6 1

Howard Hughes Medical Institute, 2 Integrated Department of Immunology, National Jewish Medical and Research Center, 3 Department of Biochemistry and Molecular Genetics, 4 Department of Medicine, 5 Department of Pharmacology, and 6 Program in Biomolecular Structure, University of Colorado Denver Health Science Center, Denver, Colorado 80206; email: [email protected], [email protected], [email protected], [email protected], [email protected]

Annu. Rev. Immunol. 2008. 26:171–203

Key Words

First published online as a Review in Advance on January 22, 2008

T cell receptor, major histocompatibility complex, evolution, conserved interactions, tolerance, selection

The Annual Review of Immunology is online at immunol.annualreviews.org This article’s doi: 10.1146/annurev.immunol.26.021607.090421 c 2008 by Annual Reviews. Copyright All rights reserved 0732-0582/08/0423-0171$20.00

Abstract The rules for the conserved reaction of αβ T cell receptors (TCRs) with major histocompatibility complex (MHC) proteins plus peptides are poorly understood, probably because thymocytes bearing TCRs with the strongest MHC reactivity are lost by negative selection. Thus, only TCRs with an attenuated ability to react with MHC appear on mature T cells. Also, the interaction sites between TCRs and MHC may be inherently ﬂexible and hence difﬁcult to spot. We reevaluated contacts between TCRs and MHC in the solved structures of their complexes with these points in mind. Relatively conserved amino acids in the TCR complementarity-determining regions (CDR) 1 and CDR2 are often used to bind exposed areas of the MHC α-helices. These areas are exposed because of small amino acids that allow somewhat ﬂexible binding of the TCRs. The TCR amino acids involved are speciﬁc to families of variable (V) regions and to some extent different rules may govern the recognition of MHCI versus MHCII.

171

ANRV338-IY26-06

ARI

26 February 2008

20:33

HISTORICAL INTRODUCTION MHC: major histocompatibility complex

Annu. Rev. Immunol. 2008.26:171-203. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

TCR: αβ T cell receptor

172

Almost 50 years have elapsed since the discovery that the thymus is involved with immune responses. Shortly thereafter, cells derived from the thymus were found to improve the ability of B cells to make antibodies. This ﬁnding was followed by the discovery of the carrier effect, the observation that the antibody response to haptens requires simultaneous recognition of both the hapten and epitopes on the attached protein carrier. These ﬁndings dovetailed unexpectedly well to give rise to the idea that T cells created in the thymus react with one portion of the antigen and then help B cells produce antibody against a different determinant on the same molecule (1–4). This satisfying explanation for cell cooperation in immune responses left one key problem unresolved for immunologists: the major histocompatibility complex (MHC). Researchers studying the rejection of grafts and tumors (5, 6) recognized that the MHC represents a special case for immune responses. They found that differences at the MHC were recognized by the immune system extraordinarily rapidly. This phenomenon led Niels Jerne (7) to propose that lymphocyte receptors (by which he meant immunoglobulin proteins) had evolved to react with alleles of the MHC. In a groundbreaking theoretical paper, he suggested that lymphocytes developing in the thymus somatically mutate their evolutionarily generated receptors such that the receptors no longer react with the MHC of their host, but retain the ability to react well with the MHC of others. Meanwhile, others were beginning to realize that T and B cells do not react with the same determinants on antigens. Senyk and coworkers (8), for example, showed that after immunization with bovine glucagons, rabbits and guinea pigs make antibodies against a glucagon N-terminal peptide, whereas their lymphocytes divide in response to the Cterminal part of the protein. This seemed to be due to different reactivities of T and B cells because we showed (9) that mouse B and

Marrack et al.

T cells cross-react differently with red blood cells of different species. Furthermore, after immunization with sheep red blood cells, B cells can bind these cells directly and form rosettes but T cells cannot, even though the T cells are clearly able to respond to the antigen (9, 10). At approximately the same time, a number of experiments showed that T cells were geared toward recognition of antigens that were cell-associated rather than soluble. These kinds of experiments suggested that T and B cells recognize antigen in radically different ways and led to a lengthy search for the antigen receptor on T cells. The search was confused by reports that T cells secrete soluble factors that could bind antigen, by intermittent reports that T cells expressed immunoglobulin molecules, and by the idea that genes encoded by the MHC might be part of T cell antigen receptors. Conversely, a giant clue came from immune response (Ir) genes, which control the immune response against certain antigens and map to the MHC (reviewed in Reference 11). A shift in perspective led to the concept that resolved all these apparent contradictions, starting with the discovery by Zinkernagel & Doherty (12) that T cells must recognize not only antigen, but also products of the MHC. The issue of whether these were properties of a single receptor or two receptors, one speciﬁc for antigen and the other speciﬁc for MHC, was cleared up by the results of a dual TCR T cell hybrid experiment. This experiment showed that fused T cell hybrids able to react with two combinations of antigen and MHC (antigen a + MHC A and antigen b + MHC B) could not react with the mixed combinations (antigen a + MHC B and antigen b + MHC A) (13). Hence, a single receptor must react with a speciﬁc combination of antigen and MHC. This conclusion was conﬁrmed by the discovery of the polypeptides and genes of the αβ T cell receptor (TCR) (14–20). TCRs are now known to comprise two chains, α and β, each composed of variable (Vα, Nα, Jα; Vβ, Dβ, Nβ, Jβ) and constant elements with all but the N regions

Annu. Rev. Immunol. 2008.26:171-203. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-06

ARI

26 February 2008

20:33

encoded by the germ line (21). Biochemical, cellular immunological, and later, crystallography experiments showed that TCRs react usually with a complicated ligand composed of the α helices of MHC proteins and peptides derived from antigen, bound to specially designed grooves of MHC molecules (22–26). Investigators have reported a number of structures of TCRs bound to their MHC/peptide ligands (27–46). TCRs bind MHC/peptide via their complementaritydetermining region (CDR) loops: CDR1α, CDR2α, CDR1β, and CDR2β, encoded in the germ line, and CDR3α and CDR3β, made up at least partially of non–germ line encoded residues and the C-terminal and N-terminal ends of Vα or Vβ and Jα or Dβ/Jβ, respectively. In these structures, the TCRs often lie on a diagonal above the face of MHC/peptide (Figure 1). The six CDR loops of TCRs contact this face, to varying degrees, usually with CDR1α and CDR2α over the α2 helix of MHC class I (MHCI) or the β helix of MHC class II (MHCII), and CDR1β and CDR2β over the α1 helix of MHCI or the α helix of MHCII. Conversely, the interactions of CDR3α and CDR3β usually focus on amino acids of the peptide. We now know that in addition to αβ T cells an entirely different set of T cells exists, which bear receptors made up of γ and δ chains. Adams and coworkers (47) solved the structure of a γδ TCR bound to its ligand. Although the interactions of such receptors with their ligands are of great interest, these receptors are not the subject of this review and are not discussed further.

EVIDENCE THAT TCRs MAY NOT HAVE BEEN SELECTED EVOLUTIONARILY TO REACT WITH MHC All these wonderful discoveries left unresolved Jerne’s (7) original hypothesis: the idea that what are now known to be TCRs have evolved to react with MHC proteins. In fact the notion fell out of favor after

a

β2

MHC α1

Peptide α1

β1

α3

β3

MHC β1 or α2

α2 β3

b β2

α2

β1 α3 α1 Peptide

MHC α1

MHC β1 or α2

Figure 1 The TCR usually contacts MHC/peptide on a diagonal, via the loops of its CDRs. (a) A schematic of the contacts between the CDR1–3 loops of the α and β chains of a TCR and a space-ﬁlling surface of MHC and peptide. The example shown here is a mouse TCR bound to the MHCII protein, IAb , engaged by the peptide, 3K (FEAQKAKANKAVD) [Protein Data Bank (pdb) XXX]. Shown are the α1/α region of MHC (cyan), the α2/β region of MHC (magenta), the peptide ( yellow), as well as the CDR loops, color coded and labeled in their corresponding colors. (b) An elevation perspective of the interactions shown in a.

the discovery of positive selection, the phenomenon by which developing thymocytes are picked out to survive on the basis of the reaction between their receptors and self MHC + self peptides in the thymus (48, 49). The existence of positive selection allowed

www.annualreviews.org • The Interaction Between αβ TCRs and MHC

CDR: complementarity determining region

173

ANRV338-IY26-06

ARI

26 February 2008

20:33

immunologists to account for the obsession of T cells with MHC without proposing that evolution was responsible. Nevertheless, some still hoped that structures of TCRs bound to their MHC/peptide ligands would shore up the evolutionary hypothesis. They proposed that conserved amino acids in the MHC helices and TCR CDR loops would serve as lynchpins for the interaction and that other interactions among variable amino acids would determine speciﬁcity and afﬁnity. However, the ﬁrst few reported structures of TCRs bound to MHC/peptide failed to reveal any obvious rules governing their interaction, at least not at the ﬁne structure level. There was no consistent pattern to the TCR amino acids that bound MHC or vice versa, thus suggesting that evolution had not selected TCRs that reacted in some predictable way with MHC. Other evidence weakens the evolutionary hypothesis. For example, TCR genes and MHC genes lie on different chromosomes; thus, there is no obvious genetic mechanism that will maintain coexpression of particular TCR variable (V) region alleles and particular versions of the rapidly evolving MHC genes. Although there are a few examples of TCR V region alleles or family members with a bias toward a particular MHC allele or class (50–52), in general most Vα and Vβ elements can be found in TCRs that recognize any of the extremely polymorphic alleles and isotypes of MHCI and MHCII. Worse still, in special cases, apparently quite conventional TCR α and β chains react with MHC-like proteins [such as the cluster of differentiation (CD1) proteins, for example CD1d] and their ligands, which are quite different stereochemically from classical MHCI and MHCII (53–60). How could evolution select for TCR V regions that could cope with all these differences? It is simplest to conclude that the somatic process of positive selection in the thymus must choose receptors that can react with MHC from an immense collection of receptors with random speciﬁcities.

V region: TCR variable region

Annu. Rev. Immunol. 2008.26:171-203. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

CD1: cluster of differentiation

174

Marrack et al.

The CDR sequences of TCR V regions do not offer many clues to help us understand this problem. TCR genes do not usually mutate (61), a fact that weakens Jerne’s idea that somatic mutation might help solve the problem. If TCR CDR regions evolved to react with MHC, then one might expect their sequences to offer some clue as to how that has happened. Clearly the evolutionary secret cannot lie in the CDR3 regions of TCRs, because CDR3 regions are created somatically and are only partly encoded in the genome. The secret, if there is one, probably lies in the CDR1 and CDR2 sequences of the V regions of the α and β chains of the TCR. However, inspection of these sequences does not offer much hope. There are many different sequences for TCRα and β CDR1s and CDR2s, and although they can be, and have been, assigned to families on the basis of their amino acid contents and predicted structures, they are not particularly well conserved between mouse and human (62–64).

EVIDENCE FOR EVOLUTIONARY SELECTION FOR TCRs TO REACT WITH MHC Despite the lack of evidence for the evolutionary hypothesis based on the sequences of the TCR V genes or the initial structural data, several results suggest that Jerne might have been correct, in principle. First, in the solved structures TCRs usually bind MHC/peptide in approximately the same orientation (as mentioned above): angled across the MHC α-helices with the TCR α chain over the α2 helix of MHCI or the β helix of MHCII, and the TCR β chain CDR regions over the MHC helices α1/α (reviewed in References 65 and 66) (Figure 1). If MHC recognition is simply a matter of positive selection, why would the reverse orientation never occur? Mazza & Malissen (67) suggest that the accessory proteins CD4, CD8, or perhaps CD3 lock the TCR/MHC/peptide complex into the observed positions by binding

Annu. Rev. Immunol. 2008.26:171-203. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-06

ARI

26 February 2008

20:33

simultaneously to both TCR and MHC; this remains an untested possibility. Second, the pivot point of the TCR on MHC is usually in approximately the same location: centered over peptide amino acids 4–6 in MHCI and peptide amino acid 5 (P5) in MHCII complexes. If TCR obsession with MHC is simply a matter of positive selection, why wouldn’t the TCR slide drastically to one end or the other of MHC, or even interact with the side of MHC? Actually a dramatic shift of this nature is seen in the reaction of a natural killer T cell (NKT) TCR with CD1d (see below) (68) but was observed only once for the reaction of TCR with classical MHC (38). Again, we can invoke the effects of CD4 and CD8 (see above) as an explanation. Third, although TCR CDR regions vary between species, they are better conserved evolutionarily in length and sequence than their counterparts in immunoglobulin (69, 70), a fact that suggests some required function. Finally, there is a small amount of direct experimental evidence that suggests evolution has played a role in the obsession of TCRs with MHC. For example, we showed that random combinations of TCR α and β chains react with MHC more frequently than expected (71), and others demonstrated that even before positive selection has had a chance to have an impact, TCRs react with surprising frequency with MHC (72, 73).

NEGATIVE SELECTION OBSCURES THE BIASES OF TCRs TO REACT WITH MHC The speciﬁcity of the TCRs on developing thymocytes is tested via both positive and negative selection. Positive selection allows the maturation of thymocytes bearing TCRs that react with self MHC + self peptides (48, 49), but negative selection deletes all thymocytes bearing TCRs that react too well (74, 75). We reasoned that if TCR V elements have been selected through evolution to react with MHC, this reactivity must be at-

tenuated in the thymus to allow escape from negative selection. Thus, whereas the CDR1s and CDR2s of most Vα/Vβ combinations can produce inherently MHC-reactive TCRs, CDR3s generated via somatic recombination will sterically interfere to varying degrees with this reactivity, producing a repertoire of TCRs with a wide range of afﬁnities for MHC. Only T cells with TCRs that exhibit reactivity for self MHC/peptides in a narrow afﬁnity window will pass the tests of both positive and negative selection. Thus, in the resulting mature TCR repertoire only a few of the germ line–encoded MHC interactions of the CDR1s and CDR2s may still be evident, although these interactions still contribute to the overall interaction of the TCRs for MHC, and their maintenance in the germ line is critical to provide a starting point for selection. The consequence of this line of reasoning is that the germ line–encoded MHC interactions may be difﬁcult to identify structurally in T cells that have experienced normal negative selection. Thus, the best place to look for these interactions is in the window between positive and negative selection. We therefore examined the properties of TCRs in mice in which positive selection is relatively normal but negative selection is limited. Although several available mice ﬁt the bill, we chose animals we had described previously, in which the MHCII protein has been replaced with an MHCII that is covalently bound to a single peptide (76). These animals are not ideal for the purposes of this experiment because they still express normal levels of MHCI, bound to the many different host peptides with which it normally engages, and they express one MHCII/peptide combination. Therefore, any thymocytes with TCRs that could react well with any of these combinations would still be deleted. However, these animals have two advantages for the planned studies: Previous characterization showed that they contain high frequencies of T cells that can react very well with MHC, and in fact the T cells cross-react with MHC of many different alleles (76), properties

www.annualreviews.org • The Interaction Between αβ TCRs and MHC

NKT cell: natural killer T cell

175

ANRV338-IY26-06

ARI

26 February 2008

Table 1 MHC

20:33

T cells that have experienced only limited negative selection react frequently with

Mouse donor

Immunogen

C57BL/6 B6→MHCI+

MHCII−

Ii− IAb /Eα+a

MHCI+ MHCII− Ii− IAb /Eα+b a

Annu. Rev. Immunol. 2008.26:171-203. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

b

IAb /3K

5

IAb /3K

2

0

IAb /3K

19

40.4

4.4

The bone marrow–derived cells are B6, but the thymus epithelial cells are MHCI+ MHCII− Ii− IAb /Eα. Mice express a single MHCII protein, IAb , bound to the Eα peptide.

expected of TCRs manifesting their evolutionarily selected abilities to bind MHC. Secondly, the animals contain mature CD4+ T cells that could be primed with MHC/peptide, and therefore we could identify at least one target MHC/peptide combination for these cells. Mice that express a single class II protein, IAb , bound to a single peptide from Eα (MHCI+or− MHCII− Ii− IAb /Eα mice) and normal C57BL/6 (B6) animals were primed with IAb bound to another peptide, called 3K because it contains three lysine residues that point straight up out of the IAb groove. Thus, Table 2 The number of deleted MHC ligands controls T cell alloreactivity

Number of TCRs tested

Mouse donor

% of target MHC tested that stimulated hybridomas bearing the TCRs

C57BL/6

20

3.1

MHCI+ MHCII− Ii− IAb /Eα+a

19

44.1

MHCI+ MHCII− Ii− IEk /99A+b

8

52.2

MHCI+ MHCII− Ii−c

3

18.2

MHCI− MHCII− Ii− IAb /Eα+d

45

41.1

MHCI− MHCII− Ii−e

28

67.1

a

Mice express a single MHCII protein, IAb , bound to the Eα peptide. Mice express wild-type MHCI of the k allele and IEk bound to the 99A peptide (83). c Mice express MHCI of the b allele but no MHCII. d Mice express no MHCI and a single MHCII protein, IAb , bound to the Eα peptide. e Mice lack almost all MHC proteins. b

176

Number of TCRs tested

% of target MHC tested that stimulated hybridomas bearing the TCRs

Marrack et al.

these three lysines should bind to TCRs that reach with IAb /3K. We prepared T cell hybridomas speciﬁc for IAb /3K from the two sets of animals. Only one of the IAb /3K speciﬁc TCRs from B6 mice showed any alloreactivity, whereas many of the TCRs speciﬁc for the same MHC/peptide combination from MHCI+or− MHCII− Ii− IAb /Eα animals were extravagantly alloreactive (Table 1) (77). We tested two of these TCRs in detail and found that they react with both MHCI and MHCII. This phenomenon is not a special feature of TCRs from the MHCI+or− MHCII− Ii− IAb /Eα mice, because we obtained similar results with TCRs from other mice in which negative selection is limited (78–83). Also, the degree of MHC reactivity of the TCRs appeared to correlate with the degree to which negative selection was absent (Table 2). The few T cells in mice lacking almost all MHC proteins (MHCI− MHCII− Ii− in Table 2) reacted most frequently with allogeneic MHC proteins. To conﬁrm that the ability to produce very MHC-reactive TCRs on mature T cells was due to lowered opportunities for negative selection in the MHCI+ MHCII− Ii− IAb /Eα mice, chimeras were examined in which the bone marrow–derived cells were B6 but the thymus epithelial cells were MHCI+ MHCII− Ii− IAb /Eα. In these animals, positive selection of most conventional T cells occurs on thymus epithelium, whereas negative selection occurs on both the epithelial and bone marrow–derived cells. IAb /3K-speciﬁc

Annu. Rev. Immunol. 2008.26:171-203. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-06

ARI

26 February 2008

20:33

T cells from these chimeric mice were not MHC cross-reactive (Table 1) (77). Therefore, mature T cells bearing very MHCcross-reactive TCRs are allowed to appear in MHCI+ MHCII− Ii− IAb /Eα mice because of the limited opportunities for negative selection in these animals. Further studies showed that the MHCcross-reactive TCRs display several unexpected properties. Although the MHC-crossreactive TCRs react with their immunogen (IAb /3K) with the same kinetics, afﬁnities, and footprints as normal TCRs do, they show less speciﬁcity for particular side chains of the amino acids of their ligand (77, 84). That is, the MHC-cross-reactive TCRs are more accepting of amino acid substitutions in both IAb and the 3K peptide than are normal TCRs. This result provides additional evidence that these TCRs are more cross-reactive. If the TCRs can accept amino acid substitutions, they are more likely to recognize different MHC alleles and classes than their wild-type counterparts. These results support the view that the T cell repertoire is intrinsically MHC reactive and that this reactivity is partially masked by negative selection in the thymus. To improve our understanding of the results, we recently solved the crystal structures of two TCRs, both bound to the IAb /3K complex (84a). One TCR (B3K506) came from a T cell developing in normal mice and was extremely peptide and MHC speciﬁc. The other TCR (YAe62) came from one of the very cross-reactive T cells described above. Both TCRs displayed approximately the same afﬁnity for the IAb /3K ligand (84). The cross-reactive TCR showed a very concentrated footprint on IAb /3K with very strong contributions from several amino acids in Vα CDR1(Y31) and Vβ CDR2 (Y48 and E54). These amino acids also contributed to the binding of the speciﬁc TCR. However, in the peptide- and MHC-speciﬁc TCR these amino acids were less important in the overall footprint, which was distributed over a much wider area. These results further supported our view that germ line–encoded interactions

may best be revealed by these cross-reactive T cells that have avoided negative selection and that normally developing T cells may have attenuated forms of these interactions.

TCR VARIABLE REGIONS HAVE BUILT-IN BIASES FOR REACTION WITH MHC Investigators have inspected the increasing numbers of solved structures of TCRs bound to MHC/peptide many times in the hope that these structures will reveal the rules that govern the reactions between TCRs and MHC (27–46). Apart from the usual diagonal mode of interaction and the usual placement of the TCR V region loops over the α-helices of the MHC, a set of general rules is not apparent. However, some researchers noticed that particular TCR amino acids often make contact with MHC, and in the case of structures involving the same TCR Vβ region, bound to different ligands, some of the V region amino acids that bind MHC are identical and bind MHC in the same positions (42, 85). This observation gave hope that rules were present, although they may be difﬁcult to make out. There are now more than 20 published structures of TCR/MHC complexes. This is both an advantage and a disadvantage for people who are searching for the rules that underlie the reactions. On the one hand, the increasing numbers of structures provide more data for analysis and a greater likelihood of spotting patterns. On the other hand, some of the new structures were chosen deliberately to illustrate unusual interactions, such as those with self antigens or with very large peptides. Therefore, these structures may not illustrate the general rules that guide the recognition of MHC by TCRs. Bearing these issues in mind, we revisited the published TCR/MHC structural information with new eyes and more ﬂexible criteria for conserved interactions. We were guided by several thoughts: 1. Almost all the structures published so far involve TCRs that have undergone

www.annualreviews.org • The Interaction Between αβ TCRs and MHC

177

ARI

26 February 2008

20:33

normal negative selection. Therefore, these TCRs are unlikely to demonstrate all their built-in abilities to react with MHC. Had the TCRs been able to react strongly with MHC, the cells that bear them would have been deleted in the thymus. Perhaps each TCR/MHC/peptide combination will manifest only a few of the evolutionarily selected interactions, and other interactions are prevented by the TCR CDR3 regions or the peptide. Thus, different TCR/MHC/peptide combinations will use different evolutionarily determined interactions, and some of the combinations may not use any at all. 2. Given the variability in TCR V region CDR1 and CDR2 sequences, the evolutionarily selected interactions may be distinct for different TCR V regions. 3. The angle and pitch with which TCRs settle onto MHC varies because of differences in peptide and CDR3 sequences. The evolutionarily selected interactions may therefore need a builtin ﬂexibility to accommodate shifts in the relative positions of the amino acids involved. 4. The evolutionarily selected interactions may not be the same for MHCI and MHCII because some TCR V regions are used preferentially to react with one or the other MHC class (50–52). With these thoughts in mind, we have reexamined the contacts between the CDR1 and CDR2s of Vα and Vβ regions and MHC in

Annu. Rev. Immunol. 2008.26:171-203. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-06

all the published structures of TCRs bound to MHC/peptide ligands. The analyses also included data from two structures we solved recently, mentioned above. The only omissions from the analyses are TCR/MHC/peptide structures that are duplicates of particular TCR/MHC combinations and those well analyzed in this context in a recent publication (85). The results of these analyses are shown in Figure 2. The analyses are inherently incomplete because only a few structures of TCRs bound to their ligands are known, in comparison with the many existing TCR V region genes in human and mouse. The results are also distorted by the fact that TCRs containing some V regions are better behaved in crystallographic studies than others, perhaps because the V regions in question allow the TCRs to fold in a more stable fashion. Whatever the reason, the TCR/ligand structures reported so far are heavily biased in favor of TCRs using Vβ8 in the mouse or Vβ13 (a related Vβ) in human, and a few other Vβ regions related to these two. The Vα regions that have been crystallized show less bias. These caveats limit our ability to make predictions about the universe of human and mouse TCR V regions. However, the structures may help us see patterns of reactivity for those V regions that are overrepresented in the solved structures. Some patterns are evident from the limited numbers of structures available. As previously reported and mentioned above, Vα CDR amino acids usually contact amino acids

−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−→ Figure 2 Contacts between TCR CDR1 and CDR2 and MHC. (a) The cells contain the sequences of CDR1α of TCRs whose structure, bound to the MHC/peptide ligands, is known. In the same cell as each CDR amino acid are the MHC amino acids bound by that CDR residue, color coded ( pink or blue) to indicate the MHC region on which they lie. Amino acids from the α1/α regions of MHCI/MHCII are shaded blue, and those from the α2/β regions are shaded pink. Dashes indicate a gap in the CDR region, introduced according to References 63 and 64 to best align TCR sequences. TCR and MHC amino acids are numbered according to References 63 and 64. Structures are from References 27–46, 84a. (b-d ) As in a, except the sequences of TCR CDRα2, CDRβ1, and CDRβ2 and their contacts are displayed. PDB, Protein Data Bank; Pep, peptide. 178

Marrack et al.

ANRV338-IY26-06

ARI

20:33

α1/α region of MHCI/II α2/β region of MHCI/II

Human TCRs binding MHCI

a

VαCDR1

Vα

PDB

TCR

MHC

Pep

10GA

JM-22

A2

MP

hVα10.1 S

–

–

V

1BD2

B7

A2

TAX

hVα21.1 N

S R170 –

M

S

A

2BNQ

1G4

A2

1AO7

A6

A2

1MI5

LC13

B8

2AK4

SB27

B35

2NX5

ELS4

B35

26

ESO-9C hVα23.1 D TAX

EBV

hVα2.1

hVα4.1

27

27a

W167

–

29

30

S Q155 S

F

D T163 Y Q155

I

Y Q155 N

G W167 S

Q Y159 S

E58 Y59

Q155

W167

T163 A150 R151

Q155

T R62 I

R

31

E154

F

K66

W167

D E58 R R170 –

13mer hVα12.1 T

28

S R62 G A158 T Y159 D

Y V152

D

Y

T

E154 Q155

T A158 Y L163

A158

EPLP hVα7.2

T

S E166 –

G E166

KK50.4 HLA-E Leader hVα4.2

T

I

S

G D162 N T163 E

–

G162 T163 Y E166 W167

F L163 N L163 G E154

2ESV

Y H155 A158

Mouse TCRs binding MHCI

1LP9

AHIII

A2

p1049 mVα8.5

S

T

Pkb1 mVα2.7

1FO0

BM3.3

Kb

Pbmi

mVα17.3 T

Q R62 D

S T163 S A158 Y

F R155

2OL3

BM3.3 Kbm8 pBM8 mVα17.3 T

Q R62 D

S T163 S

Y

F R155 Y R155

Kb

dEV8 mVα3.1

2OI9

2C

Ld

QL9

E58

E58

T W167 F

A158

Kb

2C

–

F Q155

1KJ2 KB5-C20

2CKB

D R62 S

E154

A158

S Y159 P

N T163 Y

Y R62 S R62 –

A

R62

T E166 P

Y

A E163

T Y159 P

A158

mVα3.1

S

–

Y155

Y A158

Human TCRs binding MHCII

E163

Mouse TCRs binding MHCII

Annu. Rev. Immunol. 2008.26:171-203. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

26 February 2008

1FYT

HA1.7

2IAM

1ZGL

DR1

flu HA hVα1.2

S

–

V

E8

DR1 mut TPI hVα13.1 D H81 –

–

S

3A6

DR2

T V85 –

G

MBP

S

hVα22.1 A

H81

H81

P

T77 H81

V

H81

Y159

P

Y T77

N T77 N D76 T77

Y R80 P

S

H81 D76

1YMM Ob.1A12 DR2

MBP

hVα3.1

Conalb mVα2.5

T

–

–

D

T77 S H81 –

S

I

T

T77 H81

F

N T77 N T77 H81 R70 D A73 Y R70 T77

1D9K

D10

IAk

1U3H

172.10

IAu

MBP

mVα2.3

N

S Y81 –

A

Y81

F

XXX

B3K506

IAb

3K

mVα4.1

A

S H81 –

G

T77 H81

Y T77 P

T77

D T77 Y D76

A

H81 D76

XXX

YAe62

IAb

3K

mVα4.6

T

T

–

G

Y T77 P

T

H81

www.annualreviews.org • The Interaction Between αβ TCRs and MHC

179

ANRV338-IY26-06

ARI

26 February 2008

20:33

α1/α region of MHCI/II α2/β region of MHCI /II

b PDB 10GA

TCR JM-22

MHC A2

Pep MP

VαCDR2

Vα

48

S T hVα10.1

49

50

51

H151 V E154 T

V

E154

1BD2

B7

A2

TAX

hVα21.1 S

I

G A158

S Q155 S T163

Human TCRs binding MHCI

A158

Annu. Rev. Immunol. 2008.26:171-203. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

52

1G4

A2

ESO-9C hVα23.1 N

L

G

E

D

A6

A2

TAX

hVα2.1

S

1MI5

LC13

B8

EBV

hVα4.1

H R151 G

2AK4

SB27

B35

H151

Q155 Q155 E154 Y Q155 S A158 N E166 G A158

I

D

E154

A150

hVα12.1 13mer Y Y R

H151

Q H151 S Q155 S E154 Q E154 R

I

1AO7

54

R157 A158 I E161 K G162

A150

2BNQ

53

L Q155 T

S E154 N

V R151

A158

R

E154 R157

N E154 S

F A158 D

E

E161

2NX5 2ESV

ELS4

B35

EPLP hVα7.2 G

KK50.4 HLA-E Leader hVα4.2

R151

Y E154 N

V A158 L R157 D

H

G

L R157 K

S

F E154 T E154 D

G

L

N

N

E

N

K

R

I Q155 R E161 S E166 V G162 S

D

E154

H151

1LP9

Mouse TCRs binding MHCI

1KJ2 KB5-C20

p1049 mVα8.5

H151

Kb

Pkb1 mVα2.7

E154 Y R155 K E154 K A158 E154 Y R155 K E154 K A158

mVα17.3 R

Q

D

S

2OL3

BM3.3 Kbm8 pBM8 mVα17.3 R

Q

D

S

K

Y

Y A158 S G162 G

2C

Kb

Kb

2OI9

2C

Ld

1FYT

HA1.7

DR1

Pbmi

dEV8 mVα3.1

QL9

mVα3.1

flu HA hVα1.2

K A150 Y

K

I

P

S D76 G

T

K

K

A

D

K

G

L E69 I

R

S D76 N E69 E

R

3A6

DR2

MBP

hVα22.1 T

1YMM Ob.1A12 DR2

MBP

hVα3.1

D10

IAk

1U3H

172.10

IAu

Conalb mVα2.5 MBP

mVα2.3

P

S T77

D66 E69 Q70

E69 Q70 A73

A73

D

A73 T77

A

I

S

E69

L

S

I

L

E69 A73

S T77

E69 73 T77

E69 R72 A73 D76

XXX

B3K506

IAb

3K

mVα4.1

R E66 A

S

XXX

YAe62

IAb

3K

mVα4.6

Q

T

V

A E69 A

P

E69 A73 T77

1ZGL

1D9K

D

T163 A150 G151 E154 Y E154 S R157 G R155 D Y155 A158 Y159 E69

DR1 mut TPI hVα13.1 Y

Y

A158

R155

T

E8

Marrack et al.

E166

BM3.3

2IAM

(Continued )

A158

S

1FO0

2CKB

Mouse TCRs binding MHCII

Human TCRs binding MHCII

A2

Q155

Figure 2

180

AHIII

R

T

V

E69 R72 A73

T

S

N

V A73 S

D

D

K E69 E

A

N

N

E69

ANRV338-IY26-06

ARI

26 February 2008

α1/α region of MHCI/II α2/β region of MHCI/II

Human Vβ binding MHCI

c

Annu. Rev. Immunol. 2008.26:171-203. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

20:33

TCR

MHC

Pep

Vβ

10GA

JM-22

A2

MP

hVβ17.1

N

L

N

H

D

1BD2

B7

A2

TAX

hVβ13.1 D

M

N

H

E

2BNQ

1G4

A2

1AO7

A6

A2

TAX

1MI5

LC13

B8

EBV

2AK4

SB27

B35

2NX5 2ESV

Human V β binding MHCII

Mouse V β binding MHCI

1LP9

Mouse Vβ binding MHCII

Vβ CD R 1

PDB

ELS4

26

28

27

Q72 T73

29a

29

A

–

Y

–

Y

–

Y

–

D

M

N V76

H

E

hVβ13.1

D

M

N

H

E

hVβ6.2

I

S

G

H

V

N80

S

D

M

N

H

N

T69

S

T69 T73

13mer hVβ13.3

E76

– –

Q65 T69

T

E

N

H

R

KK50.4 HLA-E Leader hVβ16.1

I

S

G

H

D K146 N

T

N

N

H

D P

W

–

P

W V76

–

P

W

–

Q149 N K146 N A150

–

A2

EPLP

25

hVβ12.1

AHIII

B35

ESO-9C hVβ13.1

24

p1049 mVβ8.1

1KJ2

KB5-C20

Kb

Pkb1

mVβ2

N

S

K146 Q Q149 Y A150 A150

1FO0

BM3.3

Kb

Pbmi

mVβ2

N

S

Q

Kbm8 pBM8

Y

Q72

Y

Y

– –

T73

–

2OL3

BM3.3

mVβ2

N

S

Q K146 Y

2CKB

2C

Kb

dEV8

mVβ8.2

T

N

N K146 H

2OI9

2C

Ld

QL9

mVβ8.2

T

N

N

H

N

V76 N77

N

–

1FYT

HA1.7

DR1

D

M

D

H

E

A64 V65 A68

N

–

2IAM

E8

DR1 mut TPI hVβ13.6

D

M

N

H

E

A61 V65

Y

1ZGL

3A6

DR2

MBP

hVβ5.1

I

S

G

H

R W61 S

1YMM Ob.1A12 DR2

MBP

hVβ2.1

L

D

F

Q

A

T

E55 Q57

T

Conalb mVβ8.2

T

N

N

H

N

N Q61

–

flu HA hVβ3.1

G58

Y60

–

–

1D9K

D10

IAk

1U3H

172.10

IAu

MBP

mVβ8.2

T

N

N

H

N H68 N Q61

–

XXX

B3K506

IAb

3K

mVβ8.1

T

N

N

H

D

Y Q61

–

XXX

YAe62

IAb

3K

mVβ8.2

T

N

N

H

N H68 N Q61

–

E55

Figure 2 (Continued ) www.annualreviews.org • The Interaction Between αβ TCRs and MHC

181

ANRV338-IY26-06

ARI

26 February 2008

20:33

α1/α region of MHCI /II α2/β region of MHCI /II

d

VβCDR2

Human Vβ binding MHCI Mouse Vβ binding MHCI Human Vβ binding MHCII

TCR

MHC

Pep

Vβ

46

10GA

JM-22

A2

MP

hVβ17.1

1BD2

B7

A2

TAX

hVβ13.1 Y

2BNQ

ESO-9C hVβ13.1

Y

1G4

A2

1AO7

A6

A2

TAX

hVβ13.1

Y

1MI5

LC13

B8

EBV

hVβ6.2

Y

2AK4

SB27

B35

2NX5

ELS4

B35

2ESV

Mouse Vβ binding MHCII

Annu. Rev. Immunol. 2008.26:171-203. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

PDB

13mer hVβ13.3 EPLP

hVβ12.1

KK50.4 HLA-E Leader hVβ16.1

S

V

S

V

S

V

F

Q

S

A

Y Q65 S

Y

H

V

Q72 E76

Y

F

G

T

V

K

D K68

Q65

Q

D

K

T

D

K

T

D

K

Q72

V76 T80

E

R79

S R75 K

Q

V76

D69 Q72 I73

D

R65

E

R65

K V

mVβ2

T

L

R

S

V76 R79

P

G

D

K

E

V

mVβ2

T

L

R

S

R79

P

G

D

K

E

V

E

K

E

K

mVβ8.2

Y

S

DR1 mut TPI hVβ13.6

Y Q57 S

DR2

E

mVβ8.2

hVβ5.1

hVβ2.1

Conalb mVβ8.2

Y

Y

Y

F

Q57

Y

T

V76 R79 T30 V76 T80 S73 V76 G69 Q72 V76

G

R79

A

R79 R75 R79

G R79 S

V76 R79

T

G R75 S

Q72 R75

T

Q72

G

V76

A

Q57 G58 A61 A64

D

A64 K67

V

K

M L60

K

K39

E

K39 Q57

K

V

Q57 G58 A61

G

A

G

I

A61

T

Q57

D Q57

K

F

A61 V65

S

E

T A61 Q Q57

R

Q57 G58 A61

N

E55 Q57

K

S

N

Y Q57 S

Y

D10

IAk

1U3H

172.10

IAu

MBP

mVβ8.2

Y Q57 S

Y

XXX

B3K506

IAb

3K

mVβ8.1

Y

Q57 Q61

S

Y

XXX

YAe62

IAb

3K

mVβ8.2

Y Q57 S

Y

Marrack et al.

E

S

D Q72 R75

E

1D9K

182

L

K

S

(Continued )

T

Q

D Q72

flu HA hVβ3.1

Figure 2

I

R79

R65

G

R65

Y

MBP

D

P

Y

S

1YMM Ob.1A12 DR2

T

Q72

Kbm8 pBM8

MBP

K68

S

BM3.3

3A6

I

Q72 V76

2OL3

1ZGL

G

Q

R

Pbmi

E8

D

Q

E

K

T

A

R79

I73 V76

Q72

G

N

G

I

K

L

Kb

2IAM

A

G

R65

T

BM3.3

DR1

G

Q72

Q

E

1FO0

HA1.7

A

F

Q72 R75

T

mVβ2

1FYT

G Q72

D

N

55

S

Pkb1

QL9

A

54

D

Kb

Ld

Q72 R75 E76 Q65 Q65 K68 T69

G

Q72 V76

53

K68 A69 Q72

A

KB5-C20

2C

R65 K68 A69 Q72

V

52

Q72

1KJ2

2OI9

I

51

V

p1049 mVβ8.1

dEV8

Q

A69 Q72 T73 V76

50

R65 K68 A69

A2

Kb

S

49

Y

AHIII

2C

R65

48

S

1LP9

2CKB

Y

R65

47

Q57 G58 L60 Q61 A64 Q57 L60 Q61 A64 Q57 L60 Q61 Q57 L60 Q61 A64

A61 A64 V65

K39

L60 A64

E

G

S

K

A

G

A

G

S

T

K39

E

K39 Q57 L60

K

G

A

G

S

T

K39

E

K39 Q57 L60

K

V

A

D

S

T

E

Q57

K

G

A

G

S

T

E

K39 Q57 L60

K

K67

T

K39

Q57

Y

Q57

Annu. Rev. Immunol. 2008.26:171-203. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-06

ARI

26 February 2008

20:33

in the α2 helix of MHCI or the β helix of MHCII. Conversely, Vβ CDR amino acids bind residues in the α1- or α-helices of MHCI or MHCII, respectively (Figures 2a–d ). However, the results also suggest that the contacts between TCRs and MHC might follow more rules than this one. For example, as previously noted, TCRs often bind MHC via the use of amino acids in positions 28, 29, and 31 of CDR1α; positions 50, 51, and 52 of CDR2α; positions 28 and 29 of CDR1β; and position 48 of CDR2β. (TCR V regions and their amino acids are numbered as listed in References 63 and 64. In all ﬁgures, MHC amino acids are from the MHC α chain unless speciﬁcally marked “β”.) This usage is to some extent independent of whether the target is MHCI or MHCII. We, among others, have discussed a number of these positions (αY29, βY46, and βY48) at length in previous publications, so in the discussion below we concentrate on positions that have not been covered as thoroughly.

Amino Acids Often Used by Vαs to Bind MHC Figure 2a and Figure 3 show that in VαCDR1, Y/F31 is very often bound to a site on MHC that includes amino acids around Q/H/R 155 of the α2 helix of MHCI or the equivalent position on MHCII, R70 on the β helix. Approximately 40% of human and mouse TCRαs have a Y or F at position 31, at the C-terminal end of their CDR1 regions (Figure 3a). So, if this is an interaction that routinely affects TCR/MHC binding, it may apply to many TCRs. Investigators have solved the structures of 13 TCRs that contain a VαY/F31, bound to different MHC ligands. Figure 3b–m shows the relative positions of VαY/F31 and MHC/peptide in 12 of these structures. (We omitted one structure, 2OL3, because it involves a TCR that was already included, bound to a closely related MHC.) VαY/F31 does not bind MHC in three of these structures (2AK4, 1KJ2, and 1U3H; Figure 3i, j,

and m). In one of these structures (2AK4), the entire TCR is lifted away from MHC by a very pronounced bulge in the engaged peptide, which correlates with an unusual 13mer in the structure. In another case (1KJ2), the TCR has a very long CDR3β, and the total number of interactions between this TCR and MHC is fewer than normal (Figure 2). The orientation of VαY/F31 is not identical in the nine structures shown in which it binds MHC; sometimes VαY/F31 adopts a vertical conﬁguration, reacting with the C-terminal side of α2H/Q/R155 or βR70 (in 1LP9, 2ESV, 2CKB, 1FO0, and 1FYT; Figure 3c, d, f, h, and l ), and in other structures VαY/F31 reacts with the N-terminal side of the same amino acid or is oriented horizontally relative to the axis of the MHC α helix (in 1MI5, 1BD2, and 1DK9; Figure 3b, g, and k). For both MHCI and MHCII, the approach of VαCDR1 to the MHC in this region is often facilitated by the lack of a side chain on a highly conserved alanine on top of the MHC α helix (A158 for MHCI and βA73 for MHCII). This leads to the formation of a cup on the surface of the MHC α helix into which Y/F of TCR α31 can nestle in various orientations while still maintaining Van der Waals–like interactions with some portion of the exposed helix backbone and the surrounding amino acid side chains. The interaction is in a way analogous to a ball and socket structure. Almost as striking as the fact that VαY/F31 tends to bind to a particular site on MHC is the fact that other amino acids at this same position do not. Alternate amino acids in known structures at position 31α include G, A, S, N, and T. These amino acids engage MHC in only one of these structures (1YMM). In many cases, the VαY/F31 interaction seems to be replaced by binding between amino acid Vα29 or Vα30 and the ligand (Figure 2a). In human Vα22 and Vα4, VαY29 is a special case. In the three available structures, VαY29 interacts strongly with βH81 and βT77 of the MHCII β chain helix (84a). An adjacent proline at position 30

www.annualreviews.org • The Interaction Between αβ TCRs and MHC

183

ANRV338-IY26-06

ARI

26 February 2008

Annu. Rev. Immunol. 2008.26:171-203. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

a

20:33

31

hVα01.2, 3, 4 hVα02 hVα04.1 hVα04.2 hVα05.1 hVα08.1 hVα08.2 hVα12.1 hVα14.1 hVα14.2.1 hVα14.2.3 hVα15.1 hVα16.1 hVα17.1 hVα20.1 hVα21.1

SS - VPPY NS - A FQY T I SGT DY T I SGN E Y NY - SPAY DS - ASNY NS - ASDY T RD T T Y Y T SESDYY T S ENDY Y T SESNYY DS - SS T Y V S - GN P Y NT - A FDY N I A T NDY NS - MF DY

mVα1.1 mVα1.2, 8 mVα1.7 mVα2.1, 5, 9 mVα2.2, 4, 7 mVα2.3, 6 mVα3.1, 3, 9 mVα3.2, 5, 6 mVα3.4, 8 mVα3.7 mVα5.1 mVα5.3 mVα6.1 mVα8.1, 6 mVα8.3 mVα8.5 mVα8.13 mVα8.14 mVα9.1 mVα12.1 mVα13.1 mVα15.1 mVα16.1P mVα17.1 mVα17.3 mVα20.1

DS - A SQY DR - N FQY DR - NVDY DS - T FDY DS - T FNY NS - A FDY YS - ATPY Y F - GT PY YG - GS I Y SS - VTPY DP - NSYY DS - A T AY T I SGN E Y T I YSNP F TTYS - PF STYS - PF TAYS - TF T I YSNA F YS - AAPY N I ATSEY NS - ASNY DT - ASSY NA - A TNY RD - S S Y F QD - S S Y F ND - MF DY

b

c

hVα α4.1 (1MI5)

mVα8.5 (1LP9)

R151 Q155

Q155

mVα3.1 (2CKB)

Y155 R155

G151

βE69

HLA-E

g

Q155

H151

A158

A158

Ld

βR70 βT77 βA73

E154

Kb

i

hVα1.2 (1FYT)

βE69

E154

E154

IAk

l

hVα21.1 (1BD2)

G151

A158

mVα17.3 (1FO0)

βR70

S151

E154

HLA-A2

f

mVα3.1 (2OI9)

mVα2.5 (1LP9)

βT77 βA73

E154

HLA-B8

h

H155 A158

E154

e

k

hVα4.2 (2ESV)

H151

A158

A158

d

hVα12.1 (2AK4)

j

HLA-A2 mVα2.7 (1KJ2)

m

HLA-DR1 mVα2.3 (1U3H) βR70

R151 R155 A158

Q155

G151

R155

K

b

βT77 βA73

A158

A158 E154

G151

E154

HLA-B35

βE69 E154

K

b

IAu

Figure 3 TCRs often bind the same site in MHC via Y/F31 in TCRα CDR1α. (a) CDR1 sequences of the human (h) and mouse (m) Vα regions that contain an F or Y residue at position 31 (highlighted in salmon pink). V regions were omitted if the sequences of both their CDR1 and CDR2 regions were identical to one already displayed. V regions and their amino acids are numbered according to References 63 and 64. The sequences were selected from 48 human Vαs and 75 mouse Vαs. (b–j ) The arrangements of MHC amino acids around Y/F31α ( green with red hydroxyl groups) in nine of the solved structures of TCRs bound to MHCI, with the α2 helix of MHCI in magenta. Also indicated are the Vα region, MHC allele, and pdb number. The structures are arranged from b to j roughly according to the predicted strength of the interaction between Y/F31α and MHCI; there is no predicted contact for Y/F31α in 2AK4 (i ) and 1KJ2 ( j ). (k–m) As in b–j, but for TCRs bound to MHCII, with the β helix of MHCII in magenta. There is no predicted contact between Y/F31α and MHCII in 1U3H (m). Structures were selected from the references in Figure 2.

of these Vαs orients VαY29 to point straight out from the tip of CDR1, making VαY29 particularly available for interaction. In the other structures in which Vα contains a P30, the amino acid at p29 (P, T, or S) also interacts with the MHC helix in the same region (Figure 2a). This Vα29 interaction may be a conserved structural feature of Vαs with this proline. 184

Marrack et al.

In VαCDR2, a serine at position 51 is the most conserved amino acid among the published structures (63, 64). In MHCI this serine most often interacts with the MHC helix slightly C-terminal to the site engaged by VαY/F31 (Figure 4b–g ). Only occasionally does VαS51 not engage MHC (2AK4 and 1FO0; Figure 4h,i ). The approach of αCDR2 to the MHCI α helix is again

ANRV338-IY26-06

ARI

26 February 2008

Annu. Rev. Immunol. 2008.26:171-203. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

a hVα1.1, 2.1 hVα1.2.5 hVα1.3 hVα1.4 hVα1.5 hVα2.1.1 hVα2.1.2 hVα2.2 hVα2.3 hVα3.1 hVα6.1.1 hVα6.1.2 hVα6.1.1 hVα9.1 hVα12.1 hVα13.1 hVα15.1 hVα19.1 hVα21.1 hVα23.1 hVα27.1 hVα28.1 hVα30.1 mVα1.1, 7 mVα1.2, 8 mVα1.5 mVα2.2, 3, 4 mVα2.6 mVα2.7 mVα3.1, 5, 6, 7, 9 mVα3.4, 8 mVα5.1 mVα5.3 mVα7.1 mVα10.1 mVα10.2, 3, 6, 9 mVα10.5 mVα11.1, 6 mVα11.6 mVα13.1 mVα15.1 mVα16.1 mVα17.1, 3 mVα18.1, 2, 3 mVα20.1

20:33

51 K Y F SG D P K Y T SA A T K Y L SG S T K Y F SG D T K Y T SA A T F I Y SN G D S I Y SN G D Y T Y SSGN S VY SSGN L I R SN E R Y QG S Y D Q Y QG S Y D E D I R SN V G R H I SR E R RN S F D E Y I P SG T K Y I F SNM D M L S SG K K S I SS I KD L I Q SSQR V L L SN G A M L T SSG I T L Y SAG E S I F SN G E S I F SD G D S I F SN G N S I S SV S D S I L SV S N S I R SV S D K Y Y SG D P K Y Y SG N P K V F SS T E S V L SN V D R QT SS S T S N P SG T Y N P SG T Y S P SWA Y L A SG T Y L A SG T D I R SNM E D I R SN V D D I R SN V N R QD S Y K K L I R SN E R S V R SN V D

b

c

hVα α21.1 (1BD2)

hVα2.1 (1AO7)

Q155 T163 E154 A158 E166

E166 T163

HLA-A2

f

g

Q155 T163

A158

E154

R155

G162

hVα1.2 (1FYT)

βT77

βA73

E154

R157

k

βT77

h

L163 E166 A158

b

hVα13.1 (2IAM) βA73

Ld

i

Q155 E154

HLA-DR1

mVα17.3 (1FO0)

T163 E166

l

G162

R157

hVα3.1 (1YMM)

βD76

R157

m

βT77 βA73

Kb

mVα2.3 (1U3H)

βT77

βA73

βD76 HLA-DR1

HLA-DR2

IAk

Figure 4 S51 in TCRα CDR2α is often used in TCRs and often engages MHC at the same site. (a) The CDR2 sequences of the human (h) and mouse (m) Vα regions that contain an S at position 51 (highlighted in salmon pink). V regions were omitted and numbered as in Figure 3a. (b–i) The arrangements of MHC amino acids around αS51 (blue with red hydroxyl group) in eight of the solved structures of TCRs bound to MHCI, with the α2 helix of MHCI in magenta. Also indicated are the Vα region, MHC allele, and pdb number. The structures are arranged from b to i roughly according to the predicted strength of the interaction or alignment between S51α and MHCI; there is no predicted contact for S51α in 2AK4 (h) and 1FO0 (i ). ( j–m). As in b–i, but for TCRs bound to MHCII, with the β helix of MHCII in magenta. Structures were selected from the references in Figure 2.

facilitated by the conserved MHC A158, as well as G151. In a few cases the hydroxyl group of VαS51 hydrogen bonds to the backbone or amino acid side chains of the MHC helix; other Van der Waals interactions can involve the participation of the backbones of VαS51 and the MHC helix. On MHCII the binding site for VαS51 is similar to that of MHCI, but more ﬁxed, and VαS51 engages MHCII βT77 in various orientations (Figure 4j–m). Particularly in the case of

R155 E154

A158

HLA-B35

βD76

βD76

R157

G162

hVα12.1 (2AK4)

G162

K

mVα3.1 (2OI9)

Kb

R157

HLA-A2

j

G162

mVα2.7 (1KJ2)

e

R155 Y155 E154 E166 E163 A158 A158 E154

E166 T163

R157

E166 T163 A158

R157

G162

E154

mVα3.1 (2CKB)

HLA-A2

hVα23.1 (2BNQ)

E166

A158

G162

R157

G162

Q155

d

MHCI, VαS51 binds at a region of the MHC α helix with some ﬂexibility in its exact site and pitch on the MHC protein. Others have mentioned the involvement of VαY50 in the interaction of several TCRs with MHCI (86). Vαs with this amino acid are not abundant (present in 12%–16% of Vαs) (Figure 5b), but in the VαCDR2s of the published structures VαY50 and other amino acids at this position very often interact with MHC, using the same area of MHCI

www.annualreviews.org • The Interaction Between αβ TCRs and MHC

185

ANRV338-IY26-06

ARI

26 February 2008

20:33

a

b Vα αs with a Y at aa29

Vαs with a Y at aa50

Annu. Rev. Immunol. 2008.26:171-203. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

29 hVα22.1 hVα31.1

Y T AT - - GYPS T ST - - GYP Y T

mVα4.1 mVα4.2 mVα4.3, 4 mVα4.5, 6 mVα4.7 mVα4.9 mVα4.10 mVα4.11 mVα4.12

Y S AS - - GYPA E TK - - QYP Y T S ATS I AYPN Y Y T S TT - - GYP S ATS I GYPN Y Y S AS - - GYPA S ATS I AYPN Y WYP S TT - - WY W Y T S TT - - GYP Y T

50 hVα 2.1. 1 hVα 2.1. 2, 3 hVα 2.2 hVα 2.3 hVα 20.1 hVα 25.1 hVα 30.1

F I YSNGD Y S I YSNGD Y Y T YSSGN Y SVY Y S SGN QGYK Y T KV A L YKAGE Y T L YSAGE Y

mVα3.1, 5, 6, 7, 9 mVα3.2 mVα3.4, 8 mVα12.1

KYYSGDP Y KYYPGDP Y K Y Y SGNP QGYKDYV Y

Figure 5 CDRα sequences that contain other amino acids that frequently bind MHC at the same position. Listed are the human and mouse V region CDR1α sequences that include a Y at position 29 (a), or the human and mouse V region CDR2α sequences that contain a Y at position 50 (b). The amino acid of interest is highlighted in salmon pink. Vαs that have been reported in structures of TCRs bound to MHC are highlighted in yellow or blue, if the structure involved binding to MHCI or MHCII respectively. The sequences were selected and numbered as in Figure 3a and structures were selected from those in Figure 2.

(around A158) and MHCII (around βA73) (Figure 2b). Perhaps these amino acids are evolutionarily selected to do this.

Amino Acids Often Used by Vβs to Bind MHC As pointed out above, the published TCR/MHC structures are dominated by TCRs that use mVβ8 family members or the related human Vβ elements (hVβ3, hVβ12, hVβ13, and hVβ17). With this large pool of data for a related set of Vβs, a number of studies have already revealed particular amino acids that interact with MHC in a similar way from structure to structure (42, 67, 85, 86). These include VβN/Y29 in CDR1 and VβY/F46, VβY48, and VβD/E54 in CDR2 of Vβ (Figure 2c,d ). In these Vβ families and a few others there is often a Y or N in position 29 of Vβ CDR1 (Figure 6). In the published structures these amino acids often make 186

Marrack et al.

contact with the α1 MHC helix, especially in the structures with MHCII in which there is often an H-bond to Q61. Thus, VβN/Y29 may be an amino acid selected by evolution to bind MHCα1. Also in VβCDR1, many different amino acids at position 28 often contact the MHC; however, there is no obvious conserved pattern of recognition for amino acids at this position. In fact, in some structures the rotation of the TCR has brought this amino acid over the peptide to contact the α2 helix of MHCI or the β1 helix of MHCII (Figure 2c); therefore, position 28 does not seem to be involved in an evolutionarily conserved interaction. The most striking example of a conserved point of interaction is position 48 of VβCDR2, which is a Y in the mVβ8 family. Originally, Maynard and coworkers (42) reported that this Y made very similar contacts with MHCII in the interactions of two different TCRs with two different MHC proteins (see 1U3H and 1D9K in Reference 42) and suggested that these residues might form an anchor point for TCRs that use mVβ8.2 to interact with MHCII. A recent paper from the Garcia group expanded on this idea (85). We subsequently found that in the B3K506 and YAe-62 TCRs (which use the closely related mVβs, 8.1 and 8.2) VβY48 binds to yet another MHCII molecule quite similarly. We and the Garcia group also pointed out a similar interaction in a human TCR that uses the related hVβ3 to bind to human HLADR1 and that when mVβ8-containing TCRs interact with MHCI, VβY48 also interacts with the MHCI α1 helix in a similar location (32, 84a, 85). The interaction of position 48 of VβCDR2 with MHC is similar to that discussed above for Vα, in that a conserved small amino acid on the top of the α1 helix at position 69 of MHCI and position 61 of MHCII creates an area for VβY48 to approach the helix. Mainly via Van der Waals interactions, VβY48 can pivot and slide somewhat on the helix without losing contact. In the Vβs of a number of structures, other amino acids (V, A, R, and Q) at Vβ48 contact

ANRV338-IY26-06

ARI

26 February 2008

20:33

a

b Vβ βs with an N/Y at aa29

c Vβs with a Y at aa48

Annu. Rev. Immunol. 2008.26:171-203. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

29 hVβ3.1 hVβ8.2 hVβ12.1 hVβ12.2 hVβ12.3 hVβ13.2 hVβ13.4, 7 hVβ13.6.1.6.4 hVβ14.1 hVβ16.1 hVβ20.1 hVβ22.1 hVβ25.1

D - MDHEN I - SGHDY T - ENHRY T - WNHNN T - WSHSY D - MNHEY D - MNHGY D - MNHNY N - MNHEY I - SGHDN EGT SNPN I - SNH L Y I - KGHSY

mVβ5.2 mVβ8.1 mVβ8.2a mVβ8.3 mVβ16 mVβ19a

I - SGHSN T - NNHDY T - NNHNN T - NSHNY V - SNH L Y I - NGHSY

Vβs with a D/E at aa54

48 hVβ1.1 hVβ1.2 hVβ3.1 hVβ5.2 hVβ5.3 hVβ5.6 hVβ11.1 hVβ12.1 hVβ12.2.1 hVβ12.2.2 hVβ12.2.3 hVβ22.1 hVβ23.1 hVβ24.1

QYY - NGEERA HYY - NGEERA F SY - DVKMKE QYY - EEEERQ QYY - EK E E RG QYY - R E E ENG YSY - GVNS T E YSY - GVKDTD YSY - GVQDTN YSY - GVKDTN YSY - GVHDTN S F Y - NN E I SE S F Y - EKMQSD HYYNKDF NN

mVβ5.1 mVβ5.2 mVβ7 mVβ8.1 mVβ8.2a mVβ8.3 mVβ9 mVβ16

QHY - - DKMER QHY - - EKVER I SY - DVDSNS YSY - VADS T E YSY - GAGS T E YSY - GAGN LQ F YYDK I L NRE NF Y - NGKVME

54 hVβ3.1 hVβ6.1 hVβ6.2 hVβ6.3 hVβ6.4 hVβ6.5 hVβ6.6 hVβ6.8 hVβ7.2 hVβ7.3 hVβ8.1, 2 hVβ8.3 hVβ11.1 hVβ12.1 hVβ12.3 hVβ13.1 hVβ13.3 hVβ13.4 hVβ13.6 hVβ13.7 hVβ14.1 hVβ16.1 hVβ18.1 hVβ21.1 hVβ21.2 hVβ21.3 hVβ22.1 hVβ23.1 hVβ25.1

F SY - DVKMKE Y FQ - GTGAAD Y FQ - NEAQL D Y FN - YEAQQD Y FQ - NEAQL E Y FQ - GNSAPD Y FN - YEAQPD YSQ - SDAQRD VYS - L EERVE VYN - F KEQT E Y FN - NNVP I D Y FR - NRAP L D YSY - GVNS T E YSY - GVKDTD YSA - AAD I TD YSV - GAG I TD YSA - SEGT TD YSV - AAG I TD YSV - GAG I TD YSA - AAGT TD YSM - NVEV TD HF V - KESKQD Y LQ - KEN I I D QFQ - DESVVD RYE - NEEAVD QFQ - NNGVVD S F Y - NNE I SE S F Y - EKMQSD S FQ - NENV FD

mVβ2a mVβ4 mVβ8.1 mVβ8.2a mVβ9 mVβ11 mVβ12 mVβ13 mVβ16 mVβ17a mVβ19a mVβ20

T L R - SPRDKE SYS - YQK LMD YSY - VADS T E YSY - GAGS T E F YYD K I L NRE Y FR - NQAP I D Y FR - SKS LME Y FR - DEAV I D NF Y - NGKVME NFR - NEE I ME Y FQ - NED I I D Y F Q - NQQP L D

Figure 6 TCR CDRβ sequences that contain amino acids that frequently bind to the same position of MHC. Listed are (a) the human and mouse V region CDR1β sequences that include an N/Y at position 29, (b) the human and mouse V region CDR2β sequences that contain a Y at position 48, and (c) the human and mouse V region CDR2β sequences that contain a D/E at position 54. Sequences are highlighted according to the criteria in Figure 5. The sequences were selected from 59 human Vβs and 23 mouse Vβs and were numbered as in Figure 3a.

www.annualreviews.org • The Interaction Between αβ TCRs and MHC

187

ANRV338-IY26-06

ARI

26 February 2008

20:33

the MHC α1 helix in the same general area. Therefore, the amino acid at this position is a key determinant in anchoring the TCR to the MHC.

Annu. Rev. Immunol. 2008.26:171-203. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

a hVβ3.1 hVβ6.1 hVβ6.2 hVβ6.3 hVβ6.4 hVβ6.5 hVβ6.6 hVβ6.8 hVβ8.1, 2 hVβ8.3 hVβ11.1 hVβ12.1 hVβ12.2.1 hVβ12.2.2 hVβ12.2.3 hVβ12.3 hVβ13.1, 6 hVβ13.2 hVβ13.3 hVβ13.4 hVβ13.5 hVβ13.7 hVβ14.1 hVβ15.1 hVβ17.1 hVβ18.1 hVβ20.1.1 hVβ20.1.3 mVβ6a mVβ8.1 mVβ8.2 mVβ8.3 mVβ9 mVβ11 mVβ12 mVβ13 mVβ14 mVβ19a mVβ20

Another position in Vβ CDR2 worth consideration is Vβ46. As shown in Figure 7a, Vβ46 is a Y or F in a wide variety of Vβs, including 16 of the 22 structures analyzed

46 F S Y - D V KMK E Y FQ - GTGA A D Y FQ - NE AQL D Y F N - Y E A Q QD Y FQ - NE AQL E Y F Q - GN S A P D Y F N - Y E AQP D Y SQ - SDAQRD Y F N - NNV P I D Y F R - NRA P L D Y S Y - GVNS T E Y S Y - GV KD T D Y S Y - GVQD T N Y S Y - GV KD T N Y S Y - GVHD T N YSA - AAD I T D Y S V - GAG I T D Y S V - GEGT T A Y S A - S EGT T D Y S V - A AG I T D Y SN - T AGT T G Y S A - A AGT T D Y SM - N V E V T D YS F - DVKDI N Y SQ - I VND F Q Y LQ - KEN I I D Y S V - G I GQ I S Y S I - G I DQ I S Y S I - T END L Q YSY - VADS T E Y S Y - GAGS T E Y S Y - GAGN L Q F Y YDK I L N RE Y F R - NQA P I D Y F R - S K S L ME Y FR - DEAV I D Y S I - - - T V GQ Y FQ - NED I I D Y F Q - N QQ P L D

b

hVβ β12.1 (2NX5)

Q72

Q65

hVβ6.2 (1MI5)

Q72

hVβ13.1 (1BD2)

Q72

T69

HLA-B35

f

c

R65

A69

hVβ17.1 (1OGA)

hVβ13.1

Q72

(1AO7)

Q72

R65

A69

Q65 G69

R65

hVβ13.3 (2AK4)

Kb

l

mVβ8.2 (1D9K)

Q72 A69

T69

HLA-A2

n

mVβ8.2 (YAe62)

Q61

Q65

R65

HLA-B35

o

mVβ8.1 (B3K506)

Q61

Q57 A64

A64

IAb

A69

p

R65

HLA-A2 hVβ8.2 (2OI9)

Q65 Q72

m

G69

Kb mVβ8.2 (1U3H)

Q61

A64

Q57 A64

IAb

Q72

Q57

Q61 Q72

hVβ8.1 (1LP9)

i

hVβ8.2 (2CKB)

HLA-A2

k

e

HLA-A2

h

Q72 A69

HLA-B8

j

hVβ13.1 (2BNQ)

HLA-A2

g

Q65 T69

d

Q57

A64

IAk hVβ13.6 (2IAM)

A61

q

Q57

Q57 A64

HLA-DR1

IAu hVβ3.1 (1FTY)

A61

HLA-DR1

Figure 7 TCRβ Y/F46 in CDR2β is often used in TCRs and often engages MHC at the same site. (a) The CDR2 sequences of the human (h) and mouse (m) Vβ regions that contain a Y/F at position 46 (highlighted in salmon pink). V regions were omitted and numbered as in Figure 3a. (b–k) The arrangements of MHC amino acids around Y46β (orange with red hydroxyl group) in ten of the solved structures of TCRs bound to MHCI, with the α1 helix of MHCI in cyan. Also indicated are the Vβ region, MHC allele, and pdb number. The structures are arranged from b to k roughly according to the predicted strength of the interaction or alignment between S51α and MHCI; there is no predicted contact for Y46β in g–k. (l–q) Structures are shown as in b–k, but for TCRs bound to MHCII, with the α helix of MHCII in cyan. Structures were selected from the references in Figure 2. 188

Marrack et al.

Annu. Rev. Immunol. 2008.26:171-203. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-06

ARI

26 February 2008

20:33

in Figure 2d. In 5 of the MHCI structures, VβY/F46 contacts the MHC α1 helix, usually via α65 (Figure 7b–f ). In the other 5 MHCI structures VβY/F46 is too far away to bind MHC, but it lies in roughly the same position (Figure 7g–k ). In all 6 VβY/F46-containing TCR/MHCII structures, this amino acid contacts Q57 of the α1 helix (Figure 7l–q). Finally, Vβ CDR2 very frequently has an acidic D or E at position 54 (Figure 6). Four of the 14 TCR structures with MHCI have VβD/E54 in contact with R65 of the α1 MHC helix. Because so many different mouse and human Vβs have D/E54, this residue is a candidate for a conserved and sometimesused interaction site. Six of the eight TCR structures with MHCII contain VβD/E54; in all cases D/E54 contacts Q57 of the MHCII α1 helix (Figure 2d ). As pointed out previously, in the ﬁve cases with an E at Vβ54, there is a salt bridge to αK39 of MHCII. αK39 is not on the α helix of MHCII, but rather lies on one of the β strands of MHCII as it protrudes beyond the peptide-binding site. This solvent-exposed amino acid is highly conserved in MHCII, although it is not involved in the structural integrity of MHCII or in peptide binding. Thus, D/E54 may represent a TCR CDR2 amino acid that has been evolutionarily selected to react with MHCI and MHCII (in this case in different ways).

The Biases for MHC Reaction Built into TCR Vαs and Vβs May Control the Orientation of TCRs on MHC Our purpose in this analysis was to determine whether the existing TCR/MHC structures could be used to make a case for germ line– encoded features of TCR Vα and Vβ elements that account for the obsession of TCRs with MHC ligands. Any analysis should account for both the conserved general diagonal orientation of the TCR on the MHC ligand as well as the considerable variation in angle and pitch of the TCR on the MHC sur-

face. We were guided in this analysis by the idea that the need to avoid negative selection in the thymus might select for TCR CDR3s that attenuated these germ line interactions and that in mice with limited negative selection highly MHC-cross-reactive T cells were common. Therefore, in examining the structures we looked for sites of interaction in which particular TCR amino acids were often but not always found and for interactions that might be ﬂexible and not necessarily lost by small shifts in orientation position. We conclude that such interactions can be identiﬁed. Our overall conclusions are summarized schematically in Figure 8. We propose that the anchor points on MHC molecules are not particular amino acid side chains, but rather two exposed areas on the tops of the MHC α-helices, centered about α169 and α2158 for MHCI and α1 64 and β173 for MHCII. These amino acids are highly conserved (mostly A and G) and contribute to dish-like areas that expose the backbones of the helices. The ﬂanking amino acids on the helices determine the size of this area. In the majority of the TCR/MHC structures, these exposed areas are major sites of interaction with speciﬁc amino acids in TCR CDR1 and CDR2 regions. Because these areas occur diagonally opposite one another on the helices, we propose that these exposed areas determine the general diagonal orientation of the TCR on the MHC. The TCR amino acids involved in these interactions are often, as previously noted (85), tyrosines that make many Van der Waals contacts with the backbones of helices and the amino acid side chains that ﬂank these areas. These types of interactions do not require a precise geometry and thus allow considerable ﬂexibility in the orientation and exact position of the TCR amino acid in question along the MHC helices, from one TCR/MHC combination to another. This may account for the ability of TCRs to bind MHCs in different structures with similar but not identical docking angles.

www.annualreviews.org • The Interaction Between αβ TCRs and MHC

189

ANRV338-IY26-06

ARI

26 February 2008

20:33

b

a α2

β1 Vβ28 Vβ29

Vβ28 Vβ29

Annu. Rev. Immunol. 2008.26:171-203. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

Vβ46 Vβ48

69 158

Vα50 Vα51

Vβ46 Vβ48 Vβ54

64

73

Vα29 Vα31

Vα29 Vα31

α1

α1

MHC I

MHC II

Figure 8 The amino acids in Vα and Vβ that frequently contact the same areas of MHC can determine the diagonal aspect of the binding of the TCR to MHC. Ribbon representations of HLA-A2/Tax peptide (pdb 1BD2) and IAb /3K (pdb 1LNU) are shown as examples of MHCI and MHCII molecules, respectively, showing the α1/α domains (cyan), the MHCI α2 domain and the MHCII β1 domains (magenta), and the peptide ( yellow). The positions of two amino acids on the helices of each MHC molecule are labeled: α69 and α158 on MHC1 and α64 and β73 on MHCII. An area around each of these amino acids is circled. TCR amino acids most often found in contact with the MHC within these areas are listed next to each circle.

Interestingly, tyrosines are also often involved in these kinds of interactions between antibodies and protein antigens (87).

Why Are Not All the Evolutionarily Selected Rules Apparent in All TCR/MHC Complexes? If there are rules that govern the interactions between TCR V regions and MHC, then one might expect that these rules would always be manifest, particularly when the V region is involved in recognition of the same MHC allele, regardless of the peptide. However, this is not always observed. For example, investigators have reported the structures of three human TCRs containing Vβ13.1, bound to the class I protein, HLA-A2 (28, 29, 35). One TCR (1G4 190

Marrack et al.

Vα50 Vα51

in 2BNQ) has many contacts between Vβ13.1 and HLA-A2, another (B7 in 1BD2) has a few, and the last (A6 in 1AO7) has none (Figure 2). These differences are due to changes in the CDR3 regions of the TCR. A6 has a very long CDR3β that lifts the TCR away from the MHC, so that contacts are not possible. We hypothesize that this ability of CDR3s to attenuate the evolutionarily selected ability of V regions to interact with MHC is needed for TCRs and the cells bearing them to escape negative selection in the thymus. The intrinsic reactivity of TCR V regions with MHC may then be even further obscured when the TCR binds MHC bound to foreign peptides, since, although these foreign peptides may provide additional positive interactions with TCRs, they may also interfere with the

ANRV338-IY26-06

ARI

26 February 2008

20:33

Annu. Rev. Immunol. 2008.26:171-203. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

built-in TCR/MHC interactions. Such may be illustrated by the 2AK4 structure, in which TCR contacts with MHC were limited by a very pronounced bulge in the surface of MHC, caused by the extraordinary length of the engaged peptide (Figure 2). Thus, the CDR3 regions of the TCR and/or the peptide amino acids projecting out of the MHC groove determine whether or not the TCR will be lifted away from MHC or pitched such that it can contact only a portion of the MHC amino acids.

Do the Evolutionarily Selected Interactions Operate for Both MHCI and MHCII Recognition? Our analysis of highly cross-reactive T cells, such as YAe62, suggested that the same conserved MHC-reactive features of a particular CDR1 and CDR2 might apply to both MHCI and MHCII recognition. In general, we found evidence for this in our analysis, but there seem to be some differences. The rules seem somewhat more apparent with MHCII than with MHCI. For example, in TCRs with mVβ8.2, the limits of the area of contact between VβCDR2 Y48 and the α1 MHC helix appear to be more restricted on MHCII than on MHCI. Also, the MHC αK39 that forms a unique salt bridge with VβCDR2 E54 does not exist in MHCI. One factor might be that a number of the TCR/MHCI structures involve MHC alloantigens, and therefore the TCRs did not come from a repertoire shaped by negative selection by that particular MHC during development. Thus, as more TCR/MHCI structures that involve conventional peptide antigens appear, some of these differences may fade.

A Caveat TCR amino acid engagement of a particular site on MHC does not necessarily mean that the reaction is predetermined by the sequences of TCR and MHC. Instead, the reaction may be forced by other elements, such

as the docking sites of CD4 and CD8 or other phenomena (67). Another possibility is that there are limited numbers of amino acids in the CDR1 and CDR2 regions of TCRs and on the α helices of MHC, so some common reactions are bound to occur. We believe that these possibilities are unlikely for two reasons: First, the interactions are determined by the nature, not the position, of the TCR amino acid (Figure 2). Second, as proposed in Figure 8, the prominent availability of particular TCR amino acids does not in itself predict a particular area of MHC contact. Moreover, differences exist between MHCI and MHCII engagement (see above), which suggests that the system is built more subtly than suggested by the forced position argument. Ultimately, the hypothesis we propose simply focuses attention on particular amino acids whose function must be conﬁrmed in proper experiments, for example, by changing the relevant TCR amino acids in the mouse germ line and observing the effects of the changes on TCR selection and function.

DO THE BIASES OF TCRs FOR RECOGNITION OF MHC APPLY TO NONCLASSICAL MHC MOLECULES? In addition to the classical polymorphic MHC molecules, mammalian species express other relatively nonpolymorphic MHCIb and MHC-like molecules, such as HLA-E, H2M3, MR1, and members of the CD1 family (39, 88, 89). These molecules are also recognized by αβTCR-bearing T cells and are important in fending off infectious diseases. For example, HLA-E-restricted T cells have been identiﬁed in responses to bacteria and viruses, including Mycobacterium tuberculosis (Mtb) and cytomegalovirus (CMV) (90, 91). In mice, H2-M3-restricted T cells have a characteristic preactivated phenotype and mediate early T cell responses against Listeria monocytogenes (92). Similarly, T cells that recognize lipid antigens in the context of the CD1 family have been implicated in

www.annualreviews.org • The Interaction Between αβ TCRs and MHC

191

ARI

26 February 2008

20:33

responses to Sphingomonas, Borrelia burgdorferi, and Mtb (93–98). One feature of this family of MHC-like proteins is that they often present nonpeptide antigens, such as glycolipids. The question then arises how TCRs that may have evolved to react with classical MHC/peptide cope with these nonconventional MHCs and their bound ligands. The nonpolymorphic MHCIb molecule, HLA-E, presents peptides from the leader sequences of conventional MHCIa molecules (99). These MHC/self-peptide complexes are recognized by inhibitory natural killer (NK) receptors as surrogate markers for MHCI ﬁdelity when MHCI expression is altered by speciﬁc pathogens (100, 101). Inhibitory NK receptors are quite tolerant of amino acid changes in HLA-E-presented peptides (39), whereas αβTCRs have conventional speciﬁcities both for HLA-E and its engaged peptides. This is exempliﬁed by the recent solution of the structure of a TCR, KK50.4, bound to HLA-E plus a CMV-encoded mimic of an MHCI leader peptide (39). The overall recognition of HLA-E by the KK50.4 TCR has the same topology as that of T cells reacting with conventional MHC, a similar diagonal binding mode, and the same TCR amino acids are used to dock with HLA-E (Figure 2). Thus, the proposed evolutionary biases of TCRs for MHC apply to reactions with both classical MHC and HLA-E. H2-M3 was originally identiﬁed as a minor histocompatibility molecule that presents a maternally linked factor (102). Like HLAE, H2-M3 is relatively nonpolymorphic but is unique to murine species. The peptidebinding groove of H2-M3 is unlike that of conventional MHCI molecules; it accommodates a formylmethionine moiety at the N terminus of the peptide that facilitates the presentation of bacterial- and mitochondrialproduced proteins (103, 104). The overall dimensions of the groove between the α-helices of H2-M3 are similar to those of conventional MHCI molecules, but the amino acids that line this pocket are primarily nonpolar, which facilitates the presentation of hy-

Annu. Rev. Immunol. 2008.26:171-203. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-06

192

Marrack et al.

drophobic peptides. The molecular basis for TCR recognition of H2-M3 remains undetermined, but the overall similarities to MHCIa suggest it may be receptive to conserved TCR interactions. MHC-related protein 1 (MR1) is another β2 m-associated, MHCIb molecule that is evolutionarily conserved among mammals (105). MR1 is associated with stimulation of, and is required for the development of, mucosal-associated invariant T (MAIT) cells. This population of T cells expresses a TCR with an invariant Vα19-Jα33 TCRα (Vα19i) in mice; in humans MAIT cells express the highly similar combination of Vα7.2 and Jα19 (Vα7.2i) (106). The natural antigens presented by MR1 in vivo are largely unknown, although researchers have suggested a role for gut ﬂora in the activation of these MAIT cells. Surprisingly, although the amino acid composition of the MR1 groove is not especially suited for glycolipid presentation [unlike that of CD1 molecules (see below)], αmannosylceramide stimulates Vα19i T cells in a MR1-dependent manner (107). The structure of MR1 is currently unknown, but, on the basis of the overall similarity to MHCIa and MHCIb, a computational analysis suggested an MHC-like fold and allowed a mutational analysis of the α-helices and the putative antigen-binding groove. The response of several T cell hybridomas to these mutants suggested both an antigen presentation function as well as a diagonal TCR docking mode similar to that of conventional T cells (108).

TCR Recognition of CD1d Molecules The human CD1 family and mouse CD1d are nonpolymorphic, β2 m-associated, MHCIlike molecules expressed predominately on hematopoetic cells. Compared with classical MHCI and MHCII molecules, the antigenbinding groove of CD1 family members is narrower, has a more pronounced bulge in its α2 helix, and is composed primarily of nonpolar amino acids to facilitate the presentation of

Annu. Rev. Immunol. 2008.26:171-203. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-06

ARI

26 February 2008

20:33

diverse hydrophobic ligands, including lipids, glycolipids, and lipopeptides. Whereas the lipid tails serve to anchor these antigens in the groove, the polar head groups extend out of the groove for recognition by T cells (reviewed in Reference 58). Group I CD1 isoforms (CD1a, b, and c) present many different antigens, including lipids and lipopeptides that vary in size and shape (58, 109–113). Most human T cells reactive to CD1a, CD1b, and CD1c express diverse Vα and Vβ gene segments (110, 111, 113), which suggests that group I CD1reactive T cells may have a broad range of unique antigen speciﬁcities. Indeed, CD1aand CD1b-reactive T cell lines are highly speciﬁc for particular peptide moieties on didehydroxymycobactin antigens (for CD1a) and for carbohydrate moieties of mycolyl lipid antigens (for CD1b) (114, 115). Although the precise molecular basis for αβTCR recognition of CD1a, CD1b, or CD1c has not yet been resolved by crystallography, results from mutational analysis of the TCR-interacting face of CD1b suggest a diagonal orientation of TCR contacts, similar to the binding mode observed in conventional T cells (116). The interesting question remains how TCRs with apparently normal geometry can contact the group I CD1 proteins and classical MHC proteins in the same way, given the quite different geometry of the two types of MHC molecules. The situation is entirely different for the group II isoform of CD1d, the only CD1 isoform conserved between mouse and human (58). In contrast to the highly diverse TCR repertoire expressed by T cells reactive to other MHC molecules and group I CD1s, most CD1d-reactive cells in humans and mice are NKT cells (117, 118). NKT cells express an invariant TCRα composed of Vα24-Jα18 (Vα24i TCRα) in humans and the nearly identical Vα14-Jα18 (Vα14i TCRα) in mice (119, 120). The peripheral NKT population uses a diverse but limited number of TCRβ gene segments; the majority of the population expresses Vβ11 in humans and Vβs 2, 7, and

8.2 in mice (117, 118). The invariant TCRα chain and the complete lack of NKT cells in Jα18-deﬁcient mice strongly suggest a critical role for the TCRα in the recognition of glycolipid/CD1d complexes (121). Conversely, the role of the more diverse TCRβ is less clear. NKT cells react with a number of glycolipid antigens (118). Perhaps different TCRβs allow reaction with different glycolipids. We recently used mutagenesis analysis to assess the role of the mouse Vα14i TCRα and TCRβ chains in the recognition of different glycolipid/CD1d complexes (122). We showed that mouse Vα14i TCRα recognition of multiple α-linked glycolipids is conferred by a functional hot spot composed of germ line–encoded amino acids within CDR3α, CDR1α, and CDR2β. This functional hot spot does not differ between structurally distinct antigens, which suggests that the Vα14i TCRα functions as a pattern-recognition receptor. Results from the mutagenesis studies highlighted the critical role of germ line–encoded residues in the Vα14i TCRα,

CD1 α1

α1

β2

Glycolipid α3 α2 β1 β3 CD1 α2 Figure 9 TCRs bind CD1d/glycolipid in an orientation that is completely different from that used to bind classical MHC/peptide. Shown is a plan of the contacts between the CDR1–3 loops of the α and β chains of the hVα24i TCR and a space-ﬁlling surface of CD1d and α-galactosylceramide (data taken from Reference 68, pdb 2PO6). Shown are the α1 region of CD1d (cyan), the α2 region of CD1d (magenta), the glycolipid ( yellow), as well as the CDR loops, color coded and labeled in their corresponding colors.

www.annualreviews.org • The Interaction Between αβ TCRs and MHC

193

ANRV338-IY26-06

ARI

26 February 2008

20:33

CDR2β residue Mouse Vβ8.1

46 47 48 49 50 51 52 53 54 Y S Y V A D S T E

Annu. Rev. Immunol. 2008.26:171-203. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

506-IA (3K)

Mouse Vβ8.2

1LP9 Y

S

Y

G

A

G

S

T

E

b

###

YAe62-IA (3K) k

D10-IA (Conalb)

1D9K

u

1U3H

172.10-IA (MBP) d

2OI9

2C-L (QL9) b

2CKB

b

1G6R

2C-K (dev8)

Mutational

Structural

Mutational

2C-K (SIYR)

NKT TCR recognition of CD1d

PDB ###

AHIII-A2 (p1049) Structural

Mouse TCR recognition of MHCI/II

b

2C-Ld (QL9)

A

A

2C-Kb (SIYR)

A

A

A

W

A

Human Vβ11

Y

Y

G

V

N

S

S

A

A

A

A

T

E

hNKT-hCD1d (αGC) Mouse Vβ8.2

2PO6 Y

S

Y

G

mNKT-mCD1d (αGC)

A

A

mNKT-hCD1d (αGC)

A

A

A

G

S

A

A

A

A

A

A

T

E

Figure 10 Some of the CDR2β amino acids used to contact classical MHCI/MHCII and CD1d are identical. The amino acid sequences of mVβ8.1 and mVβ8.2 are shown in bold. Amino acids that have been shown to bind MHC in solved structures are indicated by blue squares, along with the names of the TCRs and pdb ﬁles used. White squares indicate amino acids that do not contact MHC in the indicated structure. Also shown are the results of mutational analyses, in which the amino acid in question was mutated as shown in each square. The inﬂuence of each mutation is indicated: red-ﬁlled squares indicate >1 log change in reactivity, whereas white squares indicate a <0.5 change in log reactivity (125, 126). Contact points identiﬁed by structural analysis (68) between a hVα24i TCR and hCD1d/αGC and identiﬁed by mutational analyses, using staining with CD1d/αGC tetramers, between a mVα14i TCR and mCD1d/αGC or hCD1d/αGC (122). Red-ﬁlled squares indicate >50% loss in tetramer mean ﬂuorescent intensity (MFI), pink indicates a change between 10% and 50% in tetramer MFI, and white indicates a <10% change in tetramer MFI.

and the requirement for these residues provided a basis for the extremely biased TCR repertoire of NKT cells. Although the mutagenesis studies alone could not provide the molecular basis of the interaction between the TCR and CD1d, the addition of structural 194

Marrack et al.

data facilitated a precise deﬁnition of glycolipid recognition by NKT cells. Because CD1d has an MHC-like fold and TCRβ chains from conventional T cells could provide glycolipid/CD1d speciﬁcity, early models of the TCR-CD1d

Annu. Rev. Immunol. 2008.26:171-203. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-06

ARI

26 February 2008

20:33

interaction postulated that the TCR would dock on CD1d as it does on MHCI/MHCII (55, 56). However, this hypothesis was disproved by the recently solved crystal structure of the Vα24i TCR bound to hCD1d/αGC (68). In this structure, the Vα24i TCR is oriented parallel to, rather than diagonally over, CD1d (Figure 9). The interaction of the Vα24i TCRα chain with CD1d is dominated by CDR3α (encoded by Jα18) residues bound to many conserved residues of CD1d, whereas glycolipid speciﬁcity is contributed primarily by CDR1α (encoded by Vα24/14). A question arises from the evolutionary arguments discussed above: What controls the ability of the Vα24i/14i TCRα to bind CD1d preferentially? The phenomenon may be explained by several observations: First, hJα18 residues in CDR3α interact with a large surface on CD1d and are needed for the speciﬁcity of the NKT TCRs because, although some Vα24 human CD1d/αGC TCRs have been isolated, these TCRs use Jα18 (55, 123). Second, residues in Vα24/14 CDR1α probably also play an important role. Overall, the CDR1α are nearly identical between mouse Vα14 and human Vα24 (63, 64), which suggests that evolutionary pressure has conserved these sequences, including the Vs at 26α, unique in human Vαs, and Ps at 28α, a combination that is unique in mouse Vα14 and human Vα24. These amino acids are crucial for the interaction between NKT TCRs and

CD1d/glycolipid (122) and may be one of the features that control the unique speciﬁcity of the Vα24i/14iTCRα. NKT TCR β chain residues are focused on CD1d rather than the antigen (68). Although the residues that contact CD1d (Y46β, Y48β, and E54β) also bind classical MHC (Figures 2 and 7), they do so at very different sites (compare Figures 1 and 9). The case is most striking for Vβ8.2 Y48β, which has been shown by both structural and mutational experiments to be absolutely required for Vβ8.2+ NKT TCRs to bind CD1d/glycolipid (Figure 10) (68, 122) and which is often crucial to the interaction of conventional TCRs with classical MHC (27, 30, 32, 34, 36, 42, 46, 84a, 124) (Figure 2). Vβ8.2 Y48β binds classical MHCs at a relatively conserved site (27, 30, 32, 34, 36, 42, 46, 85) (Figure 2). Nevertheless, Vβ8.2 Y48β binds CD1d at a totally different site (Figure 9) (68). Thus, Vα24i/14i NKT TCRs behave quite differently from most TCRs that recognize other MHC/ligands. Vα24i/14i TCRs use invariant TCRα chains and a restricted number of TCRβ chains. Vα24i/14i TCRs solve the problem of the different geometry of CD1d versus classical MHC by binding the two types of protein in quite different ways. Nevertheless, it is remarkable that some of the same TCR Vβ residues are crucial for binding both ligands—an example of evolutionary exploitation by the TCRs on NKT cells.

SUMMARY POINTS 1. Certain amino acids in TCR CDR1 and CDR2 regions often contact MHC. These contact points occur in similar positions on MHC in the complexes of different TCRs bound to different MHCs. 2. The target positions on MHC are often cups on the MHC α-helices that contain small amino acids. The TCR CDR amino acids can bind at variable positions within the cups and contact the MHC backbone and the side chains of adjacent amino acids.

www.annualreviews.org • The Interaction Between αβ TCRs and MHC

195

ANRV338-IY26-06

ARI

26 February 2008

20:33

3. This arrangement allows ﬂexibility in the pitch of the CDR1/2 amino acid as it contacts MHC and allows the TCR to accommodate CDR3 regions and peptide ligands of different sequences and lengths and yet still bind the MHC/peptide ligand in approximately the same orientation. 4. TCRs do not usually use all their built-in abilities to react with MHC because negative selection in the thymus removes TCRs that react too well with MHC from mature repertoires. 5. The CDR1/2 amino acids often involved in binding MHC are not the same for all families of variable (V) regions. Annu. Rev. Immunol. 2008.26:171-203. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

6. The frequently used CDR1/2 amino acids may not always be the same in reactions with MHCI and MHCII. 7. The positions of the frequently used CDR1/2 amino acids and their targets on MHC suggest that these contacts may impose the usual diagonal mode of TCR binding on MHC. 8. The Vα24i/14i TCRs that bind CD1d and conventional TCRs that bind classical MHC use some of the same CDR2β residues to contact their ligands, even though the mode of binding is quite different. Vα24i/14i TCRs have adopted evolutionarily selected TCR residues for their own purposes.

DISCLOSURE STATEMENT The authors are not aware of any biases that might be perceived as affecting the objectivity of this review.

ACKNOWLEDGMENTS The authors thank Frances Crawford, Janice White, and Rachel Frugge for their technical help in the work that led to this analysis and Drs. Whitney MacDonald and K.C. Garcia for many helpful discussions. This work was supported in part by USPHS grants AI-17134, AI-19785, AI-22295, AI-057485, and Cancer Center CA-046934.

LITERATURE CITED 1. Claman HN, Chaperon EA, Triplett RF. 1966. Thymus-marrow cell combinations. Synergism in antibody production. Proc. Soc. Exp. Biol. Med. 122:1167–71 2. Mitchell GF, Miller JF. 1968. Cell to cell interaction in the immune response. II. The source of hemolysin-forming cells in irradiated mice given bone marrow and thymus or thoracic duct lymphocytes. J. Exp. Med. 128:821–37 3. Mitchison NA. 1971. The carrier effect in the secondary response to hapten-protein conjugates. V. Use of antilymphocyte serum to deplete animals of helper cells. Eur. J. Immunol. 1:68–75 4. Rajewsky K. 1971. The carrier effect and cellular cooperation in the induction of antibodies. Proc. R. Soc. London Ser. B 176:385–92 196

Marrack et al.

Annu. Rev. Immunol. 2008.26:171-203. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-06

ARI

26 February 2008

20:33

5. Gorer PA. 1937. Genetic and antigenic basis of tumor transplantation. J. Pathol. Bacteriol. 44:691–97 6. Demant P, Graff RJ. 1973. Transplantation analysis of the H-2 system. Transplant. Proc. 5:267–70 7. Jerne NK. 1971. The somatic generation of immune recognition. Eur. J. Immunol. 1:1–9 8. Senyk G, Nitecki D, Goodman JW. 1971. Immunogenicity of glucagon: determinants responsible for antibody binding and lymphocyte stimulation. Science 171:407–8 9. Hoffmann M, Kappler JW. 1973. Regulation of the immune response. II. Qualitative and quantitative differences between thymus- and bone marrow-derived lymphocytes in the recognition of antigen. J. Exp. Med. 137:721–39 10. Hunter P, Munro A, McConnell I. 1972. Properties of educated T cells for rosette formation and cooperation with B cells. Nat. New Biol. 236:52–3 11. McDevitt HO. 2000. Discovering the role of the major histocompatibility complex in the immune response. Annu. Rev. Immunol. 18:1–17 12. Zinkernagel RM, Doherty PC. 1974. Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature 248:701–2 13. Kappler JW, Skidmore B, White J, Marrack P. 1981. Antigen-inducible, H-2-restricted, interleukin-2-producing T cell hybridomas. Lack of independent antigen and H-2 recognition. J. Exp. Med. 153:1198–214 14. Allison JP, McIntyre BW, Bloch D. 2005. Tumor-speciﬁc antigen of murine T-lymphoma deﬁned with monoclonal antibody. 1982. J. Immunol. 174:1144–51 15. Meuer SC, Fitzgerald KA, Hussey RE, Hodgdon JC, Schlossman SF, Reinherz EL. 1983. Clonotypic structures involved in antigen-speciﬁc human T cell function. Relationship to the T3 molecular complex. J. Exp. Med. 157:705–19 16. Haskins K, Kubo R, White J, Pigeon M, Kappler J, Marrack P. 1983. The major histocompatibility complex-restricted antigen receptor on T cells. I. Isolation with a monoclonal antibody. J. Exp. Med. 157:1149–69 17. Hedrick SM, Cohen DI, Nielsen EA, Davis MM. 1984. Isolation of cDNA clones encoding T cell-speciﬁc membrane-associated proteins. Nature 308:149–53 18. Yanagi Y, Yoshikai Y, Leggett K, Clark SP, Aleksander I, Mak TW. 1984. A human T cellspeciﬁc cDNA clone encodes a protein having extensive homology to immunoglobulin chains. Nature 308:145–49 19. Chien Y, Becker DM, Lindsten T, Okamura M, Cohen DI, Davis MM. 1984. A third type of murine T-cell receptor gene. Nature 312:31–35 20. Sim GK, Yague J, Nelson J, Marrack P, Palmer E, et al. 1984. Primary structure of human T-cell receptor α-chain. Nature 312:771–75 21. Davis MM, Bjorkman PJ. 1988. T-cell antigen receptor genes and T-cell recognition. Nature 334:395–402 22. Shimonkevitz R, Colon S, Kappler JW, Marrack P, Grey HM. 1984. Antigen recognition by H-2-restricted T cells. II. A tryptic ovalbumin peptide that substitutes for processed antigen. J. Immunol. 133:2067–74 23. Babbitt BP, Allen PM, Matsueda G, Haber E, Unanue ER. 1985. Binding of immunogenic peptides to Ia histocompatibility molecules. Nature 317:359–61 24. Morrison LA, Lukacher AE, Braciale VL, Fan DP, Braciale TJ. 1986. Differences in antigen presentation to MHC class I-and class II-restricted inﬂuenza virus-speciﬁc cytolytic T lymphocyte clones. J. Exp. Med. 163:903–21 25. Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, Wiley DC. 1987. Structure of the human class I histocompatibility antigen, HLA-A2. Nature 329:506–12 www.annualreviews.org • The Interaction Between αβ TCRs and MHC

197

ARI

26 February 2008

20:33

26. Stern LJ, Brown JH, Jardetzky TS, Gorga JC, Urban RG, et al. 1994. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an inﬂuenza virus peptide. Nature 368:215–21 27. Garcia KC, Degano M, Stanﬁeld RL, Brunmark A, Jackson MR, et al. 1996. An αβ T cell receptor structure at 2.5 A˚ and its orientation in the TCR-MHC complex. Science 274:209–19 28. Garboczi DN, Ghosh P, Utz U, Fan QR, Biddison WE, Wiley DC. 1996. Structure of the complex between human T-cell receptor, viral peptide and HLA-A2. Nature 384:134–41 29. Ding YH, Smith KJ, Garboczi DN, Utz U, Biddison WE, Wiley DC. 1998. Two human T cell receptors bind in a similar diagonal mode to the HLA-A2/Tax peptide complex using different TCR amino acids. Immunity 8:403–11 30. Reinherz EL, Tan K, Tang L, Kern P, Liu J, et al. 1999. The crystal structure of a T cell receptor in complex with peptide and MHC class II. Science 286:1913–21 31. Reiser JB, Darnault C, Guimezanes A, Gregoire C, Mosser T, et al. 2000. Crystal structure of a T cell receptor bound to an allogeneic MHC molecule. Nat. Immunol. 1:291–97 32. Hennecke J, Carﬁ A, Wiley DC. 2000. Structure of a covalently stabilized complex of a human αβ T-cell receptor, inﬂuenza HA peptide and MHC class II molecule, HLA-DR1. EMBO J. 19:5611–24 33. Reiser JB, Gregoire C, Darnault C, Mosser T, Guimezanes A, et al. 2002. A T cell receptor CDR3β loop undergoes conformational changes of unprecedented magnitude upon binding to a peptide/MHC class I complex. Immunity 16:345–54 34. Buslepp J, Kerry SE, Loftus D, Frelinger JA, Appella E, Collins EJ. 2003. High afﬁnity xenoreactive TCR:MHC interaction recruits CD8 in absence of binding to MHC. J. Immunol. 170:373–83 35. Chen JL, Stewart-Jones G, Bossi G, Lissin NM, Wooldridge L, et al. 2005. Structural and kinetic basis for heightened immunogenicity of T cell vaccines. J. Exp. Med. 201:1243–55 36. Colf LA, Bankovich AJ, Hanick NA, Bowerman NA, Jones LL, et al. 2007. How a single T cell receptor recognizes both self and foreign MHC. Cell 129:135–46 37. Deng L, Langley RJ, Brown PH, Xu G, Teng L, et al. 2007. Structural basis for the recognition of mutant self by a tumor-speciﬁc, MHC class II-restricted T cell receptor. Nat. Immunol. 8:398–408 38. Hahn M, Nicholson MJ, Pyrdol J, Wucherpfennig KW. 2005. Unconventional topology of self peptide-major histocompatibility complex binding by a human autoimmune T cell receptor. Nat. Immunol. 6:490–96 39. Hoare HL, Sullivan LC, Pietra G, Clements CS, Lee EJ, et al. 2006. Structural basis for a major histocompatibility complex class Ib-restricted T cell response. Nat. Immunol. 7:256–64 40. Kjer-Nielsen L, Clements CS, Purcell AW, Brooks AG, Whisstock JC, et al. 2003. A structural basis for the selection of dominant αβ T cell receptors in antiviral immunity. Immunity 18:53–64 41. Li Y, Huang Y, Lue J, Quandt JA, Martin R, Mariuzza RA. 2005. Structure of a human autoimmune TCR bound to a myelin basic protein self-peptide and a multiple sclerosisassociated MHC class II molecule. EMBO J. 24:2968–79 42. Maynard J, Petersson K, Wilson DH, Adams EJ, Blondelle SE, et al. 2005. Structure of an autoimmune T cell receptor complexed with class II peptide-MHC: insights into MHC bias and antigen speciﬁcity. Immunity 22:81–92 43. Mazza C, Auphan-Anezin N, Gregoire C, Guimezanes A, Kellenberger C, et al. 2007. How much can a T-cell antigen receptor adapt to structurally distinct antigenic peptides? EMBO J. 26:1972–83

Annu. Rev. Immunol. 2008.26:171-203. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-06

198

Marrack et al.

Annu. Rev. Immunol. 2008.26:171-203. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-06

ARI

26 February 2008

20:33

44. Stewart-Jones GB, McMichael AJ, Bell JI, Stuart DI, Jones EY. 2003. A structural basis for immunodominant human T cell receptor recognition. Nat. Immunol. 4:657–63 45. Tynan FE, Burrows SR, Buckle AM, Clements CS, Borg NA, et al. 2005. T cell receptor recognition of a ‘superbulged’ major histocompatibility complex class I-bound peptide. Nat. Immunol. 6:1114–22 46. Tynan FE, Reid HH, Kjer-Nielsen L, Miles JJ, Wilce MC, et al. 2007. A T cell receptor ﬂattens a bulged antigenic peptide presented by a major histocompatibility complex class I molecule. Nat. Immunol. 8:268–76 47. Adams EJ, Chien YH, Garcia KC. 2005. Structure of a γδ T cell receptor in complex with the nonclassical MHC T22. Science 308:227–31 48. Fink PJ, Bevan MJ. 1978. H-2 antigens of the thymus determine lymphocyte speciﬁcity. J. Exp. Med. 148:766–75 49. Zinkernagel RM, Callahan GN, Althage A, Cooper S, Klein PA, Klein J. 1978. On the thymus in the differentiation of “H-2 self-recognition” by T cells: evidence for dual recognition? J. Exp. Med. 147:882–96 50. Sim BC, Aftahi N, Reilly C, Bogen B, Schwartz RH, et al. 1998. Thymic skewing of the CD4/CD8 ratio maps with the T-cell receptor α-chain locus. Curr. Biol. 8:701–4 51. Bill J, Appel VB, Palmer E. 1988. An analysis of T-cell receptor variable region gene expression in major histocompatibility complex disparate mice. Proc. Natl. Acad. Sci. USA 85:9184–88 52. Sim BC, Zerva L, Greene MI, Gascoigne NR. 1996. Control of MHC restriction by TCR Vα CDR1 and CDR2. Science 273:963–66 53. Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, et al. 1997. CD1d-restricted and TCR-mediated activation of vα14 NKT cells by glycosylceramides. Science 278:1626–29 54. Sullivan BA, Kronenberg M. 2007. TCR-mediated recognition of glycolipid CD1 complexes. Curr. Top. Microbiol. Immunol. 314:165–93 55. Gadola SD, Koch M, Marles-Wright J, Lissin NM, Shepherd D, et al. 2006. Structure and binding kinetics of three different human CD1d-α-galactosylceramide-speciﬁc T cell receptors. J. Exp. Med. 203:699–710 56. Kjer-Nielsen L, Borg NA, Pellicci DG, Beddoe T, Kostenko L, et al. 2006. A structural basis for selection and cross-species reactivity of the semi-invariant NKT cell receptor in CD1d/glycolipid recognition. J. Exp. Med. 203:661–73 57. Zajonc DM, Maricic I, Wu D, Halder R, Roy K, et al. 2005. Structural basis for CD1d presentation of a sulfatide derived from myelin and its implications for autoimmunity. J. Exp. Med. 202:1517–26 58. Moody DB, Zajonc DM, Wilson IA. 2005. Anatomy of CD1-lipid antigen complexes. Nat. Rev. Immunol. 5:387–99 59. Koch M, Stronge VS, Shepherd D, Gadola SD, Mathew B, et al. 2005. The crystal structure of human CD1d with and without α-galactosylceramide. Nat. Immunol. 6:819– 26 60. Giabbai B, Sidobre S, Crispin MD, Sanchez-Ruiz Y, Bachi A, et al. 2005. Crystal structure of mouse CD1d bound to the self ligand phosphatidylcholine: a molecular basis for NKT cell activation. J. Immunol. 175:977–84 61. Marrack P, Shimonkevitz R, Hannum C, Haskins K, Kappler J. 1983. The major histocompatibility complex-restricted antigen receptor on T cells. IV. An antiidiotypic antibody predicts both antigen and I-speciﬁcity. J. Exp. Med. 158:1635–46 62. Clark SP, Arden B, Kabelitz D, Mak TW. 1995. Comparison of human and mouse T-cell receptor variable gene segment subfamilies. Immunogenetics 42:531–40 www.annualreviews.org • The Interaction Between αβ TCRs and MHC

199

ARI

26 February 2008

20:33

63. Arden B, Clark SP, Kabelitz D, Mak TW. 1995. Human T-cell receptor variable gene segment families. Immunogenetics 42:455–500 64. Arden B, Clark SP, Kabelitz D, Mak TW. 1995. Mouse T-cell receptor variable gene segment families. Immunogenetics 42:501–30 65. Garcia KC, Teyton L, Wilson IA. 1999. Structural basis of T cell recognition. Annu. Rev. Immunol. 17:369–97 66. Hennecke J, Wiley DC. 2001. T cell receptor-MHC interactions up close. Cell 104:1–4 67. Mazza C, Malissen B. 2007. What guides MHC-restricted TCR recognition? Semin. Immunol. 19:225–35 68. Borg NA, Wun KS, Kjer-Nielsen L, Wilce MC, Pellicci DG, et al. 2007. CD1d-lipidantigen recognition by the semi-invariant NKT T-cell receptor. Nature 448:44–49 69. Jaeger EE, Bontrop RE, Lanchbury JS. 1994. Structure, diversity, and evolution of the T-cell receptor VB gene repertoire in primates. Immunogenetics 40:184–91 70. Tanaka T, Nei M. 1989. Positive darwinian selection observed at the variable-region genes of immunoglobulins. Mol. Biol. Evol. 6:447–59 71. Blackman M, Yague J, Kubo R, Gay D, Coleclough C, et al. 1986. The T cell repertoire may be biased in favor of MHC recognition. Cell 47:349–57 72. Zerrahn J, Held W, Raulet DH. 1997. The MHC reactivity of the T cell repertoire prior to positive and negative selection. Cell 88:627–36 73. Merkenschlager M, Graf D, Lovatt M, Bommhardt U, Zamoyska R, Fisher AG. 1997. How many thymocytes audition for selection? J. Exp. Med. 186:1149–58 74. Kappler JW, Roehm N, Marrack P. 1987. T cell tolerance by clonal elimination in the thymus. Cell 49:273–80 75. von Boehmer H, Teh HS, Kisielow P. 1989. The thymus selects the useful, neglects the useless and destroys the harmful. Immunol. Today 10:57–61 76. Ignatowicz L, Kappler J, Marrack P. 1996. The repertoire of T cells shaped by a single MHC/peptide ligand. Cell 84:521–29 77. Huseby ES, White J, Crawford F, Vass T, Becker D, et al. 2005. How the T cell repertoire becomes peptide and MHC speciﬁc. Cell 122:247–60 78. Miyazaki T, Wolf P, Tourne S, Waltzinger C, Dierich A, et al. 1996. Mice lacking H2M complexes, enigmatic elements of the MHC class II peptide-loading pathway. Cell 84:531–41 79. Fung-Leung WP, Surh CD, Liljedahl M, Pang J, Leturcq D, et al. 1996. Antigen presentation and T cell development in H2-M-deﬁcient mice. Science 271:1278–81 80. Laufer TM, DeKoning J, Markowitz JS, Lo D, Glimcher LH. 1996. Unopposed positive selection and autoreactivity in mice expressing class II MHC only on thymic cortex. Nature 383:81–85 81. Fukui Y, Ishimoto T, Utsuyama M, Gyotoku T, Koga T, et al. 1997. Positive and negative CD4+ thymocyte selection by a single MHC class II/peptide ligand affected by its expression level in the thymus. Immunity 6:401–10 82. Gapin L, Fukui Y, Kanellopoulos J, Sano T, Casrouge A, et al. 1998. Quantitative analysis of the T cell repertoire selected by a single peptide-major histocompatibility complex. J. Exp. Med. 187:1871–83 83. Huseby ES, Crawford F, White J, Kappler J, Marrack P. 2003. Negative selection imparts peptide speciﬁcity to the mature T cell repertoire. Proc. Natl. Acad. Sci. USA 100:11565–70 84. Huseby ES, Crawford F, White J, Marrack P, Kappler JW. 2006. Interface-disrupting amino acids establish speciﬁcity between T cell receptors and complexes of major histocompatibility complex and peptide. Nat. Immunol. 7:1191–99

Annu. Rev. Immunol. 2008.26:171-203. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-06

200

Marrack et al.

Annu. Rev. Immunol. 2008.26:171-203. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-06

ARI

26 February 2008

20:33

84a. Dai S, Rubtsova K, Scott-Browne J, Huseby E, Crawford R, et al. 2008. Crossreactive T cells spotlight the germline rules for αβ T cell receptor interactions with MHC molecules. Immunity. In press 85. Feng D, Bond CJ, Ely LK, Maynard J, Garcia KC. 2007. Structural evidence for a germline-encoded T cell receptor-major histocompatibility complex inreaction ‘codon’. Nat. Immunol. 8:975–83 86. Rudolph MG, Stanﬁeld RL, Wilson IA. 2006. How TCRs bind MHCs, peptides, and coreceptors. Annu. Rev. Immunol. 24:419–66 87. Mian IS, Bradwell AR, Olsen AJ. 1991. Structure, function and properties of antibody binding sites. J. Mol. Biol. 217:133–51 88. Stroynowski I, Forman J. 1995. Novel molecules related to MHC antigens. Curr. Opin. Immunol. 7:97–102 89. Hansen TH, Huang S, Arnold PL, Fremont DH. 2007. Patterns of nonclassical MHC antigen presentation. Nat. Immunol. 8:563–68 90. Heinzel AS, Grotzke JE, Lines RA, Lewinsohn DA, McNabb AL, et al. 2002. HLA-Edependent presentation of Mtb-derived antigen to human CD8+ T cells. J. Exp. Med. 196:1473–81 91. Mazzarino P, Pietra G, Vacca P, Falco M, Colau D, et al. 2005. Identiﬁcation of effectormemory CMV-speciﬁc T lymphocytes that kill CMV-infected target cells in an HLA-Erestricted fashion. Eur. J. Immunol. 35:3240–47 92. Seaman MS, Wang CR, Forman J. 2000. MHC class Ib-restricted CTL provide protection against primary and secondary Listeria monocytogenes infection. J. Immunol. 165:5192– 201 93. Wu D, Xing GW, Poles MA, Horowitz A, Kinjo Y, et al. 2005. Bacterial glycolipids and analogs as antigens for CD1d-restricted NKT cells. Proc. Natl. Acad. Sci. USA 102:1351– 56 94. Sriram V, Du W, Gervay-Hague J, Brutkiewicz RR. 2005. Cell wall glycosphingolipids of Sphingomonas paucimobilis are CD1d-speciﬁc ligands for NKT cells. Eur. J. Immunol. 35:1692–701 95. Mattner J, Debord KL, Ismail N, Goff RD, Cantu C, 3rd, et al. 2005. Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature 434:525–29 96. Kinjo Y, Wu D, Kim G, Xing GW, Poles MA, et al. 2005. Recognition of bacterial glycosphingolipids by natural killer T cells. Nature 434:520–25 97. Kinjo Y, Tupin E, Wu D, Fujio M, Garcia-Navarro R, et al. 2006. Natural killer T cells recognize diacylglycerol antigens from pathogenic bacteria. Nat. Immunol. 7:978–86 98. Behar SM, Porcelli SA. 2007. CD1-restricted T cells in host defense to infectious diseases. Curr. Top. Microbiol. Immunol. 314:215–50 99. Lee N, Goodlett DR, Ishitani A, Marquardt H, Geraghty DE. 1998. HLA-E surface expression depends on binding of TAP-dependent peptides derived from certain HLA class I signal sequences. J. Immunol. 160:4951–60 100. Braud VM, Allan DS, O’Callaghan CA, Soderstrom K, D’Andrea A, et al. 1998. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 391:795–99 101. Borrego F, Ulbrecht M, Weiss EH, Coligan JE, Brooks AG. 1998. Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequence-derived peptides by CD94/NKG2 confers protection from natural killer cellmediated lysis. J. Exp. Med. 187:813–18 102. Wang CR, Loveland BE, Lindahl KF. 1991. H-2M3 encodes the MHC class I molecule presenting the maternally transmitted antigen of the mouse. Cell 66:335–45 www.annualreviews.org • The Interaction Between αβ TCRs and MHC

201

ARI

26 February 2008

20:33

103. Vyas JM, Shawar SM, Rodgers JR, Cook RG, Rich RR. 1992. Biochemical speciﬁcity of H-2M3a. Stereospeciﬁcity and space-ﬁlling requirements at position 1 maintain Nformyl peptide binding. J. Immunol. 149:3605–11 104. Wang CR, Castano AR, Peterson PA, Slaughter C, Lindahl KF, Deisenhofer J. 1995. Nonclassical binding of formylated peptide in crystal structure of the MHC class Ib molecule H2-M3. Cell 82:655–64 105. Riegert P, Wanner V, Bahram S. 1998. Genomics, isoforms, expression, and phylogeny of the MHC class I-related MR1 gene. J. Immunol. 161:4066–77 106. Tilloy F, Treiner E, Park SH, Garcia C, Lemonnier F, et al. 1999. An invariant T cell receptor α chain deﬁnes a novel TAP-independent major histocompatibility complex class Ib-restricted αβ T cell subpopulation in mammals. J. Exp. Med. 189:1907–21 107. Shimamura M, Huang YY, Okamoto N, Suzuki N, Yasuoka J, et al. 2007. Modulation of Vα19 NKT cell immune responses by α-mannosyl ceramide derivatives consisting of a series of modiﬁed sphingosines. Eur. J. Immunol. 37:1836–44 108. Huang S, Gilﬁllan S, Cella M, Miley MJ, Lantz O, et al. 2005. Evidence for MR1 antigen presentation to mucosal-associated invariant T cells. J. Biol. Chem. 280:21183–93 109. Sieling PA, Chatterjee D, Porcelli SA, Prigozy TI, Mazzaccaro RJ, et al. 1995. CD1restricted T cell recognition of microbial lipoglycan antigens. Science 269:227–30 110. Grant EP, Degano M, Rosat JP, Stenger S, Modlin RL, et al. 1999. Molecular recognition of lipid antigens by T cell receptors. J. Exp. Med. 189:195–205 111. Grant EP, Beckman EM, Behar SM, Degano M, Frederique D, et al. 2002. Fine speciﬁcity of TCR complementarity-determining region residues and lipid antigen hydrophilic moieties in the recognition of a CD1-lipid complex. J. Immunol. 168:3933–40 112. Beckman EM, Porcelli SA, Morita CT, Behar SM, Furlong ST, Brenner MB. 1994. Recognition of a lipid antigen by CD1-restricted αβ+ T cells. Nature 372:691–4 113. Young DC, Moody DB. 2006. T-cell recognition of glycolipids presented by CD1 proteins. Glycobiology 16:103R–12R 114. Moody DB, Reinhold BB, Guy MR, Beckman EM, Frederique DE, et al. 1997. Structural requirements for glycolipid antigen recognition by CD1b-restricted T cells. Science 278:283–86 115. Moody DB, Young DC, Cheng TY, Rosat JP, Roura-Mir C, et al. 2004. T cell activation by lipopeptide antigens. Science 303:527–31 116. Melian A, Watts GF, Shamshiev A, De Libero G, Clatworthy A, et al. 2000. Molecular recognition of human CD1b antigen complexes: evidence for a common pattern of interaction with αβ TCRs. J. Immunol. 165:4494–504 117. Kronenberg M. 2005. Toward an understanding of NKT cell biology: progress and paradoxes. Annu. Rev. Immunol. 23:877–900 118. Bendelac A, Savage PB, Teyton L. 2007. The biology of NKT cells. Annu. Rev. Immunol. 25:297–336 119. Lantz O, Bendelac A. 1994. An invariant T cell receptor α chain is used by a unique subset of major histocompatibility complex class I-speciﬁc CD4+ and CD4− 8− T cells in mice and humans. J. Exp. Med. 180:1097–106 120. Dellabona P, Padovan E, Casorati G, Brockhaus M, Lanzavecchia A. 1994. An invariant Vα24-JαQ/Vβ11 T cell receptor is expressed in all individuals by clonally expanded CD4− 8− T cells. J. Exp. Med. 180:1171–76 121. Cui J, Shin T, Kawano T, Sato H, Kondo E, et al. 1997. Requirement for Vα14 NKT cells in IL-12-mediated rejection of tumors. Science 278:1623–26

Annu. Rev. Immunol. 2008.26:171-203. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-06

202

Marrack et al.

Annu. Rev. Immunol. 2008.26:171-203. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-06

ARI

26 February 2008

20:33

122. Scott-Browne JP, Matsuda JL, Mallevaey T, White J, Borg NA, et al. 2007. Germlineencoded recognition of diverse glycolipids by natural killer T cells. Nat. Immunol. 8:1105– 13 123. Brigl M, van den Elzen P, Chen X, Meyers JH, Wu D, et al. 2006. Conserved and heterogeneous lipid antigen speciﬁcities of CD1d-restricted NKT cell receptors. J. Immunol. 176:3625–34 124. Manning TC, Parke EA, Teyton L, Kranz DM. 1999. Effects of complementarity determining region mutations on the afﬁnity of an αβ T cell receptor: measuring the energy associated with CD4/CD8 repertoire skewing. J. Exp. Med. 189:461–70 125. Manning TC, Schlueter CJ, Brodnicki TC, Parke EA, Speir JA, et al. 1998. Alanine scanning mutagenesis of an αβ T cell receptor: mapping the energy of antigen recognition. Immunity 8:413–25 126. Lee PU, Churchill HR, Daniels M, Jameson SC, Kranz DM. 2000. Role of 2CT cell receptor residues in the binding of self- and allo-major histocompatibility complexes. J. Exp. Med. 191:1355–64

www.annualreviews.org • The Interaction Between αβ TCRs and MHC

203

AR338-FM

ARI

12 January 2008

18:11

Annual Review of Immunology

Annu. Rev. Immunol. 2008.26:171-203. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

Contents

Volume 26, 2008

Frontispiece K. Frank Austen p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p x Doing What I Like K. Frank Austen p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p1 Protein Tyrosine Phosphatases in Autoimmunity Torkel Vang, Ana V. Miletic, Yutaka Arimura, Lutz Tautz, Robert C. Rickert, and Tomas Mustelin p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p 29 Interleukin-21: Basic Biology and Implications for Cancer and Autoimmunity Rosanne Spolski and Warren J. Leonard p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p 57 Forward Genetic Dissection of Immunity to Infection in the Mouse S.M. Vidal, D. Malo, J.-F. Marquis, and P. Gros p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p 81 Regulation and Functions of Blimp-1 in T and B Lymphocytes Gislâine Martins and Kathryn Calame p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p133 Evolutionarily Conserved Amino Acids That Control TCR-MHC Interaction Philippa Marrack, James P. Scott-Browne, Shaodong Dai, Laurent Gapin, and John W. Kappler p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p171 T Cell Trafﬁcking in Allergic Asthma: The Ins and Outs Benjamin D. Medoff, Seddon Y. Thomas, and Andrew D. Luster p p p p p p p p p p p p p p p p p p p p p205 The Actin Cytoskeleton in T Cell Activation Janis K. Burkhardt, Esteban Carrizosa, and Meredith H. Shaffer p p p p p p p p p p p p p p p p p p p p233 Mechanism and Regulation of Class Switch Recombination Janet Stavnezer, Jeroen E.J. Guikema, and Carol E. Schrader p p p p p p p p p p p p p p p p p p p p p p p261 Migration of Dendritic Cell Subsets and their Precursors Gwendalyn J. Randolph, Jordi Ochando, and Santiago Partida-Sánchez p p p p p p p p p p p p p293

v

AR338-FM

ARI

12 January 2008

18:11

The APOBEC3 Cytidine Deaminases: An Innate Defensive Network Opposing Exogenous Retroviruses and Endogenous Retroelements Ya-Lin Chiu and Warner C. Greene p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p317 Thymus Organogenesis Hans-Reimer Rodewald p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p355 Death by a Thousand Cuts: Granzyme Pathways of Programmed Cell Death Dipanjan Chowdhury and Judy Lieberman p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p389 Annu. Rev. Immunol. 2008.26:171-203. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

Monocyte-Mediated Defense Against Microbial Pathogens Natalya V. Serbina, Ting Jia, Tobias M. Hohl, and Eric G. Pamer p p p p p p p p p p p p p p p p p p p421 The Biology of Interleukin-2 Thomas R. Malek p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p453 The Biochemistry of Somatic Hypermutation Jonathan U. Peled, Fei Li Kuang, Maria D. Iglesias-Ussel, Sergio Roa, Susan L. Kalis, Myron F. Goodman, and Matthew D. Scharff p p p p p p p p p p p p p p p p p p p p p481 Anti-Inﬂammatory Actions of Intravenous Immunoglobulin Falk Nimmerjahn and Jeffrey V. Ravetch p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p513 The IRF Family Transcription Factors in Immunity and Oncogenesis Tomohiko Tamura, Hideyuki Yanai, David Savitsky, and Tadatsugu Taniguchi p p p p p535 Choreography of Cell Motility and Interaction Dynamics Imaged by Two-Photon Microscopy in Lymphoid Organs Michael D. Cahalan and Ian Parker p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p585 Development of Secondary Lymphoid Organs Troy D. Randall, Damian M. Carragher, and Javier Rangel-Moreno p p p p p p p p p p p p p p p p627 Immunity to Citrullinated Proteins in Rheumatoid Arthritis Lars Klareskog, Johan Rönnelid, Karin Lundberg, Leonid Padyukov, and Lars Alfredsson p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p651 PD-1 and Its Ligands in Tolerance and Immunity Mary E. Keir, Manish J. Butte, Gordon J. Freeman, and Arlene H. Sharpe p p p p p p p p677 The Master Switch: The Role of Mast Cells in Autoimmunity and Tolerance Blayne A. Sayed, Alison Christy, Mary R. Quirion, and Melissa A. Brown p p p p p p p p p p705 T Follicular Helper (TFH ) Cells in Normal and Dysregulated Immune Responses Cecile King, Stuart G. Tangye, and Charles R. Mackay p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p741

vi

Contents

Annu. Rev. Immunol. 2008.26:205-232. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-07

ARI

24 February 2008

9:43

T Cell Trafﬁcking in Allergic Asthma: The Ins and Outs ∗

∗

Benjamin D. Medoff,1,2, Seddon Y. Thomas,1, and Andrew D. Luster1 1

Center for Immunology and Inﬂammatory Diseases, Division of Rheumatology, Allergy and Immunology, 2 Pulmonary and Critical Care Unit, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts 02129; email: [email protected]

Annu. Rev. Immunol. 2008. 26:205–32

Key Words

First published online as a Review in Advance on November 19, 2007

asthma, T lymphocytes, chemotaxis, chemokines

The Annual Review of Immunology is online at immunol.annualreviews.org This article’s doi: 10.1146/annurev.immunol.26.021607.090312 c 2008 by Annual Reviews. Copyright All rights reserved 0732-0582/08/0423-0205$20.00 ∗

These authors contributed equally to this work.

Abstract T cells are critical mediators of the allergic airway inﬂammation seen in asthma. Pathogenic allergen-speciﬁc T cells are generated in regional lymph nodes and are then recruited into the airway by chemoattractants produced by the asthmatic lung. These recruited effector T cells and their products then mediate the cardinal features of asthma: airway eosinophilia, mucus hypersecretion, and airway hyperreactivity. There has been considerable progress in delineating the molecular mechanisms that control T cell trafﬁcking into peripheral tissue, including the asthmatic lung. In this review, we summarize these advances and formulate them into a working model that proposes that T cell trafﬁcking into and out of the allergic lung is controlled by several discrete regulatory pathways that involve the collaboration of innate and acquired immune cells.

205

ANRV338-IY26-07

ARI

24 February 2008

9:43

INTRODUCTION

Annu. Rev. Immunol. 2008.26:205-232. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

Airway hyperresponsiveness (AHR): increase in narrowing of airways from airway smooth muscle hypercontraction in response to stimuli such as histamine or allergen exposure Mucus hypersecretion: tendency of the mucus-secreting cells in the airway lining of asthmatics to hypertrophy and increase mucus secretion DC: dendritic cell

Asthma is a complex syndrome broadly deﬁned by inﬂammation of the airways associated with airway hyperresponsiveness (AHR) and mucus hypersecretion (1). Asthma has a prevalence estimated at 5% of the population, making it one of the most common chronic diseases worldwide (2). Despite effective therapies, the incidence of this disease and the frequency of its signiﬁcant complications are increasing. New therapeutic approaches based on our understanding of the pathophysiology of asthma could have profound repercussions for the care of asthmatics and the health of the public in general. T lymphocytes are important mediators of adaptive immune responses and are vital for host defense against infection. The lung has a large network of antigen-presenting cells and lymphatics that aid in antigen presentation to T cells in associated lymphoid tissue located within the lung parenchyma and mediastinum. In addition, the adult lung contains T cells (the majority of which are memory cells) residing in the alveoli, airway (bronchial) lumen, intraepithelial layer, submucosa, and interstitium (3). Although important for immunity, aberrant accumulation of T cells in the lung is seen in numerous noninfectious pulmonary inﬂammatory diseases such as asthma, where T lymphocytes in the lung are believed to orchestrate an abnormal inﬂammatory process (4, 5). In asthma, the airways develop prominent inﬂammation with accumulation of activated effector T cells around the airways and in the airway lumen. It is thought that these cells are recruited into the lung and serve as the critical controllers of airway inﬂammation. In this review, we explore the mechanisms of T cell homing into the lung during asthma and present a paradigm for the mechanisms that control the movement of these cells into and out of the airways.

ASTHMA PATHOGENESIS The hallmark of asthma is chronic airway inﬂammation associated with reversible air206

Medoff

·

Thomas

·

Luster

way dysfunction. This causes the classic symptoms and signs of asthma: shortness of breath, cough, mucus production, and wheezing. Although there is a growing recognition that the type of inﬂammation in the airways can be heterogeneous (6), in most cases the airway inﬂammation characteristic of asthma results from an allergic-type reaction to an inhaled antigen from the environment (socalled allergic asthma). In allergic asthma, the airways develop predominantly eosinophilic inﬂammation with prominent edema and mucus production in response to inhalation of antigen. In addition, smooth muscle cells of the airways become hyperreactive, leading to reversible bronchoconstriction in response to various stimuli. In nonallergic asthma, neutrophilic and pauci-immune forms have been described, but it is unclear if these represent distinct clinical phenotypes, as they often respond to conventional asthma therapy (6). In addition, the role of T cells in nonallergic (or noneosinophilic) asthma is currently unknown. For these reasons, in this review, we focus on the homing of T cells only in the allergic form of asthma.

Sensitization One of the earliest steps in the establishment of allergic sensitization to an antigen is the generation of an antigen-speciﬁc T cell response (Figure 1a). Antigens from the environment are constantly introduced into the airways with every breath. Multitudes of airway DCs (dendritic cells) are located under the airway epithelium, where they form an antigen-sampling network in the airway mucosa (7–9). It is thought that adjuvant signals from airway epithelium such as TSLP (thymic stromal lymphopoietin) and GM-CSF (granulocyte-macrophage colony-stimulating factor), generated in response to inhaled stimuli, inﬂuence the activation/maturation state of DCs and help determine whether a particular allergen will trigger a Th2-type inﬂammatory response or will lead to tolerance (5, 8, 10–12). Once DCs mature

ANRV338-IY26-07

ARI

24 February 2008

9:43

a

b

c

Sensitization

Exacerbation

Inflammation

Antigen

Mucus

TSLP GM-CSF

IgE DC

Annu. Rev. Immunol. 2008.26:205-232. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

DC

Mast cell

MΦ

Smooth muscle cells

Memory T cell

Maturation

Cytokines Chemokines Eos PMN Th2 Treg

Naive T cell

Primed T cell

?

Th1

?

Th17 ?

Memory T cell

Lymph node

Th2

NKT

Th2 Eos

Th1 Inflammation

Proliferation

Figure 1 Asthma pathogenesis. (a) Sensitization to an allergen results from uptake by airway dendritic cells (DCs), maturation of the DCs, migration to lymphoid tissue, and antigen presentation to T cells. Maturation of the DCs requires secondary stimuli generated from epithelial cells following antigen exposure. These primed T cells then reenter the lung, where they provide surveillance for the allergen. (b) Exacerbation of allergic airway inﬂammation occurs when there is reexposure to allergen and uptake by airway DCs with presentation of antigen to airway-associated T cells as well as T cells in lymphoid tissue. T cells in the lymph node then proliferate and home to the lung, where they amplify the airway inﬂammation. (c) The full allergic airway phenotype results from cytokine production from T cells as well as from inﬂammatory mediators released from recruited eosinophils and other cells in the lung. This results in mucus hypersecretion, smooth muscle cell hyperreactivity, and airway remodeling with chronic inﬂammation. (PMN, polymorphonuclear cell; Eos, eosinophil; M, macrophage; Treg, T regulatory cell; NKT, natural killer cell.)

and migrate to the draining lymphoid tissue, they can activate antigen-speciﬁc T cells, thus sensitizing the individual to the inhaled antigen. Allergen-speciﬁc memory T cells then migrate into the airways where they can reside long term, even during asymptomatic periods (13–16).

Exacerbation Once an individual is sensitized to an antigen, reexposure in the lung rapidly leads to an exacerbation of allergic airway inﬂammation (Figure 1b). Allergic responses in the airways of sensitized individuals begin with deposition of allergen in the airway mucosa. Once in the www.annualreviews.org • T Cell Trafficking in Asthma

207

Annu. Rev. Immunol. 2008.26:205-232. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-07

ARI

24 February 2008

Early asthmatic response (EAR): initial wave of inﬂammation, airway edema, and airway narrowing occurs within minutes following allergen exposure. Results predominantly from mast cell degranulation Late asthmatic response (LAR): second wave of inﬂammation and airway narrowing occurs within hours to days. Results largely from T cell–mediated inﬂammation Chemokine receptor: seventransmembrane G protein–coupled receptor (GPCR) that induces chemotaxis and adhesion in cells after encounter with a cognate chemokine ligand CRTH2: chemoattractant receptorhomologous molecule expressed on T helper type 2 LTB4 : leukotriene B4 PGD2 : prostaglandin D2

208

9:43

airway, the allergen can react with various innate immune cells and can bind to preformed IgE and IgG antibodies in the airways, leading to immediate mediator release from mast cells and causing the so-called early asthmatic response (EAR). These mediators lead to airway edema and bronchoconstriction and initiate the inﬂammatory inﬁltrate. Inhaled allergen is also taken up by the airway DCs, which are then stimulated to mature and migrate to local lymphoid tissue (8). Once in the lymph node, the DCs present processed antigen to both memory and naive T lymphocytes, leading to T cell activation and differentiation. These activated effector T lymphocytes then migrate into the airways, where they secrete cytokines and other mediators, which direct the late asthmatic response (LAR) in the airway.

Asthma Inflammation In response to cytokines secreted by effector T cells, structural cells as well as other leukocytes in the lung are stimulated to release further inﬂammatory mediators (Figure 1c). This release then stimulates the phenotypic endpoints in asthma: recruitment of eosinophils, mucus hypersecretion by goblet cells in the airway epithelium, smooth muscle cell hyperreactivity, and airway remodeling with chronic inﬂammation. Eosinophils release further mediators and cytokines into the airways and are critical for the full manifestation of the asthma phenotype (17–20).

RECRUITMENT OF T CELLS INTO THE ASTHMATIC LUNG After exposure to allergen, the number of T cells in the airways increases dramatically, amplifying allergic inﬂammation (21, 22). Experiments in animal models have demonstrated that, following allergen challenge, antigenspeciﬁc T cells in the airways do not proliferate but are recruited into the lung from regional lymph nodes, leading to the increase in T cells in the airways (23). Allergen-speciﬁc naive and memory T cells in the lymph nodes are stimulated to proliferate by antigenMedoff

·

Thomas

·

Luster

loaded and -activated DCs that have recently migrated from the airways. Thus, a therapeutic strategy that interrupts the recruitment of pathogenic effector T cells generated in lymphoid tissue from homing to the lung or that enhances the recruitment of regulatory T cells (Tregs) into the lung should effectively interrupt airway inﬂammation in asthma (24). To accomplish this goal, the molecular mechanisms that regulate T cell homing into and out of the asthmatic lung need to be fully elucidated.

T CELL TRAFFICKING IN THE ALLERGIC ASTHMATIC RESPONSE Chemokines, Lipid Chemoattractants, and Cognate Receptors The recruitment of leukocytes into tissue during the asthmatic response is controlled by chemokines and lipid chemoattractants (14, 25). Chemokines (chemotactic cytokines) are 8- to 10-kDa proteins, which are secreted from cells to form a gradient. Chemokines signal through speciﬁc cognate chemokine receptors [seven-transmembrane G protein– coupled receptors (GPCRs)] to induce functional responses, such as adhesion and chemotaxis. Engagement of chemokine receptors with cognate chemokine ligand leads to the movement of cells toward the chemokine gradient. In addition to chemokine receptors, subsets of T cells also express speciﬁc seventransmembrane GPCR lipid chemoattractant receptors, including BLT1 and CRTH2, which play important roles in recruitment during the early asthmatic response. Leukotriene B4 (LTB4 ) and prostaglandin D2 (PGD2 ) signal through BLT1 and CRTH2, respectively, to induce chemotactic recruitment of T cells and other leukocytes.

Chemokine-Mediated T Cell Trafficking into Tissue T cell trafﬁcking is a tightly regulated and complex process that involves expression of

9:43

CCR7

Homeostatic and tissue-speciﬁc T cell trafﬁcking is required for regulated immune surveillance. Speciﬁc chemokine receptors have been associated with T cell homing to tissue-speciﬁc sites, including CCR7 and CXCR5 for the lymph node, CCR9 for the small intestine, and CCR4, CCR8, and CCR10 for the skin (27, 28) (Figure 2). It was initially proposed that CD4+ T cells could be divided into naive (CD45RA+

LY M P H N OD E

POST-C A PIL L A RY VEN U L E

CCL21

HIGH ENDOTHELIAL VENULE

Homeostatic and Organ-Specific Trafficking

CCR10

S

Afferent lymph

CLA

CD62L CCR7

L CD62L BLOOD

SKIN

L L

G

LUNGS

BLOOD

Efferent lymph

CCR9

G

Naive T cells and CCR7+ memory T cells with lymph node homing potential

Naive T cell

S

?

S DC

E-selectin CCL27

numerous different adhesion molecules and chemokines (26). These signals allow T cells to arrest on endothelial cells and migrate into the tissue. Once in the tissue, further signals generated from chemokine gradients can then guide T cells into speciﬁc microcompartments, such as the alveoli or bronchial lumen (3). Thus, the signals that determine the migration and homing of T cells into the lung are crucial for effective immune function. However, inappropriate homing of T cells into the lung may also be a critical component of asthma.

+

CCR7 central memory T cell

CCL25

24 February 2008

α 4β 7

Tissue-homing memory T cells S

L

MadCAM

ARI

PNAd

Annu. Rev. Immunol. 2008.26:205-232. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-07

G GUT

G

Figure 2 Homeostatic- and organ-speciﬁc T cell homing. Speciﬁc chemokine receptors have been associated with organ-speciﬁc trafﬁcking and recirculation. CCR7 has been associated with T cell homing and recirculation into lymphoid tissue. Initially, it was proposed that “central” memory CCR7+ T cells must lose CCR7 expression and gain tissue-speciﬁc chemokine receptors in order to home to tissue-speciﬁc locations. However, CCR7+ memory T cells have been found in the tissue, and it is now believed that CCR7 deﬁnes T cells with lymph node–homing potential. In addition, CCR10 is enriched on CLA+ skin homing T cells (S), whereas CCR9 is enriched on α4 β7 hi gut (G) homing T cells. These receptors are believed to deﬁne T cells with either skin- or gut-homing potential. No such chemoattractant receptor has yet been identiﬁed for lung-speciﬁc T cell homing (L). www.annualreviews.org • T Cell Trafficking in Asthma

209

ARI

24 February 2008

9:43

CCR7+ ), central memory (CD45RA− CCR7+ ), and effector memory (CD45RA− CCR7− ) populations based on CD45RA and CCR7 expression patterns (29). According to this model, naive and central memory T cells express CCR7 and can home to lymph nodes, whereas effector memory T cells must lose expression of CCR7 and gain tissuespeciﬁc homing receptors. This model has subsequently been reﬁned by observations that CCR7+ T cells are found in tissue sites, including the lung (22, 30–32). We and others have found that CCR7 expression on T cells in the tissue marks T cells capable of recirculation to the lymph nodes (33, 34). CCR7 expression is likely regulated dynamically in vivo and may be responsible for the return of peripheral tissue T cells to the lymph node in the process of antigen surveillance. Other examples of tissue-speciﬁc homing receptors include CCR4, CCR8, and CCR10 for the skin and CCR9 for the small intestine. CCR4, CCR8, and CCR10 expression is associated with CLA+ skin-homing T cells, and the cognate ligand for CCR10, CCL27, is highly expressed in the skin at baseline (35). The CCR4 ligand, CCL17, and the CCR8 ligand, CCL1, are also found in the skin, but their pattern of expression is less restricted than that of CCL27 (28, 36–38). Similarly, CCR9 is associated with α4 β7 hi small intestine–homing T cells, and its cognate ligand CCL25 is found in epithelial crypts of the small intestine (39, 40). Currently, no chemoattractant receptor has been speciﬁcally associated with homing to the lung or airways. This suggests that homing to the lung or airway at baseline may require a combination of chemoattractant receptors or that there is an as yet unidentiﬁed chemoattractant receptor involved in this process.

Annu. Rev. Immunol. 2008.26:205-232. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-07

Inflammation-Driven Migratory Patterns of Memory T Cells In addition to this model of homeostaticand tissue-speciﬁc trafﬁcking, T lymphocytes 210

Medoff

·

Thomas

·

Luster

must be able to respond to sites of inﬂammation (Figure 3). This inﬂammatory response can lead to control of viral or bacterial infection but can also be dysregulated and lead to an overexuberant response to an allergen in allergic asthma. In Th2-type inﬂammation, production of STAT6-inducible chemokines from resident cells at sites of inﬂammation recruits IL-4-, IL-5-, or IL-13-secreting Th2 cells through the cognate Th2-associated receptors CCR4 and CCR8 (41). This serves to locally amplify Th2-type inﬂammation. In contrast, in Th1 inﬂammation, production of STAT1-inducible chemokines from resident cells at sites of inﬂammation recruits IFN-γ-secreting Th1 and CD8 effector T cells through the cognate chemokine receptors, CCR5, CXCR3, and CXCR6 (42). This serves to locally amplify Th1-type inﬂammation. Although these receptors have been observed on in vitro polarized T cells, the ex vivo chemoattractant receptor expression pattern is more complex. For example, in human peripheral blood Th1, but not Th2, cells are CXCR3+ CCR4− , whereas Th2, but only rarely Th1, cells are CXCR3− CCR4+ (32). However, the population of CXCR3+ CCR4+ T cells is a mixture of Th1, Th2, and Th0 cells. This pattern illustrates the important interrelationship of chemokine receptor expression proﬁles on T cells in vivo. Th17 inﬂammation is only beginning to be understood. Because Th17 inﬂammation is STAT3 inducible, it will be of interest to identify STAT3-inducible chemokines that could be involved in Th17 cell recruitment (43). A recent study has shown that human Th17 cells are enriched in the CCR6+ CCR4+ subset of CD4+ T cells, whereas Th1 cells are enriched in the CCR6+ CXCR3+ and CCR6− CXCR3+ subsets and Th2 cells in the CCR6− CCR4+ subset (44). CCR6 is highly enriched on memory T cells and immature, but not mature, DCs (45, 46). The ligand for CCR6, CCL20, is highly expressed on inﬂamed epithelium, which could bring together memory T and immature DCs in the tissue

ANRV338-IY26-07

ARI

24 February 2008

LYM PH NODE

9:43

INF LA MED POST-C A PILLA RY VE N U LE

Afferent lymph Naive T cell

Th2

Th17

Annu. Rev. Immunol. 2008.26:205-232. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

Efferent lymph

Th2-type inflammation IL-4/13

DC

Th17 Th2

CCL1 CCL17 CCL22 CCL26

CCL20

Th1

Th17-type inflammation IL-17

BLOOD

Th1

CCL3 CCL4 CCL5 CXCL9 CXCL10 CXCL11 CXCL16

Th1-type inflammation IFN-γ

Figure 3 Inﬂammation-driven migratory patterns of effector T cells. CD4+ T cell–driven inﬂammation is characterized by the predominant type of cytokines secreted by inﬁltrating T cells. In Th1-type inﬂammation, IFN-γ predominates; in Th2-type inﬂammation, IL-4, IL-5, and IL-13 predominate; and in Th17-type inﬂammation, IL-17 predominates. These cytokines in turn induce speciﬁc subsets of IFN-γ-inducible chemokines; IL-4- and IL-13-inducible chemokines; or IL-17-inducible chemokines at the site of inﬂammation. These chemokines then induce the recruitment of T cells that express the speciﬁc cognate receptors for these inﬂammatory chemokines.

(47, 48). Another recent study also identiﬁed Th17 cells as enriched in the CCR2+ CCR5− subset of CD4+ memory T cells (49). Further studies are required to more fully differentiate chemoattractant receptors on Th17 cells from other subsets of T cells. In contrast to Th1, Th2, and Th17 cells, Tregs are not responsible for promoting cytokine-induced inﬂammation but rather for regulating inﬂammation generated by other T cells subsets. Tregs can trafﬁc as part of immune surveillance homeostatically, but also respond to inﬂammation-induced chemokine gradients to inhibit overly exuberant T cell responses. It is necessary to understand Treg trafﬁcking patterns in the context of the asthmatic response because these CD4+ T cells

could play an important role in controlling allergic asthma. In mouse models of disease, the chemokine receptors CCR4 and CCR7 play critical roles in Treg trafﬁcking and function in the draining lymph node (50–52), whereas CCR5 is important for Treg trafﬁcking and function at sites of inﬂammation (53, 54). In addition, CCR8 has been observed on human and mouse FoxP3+ Tregs (52, 55, 56). Tregs likely function in peripheral tissue as well as in draining lymphoid tissue and utilize different sets of chemokine receptors to accomplish these functions. A summary of the key factors for Th1, Th2, Th17, and Treg cell development and the chemokine receptors expressed on these different T cell subsets is shown in Figure 4.

www.annualreviews.org • T Cell Trafficking in Asthma

211

ANRV338-IY26-07

ARI

24 February 2008

9:43

CCR4

CCR5

CCR7 Treg

CXCR3 Th1 CXCR6

CCR5

Fo

xp 3

2 -1 t IL -be T IL G 4, I AT LA3 13

β FG t , T Rγ -6 O IL R

Naive T cell

Th17

Th2

Annu. Rev. Immunol. 2008.26:205-232. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

CCR6

CCR4

CCR8

Figure 4 Chemokine receptors and CD4+ T cell subsets. Chemokine receptors associated with the differentiation of CD4+ T cells under the inﬂuence of the indicated cytokines and transcription factors. The pattern of chemokine receptors expressed by a given CD4+ T cell subset indicated in the ﬁgure does not deﬁne that subset nor is it necessarily speciﬁc for that subset, but it does dictate the speciﬁc homing potential of that speciﬁc T cell subset. Although certain chemokine receptors have been associated with a speciﬁc CD4+ T cell subset, chemokine receptor expression in vivo is complex and overlapping. This expression allows for recruitment of a variety of T cells under inﬂammatory conditions for immune control.

CD4+ T CELL SUBSETS IN THE ALLERGIC ASTHMATIC RESPONSE Segmental allergen challenge: instillation of known allergen into a segment of the lung to induce an in vivo allergic response in sensitized individuals Bronchoalveolar lavage (BAL): wash of alveolar and bronchial airspaces using a bronchoscope to instill ﬂuid and retrieve cells and protein secretions

212

Allergic airway inﬂammation is thought to be mediated by Th2 cells and their cytokines. However, it is also becoming increasingly clear that other subsets of CD4+ T cells, such as Th1 (57–59), Th17 (60), Treg (61– 63), and CD1d-restricted NKT cells (64, 65), may also play a role in the modulating allergic pulmonary inﬂammation. Other non-CD4+ T cell subsets, such as CD8+ T cells and γδ T cells, are also present in the airway, although at numbers 2-fold and 20-fold less than CD4+ T cells, respectively (66). However, the role of CD8+ T (67, 68) and γδ T (69, 70) cells in the asthmatic response is less clear. Therefore, we focus on CD4+ T cells in this review. Medoff

·

Thomas

·

Luster

Th2 Cells In support of this central role of Th2 cells, levels of Th2-type cytokines, including IL4, IL-5, and IL-13, were elevated at baseline in the airways of human asthma patients (71, 72). Following segmental allergen challenge, increases in Th2 cytokines have been measured in allergic asthmatic subjects (21, 73–76). In addition, murine models of allergic pulmonary inﬂammation and AHR have elegantly demonstrated that Th2 cells and the cytokines they secrete were essential for the development of eosinophilia and AHR (77–80). Furthermore, adoptive transfer of effector Th2 cells into naive mice followed by exposure to inhaled antigen induced the pathophysiologic features of asthma, including eosinophilic inﬂammation, mucus hypersecretion, and AHR (81–83), demonstrating that these cells were fully capable of producing the asthma phenotype. Taken together, these data reveal that Th2 cells and the cytokines they secrete are central to the pathogenesis of asthma. Although Th2 cells play a critical role in asthma pathogenesis, they are not the predominant T cells in human BAL (bronchoalveolar lavage) from asthmatic subjects, as measured by intracellular cytokine staining (22, 84–86). Following segmental allergen challenge, the total number of IL4-producing T cells was increased, but the percentage of IL-4 producing Th2 cells was unchanged from prechallenge levels (22, 66, 84). Thus, other T cell subsets must be recruited to the asthmatic BAL along with Th2 cells.

Th1 In addition to Th2 cells, Th1 lymphocytes are also recruited into the lung, where they are capable of either increasing or decreasing the severity of the asthmatic response (57–59). In an adoptive transfer murine model of asthma, it was demonstrated that antigen-speciﬁc Th1 cells could suppress Th2-mediated airway

Annu. Rev. Immunol. 2008.26:205-232. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-07

ARI

24 February 2008

9:43

eosinophilia but did not prevent Th2 cell recruitment or eosinophilia in the lung (57). However, other adoptive transfer mouse models have shown that Th1 cells actually enhance Th2 trafﬁcking and airway eosinophilia (58, 59). Additionally, in human subjects, inhaled IFN-γ led to an increase in lymphocyte recruitment to the airway (87). Following human segmental allergen challenge, the total number of IFN-γ-producing T cells as measured by intracellular cytokine staining increased, but the percentage of IFN-γ Th1 cells decreased somewhat in comparison to prechallenge levels (22, 66, 84). This indicates that Th1 cells trafﬁc to the asthmatic lung, but the decrease in percentage of Th1 cells indicates that these cells may not be preferentially recruited in comparison to other T cell subsets. Th1 cells appear to play an important role in Th2-mediated allergic response and could be recruited through expression of CXCR3 and CCR6, as well as other chemoattractant receptors.

Th17 The role of Th17 cells in the allergic response is only beginning to be investigated. Recently, a murine model of asthma demonstrated that IL-17 is required for the induction of allergic asthma but negatively regulates established asthma (60). IL-17 production was increased following allergen challenge in this model and was further increased in the absence of regulation by the IL-4Rα. Similar to the mouse model, human IL-17 was produced by peripheral blood T cells from allergic asthmatic subjects in response to allergic stimulus and was increased in the human asthmatic airway as compared to healthy controls (88–90). These data, along with observed patterns of chemoattractant receptor expression, suggest that Th17 cells are recruited to the asthmatic airway following allergen challenge through CCR4 and/or CCR6 and may be involved in both the initiation and regulation of the asthmatic response.

Treg Recruitment of Tregs may play a role in the suppression of allergic inﬂammation. Depletion of CD4+ CD25hi Tregs before sensitization with allergen led to an increase in Th2 cytokines, IgE concentrations, eosinophilia, and AHR in C3H mice normally resistant to the allergic asthmatic response (61). Adoptive transfer of antigen-speciﬁc Tregs into allergen-sensitized mice before allergen challenge inhibited AHR, eosinophil recruitment, and Th2 cytokine production through an IL10-dependent process (63). These studies support the notion that Tregs play a key role in regulating the allergic asthmatic process. The balance of Tregs likely regulates the allergic asthmatic response in humans, although this is still being investigated. A recent study showed that the frequency of allergenspeciﬁc IL-10-producing peripheral blood T cells was increased in healthy controls, whereas the frequency of allergen-speciﬁc IL4-producing peripheral blood T cells was increased in atopic asthmatics (91). Because Tregs utilize IL-10 in regulation of T cell inﬂammatory processes, this study suggests that allergic asthmatics may lack high enough levels of IL-10 and thus Treg activity. In addition, a recent study has demonstrated that pediatric asthmatic subjects have a lower percentage of CD4+ CD25hi BAL T cells than do children with chronic cough, healthy controls, or even asthmatic subjects treated with corticosteroids (92). Tregs may play a signiﬁcant role in allergic asthma responsiveness following encounter with antigen. The chemokine receptors expressed on Tregs, including CCR4, CCR5, CCR7, and CCR8, allow these cells to be recruited to either the allergic lung or lymph node to exert their regulatory activity following allergen challenge. Tregs appear to play an important role in regulating the allergic asthmatic response, but further study is required to understand the mechanisms by which they exert their activity and their requirements for tissue localization in this process.

www.annualreviews.org • T Cell Trafficking in Asthma

213

ANRV338-IY26-07

ARI

24 February 2008

9:43

CD1d-Restricted NKT Cells

Annu. Rev. Immunol. 2008.26:205-232. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

A recent report has suggested that CD1drestricted natural killer T (NKT) cells comprise the majority (>60%) of T cells in the asthmatic BAL as compared to healthy controls or subjects with sarcoidosis (64). However, although CD1d-restricted NKT cells were signiﬁcantly enriched in the BAL as compared to blood, we have found that they made up only <2.5% of the lymphocyte gate (93). We believe that the discrepancy between the study by Akbari et al. (64) and our data (93) may be due to nonspeciﬁc staining from alveolar macrophages and cellular debris in the BAL. Further, following segmental allergen challenge, the percentage of BAL CD1d-restricted NKT cells was unchanged from prechallenge levels (22). This suggests that while CD1d-restricted NKT cells are enriched tenfold in the BAL as compared to peripheral blood, CD1d-restricted NKT cells are not the predominant T cell in the asthmatic BAL before or after segmental allergen challenge. Because CD1drestricted NKT cells express high levels of CXCR3, CCR5, and CCR6 as well as intermediate levels of CCR4 (94), these receptors would be predicted to recruit CD1drestricted NKT cells to the asthmatic lung but not with >1000-fold enrichment compared to peripheral blood NKT concentrations, as suggested by Akbari et al. (64). More recent data are consistent with the conclusion that the frequency of CD1drestricted NKT cells in the BAL may have been substantially overestimated, possibly for technical reasons (95). A number of other groups have also observed low numbers of BAL NKT cells in persons with mild, moderate, and severe asthma, subjects with chronic obstructive pulmonary disease (COPD), and healthy controls (95–99), in contrast to the ﬁndings of Akbari et al. (64). In mouse models of asthma, CD1drestricted NKT cells have also been shown to be critical for generating the allergic airway response through production of IL-4 and

214

Medoff

·

Thomas

·

Luster

IL-13 (65, 100). However, the requirement for CD1d-restricted NKT cells (and CD8 T cells) in the development of T cell–dependent airway inﬂammation has been called into question by a recent study that shows that CD4+ T cells, but not CD1d-restricted NKT or CD8 T cells, are sufﬁcient to induce allergic airway inﬂammation (68). Thus, although CD1d-restricted NKT cells likely contribute to the asthmatic response through secretion of Th2 cytokines, we believe that conventional T cells make up the predominant T cell population in the asthmatic BAL and play the predominant role in promoting the allergic asthmatic response.

CHEMOKINES AND CHEMOATTRACTANT RECEPTORS IN THE ALLERGIC ASTHMATIC RESPONSE Although the recruitment of eosinophils into the airways is an important component in the pathogenesis of asthma (see the sidebar, Eosinophil Recruitment into the Lung During Allergic Inﬂammation), the trafﬁcking of activated T lymphocytes into the airways clearly orchestrates the asthmatic inﬂammatory response (101). Consistent with this, after exposure to allergen, there is a dramatic increase in the number of T cells in the airways of humans and in murine models of asthma (1, 21, 22, 41, 71, 102, 103). In a murine model of asthma, we determined that the trafﬁcking of Th2 cells into the airway both before and following allergen challenge is controlled by G protein–coupled chemoattractant receptors (104). Although CCR4 and CCR8 are expressed on Th2 cells, deletion of these receptors in mouse models of asthma has yielded conﬂicting results (105–110). The preservation of Th2 cell trafﬁcking in the absence of individual chemoattractants or their receptors has led us to hypothesize that multiple pathways, acting through multiple chemoattractants and their receptors, direct Th2 cell trafﬁcking into the airways.

Annu. Rev. Immunol. 2008.26:205-232. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-07

ARI

24 February 2008

9:43

Comparisons between normal controls and human asthmatics, as well as human segmental allergen challenge studies, have yielded information about T cell trafﬁcking and chemoattractant receptor expression. At baseline, healthy controls and asthmatic subjects express similar chemokine receptors on BAL T cells (31, 84, 86, 111, 112). BAL T cells were enriched in expression of speciﬁc receptors as compared to peripheral blood T cells and expressed high levels of CCR5, CXCR3, and CXCR4; intermediate levels of CCR4, CCR6, CCR7, and CXCR6; and low levels of BLT1, CCR1, CCR2, CCR3, and CXCR1 along with other chemoattractant receptors. The increased expression of speciﬁc chemoattractant receptors on BAL T cells as compared to peripheral blood T cells may be related to the larger memory T cell population in the BAL and to the requirement for speciﬁc chemokine receptors in trafﬁcking to tissue sites. Following allergic stimulus, a number of chemokines are produced and lead to recruitment of T cells along with other leukocytes to the allergic lung. Human CCR2, CCR3, CCR4, CCR5, CCR6, CXCR1/2, CXCR3, CRTH2, but not CCR8 or CXCR6 ligands were increased following segmental allergen challenge (22, 102, 113–118). Similarly, in the mouse models of asthma, ligands of the chemoattractant receptors, CCR1, CCR2, CCR3, CCR4, CCR5, CCR6, CXCR1, CXCR3, and BLT1 were induced in the lung at early time points (119–122). These data suggest that a number of chemokine receptors play a role in recruitment of T cells and other allergic mediators. We and others have examined the proﬁles of chemoattractant receptor expression on T cells before and after segmental allergen challenge to determine whether speciﬁc chemoattractant receptors were preferentially utilized in T cell recruitment (22, 31). We hypothesized that the Th2-associated receptors CCR3, CCR4, and CCR8 would be increased following allergen challenge, whereas the Th1-associated receptors CCR5,

EOSINOPHIL RECRUITMENT INTO THE LUNG DURING ALLERGIC INFLAMMATION Although T cells likely orchestrate allergic asthmatic inﬂammation, it is the eosinophil that remains the primary leukocyte recruited into the airway during allergic inﬂammation. Recent data indicate that eosinophils are necessary for the full manifestations of the asthma phenotype (17, 18), and thus the mechanisms that control their recruitment into the airway are important for asthma pathogenesis. Eosinophils express the chemokine receptor CCR3 and are likely recruited via production of the STAT6-dependent chemokines CCL11 and CCL24 (in both mice and humans) and CCL26 (in humans only), all of which are upregulated in the airways of asthmatics (117, 173–175). Data in animal models indicate that both CCL11 and CCL24 contribute to eosinophil recruitment, with CCL24 likely being the dominant eosinophilactive chemokine (176). STAT6 expression in a lung cell is necessary for eosinophil recruitment (41), and recent data (159) suggest that alternatively activated macrophages may mediate eosinophil recruitment. We also have data suggesting that myeloid DCs can express CCL24 and may also help mediate eosinophil recruitment (unpublished observation). These data demonstrate that eosinophil recruitment into the airway in allergic inﬂammation is largely controlled by myeloid cells in the lung via a STAT6-dependent mechanism.

CXCR3, and CXCR6 would be decreased following challenge. Although total numbers of T cells were increased following allergen challenge, we did not observe an increase in the percentage of CD4+ or CD8+ T cells expressing any chemoattractant receptor (22). Instead, we noted a statistically signiﬁcant decrease in CCR6 and CXCR3 expression on CD4+ and CD8+ BAL T cells 24 h following allergen challenge. We believe that CCR6 and CXCR3 were downregulated following encounter with cognate ligand, indicating that these two receptors might play an underappreciated role in T cell recruitment to the asthmatic airway. However, we would also argue that these data have not ruled out the signiﬁcance of other chemoattractant receptors in the recruitment of T cells to the allergic lung. www.annualreviews.org • T Cell Trafficking in Asthma

215

ANRV338-IY26-07

ARI

24 February 2008

PAMP: pathogen-associated molecular pattern

9:43

Overall, these data suggest that T cells are recruited to the asthmatic BAL through a number of different chemoattractant receptors. Because the chemokines expressed following the asthmatic response can recruit a variety of T cells, it is important to understand the role of different T cell subsets in the asthmatic response.

Annu. Rev. Immunol. 2008.26:205-232. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

THE PHASES OF T CELL TRAFFICKING IN ALLERGIC ASTHMA: A NEW PARADIGM In the past few years, we and others have made considerable progress in delineating the mechanisms that control T cell trafﬁcking in asthma. These data have led us to the central hypothesis of this review: T cell trafﬁcking into the allergic lung is controlled by several discrete regulatory pathways that involve the collaboration of innate and acquired immune cells. We propose a four-step model that includes an initiation phase, a propagation phase, an ampliﬁcation phase, and a resolution phase (Figure 5). The ﬁrst two phases of T cell recruitment into the airways are mediated by chemoattractants produced by innate immune cells stimulated by the direct interactions of inhaled allergens. Binding and cross-linking of mast cell–associated IgE by allergens lead to mast cell activation, resulting in the release of a ﬁrst set of chemoattractants that initiate T cell recruitment (phase I). We propose that early T cell recruitment is then propagated by the recognition of allergen by PAMP (pathogen-associated molecular pattern) receptors on innate immune cells in the lung, which leads to the release of chemokines (phase II). The third phase of T cell recruitment is mediated by chemoattractants produced in response to the interactions of resident airway cells with the Th2 cells arriving in the initiation and propagation phases of recruitment. These early recruited Th2 cells elaborate Th2-type cytokines that stimulate resident innate immune cells of the airways to release this third set of STAT6inducible chemoattractants that dramatically 216

Medoff

·

Thomas

·

Luster

amplify Th2 cell recruitment (phase III), and also mediate eosinophil recruitment. Finally, a subset of T cells leaves the airways and enters the lymphatics during a resolution phase (phase IV) that we believe may be involved in both attenuating allergic pulmonary inﬂammation and in establishing immunologic memory. In this review, we present data that support this paradigm for the control of T cell migration into and out of the lung.

PHASE I: INITIATION—MAST CELL–DEPENDENT TH2 CELL RECRUITMENT Within minutes of inhaling allergen, IgE on mast cells binds the foreign substance, leading to cross-linking of mast cell IgE Fc receptors (Figure 5a). This cross-linking stimulates the mast cells to release preformed inﬂammatory mediators, such as histamine, and also stimulates the cells to produce and release other mediators, including leukotrienes, TNF-α, chemokines, and Th2-type cytokines. These mediators start the development of mucosal edema, mucus secretion, and airway reactivity. In addition, some of these mediators initiate the recruitment of T cells into the airways (123, 124). We have recently shown that one of these mediators, LTB4 , is a potent chemoattractant for Th2 and Th1 cells (125– 127). Furthermore, we have demonstrated that deletion of the LTB4 receptor, BLT1, leads to an early defect in T cell accumulation in the airways in a model of allergic pulmonary inﬂammation that involves active immunization to a foreign antigen (chicken egg albumin or OVA) with IgE formation. However, this defect was not seen when OVA-speciﬁc Th2 cells were adoptively transferred into unimmunized mice, which do not form OVAspeciﬁc IgE (127). Because one of the important differences between these two models is the formation of IgE and mast cell stimulation with OVA challenge, these results led us to hypothesize that in response to allergen challenge, IgE-activated mast cells release LTB4 into the airway, which mediates the

ANRV338-IY26-07

ARI

24 February 2008

9:43

a

b

Phase I Initiation

Phase II Propagation

Antigen IgE

Early

MΦ

Mast cell

TLR

Annu. Rev. Immunol. 2008.26:205-232. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

BLT1 CCR8

LTB4 CCL1

CXCR3 CCR6

Th2

Minutes

Th1

CXCL10 CCL20

Th17

Hours

c

d

Phase III Amplification

Phase IV Resolution Afferent lymphatics

mDC

IL-4/13R CCL21

Late

CCR4 CCL17 CCL26

Days

Lymph node

CCR3 Th2

Th2 CCR7

Eos

Weeks

Figure 5 Proposed multiphase model of T cell trafﬁcking into the asthmatic airway. (a) Phase I: initial T cell recruitment into the airways. Antigen-IgE complexes stimulate airway mast cells to release various mediators, such as leukotriene B4 (LTB4 ) and CCL1, which leads to Th2 cell recruitment through BLT1 and CCR8. (b) Phase II: propagation of T cell recruitment into the airways. Antigen directly interacts with innate immune cells, such as macrophages via TLRs, to stimulate the release of chemokines, such as CXCL10 and CCL20. These chemokines then recruit more T cells into the airways via their receptors CXCR3 and CCR6. (c) Phase III: proposed mechanism for ampliﬁcation of T cell recruitment into the airways. IL-4 and IL-13 produced by Th2 cells already recruited into the airways stimulate innate immune cells, such as myeloid DCs, to release the STAT6-dependent chemokines CCL17 and CCL22. These chemokines amplify Th2 cell recruitment into the airways through their receptor CCR4. (d ) Phase IV: proposed mechanism for resolution of T cell accumulation in the airways. Th2 cells in the airways that express CCR7 are recruited into the lymphatics through the action of CCL21. This then leads to efﬂux of the Th2 cells out of the lung and into the lymph node.

www.annualreviews.org • T Cell Trafficking in Asthma

217

ANRV338-IY26-07

ARI

24 February 2008

9:43

initial recruitment of Th2 cells into the lung (126). Mast cells also produce and release the chemokines CCL1, CCL17, CCL22, and the chemical histamine, all of which are chemotactic for Th2 cells through interactions with their G protein–coupled receptors CCR8 (CCL1), CCR4 (CCL17, CCL22), and H1R (histamine) (123, 128–130). CCL1 release may be particularly important for early Th2 cell recruitment, as recently demonstrated in a murine model of mast cell-dependent allergic airway inﬂammation (130). Mast cell stimulation by allergen-IgE complexes thus leads to the release of multiple chemoattractants able to initiate the recruitment of T lymphocytes into the airways. The sequential release of LTB4 and chemokines from mast cells is consistent with the differing time courses of the generation of these chemoattractants: LTB4 is rapidly generated enzymatically from membrane lipids within minutes, whereas the release of chemokines may require transcription and translation and consequently take several hours. In addition to generating leukotrienes, activated mast cells also generate prostaglandins, including PGD2 , which could lead to Th2 cell recruitment through the CRTH2 receptor (131–133). In addition to preformed IgE antibodies, IgG antibodies to allergens can also stimulate mast cells and macrophages to release inﬂammatory mediators (134–136). These mediators, which include LTB4 , can further enhance the recruitment of T cells into the airways following allergen exposure. The initial recruitment of T cells in the airways allows the immune system to respond to a perceived threat within minutes as opposed to the hours it would take to mount an adaptive immune response. DC maturation and function may also depend on an initial interaction with memory T cells in the airways (8). Thus, the almost immediate recruitment of memory T cells into the airways following allergen challenge may also help prime the adaptive immune response by increasing potential DC–T cell interactions. Furthermore,

Annu. Rev. Immunol. 2008.26:205-232. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

TLR: Toll-like receptor

218

Medoff

·

Thomas

·

Luster

mast cell degranulation may contribute to the efﬁciency and intensity of the LAR by enhancing T cell recruitment into the airways (124, 127). In summary, soon after the inhalation of allergen, antigen interaction with preformed IgE and IgG antibodies leads to early mediator release, including chemoattractants. These chemoattractants then rapidly induce the initial recruitment of T cells into the airways.

PHASE II: PROPAGATION—INNATE IMMUNE-DEPENDENT TH2 CELL RECRUITMENT In addition to binding to antigen-speciﬁc antibodies, components in allergens, or associated viral infections or particles in the air, can stimulate innate immune cells in the airways through interactions with PAMP receptors, such as the TLRs (Figure 5b). TLR stimulation in asthma exacerbations may occur through LPS (lipopolysaccharide) found in antigens. In addition, viral infections (a common cause of asthma exacerbations) can stimulate innate immune cells as well as epithelial cells via TLR stimulation (137– 140). We have previously shown that most Th2 cell recruitment into the lung following allergen challenge is dependent on tissuederived STAT6-induced chemokines, such as CCL22 and CCL17. Although STAT6 plays a signiﬁcant role in the regulation of antigen-speciﬁc Th2 cell trafﬁcking, there is evidence that STAT6-independent pathways contribute to T cell trafﬁcking into the allergic lung. Namely, after the adoptive transfer of antigen-speciﬁc Th2 cells and antigen challenge, a small number of antigen-speciﬁc Th2 cells do enter the lung of STAT6−/− mice (41, 104). We hypothesize that PAMP receptorinducible chemokines and their corresponding chemokine receptors represent a STAT6independent pathway of antigen-speciﬁc Th2 cell and Th1 cell trafﬁcking. This could have direct relevance to upper respiratory viral

Annu. Rev. Immunol. 2008.26:205-232. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-07

ARI

24 February 2008

9:43

infections, such as the inﬂuenza virus (141) or respiratory syncytial virus (142), which can activate TLR7 and TLR3. In addition, aeroallergens, like animal dander and house dust mites, contain LPS. The importance of TLRs in asthma is indicated by studies demonstrating that the inﬂammatory response in a murine model of asthma is partially dependent on the adaptor molecule, MyD88, a downstream mediator of TLR signaling (12). In addition, LPS in allergens can stimulate antigen-presenting cells in the lung and may play role in Th2 cell polarization (143). Recently, Jung et al. (144) have shown that TLR4 stimulation in an animal model of allergic airway inﬂammation enhances both Th1 and Th2 cell recruitment into the lung. Consistent with this, there is evidence in the published literature that TLR activation leads to CXCL10 and CCL20 expression (145, 146) and that CXCL10 and CCL20 are increased in the context of allergen exposure (22, 102, 121, 122, 147, 148). CXCR3 and CCR6, the receptors recognizing CXCL10 and CCL20, are expressed on T cells that inﬁltrate the lung during allergic inﬂammation (22, 31, 111). Furthermore, CCR6-deﬁcient mice have decreased airway resistance, fewer lung eosinophils, and reduced lung IL-5 levels compared with their wild-type counterparts (121, 149), and the transfer of CCR6+/+ T cells from sensitized wild-type mice into CCR6−/− mice results in an increase in airway eosinophilia and IL5 levels (149). In addition, studies with the CXCL10 knockout and transgenic mice suggest that recruitment of CXCR3+ T cells exacerbates the allergic asthmatic response (122). These data are also consistent with some of our recent ﬁndings suggesting that CXCR3 and CCR6 are mediators of T cell recruitment into the airways of asthmatics following allergen challenge (22). Although Th2 and Th1 cells are likely the primary mediators of allergic airway inﬂammation, some data suggest that other T cell subsets may also be involved in asthma pathogenesis. These include Th17 cells, NKT cells,

CD8+ T cells, and γδ T cells. Th17 cells express CCR6, for which the ligand (CCL20) is made in this phase (44, 150, 151). In addition, NKT cells, CD8+ T cells, and γδ T cells may all be recruited by similar mechanisms as Th1 cells in this phase, with CXCL10 and CCL20 both potentially mediating the recruitment of these cells (22, 94, 152). Allergen deposition in the lung may also interact with other inﬂammatory pathways, such as the complement cascade, and enzymes in the airways, such as chitinases, which could then inﬂuence the production of chemokines (153, 154). For example, the activation of the C5a receptor following allergen challenge increases the secretion of the CCL17 and CCL22 by airway DCs in a murine model of asthma. These data suggest that allergen-induced pattern recognition receptor stimulation on innate immune cells in the lung may contribute to T cell recruitment. We hypothesize that allergen or viral components directly stimulate innate immune cells, activating these cells to present antigen and to produce chemokines and other inﬂammatory cytokines. These mediators then propagate the inﬂammatory response and enhance the recruitment of Th2 cells into the lung. In addition, these mediators may also initiate the recruitment of Th1 cells and other T cell subsets into the lung, which could further enhance the homing of Th2 cells into the lung (58, 59, 144).

PHASE III: AMPLIFICATION— STAT6-DEPENDENT TH2 CELL RECRUITMENT Following the early trafﬁcking of Th2 cells into the airways, there is a dramatic ampliﬁcation of Th2 cell recruitment (Figure 5c). Previous research by our group has shown that deletion of STAT6 in the lung eliminates more than 80% of Th2 cell trafﬁcking following allergen (41, 42). These studies also demonstrated that STAT6 expression in a resident lung cell is necessary for effective www.annualreviews.org • T Cell Trafficking in Asthma

219

ARI

24 February 2008

9:43

Th2 cell and eosinophil recruitment into the airways. Consistent with this ﬁnding, STAT6−/− mice had signiﬁcantly lower production of the Th2-active chemokines CCL17 and CCL22 and the eosinophil-active chemokines CCL11 and CCL24. Using a model of pulmonary Th2 inﬂammation induced by infection by Nippostrongylus brasiliensis, Voehringer et al. (19, 20) demonstrated that STAT6 expression in a bone marrow– derived myeloid cell is necessary for Th2 cell trafﬁcking into the lung. These data suggest that the critical cellular mediator of Th2 cell recruitment is a bone marrow–derived nonlymphocyte cell in the lung, possibly a myeloid-derived cell such as a pulmonary macrophage or DC. We hypothesize that Th2 cells recruited into the lung in the initial and propagation phases produce IL-4 and IL-13 (155), which stimulate myeloid-derived cells in the lung, such as pulmonary macrophages and/or DCs, to produce STAT6-dependent chemokines. These chemokines then serve to amplify the recruitment of Th2 cells and initiate eosinophil trafﬁcking into the lung. Previous work by others has demonstrated that depletion of CD11c+ cells in the lung after sensitization to OVA but prior to challenge prevents the development of allergic airway inﬂammation, suggesting that airway DCs and/or alveolar macrophages (both are CD11c+ ) control key aspects in the pathogenesis of the inﬂammatory response (156). When alveolar macrophages or DCs were added back to the lung in those experiments, the phenotype was restored only with DC transfer, suggesting that DCs were necessary for allergic inﬂammation. In addition, pulmonary DCs accumulate around the airways during allergic inﬂammation and produce CCL17 and CCL22 (9, 153, 156, 157, 158). We have recently found that selective depletion of a population of CD11b+ /CD11c+ myeloid DCs in the lung signiﬁcantly impairs Th2 cell trafﬁcking into the lung following Th2 cell transfer and antigen challenge (B.D. Medoff and A.D. Luster, unpublished observation). Our data demonstrate that myeloid

Annu. Rev. Immunol. 2008.26:205-232. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-07

220

Medoff

·

Thomas

·

Luster

DCs in the lung are both necessary and sufﬁcient for Th2 cell trafﬁcking in this model. Based on these data, we propose that Th2 cells recruited into the airways in the initiation and propagation phase produce cytokines that stimulate pulmonary myeloid DCs to make CCL17 and CCL22, which ampliﬁes Th2 cell recruitment into the airways. In addition, these cells, as well as alternatively activated pulmonary macrophages (159), produce CCL24, which stimulates eosinophil recruitment into the airways. Tregs likely are involved in the control of airway inﬂammation and have been shown to accumulate in the airway during the development of allergic inﬂammation in an animal model of asthma (62). Tregs express the chemokine receptors CCR4 and CCR8 (56) and thus may be recruited by the release of CCL1 during phase I, and CCL17 and CCL22 during phase III of the paradigm.

PHASE IV: RESOLUTION/ MEMORY—CCR7-DEPENDENT TH2 CELL EXIT In murine models of asthma, intense airway inﬂammation produced by sensitization and challenge with allergen decreases over time following the cessation of allergen exposure (160–162) (Figure 5d ). The resolution of airway inﬂammation following allergen challenge is clearly an important process for limiting the allergic response and may prevent complications of inﬂammation. For example, deletion of matrix metalloproteinase2 expression in a murine model of asthma reduced the efﬂux of inﬂammatory cells out of the lung, which slowed the resolution of airway inﬂammation and was associated with increased mortality from asphyxiation (163). Despite its potential importance in asthma, the mechanisms of Th2 cell clearance from the lung are poorly understood. Some cells may become apoptotic (160), and others are likely cleared with expectoration (163). Recently, we have demonstrated that a subset of Th2 effector cells express CCR7 and migrate

Annu. Rev. Immunol. 2008.26:205-232. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-07

ARI

24 February 2008

9:43

into the lymphatics under the guidance of CCL21 expression (33). Although the exact contribution of this CCR7-directed migration for Th2 cell egress from the lung remains to be determined, this may be one of several mechanisms involved in the resolution of allergic airway inﬂammation. In addition, migration of Th2 cells from the lung into the lymphatics may help establish immunologic memory and, importantly, contribute to future exacerbations following allergen reexposure. We propose that CCR7-mediated T cell egress from the asthmatic lung contributes to both the resolution of a primary allergic response as well as to the establishment of T cell memory and generation of local lung recall immune responses.

EXPANSION OF THE PARADIGM FOR OTHER LUNG CELL TYPES The contributions of structural lung cells, such as epithelial cells, endothelial cells, ﬁbroblasts, and smooth muscle cells, in asthma pathogenesis remain less well deﬁned than other innate immune cells in the lung. All these cell types produce chemokines when properly stimulated (164–173) and thus may

also contribute to T cell recruitment into the lung in asthma. However, our data and data from others indicate that mast cells and myeloid cells in the lung are likely the primary mediators of T cell recruitment (19, 20, 156)

CONCLUSIONS In this review, we have tried to identify the critical mediators of T cell migration into and out of the lung during the development and resolution of allergic airway inﬂammation. On the basis these data, we propose a new paradigm in T cell trafﬁcking in asthma, involving three phases of chemoattractant-directed T cell recruitment into the lung, followed by a resolution phase of chemoattractant-directed T cell exit (Figure 5). This paradigm involves extensive interactions between the innate immune cells in the lung and T cells. In addition, each phase is regulated by distinct mechanisms, providing an overlapping network of pathways involved in T cell recruitment. This new paradigm may help provide novel insights into the pathogenesis of asthma and identify potential therapeutic targets to treat this common disorder.

SUMMARY POINTS 1. Asthma is a chronic inﬂammatory disease of the airways that is often caused by an allergic-type reaction to antigen. 2. In most cases the inﬂammatory reaction is orchestrated by CD4+ T cells that are recruited into the airways. 3. Recruitment of T cells into the lung is orchestrated by secretion of chemokines and chemoattractants in response to allergen exposure. 4. IgE-stimulated mast cells mediate early T cell recruitment through the secretion of leukotriene B4 and the chemokines CCL1, CCL17, and CCL22. 5. Allergen may also directly stimulate early T cell recruitment into the airway through interaction with PAMP receptors on macrophages, leading to secretion of chemokines, such as CXCL10 and CCL20. 6. The great majority of T cell recruitment is mediated by exposure of mucosal DCs to the cytokines IL-4 and IL-13, which leads to STAT6-mediated secretion of CCL17 and CCL22. www.annualreviews.org • T Cell Trafficking in Asthma

221

ANRV338-IY26-07

ARI

24 February 2008

9:43

7. Tregs may also be recruited into the airways via the action of chemokines. 8. Some T cells in the airways express CCR7 and are recruited out of the lung back into lymphoid tissue, which may reduce airway inﬂammation but may also provide a mechanism for memory responses to allergens.

DISCLOSURE STATEMENT

Annu. Rev. Immunol. 2008.26:205-232. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

The authors are not aware of any biases that might be perceived as affecting the objectivity of this review.

ACKNOWLEDGMENTS This work was supported by the National Institutes of Health grants K08 HL072775 to B.D. Medoff and R01 AI40618 and T32 AI060548 to A.D. Luster and a Dana Foundation Award in Human Immunology to A.D. Luster.

LITERATURE CITED

7. Established that specialized DCs lie beneath the airway epithelium and provide a sampling network for the airway that serves as the basis for allergen sensitization. 8. Demonstrated that airway DCs interact with airway T cells following antigen uptake, which helps stimulate DC maturation.

222

1. Busse WW, Lemanske RF Jr. 2001. Asthma. N. Engl. J. Med. 344:350–62 2. Weiss S. 1998. Asthma: epidemiology. In Fishman’s Pulmonary Diseases and Disorders, ed. J Fishman, J Elias, M Fishman, L Grippi, L Kaiser, R Senior, pp. 735–43. New York: McGraw-Hill 3. Wardlaw TJ, Guillen C, Morgan A. 2005. Mechanisms of T cell migration to the lung. Clin. Exp. Allergy 35:4–7 4. D’Ambrosio D, Mariani M, Panina-Bordignon P, Sinigaglia F. 2001. Chemokines and their receptors guiding T lymphocyte recruitment in lung inﬂammation. Am. J. Respir. Crit. Care Med. 164:1266–75 5. Herrick CA, Bottomly K. 2003. To respond or not to respond: T cells in allergic asthma. Nat. Rev. Immunol. 3:405–12 6. Haldar P, Pavord ID. 2007. Noneosinophilic asthma: a distinct clinical and pathologic phenotype. J. Allergy Clin. Immunol. 119:1043–52 7. Holt PG, Schon-Hegrad MA, Oliver J, Holt BJ, McMenamin PG. 1990. A contiguous network of dendritic antigen-presenting cells within the respiratory epithelium. Int. Arch. Allergy Appl. Immunol. 91:155–59 8. Huh JC, Strickland DH, Jahnsen FL, Turner DJ, Thomas JA, et al. 2003. Bidirectional interactions between antigen-bearing respiratory tract dendritic cells (DCs) and T cells precede the late phase reaction in experimental asthma: DC activation occurs in the airway mucosa but not in the lung parenchyma. J. Exp. Med. 198:19–30 9. van Rijt LS, Lambrecht BN. 2005. Dendritic cells in asthma: a function beyond sensitization. Clin. Exp. Allergy 35:1125–34 10. Eisenbarth SC, Cassel S, Bottomly K. 2004. Understanding asthma pathogenesis: linking innate and adaptive immunity. Curr. Opin. Pediatr. 16:659–66 11. Eisenbarth SC, Piggott DA, Bottomly K. 2003. The master regulators of allergic inﬂammation: dendritic cells in Th2 sensitization. Curr. Opin. Immunol. 15:620–26 Medoff

·

Thomas

·

Luster

Annu. Rev. Immunol. 2008.26:205-232. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-07

ARI

24 February 2008

9:43

12. Piggott DA, Eisenbarth SC, Xu L, Constant SL, Huleatt JW, et al. 2005. MyD88dependent induction of allergic Th2 responses to intranasal antigen. J. Clin. Invest. 115:459–67 13. Marathias KP, Preffer FI, Pinto C, Kradin RL. 1991. Most human pulmonary inﬁltrating lymphocytes display the surface immune phenotype and functional responses of sensitized T cells. Am. J. Respir. Cell Mol. Biol. 5:470–76 14. Medoff BD, Thomas SY, Banerji A, Wain JC, Zhang H, et al. 2005. Pathogenic T-cell recruitment into the airway in human disease. Ann. NY Acad. Sci. 1062:220–41 15. Strickland D, Kees UR, Holt PG. 1996. Regulation of T-cell activation in the lung: isolated lung T cells exhibit surface phenotypic characteristics of recent activation including down-modulated T-cell receptors, but are locked into the G0/G1 phase of the cell cycle. Immunology 87:242–49 16. Upham JW, McMenamin C, Schon-Hegrad MA, Robinson BW, Holt PG. 1994. Functional analysis of human bronchial mucosal T cells extracted with interleukin-2. Am. J. Respir. Crit. Care Med. 149:1608–13 17. Humbles AA, Lloyd CM, McMillan SJ, Friend DS, Xanthou G, et al. 2004. A critical role for eosinophils in allergic airways remodeling. Science 305:1776–79 18. Lee JJ, Dimina D, Macias MP, Ochkur SI, McGarry MP, et al. 2004. Deﬁning a link with asthma in mice congenitally deﬁcient in eosinophils. Science 305:1773–76 19. Voehringer D, Reese TA, Huang X, Shinkai K, Locksley RM. 2006. Type 2 immunity is controlled by IL-4/IL-13 expression in hematopoietic noneosinophil cells of the innate immune system. J. Exp. Med. 203:1435–46 20. Voehringer D, Shinkai K, Locksley RM. 2004. Type 2 immunity reflects orchestrated recruitment of cells committed to IL-4 production. Immunity 20:267–77 21. Lommatzsch M, Julius P, Kuepper M, Garn H, Bratke K, et al. 2006. The course of allergen-induced leukocyte inﬁltration in human and experimental asthma. J. Allergy Clin. Immunol. 118:91–97 22. Thomas SY, Banerji A, Medoff BD, Lilly CM, Luster AD. 2007. Multiple chemokine receptors, including CCR6 and CXCR3, regulate antigen-induced T cell homing to the human asthmatic airway. J. Immunol. 179:1901–12 23. Harris NL, Watt V, Ronchese F, Le Gros G. 2002. Differential T cell function and fate in lymph node and nonlymphoid tissues. J. Exp. Med. 195:317–26 24. D’Ambrosio D, Iellem A, Colantonio L, Clissi B, Pardi R, Sinigaglia F. 2000. Localization of Th-cell subsets in inﬂammation: differential thresholds for extravasation of Th1 and Th2 cells. Immunol. Today 21:183–86 25. Lukacs NW. 2001. Role of chemokines in the pathogenesis of asthma. Nat. Rev. Immunol. 1:108–16 26. von Andrian UH, Mackay CR. 2000. T-cell function and migration. Two sides of the same coin. N. Engl. J. Med. 343:1020–34 27. Campbell DJ, Kim CH, Butcher EC. 2003. Chemokines in the systemic organization of immunity. Immunol. Rev. 195:58–71 28. Schaerli P, Ebert L, Willimann K, Blaser A, Roos RS, Loetscher P, Moser B. 2004. A skin-selective homing mechanism for human immune surveillance T cells. J. Exp. Med. 199:1265–75 29. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. 1999. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401:708–12 30. Campbell JJ, Murphy KE, Kunkel EJ, Brightling CE, Soler D, et al. 2001. CCR7 expression and memory T cell diversity in humans. J. Immunol. 166:877–84 www.annualreviews.org • T Cell Trafficking in Asthma

19 and 20. These two papers demonstrated that bone marrow–derived myeloid cells control Th2 cell recruitment into the lung during the establishment of a type 2 immune response.

22. Found that multiple chemokine receptors are expressed on T cells recruited into the airway of allergic asthmatic individuals following allergen challenge, including chemokine receptors associated with Th1 cells. 23. Demonstrated that adoptively transferred Th2 cell effectors migrated into the lymph node and lung parenchyma. Following allergen challenge, lymph node T cells proliferated and migrated into lung tissue; T cells in the lung did not proliferate but produced cytokines.

223

Annu. Rev. Immunol. 2008.26:205-232. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-07

ARI

24 February 2008

41. Established that Th2 cell trafficking into the lung during allergic airway inflammation is both STAT6 dependent and independent.

224

9:43

31. Kallinich T, Schmidt S, Hamelmann E, Fischer A, Qin S, et al. 2005. Chemokine-receptor expression on T cells in lung compartments of challenged asthmatic patients. Clin. Exp. Allergy 35:26–33 32. Kim CH, Rott L, Kunkel EJ, Genovese MC, Andrew DP, et al. 2001. Rules of chemokine receptor association with T cell polarization in vivo. J. Clin. Invest. 108:1331–39 33. Bromley SK, Thomas SY, Luster AD. 2005. Chemokine receptor CCR7 guides T cell exit from peripheral tissues and entry into afferent lymphatics. Nat. Immunol. 6:895–901 34. Debes GF, Arnold CN, Young AJ, Krautwald S, Lipp M, et al. 2005. Chemokine receptor CCR7 required for T lymphocyte exit from peripheral tissues. Nat. Immunol. 6:889–94 35. Homey B, Alenius H, Muller A, Soto H, Bowman EP, et al. 2002. CCL27-CCR10 interactions regulate T cell-mediated skin inﬂammation. Nat. Med. 8:157–65 36. Campbell JJ, Haraldsen G, Pan J, Rottman J, Qin S, et al. 1999. The chemokine receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells. Nature 400:776–80 37. Hudak S, Hagen M, Liu Y, Catron D, Oldham E, et al. 2002. Immune surveillance and effector functions of CCR10+ skin homing T cells. J. Immunol. 169:1189–96 38. Clark RA, Chong B, Mirchandani N, Brinster NK, Yamanaka K, et al. 2006. The vast majority of CLA+ T cells are resident in normal skin. J. Immunol. 176:4431–39 39. Kunkel EJ, Campbell JJ, Haraldsen G, Pan J, Boisvert J, et al. 2000. Lymphocyte CC chemokine receptor 9 and epithelial thymus-expressed chemokine (TECK) expression distinguish the small intestinal immune compartment: epithelial expression of tissue-speciﬁc chemokines as an organizing principle in regional immunity. J. Exp. Med. 192:761–68 40. Papadakis KA, Prehn J, Nelson V, Cheng L, Binder SW, et al. 2000. The role of thymusexpressed chemokine and its receptor CCR9 on lymphocytes in the regional specialization of the mucosal immune system. J. Immunol. 165:5069–76 41. Mathew A, MacLean JA, DeHaan E, Tager AM, Green FH, Luster AD. 2001. Signal transducer and activator of transcription 6 controls chemokine production and T helper cell type 2 cell trafficking in allergic pulmonary inflammation. J. Exp. Med. 193:1087–96 42. Mikhak Z, Fleming CM, Medoff BD, Thomas SY, Tager AM, et al. 2006. STAT1 in peripheral tissue differentially regulates homing of antigen-speciﬁc Th1 and Th2 cells. J. Immunol. 176:4959–67 43. Chen Z, Laurence A, Kanno Y, Pacher-Zavisin M, Zhu BM, et al. 2006. Selective regulatory function of Socs3 in the formation of IL-17-secreting T cells. Proc. Natl. Acad. Sci. USA 103:8137–42 44. Acosta-Rodriguez EV, Rivino L, Geginat J, Jarrossay D, Gattorno M, et al. 2007. Surface phenotype and antigenic speciﬁcity of human interleukin 17-producing T helper memory cells. Nat. Immunol. 8:639–46 45. Dieu MC, Vanbervliet B, Vicari A, Bridon JM, Oldham E, et al. 1998. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J. Exp. Med. 188:373–86 46. Liao F, Rabin RL, Smith CS, Sharma G, Nutman TB, Farber JM. 1999. CC-chemokine receptor 6 is expressed on diverse memory subsets of T cells and determines responsiveness to macrophage inﬂammatory protein 3α. J. Immunol. 162:186–94 47. Charbonnier AS, Kohrgruber N, Kriehuber E, Stingl G, Rot A, Maurer D. 1999. Macrophage inﬂammatory protein 3α is involved in the constitutive trafﬁcking of epidermal langerhans cells. J. Exp. Med. 190:1755–68 Medoff

·

Thomas

·

Luster

Annu. Rev. Immunol. 2008.26:205-232. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-07

ARI

24 February 2008

9:43

48. Dieu-Nosjean MC, Massacrier C, Homey B, Vanbervliet B, Pin JJ, et al. 2000. Macrophage inﬂammatory protein 3α is expressed at inﬂamed epithelial surfaces and is the most potent chemokine known in attracting Langerhans cell precursors. J. Exp. Med. 192:705–18 49. Sato W, Aranami T, Yamamura T. 2007. Cutting edge: Human Th17 cells are identiﬁed as bearing CCR2+ CCR5− phenotype. J. Immunol. 178:7525–29 50. Kocks JR, Davalos-Misslitz AC, Hintzen G, Ohl L, Forster R. 2007. Regulatory T cells interfere with the development of bronchus-associated lymphoid tissue. J. Exp. Med. 204:723–34 51. Schneider MA, Meingassner JG, Lipp M, Moore HD, Rot A. 2007. CCR7 is required for the in vivo function of CD4+ CD25+ regulatory T cells. J. Exp. Med. 204:735–45 52. Yuan Q, Bromley SK, Means TK, Jones KJ, Hayashi F, et al. 2007. CCR4-dependent regulatory T cell function in inﬂammatory bowel disease. J. Exp. Med. 204:1327–34 53. Kang SG, Piniecki RJ, Hogenesch H, Lim HW, Wiebke E, et al. 2007. Identiﬁcation of a chemokine network that recruits FoxP3+ regulatory T cells into chronically inﬂamed intestine. Gastroenterology 132:966–81 54. Yurchenko E, Tritt M, Hay V, Shevach EM, Belkaid Y, Piccirillo CA. 2006. CCR5dependent homing of naturally occurring CD4+ regulatory T cells to sites of Leishmania major infection favors pathogen persistence. J. Exp. Med. 203:2451–60 55. Soler D, Chapman TR, Poisson LR, Wang L, Cote-Sierra J, et al. 2006. CCR8 expression identiﬁes CD4 memory T cells enriched for FOXP3+ regulatory and Th2 effector lymphocytes. J. Immunol. 177:6940–51 56. Iellem A, Mariani M, Lang R, Recalde H, Panina-Bordignon P, et al. 2001. Unique chemotactic response proﬁle and speciﬁc expression of chemokine receptors CCR4 and CCR8 by CD4+ CD25+ regulatory T cells. J. Exp. Med. 194:847–53 57. Huang TJ, MacAry PA, Eynott P, Moussavi A, Daniel KC, et al. 2001. Allergen-speciﬁc Th1 cells counteract efferent Th2 cell-dependent bronchial hyperresponsiveness and eosinophilic inﬂammation partly via IFN-γ. J. Immunol. 166:207–17 58. Randolph DA, Carruthers CJ, Szabo SJ, Murphy KM, Chaplin DD. 1999. Modulation of airway inﬂammation by passive transfer of allergen-speciﬁc Th1 and Th2 cells in a mouse model of asthma. J. Immunol. 162:2375–83 59. Randolph DA, Stephens R, Carruthers CJ, Chaplin DD. 1999. Cooperation between Th1 and Th2 cells in a murine model of eosinophilic airway inﬂammation. J. Clin. Invest. 104:1021–29 60. Schnyder-Candrian S, Togbe D, Couillin I, Mercier I, Brombacher F, et al. 2006. Interleukin-17 is a negative regulator of established allergic asthma. J. Exp. Med. 203:2715–25 61. Lewkowich IP, Herman NS, Schleifer KW, Dance MP, Chen BL, et al. 2005. CD4+ CD25+ T cells protect against experimentally induced asthma and alter pulmonary dendritic cell phenotype and function. J. Exp. Med. 202:1549–61 62. Strickland DH, Stumbles PA, Zosky GR, Subrata LS, Thomas JA, et al. 2006. Reversal of airway hyperresponsiveness by induction of airway mucosal CD4+ CD25+ regulatory T cells. J. Exp. Med. 203:2649–60 63. Kearley J, Barker JE, Robinson DS, Lloyd CM. 2005. Resolution of airway inﬂammation and hyperreactivity after in vivo transfer of CD4+ CD25+ regulatory T cells is interleukin 10 dependent. J. Exp. Med. 202:1539–47 64. Akbari O, Faul JL, Hoyte EG, Berry GJ, Wahlstrom J, et al. 2006. CD4+ invariant T-cell-receptor+ natural killer T cells in bronchial asthma. N. Engl. J. Med. 354:1117–29 www.annualreviews.org • T Cell Trafficking in Asthma

62. Demonstrated significant recruitment of Tregs into the airway after induction of allergic inflammation.

225

ARI

24 February 2008

9:43

65. Akbari O, Stock P, Meyer E, Kronenberg M, Sidobre S, et al. 2003. Essential role of NKT cells producing IL-4 and IL-13 in the development of allergen-induced airway hyperreactivity. Nat. Med. 9:582–88 66. Krug N, Erpenbeck VJ, Balke K, Petschallies J, Tschernig T, et al. 2001. Cytokine proﬁle of bronchoalveolar lavage-derived CD4+ , CD8+ , and γδ T cells in people with asthma after segmental allergen challenge. Am. J. Respir. Cell Mol. Biol. 25:125–31 67. Miyahara N, Swanson BJ, Takeda K, Taube C, Miyahara S, et al. 2004. Effector CD8+ T cells mediate inﬂammation and airway hyper-responsiveness. Nat. Med. 10:865–69 68. Das J, Eynott P, Jupp R, Bothwell A, Van Kaer L, et al. 2006. Natural killer T cells and CD8+ T cells are dispensable for T cell-dependent allergic airway inﬂammation. Nat. Med. 12:1345–46 69. Lahn M, Kanehio A, Takeda K, Joetham A, Schwarze J, et al. 1999. Negative regulation of airway responsiveness that is dependent on γδ T cells and independent of αβ T cells. Nat. Med. 5:1150–56 70. Zuany-Amorim C, Rufﬁe C, Haile S, Vargaftig BB, Pereira P, Pretolani M. 1998. Requirement for γδ T cells in allergic airway inﬂammation. Science 280:1265–67 71. Robinson DS, Hamid Q, Ying S, Tsicopoulos A, Barkans J, et al. 1992. Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N. Engl. J. Med. 326:298–304 72. Walker C, Bode E, Boer L, Hansel TT, Blaser K, Virchow JC Jr. 1992. Allergic and nonallergic asthmatics have distinct patterns of T-cell activation and cytokine production in peripheral blood and bronchoalveolar lavage. Am. Rev. Respir. Dis. 146:109–15 73. Batra V, Musani AI, Hastie AT, Khurana S, Carpenter KA, et al. 2004. Bronchoalveolar lavage ﬂuid concentrations of transforming growth factor (TGF)-β1, TGF-β2, interleukin (IL)-4 and IL-13 after segmental allergen challenge and their effects on alphasmooth muscle actin and collagen III synthesis by primary human lung ﬁbroblasts. Clin. Exp. Allergy 34:437–44 74. Kroegel C, Julius P, Matthys H, Virchow JC Jr, Luttmann W. 1996. Endobronchial secretion of interleukin-13 following local allergen challenge in atopic asthma: relationship to interleukin-4 and eosinophil counts. Eur. Respir. J. 9:899–904 75. Liu L, Jarjour NN, Busse WW, Kelly EA. 2004. Enhanced generation of helper T type 1 and 2 chemokines in allergen-induced asthma. Am. J. Respir. Crit. Care Med. 169:1118–24 76. Virchow JC Jr, Walker C, Hafner D, Kortsik C, Werner P, et al. 1995. T cells and cytokines in bronchoalveolar lavage ﬂuid after segmental allergen provocation in atopic asthma. Am. J. Respir. Crit. Care Med. 151:960–68 77. Brusselle G, Kips J, Joos G, Bluethmann H, Pauwels R. 1995. Allergen-induced airway inﬂammation and bronchial responsiveness in wild-type and interleukin-4-deﬁcient mice. Am. J. Respir. Cell Mol. Biol. 12:254–59 78. Foster PS, Hogan SP, Ramsay AJ, Matthaei KI, Young IG. 1996. Interleukin 5 deﬁciency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model. J. Exp. Med. 183:195–201 79. Grunig G, Warnock M, Wakil AE, Venkayya R, Brombacher F, et al. 1998. Requirement for IL-13 independently of IL-4 in experimental asthma. Science 282:2261–63 80. Wills-Karp M, Luyimbazi J, Xu X, Schoﬁeld B, Neben TY, et al. 1998. Interleukin-13: central mediator of allergic asthma. Science 282:2258–61 81. Cohn L, Homer RJ, Marinov A, Rankin J, Bottomly K. 1997. Induction of airway mucus production By T helper 2 (Th2) cells: a critical role for interleukin 4 in cell recruitment but not mucus production. J. Exp. Med. 186:1737–47

Annu. Rev. Immunol. 2008.26:205-232. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-07

226

Medoff

·

Thomas

·

Luster

Annu. Rev. Immunol. 2008.26:205-232. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-07

ARI

24 February 2008

9:43

82. Li L, Xia Y, Nguyen A, Feng L, Lo D. 1998. Th2-induced eotaxin expression and eosinophilia coexist with Th1 responses at the effector stage of lung inﬂammation. J. Immunol. 161:3128–35 83. Li XM, Schoﬁeld BH, Wang QF, Kim KH, Huang SK. 1998. Induction of pulmonary allergic responses by antigen-speciﬁc Th2 cells. J. Immunol. 160:1378–84 84. Brightling CE, Symon FA, Birring SS, Bradding P, Pavord ID, Wardlaw AJ. 2002. TH2 cytokine expression in bronchoalveolar lavage ﬂuid T lymphocytes and bronchial submucosa is a feature of asthma and eosinophilic bronchitis. J. Allergy Clin. Immunol. 110:899– 905 85. Krug N, Madden J, Redington AE, Lackie P, Djukanovic R, et al. 1996. T-cell cytokine proﬁle evaluated at the single cell level in BAL and blood in allergic asthma. Am. J. Respir. Cell Mol. Biol. 14:319–26 86. Morgan AJ, Symon FA, Berry MA, Pavord ID, Corrigan CJ, Wardlaw AJ. 2005. IL-4expressing bronchoalveolar T cells from asthmatic and healthy subjects preferentially express CCR 3 and CCR 4. J. Allergy Clin. Immunol. 116:594–600 87. Martin RJ, Boguniewicz M, Henson JE, Celniker AC, Williams M, et al. 1993. The effects of inhaled interferon γ in normal human airways. Am. Rev. Respir. Dis. 148:1677–82 88. Barczyk A, Pierzchala W, Sozanska E. 2003. Interleukin-17 in sputum correlates with airway hyperresponsiveness to methacholine. Respir. Med. 97:726–33 89. Hashimoto T, Akiyama K, Kobayashi N, Mori A. 2005. Comparison of IL-17 production by helper T cells among atopic and nonatopic asthmatics and control subjects. Int. Arch. Allergy Immunol. 137(Suppl. 1):51–54 90. Molet S, Hamid Q, Davoine F, Nutku E, Taha R, et al. 2001. IL-17 is increased in asthmatic airways and induces human bronchial ﬁbroblasts to produce cytokines. J. Allergy Clin. Immunol. 108:430–38 91. Akdis M, Verhagen J, Taylor A, Karamloo F, Karagiannidis C, et al. 2004. Immune responses in healthy and allergic individuals are characterized by a ﬁne balance between allergen-speciﬁc T regulatory 1 and T helper 2 cells. J. Exp. Med. 199:1567–75 92. Hartl D, Koller B, Mehlhorn AT, Reinhardt D, Nicolai T, et al. 2007. Quantitative and functional impairment of pulmonary CD4+ CD25hi regulatory T cells in pediatric asthma. J. Allergy Clin. Immunol. 119:1258–66 93. Thomas SY, Lilly CM, Luster AD. 2006. Invariant natural killer T cells in bronchial asthma. N. Engl. J. Med. 354:2613–16 94. Thomas SY, Hou R, Boyson JE, Means TK, Hess C, et al. 2003. CD1d-restricted NKT cells express a chemokine receptor proﬁle indicative of Th1-type inﬂammatory homing cells. J. Immunol. 171:2571–80 95. Vijayanand P, Seumois G, Pickard C, Powell RM, Angco G, et al. 2007. Invariant natural killer T cells in asthma and chronic obstructive pulmonary disease. N. Engl. J. Med. 356:1410–22 96. Bratke K, Julius P, Virchow JC. 2007. Invariant natural killer T cells in obstructive pulmonary diseases. N. Engl. J. Med. 357:194 97. Heron M, Claessen AM, Grutters JC. 2007. Invariant natural killer T cells in obstructive pulmonary diseases. N. Engl. J. Med. 357:194 98. Mutalithas K, Croudace J, Guillen C, Siddiqui S, Thickett D, et al. 2007. Bronchoalveolar lavage invariant natural killer T cells are not increased in asthma. J. Allergy Clin. Immunol. 119:1274–76 99. Pham-Thi N, de Blic J, Leite-de-Moraes MC. 2006. Invariant natural killer T cells in bronchial asthma. N. Engl. J. Med. 354:2613–16 www.annualreviews.org • T Cell Trafficking in Asthma

227

ARI

24 February 2008

9:43

100. Lisbonne M, Diem S, de Castro Keller A, Lefort J, Araujo LM, et al. 2003. Cutting edge: invariant Vα14 NKT cells are required for allergen-induced airway inﬂammation and hyperreactivity in an experimental asthma model. J. Immunol. 171:1637–41 101. Larche M, Robinson DS, Kay AB. 2003. The role of T lymphocytes in the pathogenesis of asthma. J. Allergy Clin. Immunol. 111:450–63 102. Bochner BS, Hudson SA, Xiao HQ, Liu MC. 2003. Release of both CCR4-active and CXCR3-active chemokines during human allergic pulmonary late-phase reactions. J. Allergy Clin. Immunol. 112:930–34 103. Pilette C, Francis JN, Till SJ, Durham SR. 2004. CCR4 ligands are up-regulated in the airways of atopic asthmatics after segmental allergen challenge. Eur. Respir. J. 23:876–84 104. Mathew A, Medoff BD, Carafone AD, Luster AD. 2002. Cutting edge: Th2 cell trafﬁcking into the allergic lung is dependent on chemoattractant receptor signaling. J. Immunol. 169:651–55 105. Chung CD, Kuo F, Kumer J, Motani AS, Lawrence CE, et al. 2003. CCR8 is not essential for the development of inﬂammation in a mouse model of allergic airway disease. J. Immunol. 170:581–87 106. Chvatchko Y, Hoogewerf AJ, Meyer A, Alouani S, Juillard P, et al. 2000. A key role for CC chemokine receptor 4 in lipopolysaccharide-induced endotoxic shock. J. Exp. Med. 191:1755–64 107. Gonzalo JA, Pan Y, Lloyd CM, Jia GQ, Yu G, et al. 1999. Mouse monocyte-derived chemokine is involved in airway hyperreactivity and lung inﬂammation. J. Immunol. 163:403–11 108. Goya I, Villares R, Zaballos A, Gutierrez J, Kremer L, et al. 2003. Absence of CCR8 does not impair the response to ovalbumin-induced allergic airway disease. J. Immunol. 170:2138–46 109. Lloyd CM, Delaney T, Nguyen T, Tian J, Martinez AC, et al. 2000. CC chemokine receptor (CCR)3/eotaxin is followed by CCR4/monocyte-derived chemokine in mediating pulmonary T helper lymphocyte type 2 recruitment after serial antigen challenge in vivo. J. Exp. Med. 191:265–74 110. Chensue SW, Lukacs NW, Yang TY, Shang X, Frait KA, et al. 2001. Aberrant in vivo T helper type 2 cell response and impaired eosinophil recruitment in CC chemokine receptor 8 knockout mice. J. Exp. Med. 193:573–84 111. Campbell JJ, Brightling CE, Symon FA, Qin S, Murphy KE, et al. 2001. Expression of chemokine receptors by lung T cells from normal and asthmatic subjects. J. Immunol. 166:2842–48 112. Morgan AJ, Guillen C, Symon FA, Huynh TT, Berry MA, et al. 2005. Expression of CXCR6 and its ligand CXCL16 in the lung in health and disease. Clin. Exp. Allergy 35:1572–80 113. Murray JJ, Tonnel AB, Brash AR, Roberts LJ 2nd, Gosset P, et al. 1986. Release of prostaglandin D2 into human airways during acute antigen challenge. N. Engl. J. Med. 315:800–4 114. Berkman N, Ohnona S, Chung FK, Breuer R. 2001. Eotaxin-3 but not eotaxin gene expression is upregulated in asthmatics 24 hours after allergen challenge. Am. J. Respir. Cell Mol. Biol. 24:682–87 115. Brown JR, Kleimberg J, Marini M, Sun G, Bellini A, Mattoli S. 1998. Kinetics of eotaxin expression and its relationship to eosinophil accumulation and activation in bronchial biopsies and bronchoalveolar lavage (BAL) of asthmatic patients after allergen inhalation. Clin. Exp. Immunol. 114:137–46

Annu. Rev. Immunol. 2008.26:205-232. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-07

228

Medoff

·

Thomas

·

Luster

Annu. Rev. Immunol. 2008.26:205-232. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-07

ARI

24 February 2008

9:43

116. Holgate ST, Bodey KS, Janezic A, Frew AJ, Kaplan AP, Teran LM. 1997. Release of RANTES, MIP-1α, and MCP-1 into asthmatic airways following endobronchial allergen challenge. Am. J. Respir. Crit. Care Med. 156:1377–83 117. Lilly CM, Nakamura H, Belostotsky OI, Haley KJ, Garcia-Zepeda EA, et al. 2001. Eotaxin expression after segmental allergen challenge in subjects with atopic asthma. Am. J. Respir. Crit. Care Med. 163:1669–75 118. Sur S, Kita H, Gleich GJ, Chenier TC, Hunt LW. 1996. Eosinophil recruitment is associated with IL-5, but not with RANTES, twenty-four hours after allergen challenge. J. Allergy Clin. Immunol. 97:1272–78 119. Henderson WR Jr, Lewis DB, Albert RK, Zhang Y, Lamm WJ, et al. 1996. The importance of leukotrienes in airway inﬂammation in a mouse model of asthma. J. Exp. Med. 184:1483–94 120. Fulkerson PC, Zimmermann N, Hassman LM, Finkelman FD, Rothenberg ME. 2004. Pulmonary chemokine expression is coordinately regulated by STAT1, STAT6, and IFNγ. J. Immunol. 173:7565–74 121. Lukacs NW, Prosser DM, Wiekowski M, Lira SA, Cook DN. 2001. Requirement for the chemokine receptor CCR6 in allergic pulmonary inﬂammation. J. Exp. Med. 194:551–55 122. Medoff BD, Sauty A, Tager AM, Maclean JA, Smith RN, et al. 2002. IFN-γ-inducible protein 10 (CXCL10) contributes to airway hyperreactivity and airway inﬂammation in a mouse model of asthma. J. Immunol. 168:5278–86 123. Bryce PJ, Mathias CB, Harrison KL, Watanabe T, Geha RS, Oettgen HC. 2006. The H1 histamine receptor regulates allergic lung responses. J. Clin. Invest. 116:1624–32 124. Stephens R, Chaplin DD. 2002. IgE cross-linking or lipopolysaccharide treatment induces recruitment of Th2 cells to the lung in the absence of speciﬁc antigen. J. Immunol. 169:5468–76 125. Goodarzi K, Goodarzi M, Tager AM, Luster AD, von Andrian UH. 2003. Leukotriene B4 and BLT1 control cytotoxic effector T cell recruitment to inﬂamed tissues. Nat. Immunol. 4:965–73 126. Luster AD, Tager AM. 2004. T-cell trafﬁcking in asthma: lipid mediators grease the way. Nat. Rev. Immunol. 4:711–24 127. Tager AM, Bromley SK, Medoff BD, Islam SA, Bercury SD, et al. 2003. Leukotriene B4 receptor BLT1 mediates early effector T cell recruitment. Nat. Immunol. 4:982–90 128. Gombert M, Dieu-Nosjean MC, Winterberg F, Bunemann E, Kubitza RC, et al. 2005. CCL1-CCR8 interactions: an axis mediating the recruitment of T cells and Langerhanstype dendritic cells to sites of atopic skin inﬂammation. J. Immunol. 174:5082–91 129. Oliveira SH, Lukacs NW. 2001. Stem cell factor and IgE-stimulated murine mast cells produce chemokines (CCL2, CCL17, CCL22) and express chemokine receptors. Inﬂamm. Res. 50:168–74 130. Gonzalo JA, Qiu Y, Lora JM, Al-Garawi A, Villeval JL, et al. 2007. Coordinated involvement of mast cells and T cells in allergic mucosal inﬂammation: critical role of the CC chemokine ligand 1:CCR8 axis. J. Immunol. 179:1740–50 131. Hirai H, Tanaka K, Yoshie O, Ogawa K, Kenmotsu K, et al. 2001. Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J. Exp. Med. 193:255–61 132. Nagata K, Hirai H, Tanaka K, Ogawa K, Aso T, et al. 1999. CRTH2, an orphan receptor of T-helper-2-cells, is expressed on basophils and eosinophils and responds to mast cellderived factor(s). FEBS Lett. 459:195–99 www.annualreviews.org • T Cell Trafficking in Asthma

127. Established leukotriene B4 as a potent chemoattractant for effector T cells and as a mediator of early T cell recruitment following allergen challenge in sensitized mice.

229

ARI

24 February 2008

9:43

133. Nagata K, Tanaka K, Ogawa K, Kemmotsu K, Imai T, et al. 1999. Selective expression of a novel surface molecule by human Th2 cells in vivo. J. Immunol. 162:1278–86 134. DuBourdieu DJ, Morgan DW. 1990. Multiple pathways for signal transduction in the regulation of arachidonic acid metabolism in rat peritoneal macrophages. Biochim. Biophys. Acta 1054:326–32 135. Hsueh W, Gonzalez-Crussi F, Henderson S. 1987. LTB4 production and lysosomal enzyme release by rat alveolar macrophages: effects of phagocytosis, receptor binding, and ionophore stimulation. Exp. Lung Res. 13:385–99 136. Rankin JA, Schrader CE, Smith SM, Lewis RA. 1989. Recombinant interferon-γ primes alveolar macrophages cultured in vitro for the release of leukotriene B4 in response to IgG stimulation. J. Clin. Invest. 83:1691–700 137. Everard ML. 2006. The relationship between respiratory syncytial virus infections and the development of wheezing and asthma in children. Curr. Opin. Allergy Clin. Immunol. 6:56–61 138. Heymann PW, Platts-Mills TA, Johnston SL. 2005. Role of viral infections, atopy and antiviral immunity in the etiology of wheezing exacerbations among children and young adults. Pediatr. Infect. Dis. J. 24:S217–22, discussion S220–21 139. Platts-Mills TA, Erwin EA, Woodfolk JA, Heymann PW. 2006. Environmental factors inﬂuencing allergy and asthma. Chem. Immunol. Allergy 91:3–15 140. Kato H, Takeuchi O, Sato S, Yoneyama M, Yamamoto M, et al. 2006. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441:101–5 141. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C. 2004. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303:1529–31 142. Rudd BD, Smit JJ, Flavell RA, Alexopoulou L, Schaller MA, et al. 2006. Deletion of TLR3 alters the pulmonary immune environment and mucus production during respiratory syncytial virus infection. J. Immunol. 176:1937–42 143. Eisenbarth SC, Piggott DA, Huleatt JW, Visintin I, Herrick CA, Bottomly K. 2002. Lipopolysaccharide-enhanced, Toll-like receptor 4-dependent T helper cell type 2 responses to inhaled antigen. J. Exp. Med. 196:1645–51 144. Jung YW, Schoeb TR, Weaver CT, Chaplin DD. 2006. Antigen and lipopolysaccharide play synergistic roles in the effector phase of airway inﬂammation in mice. Am. J. Pathol. 168:1425–34 145. Kawai T, Takeuchi O, Fujita T, Inoue J, Muhlradt PF, et al. 2001. Lipopolysaccharide stimulates the MyD88-independent pathway and results in activation of IFN-regulatory factor 3 and the expression of a subset of lipopolysaccharide-inducible genes. J. Immunol. 167:5887–94 146. Reibman J, Hsu Y, Chen LC, Bleck B, Gordon T. 2003. Airway epithelial cells release MIP-3α/CCL20 in response to cytokines and ambient particulate matter. Am. J. Respir. Cell Mol. Biol. 28:648–54 147. Pichavant M, Charbonnier AS, Taront S, Brichet A, Wallaert B, et al. 2005. Asthmatic bronchial epithelium activated by the proteolytic allergen Der p 1 increases selective dendritic cell recruitment. J. Allergy Clin. Immunol. 115:771–78 148. Thomas MS, Kunkel SL, Lukacs NW. 2002. Differential role of IFN-γ-inducible protein 10 kDa in a cockroach antigen-induced model of allergic airway hyperreactivity: systemic vs local effects. J. Immunol. 169:7045–53 149. Lundy SK, Lira SA, Smit JJ, Cook DN, Berlin AA, Lukacs NW. 2005. Attenuation of allergen-induced responses in CCR6−/− mice is dependent upon altered pulmonary T lymphocyte activation. J. Immunol. 174:2054–60

Annu. Rev. Immunol. 2008.26:205-232. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-07

230

Medoff

·

Thomas

·

Luster

Annu. Rev. Immunol. 2008.26:205-232. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-07

ARI

24 February 2008

9:43

150. Annunziato F, Cosmi L, Santarlasci V, Maggi L, Liotta F, et al. 2007. Phenotypic and functional features of human Th17 cells. J. Exp. Med. 204:1849–61 151. Kao CY, Huang F, Chen Y, Thai P, Wachi S, et al. 2005. Up-regulation of CC chemokine ligand 20 expression in human airway epithelium by IL-17 through a JAK-independent but MEK/NF-κB-dependent signaling pathway. J. Immunol. 175:6676–85 152. Glatzel A, Wesch D, Schiemann F, Brandt E, Janssen O, Kabelitz D. 2002. Patterns of chemokine receptor expression on peripheral blood γδ T lymphocytes: strong expression of CCR5 is a selective feature of Vδ2/Vγ9 γδ T cells. J. Immunol. 168:4920–29 153. Kohl J, Baelder R, Lewkowich IP, Pandey MK, Hawlisch H, et al. 2006. A regulatory role for the C5a anaphylatoxin in type 2 immunity in asthma. J. Clin. Invest. 116:783–96 154. Zhu Z, Zheng T, Homer RJ, Kim YK, Chen NY, et al. 2004. Acidic mammalian chitinase in asthmatic Th2 inﬂammation and IL-13 pathway activation. Science 304:1678–82 155. Venkayya R, Lam M, Willkom M, Grunig G, Corry DB, Erle DJ. 2002. The Th2 lymphocyte products IL-4 and IL-13 rapidly induce airway hyperresponsiveness through direct effects on resident airway cells. Am. J. Respir. Cell Mol. Biol. 26:202–8 156. van Rijt LS, Jung S, Kleinjan A, Vos N, Willart M, et al. 2005. In vivo depletion of lung CD11c+ dendritic cells during allergen challenge abrogates the characteristic features of asthma. J. Exp. Med. 201:981–91 157. Hammad H, Smits HH, Ratajczak C, Nithiananthan A, Wierenga EA, et al. 2003. Monocyte-derived dendritic cells exposed to Der p 1 allergen enhance the recruitment of Th2 cells: major involvement of the chemokines TARC/CCL17 and MDC/CCL22. Eur. Cytokine Netw. 14:219–28 158. Beaty SR, Rose CE, Sung SJ. 2007. Diverse and potent chemokine production by lung CD11bhigh dendritic cells in homeostasis and in allergic lung inﬂammation. J. Immunol. 178:1882–95 159. Voehringer D, van Rooijen N, Locksley RM. 2007. Eosinophils develop in distinct stages and are recruited to peripheral sites by alternatively activated macrophages. J. Leukoc. Biol. 81:1434–44 160. Duez C, Tomkinson A, Shultz LD, Bratton DL, Gelfand EW. 2001. Fas deﬁciency delays the resolution of airway hyperresponsiveness after allergen sensitization and challenge. J. Allergy Clin. Immunol. 108:547–56 161. Mojtabavi N, Dekan G, Stingl G, Epstein MM. 2002. Long-lived Th2 memory in experimental allergic asthma. J. Immunol. 169:4788–96 162. Tomkinson A, Cieslewicz G, Duez C, Larson KA, Lee JJ, Gelfand EW. 2001. Temporal association between airway hyperresponsiveness and airway eosinophilia in ovalbuminsensitized mice. Am. J. Respir. Crit. Care Med. 163:721–30 163. Corry DB, Rishi K, Kanellis J, Kiss A, Song LZ, et al. 2002. Decreased allergic lung inﬂammatory cell egression and increased susceptibility to asphyxiation in MMP2-deﬁciency. Nat. Immunol. 3:347–53 164. Gounni AS, Hamid Q, Rahman SM, Hoeck J, Yang J, Shan L. 2004. IL-9-mediated induction of eotaxin1/CCL11 in human airway smooth muscle cells. J. Immunol. 173:2771–79 165. Kumagai N, Fukuda K, Nishida T. 2000. Synergistic effect of TNF-α and IL-4 on the expression of thymus- and activation-regulated chemokine in human corneal ﬁbroblasts. Biochem. Biophys. Res. Commun. 279:1–5 166. Li L, Xia Y, Nguyen A, Lai YH, Feng L, et al. 1999. Effects of Th2 cytokines on chemokine expression in the lung: IL-13 potently induces eotaxin expression by airway epithelial cells. J. Immunol. 162:2477–87 www.annualreviews.org • T Cell Trafficking in Asthma

156. Suggests that CD11c+ DCs in the airway control Th2 cell recruitment into the lung during allergic inflammation.

231

ARI

24 February 2008

9:43

167. Lilly CM, Nakamura H, Kesselman H, Nagler-Anderson C, Asano K, et al. 1997. Expression of eotaxin by human lung epithelial cells: induction by cytokines and inhibition by glucocorticoids. J. Clin. Invest. 99:1767–73 168. Matsukura S, Stellato C, Plitt JR, Bickel C, Miura K, et al. 1999. Activation of eotaxin gene transcription by NF-κB and STAT6 in human airway epithelial cells. J. Immunol. 163:6876–83 169. Miyamasu M, Misaki Y, Yamaguchi M, Yamamoto K, Morita Y, et al. 2000. Regulation of human eotaxin generation by Th1-/Th2-derived cytokines. Int. Arch. Allergy Immunol. 122(Suppl. 1):54–58 170. Rothenberg ME, Luster AD, Leder P. 1995. Murine eotaxin: an eosinophil chemoattractant inducible in endothelial cells and in interleukin 4-induced tumor suppression. Proc. Natl. Acad. Sci. USA 92:8960–64 171. Sekiya T, Miyamasu M, Imanishi M, Yamada H, Nakajima T, et al. 2000. Inducible expression of a Th2-type CC chemokine thymus- and activation-regulated chemokine by human bronchial epithelial cells. J. Immunol. 165:2205–13 172. Shore SA. 2004. Direct effects of Th2 cytokines on airway smooth muscle. Curr. Opin. Pharmacol. 4:235–40 173. Ying S, Meng Q, Zeibecoglou K, Robinson DS, Macfarlane A, et al. 1999. Eosinophil chemotactic chemokines (eotaxin, eotaxin-2, RANTES, monocyte chemoattractant protein-3 (MCP-3), and MCP-4), and C-C chemokine receptor 3 expression in bronchial biopsies from atopic and nonatopic (Intrinsic) asthmatics. J. Immunol. 163:6321–29 174. Lilly CM, Woodruff PG, Camargo CA Jr, Nakamura H, Drazen JM, et al. 1999. Elevated plasma eotaxin levels in patients with acute asthma. J. Allergy Clin. Immunol. 104:786–90 175. Yuan Q, Campanella GS, Colvin RA, Hamilos DL, Jones KJ, et al. 2006. Membranebound eotaxin-3 mediates eosinophil transepithelial migration in IL-4-stimulated epithelial cells. Eur. J. Immunol. 36:2700–14 176. Pope SM, Zimmermann N, Stringer KF, Karow ML, Rothenberg ME. 2005. The eotaxin chemokines and CCR3 are fundamental regulators of allergen-induced pulmonary eosinophilia. J. Immunol. 175:5341–50

Annu. Rev. Immunol. 2008.26:205-232. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-07

232

Medoff

·

Thomas

·

Luster

AR338-FM

ARI

12 January 2008

18:11

Annual Review of Immunology

Annu. Rev. Immunol. 2008.26:205-232. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

Contents

Volume 26, 2008

Frontispiece K. Frank Austen p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p x Doing What I Like K. Frank Austen p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p1 Protein Tyrosine Phosphatases in Autoimmunity Torkel Vang, Ana V. Miletic, Yutaka Arimura, Lutz Tautz, Robert C. Rickert, and Tomas Mustelin p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p 29 Interleukin-21: Basic Biology and Implications for Cancer and Autoimmunity Rosanne Spolski and Warren J. Leonard p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p 57 Forward Genetic Dissection of Immunity to Infection in the Mouse S.M. Vidal, D. Malo, J.-F. Marquis, and P. Gros p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p 81 Regulation and Functions of Blimp-1 in T and B Lymphocytes Gislâine Martins and Kathryn Calame p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p133 Evolutionarily Conserved Amino Acids That Control TCR-MHC Interaction Philippa Marrack, James P. Scott-Browne, Shaodong Dai, Laurent Gapin, and John W. Kappler p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p171 T Cell Trafﬁcking in Allergic Asthma: The Ins and Outs Benjamin D. Medoff, Seddon Y. Thomas, and Andrew D. Luster p p p p p p p p p p p p p p p p p p p p p205 The Actin Cytoskeleton in T Cell Activation Janis K. Burkhardt, Esteban Carrizosa, and Meredith H. Shaffer p p p p p p p p p p p p p p p p p p p p233 Mechanism and Regulation of Class Switch Recombination Janet Stavnezer, Jeroen E.J. Guikema, and Carol E. Schrader p p p p p p p p p p p p p p p p p p p p p p p261 Migration of Dendritic Cell Subsets and their Precursors Gwendalyn J. Randolph, Jordi Ochando, and Santiago Partida-Sánchez p p p p p p p p p p p p p293

v

AR338-FM

ARI

12 January 2008

18:11

The APOBEC3 Cytidine Deaminases: An Innate Defensive Network Opposing Exogenous Retroviruses and Endogenous Retroelements Ya-Lin Chiu and Warner C. Greene p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p317 Thymus Organogenesis Hans-Reimer Rodewald p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p355 Death by a Thousand Cuts: Granzyme Pathways of Programmed Cell Death Dipanjan Chowdhury and Judy Lieberman p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p389 Annu. Rev. Immunol. 2008.26:205-232. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

Monocyte-Mediated Defense Against Microbial Pathogens Natalya V. Serbina, Ting Jia, Tobias M. Hohl, and Eric G. Pamer p p p p p p p p p p p p p p p p p p p421 The Biology of Interleukin-2 Thomas R. Malek p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p453 The Biochemistry of Somatic Hypermutation Jonathan U. Peled, Fei Li Kuang, Maria D. Iglesias-Ussel, Sergio Roa, Susan L. Kalis, Myron F. Goodman, and Matthew D. Scharff p p p p p p p p p p p p p p p p p p p p p481 Anti-Inﬂammatory Actions of Intravenous Immunoglobulin Falk Nimmerjahn and Jeffrey V. Ravetch p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p513 The IRF Family Transcription Factors in Immunity and Oncogenesis Tomohiko Tamura, Hideyuki Yanai, David Savitsky, and Tadatsugu Taniguchi p p p p p535 Choreography of Cell Motility and Interaction Dynamics Imaged by Two-Photon Microscopy in Lymphoid Organs Michael D. Cahalan and Ian Parker p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p585 Development of Secondary Lymphoid Organs Troy D. Randall, Damian M. Carragher, and Javier Rangel-Moreno p p p p p p p p p p p p p p p p627 Immunity to Citrullinated Proteins in Rheumatoid Arthritis Lars Klareskog, Johan Rönnelid, Karin Lundberg, Leonid Padyukov, and Lars Alfredsson p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p651 PD-1 and Its Ligands in Tolerance and Immunity Mary E. Keir, Manish J. Butte, Gordon J. Freeman, and Arlene H. Sharpe p p p p p p p p677 The Master Switch: The Role of Mast Cells in Autoimmunity and Tolerance Blayne A. Sayed, Alison Christy, Mary R. Quirion, and Melissa A. Brown p p p p p p p p p p705 T Follicular Helper (TFH ) Cells in Normal and Dysregulated Immune Responses Cecile King, Stuart G. Tangye, and Charles R. Mackay p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p741

vi

Contents

ANRV338-IY26-08

ARI

16 February 2008

12:16

Annu. Rev. Immunol. 2008.26:233-259. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

The Actin Cytoskeleton in T Cell Activation Janis K. Burkhardt, Esteban Carrizosa, and Meredith H. Shaffer Department of Pathology and Laboratory Medicine, Children’s Hospital of Philadelphia and University of Pennsylvania, Philadelphia, Pennsylvania 19104; email: [email protected], [email protected], [email protected]

Annu. Rev. Immunol. 2008. 26:233–59

Key Words

First published online as a Review in Advance on November 19, 2007

immunological synapse, distal pole complex, signaling, lymphocyte

The Annual Review of Immunology is online at immunol.annualreviews.org This article’s doi: 10.1146/annurev.immunol.26.021607.090347 c 2008 by Annual Reviews. Copyright All rights reserved 0732-0582/08/0423-0233$20.00

Abstract T cell cytoarchitecture differs dramatically depending on whether the cell is circulating within the bloodstream, migrating through tissues, or interacting with antigen-presenting cells. The transition between these states requires important signaling-dependent changes in actin cytoskeletal dynamics. Recently, analysis of actin-regulatory proteins associated with T cell activation has provided new insights into how T cells control actin dynamics in response to external stimuli and how actin facilitates downstream signaling events and effector functions. Among the actin-regulatory proteins that have been identiﬁed are nucleation-promoting factors such as WASp, WAVE2, and HS1; severing proteins such as coﬁlin; motor proteins such as myosin II; and linker proteins such as ezrin and moesin. We review the current literature on how signaling pathways leading from diverse cell surface receptors regulate the coordinated activity of these and other actin-regulatory proteins and how these proteins control T cell function.

233

ANRV338-IY26-08

ARI

16 February 2008

12:16

INTRODUCTION APC: antigen-presenting cell IL-2: interleukin-2

Annu. Rev. Immunol. 2008.26:233-259. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

TCR: T cell receptor

Regulated reorganization of the actin cytoskeleton is important for multiple aspects of T cell function, including signaling and differentiation along discrete developmental lineages, migration through tissues, and execution of effector functions. Early studies testing the role of actin in T cell activation were based on the use of actin-disrupting agents such as cytochalasin D (CytoD) (see sidebar: Actin Depolymerizing Agents). These studies showed that actin is required for adherence to target cells and cytotoxic activity (1), as well as for signaling events associated with Ca2+ ﬂux and downstream changes in gene expression (2). However, these studies revealed a complex role for actin. For example, in T cells stimulated with superantigen-pulsed antigenpresenting cells (APCs), CytoD treatment results in diminished Ca2+ ﬂux, but stimulation with anti-CD3 antibodies results in a prolonged Ca2+ response (2). Similarly, although one study showed that CytoD treatment impairs the activation of the interleukin-2 (IL-2) promoter (3), another found that at low doses of CytoD, Ca2+ signaling is prolonged and IL2 production increases (4). These ﬁndings and more recent data described below suggest that actin ﬁlaments play a dual role, enhancing T cell activation by promoting conjugate formation and the assembly of signaling complexes, but also downregulating activation, perhaps by facilitating molecular movements that culminate in the internalization of the T cell receptor (TCR).

ACTIN DEPOLYMERIZING AGENTS The two most commonly used pharmacological agents to perturb actin dynamics are cytochalasin D and latrunculin A. Neither inhibitor actually disassembles polymerized actin ﬁlaments. Instead, they induce net actin depolymerization by preventing new actin polymerization. Latrunculin A sequesters actin monomers, whereas cytochalasin D binds to the fast-growing (barbed) ends of actin ﬁlaments, preventing monomer addition.

234

Burkhardt

·

Carrizosa

·

Shaffer

Recent studies focusing on individual actin-regulatory proteins have greatly advanced our understanding of how actin dynamics are regulated and have provided new insights into how actin functions to facilitate or terminate T cell activation. This review focuses on the roles of those proteins in T cell function and on the interplay between cytoskeletal changes and the signaling events associated with T cell activation.

T CELL MOVEMENTS AND SHAPE CHANGES The actin cytoskeleton controls T cell shape, which changes dramatically depending on whether the cell is circulating in the bloodstream, migrating through tissues, or interacting with APCs (Figure 1).

Microvillar Dynamics in Circulating T Cells Circulating T cells are covered in short microvilli containing parallel bundles of highly dynamic actin ﬁlaments (Figure 1, cell 1) (5). Low-afﬁnity adhesion molecules such as Lselectin and α4β7 integrin (VLA-4) are concentrated at the tips of the microvilli (6), whereas molecules involved in tight adhesion, e.g., leukocyte function–associated antigen 1 (LFA-1, αLβ2), are distributed randomly or excluded from microvilli (7, 8). This segregation is thought to facilitate tethering and rolling along vessel walls and to minimize nonspeciﬁc adhesion (Figure 1, cell 2) (9). Interaction of T cells with soluble and endothelium-displayed chemokines triggers rapid microvillar collapse as well as upregulation of integrin avidity through a process involving release of integrins from the cortical actin cytoskeleton (9, 10). This leads to the arrest of the lymphocyte on the endothelium and, ultimately, to transmigration across the endothelial wall (Figure 1, cells 3 and 4). The mechanisms that control microvillar formation and collapse in T cells are not fully understood. Several studies point to a key role

ANRV338-IY26-08

ARI

16 February 2008

12:16

5 3

4 6

Annu. Rev. Immunol. 2008.26:233-259. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

Target cell

2

1

Figure 1 Actin remodeling in response to environmental cues. 1. Circulating T cells are decorated with microvilli containing parallel actin bundles anchored in cortical actin ﬁlaments. 2. Segregation of adhesion molecules with respect to microvilli facilitates tethering and rolling along the vascular endothelium. 3. Chemokine stimulation induces microvillar collapse and a switch from tethering and rolling to tight adhesion mediated by high-afﬁnity integrin interactions. 4. The T cell must then squeeze between endothelial junctions to enter the underlying tissue. 5. As the T cell migrates through tissues, a leading edge rich in branched actin ﬁlaments pushes the cell forward, while the uropod trails behind. 6. Upon recognizing an APC, the T cell forms a tight contact rich in branched actin ﬁlaments. This contact leads to the formation of the immunological synapse (IS), where active actin polymerization is associated with formation and inward movement of TCR microclusters. Cortical actin, most likely comprised of linear ﬁlaments, remains at sites peripheral to the IS, forming a scaffold for protein sequestration at the distal pole complex (DPC).

for proteins of the ezrin, radixin, and moesin (ERM) family, which link plasma membrane proteins to cortical actin ﬁlaments. Treatment of T cells with antisense oligonucleotides to both ezrin and moesin results in dramatic loss of microvilli (11). Similarly, T cells expressing a dominant-negative ERM mutant are devoid of microvilli, whereas cells expressing a constitutively active form exhibit enhanced microvillar structures (9). Chemokine-induced microvillar loss is accompanied by dephosphorylation of ERM proteins at a regulatory C-terminal threonine (see below), an event that inhibits their linker function (9). In addition to ezrin and moesin, WASp may contribute to microvillar structure, as T cells

from patients with mutations in WASp exhibit defective microvilli (12–14). However, a recent study by Higgs and coworkers failed to ﬁnd microvillar abnormalities in WASpdeﬁcient T cells, when analyzed immediately ex vivo (5). Because WASp promotes the formation of branched actin ﬁlaments rather than the linear ﬁlaments found in microvilli, WASp may affect microvillar dynamics only indirectly.

Migration Within Tissues Once a T cell receives the appropriate cues to cross the vascular wall, it begins to migrate within tissues. Migrating T cells exhibit a www.annualreviews.org • Actin in T Cell Activation

ERM: ezrin, radixin, moesin

235

ANRV338-IY26-08

ARI

16 February 2008

Annu. Rev. Immunol. 2008.26:233-259. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

Inside-out signaling: cytoplasmic signaling pathways (typically downstream of TCR or chemokine receptors) leading to conformational changes that enhance integrin afﬁnity

236

12:16

“hand mirror” morphology, with a large cell body comprised of the nucleus and a thin band of cytoplasm, and a narrow trailing uropod that projects above the substrate surface (Figure 1, cell 5). The leading edge is enriched in chemokine receptors and is sensitized for antigen recognition (15, 16). The uropod contains a meshwork of cytoskeletal elements, including the microtubule organizing center (MTOC), vimentin ﬁlaments, actin ﬁlaments, ERM proteins, and the cytoskeletal linker protein plectin (17). Within tissues, T cells can be highly motile, sampling multiple APCs, or can pause to engage in more prolonged interactions. Transition between these states is controlled in part by the presence of antigen, but also involves the activation state of both the T cell and the APC, as well as the three-dimensional nature of the matrix (18). Motile T cells move much faster than most nonhematopoietic cells, averaging 10 μm/min, and reaching rates of 25 μm/min (19). T cell movement is essentially amoeboid in nature, and is driven by protrusion of actin-rich pseudopodia at the leading edge, working in concert with contractile forces at the rear of the cell (19). A fundamental feature of this mechanism is the ability to form protrusions at the leading edge, and not at the uropod. As in other cell types, it is thought that Rho GTPases control this cycle (20–26). Leading edge protrusion is controlled largely by Rac1, whereas the lack of protrusion within the uropod is controlled by Rho. Cdc42 serves as a “compass” controlling overall cell polarity. Myosins, in particular MyH9, the heavy chain of nonmuscle myosin IIA, are also required for uropod formation and crawling (19). Using video analysis, Krummel and coworkers (19) have shown that MyH9 moves in clusters toward the uropod of crawling T cells. Thus, as in other amoeboid cells, it appears that actomyosin-based contraction within the uropod generates an extrusive force that propels the bulk of the T cell cytoplasm forward. Burkhardt

·

Carrizosa

·

Shaffer

Interaction with APCs and Immunological Synapse Formation Upon interaction with an APC bearing appropriate MHC-peptide complexes, the T cell rounds up, draws in its uropod, and extends large pseudopodia and lamellipodia toward the APC. This process results in the formation of a ﬂattened, F-actin-rich interface with the APC. In parallel with these shape changes, the MTOC and associated secretory organelles reorient within the T cell cytoplasm and come to lie just beneath the plasma membrane, near the center of the APC contact site. This reorientation of T cell cytoskeletal elements was observed by several investigators in the early 1980s and was recognized as a hallmark of productive T cell engagement and a prerequisite for directed cytolysis and T cell help (27–29). The morphological transition induced by interaction with an APC is associated with several changes in cytoskeletal proteins. Myosin IIA heavy chain is phosphorylated at a site known to lead to downregulation of motor function (19). This event is thought to be a key factor in controlling uropod resorption. Indeed, the idea that myosin II activity is “switched off” upon TCR engagement is consistent with the ﬁnding that this protein is dispensable for organizing signaling molecules at the T cell–APC contact site. TCR crosslinking also leads to the transient dephosphorylation of ERM proteins, an event that is proposed to facilitate membrane protrusion and receptor clustering at the site of TCR engagement by increasing the ﬂuidity of the plasma membrane (9, 30–32). Ca2+ -dependent cleavage of actin-binding proteins and severing of actin ﬁlaments by proteins such as calpain and gelsolin probably also contribute to this process (33–35). TCR-induced “inside-out signaling” leads to conformational changes in T cell integrins, particularly LFA-1 (reviewed in 36, 37). This process, which results in high-afﬁnity binding to ligands such as ICAM-1 (intercellular adhesion molecule-1) on the APC, is controlled in part by regulated interactions of the β integrin

Annu. Rev. Immunol. 2008.26:233-259. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-08

ARI

16 February 2008

12:16

cytoplasmic tail with actin-binding proteins such as ﬁlamin and talin (38–40). Once integrins have undergone this conformational change, these proteins cluster as a result of binding to multivalent ligands on the APC, resulting in strengthening of adhesion between the T cell and APC (41). This latter facet of integrin function is closely tied to the increased membrane ﬂuidity that results from the release of cortical cytoskeletal tethers. LFA-1 clustering is largely ligand-driven, although there is also evidence for the active involvement of talin in this process (40). In concert with all these changes, TCR cross-linking leads to localized activation of actin polymerizing proteins and actin-binding proteins at the site of TCR engagement, resulting in lamellipodial protrusion toward the APC and the formation of a dense actin network at the cell-cell contact site (see below). Actin responses at the T cell–APC contact site are important for the organization of signaling molecules at this site, to form the immunological synapse (IS) (42–45). IS organization and function has been an area of intense study (reviewed in 46–48). Protein segregation within the IS was initially described as forming a “supramolecular activation cluster (SMAC)” comprised of a central region (cSMAC) containing TCR and associated signaling proteins within a peripheral ring (pSMAC) containing LFA-1 and associated adhesion molecules (49). Recent studies have shown, however, that IS architecture and dynamics vary greatly depending on several variables, including the nature of the T cell and the APC, agonist strength, costimulatory interactions, and the tissue context in which the interaction is taking place (48, 50). Our understanding of IS function has evolved considerably over the past decade. Once thought to facilitate TCR signaling by bringing interacting molecules together, the c-SMAC was subsequently shown to be a site where signaling is terminated by internalization of TCR signaling complexes (51, 52). The role of the c-SMAC in downregulating T cell signaling is supported by studies in which signaling is en-

hanced under conditions where c-SMAC formation is blocked and inhibited under conditions where c-SMAC formation is induced. (51–53). Recently, an interesting study combining empirical analysis with mathematical modeling has shown that the IS probably both augments and downregulates TCR cell signaling and that parameters such as peptideMHC half-life determine the balance between these two interrelated facets of IS function (52). Video analysis of molecular movements during IS formation shows that the TCR and associated signaling molecules form microclusters around the periphery of the cell-cell contact site and converge to form the cSMAC (43, 54–56). Sustained signaling occurs in the peripheral clusters, while central clusters are destined for degradation, at least in the context of a strong signal. Microcluster formation and centripetal movement are actin-dependent processes, controlled in part by Cdc42 (42, 43, 56). Once formed, however, these signaling complexes are highly stable and are largely unaffected by actindepolymerizing agents. It will be interesting to learn how speciﬁc actin regulatory molecules work to orchestrate microcluster formation and movement, especially as this relates to parameters such as peptide-MHC half-life and T cell subset.

Immunological synapse (IS): specialized membrane domain enriched in signaling molecules formed at the T cell–APC contact site SMAC: supramolecular activation cluster Guanine nucleotide exchange factor (GEF): protein that activates small GTPases by catalyzing the exchange of GDP for GTP

CONTROL OF ACTIN DYNAMICS AT THE IMMUNOLOGICAL SYNAPSE Engagement of the TCR activates multiple actin-regulatory proteins that work in concert to drive actin polymerization at the IS. The best understood of these molecules function downstream of Vav1 and other guanine nucleotide exchange factors (GEFs), which activate the Rho GTPases Rac1 and Cdc42 at sites of TCR engagement (Figure 2). The signaling pathways linking TCR ligation to Rho GTPase activation are addressed in a later section. Here, we focus on molecules that directly inﬂuence actin dynamics at the IS. www.annualreviews.org • Actin in T Cell Activation

237

ANRV338-IY26-08

ARI

16 February 2008

12:16

CD4 TCR LFA-1

Actin

Annu. Rev. Immunol. 2008.26:233-259. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

HS 1

Costimulation (e.g., CD28)

L Lck Zap70 A T WASp Nck Slp76 WIP Vav Itk

PP2A Cofilin

Cdc42 Rac1 WAVE2 complex

Arp2/3

?

NF- B, NFAT, AP-1 IL-2

?

Dephosphoryation/ rephosphorylation

ER

M

ER

M

Scribble DLG1

ER

M

Cytoplasmic DPC proteins (e.g., RhoDGI)

Transmembrane DPC proteins (e.g., CD43)

Figure 2 Simpliﬁed model of signaling pathways linking TCR signaling to actin remodeling. Encounter of an APC induces a signaling cascade comprised of tyrosine kinases (dark green), adaptor proteins (light green), and immediate upstream actin-regulatory proteins (dark blue). The latter transduce signals to several nucleation-promoting factors (red ) that direct the polymerization of branched actin ﬁlaments at sites of TCR engagement. Engagement of costimulatory molecules leads to activation of proteins that sever actin ﬁlaments (dark brown), creating new barbed ends as substrates for ﬁlament growth. Signals emanating from the TCR also lead to transient dephosphorylation and rephosphorylation of ERM proteins (orange), which direct the localization of transmembrane and cytoplasmic proteins (light blue) to cortical actin ﬁlaments at the distal pole complex (DPC). Also localized to the DPC are proteins containing PDZ (PSD-95/Discs large/ZO-1) domains ( purple), which form a network at this site. Question marks indicate the unknown mechanisms by which actin remodeling leads to IL-2 promoter activation and other changes in gene expression.

238

Burkhardt

·

Carrizosa

·

Shaffer

ANRV338-IY26-08

ARI

16 February 2008

12:16

Annu. Rev. Immunol. 2008.26:233-259. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

Arp2/3 Complex–Dependent Actin-Regulatory Proteins The initiation of actin ﬁlament formation is a kinetically unfavorable process, requiring the action of nucleation-promoting factors (NPFs) to generate a “seed” from which a ﬁlament can elongate. Many of the bestunderstood NPFs work in concert with the seven-subunit Arp2/3 complex to form new actin branches on the sides of existing actin ﬁlaments (reviewed in 57). This complex, which contains two actin-related proteins, Arp2 and Arp3, binds to the side of an existing actin ﬁlament, where Arp2 and Arp3 mimic two actin monomers as part of the core nucleus. NPFs such as WASp and WAVE2 then bind to the Arp2/3 complex and present an actin monomer, allowing elongation to take place. Using an RNAi-based strategy, the Billadeau group showed that suppression of either Arp2 or Arp3 in Jurkat T cells results in degradation of other complex components (58). Arp2/3-deﬁcient cells fail both to polymerize F-actin at the IS and to form lamellipodia in spreading assays using anti-TCR-coated coverslips. These cells generate highly dynamic F-actin-rich ﬁlopodia in response to either APCs or anti-TCR-coated surfaces, a ﬁnding that points toward additional Arp2/3 complex–independent actin regulatory pathways. Nonetheless, this study demonstrates that the Arp2/3 complex and its upstream activators are central effectors of actin polymerization at the IS. The best-characterized activator of the Arp2/3 complex is WASp, named for its causative role in Wiskott Aldrich syndrome (WAS), a severe immune deﬁciency disorder. The domain structure of WASp is shown in Figure 3. The N-terminal WASp-homology region (WH1) binds constitutively to WASp interacting protein (WIP). Disruption of this interaction results in degradation of WASp (59, 60). Most mutations associated with WAS are found in this region and interfere with WIP binding (61). WIP is almost certainly an important actin-regulatory protein in its own

right, but WIP function per se has not been tested, presumably because of the challenges associated with constructing WIP-deﬁcient cells that express normal amounts of WASp. However, evidence that WIP and WASp play nonredundant roles comes from analysis of WIP/WASp double-knockout mice; T cells lacking both proteins migrate less well than T cells from either of the single knockouts (62). WASp recruitment and activation at the IS are relatively well understood. Recruitment occurs through an interaction between the WASp proline-rich domain (PRD) and the SH3 domains of the adaptors Nck and PSTPIP (63, 64). Localization to the IS facilitates WASp contact with Cdc42-GTP, which binds to the GTPase-binding domain (GBD) (63), leading to a conformational change in WASp. In resting cells, WASp exists in a closed, inactive state in which the GBD contacts the verprolin, coﬁlin, acidic (VCA) region. Cdc42 binding releases the VCA domain, allowing the VCA to interact with the Arp2/3 complex (65). Phosphorylation of WASp at tyrosine 291 by the Src family kinase Fyn, and subsequent binding of the SH2-SH3 domain module of Src kinases to WASp, works in a synergistic manner with Cdc42 binding to induce optimal WASp activity (66–68). WASp-deﬁcient T cells from both mice and humans exhibit consistent defects in signaling pathways leading to IL-2 production, but the literature is divided about the importance of WASp for controlling actin polymerization at the IS. Although there are numerous reports that T cells from WAS patients exhibit defective actin responses (reviewed in 61), Jurkat cells depleted of WASp using RNAi polymerize actin normally (69). Moreover, T cells from two different WASp-knockout mice behave differently with respect to their ability to polymerize actin in response to TCR engagement (67, 70, 71). A possible explanation for these discrepancies is that other proteins (including the close homolog N-WASp, as well as less closely related proteins such as WAVE2 and HS1) have partially overlapping functions. Recent work from the Dustin lab www.annualreviews.org • Actin in T Cell Activation

Nucleationpromoting factor (NPF): protein that promotes the nucleation of actin ﬁlaments, either alone or by activating Arp2/3 complex Arp2/3 complex: seven subunit complex that nucleates the formation of new actin ﬁlaments on the sides of preexisting ﬁlaments Wiskott Aldrich syndrome (WAS): X-linked immunodeﬁciency disorder characterized by eczema, recurring infections, and thrombocytopenia. WAS results from mutations in WASp

239

ANRV338-IY26-08

ARI

16 February 2008

12:16

1

HS1

YY NTA

HTH

CC

PRD

Arp2/3

F-actin

F-actin

Lck

1

WASp

Lck Vav1

Y WH1

GBD

WIP

Cdc42

1

502 PRD

V CA

Nck G- Arp2/3 PST-PIP Actin

Y

WAVE2

WHD

498 Basic

PRD

V CA G- Arp2/3 Actin

Abi1/2 PtIns(3,4,5)P3 IRSp53

Annu. Rev. Immunol. 2008.26:233-259. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

486 SH3

1

WIP

503

PRD WH2 WH2

WASpbinding WASp

PRD

Profilin G-actin

Nck

166

1S

Cofilin F-actin 1

Y

Ezrin

N-ERMAD

Y

C-ERMAD T 586

α-helical

FERM

PRD ABD F-actin

CD43, RhoGDI, etc. 1

Moesin

Y

N-ERMAD

C-ERMAD T 577 α-helical

FERM

ABD F-actin

CD43, RhoGDI, etc. 1

904

Dlg1

PRD

PDZ

PDZ PDZ

PDZ

Lck

Ezrin p38 MAPK

Ezrin

p38 MAPK

SH3

I3

MAGUK

Ezrin

1

1655

Scribble

LRR

PDZ

PDZ

PDZ

PDZ

Figure 3 Structure of proteins involved in regulating actin dynamics and T cell polarity. The domain structure of the indicated molecules is shown, with related regions colored similarly. Important binding partners are indicated below the domains to which they bind. Total amino acid number is shown at the upper right of each protein. Important phosphorylation sites are indicated (Y, T, S). NTA, N-terminal acidic region; HTH, helix-turn-helix repeats; CC, coiled-coil; PRD, proline-rich domain; SH3, Src homology 3; WH1, WASp homology 1; GBD, GTPase-binding domain; VCA, verprolin homology, coﬁlin homology, acidic region; WHD, WAVE homology domain; WH2, WASp homology 2; FERM, Band 4.1, ezrin, radixin, and moesin; ABD, actin-binding domain; PDZ, PSD-95/Discs large/ZO-1; I3, splice insert 3; MAGUK, membrane-associated guanylate kinase; LRR, leucine-rich repeats.

supports the idea that WASp-dependent actin polymerization is indispensable for T cell activation (44). This study shows that naive T cells contacting APCs or lipid bilayers con240

Burkhardt

·

Carrizosa

·

Shaffer

taining MHC-peptide complexes and ICAM1 form a short-lived IS, then migrate some distance before generating a second, more stable contact. Although WASp−/− T cells form

Annu. Rev. Immunol. 2008.26:233-259. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-08

ARI

16 February 2008

12:16

an initial contact in this assay, they continue to migrate and fail to re-form and maintain a long-lived IS. Another important activator of the Arp2/3 complex is the WAVE/SCAR family member WAVE2, an NPF that functions as an effector for Rac1. RNAi-mediated suppression of WAVE2 in Jurkat T cells results in loss of actin polymerization at the IS (69, 72). In addition, WAVE2 suppression perturbs conjugate formation, suggesting a role in integrin function. WAVE2 resembles WASp in that it binds the Arp2/3 complex via a C-terminal VCA domain (Figure 3), but WAVE2 lacks a GBD and does not bind Rac1 directly (73). WAVE2 exists as part of a constitutive complex containing Abi1/2, Sra1/PIR121, Hspc300, IRSp53, and HEM1 (reviewed in 37). WAVE complex components stabilize one another against degradation, and suppression of Abi1/2 or HEM-1 also results in actin defects (69, 72, 74, 75). WAVE complex components also function in WAVE2 targeting and activation. IRSp53 acts as an adaptor between Rac1 and WAVE2, and this interaction leads to the recruitment of WAVE2 to the membrane (75). Abi1/2 can mediate an interaction between Abl kinase and WAVE2, resulting in phosphorylation at Y150, which increases the actin polymerization activity of WAVE2 (76). A third activator of the Arp2/3 complex is HS1, the hematopoietic lineage–restricted homolog of the actin-binding protein cortactin (Figure 3). Like WASp and WAVE, HS1 contains an acidic region (NTA) that binds the Arp2/3 complex, and HS1 can modestly activate Arp2/3-dependent actin polymerization (Figure 3). However, HS1 also binds to F-actin directly through its helixturn-helix (HTH) repeats and coiled-coil (CC) domain (77). It is therefore thought that HS1 functions primarily to stabilize existing branched actin ﬁlaments by bridging the Arp2/3 complex with F-actin (78–80). In keeping with this idea, HS1-suppressed T cells extend unstable lamellipodia on antiTCR-coated coverslips and exhibit short-

lived actin responses at the IS (81). TCR engagement induces ZAP-70-dependent phosphorylation of HS1 at Y378 and Y397, an event that is required for HS1 function at the IS. WASp, WAVE2, and HS1 are highly modular in structure and can interact with multiple signaling molecules at the IS. The adapter properties of these proteins undoubtedly facilitate coordination of actin polymerization. For example, phosphorylation of HS1 creates binding sites for Vav1, such that HS1 contributes to Cdc42 and Rac1 activation upstream of WASp and WAVE2. It is also likely that these proteins facilitate T cell activation by coordinating other signaling molecules independent of their role in actin polymerization.

Arp2/3 Complex–Independent Actin-Regulatory Proteins In other cell types, the function of Arp2/3 complex–dependent NPFs is complemented by proteins that drive actin polymerization independently of Arp2/3 complex, as well as by proteins that cap, sever, cross-link, and bundle actin ﬁlaments. Only a few of these proteins have been analyzed in T cells. One actinsevering protein, coﬁlin, has been shown to play an important role in controlling actin responses at the IS (82). Coﬁlin is a small (19-kDa) protein that severs actin ﬁlaments, promoting depolymerization but also generating fresh barbed ends that serve as substrates for elongation factors. Because of its requirement for cell viability, coﬁlin has been difﬁcult to study. However, the Samstag group has used cell-permeant peptides that compete with actin for coﬁlin binding to approximate a loss-of-function phenotype. Cells treated with these peptides form conjugates inefﬁciently, polarize CD2 and coﬁlin to the IS poorly, and exhibit severe defects in proliferation and cytokine secretion (82). Phosphorylation at serine 3 negatively regulates coﬁlin activity by antagonizing its capacity to bind actin (83). Coﬁlin is phosphorylated in resting www.annualreviews.org • Actin in T Cell Activation

241

ARI

16 February 2008

12:16

normal human T cells, but upon accessory receptor (CD2, CD4, CD8, or CD28) ligation, the serine phosphatases PP1 and PP2a can dephosphorylate and activate it (84, 85). Regulation of coﬁlin activity is likely to be an important control point for actin dynamics at the IS because coﬁlin can either promote lamellar growth or collapse, depending on whether Arp2/3-dependent NPFs are activated in parallel. Among the other Arp2/3-independent actin-regulatory proteins that have been studied in T cells are members of two important families, formins and Ena/VASP proteins. Members of both families localize to sites of TCR engagement (86, 87); however, their role in controlling actin responses at the IS is not clear. Formins are NPFs that promote the formation of long, linear actin ﬁlaments (87). So far, two formins have been found at signiﬁcant levels in T cells, FMNL1 and Dia1 (58). Jurkat T cells suppressed for these proteins (alone or together) polymerize F-actin at the IS normally. Ena/VASP proteins bind to the barbed ends of actin ﬁlaments and promote ﬁlament growth by antagonizing the binding of capping proteins (88). The predominant Ena/VASP protein expressed in T cells is EVL. Overexpression of sequences derived from the protein ActA in Listeria monocytogenes competes for binding of EVL to other proteins. This treatment displaces EVL from sites of TCR engagement and disrupts actin responses at the IS. However, it is not clear that the effects of this construct are speciﬁc, as suppression of EVL (alone or together with the related protein VASP) has no effect on T cell spreading or actin responses at the IS (58). One possibility is that the activity of formins and Ena/VASP proteins, which can work together to generate ﬁlopodia, is masked by the broader lamellipodia generated by Arp2/3-dependent NPFs. However, even the ﬁne ﬁlopodia generated in Arp2/3-deﬁcient cells do not depend on the expression of formins or Ena/VASP proteins (58). Thus, it appears that the presence of these proteins at the IS reﬂects a role

Annu. Rev. Immunol. 2008.26:233-259. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-08

242

Burkhardt

·

Carrizosa

·

Shaffer

in processes other than control of actin polymerization. Formins are crucial for polarization of the MTOC and directed cytolysis (58), whereas EVL, which binds to the adaptor protein ADAP and the Rap1 activator RIAM, is likely to function in integrin-based adhesion (reviewed in 37).

Proteins that Affect IS Actin Dynamics by Unknown Mechanisms Among the many proteins required for efﬁcient actin polymerization at the IS are the immediate regulators of actin dynamics described above and several well-understood signaling molecules that function upstream of these proteins. However, some proteins affect actin dynamics in ways that are not yet understood. One such protein is the methyltransferase Ezh2. Better known as a nuclear protein that methylates histones on lysine residues, Ezh2 is also found in the cytoplasm of T cells in a complex containing Vav1 (89). Recently, the Tarakhovsky group has made the unexpected observation that mature T cells deﬁcient for Ezh2 completely fail to polymerize actin at the IS (89). Cytoplasmic Ezh2 possesses methyltransferase activity, but cytoplasmic substrates have not yet been identiﬁed. Indeed, it is not known if Ezh2 requires its methyltransferase activity to control actin responses; it could play an adaptor function by binding Vav1 and stabilizing its open active conformation (90). The position of Ezh2 within the TCR signaling pathway appears to be upstream of Cdc42 function, as Ezh2−/− T cells activate Cdc42 inefﬁciently, and constitutively active Cdc42 rescues TCR signaling–dependent actin polymerization in these cells (89). The large GTPase dynamin2 is also required for actin polymerization at the IS (91). Dynamin2 interacts directly with Vav1, and requires the presence of Vav1 for its localization to the IS. Although dynamin has been shown to interact with several actin-binding proteins and to affect actin dynamics in many cell types, its mechanism of action is not

ANRV338-IY26-08

ARI

16 February 2008

12:16

understood (92). Because dynamin plays a critical role in endocytosis, it is interesting to speculate that it functions at a point of crosstalk between actin regulatory and endocytic machinery.

Annu. Rev. Immunol. 2008.26:233-259. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ORGANIZATION OF THE DISTAL POLE COMPLEX BY ACTIN LINKER PROTEINS In addition to organizing signaling proteins at the IS, actin and actin-binding proteins organize a second protein complex at the opposite face of the T cell, termed the distal pole complex (DPC) (93). The DPC was initially discovered based on the localization of CD43 and ERM proteins to a region that was clearly outside the IS, and in many cases distributed in a tight cap opposite the IS (30, 94). Further study showed that basic residues within the cytoplasmic tail of CD43 are required for its localization and function in T cell activation (30, 95). These residues bind to the ERM proteins ezrin and moesin (T cells Table 1

express low levels of the third family member, radixin). As detailed below, these ERM proteins bind through their N-terminal FERM (Band 4.1, ezrin, radixin, and moesin) domain to CD43 and other cargo molecules, linking them to the actin cytoskeleton in a regulated fashion. Localization of CD43 and other ERM binding proteins (e.g., RhoGDI and DLG1) to the DPC is ERM dependent because mutation of interacting residues or overexpression of a dominant-negative ERM mutant disrupts their distribution (93–95). A survey of the literature reveals that many proteins exhibit an antipodal distribution during at least some phases of the T cell response (Table 1). It is not known if ERM proteins control the localization of all of these; some may prove to lie upstream of ERM proteins in assembly of the protein network. For example, the polarity protein scribble, recently found to be required for DPC formation, T cell conjugation, and activation, is required to generate a polarized ERM protein response (96).

Distal pole complex (DPC): specialized membrane domain formed at the T cell pole distal to the site of TCR engagement DLG1: discs large; also known as SAP97

Molecules displaying patterns of localization corresponding to the DPC

DPC component

Proposed function in T cells

References

Ezrin/moesin

Linker of molecules to actin; required for localization of multiple DPC proteins and T cell activation

30, 94, 95, 97

CD43

Highly glycosylated transmembrane protein (mucin); regulator of T cell proliferation, adhesion, and migration

30, 94, 95

DLG1

PDZ domain–containing polarity protein; regulator of actin polymerization, NFAT, alternate p38 pathway

93, 98, 99

Scribble

PDZ domain–containing polarity protein; required for uropod and IS formation, migration, T cell activation

96

CD148

Tyrosine phosphatase; negative regulator of TCR-dependent NFAT activation

100

PDE4B2

Cyclic nucleotide phosphodiesterase; antagonizes PKA; associates with TCRζ and enhances IL-2 production

101

PKCζ

Atypical protein kinase C; positive regulator of NF-κB and JAK/STAT signaling

102

PtIns(3,4,5)P3

Phospholipid; required for the localization and activation of PH domain–containing proteins

103

RhoGDI

Rho GTPase guanine dissociation inhibitor; inhibits Rho GTPases; regulator of T cell development and migration

25, 94

SHP-1

Tyrosine phosphatase; negative regulator of early T cell activation signaling events

104a

EBP50

Adaptor protein; links CBP to actin through ERM proteins

105a

PTP-BL

Tyrosine phosphatase; downregulator of STAT activity and TH cell differentiation

106a

a

Localization to the DPC was ascertained by P. Cullinan, R.S. Dupree, M.H. Shaffer & J.K. Burkhardt, unpublished data.

www.annualreviews.org • Actin in T Cell Activation

243

ARI

16 February 2008

12:16

Although there is good evidence that the DPC is important for T cell activation, the function of this complex is still not well understood. Based on the proteins that have been identiﬁed in the DPC to date, three models have emerged. First, the DPC may modulate signaling events at the IS by serving as a sink for negative regulators of T cell activation. It is sensible that the sequestration of SHP1, CD148, PTP-BL, CD43, RhoGDI, and DLG1 away from the IS enhances T cell function because each of these molecules can antagonize events occurring at the IS (Table 1). ERM proteins also interact via EBP50 with CBP/PAG, a negative regulator of Src kinases (105), although the role of ERM proteins in regulation of CBP/PAG activity has not been established. However, some DPC proteins are not negative regulatory molecules (or play dual roles), suggesting that DPC function is more complex than simple protein sequestration. A second model is that the DPC serves as an active signaling complex, separate from the IS. In support of this idea, cross-linking CD43 with certain antibodies leads to MAP (mitogen-activated protein) kinase and NFAT (nuclear factor of activated T cells) activation (107), and coligation with TCR enhances T cell signaling (108). Cross-linking CD46 (using antibodies or by binding to measles virus) inhibits T cell activation and drives T cells to a regulatory fate (109, 110). Finally, crosslinking ICAM-2, an ERM binding protein, can activate PI3K-dependent survival signaling (111). A third model for DPC function is that it establishes overall T cell polarity, as discussed below. These models are not mutually exclusive; resolution of their relative importance will require functional analysis of individual DPC proteins.

Annu. Rev. Immunol. 2008.26:233-259. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-08

Regulation of ERM Proteins The best-understood organizers of the DPC are the ERM proteins ezrin and moesin, which tether transmembrane and cytoplasmic molecules to actin ﬁlaments at the cell cortex. ERM proteins are important for T cell 244

Burkhardt

·

Carrizosa

·

Shaffer

functions ranging from maintenance of microvilli, TCR-induced signaling events leading to cytokine production, and regulation of CD95-induced cell death (9, 30, 32, 94, 97, 112, 113). ERM proteins are present in two conformations. In the inactive form, the N-terminal FERM domain (equivalent to the N-terminal ERM-association domain, NERMAD) interacts with a C-terminal region (C-ERMAD), which encompasses the actinbinding region. This intramolecular interaction masks both the actin and cargo binding sites (Figure 3) (114, 115). In the active conformation, this intramolecular interaction is relieved, allowing linkage of cargo proteins to actin ﬁlaments. Conversion to the activated state is regulated by phosphorylation of a conserved threonine (T558 in moesin, T567 in ezrin) in the C terminus. In response to TCR engagement, active ERM proteins undergo transient dephosphorylation, temporarily relaxing their constraint of cortical protein mobility. Reactivation is then achieved by concerted binding of PtIns(4,5)P2 to the FERM domain and phosphorylation of the regulatory threonine. In parallel with rephosphorylation, ERM proteins move away from the site of TCR engagement by an unknown mechanism. The inactivation/reactivation of ERM proteins is associated with changes in cellular morphology, including the collapse of microvilli and the ﬂattening of the T cell against an APC (9, 32). So far, neither the relevant kinase nor the phosphatase in T cells has been identiﬁed. ERM dephosphorylation requires Vav1-dependent activation of Rac1, independently of Rho and Cdc42 (Figure 2) (116). ERM proteins may use this transient dephosphorylation to alter cargo binding patterns and therefore change the localization of a subset of binding proteins, but this idea has not been tested. Prolonged ERM threonine dephosphorylation is associated with unresponsiveness induced by measles virus binding to CD46 (117). In addition to on/off regulation by phosphorylation at T567, ezrin is tyrosine phosphorylated in response to cross-linking of

Annu. Rev. Immunol. 2008.26:233-259. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-08

ARI

16 February 2008

12:16

TCR, CD4, or ICAM-2 (111, 118, 119). Tyrosine phosphorylation of ezrin downstream of TCR or CD4 is dependent on the Src family kinase Lck, which can phosphorylate ezrin at Y146 in vitro (118, 120). The signiﬁcance of ezrin tyrosine phosphorylation in T cells is unknown. In nonhematopoietic cells, ezrin tyrosine phosphorylation leads to activation of the PI3K/Akt pathway and enhanced cell survival (121). In T cells, ezrin phosphorylation in response to ICAM-2 cross-linking may play a similar role (111). Although the dogma in the ﬁeld has been that ezrin and moesin are functionally redundant, two of the known tyrosine phosphorylation sites in ezrin are not conserved in moesin and differences in cargo binding have been described. In lymphocytes, l-selectin and CD95/Fas bind ezrin and moesin differentially (113, 122). Thus, ezrin and moesin may play unique roles in DPC function.

The DPC in T Cell Polarity Several DPC proteins (PKCζ, DLG1, and scribble) control cell polarity in epithelial cells, neurons, and developing organisms (123). These proteins, many of which contain PDZ domains, function in complex networks (124). Analysis of polarity proteins in T cells is still in its infancy, but it is already clear that they play key roles. Scribble appears to be important for polarity per se; T cells in which scribble is suppressed using RNAi fail both to form a uropod and to segregate IS and DPC proteins in response to contact with APCs (96). DLG1 is required for TCR-induced actin polymerization and regulates p38 and NFAT activation (98, 99, 125). PKCζ, an initiator of polarity cascades in other systems, has been implicated in Rap1-induced T cell polarization and chemokineinduced migration (126), as well as NF-κB and JAK/STAT activation (102). Recently, a role for polarity proteins has been established in T cell responses in vivo. Reiner and colleagues showed that during the ﬁrst cell division after stimulation, PKCζ and scribble, as well as sig-

naling proteins such as CD3, IFN-γR, CD8, LFA-1, and Numb, segregate asymmetrically to the two daughter cells (127). This segregation leads to functionally distinct daughter cells; the “proximal” daughter takes on an effector phenotype, whereas the “distal” daughter is more memory-like. Many DPC proteins also localize to the uropod in migrating T cells (31). Both the uropod and DPC sequester proteins away from the site of active actin polymerization (leading edge or IS, respectively), reﬂecting the fundamental role of cytoskeletal architecture in dictating intrinsic cell polarity, as well as regulating signaling complexes.

INTERPLAY BETWEEN T CELL SIGNALING AND ACTIN DYNAMICS The actin cytoskeleton functions as a key intermediate in diverse signaling pathways downstream of the TCR, chemokines, death receptors, and integrins. The role of actin in integrin function is complex and has been recently reviewed elsewhere (36, 37). Here, we summarize brieﬂy the literature regarding TCR signaling pathways, and review what is known about signaling downstream of chemokines and death receptors.

TCR Signaling To and Through the Actin Cytoskeleton Signaling pathways leading from TCR engagement to actin remodeling have been reviewed elsewhere (128). Brieﬂy, the primary pathway involves signaling through Lck and ZAP-70, leading to the formation of a signaling complex at the IS containing the adaptor proteins LAT and SLP-76, the Tec family kinase Itk, and the Rho GEF Vav1 (diagrammed in Figure 2) (128). These proteins stabilize one another at sites of TCR engagement, and loss of any of these molecules results in disruption of actin polymerization at the IS. Interaction with complex components promotes the activation of Vav1 by phosphorylation and www.annualreviews.org • Actin in T Cell Activation

245

ANRV338-IY26-08

ARI

16 February 2008

12:16

phosphoinositide-dependent engagement of its PH domain (129). Vav1 then generates localized pools of active Cdc42 and Rac1, promoting actin polymerization by WASp and WAVE2, respectively (130, 131). As discussed above, other events also contribute to WASp and WAVE2 activation; however, Vav1 function is clearly critical (3, 132). Importantly, Vav1 binds to multiple actin regulatory molecules, suggesting that its central role in controlling actin dynamics involves adaptor functions as well as GEF activity. Costimulatory signaling also controls actin responses at the IS (42). A major consequence of costimulation via CD28 is the activation of PI3K. Through the production of PtIns(3,4,5)P3, PI3K can inﬂuence the localization and activation of PH domain–containing signaling molecules including Vav1 and Itk, leading to enhanced and/or sustained activation of the pathways described above (133–135). CD28 can also signal through a PI3K-Ras pathway to dephosphorylate and activate coﬁlin (136). Though less well studied, costimulatory signaling via other molecules such as CD2, CD82, CD46, and ICOS also affects TCRinduced actin responses (137–140). Thus, one way that costimulation promotes full T cell activation is by augmenting actin-dependent signaling events at the IS. Despite signiﬁcant progress in determining the upstream events linking TCR engagement to actin remodeling, our understanding of how actin contributes to downstream signaling events is largely restricted to activation of the IL-2 promoter. Disruption of the actin network perturbs the activation of each of the three key elements within the IL2 promoter (NFAT, NF-κB, and AP-1). Virtually every condition that affects actin dynamics also affects Ca2+ signaling pathways leading to NFAT activation. Treatment of T cells with CytoD affects Ca2+ ﬂux and NFAT activation, although, as noted above, the effects vary depending on the time of treatment and dose of inhibitor (2–4). Diminished Ca2+ inﬂux and inefﬁcient NFAT activation

Annu. Rev. Immunol. 2008.26:233-259. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

CRAC: calcium release–activated calcium

246

Burkhardt

·

Carrizosa

·

Shaffer

have also been observed in T cells deﬁcient for Vav1, WASp, WAVE2, and HS1 (3, 69, 71, 81, 132, 141, 142). However, the requirement is not simply for actin per se, because individual actin-regulatory proteins facilitate Ca2+ signaling in distinct ways. For example, WAVE2-deﬁcient T cells exhibit defects in coupling store release to calcium release– activated calcium (CRAC) channel activation (69), whereas HS1-deﬁcient T cells exhibit a defect at the level of release from stores (81). The defect in release from stores presumably reﬂects defects in PLCγ1 activation, but this has not been demonstrated. T cells deﬁcient for Vav1 and WASp also fail to activate AP1, likely stemming from upstream defects in ERK activation (142, 143). Activation of NFκB is defective in T cells lacking Vav1 or HS1 (81, 143). The molecular basis for this defect has not been established, but it may reﬂect defects in PKCθ signaling. Additional analysis of signaling events in T cells lacking actin-regulatory proteins will be required to ﬁll in the “black box” linking actin polymerization and changes in T cell gene expression, but it is unlikely that these events represent simple, linear pathways. There is growing evidence that actin networks facilitate formation or stabilization of proteinprotein interactions to promote sustained signaling (43, 81). In addition, actin promotes the internalization of TCR signaling complexes and costimulatory molecules, an event that is thought in some cases to downregulate signaling and in others to sustain it (144, 145).

Chemokine-Induced Migration Chemoattractant signaling pathways leading to actomyosin-based motility have been studied in many cell types, but remarkably little is known about how chemokine signaling in T cells reshapes the actin cytoskeleton. Even the role of PI3 kinases, central regulators of migration in other systems, is unclear in lymphocytes (146). In T cells, chemokine receptor engagement induces activation of G protein–coupled receptors. This

Annu. Rev. Immunol. 2008.26:233-259. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-08

ARI

16 February 2008

12:16

induces activation of Tec kinases (Itk/Rlk), Ilk, Vav, and CrkL (147–150) and downstream activation of small GTPases, especially Rac but also Cdc42 and Rho. The primary function for Cdc42 seems to be in the activation of WASp, which together with WIP promotes T cell migration through tissues (62). In contrast, Rac activation leads to the dephosphorylation of ERM proteins and microvillar collapse that precedes the initiation of polarization and movement. Rac activity also leads to the activation of additional actinregulatory proteins, including PAK, LIMK, and p160ROCK (24, 151, 152). The central role of Rac is highlighted by the migratory defects in cells lacking Rac2, RhoGDI, and the Rac-activating proteins DOCK2 and TIAM1 (25, 126, 153, 154). DOCK2 appears to be a particularly important upstream regulator of Rac in chemokine-activated T cells. T cells from DOCK2−/− mice exhibit profound defects in Rac activation, motility, and microvillar collapse in vitro (155), and diminished migration within lymph nodes, limited egress, and impaired homing in vivo (156, 157). Recently, coﬁlin has emerged as another central player in signaling pathways leading to T cell migration. Regulation of coﬁlin activity is maintained by the opposing action of LIMK1 and the slingshot phosphatase SSH1L. Both LIMK1 and SSH1L are required for chemokine-induced T cell migration, but loss of LIMK1 suppresses lamellipodial formation, whereas loss of SSH1L results in the generation of multiple lamellipodia (158). In chemokine-stimulated cells, SSH1L and dephospho-coﬁlin accumulate in the leading edge, consistent with the idea that SSH1L activates coﬁlin-dependent actin dynamics locally, establishing actin polarity and directional migration. Other pathways also converge on coﬁlin activity. For example, actin-interacting protein 1 (Aip1) and caspase-11 function together to promote migration by activating coﬁlin (159). T cells lacking the β-propeller protein coronin 1 have a distinct phenotype, characterized by excessive F-actin accumulation at the cortex and

drastically impaired cell movement (160). Recent work in nonhematopoietic cells shows that coronin plays a dual role, inhibiting ﬁlament nucleation by the Arp2/3 complex and recruiting SSH1L to lamellipodia, where it activates coﬁlin (161). It remains to be demonstrated whether coronin 1 targets SSH1L in response to chemokine signaling. Nonetheless, because coﬁlin can promote either actin depolymerization or new growth, depending on whether the Arp2/3 complex is activated in parallel, this axis may prove to be particularly important in controlling lamellipodial dynamics.

DISC: death-inducing signaling complex

Death Receptor Signaling Some T cell signaling pathways leading to apoptosis are highly actin dependent (162). In cells where CD95/FasL signaling induces sufﬁcient active caspase-8 to directly activate downstream caspases (Type I cells), maintenance of an intact actin cytoskeleton is required for assembly of the death-inducing signaling complex (DISC) and CD95 internalization (163). Thus, treatment of these cells with actin depolymerizing agents reduces the generation of activated caspase8 and signiﬁcantly inhibits apoptosis (164). This mechanism is mediated, in part, by interactions between CD95 and ezrin. Ezrin (but not moesin or radixin) interacts directly with CD95, and antisense suppression of ezrin or mutation of its CD95 binding site inhibits CD95-mediated apoptosis (112, 113). Ezrin is cointernalized with CD95 in Type I cells, and ezrin-suppressed B cells fail to undergo CD95 internalization and DISC formation (165). It remains unclear exactly how ezrin facilitates CD95 uptake or what distinguishes Type I from Type II cells, in which CD95 is not internalized efﬁciently. No differences in ezrin expression were observed in Type I versus Type II cells, although differences in other actin-regulatory proteins, including HS1, have been described (164). Finally, we note that under some conditions, ERM proteins also function to oppose CD95 www.annualreviews.org • Actin in T Cell Activation

247

ANRV338-IY26-08

ARI

16 February 2008

12:16

signaling. Engagement of ICAM-2, an ERM cargo protein within the DPC, leads to tyrosine phosphorylation of ezrin, thereby creating a binding site for PI3K and initiating Akt-dependent survival signaling that protects against apoptosis induced by Fas or TNF-α (111).

PERSPECTIVES

Annu. Rev. Immunol. 2008.26:233-259. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

Actin polymerization at the site of APC binding was recognized as a hallmark of T cell activation over 25 years ago (27), but for many years the cytoskeleton was thought to play a “housekeeping” role in T cell biology. Today, it is well known that regulated actin dynamics are important for T cell development and homeostasis, activation, migration, and effector function. The past few years have seen an explosion in the identiﬁ-

cation of proteins that control actin dynamics in response to environmental cues. Progress has also been made in understanding how signaling from the TCR, in particular, regulates the activity of these molecules. The challenge now is to understand how the function of these proteins is coordinated. It will be interesting to learn how the cytoskeletal response varies with respect to T cell subtype, agonist strength, and costimulatory signaling and how T cells integrate chemokine signals with TCR signals. Finally, it will be important to learn more about how actin dynamics promote T cell activation and effector function. Answers to these basic cell biological questions will provide important insights into how the assembly of signaling modules at the appropriate time and place within the cell works to “ﬁne-tune” the cellular immune response.

SUMMARY POINTS 1. Depending on the physiological context in which they ﬁnd themselves, T cells exhibit distinct cytoarchitectural features that are required to carry out specialized functions. These features facilitate tethering and rolling in the vasculature, extravasation, and migration through tissues and interactions with APCs. 2. During interaction with APCs, signaling events initiated by ligation of the TCR and costimulatory molecules lead to formation of a dense, branched actin network at the site of APC binding. This network helps to facilitate T cell activation by organizing signaling molecules into microclusters at the IS. The actin network is also important for the movement of signaling molecules to the center of the IS, where the complexes are internalized and signaling is terminated. 3. TCR engagement activates the assembly of a signaling complex containing Vav1, an important GEF for the Rho GTPases Cdc42 and Rac1. These and other events lead to the localized activation of Arp2/3 complex–dependent NPFs, including WASp, WAVE2, and HS1, which work in concert with proteins such as coﬁlin to generate F-actin ﬁlaments at the IS. 4. TCR engagement also leads to the formation of the DPC at the opposite pole of the T cell. Many proteins are brought into the DPC by binding to ezrin and moesin, which link transmembrane and cytoplasmic proteins to actin ﬁlaments in a regulated fashion. The function of the DPC is poorly understood. It is proposed to sequester negative regulators of T cell activation and serve to organize overall T cell polarity.

248

Burkhardt

·

Carrizosa

·

Shaffer

ANRV338-IY26-08

ARI

16 February 2008

12:16

5. Signaling through chemokine receptors and CD95 also affects actin dynamics. Reorganization of the actin cytoskeleton is important for downstream activation of directed cell migration and cell death, respectively. Some proteins involved in these pathways, e.g., Rac, coﬁlin, ezrin, are shared with TCR-dependent actin regulatory pathways. Other proteins, e.g., coronin, are so far known to function only in chemokine-mediated signaling.

Annu. Rev. Immunol. 2008.26:233-259. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

FUTURE ISSUES 1. Although the list of proteins known to control actin remodeling in T cells has grown considerably, future research will undoubtedly reveal other key players. Future studies must ask how these proteins work together to generate the appropriate response to speciﬁc stimuli. 2. Our understanding of how actin responses affect downstream events such as IL-2 promoter activation is still very rudimentary. Actin responses need to be better deﬁned using video microscopy and electron microscopy, and structure-function analysis of individual actin-regulatory proteins will be needed to separate adaptor functions from events that depend on actin per se. Finally, mathematical modeling and other new tools will be needed to help us envision how cytoarchitectural dynamics can affect signaling cascades. 3. The importance of actin-regulatory proteins for in vivo immune responses is highlighted by the severe immunodeﬁciency that afﬂicts patients with mutations in WASp, WIP, or Vav. Recent studies have also linked changes in actin-regulatory proteins to autoimmune disease (166–168). Finally, cytoskeletal proteins play a critical role in infection by HIV and other retroviruses (reviewed in 169). Going forward, it will be important to understand how dysregulation of actin-regulatory proteins contributes to human disease and to develop new therapeutic approaches based on modulating the function of these proteins.

DISCLOSURE STATEMENT The authors are not aware of any biases that might be perceived as affecting the objectivity of this review.

ACKNOWLEDGMENTS Owing to space limitations, it was impossible to cite every relevant reference. We apologize to those whose work was not included here. We thank Yair Argon, Keri Sanborn, and members of the Burkhardt laboratory for critical reading of the manuscript. This work was supported by NIH grants R01-AI065644 and R01-AI50098 to J.K.B., F31-AI071385 to E.C., and T32HD07516 to M.H.S.

www.annualreviews.org • Actin in T Cell Activation

249

ANRV338-IY26-08

ARI

16 February 2008

12:16

LITERATURE CITED

Annu. Rev. Immunol. 2008.26:233-259. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

1. Henney CS, Bubbers JE. 1973. Antigen-T lymphocyte interactions: inhibition by cytochalasin B. J. Immunol. 111:85–90 2. Valitutti S, Dessing M, Aktories K, Gallati H, Lanzavecchia A. 1995. Sustained signaling leading to T cell activation results from prolonged T cell receptor occupancy. Role of T cell actin cytoskeleton. J. Exp. Med. 181:577–84 3. Holsinger LJ, Graef IA, Swat W, Chi T, Bautista DM, et al. 1998. Defects in actin-cap formation in Vav-deﬁcient mice implicate an actin requirement for lymphocyte signal transduction. Curr. Biol. 8:563–72 4. Rivas FV, O’Keefe JP, Alegre ML, Gajewski TF. 2004. Actin cytoskeleton regulates calcium dynamics and NFAT nuclear duration. Mol. Cell. Biol. 24:1628–39 5. Majstoravich S, Zhang J, Nicholson-Dykstra S, Linder S, Friedrich W, et al. 2004. Lymphocyte microvilli are dynamic, actin-dependent structures that do not require WiskottAldrich syndrome protein (WASp) for their morphology. Blood 104:1396–403 6. Stein JV, Cheng G, Stockton BM, Fors BP, Butcher EC, von Andrian UH. 1999. lselectin-mediated leukocyte adhesion in vivo: microvillous distribution determines tethering efﬁciency, but not rolling velocity. J. Exp. Med. 189:37–50 7. Berlin C, Bargatze RF, Campbell JJ, von Andrian UH, Szabo MC, et al. 1995. α 4 integrins mediate lymphocyte attachment and rolling under physiologic ﬂow. Cell 80:413–22 8. Bruehl RE, Springer TA, Bainton DF. 1996. Quantitation of l-selectin distribution on human leukocyte microvilli by immunogold labeling and electron microscopy. J. Histochem. Cytochem. 44:835–44 9. Brown MJ, Nijhara R, Hallam JA, Gignac M, Yamada KM, et al. 2003. Chemokine stimulation of human peripheral blood T lymphocytes induces rapid dephosphorylation of ERM proteins, which facilitates loss of microvilli and polarization. Blood 102:3890–99 10. Alon R, Feigelson S. 2002. From rolling to arrest on blood vessels: leukocyte tap dancing on endothelial integrin ligands and chemokines at subsecond contacts. Semin. Immunol. 14:93–104 11. Takeuchi K, Sato N, Kasahara H, Funayama N, Nagafuchi A, et al. 1994. Perturbation of cell adhesion and microvilli formation by antisense oligonucleotides to ERM family members. J. Cell Biol. 125:1371–84 12. Kenney D, Cairns L, Remold-O’Donnell E, Peterson J, Rosen F, Parkman R. 1986. Morphological abnormalities in the lymphocytes of patients with the Wiscott-Aldrich Syndrome. Blood 68:1329–32 13. Gallego MD, Santamaria M, Pena J, Molina IJ. 1997. Defective actin reorganization and polymerization of Wiskott-Aldrich T cells in response to CD3-mediated stimulation. Blood 90:3089–97 14. Molina I, Kenney D, Rosen F, Remold-O’Donnell E. 1992. T cell lines characterize events in the pathogenesis of the Wiscott-Aldrich Syndrome. J. Exp. Med. 176:867–74 15. Nieto M, Frade JM, Sancho D, Mellado M, Martinez AC, Sanchez-Madrid F. 1997. Polarization of chemokine receptors to the leading edge during lymphocyte chemotaxis. J. Exp. Med. 186:153–58 16. Wei X, Tromberg BJ, Cahalan MD. 1999. Mapping the sensitivity of T cells with an optical trap: polarity and minimal number of receptors for Ca2+ signaling. Proc. Natl. Acad. Sci. USA 96:8471–76 17. Brown MJ, Hallam JA, Liu Y, Yamada KM, Shaw S. 2001. Cutting edge: integration of human T lymphocyte cytoskeleton by the cytolinker plectin. J. Immunol. 167:641–45 250

Burkhardt

·

Carrizosa

·

Shaffer

Annu. Rev. Immunol. 2008.26:233-259. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-08

ARI

16 February 2008

12:16

18. Friedman RS, Jacobelli J, Krummel MF. 2005. Mechanisms of T cell motility and arrest: deciphering the relationship between intra- and extracellular determinants. Semin. Immunol. 17:387–99 19. Jacobelli J, Chmura SA, Buxton DB, Davis MM, Krummel MF. 2004. A single class II myosin modulates T cell motility and stopping, but not synapse formation. Nat. Immunol. 5:531–38 20. del Pozo MA, Vicente-Manzanares M, Tejedor R, Serrador JM, Sanchez-Madrid F. 1999. Rho GTPases control migration and polarization of adhesion molecules and cytoskeletal ERM components in T lymphocytes. Eur. J. Immunol. 29:3609–20 21. Bustelo XR. 2002. Understanding Rho/Rac biology in T-cells using animal models. BioEssays 24:602–12 22. Bardi G, Niggli V, Loetscher P. 2003. Rho kinase is required for CCR7-mediated polarization and chemotaxis of T lymphocytes. FEBS Lett. 542:79–83 23. Lee JH, Katakai T, Hara T, Gonda H, Sugai M, Shimizu A. 2004. Roles of p-ERM and Rho-ROCK signaling in lymphocyte polarity and uropod formation. J. Cell Biol. 167:327–37 24. Volinsky N, Gantman A, Yablonski D. 2006. A Pak- and Pix-dependent branch of the SDF-1α signalling pathway mediates T cell chemotaxis across restrictive barriers. Biochem. J. 397:213–22 25. Ishizaki H, Togawa A, Tanaka-Okamoto M, Hori K, Nishimura M, et al. 2006. Defective chemokine-directed lymphocyte migration and development in the absence of Rho guanosine diphosphate-dissociation inhibitors α and β. J. Immunol. 177:8512–21 26. Ratner S, Piechocki MP, Galy A. 2003. Role of Rho-family GTPase Cdc42 in polarized expression of lymphocyte appendages. J. Leukoc. Biol. 73:830–40 27. Ryser JE, Rungger-Brandle E, Chaponnier C, Gabbiani G, Vassalli P. 1982. The area of attachment of cytotoxic T lymphocytes to their target cells shows high motility and polarization of actin, but not myosin. J. Immunol. 128:1159–62 28. Kupfer A, Dennert G, Singer SJ. 1985. The reorientation of the Golgi apparatus and the microtubule-organizing center in the cytotoxic effector cell is a prerequisite in the lysis of bound target cells. J. Mol. Cell. Immunol. 2:37–49 29. Kupfer H, Monks C, Kupfer A. 1994. Small splenic B cells that bind to antigen-speciﬁc T helper (Th) cells and face the site of cytokine production in the Th cells selectively proliferate: immunoﬂuorescence microscopy studies of Th-B antigen-presenting cell interactions. J. Exp. Med. 179:1507–15 30. Delon J, Kaibuchi K, Germain RN. 2001. Exclusion of CD43 from the immunological synapse is mediated by phosphorylation-regulated relocation of the cytoskeletal adaptor moesin. Immunity 15:691–701 31. Cullinan P, Sperling AI, Burkhardt JK. 2002. The distal pole complex: a novel membrane domain distal to the immunological synapse. Immunol. Rev. 189:111–22 32. Faure S, Salazar-Fontana LI, Semichon M, Tybulewicz VL, Bismuth G, et al. 2004. ERM proteins regulate cytoskeleton relaxation promoting T cell-APC conjugation. Nat. Immunol. 5:272–79 33. Selliah N, Brooks WH, Roszman TL. 1996. Proteolytic cleavage of α-actinin by calpain in T cells stimulated with anti-CD3 monoclonal antibody. J. Immunol. 156:3215–21 34. Cairo CW, Mirchev R, Golan DE. 2006. Cytoskeletal regulation couples LFA-1 conformational changes to receptor lateral mobility and clustering. Immunity 25:297–308 35. Morley SC, Sung J, Sun GP, Martelli MP, Bunnell SC, Bierer BE. 2007. Gelsolin overexpression alters actin dynamics and tyrosine phosphorylation of lipid raft-associated proteins in Jurkat T cells. Mol. Immunol. 44:2469–80 www.annualreviews.org • Actin in T Cell Activation

251

ARI

16 February 2008

12:16

36. Luo BH, Carman CV, Springer TA. 2007. Structural basis of integrin regulation and signaling. Annu. Rev. Immunol. 25:619–47 37. Billadeau DD, Nolz JC, Gomez TS. 2007. Regulation of T-cell activation by the cytoskeleton. Nat. Rev. Immunol. 7:131–43 38. Valmu L, Fagerholm S, Suila H, Gahmberg CG. 1999. The cytoskeletal association of CD11/CD18 leukocyte integrins in phorbol ester-activated cells correlates with CD18 phosphorylation. Eur. J. Immunol. 29:2107–18 39. Nurmi SM, Gahmberg CG, Fagerholm SC. 2006. 14-3-3 proteins bind both ﬁlamin and αLβ2 integrin in activated T cells. Ann. NY Acad. Sci. 1090:318–25 40. Simonson WT, Franco SJ, Huttenlocher A. 2006. Talin1 regulates TCR-mediated LFA-1 function. J. Immunol. 177:7707–14 41. Kim M, Carman CV, Yang W, Salas A, Springer TA. 2004. The primacy of afﬁnity over clustering in regulation of adhesiveness of the integrin αLβ2. J. Cell Biol. 167:1241–53 42. Tskvitaria-Fuller I, Rozelle AL, Yin HL, Wulﬁng C. 2003. Regulation of sustained actin dynamics by the TCR and costimulation as a mechanism of receptor localization. J. Immunol. 171:2287–95 43. Campi G, Varma R, Dustin ML. 2005. Actin and agonist MHC-peptide complexdependent T cell receptor microclusters as scaffolds for signaling. J. Exp. Med. 202:1031– 36 44. Sims TN, Soos TJ, Xenias HS, Dubin-Thaler B, Hofman JM, et al. 2007. Opposing effects of PKCθ and WASp on symmetry breaking and relocation of the immunological synapse. Cell 129:773–85 45. Wulﬁng C, Bauch A, Crabtree GR, Davis MM. 2000. The vav exchange factor is an essential regulator in actin-dependent receptor translocation to the lymphocyte-antigenpresenting cell interface. Proc. Natl. Acad. Sci. USA 97:10150–55 46. Dustin ML, Tseng SY, Varma R, Campi G. 2006. T cell-dendritic cell immunological synapses. Curr. Opin. Immunol. 18:512–16 47. Cemerski S, Shaw A. 2006. Immune synapses in T-cell activation. Curr. Opin. Immunol. 18:298–304 48. Friedl P, den Boer AT, Gunzer M. 2005. Tuning immune responses: diversity and adaptation of the immunological synapse. Nat. Rev. Immunol. 5:532–45 49. Monks CR, Freiberg BA, Kupfer H, Sciaky N, Kupfer A. 1998. Three-dimensional segregation of supramolecular activation clusters in T cells. Nature 395:82–86 50. Jacobelli J, Andres PG, Boisvert J, Krummel MF. 2004. New views of the immunological synapse: variations in assembly and function. Curr. Opin. Immunol. 16:345–52 51. Mossman KD, Campi G, Groves JT, Dustin ML. 2005. Altered TCR signaling from geometrically repatterned immunological synapses. Science 310:1191–93 52. Cemerski S, Das J, Locasale J, Arnold P, Giurisato E, et al. 2007. The stimulatory potency of T cell antigens is inﬂuenced by the formation of the immunological synapse. Immunity 26:345–55 53. Lee KH, Dinner AR, Tu C, Campi G, Raychaudhuri S, et al. 2003. The immunological synapse balances T cell receptor signaling and degradation. Science 302:1218–22 54. Bunnell SC, Hong DI, Kardon JR, Yamazaki T, McGlade CJ, et al. 2002. T cell receptor ligation induces the formation of dynamically regulated signaling assemblies. J. Cell Biol. 158:1263–75 55. Yokosuka T, Sakata-Sogawa K, Kobayashi W, Hiroshima M, Hashimoto-Tane A, et al. 2005. Newly generated T cell receptor microclusters initiate and sustain T cell activation by recruitment of Zap70 and SLP-76. Nat. Immunol. 6:1253–62

Annu. Rev. Immunol. 2008.26:233-259. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-08

252

Burkhardt

·

Carrizosa

·

Shaffer

Annu. Rev. Immunol. 2008.26:233-259. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-08

ARI

16 February 2008

12:16

56. Varma R, Campi G, Yokosuka T, Saito T, Dustin ML. 2006. T cell receptor-proximal signals are sustained in peripheral microclusters and terminated in the central supramolecular activation cluster. Immunity 25:117–27 57. Goley ED, Welch MD. 2006. The ARP2/3 complex: an actin nucleator comes of age. Nat. Rev. Mol. Cell Biol. 7:713–26 58. Gomez TS, Kumar K, Medeiros RB, Shimizu Y, Leibson PJ, Billadeau DD. 2007. Formins regulate the actin-related protein 2/3 complex-independent polarization of the centrosome to the immunological synapse. Immunity 26:177–90 59. Volkman BF, Prehoda KE, Scott JA, Peterson FC, Lim WA. 2002. Structure of the NWASP EVH1 domain-WIP complex: insight into the molecular basis of Wiskott-Aldrich Syndrome. Cell 111:565–76 60. de la Fuente MA, Sasahara Y, Calamito M, Anton IM, Elkhal A, et al. 2007. WIP is a chaperone for Wiskott-Aldrich syndrome protein (WASP). Proc. Natl. Acad. Sci. USA 104:926–31 61. Notarangelo LD, Ochs HD. 2003. Wiskott-Aldrich Syndrome: a model for defective actin reorganization, cell trafﬁcking and synapse formation. Curr. Opin. Immunol. 15:585–91 62. Gallego MD, de la Fuente MA, Anton IM, Snapper S, Fuhlbrigge R, Geha RS. 2006. WIP and WASP play complementary roles in T cell homing and chemotaxis to SDF-1α. Int. Immunol. 18:221–32 63. Zeng R, Cannon JL, Abraham RT, Way M, Billadeau DD, et al. 2003. SLP-76 coordinates Nck-dependent Wiskott-Aldrich syndrome protein recruitment with Vav-1/Cdc42dependent Wiskott-Aldrich syndrome protein activation at the T cell-APC contact site. J. Immunol. 171:1360–68 64. Badour K, Zhang J, Shi F, McGavin MK, Rampersad V, et al. 2003. The Wiskott-Aldrich syndrome protein acts downstream of CD2 and the CD2AP and PSTPIP1 adaptors to promote formation of the immunological synapse. Immunity 18:141–54 65. Kim AS, Kakalis LT, Abdul-Manan N, Liu GA, Rosen MK. 2000. Autoinhibition and activation mechanisms of the Wiskott-Aldrich syndrome protein. Nature 404:151–58 66. Torres E, Rosen MK. 2003. Contingent phosphorylation/dephosphorylation provides a mechanism of molecular memory in WASP. Mol. Cell 11:1215–27 67. Badour K, Zhang J, Shi F, Leng Y, Collins M, Siminovitch KA. 2004. Fyn and PTPPEST-mediated regulation of Wiskott-Aldrich syndrome protein (WASp) tyrosine phosphorylation is required for coupling T cell antigen receptor engagement to WASp effector function and T cell activation. J. Exp. Med. 199:99–112 68. Torres E, Rosen MK. 2006. Protein-tyrosine kinase and GTPase signals cooperate to phosphorylate and activate Wiskott-Aldrich syndrome protein (WASP)/neuronal WASP. J. Biol. Chem. 281:3513–20 69. Nolz JC, Gomez TS, Zhu P, Li S, Medeiros RB, et al. 2006. The WAVE2 complex regulates actin cytoskeletal reorganization and CRAC-mediated calcium entry during T cell activation. Curr. Biol. 16:24–34 70. Krawczyk C, Oliveira-dos-Santos A, Sasaki T, Grifﬁths E, Ohashi PS, et al. 2002. Vav1 controls integrin clustering and MHC/peptide-speciﬁc cell adhesion to antigenpresenting cells. Immunity 16:331–43 71. Cannon JL, Burkhardt JK. 2004. Differential roles for Wiskott-Aldrich syndrome protein in immune synapse formation and IL-2 production. J. Immunol. 173:1658–62 72. Zipfel PA, Bunnell SC, Witherow DS, Gu JJ, Chislock EM, et al. 2006. Role for the Abi/wave protein complex in T cell receptor-mediated proliferation and cytoskeletal remodeling. Curr. Biol. 16:35–46 www.annualreviews.org • Actin in T Cell Activation

253

ARI

16 February 2008

12:16

73. Miki H, Suetsugu S, Takenawa T. 1998. WAVE, a novel WASP-family protein involved in actin reorganization induced by Rac. EMBO J. 17:6932–41 74. Innocenti M, Zucconi A, Disanza A, Frittoli E, Areces LB, et al. 2004. Abi1 is essential for the formation and activation of a WAVE2 signalling complex. Nat. Cell Biol. 6:319–27 75. Miki H, Yamaguchi H, Suetsugu S, Takenawa T. 2000. IRSp53 is an essential intermediate between Rac and WAVE in the regulation of membrane rufﬂing. Nature 408:732–35 76. Leng Y, Zhang J, Badour K, Arpaia E, Freeman S, et al. 2005. Abelson-interactor-1 promotes WAVE2 membrane translocation and Abelson-mediated tyrosine phosphorylation required for WAVE2 activation. Proc. Natl. Acad. Sci. USA 102:1098–103 77. Hao JJ, Zhu J, Zhou K, Smith N, Zhan X. 2005. The coiled-coil domain is required for HS1 to bind to F-actin and activate Arp2/3 complex. J. Biol. Chem. 280:37988–94 78. Uruno T, Liu J, Zhang P, Fan Y, Egile C, et al. 2001. Activation of Arp2/3 complexmediated actin polymerization by cortactin. Nat. Cell Biol. 3:259–66 79. Uruno T, Zhang P, Liu J, Hao JJ, Zhan X. 2003. Haematopoietic lineage cell-speciﬁc protein 1 (HS1) promotes actin-related protein (Arp) 2/3 complex-mediated actin polymerization. Biochem. J. 371:485–93 80. Weaver AM, Karginov AV, Kinley AW, Weed SA, Li Y, et al. 2001. Cortactin promotes and stabilizes Arp2/3-induced actin ﬁlament network formation. Curr. Biol. 11:370–74 81. Gomez TS, McCarney SD, Carrizosa E, Labno CM, Comiskey EO, et al. 2006. HS1 functions as an essential actin-regulatory adaptor protein at the immune synapse. Immunity 24:741–52 82. Eibert SM, Lee KH, Pipkorn R, Sester U, Wabnitz GH, et al. 2004. Coﬁlin peptide homologs interfere with immunological synapse formation and T cell activation. Proc. Natl. Acad. Sci. USA 101:1957–62 83. DesMarais V, Ghosh M, Eddy R, Condeelis J. 2005. Coﬁlin takes the lead. J. Cell Sci. 118:19–26 84. Ambach A, Saunus J, Konstandin M, Wesselborg S, Meuer SC, Samstag Y. 2000. The serine phosphatases PP1 and PP2A associate with and activate the actin-binding protein coﬁlin in human T lymphocytes. Eur. J. Immunol. 30:3422–31 85. Samstag Y, Henning SW, Bader A, Meuer SC. 1992. Dephosphorylation of pp19: a common second signal for human T cell activation mediated through different accessory molecules. Int. Immunol. 4:1255–62 86. Krause M, Sechi AS, Konradt M, Monner D, Gertler FB, Wehland J. 2000. Fyn-binding protein (Fyb)/SLP-76-associated protein (SLAP), Ena/vasodilator-stimulated phosphoprotein (VASP) proteins and the Arp2/3 complex link T cell receptor (TCR) signaling to the actin cytoskeleton. J. Cell Biol. 149:181–94 87. Faix J, Grosse R. 2006. Staying in shape with formins. Dev. Cell 10:693–706 88. Krause M, Dent EW, Bear JE, Loureiro JJ, Gertler FB. 2003. Ena/VASP proteins: regulators of the actin cytoskeleton and cell migration. Annu. Rev. Cell Dev. Biol. 19:541–64 89. Su IH, Dobenecker MW, Dickinson E, Oser M, Basavaraj A, et al. 2005. Polycomb group protein ezh2 controls actin polymerization and cell signaling. Cell 121:425–36 90. Su IH, Tarakhovsky A. 2006. Lysine methylation and ‘signaling memory’. Curr. Opin. Immunol. 18:152–57 91. Gomez TS, Hamann MJ, McCarney S, Savoy DN, Lubking CM, et al. 2005. Dynamin 2 regulates T cell activation by controlling actin polymerization at the immunological synapse. Nat. Immunol. 6:261–70 92. Kruchten AE, McNiven MA. 2006. Dynamin as a mover and pincher during cell migration and invasion. J. Cell Sci. 119:1683–90

Annu. Rev. Immunol. 2008.26:233-259. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-08

254

Burkhardt

·

Carrizosa

·

Shaffer

Annu. Rev. Immunol. 2008.26:233-259. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-08

ARI

16 February 2008

12:16

93. Cullinan P, Sperling AI, Burkhardt JK. 2002. The distal pole complex: a novel membrane domain distal to the immunological synapse. Immunol. Rev. 189:111–22 94. Allenspach EJ, Cullinan P, Tong J, Tang Q, Tesciuba AG, et al. 2001. ERM-dependent movement of CD43 deﬁnes a novel protein complex distal to the immunological synapse. Immunity 15:739–50 95. Savage ND, Kimzey SL, Bromley SK, Johnson KG, Dustin ML, Green JM. 2002. Polar redistribution of the sialoglycoprotein CD43: implications for T cell function. J. Immunol. 168:3740–46 96. Ludford-Menting MJ, Oliaro J, Sacirbegovic F, Cheah ET, Pedersen N, et al. 2005. A network of PDZ-containing proteins regulates T cell polarity and morphology during migration and immunological synapse formation. Immunity 22:737–48 97. Roumier A, Olivo-Marin JC, Arpin M, Michel F, Martin M, et al. 2001. The membranemicroﬁlament linker ezrin is involved in the formation of the immunological synapse and in T cell activation. Immunity 15:715–28 98. Round JL, Humphries LA, Tomassian T, Mittelstadt P, Zhang M, Miceli MC. 2007. Scaffold protein Dlgh1 coordinates alternative p38 kinase activation, directing T cell receptor signals toward NFAT but not NF-κB transcription factors. Nat. Immunol. 8:154– 61 99. Round JL, Tomassian T, Zhang M, Patel V, Schoenberger SP, Miceli MC. 2005. Dlgh1 coordinates actin polymerization, synaptic T cell receptor and lipid raft aggregation, and effector function in T cells. J. Exp. Med. 201:419–30 100. Lin J, Weiss A. 2003. The tyrosine phosphatase CD148 is excluded from the immunologic synapse and down-regulates prolonged T cell signaling. J. Cell Biol. 162:673–82 101. Arp J, Kirchhof MG, Baroja ML, Nazarian SH, Chau TA, et al. 2003. Regulation of T-cell activation by phosphodiesterase 4B2 requires its dynamic redistribution during immunological synapse formation. Mol. Cell. Biol. 23:8042–57 102. Moscat J, Rennert P, Diaz-Meco MT. 2006. PKCζ at the crossroad of NF-κB and Jak1/Stat6 signaling pathways. Cell Death Differ. 13:702–11 103. Costello PS, Gallagher M, Cantrell DA. 2002. Sustained and dynamic inositol lipid metabolism inside and outside the immunological synapse. Nat. Immunol. 3:1082–89 104. Stefanova I, Hemmer B, Vergelli M, Martin R, Biddison WE, Germain RN. 2003. TCR ligand discrimination is enforced by competing ERK positive and SHP-1 negative feedback pathways. Nat. Immunol. 4:248–54 105. Itoh K, Sakakibara M, Yamasaki S, Takeuchi A, Arase H, et al. 2002. Cutting edge: negative regulation of immune synapse formation by anchoring lipid raft to cytoskeleton through Cbp-EBP50-ERM assembly. J. Immunol. 168:541–44 106. Nakahira M, Tanaka T, Robson BE, Mizgerd JP, Grusby MJ. 2007. Regulation of signal transducer and activator of transcription signaling by the tyrosine phosphatase PTP-BL. Immunity 26:163–76 107. del Rio R, Rincon M, Layseca-Espinosa E, Fierro NA, Rosenstein Y, Pedraza-Alva G. 2004. PKCθ is required for the activation of human T lymphocytes induced by CD43 engagement. Biochem. Biophys. Res. Commun. 325:133–43 108. Sperling AI, Green JM, Mosley RL, Smith PL, DiPaolo RJ, et al. 1995. CD43 is a murine T cell costimulatory receptor that functions independently of CD28. J. Exp. Med. 182:139–46 109. Oliaro J, Pasam A, Waterhouse NJ, Browne KA, Ludford-Menting MJ, et al. 2006. Ligation of the cell surface receptor, CD46, alters T cell polarity and response to antigen presentation. Proc. Natl. Acad. Sci. USA 103:18685–90 www.annualreviews.org • Actin in T Cell Activation

255

ARI

16 February 2008

12:16

110. Kemper C, Verbsky JW, Price JD, Atkinson JP. 2005. T-cell stimulation and regulation: with complements from CD46. Immunol. Res. 32:31–43 111. Perez OD, Kinoshita S, Hitoshi Y, Payan DG, Kitamura T, et al. 2002. Activation of the PKB/AKT pathway by ICAM-2. Immunity 16:51–65 112. Parlato S, Giammarioli AM, Logozzi M, Lozupone F, Matarrese P, et al. 2000. CD95 (APO-1/Fas) linkage to the actin cytoskeleton through ezrin in human T lymphocytes: a novel regulatory mechanism of the CD95 apoptotic pathway. EMBO J. 19:5123–34 113. Lozupone F, Lugini L, Matarrese P, Luciani F, Federici C, et al. 2004. Identiﬁcation and relevance of the CD95-binding domain in the N-terminal region of ezrin. J. Biol. Chem. 279:9199–207 114. Li Q, Nance MR, Kulikauskas R, Nyberg K, Fehon R, et al. 2007. Self-masking in an intact ERM-merlin protein: an active role for the central α-helical domain. J. Mol. Biol. 365:1446–59 115. Bretscher A, Edwards K, Fehon RG. 2002. ERM proteins and merlin: integrators at the cell cortex. Nat. Rev. Mol. Cell Biol. 3:586–99 116. Nijhara R, van Hennik PB, Gignac ML, Kruhlak MJ, Hordijk PL, et al. 2004. Rac1 mediates collapse of microvilli on chemokine-activated T lymphocytes. J. Immunol. 173:4985– 93 117. Muller N, Avota E, Schneider-Schaulies J, Harms H, Krohne G, Schneider-Schaulies S. 2006. Measles virus contact with T cells impedes cytoskeletal remodeling associated with spreading, polarization, and CD3 clustering. Trafﬁc 7:849–58 118. Thuillier L, Hivroz C, Fagard R, Andreoli C, Mangeat P. 1994. Ligation of CD4 surface antigen induces rapid tyrosine phosphorylation of the cytoskeletal protein ezrin. Cell. Immunol. 156:322–31 119. Egerton M, Burgess WH, Chen D, Druker BJ, Bretscher A, Samelson LE. 1992. Identiﬁcation of ezrin as an 81-kDa tyrosine-phosphorylated protein in T cells. J. Immunol. 149:1847–52 120. Autero M, Heiska L, Ronnstrand L, Vaheri A, Gahmberg CG, Carpen O. 2003. Ezrin is a substrate for Lck in T cells. FEBS Lett. 535:82–86 121. Gautreau A, Poullet P, Louvard D, Arpin M. 1999. Ezrin, a plasma membranemicroﬁlament linker, signals cell survival through the phosphatidylinositol 3-kinase/Akt pathway. Proc. Natl. Acad. Sci. USA 96:7300–5 122. Ivetic A, Deka J, Ridley A, Ager A. 2002. The cytoplasmic tail of l-selectin interacts with members of the Ezrin-Radixin-Moesin (ERM) family of proteins: cell activationdependent binding of Moesin but not Ezrin. J. Biol. Chem. 277:2321–29 123. Suzuki A, Ohno S. 2006. The PAR-aPKC system: lessons in polarity. J. Cell Sci. 119:979– 87 124. Xavier R, Seed B. 2005. PDZ domains and the politics of polarity in lymphocytes. Immunity 22:655–56 125. Xavier R, Rabizadeh S, Ishiguro K, Andre N, Ortiz JB, et al. 2004. Discs large (Dlg1) complexes in lymphocyte activation. J. Cell Biol. 166:173–78 126. Gerard A, Mertens AE, Van Der Kammen RA, Collard JG. 2007. The Par polarity complex regulates Rap1- and chemokine-induced T cell polarization. J. Cell Biol. 176:863– 75 127. Chang JT, Palanivel VR, Kinjyo I, Schambach F, Intlekofer AM, et al. 2007. Asymmetric T lymphocyte division in the initiation of adaptive immune responses. Science 315:1687– 91 128. Fuller CL, Braciale VL, Samelson LE. 2003. All roads lead to actin: the intimate relationship between TCR signaling and the cytoskeleton. Immunol. Rev. 191:220–36

Annu. Rev. Immunol. 2008.26:233-259. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-08

256

Burkhardt

·

Carrizosa

·

Shaffer

Annu. Rev. Immunol. 2008.26:233-259. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-08

ARI

16 February 2008

12:16

129. Bustelo XR. 2002. Regulation of Vav proteins by intramolecular events. Front. Biosci. 7:d24–30 130. Dombroski D, Houghtling RA, Labno CM, Precht P, Takesono A, et al. 2005. Kinaseindependent functions for Itk in TCR-induced regulation of Vav and the actin cytoskeleton. J. Immunol. 174:1385–92 131. Labno CM, Lewis CM, You D, Leung DW, Takesono A, et al. 2003. Itk functions to control actin polymerization at the immune synapse through localized activation of Cdc42 and WASP. Curr. Biol. 13:1619–24 132. Fischer KD, Kong YY, Nishina H, Tedford K, Marengere LE, et al. 1998. Vav is a regulator of cytoskeletal reorganization mediated by the T-cell receptor. Curr. Biol. 8:554– 62 133. Michel F, Mangino G, Attal-Bonnefoy G, Tuosto L, Alcover A, et al. 2000. CD28 utilizes Vav-1 to enhance TCR-proximal signaling and NF-AT activation. J. Immunol. 165:3820– 29 134. Han J, Luby-Phelps K, Das B, Shu X, Xia Y, et al. 1998. Role of substrates and products of PI 3-kinase in regulating activation of Rac-related guanosine triphosphatases by Vav. Science 279:558–60 135. Finkelstein LD, Schwartzberg PL. 2004. Tec kinases: shaping T-cell activation through actin. Trends Cell Biol. 14:443–51 136. Wabnitz GH, Nebl G, Klemke M, Schroder AJ, Samstag Y. 2006. Phosphatidylinositol 3kinase functions as a Ras effector in the signaling cascade that regulates dephosphorylation of the actin-remodeling protein coﬁlin after costimulation of untransformed human T lymphocytes. J. Immunol. 176:1668–74 137. Wabnitz GH, Kocher T, Lohneis P, Stober C, Konstandin MH, et al. 2007. Costimulation induced phosphorylation of l-plastin facilitates surface transport of the T cell activation molecules CD69 and CD25. Eur. J. Immunol. 37:649–62 138. Delaguillaumie A, Lagaudriere-Gesbert C, Popoff MR, Conjeaud H. 2002. Rho GTPases link cytoskeletal rearrangements and activation processes induced via the tetraspanin CD82 in T lymphocytes. J. Cell Sci. 115:433–43 139. Zaffran Y, Destaing O, Roux A, Ory S, Nheu T, et al. 2001. CD46/CD3 costimulation induces morphological changes of human T cells and activation of Vav, Rac, and extracellular signal-regulated kinase mitogen-activated protein kinase. J. Immunol. 167:6780–85 140. Nukada Y, Okamoto N, Konakahara S, Tezuka K, Ohashi K, et al. 2006. AILIM/ICOSmediated elongation of activated T cells is regulated by both the PI3-kinase/Akt and Rho family cascade. Int. Immunol. 18:1815–24 141. Zhang J, Shehabeldin A, da Cruz LA, Butler J, Somani AK, et al. 1999. Antigen receptorinduced activation and cytoskeletal rearrangement are impaired in Wiskott-Aldrich syndrome protein-deﬁcient lymphocytes. J. Exp. Med. 190:1329–42 142. Cianferoni A, Massaad M, Feske S, de la Fuente MA, Gallego L, et al. 2005. Defective nuclear translocation of nuclear factor of activated T cells and extracellular signal-regulated kinase underlies deﬁcient IL-2 gene expression in Wiskott-Aldrich syndrome. J. Allergy Clin. Immunol. 116:1364–71 143. Costello PS, Walters AE, Mee PJ, Turner M, Reynolds LF, et al. 1999. The Rho-family GTP exchange factor Vav is a critical transducer of T cell receptor signals to the calcium, ERK, and NF-κB pathways. Proc. Natl. Acad. Sci. USA 96:3035–40 144. Badour K, McGavin MK, Zhang J, Freeman S, Vieira C, et al. 2007. Interaction of the Wiskott-Aldrich syndrome protein with sorting nexin 9 is required for CD28 endocytosis and cosignaling in T cells. Proc. Natl. Acad. Sci. USA 104:1593–98 www.annualreviews.org • Actin in T Cell Activation

257

ARI

16 February 2008

12:16

145. McGavin MK, Badour K, Hardy LA, Kubiseski TJ, Zhang J, Siminovitch KA. 2001. The intersectin 2 adaptor links Wiskott Aldrich Syndrome protein (WASp)-mediated actin polymerization to T cell antigen receptor endocytosis. J. Exp. Med. 194:1777–87 146. Ward SG. 2004. Do phosphoinositide 3-kinases direct lymphocyte navigation? Trends Immunol. 25:67–74 147. Takesono A, Horai R, Mandai M, Dombroski D, Schwartzberg PL. 2004. Requirement for Tec kinases in chemokine-induced migration and activation of Cdc42 and Rac. Curr. Biol. 14:917–22 148. Liu E, Sinha S, Williams C, Cyrille M, Heller E, et al. 2005. Targeted deletion of integrinlinked kinase reveals a role in T-cell chemotaxis and survival. Mol. Cell. Biol. 25:11145–55 149. Vicente-Manzanares M, Cruz-Adalia A, Martin-Cofreces NB, Cabrero JR, Dosil M, et al. 2005. Control of lymphocyte shape and the chemotactic response by the GTP exchange factor Vav. Blood 105:3026–34 150. Arai A, Aoki M, Weihua Y, Jin A, Miura O. 2006. CrkL plays a role in SDF-1-induced activation of the Raf-1/MEK/Erk pathway through Ras and Rac to mediate chemotactic signaling in hematopoietic cells. Cell. Signal. 18:2162–71 151. Nishita M, Aizawa H, Mizuno K. 2002. Stromal cell-derived factor 1α activates LIM kinase 1 and induces coﬁlin phosphorylation for T-cell chemotaxis. Mol. Cell. Biol. 22:774– 83 152. Vicente-Manzanares M, Cabrero JR, Rey M, Perez-Martinez M, Ursa A, et al. 2002. A role for the Rho-p160 Rho coiled-coil kinase axis in the chemokine stromal cell-derived factor1α-induced lymphocyte actomyosin and microtubular organization and chemotaxis. J. Immunol. 168:400–10 153. Croker BA, Handman E, Hayball JD, Baldwin TM, Voigt V, et al. 2002. Rac2-deﬁcient mice display perturbed T-cell distribution and chemotaxis, but only minor abnormalities in TH1 responses. Immunol. Cell Biol. 80:231–40 154. Fukui Y, Hashimoto O, Sanui T, Oono T, Koga H, et al. 2001. Haematopoietic cellspeciﬁc CDM family protein DOCK2 is essential for lymphocyte migration. Nature 412:826–31 155. Shulman Z, Pasvolsky R, Woolf E, Grabovsky V, Feigelson SW, et al. 2006. DOCK2 regulates chemokine-triggered lateral lymphocyte motility but not transendothelial migration. Blood 108:2150–58 156. Nombela-Arrieta C, Mempel TR, Soriano SF, Mazo I, Wymann MP, et al. 2007. A central role for DOCK2 during interstitial lymphocyte motility and sphingosine-1-phosphatemediated egress. J. Exp. Med. 204:497–510 157. Nombela-Arrieta C, Lacalle RA, Montoya MC, Kunisaki Y, Megias D, et al. 2004. Differential requirements for DOCK2 and phosphoinositide-3-kinase γ during T and B lymphocyte homing. Immunity 21:429–41 158. Nishita M, Tomizawa C, Yamamoto M, Horita Y, Ohashi K, Mizuno K. 2005. Spatial and temporal regulation of coﬁlin activity by LIM kinase and Slingshot is critical for directional cell migration. J. Cell Biol. 171:349–59 159. Li J, Brieher WM, Scimone ML, Kang SJ, Zhu H, et al. 2007. Caspase-11 regulates cell migration by promoting Aip1-Coﬁlin-mediated actin depolymerization. Nat. Cell Biol. 9:276–86 160. Foger N, Rangell L, Danilenko DM, Chan AC. 2006. Requirement for coronin 1 in T lymphocyte trafﬁcking and cellular homeostasis. Science 313:839–42 161. Cai L, Marshall TW, Uetrecht AC, Schafer DA, Bear JE. 2007. Coronin 1B coordinates Arp2/3 complex and coﬁlin activities at the leading edge. Cell 128:915–29

Annu. Rev. Immunol. 2008.26:233-259. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-08

258

Burkhardt

·

Carrizosa

·

Shaffer

Annu. Rev. Immunol. 2008.26:233-259. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-08

ARI

16 February 2008

12:16

162. Celeste Morley S, Sun GP, Bierer BE. 2003. Inhibition of actin polymerization enhances commitment to and execution of apoptosis induced by withdrawal of trophic support. J. Cell. Biochem. 88:1066–76 163. Algeciras-Schimnich A, Shen L, Barnhart BC, Murmann AE, Burkhardt JK, Peter ME. 2002. Molecular ordering of the initial signaling events of CD95. Mol. Cell. Biol. 22:207– 20 164. Algeciras-Schimnich A, Peter ME. 2003. Actin dependent CD95 internalization is speciﬁc for Type I cells. FEBS Lett. 546:185–88 165. Chakrabandhu K, Herincs Z, Huault S, Dost B, Peng L, et al. 2007. Palmitoylation is required for efﬁcient Fas cell death signaling. EMBO J. 26:209–20 166. Otsuka J, Horiuchi T, Yoshizawa S, Tsukamoto H, Sawabe T, et al. 2004. Association of a four-amino acid residue insertion polymorphism of the HS1 gene with systemic lupus erythematosus: molecular and functional analysis. Arthritis Rheum. 50:871–81 167. Sawabe T, Horiuchi T, Koga R, Tsukamoto H, Kojima T, et al. 2003. Aberrant HS1 molecule in a patient with systemic lupus erythematosus. Genes Immun. 4:122–31 168. Li Y, Harada T, Juang YT, Kyttaris VC, Wang Y, et al. 2007. Phosphorylated ERM is responsible for increased T cell polarization, adhesion, and migration in patients with systemic lupus erythematosus. J. Immunol. 178:1938–47 169. Fackler OT, Krausslich HG. 2006. Interactions of human retroviruses with the host cell cytoskeleton. Curr. Opin. Microbiol. 9:409–15

www.annualreviews.org • Actin in T Cell Activation

259

AR338-FM

ARI

12 January 2008

18:11

Annual Review of Immunology

Annu. Rev. Immunol. 2008.26:233-259. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

Contents

Volume 26, 2008

Frontispiece K. Frank Austen p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p x Doing What I Like K. Frank Austen p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p1 Protein Tyrosine Phosphatases in Autoimmunity Torkel Vang, Ana V. Miletic, Yutaka Arimura, Lutz Tautz, Robert C. Rickert, and Tomas Mustelin p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p 29 Interleukin-21: Basic Biology and Implications for Cancer and Autoimmunity Rosanne Spolski and Warren J. Leonard p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p 57 Forward Genetic Dissection of Immunity to Infection in the Mouse S.M. Vidal, D. Malo, J.-F. Marquis, and P. Gros p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p 81 Regulation and Functions of Blimp-1 in T and B Lymphocytes Gislâine Martins and Kathryn Calame p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p133 Evolutionarily Conserved Amino Acids That Control TCR-MHC Interaction Philippa Marrack, James P. Scott-Browne, Shaodong Dai, Laurent Gapin, and John W. Kappler p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p171 T Cell Trafﬁcking in Allergic Asthma: The Ins and Outs Benjamin D. Medoff, Seddon Y. Thomas, and Andrew D. Luster p p p p p p p p p p p p p p p p p p p p p205 The Actin Cytoskeleton in T Cell Activation Janis K. Burkhardt, Esteban Carrizosa, and Meredith H. Shaffer p p p p p p p p p p p p p p p p p p p p233 Mechanism and Regulation of Class Switch Recombination Janet Stavnezer, Jeroen E.J. Guikema, and Carol E. Schrader p p p p p p p p p p p p p p p p p p p p p p p261 Migration of Dendritic Cell Subsets and their Precursors Gwendalyn J. Randolph, Jordi Ochando, and Santiago Partida-Sánchez p p p p p p p p p p p p p293

v

AR338-FM

ARI

12 January 2008

18:11

The APOBEC3 Cytidine Deaminases: An Innate Defensive Network Opposing Exogenous Retroviruses and Endogenous Retroelements Ya-Lin Chiu and Warner C. Greene p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p317 Thymus Organogenesis Hans-Reimer Rodewald p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p355 Death by a Thousand Cuts: Granzyme Pathways of Programmed Cell Death Dipanjan Chowdhury and Judy Lieberman p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p389 Annu. Rev. Immunol. 2008.26:233-259. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

Monocyte-Mediated Defense Against Microbial Pathogens Natalya V. Serbina, Ting Jia, Tobias M. Hohl, and Eric G. Pamer p p p p p p p p p p p p p p p p p p p421 The Biology of Interleukin-2 Thomas R. Malek p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p453 The Biochemistry of Somatic Hypermutation Jonathan U. Peled, Fei Li Kuang, Maria D. Iglesias-Ussel, Sergio Roa, Susan L. Kalis, Myron F. Goodman, and Matthew D. Scharff p p p p p p p p p p p p p p p p p p p p p481 Anti-Inﬂammatory Actions of Intravenous Immunoglobulin Falk Nimmerjahn and Jeffrey V. Ravetch p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p513 The IRF Family Transcription Factors in Immunity and Oncogenesis Tomohiko Tamura, Hideyuki Yanai, David Savitsky, and Tadatsugu Taniguchi p p p p p535 Choreography of Cell Motility and Interaction Dynamics Imaged by Two-Photon Microscopy in Lymphoid Organs Michael D. Cahalan and Ian Parker p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p585 Development of Secondary Lymphoid Organs Troy D. Randall, Damian M. Carragher, and Javier Rangel-Moreno p p p p p p p p p p p p p p p p627 Immunity to Citrullinated Proteins in Rheumatoid Arthritis Lars Klareskog, Johan Rönnelid, Karin Lundberg, Leonid Padyukov, and Lars Alfredsson p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p651 PD-1 and Its Ligands in Tolerance and Immunity Mary E. Keir, Manish J. Butte, Gordon J. Freeman, and Arlene H. Sharpe p p p p p p p p677 The Master Switch: The Role of Mast Cells in Autoimmunity and Tolerance Blayne A. Sayed, Alison Christy, Mary R. Quirion, and Melissa A. Brown p p p p p p p p p p705 T Follicular Helper (TFH ) Cells in Normal and Dysregulated Immune Responses Cecile King, Stuart G. Tangye, and Charles R. Mackay p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p741

vi

Contents

ANRV338-IY26-09

ARI

16 February 2008

12:18

Annu. Rev. Immunol. 2008.26:261-292. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

Mechanism and Regulation of Class Switch Recombination Janet Stavnezer, Jeroen E.J. Guikema, and Carol E. Schrader Department of Molecular Genetics and Microbiology, Program in Immunology and Virology, University of Massachusetts Medical School, Worcester, Massachusetts 01655-012; email: [email protected], [email protected], [email protected]

Annu. Rev. Immunol. 2008. 26:261–92

Key Words

The Annual Review of Immunology is online at immunol.annualreviews.org

AID, UNG, AP endonuclease, DNA Pol β, DNA-PK, XRCC4-DNA ligase IV, ATM, Mre11-Nbs1-Rad50, 53BP1, γH2AX, germline transcripts, R-loops, end joining

This article’s doi: 10.1146/annurev.immunol.26.021607.090248 c 2008 by Annual Reviews. Copyright All rights reserved 0732-0582/08/0423-0261$20.00

Abstract Antibody class switching occurs in mature B cells in response to antigen stimulation and costimulatory signals. It occurs by a unique type of intrachromosomal deletional recombination within special G-rich tandem repeated DNA sequences [called switch, or S, regions located upstream of each of the heavy chain constant (CH ) region genes, except Cδ]. The recombination is initiated by the B cell– speciﬁc activation-induced cytidine deaminase (AID), which deaminates cytosines in both the donor and acceptor S regions. AID activity converts several dC bases to dU bases in each S region, and the dU bases are then excised by the uracil DNA glycosylase UNG; the resulting abasic sites are nicked by apurinic/apyrimidinic endonuclease (APE). AID attacks both strands of transcriptionally active S regions, but how transcription promotes AID targeting is not entirely clear. Mismatch repair proteins are then involved in converting the resulting single-strand DNA breaks to double-strand breaks with DNA ends appropriate for end-joining recombination. Proteins required for the subsequent S-S recombination include DNA-PK, ATM, Mre11-Rad50-Nbs1, γH2AX, 53BP1, Mdc1, and XRCC4ligase IV. These proteins are important for faithful joining of S regions, and in their absence aberrant recombination and chromosomal translocations involving S regions occur.

261

ANRV338-IY26-09

ARI

16 February 2008

12:18

INTRODUCTION AND OVERVIEW

Annu. Rev. Immunol. 2008.26:261-292. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

CSR: class switch recombination SHM (somatic hypermutation): the process that introduces mostly single-nucleotide mutations into the variable regions of antibodies after antigen activation during infection or after immunization AID: activation-induced cytidine deaminase GC (germinal centers): highly dividing B cells undergoing SHM that form in B cell follicles in spleen and lymph nodes during a T cell–dependent immune response

262

Antibody class, or isotype, is determined by the heavy chain constant (CH ) region, which is important for determining the antibody’s effector function. The CH region is bound by cell-surface receptors, e.g., Fc receptors on many cell types and poly immunoglobulin (Ig) receptors on mucosal epithelial cells, and also by complement. Different CH regions have different afﬁnities for these proteins, thus greatly inﬂuencing antibody function and determining whether antibody-antigen complexes will activate cells that help to eliminate pathogens, e.g., macrophages, NK cells, or mast cells. Also, the CH region determines whether an antibody can be transcytosed through epithelial membranes at mucosal surfaces, can diffuse into tissues, and will polymerize and thereby have a greater avidity. The CH region also inﬂuences the stability of the antibody (reviewed in 1). The membrane-bound forms of the various isotypes differ in their intracytoplasmic carboxy termini; the different termini result in varying abilities to associate at cell membranes with intracellular signaling proteins, although the biological roles of these differences are not yet understood (2–4). Ig isotype switching occurs by an intrachromosomal deletional recombination event, diagrammed in Figure 1 for the mouse H chain locus. The human H chain locus is similarly organized but not identical. Class switch recombination (CSR) occurs between switch (S) regions located upstream of each of the CH regions except Cδ and results in a change from IgM and IgD expression by naive B cells to expression of one of the downstream isotypes. IgD expression occurs by alternative transcription termination/splicing of the CμCδ genes. S regions consist of tandem repeats of short G-rich sequences (20–80 bp), which differ for each isotype, with an overall length varying from ∼1 kb to 12 kb, and CSR can occur anywhere within or near the S regions (5, 6). CSR occurs by an end-joining type of

Stavnezer

·

Guikema

·

Schrader

recombination, rather than by homologous recombination (7, 8). CSR and somatic hypermutation (SHM) are initiated by activation-induced cytidine deaminase (AID), which converts cytosines in S regions and Ig variable regions to uracils by deamination (9–14). Subsequent repair of the dU residues leads to single-strand DNA breaks (SSBs) that must be converted to double-strand breaks (DSBs) within the donor Sμ region and within an acceptor Sx region, to initiate the process of intrachromosomal DNA recombination. This review focuses mainly on the overall mechanism of CSR, which is discussed in the next section. Although there are interesting similarities and differences between CSR and SHM, we do not discuss them owing to space constraints. SHM is reviewed in another article in this volume by M.D. Scharff (15). Also, we do not extensively review all the information available about AID, as this protein is extensively discussed in the Scharff article (15) and in several other reviews (16–19). B cells undergo antibody, or Ig, class switching in vivo after immunization or infection or upon appropriate activation in culture. Engagement of the CD40 receptor on B cells by CD154 (CD40L) or, speciﬁcally for mouse B cells, the Toll-like receptor 4 (TLR4) by lipopolysaccharide (LPS), provides crucial signaling for CSR. AID expression is induced in mouse splenic B cells activated to switch in culture, and also in vivo, with especially high levels detected in germinal center (GC) B cells, which are undergoing SHM and probably CSR (9, 20, 21). Most investigations into the roles of various genes in CSR examine their effects in mouse splenic B cells induced to switch in culture. This model allows one to use the numerous mouse gene knockout models and also ensures that the effects of the genes are B cell intrinsic and not due to effects on other cell types. CSR requires cell proliferation, appearing to require a minimum of two complete rounds of cell division for IgG and IgA CSR and perhaps additional rounds for IgE CSR

ANRV338-IY26-09

ARI

a

16 February 2008

12:18

Heavy chain genes in IgM-expressing cells VDJ

AID

Cμ

AID

Cδ μ mRNA

C γ3 S

S

Cγ2 b

C γ1 S

Cγ2 a S

Cε S

C γ1

Annu. Rev. Immunol. 2008.26:261-292. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

C γ3 Switch recombination (requires DSBs)

Cδ

VDJ

Heavy chain genes in IgA-expressing cell

C γ2 b Cγ2 a

Cμ

c

AID

Cα S

Germline transcript

δ mRNA

b

AID

Cε Cα

VDJ

Cα α mRNA

Figure 1 Diagram of Ig class switch recombination (CSR) to IgA. (a) The mouse IgH locus in B cells expressing IgM and IgD (by alternative RNA transcription/processing). During CSR, activation-induced cytidine deaminase (AID) deaminates dC residues in the top and bottom strands of transcriptionally active S regions (Sμ and Sα in the diagram shown), initiating a process (described in the text) that results in double-strand DNA breaks (DSBs) in both S regions and CSR by intrachromosomal deletion (b). (c) The IgH locus after CSR to IgA. Splicing diagrams of the μ, δ mRNAs and the germline α transcript are indicated below the diagram of the locus. Similar germline transcripts are induced from unrearranged Cγ, Cε, and Cα genes, depending on the cytokine stimulation received by the B cell.

(22–25). This requirement appears to be at least partly due to the requirements for induction of AID expression (25). Transcription of AID mRNA is induced synergistically by IL4 and CD40 signaling via induction of Stat6 and NF-κB transcription factors (26). However, these signals are very rapid. Pax5 is also essential for AID mRNA transcription, and Pax5 binds to the AID promoter in LPS+IL4-treated splenic B cells (27). Most interestingly, binding of Pax5 to the AID promoter is not detected until two days after addition of the activators, suggesting that the kinetics

of Pax5 binding might be important for explaining the requirement for cell division for AID induction. Furthermore, AID function is regulated by active export from the nucleus (28–30), which might also contribute to the delay in CSR. Naive B cells have the potential to switch to any isotype, and cytokines secreted by T cells and other cells direct the isotype switch (reviewed in 7, 31, 32). Although there is more to be discovered, the predominant mechanism for regulating isotype speciﬁcity is by regulation of transcription through S regions, www.annualreviews.org • Class Switch Recombination

263

ANRV338-IY26-09

ARI

16 February 2008

BER (base excision repair): a ubiquitous repair pathway that repairs damaged DNA bases

12:18

and only transcriptionally active S regions undergo CSR. The regulation of isotype speciﬁcity is further discussed in the section on “Regulation of Switching.”

MECHANISM OF CSR

Annu. Rev. Immunol. 2008.26:261-292. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

Recently, the greatest progress in the ﬁeld of CSR has occurred in identifying and understanding the roles of the enzymes and proteins involved in both creating DNA breaks and recombining the S regions. This, then, is the focus of our review. In this section, we start with the enzymes that create the DSBs required for CSR and then discuss the joining mechanism and its regulation. We restrict our discussion to proteins known to contribute to CSR and do not mention proteins shown not to be involved or for which the contribution is only suggestive or might have only minor effects. Pan-Hammarstrom et al. (33) comprehensively reviewed which DNA repair proteins are involved in V(D)J, CSR, and/or SHM. Other recent reviews discuss the mechanism and regulation of CSR (18, 34–37).

Creation of DSBs for CSR A reasonably convincing model for how single-strand breaks (SSBs) are introduced into S regions and how they are converted to the DSBs required for CSR has been developed in recent years. After initiation of the process by AID, the base excision repair (BER) pathway creates the SSBs, and if the SSBs on opposite strands are sufﬁciently near, this results in a DSB. However, conversion of more distal SSBs to DSBs appears to require another DNA repair pathway, mismatch repair (MMR). The proteins and their function at each step in this process are discussed in this section. Activation-induced cytidine deaminase (AID). The ﬁnding that AID is essential for both CSR and SHM was a major breakthrough for these ﬁelds (9, 10). Although originally investigators postulated that AID is an 264

Stavnezer

·

Guikema

·

Schrader

RNA-editing enzyme, owing to its homology with the RNA-editing cytidine deaminase APOBEC-1 (9), a second major breakthrough came with the discovery that the role of AID is to initiate these processes by deamination of dC nucleotides within S regions and antibody variable regions (11–14, 38, 39). In 2000, a model was proposed by Poltoratsky et al. (40) for how deamination of dC in DNA could lead to the SSBs required for CSR, and shortly thereafter Petersen-Mahrt et al. (11) provided evidence for this model. This model is now supported by numerous studies. Using the technique of linker-ligation-mediated PCR (LM-PCR), researchers demonstrated that AID is required for generation of S region DSBs in both mouse and human B cells (21, 41, 42). Also, localization of γH2AX foci at the Ig locus during CSR is AID-dependent (43). Figure 2a presents the portion of this model that is relevant for CSR. Puriﬁed recombinant AID converts dC to dU nucleotides in single-stranded (ss) DNA and in supercoiled transcribed plasmids (12– 16, 18, 44–46). It is clear that ssDNA but not dsDNA is the AID substrate. When transcribed duplex DNA substrates are used in vitro or in Escherichia coli, the nontranscribed strand (top strand if the DNA sequence is oriented with the 5 side to the left) is preferentially targeted. This may be because the nontranscribed strand in these substrates is single-stranded at the small bubble formed by RNA polymerase, whereas the transcribed strand is transiently hydrogen bonded to RNA (12, 14, 44, 47). However, both strands can be targeted by AID in vitro in transcribed supercoiled plasmid DNA, presumably because single-strand extrusions can occur in supercoiled plasmids (45, 46). It is clear that in B cells, dC on both transcribed and nontranscribed strands is equally mutated in proportion to its distribution in V genes and S regions, indicating that AID attacks both strands (48–50). AID preferentially, but not exclusively, deaminates the underlined dC in WRC (W = A or T, R = purine, Y = pyrimidine), the

ANRV338-IY26-09

ARI

16 February 2008

a

12:18

b

G C

AID U

5' U

AID

U U

G U

U 5'

U

UNG, APE U

5'

UNG

U

U

U 5'

U

G Msh2-Msh6

Annu. Rev. Immunol. 2008.26:261-292. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

APE G

U

5' U

DSB Sμ

Sγ3

Class switching

Mlh1-Pms2

Exo1

DNA Pol β

Pol η Pol θ

G C

G N

Repair

Mutation

G

U

U U

Translocations

5'

U

c-myc

DSB 5'

Pol U

U

Figure 2 Diagrams of (a) model for generation of DNA breaks, mutations, and translocations in IgS regions by AID-UNG-APE and (b) model for conversion of SSBs to DSBs by mismatch repair. (a) AID deaminates dC, resulting in dU bases, which are excised by one of the uracil DNA glycosylases, UNG. Abasic sites are cut by AP-endonuclease (APE1 and APE2) (74), creating SSBs that can spontaneously form DSBs if they are near each other on opposite DNA strands, or, if not, mismatch repair activity converts them to DSBs (see b). Alternatively, DNA Pol β can correctly repair the nick, preventing CSR, or error-prone translesion polymerases can repair the nick but introduce mutations. Finally, the DNA breaks can lead to aberrant recombinations/translocations. (b) AID is hypothesized to introduce several dU residues in S regions during one cell cycle. Some of the dU residues are excised by UNG, and some of the abasic sites are nicked by APE. The U:G mismatches that remain would be substrates for Msh2-Msh6 (100). Msh2-Msh6, along with Mlh1-Pms2, recruit Exo1 (and accessory proteins) to a nearby 5 nick, from where Exo1 begins to excise toward the mismatch (90, 91), creating a DSB with a 5 single-strand overhang, which can be ﬁlled in by DNA polymerase. Fill-in synthesis is probably performed by translesion polymerases owing to the presence of abasic sites. Alternatively, the overhang is removed by a 5 ﬂap endonuclease (Fen1) or by Exo1.

AID hotspot target (51–53), in transcribed targets in vitro (54), in oligonucleotide substrates (55), and in vivo (50). S regions contain numerous AID hotspot targets. However, experiments using puriﬁed recombinant AID and plasmid DNA substrates suggest that AID is highly processive (14, 45, 54), and in this process AID deaminates many dC nucleotides

5'

U

5'

Sμ

U

that are not in WRC motifs. Furthermore, studies in ung−/− msh2−/− B cells, in which the initial AID-induced lesions cannot be repaired and thus can be examined, also suggest that AID acts processively across S regions in vivo (50). The regulation of AID function is just beginning to be studied. AID is phosphorylated www.annualreviews.org • Class Switch Recombination

265

ANRV338-IY26-09

ARI

16 February 2008

UNG: one of four mammalian uracil DNA glycosylases

Annu. Rev. Immunol. 2008.26:261-292. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

APE (APE1 and APE2): apurinic/ apyrimidinic endonuclease, incises DNA at abasic sites

12:18

by protein kinase A at S38 and T27, and alanine mutations at either of these sites nearly eliminate the ability of AID to initiate CSR when retrovirally transduced into aid−/− splenic B cells (56, 57, 58). Phosphorylation by protein kinase A is required for binding of AID by replication protein A, which enables AID to deaminate transcribed duplex DNA. Replication protein A appears to increase the interaction of AID with DNA. Another very interesting but not understood discovery about AID is that the C-terminal 10 amino acids of AID are required for CSR but not for SHM (59, 60). The C terminus may be required for interaction with a protein essential for CSR but not for SHM.

UNG. Removal of the dU residues by enzymes within the BER pathway is required to introduce the DNA breaks necessary for CSR (11, 21, 38). BER consists of highly active ubiquitous DNA repair pathways for repairing oxidized and deaminated bases, which are generated more than 104 times per cell per day by oxidation, especially during inﬂammation, and by spontaneous hydrolysis (61). There are four mammalian uracil DNA glycosylases in the BER pathway (i.e., enzymes that excise dU bases), UNG, SMUG1, MBD4, and TDG. CSR is reduced by 95% in B cells from UNGdeﬁcient mice and in patients that have deleterious mutations in UNG (21, 38, 62). Furthermore, S region DSBs are also greatly reduced in ung−/− mouse splenic B cells induced to undergo CSR (21). Thus, it is reasonable to conclude that UNG is the uracil DNA glycosylase that excises the dU residue created by AID activity. Two other uracil glycosylases (MBD4 and SMUG1) appear to have no role in CSR (38, 63). However, when SMUG1 is greatly overexpressed by retroviral transduction, it can support a limited amount of CSR in ung−/− cells, although in the presence of UNG, SMUG1 actually inhibits CSR (64). These data suggest that UNG may be speciﬁcally recruited to sites of AID activity and perhaps has a unique property that makes it the 266

Stavnezer

·

Guikema

·

Schrader

preferred uracil DNA glycosylase for generation of the DNA breaks required for CSR. Apurinic/apyrimidinic endonuclease (AP endonuclease/APE). The BER enzyme that repairs the abasic sites left by UNG activity is APE, which incises the phosphate backbone of DNA at abasic sites, producing SSBs (61). In mammals, there are three enzymes with AP endonuclease activity, APE1 and APE2, which share homology (65), and a very different, recently discovered enzyme, PALF/APLF/XIP1 (66–68). The main AP endonuclease known to be involved in BER is APE1. APE1 endonuclease activity is essential for early embryonic development and for viability of human cell lines (69, 70). Much less is known about APE2, which is encoded on the X chromosome. APE2-deﬁcient mice show a slight growth defect and have a twofold reduction of white blood cells in the periphery, mainly affecting T and B cells (71). Enzyme assays using abasic site-containing oligonucleotide substrates showed that puriﬁed recombinant human APE2 has weaker AP endonuclease activity than APE1 (65, 72, 73). Examination of APE1- and/or APE2deﬁcient mouse splenic B cells activated to switch in culture demonstrated that both of these enzymes contribute to CSR (74). Because APE1 is an essential gene, the investigators used ape1+/− mice, which have DNA repair defects (75, 76), although the phenotype was probably less severe than if ape1−/− mice could have been studied. Splenic B cells from mice deﬁcient for APE2 and heterozygous for APE1 switch 60%–80% as well as wild-type B cells, depending on the isotype, and have very few S region DSBs, almost as few as in aid−/− cells, which have approximately 10% of wildtype (77). These cells divide in culture as well as wild-type cells, so the reduced CSR is not due to poor proliferation (74). Although CSR is modestly reduced, the much greater reduction in Sμ DSBs suggests that Sμ DSBs are not limiting for CSR. In wild-type cells, AID-dependent blunt and staggered DSBs in the Sμ region occur

Annu. Rev. Immunol. 2008.26:261-292. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-09

ARI

16 February 2008

12:18

preferentially at G:C bp and at AID hotspot targets, with p values for blunt DSBs ≤ 0.002 relative to random (21, 74). This indicates that SSBs and DSBs occur at the dC nucleotides that are targeted by AID, as predicted by the DNA-deamination model (Figure 2a). In aid−/− or ung−/− or APE-deﬁcient cells, DSBs do not speciﬁcally occur at AID hotspot targets, although B cells deﬁcient in only one of the APEs maintain some speciﬁcity for AID targets (21, 74). These data suggest that APE1 and APE2 both serve as endonucleases to incise abasic sites introduced by AID and UNG. However, whether the third AP endonuclease PALF/APLF/XIP-1 also has a role is unknown. DNA polymerase β (Pol β). In the canonical BER pathway, the single-nucleotide gap generated by the action of UNG and APE is ﬁlled in by DNA polymerase β (Pol β) (78, 79). A multiprotein complex that can perform BER and that contains UNG2 (nuclear form of UNG), APE1, Pol β, replicative DNA polymerases δ and ε, XRCC1, and DNA ligase I has been isolated from both proliferating and growth-arrested HeLa cells and also from human peripheral blood lymphocytes (80, 81). Furthermore, physical interactions among BER enzymes increase repair efﬁciency (82–84). These ﬁndings suggest that BER will proceed to completion once it is initiated by UNG. Therefore, Pol β activity could reduce SSBs and therefore reduce CSR. Hence, an intriguing question arises as to how S region breaks are spared from faithful repair. One appealing hypothesis is that BER components downstream of UNG and APE might be downregulated in cells undergoing CSR or speciﬁcally prevented from accessing S region lesions. As Pol β is recruited by APE1 (78), the levels of Pol β or its activity may be inhibited during CSR, or APE2 may not recruit Pol β, which could explain why APE2 is used for CSR. Alternatively, the introduction of numerous S region lesions may overwhelm the BER machinery, although BER activity is not inhibited during CSR. A recent

report supports the second alternative (85). Pol β levels were increased in nuclear extracts from mouse splenic B cells induced to undergo CSR, and chromatin immunoprecipitation showed that Pol β associates speciﬁcally with the Sμ region, but not with Cμ or Cα genes, in switching B cells. Although Pol β–deﬁcient mice die in utero, one can obtain polβ −/− splenic B cells by transfer of polβ −/− fetal liver cells into irradiated wild-type mice. Using polβ −/− and polβ +/+ splenic B cells obtained by fetal liver transfer, investigators found that polβ −/− cells actually show modestly increased CSR (1.5to 1.7-fold) to a subset of isotypes (IgG2a, IgG2b, and IgG3) relative to polβ +/+ controls. Furthermore, LM-PCR experiments showed that polβ −/− cells have a two- to threefold increase in Sμ and Sγ3 DSBs and a twofold increase in mutations in the germline (GL) Sμ and recombined Sμ segments. These data indicate that Pol β indeed functions to accurately repair AID-instigated SSBs but cannot repair them all, and the authors hypothesize that Pol β only inhibits switching when SSBs are limiting (85). If B cells were to downregulate BER during CSR, this could be dangerous, given the great amount of reactive oxygen species produced during B cell activation and proliferation (86). Therefore, it is plausible that instead a mechanism is adopted that endows S regions with such numerous AID targets that the ability of BER to repair them is overwhelmed, rather than abrogating overall BER ability and thus jeopardizing the integrity of the B cell genome. Consistent with this hypothesis is the ﬁnding that, in ung−/− msh2−/− B cells, AID introduces many more lesions into the Sμ region than result in mutations in wild-type cells, most likely because they are correctly repaired in wildtype cells (50). Furthermore, recent experiments show that artiﬁcially introduced I-SceI sites in Sμ and Sγ1 regions mediate CSR to IgG1. These experiments suggest that only a single DSB in the donor and acceptor S region is sufﬁcient for CSR (87). Introduction of www.annualreviews.org • Class Switch Recombination

267

ANRV338-IY26-09

ARI

16 February 2008

Annu. Rev. Immunol. 2008.26:261-292. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

MMR (mismatch repair): a ubiquitous repair pathway that corrects DNA synthesis errors, including mismatches and deletions/insertions

268

12:18

numerous dU residues increases the likelihood of DSBs occurring in the donor and acceptor S regions simultaneously. In conclusion, Pol β may function normally during CSR to repair AID-initiated DNA lesions, but the numerous AID lesions overwhelm it, and thus some breaks remain unrepaired. Role of mismatch repair in CSR: to convert SSBs to DSBs. A second repair pathway, mismatch repair (MMR), contributes to CSR but is not essential. The major role of MMR in all cells is to correct misincorporated nucleotides during DNA synthesis (88). This process involves recognition of the mismatch by a heterodimer of Msh2-Msh6 (for nucleotide substitutions and small loops) or Msh2-Msh3 (for larger loops), followed by recruitment of the Mlh1-Pms2 heterodimer (88). The combined heterotetramer recruits replication factor C, the processivity factor proliferating cell nuclear antigen (PCNA), and Exonuclease1 (Exo1) to a nearby nick, and together they excise the single-strand segment containing the mutated nucleotide (89, 90). The excised single-strand patch can be hundreds of nucleotides long in vitro, but the length in vivo is unknown. MMR speciﬁcally repairs the newly synthesized DNA strand, probably because of its predilection to excise and resynthesize the nicked DNA strand (91). In mice that lack one of the MMR genes (Msh2, Msh6, Mlh1, Pms2, or Exo1), CSR is reduced by two- to sevenfold, depending on the gene and the Ig isotype (92–98). The most attractive model for the role of MMR during CSR is to convert SSBs that are not near each other on the opposite DNA strands to DSBs (77, 99). If the SSBs that are introduced by AID-UNG-APE are near each other on opposite DNA strands, they can spontaneously form a DSB, but if not, the SSBs do not destabilize the duplex and are simply repaired. As S regions are large and the breaks appear to occur anywhere within S regions (5, 6, 21), it seems unlikely that the SSBs would be sufﬁciently proximal to form a DSB most of the time. MMR could conStavnezer

·

Guikema

·

Schrader

vert these distal SSBs to the DSBs that are required for CSR. Figure 2b presents a model for how MMR could do this (99). Msh2-Msh6 can recognize and bind U:G mismatches created by AID activity (100). Mlh1-Pms2 would be recruited and Exo1 would excise from the nearest 5 SSB created by AID-UNG-APE activity toward the mismatched dU:dG. Exo1 is hypothesized to continue past the mismatch until it reaches a SSB on the other strand, thus creating a DSB. Several additional experimental results support this model. First, B cells in which the tandem repeats of Sμ have been deleted (SμTR−/− ), which thus have very few AID hotspot targets, only show a ∼twofold reduction in CSR (101). However, in these B cells, CSR is nearly ablated in the absence of Msh2 or Mlh1 (77, 102; J. Eccleston, C.E. Schrader, J. Stavnezer & E. Selsing, manuscript in preparation). Second, IgG2a, the isotype with the fewest AID hotspot targets in its S region, is the isotype most dependent upon MMR (93). Third, the great majority of S-S junctions in msh2−/− B cells occurs within the Sμ tandem repeat region, whereas in wild-type cells they can also occur upstream of Sμ, where the AID hotspot targets are infrequent (92). Fourth, the S-S junctions differ between wild-type and MMR-deﬁcient B cells as to the lengths of microhomology between the donor (Sμ) and acceptor (downstream) S regions. This suggests that MMR is involved in end processing from the sites of the SSBs, resulting in different lengths of single-stranded tails that can participate in homology search during S-S recombination (94, 95, 98, 103). Fifth and most importantly, LMPCR experiments show that MMR-deﬁcient B cells have fewer S region DSBs than do wildtype B cells (77). End processing and mutations. After DSB formation, 5 or 3 single-strand overhangs remain. These tails must be either excised or ﬁlled in to create blunt, or nearly blunt, DSBs appropriate for an end-joining recombination with the other S region. The

Annu. Rev. Immunol. 2008.26:261-292. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-09

ARI

16 February 2008

12:18

structure-speciﬁc endonuclease ERCC1XPF excises 3 single-strand tails at the junction with dsDNA and has a minor role in CSR (104). MMR normally recruits PCNA and replicative DNA polymerase for ﬁll-in synthesis of 5 overhangs (88). However, replicative Pol cannot replicate past an abasic site, resulting in the recruitment of error-prone translesion Pols. Msh2-Msh6 recruit the translesion Pol η (100), which is the most important translesion Pol for introducing mutations at A:T bps into V region genes and into both unrecombined (GL) Sμ and recombined S-S junction regions during CSR (105, 106). There are numerous mutations at both A:T and G:C bp in the regions surrounding S-S junctions (107, 108, 145). The mutations at G:C bp could be due to ﬁll-in DNA synthesis across dU nucleotides by replicative Pols or across abasic sites, probably by the translesion DNA Pol θ (109–111). Additionally, not all mutations in S regions are likely to be due to ﬁll-in DNA synthesis after creation of DSBs. It is likely that sometimes the excision by Exo1 does not lead to DSBs, but instead the single-strand patch is simply repaired by translesion Pols. Also, sometimes DSBs will form that do not successfully synapse with acceptor downstream S regions and that result in internal Sμ deletions rather than S-S recombination (112, 113).

Joining of Donor and Acceptor S Regions After formation of the DSBs in the donor and acceptor S regions, the S regions are recombined using ubiquitous proteins that perform nonhomologous end-joining (NHEJ) in all cell types. These proteins are observed within a complex visible by in situ immunoﬂuorescence in cells that have been treated with gamma radiation to induce DSBs, which is consistent with the fact that these proteins are involved in repair of DSBs after gamma radiation as well as repair of DSBs generated during CSR. Many of these proteins are also

involved in V(D)J recombination during lymphocyte development. S-S recombination occurs by an endjoining type of recombination. DNA DSBs can be induced by ionizing radiation or during repair of oxidative damage or replication. Numerous ubiquitous repair proteins exist that rapidly repair DSBs in all cells, many of which are also involved in CSR. DSBs produced during DNA replication or during G2 phase of the cell cycle are generally repaired by homologous recombination, as there is a chromosomal homolog that can be copied. However, S region DSBs in B cells induced during CSR are generated and resolved during G1 phase (77), and S regions lack sufﬁcient homology to undergo homologous recombination. Four proteins known to be essential for NHEJ, Ku70, Ku80, and the two-protein ligase complex XRCC4-ligase IV, are very important for CSR (113–120). Ku70-Ku80 binds to the DNA ends and serves as a tool belt for the end-joining reaction by recruiting enzymes that effect the recombination. Ku70Ku80 improves the binding of XRCC4-ligase IV to DNA ends (121–123). Although Kudeﬁcient cells apoptose upon induction of CSR, Reina-San-Martin et al. (113) showed by CFSE staining that, at each cell division, CSR in the few viable ku80−/− cells is nearly ablated. These investigators also increased cell viability by expressing Bcl2 from a transgene in ku80−/− cells and again showed that CSR is nearly ablated. XRCC4 or ligase IV deﬁciency is incompatible with life owing to problems during brain development, although human patients with hypomorphic mutations have been described, and mice with deﬁciencies have been created (120, 124, 125). Mice entirely lacking XRCC4 were produced by mating xrcc4+/− mice with p53-deﬁcient mice, allowing survival of xrcc4−/− mice, which have ∼25% of normal levels of CSR, indicating that XRCC4 is important but not essential for CSR (125). Also, humans with mutations in ligase IV have fewer peripheral blood cells that have www.annualreviews.org • Class Switch Recombination

269

ANRV338-IY26-09

ARI

16 February 2008

Annu. Rev. Immunol. 2008.26:261-292. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ATM (ataxia telangiectasia mutated): a phosphoinositol 3-kinase-like kinase, which is mutated in the human syndrome Ataxia telangiectasia

12:18

undergone CSR than normal controls (119). Examination of the S-S junctions in the xrcc4−/− mouse B cells and in the human patients demonstrated that the S-S junctions are aberrant, as they have greatly increased lengths of junctional microhomology (119, 125). Numerous studies have shown that SS junctions in wild-type mice or normal individuals show very little microhomology, or identity, between the donor Sμ and acceptor S regions at the junction, usually 0 or 1 bp of identity (5), consistent with recombination by NHEJ. In contrast, in the xrcc4−/− mice and human ligase IV hypomorphs, many junctions have up to 10 bp or more of identity. Taken together, the data indicate that CSR occurs by NHEJ but can also occur by an alternative type of end-joining reaction that favors the use of microhomologies. XRCC4-ligase IV in the presence of Ku70-Ku80 ligates incompatible ends, consistent with the lack of microhomology at S-S junctions in wild-type cells (126). It is unknown, however, whether in wild-type cells the alternative pathway is actually used. A fundamental unanswered question regarding the joining process is whether the donor and acceptor S regions are in close proximity before AID attacks the donor (Sμ) or acceptor (downstream) S region. It is attractive to expect that they are preassociated in order to increase the likelihood of correct S-S recombination. This association could be directed to the correct S region by GL transcription. Another reasonable possibility is that the association occurs immediately after AID attacks Sμ. In situ studies suggest that the Ig loci form loops, apparently bringing the V and J genes in proximity prior to V(D)J recombination (127, 128). Mre11-Rad50-Nbs1. Accumulating evidence indicates that this complex of three proteins (MRN complex) travels along the DNA duplex scanning for DNA breaks and that MRN binds DSBs within seconds of their formation (129, 130). However, owing to its great abundance, Ku is likely to bind

270

Stavnezer

·

Guikema

·

Schrader

DSBs even faster during CSR (see the section below, Ku70-Ku80-DNA-PKcs). When a DSB is encountered, the conformation of Mre11 and Rad50 changes, resulting in unwinding the DNA ends at the break. Mre11 is a globular protein associated with the DNA, whereas Rad50 forms a long coiled-coil that at its middle abruptly reverses direction, forming a loop with a zinc hook at its apex. The hooks from two Rad50 molecules associate homotypically, and this is thought to be important for holding two DNA duplexes together at the DSB (131, 132). Once bound to a DSB, the kinase ataxia telangiectasia mutated (ATM) binds the complex via Nbs1, becomes activated, and phosphorylates several substrates, among which are Nbs1, 53BP1, p53, Chk2, and H2AX, causing a further accumulation of MRN and several other repair proteins and also activating cell-cycle checkpoints (133– 135) (Figure 3). Thus, MRN is upstream of a cascade of events that function to sense the DSB, resulting in repair by end joining or by homologous recombination. Null mutations in any component of MRN are lethal, and hypomorphic mutations result in aberrant chromosomes and translocations (136) and the disease syndromes Nijmegen breakage syndrome (Nbs-1 mutations) and ataxia-telangiectasia-like disorder (Mre11 mutations), characterized by increased sensitivity to ionizing radiation and other DSB-inducing agents (137, 138). Two groups have shown that CSR is reduced two- to threefold in cultured splenic B cells from mice in which the Nbs1 gene is inactivated by a conditional mutation (136, 139). The reduced CSR was analyzed in cells stained with CFSE, measuring switched cells at each cell division, as cell viability and proliferation are reduced in the mutant cells. Because some Nbs1 remains in the cells, these are most likely underestimates of the importance of Nbs1 for CSR. When wildtype mouse splenic B cells are treated with switch inducers in culture, the Sμ region undergoes rare translocations with the c-myc

ANRV338-IY26-09

ARI

16 February 2008

12:18

DNA-PKcs H4-K20me2 H2AX

Ku70Ku80 53BP1

P

CH3 CH3

P Mre11

MDC1

Nbs1

Rad50

Annu. Rev. Immunol. 2008.26:261-292. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

P ATM

Cell-cycle regulation, apoptosis Figure 3 Proteins that bind to DSBs that are involved in CSR. The evidence supporting this diagram is discussed in the text. DNA-PK, which consists of Ku70-Ku80 and DNA-PKcs, most likely binds DSB ends ﬁrst. Mre11-Rad50-Nbs1 (MRN) probably binds next, perhaps helping to hold the DNA ends together, and MRN recruits and activates ATM (ataxia telangiectasia mutated), which phosphorylates H2AX, 53BP1, and Mdc1, resulting in accumulation of large amounts of these proteins and MRN around the DSB sites. After the DNA ends are brought sufﬁciently near by activities of these other proteins, DNA-PK can hold the DNA ends in the correct position for recombination. These proteins are all important for correct S-S recombination, and they inhibit aberrant recombinations and translocations. ATM also phosphorylates proteins that regulate the cell cycle and induce apoptosis, but nothing is known about how important this is during CSR.

gene, which is located on a different chromosome (140–142). This translocation is AIDdependent and, most interestingly, occurs six times more frequently in Nbs1-hypomorph B cells than in wild-type B cells (140, 143). Patients with hypomorphic mutations in Nbs1 or Mre11 also have a lower percentage of peripheral blood lymphocytes that have undergone CSR, as assayed by detection of Sμ-Sα junctions in these cells (33, 144, 145). Further evidence for the participation of Nbs1 in CSR is the demonstration by immunocytochemistry-fluorescence in situ hybridization (immuno-FISH) that Nbs1 foci colocalize with the IgH loci, but not with Igκ loci, in wild-type, but not aid−/− , splenic B cells induced to undergo CSR (43). The ﬁnding of increased translocations with c-myc in MRN-deﬁcient B cells suggests that the MRN

complex is involved in organizing efﬁcient and accurate S-S recombination.

Ataxia telangiectasia mutated (ATM). ATM is a ser/thr protein kinase, a member of the phosphoinositol 3-kinase-like kinase (PIKK) family, which includes DNA-PKcs and ATR and which is involved in cell-cycle control and DNA damage responses. Upon activation by MRN, ATM accumulates at repair foci, orchestrates repair of the DSB, and initiates a cell-cycle checkpoint until repair is complete (146, 147). Recently, investigators demonstrated that V(D)J recombination is abnormal and that DSBs resulting from incomplete V(D)J recombination during lymphocyte development are maintained over several cell generations in atm−/− mice (148–150). www.annualreviews.org • Class Switch Recombination

271

ANRV338-IY26-09

ARI

16 February 2008

Annu. Rev. Immunol. 2008.26:261-292. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

RAGs (recombinationactivating genes): initiate and are required for V(D)J recombination

12:18

Thus, both repair and the cell-cycle checkpoints are compromised, as atm−/− lymphocytes continue to replicate despite chromosomal breaks (142, 143). CSR is reduced about threefold at each cell division cycle in cultured atm−/− splenic B cells relative to wild-type B cells (151, 152). Also, lower titers of switched antibodies are detected in sera after immunization. However, GL transcripts are expressed at normal levels. In B cells induced to switch in culture, the Sμ region undergoes translocations with the c-myc gene eight times more frequently in atm−/− cells than in wild-type cells (143). Thus, it seems likely that when atm−/− B cells are activated to switch, DSBs are generated as usual, are maintained longer than usual, and do not undergo normal Sμ-Sx recombination; this can result in aberrant recombinations with other chromosomes. Ataxia telangiectasia patients often have IgA and IgG deﬁciencies and have peripheral blood lymphocytes with fewer Sμ-Sα junctions than normal individuals, similar to patients with mutated Nbs1 or Mre11 and consistent with reduced CSR (33, 144). Thus, during CSR, ATM likely organizes the repair complex and perhaps halts the cell cycle, and it contributes to the correct positioning of DSBs together during the long-range interaction required for accurate S-S recombination. In the absence of ATM, prolonged duration of unrepaired DSBs and aberrant recombination events result in translocations. 53BP1. 53BP1 was ﬁrst discovered in a yeast two-hybrid screen as a protein that binds p53 (153). 53BP1 is a transcriptional coactivator for p53, binding through its tandem Tudor domains to p53 dimethylated at lysine 370 (154). However, this is not its only function. 53BP1 accumulates at DSBs within 2 min after ionizing radiation treatment (155). Its initial recruitment to DSBs does not depend on any other known protein, including Nbs1, ATM, or DNA-PK (156), although its subsequent accumulation in foci does depend on γH2AX and Mdc1 (157–159). 53BP1 func-

272

Stavnezer

·

Guikema

·

Schrader

tions to induce phosphorylation of ATM and ATR (160), and thus it might also increase MRN activity and MRN’s accumulation at DSBs. Strikingly, CSR is reduced about 90% in cultured 53bp1−/− splenic B cells relative to wild-type B cells, which is not due to decreased cell proliferation nor to reduced GL transcripts. Serum IgG, IgE, and IgA isotypes are reduced even more, although IgM levels are normal (161, 162). The S-S junctions are normal. 53BP1-deﬁcient cells do not have a dramatic increase in general chromosome instability, unlike atm−/− and h2ax−/− cells, but a much higher proportion of the chromosomal aberrancies in 53bp1−/− cells involve the IgH locus, suggesting that 53BP1 has a special role at this locus (142, 159). Another hint about the role of 53BP1 in CSR comes from the ﬁnding that there is a threefold increase in internal deletions within S regions in IgM hybridomas produced from 53bp1−/− B cells induced to undergo CSR in culture in comparison to IgM hybridomas from wildtype mice (163). Interestingly, these deletions are not increased in atm−/− or h2ax−/− B cells, despite the general increase in unrepaired DSBs in the genome. These results suggest that 53BP1 might also be important for bringing together, or synapsing, the donor Sμ and downstream S regions (159, 161). How 53BP1 performs this role, however, is completely unknown. This role would be consistent with the lack of a role for 53BP1 during V(D)J joining because the RAG complex itself possesses synaptic activity (161, 162). Mammalian 53BP1 binds dimethyl-lysine 20 of histone H4 (H4-K20-me2), but not mono- or trimethyl K20, via its Tudor domains (164). Most interestingly, 53BP1 with single amino acid mutations within the Tudor domains that prevent H4-K20me2-binding and RNAi-mediated knockdown of PrSet7/Set8, the histone methyltransferase that monomethylates K20 (a prerequisite for the dimethylation), decrease 53BP1 foci (164). Association of 53BP1 with

Annu. Rev. Immunol. 2008.26:261-292. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-09

ARI

16 February 2008

12:18

irradiation-induced foci is disrupted by RNase A treatment, suggesting that there may be an RNA component involved in its binding (155). Taken together, H4-K20-me2 may be important for recruiting 53BP1 to chromatin, perhaps to the IgH locus, although this modiﬁcation would probably need to be present before induction of DSBs during CSR because 53BP1 binding to DSBs is so rapid. The GL RNA transcribed from S regions may help 53BP1 recruitment. This hypothesis requires that the H4-K20-me2 mark is associated with actively transcribed regions on the IgH locus during G1 phase, which would differ from its distribution on bulk chromatin. γH2AX (phosphorylated form of H2AX). H2AX is a variant of histone H2A, representing about 15% of the cellular pool of H2A. It is randomly incorporated into nucleosomes (165). Within seconds after formation of a DSB induced by ionizing radiation or by a restriction enzyme, the extended C-terminal tail of H2AX is phosphorylated by a PIKK kinase, most frequently ATM (166, 167), and this phosphorylation spreads over a region estimated to span up to a megabase surrounding the break (147, 168). In fact, the peak accumulation of γH2AX (phosphorylated H2AX) is not directly at the DSB but instead located at 8–10 kb on either side in mammals (168). ATM also phosphorylates 53BP1, Nbs1, and Mdc1, which then all bind the phosphorylated tail of γH2AX, which serves as a docking site for these proteins. This phosphorylation results in a rapid assembly of these factors, plus Mre11, Rad50, and Brca1, into a large multiprotein complex. γH2AX is required for the accumulation of these proteins into foci near DSBs (169, 170). However, mice lacking H2AX can still repair DSBs, although with lower efﬁciency, and they can still induce cellcycle checkpoints (169), probably because the initial assembly of repair proteins, including MRN, ATM, and 53BP1, does not depend on γH2AX (157). CSR is markedly reduced in H2AXdeﬁcient mice. In vitro CSR to IgG3 and IgG1

is reduced to ∼25%–30% of wild-type, and this is not due to defective cell proliferation. The antigen-speciﬁc IgG1 response to immunization is reduced to about 30% of wild-type mice, and nonimmune serum levels of IgG1, IgG3, and IgA are all reduced to 15%–50% of wild-type (43, 113, 142, 169). Similar to cells deﬁcient in either ATM, 53BP1, or Mdc1 or cells having Mre11 or Nbs1 hypomorphic mutations, h2ax−/− B cells show numerous chromosome breaks and aberrant recombination events (142, 143, 169, 171). In h2ax−/− B cells induced to switch in culture, there is a greater than tenfold increase in AID-dependent chromosome breaks within the IgH locus relative to wild-type cells, resulting in separation of the V genes and 3 end of the CH genes and translocations in metaphase chromosome spreads (142). The breaks occur on both chromatids, indicating that they occur prior to S phase, consistent with evidence that S region DSBs are observed in G1 phase (77). Also, foci containing γH2AX (and Nbs1) colocalize with the IgH locus in mouse splenic B cells induced to switch, in wild-type cells in the G1/early S phase of the cell cycle, but not in aid−/− cells, as detected by immuno-FISH (43). Taken together, these data suggest that γH2AX, like MRN, Mdc1, ATM, and 53BP1, is involved in holding AID-initiated DSBs in a structure that promotes accurate synapsis between Sμ and the downstream acceptor S region and also prevents recombinations with DSBs on other chromosomes.

Mdc1 (mediator of DNA damage checkpoint protein 1). Mdc1 is a mediator protein that is recruited to DSBs by binding to Nbs1 and is phosphorylated by ATM (172, 173). Mdc1 subsequently recruits ATM to γH2AX and is required for accumulation of γH2AX at DSBs (167, 173). Without Mdc1, the initial recruitment by MRN of ATM and γH2AX occurs, but the complexes are unstable and do not form the large repair foci observed in wildtype cells. CSR in cultured mdc1−/− B cells is www.annualreviews.org • Class Switch Recombination

273

ANRV338-IY26-09

ARI

16 February 2008

12:18

only mildly reduced, to about 50%–70% of wild-type B cells (167).

Annu. Rev. Immunol. 2008.26:261-292. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

Ku70-Ku80, DNA-PKcs. The proteins discussed above are all involved in repairing DSBs both by end joining and by homologous recombination. However, Ku70 and Ku80 are only involved in end joining and appear to prevent the use of homologies during recombination. Ku70-Ku80 binds DNA ends at DSBs and telomeres and mediates synapsis of the two DNA ends, positioning the ends to allow end processing and direct end-to-end joining (174, 175). Ku70-Ku80 forms a ring with a broad base that encircles DNA and can only dissociate at an end (176). After binding, Ku slides away from the ends, allowing the catalytic subunit, the kinase DNA-PKcs, to bind to each end (177). Ku binds the nuclear matrix, and this binding might localize the DSBs and telomeres to the matrix (178). DNA-PKcs is transphosphorylated by the other DNA-PKcs bound at the other end of the DSB and also phosphorylates Ku70, Ku80, and XRCC4 (175, 179). Thus, DNA-PK appears to be acting both as an activator and scaffold during the actual ligation event. DNA-PKcs has several transautophosphorylation sites, and mutation studies demonstrate that their phosphorylation regulates the accessibility of the DNA ends to end-processing activities required for recombination (179). All three components of the DNA-PK holocomplex are involved in CSR, as they are essential for NHEJ, although Ku70 and Ku80 are much more important than DNA-PKcs. All three proteins are essential for V(D)J recombination, which occurs by NHEJ, so mice lacking any of these proteins do not develop B cells, unless they are supplied with transgenic (Tg) recombined heavy (H) and light (L) chain genes. Ku70- and Ku80-deﬁcient B cells reconstituted with a Tg L chain gene and a H chain gene knocked into the endogenous locus do not have switched isotypes in their serum nor do they undergo CSR when induced to switch in culture, although they 274

Stavnezer

·

Guikema

·

Schrader

have normal levels of GL transcripts (113, 117, 118). Unlike wild-type cells, internal Sμ deletions do not occur in ku80−/− cells (113). These data suggest that Ku80-deﬁcient B cells that sustain DNA breaks owing to AID activity cannot recombine these DSBs, even by internal Sμ deletions, and therefore die. This would also explain why cells with mutations in the unrecombined Sμ segment are not observed in ku80−/− cells (113). Although the investigators did not demonstrate that ku80−/− cells express AID, this is highly likely. It is puzzling, however, that transition mutations that result from dU bases being replicated prior to UNG and APE activity, which would not lead to DNA breaks, were not observed in the GL Sμ. Perhaps Sμ regions with dU bases also have UNG-APE induced DNA breaks, resulting in death of these Ku-deﬁcient cells. It is surprising that Ku is essential for CSR, although XRCC4 is not, given the evidence that CSR can occur by an alternative endjoining pathway. This suggests that Ku might have another function and perhaps even function in the alternative pathway. Also, Ku appears to be more important than MRN for CSR. Ku is one of the most abundant nuclear proteins (∼4 × 105 molecules per cell) and has a very high afﬁnity for DNA ends (5 × 10−10 ) (174). Thus, it might bind prior to MRN. Perhaps MRN is more important for recruiting additional proteins involved in chromatin accessibility and perhaps for cellcycle regulation, whereas Ku is bound at the ends, positioning them precisely for recombination and for end processing by nucleases and polymerases and for recruiting XRCC4DNA ligase-IV (121, 122). It is interesting that Ku is required for V(D)J recombination, but MRN is not, suggesting that the synaptic activity of RAG cannot replace the role of Ku but can replace MRN. By contrast, DNA-PKcs is not essential for CSR, and its importance is controversial, with different results obtained by three different groups. DNA-PKcs deletion was reported to eliminate CSR in cultured B cells to every isotype except IgG1 (180, 181). Two

Annu. Rev. Immunol. 2008.26:261-292. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-09

ARI

16 February 2008

12:18

groups (182, 183) studied B cells from scid mice, which have a deletion in the DNAPKcs gene resulting in loss of the C-terminal 83 amino acids, in barely detectable protein levels, and in no detectable kinase activity. These two groups found a smaller reduction in CSR. It was reduced to 25%–50% of wildtype for all isotypes in the study by Cook et al. (183), but CSR occurred at 50%–100% of wild-type, depending on the isotype, in the Bosma et al. (182) study. There was no difference in proliferation between the wild-type and DNA-PKcs-deﬁcient B cells induced to switch, but there was more cell death in the mutant cell cultures (183). It is difﬁcult to reconcile the different results among the three groups, except that Manis et al. (180, 181) studied mice with no DNA-PKcs, whereas the Bosma (182) and Cook (183) groups studied scid mice, suggesting that the tiny amount of protein present that lacks kinase activity has some function, perhaps as a scaffolding protein. The differences in CSR between the scid mice studied by the two groups might be due to different amounts of back-crossing, as B cells from different mouse strains have different abilities to switch (184). The role of DNA-PKcs in V(D)J recombination appears to be to stimulate the hairpin cutting activity of Artemis (185), which is consistent with its importance for joining the coding ends but not the signal ends. As CSR does not involve hairpin ends, and Artemis appears to have no role in CSR (181), DNAPKcs must have another role in CSR. This may involve its ability to regulate end processing, which may help recombination at some S-S junctions and possibly involves its ability to phosphorylate other proteins (174).

REGULATION OF SWITCHING Germline (GL) Transcripts As described above, CD40 and/or TLR stimulation provides essential activation for B cells to undergo CSR. Additionally, cytokines produced by T helper cells and dendritic cells de-

termine the isotype to which B cells will switch by inducing transcription from GL promoters located upstream, i.e., 5 , to each acceptor S region. The resulting GL transcripts do not encode proteins and are therefore also referred to as sterile RNAs. Figure 1 shows the transcription unit and splicing diagram for an example, GL α RNA. The exon located 5 to the S region is called the I exon. Each GL transcript has a similar transcription and splicing pattern (31). There is also a similar GL Sμ RNA, initiating near the μ intron enhancer. Gene-targeting experiments in which a single I exon and/or promoter for a speciﬁc GL transcript is deleted showed that GL transcription of the acceptor S region is required for CSR to that isotype and that the GL transcription only functions in cis, i.e., not on the other chromosome (186, 187). Surprisingly, deletion of the GL γ1 exon splice donor also prevents IgG1 CSR, although there is no known role for the spliced transcript (31, 188, 189). The role of splicing is an intriguing unanswered question. GL promoters have cytokine-responsive elements within them. GL γ1 and promoters, which are induced by IL-4, have binding sites for the IL-4-induced transcriptional activator Stat6. Several promoters have binding sites for NF-κB, which is induced in response to both CD40 and TLR signaling. GL γ2b and α promoters have binding sites for Smad and Runx, two factors induced by TGF-β, which induces CSR to IgG2b and IgA. A thorough review of GL transcriptional regulation was recently published (32). The function of GL transcription appears to be to direct AID to a speciﬁc S region and to make the S region a suitable substrate for AID. There are at least three possible roles for GL transcription, which are not mutually exclusive. First, the substrate for AID is ssDNA, and the act of transcription creates short regions of ssDNA at the transcription bubble. In addition, RNA transcribed from S regions is G-rich and therefore can form an RNA-DNA hybrid (R-loop) with the bottom C-rich DNA strand. This hybrid formation leaves the top www.annualreviews.org • Class Switch Recombination

R-loops: RNA-DNA hybrids that form cotranscriptionally if the DNA is highly G-rich, which results in extensive single-strand regions on the G-rich DNA strand

275

ARI

16 February 2008

12:18

G-rich DNA strand single-stranded over long stretches (190, 191), thereby making the top strand a target for AID. However, as AID appears to target both top and bottom strands equally in vivo (50), this makes the importance of R-loops unclear. Furthermore, when the Xenopus Sμ region, which is A:T rich and cannot form R-loops, is substituted into the Sγ1 locus by gene targeting, CSR is reduced only about twofold relative to a Sγ1 segment of the same length (192, 193). However, as R-loops form at both the Sμ and acceptor S regions normally, the effect of both R-loops might be to increase CSR by fourfold, which should be physiologically signiﬁcant. Evidence suggests that R-loops at the Sμ region begin upstream of the tandem repeats, at a particular sequence GGGGCTGGG, which is within a zone that has a high content of G (50%) (190), and, interestingly, S-S junctions often involve sequences 5 to Sμ, although many also occur 5 to this sequence (5, 102). Mice with a targeted deletion of the Sμ tandem repeats retain this sequence and have R-loops and extensive single-strand regions on the nontranscribed strand, consistent with their modest reduction in CSR efﬁciency (101, 190). A likely explanation for why both the top and bottom strands are equally targeted during SHM of Ig V regions comes from the recent demonstration by Ronai et al. (194) that in human B cell lines undergoing SHM both the top and bottom VH region strands have single-strand patches averaging ∼11 nucleotides in length. These single-strand patches were detected by treating ﬁxed, permeabilized nuclei with sodium bisulﬁte, which deaminates dC bases within ssDNA. This group also showed that in these cell lines V regions are transcribed in both directions, and the length of the patches are consistent with being caused by the bubble that forms at the site of transcription. However, no one has shown that S regions are transcribed in both directions, and thus it is not known if this explains why the top and bottom S region strands are equally targeted by AID. Ronai et al. (194) found that if they ﬁrst depro-

Annu. Rev. Immunol. 2008.26:261-292. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-09

276

Stavnezer

·

Guikema

·

Schrader

teinized the V region DNA they could not detect the single-strand patches, and thus far experiments to detect single-strand patches in S regions have always used deproteinized DNA. Thus, undetected single-strand patches may exist on both strands at S regions. However, the putative antisense transcripts would not be G-rich and therefore should not form R-loops. The second likely role for GL transcription is to recruit AID. AID coimmunoprecipitates with RNA polymerase II in splenic B cells undergoing CSR (195). This hypothesis is also supported by the ﬁnding that AID-induced dU lesions are found in a region beginning ∼150 bp 3 to the GL RNA initiation site and extending over several kb downstream, with more mutations near the 5 end of the S regions and fewer at the 3 ends (50). Thus, investigators have proposed that AID is recruited to RNA Pol II either at the initiation phase of transcription or when it switches to the elongation phase at ∼150 bp 3 to the initiation site (18, 19, 49). AID may leave the transcription complex stochastically as it progresses through the S region. A third possible role is that transcription can alter histone modiﬁcation of the transcribed region, which might make the DNA more accessible to AID (196–198). Transcription clearly does alter chromatin accessibility, but whether the histone modiﬁcations affect AID binding has not yet been shown.

Roles of IgH Intron Enhancer and 3 Enhancers There are two enhancer regions in the IgH locus. The μ intron enhancer is located 3 to JH 4 and just 5 to the Sμ region and is essential during B cell development for normal V(D)J recombination. Consistent with the fact that the Iμ promoter lies within the enhancer core, deletion of the enhancer core reduces CSR on that allele by about twofold (199). As neither GL Sμ transcription nor DJ transcription is eliminated, this might explain why CSR, albeit at a reduced frequency, still occurs. There

Annu. Rev. Immunol. 2008.26:261-292. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-09

ARI

16 February 2008

12:18

are matrix attachment regions located 5 and 3 to the core enhancer, but this same study found no role for the matrix attachment regions in CSR. A second set of enhancers is located 3 to the Cα gene in mouse and 3 to each of the two Cα genes in human. The mouse 3 IgH enhancers are spread over 30 kb and contain four DNase hypersensitive regions, termed (from 5 to 3 ) hs3A, hs1,2, hs3B, and hs4. Although the entire 30-kb enhancer region has not been successfully deleted, various segments have been deleted by gene targeting using Cre-mediated deletion after insertion of loxP sites. Deletion of hs3A or hs1,2 has no effect on CSR (200); however, combined deletion of hs3B and hs4 greatly reduces CSR to all isotypes except IgG1 (201). Neither hs3B nor hs4 has been individually deleted. The hs3Bhs4 deletion eliminates GL transcripts (except for GLγ1 RNA). Thus far, the only known role for hs3B-hs4 during CSR is to enhance GL transcription. The levels of Ig μ mRNA are also reduced in these mice. Further evidence that the role of the 3 IgH enhancer is to stimulate GL transcription was provided by transient transfection experiments in which a DNA segment containing all four human 3 DNase-hypersensitive sites was found to stimulate human GL γ3 RNA promoter activity (202). There is some evidence from transgene experiments that the region just 5 to Sγ1 has enhancer activity for GL γ1 RNA, perhaps explaining the independence of IgG1 and GLγ1 transcripts from hs3B-hs4 (203, 204). As the hs3B-hs4 enhancers are located far downstream from the GL promoters, their ability to stimulate GL transcription likely involves formation of a loop between the 3 IgH enhancers and GL promoters (32). This might involve complex formation between transcription-activating factors bound to the enhancers and promoters, as has been demonstrated between the T cell receptor Dβ promoter and the 3 T cell receptor β enhancer (205). This complex would most likely recruit histone acetylases and other chromatin modiﬁers to increase accessibility of the promot-

ers to RNA polymerase and also position the donor and acceptor S regions near each other. Direct evidence for the existence of loops between the 3 IgH enhancers and the DNA segments containing the promoters for speciﬁc GL transcripts in splenic B cells under conditions that induce CSR to that speciﬁc isotype has recently been obtained using the chromosome conformation capture technique (206). Most interestingly, the loops depend on the hs3B-hs4 enhancer segment and are reduced in aid−/− cells. It will be very interesting and important to determine which sequences and proteins are involved.

Regulation of Isotype Specificity by S Regions Although GL transcription is clearly essential for CSR, a few reports suggest that isotype speciﬁcity is also regulated by the S region sequence. The evidence for this was obtained by using transiently transfected plasmid switch substrates (207). The acceptor S region isotype determines whether the plasmid will switch in particular B cell lines or in splenic B cells activated under conditions that induce CSR on the chromosome to speciﬁc isotypes. For example, plasmids containing an acceptor Sγ1 or Sγ3 sequence will not switch in two different B cell lines that switch on their endogenous chromosome to IgA, but not to IgG1 or IgG3. However, plasmids with acceptor Sα sequences will undergo Sμ-Sα recombination in these cell lines. Likewise, a plasmid with the Sγ1 acceptor S region will undergo Sμ-Sγ1 recombination in splenic B cells treated with LPS+IL-4, which induces IgG1 CSR on the chromosome, but not if the B cells are treated with LPS alone, which induces IgG3 but not IgG1 CSR. Likewise, the plasmid with an Sγ3 acceptor S region will undergo CSR in B cells induced with LPS, but not if the cells are treated with LPS+IL4. Kenter et al. (208) also showed that mutations of 3 bp within a repeat unit of the Sγ1 sequence to the sequence found in Sγ3 allowed the plasmid to switch in the absence www.annualreviews.org • Class Switch Recombination

277

ARI

16 February 2008

12:18

of IL-4, further supporting the hypothesis that isotype speciﬁcity is also controlled by switch sequences. The element that was mutated is part of a NF-κB binding motif, which therefore might be involved in determining the isotype speciﬁcity. It was not determined whether the mutations affected transcription across the plasmid S regions, although there are no Ig isotype–speciﬁc promoters in these plasmids, so this is an unlikely explanation. Another example of isotype speciﬁc regulation by a S region comes from the ﬁnding that plasmid Sμ-Sα recombination in cell lines and splenic B cells can be stimulated threefold and tenfold, respectively, by the histone methyltransferase Suv39h1, which trimethylates histone H3 on lysine 9. Suv39h1 does not stimulate switch recombination in plasmids with any other acceptor S region (209). Mice deﬁcient in Suv39h1 show a 50% reduction in chromosomal CSR to IgA, but to no other isotype. This reduction is not accompanied by a reduction in GL α transcripts, suggesting that the Sα sequence itself is responding to Suv39h1. The Suv39h1 target in these switching cells is unknown. Furthermore, the K9-trimethyl mark is repressive and is usually found on heterochromatin associated with centromeres, making the stimulatory role of Suv39h1 on IgA switching even more puzzling. Taken together, these two sets of results suggest that isotype speciﬁcity is not regulated solely by GL transcription but is also regulated by S region sequences by an unknown mechanism.

Annu. Rev. Immunol. 2008.26:261-292. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-09

ISOTYPE SWITCHING OCCURS PRIOR TO GERMINAL CENTER (GC) FORMATION, AND PERHAPS ALSO IN GCs The GC provides a unique environment that allows rapid proliferation of cells despite sustaining DNA damage initiated by AID activity. Bcl-6 is upregulated in GC cells and is required for GC formation (210, 211). Ranuncolo et al. (212) suggest that GC centroblasts are uniquely able to withstand the DNA 278

Stavnezer

·

Guikema

·

Schrader

damage caused by AID because of the repression of the ATR damage-sensing pathway by Bcl-6. Protection from cell death in GC cells had previously been thought to be due to the downregulation of p53 by Bcl-6, as demonstrated in Ramos cells (213), but Ranuncolo et al. (212) found that primary human centroblasts express p53 and that its expression is not affected by downregulation or inhibition of Bcl-6. Although both isotype-switched cells and high levels of AID are found in GCs, class switching clearly can occur very early after antigen exposure, prior to GC formation. By adoptive transfer of B cell receptor Tg B cells and carrier-speciﬁc Tg CD4 T cells into normal recipients, Pape et al. (214) were able to visualize very early stages in the antibody response, tracking the B cells with anti-idiotype antibody. Tg+ isotype-switched B cells (IgG2a+ ) appeared in splenic B cell follicles as early as two days after immunization with cognate antigen and peaked on days 3 and 4, prior to formation of GCs. The B cells had divided at least three times and appeared to have migrated away from the Tg T cells. Their appearance was antigenand T cell–dependent. By day 4, progeny of the Tg+ IgG2a+ follicular B cells could be found in the outer edges of the periarteriolar lymphoid sheath near the red pulp, in the marginal zone, and in pre-GCs. By day 10, GCs contained PNA+ IgG2a+ Tg B cells that showed evidence of many cell divisions. IgM+ Tg B cells were abundant in follicles and the marginal zone at this time but were not in GCs. As only IgG2a+ Tg B cells were found in GCs, this suggests that CSR does not occur in GCs in this model, but instead occurs prior to GC formation. In another model, normal mice infected with attenuated Salmonella typhimurium also showed very rapid (day 4) Tdependent IgG2a isotype switching, occurring much before GC formation (215). Also, AID is expressed in large proliferating B cells in the extrafollicular areas of human tonsil and lymph node (216). However, Kolar et al. (217) have recently suggested that a population that

Annu. Rev. Immunol. 2008.26:261-292. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-09

ARI

16 February 2008

12:18

expresses IgD+ CD38− CD23− FSChi CD71+ in human tonsil may be the initial GC cell to express AID. V region mutation frequency places these cells between naive and GC cells. This ﬁnding is consistent with previous assumptions that CSR also occurs in GCs. CSR can also occur independently of T cell help. B cell activating factor (BAFF) can synergize with IL-4 to induce AID expression in CD40−/− B cells in culture (218). Near normal levels of gut IgA were detected in CD40−/− mice despite a lack of GCs (219). The site where this T-independent IgA switching occurred was not identiﬁed in this study, although the authors excluded the gutassociated lymphoid tissue (GALT), the lamina propria, and the peritoneal cavity. Mucosal epithelial cells lining the crypts of human tonsils can support class switching through the production of BAFF and IL-10 upon TLR stimulation. These epithelial cells also secrete thymic stromal lymphopoietin (TSLP), which stimulates production of BAFF by dendritic cells (220, 221). Furthermore, CSR is detectable in pre-B and immature B cells isolated from bone marrow, as assayed by AID expression, detection of transcripts from excised DNA circles owing to S-S recombination, and detection of postswitch (Iμ-Cx) transcripts (222, 223). AID expression, circle transcripts, and postswitch transcripts were also observed in developing B cells from nude mice, further indicating T cell independence. The expression of AID in both wild-type and nude mice depends on B cell receptor signaling

through Bruton’s agammaglobulinemia tyrosine kinase (BTK) in immature B cells and on TLR signaling in both pre-B and immature B cells (222).

REMAINING QUESTIONS Numerous interesting questions remain in the ﬁeld of CSR. For example, how does AID target the V and S regions speciﬁcally? CSR and SHM do not appear to occur simultaneously in a cell. Why not? What determines whether a cell will undergo CSR or instead undergo SHM? What proteins does AID interact with? Most interestingly, what is the role of the C terminus of AID? Why is UNG required for CSR, i.e., why do other uracil DNA glycosylases not substitute? Why is APE2 used to create SSBs in S regions, in addition to APE1? Is another AP endonuclease also involved? How is synapsis of two distal S regions achieved? What is the contribution of S region sequence to isotype speciﬁcity? What is the role of 53BP1? Does 53BP1 bind specifically to the IgH locus? If so, does it require a speciﬁc histone modiﬁcation, and is this modiﬁcation speciﬁc to the IgH locus? How is this regulated? Does the binding require GL transcripts? Why is Ku70-Ku80 essential for CSR but XRCC4-ligase IV is not? Is the ability of Ku to bind nuclear matrix important for CSR? Many very interesting questions are approachable with current techniques and will be addressed in the near future, thus promising much excitement for this ﬁeld in the coming years.

DISCLOSURE STATEMENT The authors are not aware of any biases that might be perceived as affecting the objectivity of this review.

ACKNOWLEDGMENTS We thank Drs. Katheryn Meek for helpful information on DNA-PK and Amy Kenter for her manuscript in press. We acknowledge support by NIH to J.S. (RO1AI23283, RO1 AI63026, R21AI62738) and to C.E.S. (RO1 AI65639) and a postdoctoral fellowship from the Cancer Research Institute to J.E.J.G. www.annualreviews.org • Class Switch Recombination

279

ANRV338-IY26-09

ARI

16 February 2008

12:18

LITERATURE CITED

Annu. Rev. Immunol. 2008.26:261-292. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

1. Snapper CM, Finkelman FD. 1998. Immunoglobulin class switching. In Fundamental Immunology, ed. WE Paul, pp. 831–61, Philadelphia: Lippincott-Raven. 4th ed. 2. Martin SW, Goodnow CC. 2002. Burst-enhancing role of the IgG membrane tail as a molecular determinant of memory. Nat. Immunol. 3:182–88 3. Waisman A, Kraus M, Seagal J, Ghosh S, Melamed D, et al. 2007. IgG1 B cell receptor signaling is inhibited by CD22 and promotes the development of B cells whose survival is less dependent on Ig α/β. J. Exp. Med. 204:747–58 4. Horikawa K, Martin SW, Pogue SL, Silver K, Peng K, et al. 2007. Enhancement and suppression of signaling by the conserved tail of IgG memory-type B cell antigen receptors. J. Exp. Med. 204:759–69 5. Dunnick W, Hertz GZ, Scappino L, Gritzmacher C. 1993. DNA sequences at immunoglobulin switch region recombination sites. Nucleic Acids Res. 21:365–72 6. Min I, Rothlein L, Schrader C, Stavnezer J, Selsing E. 2005. Shifts in targeting of class switch recombination sites in mice that lack μ switch region tandem repeats or Msh2. J. Exp. Med. 201:1885–90 7. Stavnezer J. 1996. Antibody class switching. Adv. Immunol. 61:79–146 8. Manis JP, Tian M, Alt FW. 2002. Mechanism and control of class-switch recombination. Trends Immunol. 23:31–39 9. Muramatsu M, Kinoshita K, Fagarasan S, Yamada S, Shinkai Y, Honjo T. 2000. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 102:553–63 10. Revy P, Muto T, Levy Y, Geissmann F, Plebani A, et al. 2000. Activation-induced cytidine deaminase (AID) deﬁciency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2). Cell 102:565–75 11. Petersen-Mahrt SK, Harris RS, Neuberger MS. 2002. AID mutates E. coli suggesting a DNA deamination mechanism for antibody diversiﬁcation. Nature 418:99–104 12. Chaudhuri J, Tian M, Khuong C, Chua K, Pinaud E, Alt FW. 2003. Transcriptiontargeted DNA deamination by the AID antibody diversiﬁcation enzyme. Nature 422:726– 30 13. Dickerson SK, Market E, Besmer E, Papavasiliou FN. 2003. AID mediates hypermutation by deaminating single stranded DNA. J. Exp. Med. 197:1291–96 14. Pham P, Bransteitter R, Petruska J, Goodman MF. 2003. Processive AID-catalysed cytosine deamination on single-stranded DNA simulates somatic hypermutation. Nature 424:103–7 15. Peled JU, Kuang FL, Iglesias-Ussel MD, Roa S, Kalis SL, et al. 2008. The biochemistry of somatic hypermutation. Annu. Rev. Immunol. 26:481–511 16. Barreto VM, Ramiro AR, Nussenzweig MC. 2005. Activation-induced deaminase: controversies and open questions. Trends Immunol. 26:90–96 17. Ramiro A, San-Martin BR, McBride K, Jankovic M, Barreto V, et al. 2007. The role of activation-induced deaminase in antibody diversiﬁcation and chromosome translocations. Adv. Immunol. 94:75–107 18. Longerich S, Basu U, Alt F, Storb U. 2006. AID in somatic hypermutation and class switch recombination. Curr. Opin. Immunol. 18:164–74 19. Bransteitter R, Sneeden JL, Allen S, Pham P, Goodman MF. 2006. First AID (activationinduced cytidine deaminase) is needed to produce high afﬁnity isotype-switched antibodies. J. Biol. Chem. 281:16833–36 280

Stavnezer

·

Guikema

·

Schrader

Annu. Rev. Immunol. 2008.26:261-292. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-09

ARI

16 February 2008

12:18

20. Muramatsu M, Sankaranand VS, Anant S, Sugai M, Kinoshita K, et al. 1999. Speciﬁc expression of activation-induced cytidine deaminase (AID), a novel member of the RNAediting deaminase family in germinal center B cells. J. Biol. Chem. 274:18470–76 21. Schrader CE, Linehan EK, Mochegova SN, Woodland RT, Stavnezer J. 2005. Inducible DNA breaks in Ig S regions are dependent upon AID and UNG. J. Exp. Med. 202:561–68 22. Hodgkin PD, Lee J-H, Lyons AB. 1996. B cell differentiation and isotype switching is related to division cycle number. J. Exp. Med. 184:277–81 23. Hasbold J, Lyons AB, Kehry MR, Hodgkin PD. 1998. Cell division number regulates IgG1 and IgE switching of B cells following stimulation by CD40 ligand and IL-4. Eur. J. Immunol. 28:1040–51 24. Deenick EK, Hasbold J, Hodgkin PD. 1999. Switching to IgG3, IgG2b, and IgA is division linked and independent, revealing a stochastic framework for describing differentiation. J. Immunol. 163:4707–14 25. Rush JS, Liu M, Odegard VH, Unniraman S, Schatz DG. 2005. Expression of activationinduced cytidine deaminase is regulated by cell division, providing a mechanistic basis for division-linked class switch recombination. Proc. Natl. Acad. Sci. USA 102:13242–47 26. Dedeoglu F, Horwitz B, Chaudhuri J, Alt FW, Geha RS. 2004. Induction of activationinduced cytidine deaminase gene expression by IL-4 and CD40 ligation is dependent on STAT6 and NFκB. Int. Immunol. 16:395–404 27. Gonda H, Sugai M, Nambu Y, Katakai T, Agata Y, et al. 2003. The balance between Pax5 and Id2 activities is the key to AID gene expression. J. Exp. Med. 198:1427–37 28. Ito S, Nagaoka H, Shinkura R, Begum N, Muramatsu M, et al. 2004. Activation-induced cytidine deaminase shuttles between nucleus and cytoplasm like apolipoprotein B mRNA editing catalytic polypeptide 1. Proc. Natl. Acad. Sci. USA 101:1975–80 29. McBride KM, Barreto V, Ramiro AR, Stavropoulos P, Nussenzweig MC. 2004. Somatic hypermutation is limited by CRM1-dependent nuclear export of activation-induced deaminase. J. Exp. Med. 199:1235–44 30. Brar SS, Watson M, Diaz M. 2004. Activation-induced cytosine deaminase (AID) is actively exported out of the nucleus but retained by the induction of DNA breaks. J. Biol. Chem. 279:26395–401 31. Stavnezer J. 1996. Immunoglobulin class switching. Curr. Opin. Immunol. 8:199–205 32. Cogne M, Birshtein BK. 2004. Regulation of class switch recombination. In Molecular Biology of B Cells, ed. T Honjo, FW Alt, MS Neuberger, pp. 289–305. London: Elsevier 33. Pan-Hammarstrom Q, Zhao Y, Hammarstrom L. 2007. Class switch recombination: a comparison between mouse and human. Adv. Immunol. 93:1–61 34. Chaudhuri J, Alt FW. 2004. Class-switch recombination: interplay of transcription, DNA deamination and DNA repair. Nat. Rev. Immunol. 4:541–52 35. Li Z, Woo CJ, Iglesias-Ussel MD, Ronai D, Scharff MD. 2004. The generation of antibody diversity through somatic hypermutation and class switch recombination. Genes Dev. 18:1–11 36. Kenter AL. 2005. Class switch recombination: an emerging mechanism. Curr. Top. Microbiol. Immunol. 290:171–99 37. Stavnezer J, Kinoshita K, Muramatsu M, Honjo T. 2004. Molecular mechanisms of class switch recombination. In Molecular Biology of B Cells, ed. T Honjo, MS Neuberger, FW Alt, pp. 307–26. London: Elsevier 38. Rada C, Williams GT, Nilsen H, Barnes DE, Lindahl T, Neuberger MS. 2002. Immunoglobulin isotype switching is inhibited and somatic hypermutation perturbed in UNG-deﬁcient mice. Curr. Biol. 12:1748–55 www.annualreviews.org • Class Switch Recombination

281

ARI

16 February 2008

12:18

39. Di Noia J, Neuberger MS. 2002. Altering the pathway of immunoglobulin hypermutation by inhibiting uracil-DNA glycosylase. Nature 419:43–48 40. Poltoratsky V, Goodman MF, Scharff MD. 2000. Error-prone candidates vie for somatic mutation. J. Exp. Med. 192:F27–30 41. Catalan N, Selz F, Imai K, Revy P, Fischer A, Durandy A. 2003. The block in immunoglobulin class switch recombination caused by activation-induced cytidine deaminase deﬁciency occurs prior to the generation of DNA double strand breaks in switch μ region. J. Immunol. 171:2504–9 42. Rush JS, Fugmann SD, Schatz DG. 2004. Staggered AID-dependent DNA double strand breaks are the predominant DNA lesions targeted to Sμ in Ig class switch recombination. Int. Immunol. 16:549–57 43. Petersen S, Casellas R, Reina-San-Martin B, Chen HT, Diﬁlippantonio MJ, et al. 2001. AID is required to initiate Nbs1/γ-H2AX focus formation and mutations at sites of class switching. Nature 414:660–65 44. Ramiro AR, Stavropoulos P, Jankovic M, Nussenzweig MC. 2003. Transcription enhances AID-mediated cytidine deamination by exposing single-stranded DNA on the nontemplate strand. Nat. Immunol. 4:452–56 45. Shen HM, Storb U. 2004. Activation-induced cytidine deaminase (AID) can target both DNA strands when the DNA is supercoiled. Proc. Natl. Acad. Sci. USA 101:12997–3002 46. Shen HM, Ratnam S, Storb U. 2005. Targeting of the activation-induced cytosine deaminase is strongly inﬂuenced by the sequence and structure of the targeted DNA. Mol. Cell. Biol. 25:10815–21 47. Martomo SA, Fu D, Yang WW, Joshi NS, Gearhart PJ. 2005. Deoxyuridine is generated preferentially in the nontranscribed strand of DNA from cells expressing activationinduced cytidine deaminase. J. Immunol. 174:7787–91 48. Milstein C, Neuberger MS, Staden R. 1998. Both DNA strands of antibody genes are hypermutation targets. Proc. Natl. Acad. Sci. USA 95:8791–94 49. Longerich S, Tanaka A, Bozek G, Nicolae D, Storb U. 2005. The very 5 end and the constant region of Ig genes are spared from somatic mutation because AID does not access these regions. J. Exp. Med. 202:1443–54 50. Xue K, Rada C, Neuberger MS. 2006. The in vivo pattern of AID targeting to immunoglobulin switch regions deduced from mutation spectra in msh2−/− ung−/− mice. J. Exp. Med. 203:2085–94 51. Betz AG, Milstein C, Gonzalez-Fernandez A, Pannell R, Larson T, Neuberger MS. 1994. Elements regulating somatic hypermutation of an immunoglobulin κ gene: critical role for the intron enhancer/matrix attachment region. Cell 77:239–48 52. Rogozin IB, Kolchanov NA. 1992. Somatic hypermutagenesis in immunoglobulin genes. II. Inﬂuence of neighbouring base sequences on mutagenesis. Biochim. Biophys. Acta 1171:11–18 53. Shapiro GS, Aviszus K, Ikle D, Wysocki LJ. 1999. Predicting regional mutability in antibody V genes based solely on di- and trinucleotide sequence composition. J. Immunol. 163:259–68 54. Bransteitter R, Pham P, Calabrese P, Goodman MF. 2004. Biochemical analysis of hypermutational targeting by wild type and mutant activation-induced cytidine deaminase. J. Biol. Chem. 279:51612–21 55. Yu K, Huang FT, Lieber MR. 2004. DNA substrate length and surrounding sequence affect the activation-induced deaminase activity at cytidine. J. Biol. Chem. 279:6496–500 56. Chaudhuri J, Khuong C, Alt FW. 2004. Replication protein A interacts with AID to promote deamination of somatic hypermutation targets. Nature 430:992–98

Annu. Rev. Immunol. 2008.26:261-292. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-09

282

Stavnezer

·

Guikema

·

Schrader

Annu. Rev. Immunol. 2008.26:261-292. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-09

ARI

16 February 2008

12:18

57. Basu U, Chaudhuri J, Alpert C, Dutt S, Ranganath S, et al. 2005. The AID antibody diversiﬁcation enzyme is regulated by protein kinase A phosphorylation. Nature 438:508– 11 58. McBride KM, Gazumyan A, Woo EM, Barreto VM, Robbiani DV, et al. 2006. Regulation of hypermutation by activation-induced cytidine deaminase phosphorylation. Proc. Natl. Acad. Sci. USA 103:8798–803 59. Ta VT, Nagaoka H, Catalan N, Durandy A, Fischer A, et al. 2003. AID mutant analyses indicate requirement for class-switch-speciﬁc cofactors. Nat. Immunol. 4:843–48 60. Barreto V, Reina-San-Martin B, Ramiro AR, McBride KM, Nussenzweig MC. 2003. C-terminal deletion of AID uncouples class switch recombination from somatic hypermutation and gene conversion. Mol. Cell 12:501–8 61. Christmann M, Tomicic MT, Roos WP, Kaina B. 2003. Mechanisms of human DNA repair: an update. Toxicology 193:3–34 62. Imai K, Slupphaug G, Lee WI, Revy P, Nonoyama S, et al. 2003. Human uracil-DNA glycosylase deﬁciency associated with profoundly impaired immunoglobulin class-switch recombination. Nat. Immunol. 4:1023–28 63. Bardwell PD, Martin A, Wong E, Li Z, Edelmann W, Scharff MD. 2003. Cutting edge: the G-U mismatch glycosylase methyl-CpG binding domain 4 is dispensable for somatic hypermutation and class switch recombination. J. Immunol. 170:1620–24 64. Di Noia JM, Rada C, Neuberger MS. 2006. SMUG1 is able to excise uracil from immunoglobulin genes: insight into mutation vs repair. EMBO J. 25:585–95 65. Hadi MZ, Ginalski K, Nguyen LH, Wilson DM 3rd. 2002. Determinants in nuclease speciﬁcity of Ape1 and Ape2, human homologues of Escherichia coli exonuclease III. J. Mol. Biol. 316:853–66 66. Kanno S, Kuzuoka H, Sasao S, Hong Z, Lan L, et al. 2007. A novel human AP endonuclease with conserved zinc-ﬁnger-like motifs involved in DNA strand break responses. EMBO J. 26:2094–103 67. Iles N, Rulten S, El-Khamisy SF, Caldecott KW. 2007. APLF (C2orf13) is a novel human protein involved in the cellular response to chromosomal DNA strand breaks. Mol. Cell. Biol. 27:3793–803 68. Bekker-Jensen S, Fugger K, Danielsen JR, Gromova I, Sehested M, et al. 2007. Human xip1 (c2orf13) is a novel regulator of cellular responses to DNA strand breaks. J. Biol. Chem. 282:19638–43 69. Xanthoudakis S, Smeyne RJ, Wallace JD, Curran T. 1996. The redox/DNA repair protein, Ref-1, is essential for early embryonic development in mice. Proc. Natl. Acad. Sci. USA 93:8919–23 70. Fung H, Demple B. 2005. A vital role for Ape1/Ref1 protein in repairing spontaneous DNA damage in human cells. Mol. Cell 17:463–70 71. Ide Y, Tsuchimoto D, Tominaga Y, Nakashima M, Watanabe T, et al. 2004. Growth retardation and dyslymphopoiesis accompanied by G2/M arrest in APEX2-null mice. Blood 104:4097–103 72. Ide Y, Tsuchimoto D, Tominaga Y, Iwamoto Y, Nakabeppu Y. 2003. Characterization of the genomic structure and expression of the mouse Apex2 gene. Genomics 81:47–57 73. Burkovics P, Szukacsov V, Unk I, Haracska L. 2006. Human Ape2 protein has a 3 -5 exonuclease activity that acts preferentially on mismatched base pairs. Nucleic Acids Res. 34:2508–15 74. Guikema JEJ, Linehan EK, Tsuchimoto D, Nakabeppu Y, Strauss PR, et al. 2007. APE1 and APE2 dependent DNA breaks in immunoglobulin class switch recombination. J. Exp. Med. 204:3017–26 www.annualreviews.org • Class Switch Recombination

283

ARI

16 February 2008

12:18

75. Meira LB, Devaraj S, Kisby GE, Burns DK, Daniel RL, et al. 2001. Heterozygosity for the mouse Apex gene results in phenotypes associated with oxidative stress. Cancer Res. 61:5552–57 76. Raffoul JJ, Cabelof DC, Nakamura J, Meira LB, Friedberg EC, Heydari AR. 2004. Apurinic/apyrimidinic endonuclease (APE/REF-1) haploinsufﬁcient mice display tissuespeciﬁc differences in DNA polymerase β-dependent base excision repair. J. Biol. Chem. 279:18425–33 77. Schrader CE, Guikema JEJ, Linehan EK, Selsing E, Stavnezer J. 2007. AID-dependent DNA breaks in class switch recombination occur during G1 phase and are mismatch repair-dependent. J. Immunol. 179:6064–71 78. Barnes DE, Lindahl T. 2004. Repair and genetic consequences of endogenous DNA base damage in mammalian cells. Annu. Rev. Genet. 38:445–76 79. Beard WA, Wilson SH. 2006. Structure and mechanism of DNA polymerase β. Chem. Rev. 106:361–82 80. Akbari M, Otterlei M, Pena-Diaz J, Aas PA, Kavli B, et al. 2004. Repair of U/G and U/A in DNA by UNG2-associated repair complexes takes place predominantly by shortpatch repair both in proliferating and growth-arrested cells. Nucleic Acids Res. 32:5486– 98 81. Parlanti E, Locatelli G, Maga G, Dogliotti E. 2007. Human base excision repair complex is physically associated to DNA replication and cell cycle regulatory proteins. Nucleic Acids Res. 35:1569–77 82. Wong D, Demple B. 2004. Modulation of the 5 -deoxyribose-5-phosphate lyase and DNA synthesis activities of mammalian DNA polymerase β by apurinic/apyrimidinic endonuclease 1. J. Biol. Chem. 279:25268–75 83. Parsons JL, Dianova II, Allinson SL, Dianov GL. 2005. DNA polymerase β promotes recruitment of DNA ligase IIIα-XRCC1 to sites of base excision repair. Biochemistry 44:10613–19 84. Liu Y, Prasad R, Beard WA, Kedar PS, Hou EW, et al. 2007. Coordination of steps in single-nucleotide base excision repair mediated by apurinic/apyrimidinic endonuclease 1 and DNA polymerase β. J. Biol. Chem. 282:13532–41 85. Wu X, Stavnezer J. 2007. DNA polymerase β is able to repair breaks in switch regions and plays an inhibitory role during immunoglobulin class switch recombination. J. Exp. Med. 204:1677–89 86. Ito K, Hirao A, Arai F, Matsuoka S, Takubo K, et al. 2004. Regulation of oxidative stress by ATM is required for self-renewal of haematopoietic stem cells. Nature 431:997– 1002 87. Zarrin AA, Del Vecchio C, Tseng E, Gleason M, Zarin P, et al. 2007. Antibody class switching mediated by yeast endonuclease-generated DNA breaks. Science 315:377–81 88. Kunkel T, Erie D. 2005. DNA mismatch repair. Annu. Rev. Biochem. 74:681–710 89. Genschel J, Bazemore LR, Modrich P. 2002. Human exonuclease I is required for 5 and 3 mismatch repair. J. Biol. Chem. 277:13302–11 90. Genschel J, Modrich P. 2003. Mechanism of 5 -directed excision in human mismatch repair. Mol. Cell 12:1077–86 91. Kadyrov FA, Dzantiev L, Constantin N, Modrich P. 2006. Endonucleolytic function of MutLα in human mismatch repair. Cell 126:297–308 92. Ehrenstein MR, Neuberger MS. 1999. Deﬁciency in Msh2 affects the efﬁciency and local sequence speciﬁcity of immunoglobulin class-switch recombination: parallels with somatic hypermutation. EMBO J. 18:3484–90

Annu. Rev. Immunol. 2008.26:261-292. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-09

284

Stavnezer

·

Guikema

·

Schrader

Annu. Rev. Immunol. 2008.26:261-292. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-09

ARI

16 February 2008

12:18

93. Schrader CE, Edelmann W, Kucherlapati R, Stavnezer J. 1999. Reduced isotype switching in splenic B cells from mice deﬁcient in mismatch repair enzymes. J. Exp. Med. 190:323–30 94. Ehrenstein MR, Rada C, Jones AM, Milstein C, Neuberger MS. 2001. Switch junction sequences in PMS2-deﬁcient mice reveal a microhomology-mediated mechanism of Ig class switch recombination. Proc. Natl. Acad. Sci. USA 98:14553–58 95. Li Z, Scherer SJ, Ronai D, Iglesias-Ussel MD, Peled JU, et al. 2004. Examination of Msh6- and Msh3-deﬁcient mice in class switching reveals overlapping and distinct roles of MutS homologues in antibody diversiﬁcation. J. Exp. Med. 200:47–59 96. Martin A, Li Z, Lin DP, Bardwell PD, Iglesias-Ussel MD, et al. 2003. Msh2 ATPase activity is essential for somatic hypermutation at A-T basepairs and for efﬁcient class switch recombination. J. Exp. Med. 198:1171–78 97. Martomo SA, Yang WW, Gearhart PJ. 2004. A role for Msh6 but not Msh3 in somatic hypermutation and class switch recombination. J. Exp. Med. 200:61–68 98. Bardwell PD, Woo CJ, Wei K, Li Z, Martin A, et al. 2004. Altered somatic hypermutation and reduced class-switch recombination in exonuclease 1-mutant mice. Nat. Immunol. 5:224–29 99. Stavnezer J, Schrader CE. 2006. Mismatch repair converts AID-instigated nicks to double-strand breaks for antibody class-switch recombination. Trends Genet. 22:23–28 100. Wilson TM, Vaisman A, Martomo SA, Sullivan P, Lan L, et al. 2005. MSH2-MSH6 stimulates DNA polymerase η, suggesting a role for A:T mutations in antibody genes. J. Exp. Med. 201:637–45 101. Luby TM, Schrader CE, Stavnezer J, Selsing E. 2001. The μ switch region tandem repeats are important, but not required, for antibody class switch recombination. J. Exp. Med. 193:159–68 102. Min I, Schrader C, Vardo J, D’Avirro N, Luby T, et al. 2003. The Sμ tandem repeat region is critical for isotype switching in the absence of Msh2. Immunity 19:515–24 103. Schrader CE, Vardo J, Stavnezer J. 2002. Role for mismatch repair proteins Msh2, Mlh1, and Pms2 in immunoglobulin class switching shown by sequence analysis of recombination junctions. J. Exp. Med. 195:367–73 104. Schrader CE, Vardo J, Linehan E, Twarog MZ, Niedernhofer LJ, et al. 2004. Deletion of the nucleotide excision repair gene Ercc1 reduces Ig class switching and alters mutations near switch recombination junctions. J. Exp. Med. 200:321–30 105. Faili A, Aoufouchi S, Weller S, Vuillier F, Stary A, et al. 2004. DNA polymerase η is involved in hypermutation occurring during immunoglobulin class switch recombination. J. Exp. Med. 199:265–70 106. Delbos F, Aoufouchi S, Faili A, Weill JC, Reynaud CA. 2007. DNA polymerase η is the sole contributor of A/T modiﬁcations during immunoglobulin gene hypermutation in the mouse. J. Exp. Med. 204:17–23 107. Dunnick W, Wilson M, Stavnezer J. 1989. Mutations, duplications, and deletion of recombined switch regions suggest a role for DNA replication in the immunoglobulin heavy chain switch. Mol. Cell. Biol. 9:1850–56 108. Schrader CE, Bradley SP, Vardo J, Mochegova SN, Flanagan E, Stavnezer J. 2003. Mutations occur in the Ig Sμ region but rarely in Sγ regions prior to class switch recombination. EMBO J. 22:5893–903 109. Masuda K, Ouchida R, Takeuchi A, Saito T, Koseki H, et al. 2005. DNA polymerase θ contributes to the generation of C/G mutations during somatic hypermutation of Ig genes. Proc. Natl. Acad. Sci. USA 102:13986–91 www.annualreviews.org • Class Switch Recombination

285

ARI

16 February 2008

12:18

110. Zan H, Shima N, Xu Z, Al-Qahtani A, Evinger AJ Iii, et al. 2005. The translesion DNA polymerase θ plays a dominant role in immunoglobulin gene somatic hypermutation. EMBO J. 24:3757–69 111. Masuda K, Ouchida R, Hikida M, Nakayama M, Ohara O, et al. 2006. Absence of DNA polymerase θ results in decreased somatic hypermutation frequency and altered mutation patterns in Ig genes. DNA Repair 5:1384–91 112. Dudley DD, Manis JP, Zarrin AA, Kaylor L, Tian M, Alt FW. 2002. Internal IgH class switch region deletions are position-independent and enhanced by AID expression. Proc. Natl. Acad. Sci. USA 99:9984–89 113. Reina-San-Martin B, Diﬁlippantonio S, Hanitsch L, Masilamani RF, Nussenzweig A, Nussenzweig MC. 2003. H2AX is required for recombination between immunoglobulin switch regions but not for intraswitch region recombination or somatic hypermutation. J. Exp. Med. 197:1767–78 114. Rooney S, Chaudhuri J, Alt FW. 2004. The role of the nonhomologous end-joining pathway in lymphocyte development. Immunol. Rev. 200:115–31 115. Ma Y, Lu H, Schwarz K, Lieber MR. 2005. Repair of double-strand DNA breaks by the human nonhomologous DNA end joining pathway: the iterative processing model. Cell Cycle 4:1193–200 116. Sonoda E, Hochegger H, Saberi A, Taniguchi Y, Takeda S. 2006. Differential usage of nonhomologous end-joining and homologous recombination in double strand break repair. DNA Repair 5:1021–29 117. Manis JP, Gu Y, Lansford R, Sonoda E, Ferrini R, et al. 1998. Ku70 is required for late B cell development and immunoglobulin heavy chain switching. J. Exp. Med. 187:2081– 89 118. Casellas R, Nussenzweig A, Wuerffel R, Pelanda R, Reichlin A, et al. 1998. Ku80 is required for immunoglobulin isotype switching. EMBO J. 17:2404–11 119. Pan-Hammarstrom Q, Jones AM, Lahdesmaki A, Zhou W, Gatti RA, et al. 2005. Impact of DNA ligase IV on nonhomologous end joining pathways during class switch recombination in human cells. J. Exp. Med. 201:189–94 120. Soulas-Sprauel P, Guyader GL, Rivera-Munoz P, Abramowski V, Olivier-Martin C, et al. 2007. Role for DNA repair factor XRCC4 in immunoglobulin class switch recombination. J. Exp. Med. 204:1717–27 121. Chen L, Trujillo K, Sung P, Tomkinson AE. 2000. Interactions of the DNA ligase IVXRCC4 complex with DNA ends and the DNA-dependent protein kinase. J. Biol. Chem. 275:26196–205 122. Nick McElhinny SA, Snowden CM, McCarville J, Ramsden DA. 2000. Ku recruits the XRCC4-ligase IV complex to DNA ends. Mol. Cell. Biol. 20:2996–3003 123. Costantini S, Woodbine L, Andreoli L, Jeggo PA, Vindigni A. 2007. Interaction of the Ku heterodimer with the DNA ligase IV/Xrcc4 complex and its regulation by DNA-PK. DNA Repair 6:712–22 124. Frank KM, Sekiguchi JM, Seidl KJ, Swat W, Rathbun GA, et al. 1998. Late embryonic lethality and impaired V(D)J recombination in mice lacking DNA ligase IV. Nature 396:173–77 125. Yan CT, Boboila C, Souza EK, Franco S, Hickernell TR, et al. 2007. IgH class switching and translocations use a robust nonclassical end-joining pathway. Nature. 449:478–82 126. Gu J, Lu H, Tippin B, Shimazaki N, Goodman MF, Lieber MR. 2007. XRCC4:DNA ligase IV can ligate incompatible DNA ends and can ligate across gaps. EMBO J. 26:1010– 23

Annu. Rev. Immunol. 2008.26:261-292. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-09

286

Stavnezer

·

Guikema

·

Schrader

Annu. Rev. Immunol. 2008.26:261-292. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-09

ARI

16 February 2008

12:18

127. Sayegh C, Jhunjhunwala S, Riblet R, Murre C. 2005. Visualization of looping involving the immunoglobulin heavy-chain locus in developing B cells. Genes. Dev. 19:322–27 128. Roldan E, Fuxa M, Chong W, Martinez D, Novatchkova M, et al. 2005. Locus ‘decontraction’ and centromeric recruitment contribute to allelic exclusion of the immunoglobulin heavy-chain gene. Nat. Immunol. 6:31–41 129. Moreno-Herrero F, de Jager M, Dekker NH, Kanaar R, Wyman C, Dekker C. 2005. Mesoscale conformational changes in the DNA-repair complex Rad50/Mre11/Nbs1 upon binding DNA. Nature 437:440–43 130. Lee JH, Paull TT. 2005. ATM activation by DNA double-strand breaks through the Mre11-Rad50-Nbs1 complex. Science 308:551–54 131. Hopfner KP, Karcher A, Shin DS, Craig L, Arthur LM, et al. 2000. Structural biology of Rad50 ATPase: ATP-driven conformational control in DNA double-strand break repair and the ABC-ATPase superfamily. Cell 101:789–800 132. de Jager M, Dronkert ML, Modesti M, Beerens CE, Kanaar R, van Gent DC. 2001. DNA-binding and strand-annealing activities of human Mre11: implications for its roles in DNA double-strand break repair pathways. Nucleic Acids Res. 29:1317–25 133. Diﬁlippantonio S, Celeste A, Fernandez-Capetillo O, Chen HT, Reina San Martin B, et al. 2005. Role of Nbs1 in the activation of the Atm kinase revealed in humanized mouse models. Nat. Cell Biol. 7:675–85 134. Falck J, Coates J, Jackson SP. 2005. Conserved modes of recruitment of ATM, ATR and DNA-PKcs to sites of DNA damage. Nature 434:605–11 135. Cerosaletti K, Wright J, Concannon P. 2006. Active role for nibrin in the kinetics of atm activation. Mol. Cell. Biol. 26:1691–99 136. Reina-San-Martin B, Nussenzweig MC, Nussenzweig A, Diﬁlippantonio S. 2005. Genomic instability, endoreduplication, and diminished Ig class-switch recombination in B cells lacking Nbs1. Proc. Natl. Acad. Sci. USA 102:1590–95 137. Carney JP, Maser RS, Olivares H, Davis EM, LeBeau M, et al. 1998. The hMre11/hRad50 protein complex and Nijmegen breakage syndrome: linkage of double-strand break repair (DBSR) to the cellular DNA damage response. Cell 93:477–86 138. Varon R, Vissinga C, Platzer M, Cerosaletti KM, Chrzanowska KH, et al. 1998. Nibrin, a novel DNA double-strand break repair protein, is mutated in Nijmegen breakage syndrome. Cell 93:467–76 139. Kracker S, Bergmann Y, Demuth I, Frappart PO, Hildebrand G, et al. 2005. Nibrin functions in Ig class-switch recombination. Proc. Natl. Acad. Sci. USA 102:1584– 89 140. Ramiro AR, Jankovic M, Eisenreich T, Diﬁlippantonio S, Chen-Kiang S, et al. 2004. AID is required for c-myc/IgH chromosome translocations in vivo. Cell 118:431–38 141. Unniraman S, Zhou S, Schatz DG. 2004. Identiﬁcation of an AID-independent pathway for chromosomal translocations between the Igh switch region and Myc. Nat. Immunol. 5:1117–23 142. Franco S, Gostissa M, Zha S, Lombard DB, Murphy MM, et al. 2006. H2AX prevents DNA breaks from progressing to chromosome breaks and translocations. Mol. Cell 21:201–14 143. Ramiro AR, Jankovic M, Callen E, Diﬁlippantonio S, Chen HT, et al. 2006. Role of genomic instability and p53 in AID-induced c-myc-Igh translocations. Nature 440:105–9 144. Pan Q, Petit-Frere C, Lahdesmaki A, Gregorek H, Chrzanowska KH, Hammarstrom L. 2002. Alternative end joining during switch recombination in patients with ataxiatelangiectasia. Eur. J. Immunol. 32:1300–8 www.annualreviews.org • Class Switch Recombination

287

ARI

16 February 2008

12:18

145. Lahdesmaki A, Taylor AM, Chrzanowska KH, Pan-Hammarstrom Q. 2004. Delineation of the role of the Mre11 complex in class switch recombination. J. Biol. Chem. 279:16479– 87 146. Bakkenist CJ, Kastan MB. 2003. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 421:499–506 147. Downs JA, Nussenzweig MC, Nussenzweig A. 2007. Chromatin dynamics and the preservation of genetic information. Nature 447:951–58 148. Bredemeyer AL, Sharma GG, Huang CY, Helmink BA, Walker LM, et al. 2006. ATM stabilizes DNA double-strand-break complexes during V(D)J recombination. Nature 442:466–70 149. Callen E, Jankovic M, Diﬁlippantonio S, Daniel JA, Chen HT, et al. 2007. ATM prevents the persistence and propagation of chromosome breaks in lymphocytes. Cell. 130:63–75 150. Vacchio MS, Olaru A, Livak F, Hodes RJ. 2007. ATM deﬁciency impairs thymocyte maturation because of defective resolution of T cell receptor a locus coding end breaks. Proc. Natl. Acad. Sci. USA 104:6323–28 151. Lumsden JM, McCarty T, Petiniot LK, Shen R, Barlow C, et al. 2004. Immunoglobulin class switch recombination is impaired in Atm-deﬁcient mice. J. Exp. Med. 200:1111–21 152. Reina-San-Martin B, Chen HT, Nussenzweig A, Nussenzweig MC. 2004. ATM is required for efﬁcient recombination between immunoglobulin switch regions. J. Exp. Med. 200:1103–10 153. Iwabuchi K, Bartel PL, Li B, Marraccino R, Fields S. 1994. Two cellular proteins that bind to wild-type but not mutant p53. Proc. Natl. Acad. Sci. USA 91:6098–102 154. Huang J, Sengupta R, Espejo B, Lee MG, Dorsey JA, et al. 2007. p53 is regulated by the lysine demethylase LSD1. Nature 449:105–8 155. Pryde F, Khalili S, Robertson K, Selfridge J, Ritchie AM, et al. 2005. 53BP1 exchanges slowly at the sites of DNA damage and appears to require RNA for its association with chromatin. J. Cell Sci. 118:2043–55 156. Schultz LB, Chehab NH, Malikzay A, Halazonetis TD. 2000. p53 binding protein 1 (53BP1) is an early participant in the cellular response to DNA double-strand breaks. J. Cell Biol. 151:1381–90 157. Celeste A, Fernandez-Capetillo O, Kruhlak MJ, Pilch DR, Staudt DW, et al. 2003. Histone H2AX phosphorylation is dispensable for the initial recognition of DNA breaks. Nat. Cell Biol. 5:675–79 158. Ward IM, Minn K, Jorda KG, Chen J. 2003. Accumulation of checkpoint protein 53BP1 at DNA breaks involves its binding to phosphorylated histone H2AX. J. Biol. Chem. 278:19579–82 159. Adams MM, Carpenter PB. 2006. Tying the loose ends together in DNA double strand break repair with 53BP1. Cell Div. 1:19 160. Mochan TA, Venere M, DiTullio RA Jr, Halazonetis TD. 2004. 53BP1, an activator of ATM in response to DNA damage. DNA Repair 3:945–52 161. Manis JP, Morales JC, Xia Z, Kutok JL, Alt FW, Carpenter PB. 2004. 53BP1 links DNA damage-response pathways to immunoglobulin heavy chain class-switch recombination. Nat. Immunol. 5:481–87 162. Ward IM, Reina-San-Martin B, Olaru A, Minn K, Tamada K, et al. 2004. 53BP1 is required for class switch recombination. J. Cell Biol. 165:459–64 163. Reina-San-Martin B, Chen J, Nussenzweig A, Nussenzweig MC. 2007. Enhanced intraswitch region recombination during immunoglobulin class switch recombination in 53BP1−/− B cells. Eur. J. Immunol. 37:235–39

Annu. Rev. Immunol. 2008.26:261-292. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-09

288

Stavnezer

·

Guikema

·

Schrader

Annu. Rev. Immunol. 2008.26:261-292. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-09

ARI

16 February 2008

12:18

164. Botuyan MV, Lee J, Ward IM, Kim JE, Thompson JR, et al. 2006. Structural basis for the methylation state-speciﬁc recognition of histone H4-K20 by 53BP1 and Crb2 in DNA repair. Cell 127:1361–73 165. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. 1998. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J. Biol. Chem. 273:5858–68 166. Burma S, Chen BP, Murphy M, Kurimasa A, Chen DJ. 2001. ATM phosphorylates histone H2AX in response to DNA double-strand breaks. J. Biol. Chem. 276:42462–67 167. Lou Z, Minter-Dykhouse K, Franco S, Gostissa M, Rivera MA, et al. 2006. MDC1 maintains genomic stability by participating in the ampliﬁcation of ATM-dependent DNA damage signals. Mol. Cell 21:187–200 168. Berkovich E, Monnat RJ Jr, Kastan MB. 2007. Roles of ATM and NBS1 in chromatin structure modulation and DNA double-strand break repair. Nat. Cell Biol. 9:683–90 169. Celeste A, Petersen S, Romanienko PJ, Fernandez-Capetillo O, Chen HT, et al. 2002. Genomic instability in mice lacking histone H2AX. Science 296:922–27 170. Fernandez-Capetillo O, Celeste A, Nussenzweig A. 2003. Focusing on foci: H2AX and the recruitment of DNA-damage response factors. Cell Cycle 2:426–27 171. Bassing CH, Suh H, Ferguson DO, Chua KF, Manis J, et al. 2003. Histone H2AX: a dosage-dependent suppressor of oncogenic translocations and tumors. Cell 114:359–70 172. Stewart GS, Wang B, Bignell CR, Taylor AM, Elledge SJ. 2003. MDC1 is a mediator of the mammalian DNA damage checkpoint. Nature 421:961–66 173. Stucki M, Clapperton JA, Mohammad D, Yaffe MB, Smerdon SJ, Jackson SP. 2005. MDC1 directly binds phosphorylated histone H2AX to regulate cellular responses to DNA double-strand breaks. Cell 123:1213–26 174. Lieber MR, Ma Y, Pannicke U, Schwarz K. 2003. Mechanism and regulation of human nonhomologous DNA end-joining. Nat. Rev. Mol. Cell Biol. 4:712–20 175. Meek K, Gupta S, Ramsden DA, Lees-Miller SP. 2004. The DNA-dependent protein kinase: the director at the end. Immunol. Rev. 200:132–41 176. Walker JR, Corpina RA, Goldberg J. 2001. Structure of the Ku heterodimer bound to DNA and its implications for double-strand break repair. Nature 412:607–14 177. Spagnolo L, Rivera-Calzada A, Pearl LH, Llorca O. 2006. Three-dimensional structure of the human DNA-PKcs/Ku70/Ku80 complex assembled on DNA and its implications for DNA DSB repair. Mol. Cell 22:511–19 178. Soutoglou E, Dorn JF, Sengupta K, Jasin M, Nussenzweig A, et al. 2007. Positional stability of single double-strand breaks in mammalian cells. Nat. Cell Biol. 9:675–82 179. Meek K, Douglas P, Cui X, Ding Q, Lees-Miller SP. 2007. Trans autophosphorylation at DNA-dependent protein kinase’s two major autophosphorylation site clusters facilitates end processing but not end joining. Mol. Cell. Biol. 27:3881–90 180. Manis JP, Dudley D, Kaylor L, Alt FW. 2002. IgH class switch recombination to IgG1 in DNA-PKcs-deﬁcient B cells. Immunity 16:607–17 181. Rooney S, Alt FW, Sekiguchi J, Manis JP. 2005. Artemis-independent functions of DNAdependent protein kinase in Ig heavy chain class switch recombination and development. Proc. Natl. Acad. Sci. USA 102:2471–75 182. Bosma GC, Kim J, Urich T, Fath DM, Cotticelli MG, et al. 2002. DNA-dependent protein kinase activity is not required for immunoglobulin class switching. J. Exp. Med. 196:1483–95 183. Cook AJ, Oganesian L, Harumal P, Basten A, Brink R, Jolly CJ. 2003. Reduced switching in SCID B cells is associated with altered somatic mutation of recombined S regions. J. Immunol. 171:6556–64 www.annualreviews.org • Class Switch Recombination

289

ARI

16 February 2008

12:18

184. Kaminski DA, Stavnezer J. 2007. Antibody class switching differs among SJL, C57BL/6 and 129 mice. Int. Immunol. 19:545–56 185. Ma Y, Pannicke U, Schwarz K, Lieber MR. 2002. Hairpin opening and overhang processing by an Artemis/DNA-dependent protein kinase complex in nonhomologous end joining and V(D)J recombination. Cell 108:781–94 186. Jung S, Rajewsky K, Radbruch A. 1993. Shutdown of class switch recombination by deletion of a switch region control element. Science 259:984–87 187. Bottaro A, Lansford R, Xu L, Zhang J, Rothman P, Alt F. 1994. I region transcription (per se) promotes basal IgE class switch recombination but additional factors regulate the efﬁciency of the process. EMBO J. 13:665–74 188. Lorenz M, Jung S, Radbruch A. 1995. Switch transcripts in immunoglobulin class switching. Science 267:1825–28 189. Hein K, Lorenz MG, Siebenkotten G, Petry K, Christine R, Radbruch A. 1998. Processing of switch transcripts is required for targeting of antibody class switch recombination. J. Exp. Med. 188:2369–74 190. Huang FT, Yu K, Balter BB, Selsing E, Oruc Z, et al. 2007. Sequence-dependence of chromosomal R-loops at the immunoglobulin heavy chain Sμ class switch region. Mol. Cell. Biol. 27:5921–32 191. Yu K, Chedin F, Hsieh CL, Wilson TE, Lieber MR. 2003. R-loops at immunoglobulin class switch regions in the chromosomes of stimulated B cells. Nat. Immunol. 4:442–51 192. Zarrin AA, Alt FW, Chaudhuri J, Stokes N, Kaushal D, et al. 2004. An evolutionarily conserved target motif for immunoglobulin class-switch recombination. Nat. Immunol. 5:1275–81 193. Zarrin AA, Tian M, Wang J, Borjeson T, Alt FW. 2005. Inﬂuence of switch region length on immunoglobulin class switch recombination. Proc. Natl. Acad. Sci. USA 102:2466–70 194. Ronai D, Iglesias-Ussel MD, Fan M, Li Z, Martin A, Scharff MD. 2007. Detection of chromatin-associated single-stranded DNA in regions targeted for somatic hypermutation. J. Exp. Med. 204:181–90 195. Nambu Y, Sugai M, Gonda H, Lee CG, Katakai T, et al. 2003. Transcription-coupled events associating with immunoglobulin switch region chromatin. Science 302:2137– 40 196. Workman JL. 2006. Nucleosome displacement in transcription. Genes Dev. 20:2009–17 197. Woo CJ, Martin A, Scharff MD. 2003. Induction of somatic hypermutation is associated with modiﬁcations in immunoglobulin variable region chromatin. Immunity 19:479–89 198. Wang L, Whang N, Wuerffel R, Kenter AL. 2006. AID-dependent histone acetylation is detected in immunoglobulin S regions. J. Exp. Med. 203:215–26 199. Sakai E, Bottaro A, Alt FW. 1999. The Ig heavy chain intronic enhancer core region is necessary and sufﬁcient to promote efﬁcient class switch recombination. Int. Immunol. 11:1709–13 200. Manis JP, van der Stoep N, Tian M, Ferrini R, Davidson L, et al. 1998. Class switching in B cells lacking 3 immunoglobulin heavy chain enhancers. J. Exp. Med. 188:1421– 31 201. Pinaud E, Khamlichi AA, Le Morvan C, Drouet M, Nalesso V, et al. 2001. Localization of the 3 IgH locus elements that effect long-distance regulation of class switch recombination. Immunity 15:187–99 202. Pan Q, Petit-Frere C, Stavnezer J, Hammarstrom L. 2000. Regulation of the promoter for human immunoglobulin γ3 germ-line transcription and its interaction with the 3 α enhancer. Eur. J. Immunol. 30:1019–29

Annu. Rev. Immunol. 2008.26:261-292. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-09

290

Stavnezer

·

Guikema

·

Schrader

Annu. Rev. Immunol. 2008.26:261-292. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-09

ARI

16 February 2008

12:18

203. Cunningham K, Ackerly H, Alt F, Dunnick W. 1998. Potential regulatory elements for germline transcription in or near murine Sγ1. Int. Immunol. 10:527–36 204. Adams K, Ackerly H, Cunningham K, Dunnick W. 2000. A DNase I hypersensitive site near the murine γ1 switch region contributes to insertion site independence of transgenes and modulates the amount of transcripts induced by CD40 ligation. Int. Immunol. 12:1705–13 205. Oestreich KJ, Cobb RM, Pierce S, Chen J, Ferrier P, Oltz EM. 2006. Regulation of TCRβ gene assembly by a promoter/enhancer holocomplex. Immunity 24:381–91 206. Wuerffel R, Wang L, Grigera F, Manis J, Selsing E, et al. 2007. S/S synapsis during class switch recombination is promoted by distantly located transcriptional elements and activation-induced deaminase. Immunity. 27:711–22 207. Shanmugam A, Shi M-J, Yauch L, Stavnezer J, Kenter AL. 2000. Evidence for class speciﬁc factors in immunoglobulin isotype switching. J. Exp. Med. 191:1365–80 208. Kenter AL, Wuerffel R, Dominguez C, Shanmugam A, Zhang H. 2004. Mapping of a functional recombination motif that deﬁnes isotype speciﬁcity for μ->γ3 switch recombination implicates NF-κB p50 as the isotype-speciﬁc switching factor. J. Exp. Med. 199:617–27 209. Bradley SP, Kaminski DA, Peters AH, Jenuwein T, Stavnezer J. 2006. The histone methyltransferase Suv39h1 increases class switch recombination speciﬁcally to IgA. J. Immunol. 177:1179–88 210. Dent AL, Shaffer AL, Yu X, Allman D, Staudt LM. 1997. Control of inﬂammation, cytokine expression, and germinal center formation by BCL-6. Science 276:589–92 211. Ye BH, Cattoretti G, Shen Q, Zhang J, Hawe N, et al. 1997. The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inﬂammation. Nat. Genet. 16:161–70 212. Ranuncolo SM, Polo JM, Dierov J, Singer M, Kuo T, et al. 2007. Bcl-6 mediates the germinal center B cell phenotype and lymphomagenesis through transcriptional repression of the DNA-damage sensor ATR. Nat. Immunol. 8:705–14 213. Phan RT, Dalla-Favera R. 2004. The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells. Nature 432:635–39 214. Pape KA, Kouskoff V, Nemazee D, Tang HL, Cyster JG, et al. 2003. Visualization of the genesis and fate of isotype-switched B cells during a primary immune response. J. Exp. Med. 197:1677–87 215. Cunningham AF, Gaspal F, Serre K, Mohr E, Henderson IR, et al. 2007. Salmonella induces a switched antibody response without germinal centers that impedes the extracellular spread of infection. J. Immunol. 178:6200–7 216. Cattoretti G, Buttner M, Shaknovich R, Kremmer E, Alobeid B, Niedobitek G. 2006. Nuclear and cytoplasmic AID in extrafollicular and germinal center B cells. Blood 107:3967– 75 217. Kolar GR, Mehta D, Pelayo R, Capra JD. 2007. A novel human B cell subpopulation representing the initial germinal center population to express AID. Blood 109:2545–52 218. Castigli E, Wilson SA, Scott S, Dedeoglu F, Xu S, et al. 2005. TACI and BAFF-R mediate isotype switching in B cells. J. Exp. Med. 201:35–39 219. Bergqvist P, Gardby E, Stensson A, Bemark M, Lycke NY. 2006. Gut IgA class switch recombination in the absence of CD40 does not occur in the lamina propria and is independent of germinal centers. J. Immunol. 177:7772–83 220. Xu W, He B, Chiu A, Chadburn A, Shan M, et al. 2007. Epithelial cells trigger frontline immunoglobulin class switching through a pathway regulated by the inhibitor SLPI. Nat. Immunol. 8:294–303 www.annualreviews.org • Class Switch Recombination

291

ANRV338-IY26-09

ARI

16 February 2008

12:18

Annu. Rev. Immunol. 2008.26:261-292. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

221. He B, Xu W, Santini PA, Polydorides AD, Chiu A, et al. 2007. Intestinal bacteria trigger T cell-independent immunoglobulin A(2) class switching by inducing epithelial-cell secretion of the cytokine APRIL. Immunity 26:812–26 222. Han JH, Akira S, Calame K, Beutler B, Selsing E, Imanishi-Kari T. 2007. Class switch recombination and somatic hypermutation in early mouse B cells are mediated by B cell and Toll-like receptors. Immunity 27:64–75 223. Ueda Y, Liao D, Yang K, Patel A, Kelsoe G. 2007. T-independent activation-induced cytidine deaminase expression, class-switch recombination, and antibody production by immature/transitional 1 B cells. J. Immunol. 178:3593–601

292

Stavnezer

·

Guikema

·

Schrader

AR338-FM

ARI

12 January 2008

18:11

Annual Review of Immunology

Annu. Rev. Immunol. 2008.26:261-292. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

Contents

Volume 26, 2008

Frontispiece K. Frank Austen p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p x Doing What I Like K. Frank Austen p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p1 Protein Tyrosine Phosphatases in Autoimmunity Torkel Vang, Ana V. Miletic, Yutaka Arimura, Lutz Tautz, Robert C. Rickert, and Tomas Mustelin p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p 29 Interleukin-21: Basic Biology and Implications for Cancer and Autoimmunity Rosanne Spolski and Warren J. Leonard p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p 57 Forward Genetic Dissection of Immunity to Infection in the Mouse S.M. Vidal, D. Malo, J.-F. Marquis, and P. Gros p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p 81 Regulation and Functions of Blimp-1 in T and B Lymphocytes Gislâine Martins and Kathryn Calame p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p133 Evolutionarily Conserved Amino Acids That Control TCR-MHC Interaction Philippa Marrack, James P. Scott-Browne, Shaodong Dai, Laurent Gapin, and John W. Kappler p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p171 T Cell Trafﬁcking in Allergic Asthma: The Ins and Outs Benjamin D. Medoff, Seddon Y. Thomas, and Andrew D. Luster p p p p p p p p p p p p p p p p p p p p p205 The Actin Cytoskeleton in T Cell Activation Janis K. Burkhardt, Esteban Carrizosa, and Meredith H. Shaffer p p p p p p p p p p p p p p p p p p p p233 Mechanism and Regulation of Class Switch Recombination Janet Stavnezer, Jeroen E.J. Guikema, and Carol E. Schrader p p p p p p p p p p p p p p p p p p p p p p p261 Migration of Dendritic Cell Subsets and their Precursors Gwendalyn J. Randolph, Jordi Ochando, and Santiago Partida-Sánchez p p p p p p p p p p p p p293

v

AR338-FM

ARI

12 January 2008

18:11

The APOBEC3 Cytidine Deaminases: An Innate Defensive Network Opposing Exogenous Retroviruses and Endogenous Retroelements Ya-Lin Chiu and Warner C. Greene p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p317 Thymus Organogenesis Hans-Reimer Rodewald p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p355 Death by a Thousand Cuts: Granzyme Pathways of Programmed Cell Death Dipanjan Chowdhury and Judy Lieberman p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p389 Annu. Rev. Immunol. 2008.26:261-292. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

Monocyte-Mediated Defense Against Microbial Pathogens Natalya V. Serbina, Ting Jia, Tobias M. Hohl, and Eric G. Pamer p p p p p p p p p p p p p p p p p p p421 The Biology of Interleukin-2 Thomas R. Malek p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p453 The Biochemistry of Somatic Hypermutation Jonathan U. Peled, Fei Li Kuang, Maria D. Iglesias-Ussel, Sergio Roa, Susan L. Kalis, Myron F. Goodman, and Matthew D. Scharff p p p p p p p p p p p p p p p p p p p p p481 Anti-Inﬂammatory Actions of Intravenous Immunoglobulin Falk Nimmerjahn and Jeffrey V. Ravetch p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p513 The IRF Family Transcription Factors in Immunity and Oncogenesis Tomohiko Tamura, Hideyuki Yanai, David Savitsky, and Tadatsugu Taniguchi p p p p p535 Choreography of Cell Motility and Interaction Dynamics Imaged by Two-Photon Microscopy in Lymphoid Organs Michael D. Cahalan and Ian Parker p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p585 Development of Secondary Lymphoid Organs Troy D. Randall, Damian M. Carragher, and Javier Rangel-Moreno p p p p p p p p p p p p p p p p627 Immunity to Citrullinated Proteins in Rheumatoid Arthritis Lars Klareskog, Johan Rönnelid, Karin Lundberg, Leonid Padyukov, and Lars Alfredsson p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p651 PD-1 and Its Ligands in Tolerance and Immunity Mary E. Keir, Manish J. Butte, Gordon J. Freeman, and Arlene H. Sharpe p p p p p p p p677 The Master Switch: The Role of Mast Cells in Autoimmunity and Tolerance Blayne A. Sayed, Alison Christy, Mary R. Quirion, and Melissa A. Brown p p p p p p p p p p705 T Follicular Helper (TFH ) Cells in Normal and Dysregulated Immune Responses Cecile King, Stuart G. Tangye, and Charles R. Mackay p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p741

vi

Contents

ANRV338-IY26-10

ARI

25 March 2008

22:6

Annu. Rev. Immunol. 2008.26:293-316. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

Migration of Dendritic Cell Subsets and their Precursors Gwendalyn J. Randolph,1 Jordi Ochando,2 and Santiago Partida-S´anchez3 1

Department of Gene and Cell Medicine, Immunology Institute, Mount Sinai School of Medicine, New York, New York 10029; email: [email protected]

2

Unidad de Immunolog´ıa de Trasplantes, Centro Nacional de Microbiologia, Instituto de Salud Carlos III, 28220 Madrid, Spain

3

Department of Pediatrics, The Research Institute at Nationwide Children’s Hospital and Ohio State University College of Medicine, Columbus, Ohio 43205

Annu. Rev. Immunol. 2008. 26:293–316

Key Words

First published online as a Review in Advance on November 28, 2007

chemotaxis, lymphatic vessel, postcapillary venule, lymph node

The Annual Review of Immunology is online at immunol.annualreviews.org This article’s doi: 10.1146/annurev.immunol.26.021607.090254 c 2008 by Annual Reviews. Copyright All rights reserved 0732-0582/08/0423-0293$20.00

Abstract The ability of dendritic cells (DCs) to initiate and orchestrate immune responses is a consequence of their localization within tissues and their specialized capacity for mobilization. The migration of a given DC subset is typiﬁed by a restricted capacity for recirculation, contrasting markedly with T cells. Routes of DC migration into lymph nodes differ notably for distinct DC subsets. Here, we compare the distinct migratory patterns of plasmacytoid DCs (pDCs), CD8α+ DCs, Langerhans cells, and conventional myeloid DCs and discuss how the highly regulated patterns of DC migration in vivo may affect their roles in immunity. Finally, to gain a more molecular appreciation of the specialized migratory properties of DCs, we review the signaling cascades that govern the process of DC migration.

293

ANRV338-IY26-10

ARI

25 March 2008

22:6

INTRODUCTION

Annu. Rev. Immunol. 2008.26:293-316. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

Dendritic cells (DCs) are highly efﬁcient antigen-presenting cells that are central to the induction and regulation of most adaptive immune responses. Their specialized capacities for acquiring, processing, retaining, and ﬁnally presenting peptides on major histocompatibility complex (MHC) molecules are critical properties that account in part for their superior role in antigen presentation (1). Unlike other antigen-presenting cells, DCs are specialized for homing efﬁciently to the T cell zones of lymphoid organs for optimal interactions with T lymphocytes. Their migratory capacity distinguishes them from macrophages. For example, alveolar macrophages outnumber DCs by 100-fold in the airways, yet DCs that migrate from the airways to lung-draining lymph nodes vastly outnumber macrophages that migrate through lymph (2). The distinct migratory properties that lead to DCs being present where macrophages clearly are not found underlie a critical difference in the distinct immune-priming capacity of these two cell types. For example, even in instances when macrophages and DCs bear viral antigens for presentation, productive presentation to CD8+ T cells is limited to DCs, seemingly in part because macrophages are not appropriately localized (3). Many DCs in lymph nodes mobilize, with antigen in tow, from peripheral tissues that drain to downstream lymph nodes via a network of lymphatic vessels (4), though some antigens may travel to the lymph node freely through lymph and then gain access to DCs therein. Molecules smaller than ≈70 kDa that travel within lymph are ﬁltered from the subcapsular sinus into conduits that limit, but do not prevent, access of lymph node DCs to these antigens (5–7). Thus, some DCs may pick up antigens directly in lymph nodes. Regardless of whether DCs pick up antigen before or after entering lymphoid organs, the pathways and mechanisms that govern how DCs migrate to lymphoid and nonlym-

294

Randolph

·

Ochando

·

Partida-S´anchez

phoid tissues ﬁgure importantly in immune responses. Thus, we discuss herein how different subpopulations of DCs get to where they are going and how the migratory routes that they take affect their role in immune responses. In many instances, molecular details behind the routes of trafﬁcking we discuss are unknown. After discussing DC migratory behavior in the context of DC subtypes and the anatomy of trafﬁcking at the level of the whole organism, we take a step back and view the DC more generically, but with more molecular detail: We consider the signaling cascades that occur during DC mobilization, as these signals unite many DC subtypes around the potent capacity for migration in general.

DENDRITIC CELL MIGRATION AND LYMPHOID ORGANS: TRAFFICKING FROM SKIN TO LYMPH NODES AS A PARADIGM Given that the genesis of immune responses occurs largely in secondary lymphoid organs, the spleen and lymph nodes, the ﬁrst consideration with regard to DC trafﬁcking is to ask how DCs seed these organs. The spleen is one of the most widely studied sources of DCs in mice, but the mechanisms by which DC precursors access the spleen have not been explored in detail. The anatomic properties of the spleen preclude a role for lymphatics as a means of DC delivery (8). Instead, DC precursors, continuously replenished from blood precursors (9), necessarily arrive to the spleen by a hematogenous route and likely initially gain access to the marginal zone as they develop into “conventional” populations of immature DCs: CD8α− and CD8α+ DC subpopulations (10). DCs do not arise from monocytes in resting spleen, but instead derive from other blood precursors that are difﬁcult to detect in the circulation owing to low frequency. Consequently, entry of DC precursors into spleen has not been characterized in detail, but there is evidence that they largely reside as immature DCs in the marginal zone.

ANRV338-IY26-10

ARI

25 March 2008

22:6

Annu. Rev. Immunol. 2008.26:293-316. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

During maturation/terminal activation, DCs mobilize from the marginal zone to the T cell zone of the splenic white pulp, as they upregulate CCR7 and become responsive to CCR7 ligands CCL19 and CCL21 therein (11–13). In the absence of these signals, DCs are found scattered in the spleen in regions outside of the white pulp or in the marginal zone (12, 13).

Dendritic Cells in Lymph Nodes: Arrival by Afferent Lymphatics As in the spleen, the subsets of DCs in lymph nodes also include CD8α− and CD8α+ DCs. CD8α− DCs in lymph nodes are not absolute counterparts to splenic CD8α− DCs, in part because lymph node CD8α− DCs include DCs that travel through afferent lymph from upstream peripheral organs. CD8α− DCs in spleen and lymph nodes have different rates of turnover (14). At least some CD8α− DCs within peripheral organs can arise from monocytes (15), whereas splenic DCs cannot (15, 16); thus, some DCs in lymph nodes, but not spleen, are expected to be monocyte derived. The classical view regarding how lymph nodes are populated with DCs suggests that they emigrate there from tissues through afferent lymph constitutively (4). Lymph output of DCs in the steady state is substantial and is further augmented during inﬂammatory conditions (17, 18). The potent effects of inﬂammation in inducing DC migration are related to the fact that inﬂammatory cues will trigger maturation of DCs and concomitant upregulation of CCR7, the chemokine receptor centrally required for DC trafﬁcking to lymph nodes (19, 20). The functional advantage of trafﬁcking through afferent lymph is that it permits DCs to acquire and process antigen within peripheral organs; some antigen may be cell associated and unable to travel freely through lymph to reach the T cell zone of lymph nodes for optimal interactions with T cells.

Lymph Node–Homing Langerhans Cells: Seemingly Slower and Fewer than Expected Langerhans cells, the DCs present within epidermis, have for many years served as a paradigm for the general study of DC biology (21). Yet, as we have learned over the past few years, many aspects of their life cycle do not comply with the paradigmatic view previously developed. First, they are not continuously replenished by migratory blood precursors as anticipated, but rather renew through local proliferation under homeostatic conditions (22). Furthermore, older, seemingly established models regarding the mobilization of DCs from the epidermis to lymph nodes in response to activating stimuli are not entirely accurate, as described below. A popular assay to study DC migration involves the epicutaneous application of ﬂuorescent contact sensitizers (23) that were once widely thought primarily to label Langerhans cells within the epidermis. However, two recent developments allowed the contribution of Langerhans cells to contact sensitization and the overall migratory DC population after epicutaneous ﬂuorochrome application to be directly and deﬁnitively assessed: (a) the identiﬁcation of the Langerhans cell–restricted (but not entirely speciﬁc) marker Langerin (24) and (b) the generation of transgenic mice in which the Langerin promoter drives GFP expression (25), such that Langerhans cells are largely distinguished from other sources of DCs. The astounding surprise resulting from the application of these new tools was that peak arrival of Langerhans cells in the lymph node is slow (Figure 1), reaching a maximum three to four days after application of sensitizer (14, 25) when immune responses are already well under way. The vast majority of contact antigen–bearing DCs are Langerin− , and they arrive within the lymph node abundantly during the ﬁrst two days after sensitization. The late entry of Langerhans cells to the lymph node, along with additional recent evidence that Langerhans cells may not

www.annualreviews.org • Migration of Dendritic Cell Subsets

295

ANRV338-IY26-10

ARI

25 March 2008

22:6

“dDC” Day 1 LC Day 3 pDC

?

CD8+ DC

Annu. Rev. Immunol. 2008.26:293-316. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

Afferent lymphatic

Rare entry into efferent lymph

Venule (HEV)

Rare return to blood Venule in nonlymphoid organ

pDC

CD8+ DC

?

Figure 1 Anatomical routes of dendritic cell (DC) trafﬁcking. Many DCs that seed peripheral organs enter lymph nodes through afferent lymph. In skin, apparent dermal DCs migrate to lymph nodes much faster than epidermal Langerhans cells after contact sensitization. These different types of DCs emigrate to distinct areas of the lymph node. Only a few DCs enter the blood either through reentry into venules found within peripheral tissues or through escape into efferent lymph. CD8α+ DCs are often referred to as lymph node–resident DCs, and they are believed to enter the lymph node through high endothelial venules (HEVs), rather than afferent lymphatics. However, their true trafﬁcking patterns remain to be determined. By contrast, plasmacytoid DCs (pDCs) are known to enter inﬂamed lymph nodes through HEVs; unlike other DCs, they appear incapable of mobilizing from peripheral organs into afferent lymph. 296

Randolph

·

Ochando

·

Partida-S´anchez

Annu. Rev. Immunol. 2008.26:293-316. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-10

ARI

25 March 2008

22:6

be essential for immune priming to at least some antigens that enter skin (25–27), raises the possibility that Langerhans cells in particular fulﬁll an immunoregulatory role upon their tardy arrival to the lymph node. This revised concept raises many new questions in the ﬁeld. From the perspective of migration, it will be important to determine whether Langerhans cells are sometimes more rapidly and robustly mobilized to lymph nodes than observed thus far in response to contact sensitizers. Studies using TNF-α, rather than contact sensitizers, should be useful to address this question. Within 1 h, local, exogenous TNF-α dramatically reduces the density of Langerhans cells from the epidermis, presumably as a result of robust migration to lymph nodes (28, 29), whereas a far more modest reduction in Langerhans cell density within epidermis is seen one day after contact sensitization (30). The rapid and robust mobilization of Langerhans cells induced by exogenous TNF-α might lead to a correspondingly rapid and robust accumulation of Langerhans cells in the T cell zone of lymph nodes. If so, then it would be important to determine if Langerhans cells participate more centrally in immune priming under conditions where they are more efﬁciently mobilized, as compared with their apparently dispensable role in contact sensitivity.

Dermal Dendritic Cells Take Center Stage The failure of Langerhans cells to account for the migratory skin DCs after contact sensitization has turned renewed attention to dermal DCs (25), because the ready explanation for the origin of the Langerin− migratory DC population was that these were dermal DCs. However, it remains to be determined how many of the DCs mobilized by application of contact sensitizer are dermalresident DCs. Hypothetically, the migratory DC population could also include blood DC precursors like monocytes that enter the skin, acquire labeled antigen/sensitizer as they ma-

ture, and then rapidly mobilize to the lymph node.

Distinct Localization of Dendritic Cell Subtypes Within Lymph Nodes Upon arrival of so-called dermal DCs and Langerhans cells to the lymph node through lymphatics, the two populations assume distinctive positions within the lymph node. At all times examined, Langerin+ DCs mobilized to the deep paracortex of the T cell zone, but dermal DCs remained nearer B cell follicles (25). This distinct localization likely permits these different DC populations to carry out nonoverlapping roles in immune responses. The molecular events that account for the differing distribution of DC subtypes within the lymph nodes are unknown. One regulatory event affecting DC localization may relate to how strongly particular DCs bind to conduits in the lymph node. Compared with more mature DCs, immature DCs are anticipated to have a stronger capacity to bind to conduits (6). Thus, the phenotype and relative maturation status of a given DC type upon entry into the lymph node may dictate its positioning therein.

HEMATOGENOUS ENTRY INTO LYMPH NODES Although accumulation of DCs in lymph nodes by way of afferent lymphatics is the most well-established route of entry, the presence of DCs in lymph nodes does not depend entirely on input of DCs from afferent lymph. Some DCs or their DC precursors can enter lymph nodes through the same hematogenous route that naive lymphocytes use to access lymph nodes: passage across the specialized high endothelial venules (HEVs) within lymph nodes. DCs thought to use this route into the lymph node include CD8α+ DCs or their precursors (14), plasmacytoid DCs (pDCs) (31, 32), and CCR2hi monocytes (33) (Figure 1). For example, some monocytes that enter through the HEV during the www.annualreviews.org • Migration of Dendritic Cell Subsets

297

ANRV338-IY26-10

ARI

25 March 2008

22:6

course of Leishmania infection may develop into DCs within the lymph node, although routes of trafﬁcking for these monocytes that later became DCs were not directly explored (34).

CD8α+ DCs: From Blood to Lymph Node

Annu. Rev. Immunol. 2008.26:293-316. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

The idea that CD8α+ DCs enter lymph nodes through the blood, by crossing HEVs, rather than through afferent lymph is widely circulated. The concept bears substantial consequences on the events that initiate immune responses. CD8α+ DCs possess superior capacity for cross-presentation of antigen to CD8+ T cells, but if these DCs do not pick up antigens in peripheral organs to transport them through lymph, then their access to antigen for cross-priming may depend on antigen transfer from other DCs that do trafﬁc through lymph (35, 36). Consequently, some DCs, such as monocyte-derived DCs that mediate cross-presentation (37), may mainly function to deliver, but not present, antigen to lymph node T cells, at least in the context of certain infections or conditions. We now review the evidence that CD8α+ DCs enter lymph nodes only through a blood route, requiring passage across HEVs. Organs that feed lymph nodes through lymphatic drainage do not contain DCs with a CD8α+ phenotype. When CD8α+ DCs are adoptively transferred into skin, they do not migrate to downstream LNs via afferent lymphatics (38), in contrast to their CD8α− counterparts. Moreover, the rate of labeling with bromo-deoxyuridine is observed to be more rapid in CD8α+ DCs from skin-draining lymph nodes than the rate in dermal and epidermal DCs that accumulate in the same lymph nodes, suggesting that CD8α+ DCs probably did not arise from these skin-derived populations (14). In addition, CD8α+ DCs in lymph nodes never seem to acquire tracers like epicutaneously applied FITC that mark other DCs that originated within peripheral organs (35, 36), but there is precedence for 298

Randolph

·

Ochando

·

Partida-S´anchez

the possibility that the tracers tested may not be accessible to all DCs within a given peripheral organ (39). Finally, researchers have argued that the population of CD8α+ DCs in the spleen must by nature of the organ come from a blood route, so this is likely true of the lymph node CD8α+ DCs as well (21). However, entry of DCs into the spleen from the blood is not regulated by passage across an HEV (8), so there is little basis for suggesting that the pathways of entry into the two lymphoid organs would be similar. Attempts to demonstrate directly that CD8α+ DCs traverse HEV to enter lymph nodes have so far failed. Speciﬁcally, Reinhardt and colleagues created knockin mice that expressed eYFP from the p40 IL-12/23 subunit locus. CD8α+ DCs robustly produce IL-12 upon activation, so eYFP+ CD8α+ DCs were readily detected in this model (40). Following lipopolysaccharide injection or Leishmania monocytogenes infection, the number of eYFP+ CD8α+ DCs in lymph nodes was greatly elevated. Migration seemed required to elevate the number of CD8α+ DCs in lymph nodes because their increase was blocked with pertussis toxin. However, the increased number of CD8α+ DCs was surprisingly unaffected by neutralizing mAb to CD62L (40), a selectin typically required for leukocyte passage across HEV. Thus, these data failed to support a model in which CD8α+ DCs enter the lymph node via the bloodstream/HEV route, at least during inﬂammation. Therefore, at present, the concept that CD8α+ DCs enter lymph nodes only through a blood route, rather than through lymph, is supported only by indirect evidence, as attempts to provide direct evidence have not succeeded. Without this pattern of trafﬁcking established, some of the strength behind the idea that CD8α+ DCs must acquire antigen through transfer from DCs that migrated through lymph dissipates because the CD8α+ DCs may be among the lymph-migrating DC population. Of course, antigen transfer can also take place between two DCs that emigrate into the lymph node

ANRV338-IY26-10

ARI

25 March 2008

22:6

from lymphatics. Identiﬁcation of the elusive circulating precursor for CD8α+ lymph node DCs would permit a direct analysis of the migratory routes and mechanisms by which this population of DCs seeds lymph nodes.

Annu. Rev. Immunol. 2008.26:293-316. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

Plasmacytoid Dendritic Cells: Definitive Use of a Hematogenous Route to the Lymph Node In contrast to CD8α+ DCs, pDCs have been experimentally established to have the capacity to enter lymph nodes through HEV (Figure 1). In humans, markers for pDCs include BDCA-2, BDCA-4, and IL-3 receptor (41, 42). pDCs, in contrast to myeloid DCs and monocytes in humans, lack expression of CD11c. In mice, pDCs are identiﬁed as CD11clo cells that coexpress B220, Gr-1, and 120G8 (42, 43) and selectively express siglec-H (44, 45). Functionally, in both species, they are well known as principal producers of type I interferon and hence are often alternatively called interferon-producing cells (IPCs). Soon after the discovery of this cell type, Cella and colleagues reported that IPCs accumulated in human inﬂamed lymph nodes just beneath HEVs, suggesting that they may enter lymph nodes through this route (31). Formal demonstration of this trafﬁcking pattern was carried out in mouse models by intravital microscopy (32). Noninﬂamed lymph nodes support adhesion but not transmigration of pDCs, whereas inﬂamed lymph nodes permit robust emigration of pDCs across the HEV in a manner that utilizes L-selectin (CD62L) and E-selectin (CD62E) during attachment and rolling, and involves β1 and β2 integrins for ﬁrm attachment to the endothelium (32). Accordingly, pDCs are reduced in lymph nodes of CD62L-deﬁcient mice (46). Contrary to expectations that CXCR3 would be a requisite chemokine receptor for pDC migration across HEVs (31), CCR5 but not CXCR3 was found to have a critical role (32).

In humans, chemokine-like receptor 1 (CMKLR1), also called ChemR23, is expressed by pDCs and appears to mediate their recruitment across HEVs (47, 48), which facilitate recruitment by displaying chemerin, the ligand for this receptor. In mice, CMKLR1 is not expressed by pDCs and may instead participate in macrophage recruitment (48).

MYELOID AND PLASMACYTOID DENDRITIC CELL RECRUITMENT AND INTERPLAY IN PERIPHERAL ORGANS Myeloid Blood Dendritic Cells and Monocytes As with lymphoid organs, the seeding of peripheral organs with DCs is a topic of immunological relevance because DCs in peripheral organs are the ﬁrst to interact with most pathogens. However, it is not possible to discuss some DC precursors or subsets in depth with regard to trafﬁcking or function because so little is known about them. In particular, CD14− BDCA-1+ /CD1c+ and CD14− BDCA-3+ DCs (41), which may be very relevant human DC precursors in the blood, have no established destinations in vivo. Some studies have operated under the assumption that BDCA-1+ DCs within human tissues arise from BDCA-1+ DCs in blood, but this point has not been ﬁrmly established and seems unlikely given that BDCA1+ myeloid DCs in blood are CD14− , whereas some BDCA-1+ cells in lung are CD14+ (49). Moreover, the murine counterparts to these cells are also unknown. Indeed, among potential DC precursors, only pDCs and monocytes have been studied in sufﬁcient detail for researchers to begin to develop a picture of their full life cycle. Monocytes can serve as precursors for DCs in the periphery during various conditions of inﬂammation (10) or in the absence of inﬂammation (15). Monocytes may thus serve as www.annualreviews.org • Migration of Dendritic Cell Subsets

299

ANRV338-IY26-10

ARI

25 March 2008

22:6

precursors for many of the myeloid peripheral tissue DCs that ultimately emigrate through afferent lymph, although they play a small role in becoming splenic DCs (15). The signals and molecular events involved in recruitment of monocytes into tissues have been recently reviewed in detail (50).

Plasmacytoid Dendritic Cells in Peripheral Organs Annu. Rev. Immunol. 2008.26:293-316. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

Compared with the difﬁculty of discerning whether myeloid DCs in peripheral organs are derived from monocytes or myeloid blood DCs or are otherwise macrophages, pDCs are easy to trace by staining for their particular signature markers within tissues. pDCs can apparently enter normal organs at very low levels in humans (49, 51, 52) and mice (53, 54). However, they are far more numerous in diseased or inﬂamed tissues. For example, in humans and mice, they have been described in skin inﬂammatory diseases (47, 55), in allergic diseases of the airway (52), and in mouse allografts (56). pDCs also home to the small intestine of mice in the steady state, with increased recruitment during inﬂammation, by a mechanism that relies on CCR9 (54). By contrast, CCR9 is not required for pDC entry into lymph nodes or other organs. Thus, there may be speciﬁc requirements for pDC migration into peripheral organs that are distinct from mechanisms used by pDCs to enter lymphoid organs. However, some receptors may be used by pDCs to trafﬁc to multiple tissues. For example, CKLR1/ChemR23 appears to mediate human pDC migration into lymph nodes and inﬂamed skin (47).

Exit of Plasmacytoid Dendritic Cells from Peripheral Organs The classical paradigm that activated DCs become induced to enter lymphatic vessels from tissues (Figure 1) prompts the possibility that pDCs within tissues will enter lymph nodes through not only HEVs (as discussed 300

Randolph

·

Ochando

·

Partida-S´anchez

above), but also afferent lymphatics. Surprisingly, this predicted pattern of trafﬁcking has not been upheld experimentally. On the contrary, afferent lymph is devoid of pDCs under homeostatic and inﬂammatory conditions (57). Researchers drew this conclusion in a rat model (57) using a well-established technique to sample pseudoafferent lymph directly (17). The possibility that pDCs do not enter afferent lymph vessels has pivotal implications for the role of tissue pDCs in presenting antigen that they may acquire within tissues. Without the capacity to home to a T cell–rich environment, pDCs that localize to peripheral tissues may not be there primarily to acquire antigen for the purposes of antigen presentation. They may instead mainly support the antigen-presentation function of myeloid DCs. For instance, the activation of pDCs within the intestine in turn enhances mobilization of myeloid DCs during intestinal inﬂammation (47). On the other hand, limited lymphatic access may not affect the capacity of pDCs to bring tissue-derived antigens to lymph nodes. Following allograft transplantation, pDCs acquire MHC II antigen-containing peptide derived from the allograft, and these pDCs are found in the blood and accumulate in lymph nodes by a CD62L-dependent mechanism (56). Putting these data together with the observations described above generates an unexpected picture in which pDCs have access to lymph nodes through only a hematogenous route, in striking contrast to the trafﬁcking patterns of conventional DCs.

CAN MATURE DENDRITIC CELLS RETURN TO THE BLOOD AND ENTER OTHER ORGANS? The possibility that pDCs carry antigen from an allograft or spleen to lymph nodes via a hematogenous route raises the broader issue of whether DCs derived from a peripheral organ or lymph node can generally mobilize back into blood and ultimately home

Annu. Rev. Immunol. 2008.26:293-316. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-10

ARI

25 March 2008

22:6

to another organ. Mechanisms to reenter the bloodstream would include either (a) direct migration across vascular endothelium in the ablumenal-to-lumenal direction, or (b) failure of DCs to be trapped in lymph nodes such that they emerge into efferent lymph that accesses the bloodstream through the thoracic duct. Either route of entry into the bloodstream could have a major impact on immunity and inﬂammation. For example, such trafﬁcking might facilitate the spread of infectious microbes from tissue to tissue, carried by DCs serving as Trojan horses. Indirect evidence for this possibility exists (58, 59). In addition, presentation of antigen at distal sites may become possible. A fraction of DCs is known to enter efferent lymph at a low frequency (4, 60, 61). Until recently, researchers had only indirect evidence for the possibility that immune responses are mediated by DCs that pass through the lymph node into efferent lymph or return to blood directly (4). In addition to gaining access to the bloodstream, DCs would need to express the right subset of molecules to home into other organs, but mature DCs have downregulated many chemokine receptors and adhesion molecules that are generally used for leukocyte homing into other organs. In mice whose lymphotoxin β receptor pathway has been manipulated so that the mice lack skin-draining lymph nodes, but possess mesenteric lymph nodes (62), endogenous skin DCs are not ﬁltered by skindraining lymph nodes and therefore enter the efferent lymph and blood unimpeded. After accessing blood, these DCs fail to accumulate in the spleen but instead enter in mesenteric lymph nodes (62), implying that, against expectations, homing mechanisms are in place for matured skin DCs to enter mesenteric lymph nodes. The molecular nature of this homing pathway is unknown. Other recent publications, discussed below, have elaborated on whether and with what consequences DCs leave one tissue, traverse blood, and enter another tissue to modulate immunity. Bone marrow–derived

DCs injected into the rear footpad of mice migrate exclusively to popliteal lymph nodes as expected. However, coinjecting these mice with vitamin D3 (63) appears to cause the transferred DCs to home to mesenteric lymph node and Peyer’s patches (63), allowing induction of mucosal immunity. Homing of adoptively transferred splenic DCs from the footpad to the bone marrow, where central memory T cells expand, has also been described (60). This migration occurred at a very low frequency. Nonetheless, on the basis of the frequency of labeled DCs found in the bone marrow, researchers developed the argument that the migration most likely involved direct reentry into the bloodstream by the transferred DCs rather than passage through efferent lymph (60). Both of these studies used adoptive transfer models and did not probe endogenous DCs. When large numbers of endogenous skin DCs were labeled by epicutaneous administration of a ﬂuorescent sensitizer, labeled endogenous DCs were not recovered in the bone marrow (61), suggesting that the bone marrow is an extremely minor destination for endogenous DCs, at least those from skin.

Dendritic Cell Migration to the Thymus If antigen-bearing DCs that return to blood subsequently emigrate into the thymus, they may be a source of self-antigen for the induction of central tolerance (64). This issue assumes that regulation by autoimmune regulator (AIRE) of the expression of tissuerestricted antigens by thymic epithelium (65) leaves gaps in the repertoire of self-antigens that are presented to thymocytes during thymic selection and that antigen-bearing DCs that enter from the periphery might be able to present antigen to ﬁll in those gaps (64). When millions of labeled crude splenic cells, mainly CD11c+ cells, were injected directly into the bloodstream as a model designed to mimic DC reentry into blood, bypassing the tremendous hurdle of www.annualreviews.org • Migration of Dendritic Cell Subsets

301

ARI

25 March 2008

22:6

leaving a peripheral organ, a few labeled DCs entered the thymus by a mechanism that required P-selectin and α4β1 integrin (66). Studies in parabiotic mice conﬁrmed that blood DCs or their precursors can enter the thymus (66). However, neither of these approaches addresses the most interesting and relevant question of whether DCs that might have picked up antigen in one tissue reenter the blood and home to thymus for antigen presentation. Further experiments in the same study were designed to probe whether endogenous, FITC antigen-bearing DCs can leave a tissue like skin, gain access to blood, and then home to the thymus. In these experiments, mice were treated epicutaneously with FITC. Subsequently, FITC+ CD11c+ DCs were found in the thymus, although at a frequency so low that fewer than 10 scattered events said to correspond with the labeled cells were typically detected by FACS (66). Moreover, the protocol of delivering FITC as antigen to the skin was unusual; the skin was tape-stripped prior to FITC application to remove the stratum corneum that largely absorbs most of the applied FITC (30), and a very large volume of FITC was applied. The investigators in the study also found FITC+ DCs in the spleen using this protocol, in contrast to others who have used epicutaneous FITC via a more standard protocol (61, 62). As a result, the use of FITC painting in conjunction with removal of the stratum corneum may be ﬂawed, likely because it leads to systemic spread of the FITC label that may not require any DC transport from the skin. In any case, given the probability that only a very small number of DCs mobilize from tissues to thymus (66) and that only a very small fraction of those DCs bears significant self-antigens from tissues that may not be expressed in the thymus (antigens acquired by DC engulfment of apoptotic parenchymal cells), DC trafﬁcking to the thymus from other tissues, even if it occurs, is most likely irrelevant for presentation of self-antigens and clonal deletion of lymphocytes.

Annu. Rev. Immunol. 2008.26:293-316. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-10

302

Randolph

·

Ochando

·

Partida-S´anchez

Anatomic Restrictions that May Affect Migration Routes from Tissue to Blood Versus Lymph In the context of transplantation, pDCs, conventional DCs, and cells closely resembling DCs can be found to leave tissues and reenter the bloodstream (56, 67–70). These observations may reveal a pattern of trafﬁcking that is always ongoing but difﬁcult to observe. Alternatively, the transplantation may have an impact on DC trafﬁcking. In particular, because lymphatic vessels sometimes reanastomose slowly after transplantation, migratory cells may instead mobilize via atypical or normally less-favored routes. Indeed, accumulation of DCs or their precursors in tissues that for any reason have restricted access to lymphatics may provoke nonstandard routes of emigration. For example, priming of immune responses by DCs within lymph nodes is redirected to the spleen when emigration to lymph nodes is hindered by genetic deﬁciency in CCR7 ligands that normally mediate DC mobilization to lymph nodes (71). An example of naturally restricted access to lymphatics may be found in atherosclerosis. Early in this disease, monocyte-derived cells that can develop into macrophages or DCs accumulate beneath arterial endothelium in a position lumenal to the internal elastic lamina (72). Mononuclear phagocytes with a “veiled” morphological appearance akin to DCs have been observed to return across arterial endothelium in the ablumenal-to-lumenal direction (73), allowing their escape from atherosclerotic plaques by reentry into the bloodstream. Within atherosclerotic lesions, monocyte-derived cells that differentiate into would-be lymph-homing DCs are expected to have limited capacity to mobilize toward the lymphatic vessels, which are located in the periadventitial space of the artery, because they are separated from those lymphatics by the imposing arterial media lined with smooth muscle cells and elastic laminae. As mentioned, the internal elastic lamina provides a ﬂoor for developing atherosclerotic plaques,

Annu. Rev. Immunol. 2008.26:293-316. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-10

ARI

25 March 2008

22:6

and this lamina acts as a barrier to transport of large molecules. After traversing the arterial endothelium, low-density lipoproteins, for example, travel beneath and laterally along the endothelium rather than passing through the elastic lamina (74). Likewise, the elastic laminae may impede cellular passage and possibly even perceptions of chemotactic signals that would support movement toward the periadventitia. Consistent with the possibility that cellular passage into and across the media is very limited are observations that herpes virus–infected smooth muscle cells within elastic arteries are inaccessible to clearance by phagocytes and lymphocytes (75). In the absence of an open pathway to lymphatics and without a physical barrier between them and the ablumenal surface of the endothelium, “veiled” mononuclear phagocytes that may be akin to DCs from atherosclerotic plaques return to blood (73, 77) using what is likely an alternative, secondary route.

SIGNALING CASCADES THAT GOVERN MIGRATION OF DENDRITIC CELLS Migratory cells use highly conserved mechanisms to sense and respond to small changes in the concentration of chemoattractants in their external milieu (78). Over the past few years, many key intracellular pathways and signaling molecules downstream of chemokine receptors in DCs have begun to be identiﬁed, and some signal transduction models have been proposed (79). Yet a global uniﬁed model encompassing the diversity of chemokine receptors, their complex downstream signaling cascades, and the remarkable heterogeneity of their biological effects is not achievable at this time. Most of the research on signaling during DC migration has been carried out using monocyte- or bone marrow–derived DCs. These DCs differ substantially from some DC subsets described above, but they do provide a valuable tool for researchers to develop a generic model of the proximal signals that govern DC motility and migration.

Before activation, conventional myeloid DCs found in peripheral organs can express CCR1, CCR2, CCR5, CCR6, CXCR1, CXCR2 and CXCR4, with these expression patterns differing somewhat among DC subsets. Upon stimulation by pathogenderived antigens and/or endogenously generated danger-associated signaling molecules, activated DCs acquire a migratory phenotype associated with the upregulation of CCR7 and express receptors linked with DC maturation, including CD40, CD80, CD86, and MHC class II. As mentioned above, the G protein–coupled receptor CCR7 is the dominant mediator of DC mobilization to the T cell compartment of lymphoid organs (19). CCR7 expression alone, however, is not sufﬁcient to confer mobilization to the T cell zone of lymph nodes and spleen; additional DC receptors are required to positively regulate CCR7 function (79).

CCR7-Mediated Migration: A “Multimodule” Model DC signaling through CCR7 initiates and orchestrates a vast repertoire of molecular events that control chemotaxis and several other biological functions in these cells (reviewed in Reference 79). The CCR7 polyfunctional signal transduction apparatus exempliﬁes the complexity of the molecular events initiated upon ligation of most chemokine receptors. Various nonoverlapping signaling modules, rather than a single pathway, appear to regulate distinct DC migratory responses, such as chemotaxis or migratory speed, induced by the chemokine ligands for CCR7, CCL19, and CCL21. Similar to all G protein–coupled receptors, CCR7 interacts with G proteins to transmit intracellular signals. A classical G protein– dependent mechanism involves the use of the alpha (α) subunit and the release of the beta and gamma dimer (βγ) of the heterotrimeric G protein (80, 81) (Figure 2). Four families of α subunits are known: Gαs , Gαq , Gαi , and Gα12 . Each family is composed of several www.annualreviews.org • Migration of Dendritic Cell Subsets

303

ARI

25 March 2008

22:6

Cx

Cx

Cx

CD38

CR PLC β2

α G12 12

GTP

β

PLC

β1,3

α Gi

α Gq

γ

DAG

GDP

β γ

GDP

GDP

Ca2+ channel

NAD

ANRV338-IY26-10

cADPR

IP3

DAG

β γ

GDP

IP3

β γ [Ca2+]i

Pl3Kγ

Annu. Rev. Immunol. 2008.26:293-316. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

Rho Src

p38

Erk1/2

Akt1

IP3R

RyR

Pyk2 PKCβ DAG

JNK

NF-κB ER

Cofilin

Cell activation

Migratory speed

Chemotaxis

Chemotaxis

Figure 2 Various signaling pathway modules regulate distinct DC migratory responses induced by chemokines through CCR7. Upon agonist binding, trimeric G proteins are uncoupled, and a series of signal transduction events ensue that result in cell activation followed by enhanced motility. At least two nonoverlapping independent signaling modules are activated upon CCR7 ligation. One module is initiated by Gα12 activation, resulting in the release of the free βγ subunit, which in turn activates downstream effectors including Rho GTPases, the proline-rich tyrosine kinase 2 (Pyk2) and the actin-binding protein coﬁlin. This module may regulate the basal migratory speed of DCs, but not DC chemotaxis. Conversely, another signaling module engages upon Gαi stimulation, leading to mitogen-activated protein kinase (MAPK) activation, including p38, ERK1/2, and JNK. In addition, free βγ activates phosphatidylinositol 3-kinase (PI3K), protein kinase C (PKC), and Akt-NF-κB pathways, which are important for activation and survival of the cells. Moreover, phospholipase Cβ2 (PLCβ2) breaks down plasma membrane lipids into diacylglycerol (DAG) and the calcium second messenger, inositol trisphosphate (IP3), which in turn induces the intracellular release of calcium ions (Ca2+ ) from IP3-gated stores on the endoplasmic reticulum (ER). This second module may regulate chemotaxis in most cellular systems. A third module appears to be required for CCR7-induced DC chemotaxis, and it would be sparked by sequential Gαi and Gαq activation. The free Gαq or βγ subunit would then activate PLCβ1,3 favoring the generation of IP3 and consequently intracellular Ca2+ release. The ectoenzyme CD38 may function as a coadjuvant of this module by converting NAD+ to cyclic ADP-ribose (cADPR), which may act at ryanodine receptors to expand release of Ca2+ from intracellular stores. This capacitates a calcium channel on the cell membrane, resulting in a sustained inﬂux of extracellular Ca2+ required for DC migration.

members, thereby contributing to diversity in chemokine receptor–mediated signaling (82). Chemotaxis is thought to be regulated primarily through the Gαi subfamily, which contains three subunits, Gαi2 , β, and γ. The activation of Gαi , induced by the binding of GTP 304

Randolph

·

Ochando

·

Partida-S´anchez

to Gαi2 and the release of free βγ, initiates the chemokine receptor signaling cascade (78) (Figure 2). The free βγ subunit subsequently activates downstream effectors such as PI3K which regulate the Akt pathway that plays a pivotal

Annu. Rev. Immunol. 2008.26:293-316. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-10

ARI

25 March 2008

22:6

role in regulating chemotaxis in leukocytes, including DCs (83, 84). However, alternative pathways may also regulate chemotaxis in a PI3K/Akt-independent manner (85–88). Overall, it seems that PI3K/Akt and the transcription factor nuclear factor κB (NFκB) regulate CCR7-dependent DC survival, whereas PI3K/Akt-independent signaling pathways may be preferred, but not required, during chemokine receptor engagement in DCs (87, 88). In this model, the Gαi -proteinderived βγ subunit preferentially triggers signal transduction via mitogen-activated protein kinase (MAPK) family members p38, ERK1/2, and JNK (84, 87, 89), whereas Cdc42 and Rac, but not RhoA GTPases, coordinate actin polarization, cytoskeletal rearrangement, cell polarity, and ultimately motility (84, 87, 89). It is difﬁcult to dissect the true importance of each kinase toward a speciﬁc biological endpoint because MAPKs play important roles in many DC functions, including maturation, migration, cell proliferation, cytokine production, and survival. The literature points to a critical role for MAPKs during the upstream events that lead to DC migration (90–93). Activity of the p38 MAPK regulates IL-12p40 production in macrophages and DCs (94, 95). Homodimers of IL-12p40 facilitate DC migration from the lung to the draining lymph nodes after Mycobacterium tuberculosis infection (96), and IL-12p40 also supports migration of adoptively transferred DCs to draining lymph nodes (40). Phosphorylation of p38 MAPK is required for DC maturation and the synthesis of cytokines (97–100), but DCs are at least partially competent to chemotax when p38 is inhibited (84, 88), suggesting that p38 MAPK in particular may support DC migration through production of cytokines that in turn participate in migration. When p38 MAPK is blocked, another MAPK may take over. Riol-Blanco and colleagues (87) recently proposed an integrated signaling module to regulate chemotaxis in CCR7-stimulated DCs. This pathway is ignited by Gαi -mediated activation of either

p38 or ERK1/2, and this activation is thought to be upstream of JNK. Interestingly, inhibition of all these kinases does not completely blunt CCR7-dependent chemotaxis (87, 88), suggesting that additional unidentiﬁed molecules or signaling pathways may also regulate chemotaxis of DCs. Although the pertussis toxin–sensitive Gαi subunit is known to be the nascent component regulating various independent signaling/functional arms during DC chemotaxis (101, 102), chemokine receptor coupling to other Gα subunit families has not been thoroughly examined. By using Gα subunit– deﬁcient mice, we recently identiﬁed a novel alternative chemokine receptor signaling module that requires Gαi as well as Gαq for the in vitro chemotaxis of bone marrow– derived DCs to the ligands of CXCR4 and CCR7 (103). Gαq -coupled pathways directly activate PLCβ1 and PLCβ3, resulting in the generation of diacylglycerol and the subsequent activation of protein kinase C. This in turn leads to PI3K-dependent inositol trisphosphate production and calcium mobilization (81, 104). Immature or mature DCs from Gαq −/− mice have signiﬁcantly reduced calcium ﬂuxes in response to chemokine receptor stimulation and are unable to migrate to inﬂammatory sites or lymph nodes in vivo (103), indicating that signaling modules dependent on Gαi and Gαq are critical for DC migration. Strikingly, T cells, which also use CCR7 to migrate to CCR7 ligands, did not require Gαq , indicating unexpectedly that distinct signaling pathways are used by DCs and T cells to respond to the same chemokines (103). In addition to the Gαq pathway, another Gαi -independent signaling module via Rho/Pyk2/coﬁlin has been reported (87). Like the Gαq pathway, this signaling module is engaged by a pertussis toxin–insensitive class of G proteins, presumably G12 /G13 . However, unlike the Gαq pathway, this module was dispensable for chemotaxis and instead was found to control DC migratory speed (79, 87, 105) (Figure 2). Further understanding of www.annualreviews.org • Migration of Dendritic Cell Subsets

305

ANRV338-IY26-10

ARI

25 March 2008

22:6

the different signaling networks downstream of chemokine receptors and identiﬁcation of the individual signaling components that regulate each pathway are needed. This knowledge may lead to improved DC vaccination protocols or application in other therapeutic settings where modulation of DC migration may be desirable.

Annu. Rev. Immunol. 2008.26:293-316. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

Signaling Through Cell Surface Enzymes and Nonchemokine Dendritic Cell Receptors A myriad of maturation and nonchemokine chemotactic factors, which can be rapidly produced within inﬂamed or damaged tissue, plays a central role in stimulating recruitment of DCs and preparing them for subsequent mobilization to lymph nodes (106–109). Immature DCs express several chemotactic receptors for nonchemokine agonists (110, 111). Several of these receptors promote DC activation and are upregulated by endogenous maturation signals such as IL-1, TNF-α, and CD40L or exogenous microbial products that activate Toll-like receptors (TLRs) (112– 114). Most of the aforementioned stimuli trigger downstream signaling pathways that activate NF-κB and induce proinﬂammatory gene expression (115, 116). Inﬂammatory and cellular stress–linked signals expand the array of signaling mechanisms that can directly affect DC migration. For example, the activating surface receptor TREM-2, which induces DC maturation by a mechanism independent of NF-κB, critically regulates CCR7-dependent DC chemotaxis (117, 118). TREM-2 associates with DAP12, an ITAM-containing adaptor molecule that also regulates DC migration (119, 120). Intriguingly, TREM-2-mediated upregulation of CCR7 does not correlate with a greater capacity of DCs for chemotaxis, consistent with the notion that CCR7 responses require additional extracellular signals (118). It is not yet understood how the TREM/DAP12 pathway may converge with other intracellular signals downstream of CCR7. Knockdown of 306

Randolph

·

Ochando

·

Partida-S´anchez

the transmembrane adapter protein NTAL, a novel component of the TREM-1/DAP12 pathway, yields signiﬁcantly reduced calcium inﬂux (121), supporting the idea that NTAL may mediate calcium mobilization that is required for DC chemotaxis to a variety of chemokines and nonchemokine stimuli (122– 125). Chemoattractant-triggered DC chemotaxis is thought to be controlled, at least in part, by cADPR and ADPR calciummobilizing metabolites (126, 127) (Figure 2), both catalytic products of the nucleotidemetabolizing ectoenzyme CD38 and the NAD+ substrate. CD38-deﬁcient neutrophils, monocytes, and DCs show impaired calcium and chemotactic responses to a variety of chemokines in vitro and in vivo (128, 129). CD38-derived metabolites have a broad impact on chemokine receptor–mediated signaling in myeloid cells, presumably by inducing calcium ﬂuxes conducted through the cADPR- and ADPR-activated plasma membrane channel TRPM2 (130), a member of the transient receptor potential TRP channel superfamily (131, 132). TRPM2 is a nonselective cation channel widely expressed by leukocytes, including DCs (130, 133, 134). Other DC receptors that induce calcium mobilization may also rely on a CD38-generated calcium second messenger to transmit signals that promote migration. Inﬂammatory signals and bacterial products that induce DC maturation and CCR7 expression often induce upregulation of CD38 (128, 135–137). By contrast, activation of monocytes through TLR2, 4, and 5 induces CD38 downregulation (135), which is possibly linked to the observation that monocyte-derived cells can become impaired in their migration to lymph nodes by bacterial signals (138). TLR signaling triggers a cascade of events in DCs that includes modiﬁed chemokine and cytokine production, altered chemokine receptor expression, and changes in signaling through G protein–coupled receptors (112, 139–141). These changes may often

Annu. Rev. Immunol. 2008.26:293-316. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-10

ARI

25 March 2008

22:6

synergistically support migration of DCs, but crosstalk between TLR-mediated signaling pathways in DCs may sometimes result in antagonistic effects. For example, engagement of TLR3 or TLR4 on monocyte-derived DCs markedly increases expression of regulator of G protein signaling 1 (RGS1) protein (101), which has been well documented as accelerating the intrinsic GTPase activity linked with Gαi subunits. Thus, increased levels of RSG1 inhibit DC migration to lymph nodes (101). How pathogen-derived signals, including but not limited to signals through TLRs, regulate DC migration needs more study. Clearly, some pathogens use mechanisms to arrest DC migration to protect themselves from the generation of potent adaptive immune responses. Schistosomal parasites produce prostaglandin D2 to inhibit DC migration to lymph nodes after an experimental infection through skin (142), and microbial antigens derived from Borrelia garinii, the causative agent of chronic Lyme disease, signiﬁcantly downregulate CD38 and CCR7 expression in DCs, thereby hampering their migratory capacity (143).

Signals that Modulate Migration as Part of a Tissue Damage Response Under conditions of cell stress, inﬂammation, or tissue insult, ordinary metabolites that are otherwise maintained intracellularly may be released to the extracellular milieu. Such molecules may then target receptors present on the surface of DCs to modulate their maturation and/or migration. One cytokine-like molecule released in necrotic tissues or by some cells in response to TLR signals is high mobility group box 1 (HMGB1), which may regulate DC migration (144). Another class of metabolites released in injured tissues includes purine nucleotides, such as NAD, ATP, ADP, ADPR, and AMP (Figure 2). DCs express a variety of purine sensors on their surface; some, like CD38, work as ectoenzymes metabolizing purine nucleotides, whereas others are a class of

plasma membrane receptors ligated by extracellular nucleotides (145, 146). Two main types of purinoreceptors, P2YR and P2XR, have been identiﬁed. P2YRs are a family of G protein–coupled receptors that are abundantly expressed on DCs. Upon activation, they induce generation of inositol trisphosphate, release of calcium, and stimulation of adenylate cyclase via Gαi or Gαq proteins. Selective P2YR agonists (e.g., ATP, ADP, and UTP) are potent chemotactic stimuli for immature, but not mature, DCs (125, 147). P2YR-dependent, downstream signals mobilize calcium and couple to pertussis toxin–sensitive G proteins (125). Thus, purinoreceptors and NAD+ -ases such as CD38 may function in a concerted manner during inﬂammation or tissue damage to regulate DC recruitment and emigration. Given both that these signals may couple with CCR7 to optimize migration of DCs and that regulating the availability of extracellular nucleotides may be feasible pharmacologically, these pathways merit further attention in future research.

SUMMARY AND FUTURE DIRECTIONS As discussed herein, it is clear that trafﬁcking patterns of DCs are highly regulated and differ greatly among different types of DCs (Figure 1). The variation in trafﬁcking patterns sets the stage for the many roles different DC subsets play in immunity. For example, the slow arrival and distinct localization of Langerhans cells to lymph nodes in response to contact sensitizers naturally limits their importance in inducing immunity to sensitizers and suggests that they play a different role in the ensuing immune response than do the earlier arriving DCs. In some cases, the immunologic signiﬁcance behind a particular pattern or restriction in trafﬁcking seems obvious. For example, the retention of most DCs within the lymph node through limited circulation into efferent lymph concentrates antigen within www.annualreviews.org • Migration of Dendritic Cell Subsets

307

ARI

25 March 2008

22:6

the lymph node, thereby likely increasing the relative density of particular peptide-MHC complexes for improved antigen presentation to a cognate population of T cells. Furthermore, the relative sequestration of activated DCs in the lymphatic system, permitting only rare return of mature DCs to blood, may protect the host. Indeed, it has been argued that the passage of highly activated, cytokine-producing and procoagulant-prone macrophages and DCs in the circulation during Ebola virus infection contributes pivotally to the deadly nature of this pathogen (148). However, especially under conditions when DCs fail to access lymphatics appropriately, they can gain at least limited access to blood and go on to mediate immune responses in distal lymphoid organs. The migratory patterns of pDCs are in almost every way different from those of conventional DCs, as we discuss in this review (Figure 1). Any immunological advantage that may be conferred by the fact that pDCs take distinct routes to the lymph node that differ so greatly from the routes of conventional DCs remains unknown. It is unclear, in particular, if there is an underlying immunological advantage in their apparent failure to move from tissues to lymph nodes through lymphatics. Why do they enter lymph nodes primarily through HEVs? Leaving the tissue of transplant immunity aside, entry of pDCs through HEVs when viruses or other antigens enter lymph nodes through afferent lymph seems to put pDCs at a disadvantage in accessing relevant antigen for presen-

Annu. Rev. Immunol. 2008.26:293-316. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-10

tation. Their trafﬁcking pattern seemingly ﬁts best with the concept that in many instances pDCs support antigen presentation mediated by conventional DCs, rather than present themselves. Alternatively, the entry of pDCs into the lymph node through HEVs may set up an important backup system. Upon entry through HEVs, pDCs could acquire viral particles that may have escaped capture by conventional DCs and that may be freely available in lymph ﬂuid. They may then process and present these antigens, such that their participation in presenting viral antigen in the lymph node may be a “second-tier” level of defense and depend on how well conventional DCs and other cells in tissues and the lymphatic system have managed to contain the virus. Obviously, we still have much to learn regarding how DC migration is regulated, why it is regulated the way it is, and what happens when normal migration and trafﬁcking patterns are disrupted. In addition, much work remains to be done to explain how signaling pathways work together to coordinate DC migration. Recent ﬁndings discussed herein indicate that DCs employ distinct signaling cascades to respond to chemokines like CCR7 ligands, raising the possibility that DC migration could be manipulated by means that will not alter T cell migration. Ultimately, the goal is to integrate our understanding of the signals that regulate DC migration and the molecular changes within tissues where DC migration occurs with our knowledge of the overall trafﬁcking patterns of different DC subsets in vivo.

DISCLOSURE STATEMENT The authors are not aware of any biases that might be perceived as affecting the objectivity of this review.

ACKNOWLEDGMENTS We thank Dr. Claudia Jakubzick for critical reading of the manuscript. G.J.R. is supported in part by NIH grants and an Established Investigator Award from the American Heart Associa´ y Ciencia, Spain (reference SAF2007tion, J.O. by a grant from the Ministerio de Educacion 63579), and S.P-S. by CCRI-175404. 308

Randolph

·

Ochando

·

Partida-S´anchez

ANRV338-IY26-10

ARI

25 March 2008

22:6

Annu. Rev. Immunol. 2008.26:293-316. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

LITERATURE CITED 1. Trombetta ES, Mellman I. 2005. Cell biology of antigen processing in vitro and in vivo. Annu. Rev. Immunol. 23:975–1028 2. Jakubzick C, Tacke F, Llodra J, van Rooijen N, Randolph GJ. 2006. Modulation of dendritic cell trafﬁcking to and from the airways. J. Immunol. 176:3578–84 3. Norbury CC, Malide D, Gibbs JS, Bennink JR, Yewdell JW. 2002. Visualizing priming of virus-speciﬁc CD8+ T cells by infected dendritic cells in vivo. Nat. Immunol. 3:265–71 4. Randolph GJ, Angeli V, Swartz MA. 2005. Dendritic-cell trafﬁcking to lymph nodes through lymphatic vessels. Nat. Rev. Immunol. 5:617–28 5. Gretz JE, Anderson AO, Shaw S. 1997. Cords, channels, corridors and conduits: critical architectural elements facilitating cell interactions in the lymph node cortex. Immunol. Rev. 156:11–24 6. Sixt M, Kanazawa N, Selg M, Samson T, Roos G, et al. 2005. The conduit system transports soluble antigens from the afferent lymph to resident dendritic cells in the T cell area of the lymph node. Immunity 22:19–29 7. Itano AA, McSorley SJ, Reinhardt RL, Ehst BD, Ingulli E, et al. 2003. Distinct dendritic cell populations sequentially present antigen to CD4 T cells and stimulate different aspects of cell-mediated immunity. Immunity 19:47–57 8. Mebius RE, Kraal G. 2005. Structure and function of the spleen. Nat. Rev. Immunol. 5:606–16 9. Liu K, Waskow C, Liu X, Yao K, Hoh J, Nussenzweig M. 2007. Origin of dendritic cells in peripheral lymphoid organs of mice. Nat. Immunol. 8:578–83 10. Shortman K, Naik SH. 2007. Steady-state and inﬂammatory dendritic-cell development. Nat. Rev. Immunol. 7:19–30 11. Reis e Sousa C, Hieny S, Scharton-Kersten T, Jankovic D, Charest H, et al. 1997. In vivo microbial stimulation induces rapid CD40 ligand-independent production of interleukin 12 by dendritic cells and their redistribution to T cell areas. J. Exp. Med. 186:1819–29 12. Gunn MD, Kyuwa S, Tam C, Kakiuchi T, Matsuzawa A, et al. 1999. Mice lacking expression of secondary lymphoid organ chemokine have defects in lymphocyte homing and dendritic cell localization. J. Exp. Med. 189:451–60 13. Ato M, Stager S, Engwerda CR, Kaye PM. 2002. Defective CCR7 expression on dendritic cells contributes to the development of visceral leishmaniasis. Nat. Immunol. 3:1185–91 14. Kamath AT, Henri S, Battye F, Tough DF, Shortman K. 2002. Developmental kinetics and lifespan of dendritic cells in mouse lymphoid organs. Blood 100:1734–41 15. Varol C, Landsman L, Fogg DK, Greenshtein L, Gildor B, et al. 2007. Monocytes give rise to mucosal, but not splenic, conventional dendritic cells. J. Exp. Med. 204:171–80 16. Naik SH, Metcalf D, van Nieuwenhuijze A, Wicks I, Wu L, et al. 2006. Intrasplenic steady-state dendritic cell precursors that are distinct from monocytes. Nat. Immunol. 7:663–71 17. Pugh CW, MacPherson GG, Steer HW. 1983. Characterization of nonlymphoid cells derived from rat peripheral lymph. J. Exp. Med. 157:1758–79 18. MacPherson GG, Jenkins CD, Stein MJ, Edwards C. 1995. Endotoxin-mediated dendritic cell release from the intestine: characterization of released dendritic cells and TNF dependence. J. Immunol. 154:1317–22 ¨ ¨ 19. Forster R, Schubel A, Breitfeld D, Kremmer E, Renner-Muller I, et al. 1999. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 99:23–33 www.annualreviews.org • Migration of Dendritic Cell Subsets

309

ARI

25 March 2008

22:6

20. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. 1999. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401:708–12 21. Villadangos JA, Heath WR. 2005. Life cycle, migration and antigen presenting functions of spleen and lymph node dendritic cells: limitations of the Langerhans cells paradigm. Semin. Immunol. 17:262–72 22. Merad M, Manz MG, Karsunky H, Wagers A, Peters W, et al. 2002. Langerhans cells renew in the skin throughout life under steady-state conditions. Nat. Immunol. 3:1135–41 23. Macatonia SE, Edwards AJ, Knight SC. 1986. Dendritic cells and the initiation of contact sensitivity to ﬂuorescein isothiocyanate. Immunology 59:509–14 24. Valladeau J, Duvert-Frances V, Pin JJ, Dezutter-Dambuyant C, Vincent C, et al. 1999. The monoclonal antibody DCGM4 recognizes Langerin, a protein speciﬁc of Langerhans cells, and is rapidly internalized from the cell surface. Eur. J. Immunol. 29:2695–704 25. Kissenpfennig A, Henri S, Dubois B, Laplace-Builhe C, Perrin P, et al. 2005. Dynamics and function of Langerhans cells in vivo: dermal dendritic cells colonize lymph node areas distinct from slower migrating Langerhans cells. Immunity 22:643–54 26. Kaplan DH, Jenison MC, Saeland S, Shlomchik WD, Shlomchik MJ. 2005. Epidermal langerhans cell-deﬁcient mice develop enhanced contact hypersensitivity. Immunity 23:611–20 27. Allan RS, Smith CM, Belz GT, van Lint AL, Wakim LM, et al. 2003. Epidermal viral immunity induced by CD8α+ dendritic cells but not by Langerhans cells. Science 301:1925–28 28. Kimber I, Cumberbatch M. 1992. Stimulation of Langerhans cell migration by tumor necrosis factor α (TNF-α). J. Invest. Dermatol. 99:48S–50S 29. Cumberbatch M, Grifﬁths CE, Tucker SC, Dearman RJ, Kimber I. 1999. Tumour necrosis factor-α induces Langerhans cell migration in humans. Br. J. Dermatol. 141:192–200 30. Robbiani DF, Finch RA, Jager D, Muller WA, Sartorelli AC, Randolph GJ. 2000. The leukotriene C(4) transporter MRP1 regulates CCL19 (MIP-3β, ELC)-dependent mobilization of dendritic cells to lymph nodes. Cell 103:757–68 31. Cella M, Jarrossay D, Facchetti F, Alebardi O, Nakajima H, et al. 1999. Plasmacytoid monocytes migrate to inﬂamed lymph nodes and produce large amounts of type I interferon. Nat. Med. 5:919–23 32. Diacovo TG, Blasius AL, Mak TW, Cella M, Colonna M. 2005. Adhesive mechanisms governing interferon-producing cell recruitment into lymph nodes. J. Exp. Med. 202:687– 96 33. Palframan RT, Jung S, Cheng G, Weninger W, Luo Y, et al. 2001. Inﬂammatory chemokine transport and presentation in HEV: a remote control mechanism for monocyte recruitment to lymph nodes in inﬂamed tissues. J. Exp. Med. 194:1361–73 34. Leon B, Lopez-Bravo M, Ardavin C. 2007. Monocyte-derived dendritic cells formed at the infection site control the induction of protective T helper 1 responses against Leishmania. Immunity 26:519–31 35. Belz GT, Smith CM, Kleinert L, Reading P, Brooks A, et al. 2004. Distinct migrating and nonmigrating dendritic cell populations are involved in MHC class I-restricted antigen presentation after lung infection with virus. Proc. Natl. Acad. Sci. USA 101:8670–75 36. Allan RS, Waithman J, Bedoui S, Jones CM, Villadangos JA, et al. 2006. Migratory dendritic cells transfer antigen to a lymph node-resident dendritic cell population for efﬁcient CTL priming. Immunity 25:153–62 37. Le Borgne M, Etchart N, Goubier A, Lira SA, Sirard JC, et al. 2006. Dendritic cells rapidly recruited into epithelial tissues via CCR6/CCL20 are responsible for CD8(+) T cell crosspriming in vivo. Immunity 24:191–201

Annu. Rev. Immunol. 2008.26:293-316. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-10

310

Randolph

·

Ochando

·

Partida-S´anchez

Annu. Rev. Immunol. 2008.26:293-316. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-10

ARI

25 March 2008

22:6

38. Smith AL, Fazekas de St Groth B. 1999. Antigen-pulsed CD8α+ dendritic cells generate an immune response after subcutaneous injection without homing to the draining lymph node. J. Exp. Med. 189:593–98 39. Randolph GJ, Inaba K, Robbiani DF, Steinman RM, Muller WA. 1999. Differentiation of phagocytic monocytes into lymph node dendritic cells in vivo. Immunity 11:753–61 40. Reinhardt RL, Hong S, Kang SJ, Wang ZE, Locksley RM. 2006. Visualization of IL12/23p40 in vivo reveals immunostimulatory dendritic cell migrants that promote Th1 differentiation. J. Immunol. 177:1618–27 41. Dzionek A, Fuchs A, Schmidt P, Cremer S, Zysk M, et al. 2000. BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood. J. Immunol. 165:6037–46 42. Shortman K, Liu YJ. 2002. Mouse and human dendritic cell subtypes. Nat. Rev. Immunol. 2:151–61 43. Asselin-Paturel C, Brizard G, Pin JJ, Briere F, Trinchieri G. 2003. Mouse strain differences in plasmacytoid dendritic cell frequency and function revealed by a novel monoclonal antibody. J. Immunol. 171:6466–77 44. Blasius A, Vermi W, Krug A, Facchetti F, Cella M, Colonna M. 2004. A cell-surface molecule selectively expressed on murine natural interferon-producing cells that blocks secretion of interferon-α. Blood 103:4201–6 45. Zhang J, Raper A, Sugita N, Hingorani R, Salio M, et al. 2006. Characterization of Siglec-H as a novel endocytic receptor expressed on murine plasmacytoid dendritic cell precursors. Blood 107:3600–8 46. Nakano H, Yanagita M, Gunn MD. 2001. CD11c+ B220+ Gr-1+ cells in mouse lymph nodes and spleen display characteristics of plasmacytoid dendritic cells. J. Exp. Med. 194:1171–78 47. Vermi W, Riboldi E, Wittamer V, Gentili F, Luini W, et al. 2005. Role of ChemR23 in directing the migration of myeloid and plasmacytoid dendritic cells to lymphoid organs and inﬂamed skin. J. Exp. Med. 201:509–15 48. Zabel BA, Silverio AM, Butcher EC. 2005. Chemokine-like receptor 1 expression and chemerin-directed chemotaxis distinguish plasmacytoid from myeloid dendritic cells in human blood. J. Immunol. 174:244–51 49. Masten BJ, Olson GK, Tarleton CA, Rund C, Schuyler M, et al. 2006. Characterization of myeloid and plasmacytoid dendritic cells in human lung. J. Immunol. 177:7784–93 50. Imhof BA, Aurrand-Lions M. 2004. Adhesion mechanisms regulating the migration of monocytes. Nat. Rev. Immunol. 4:432–44 51. Woltman AM, de Fijter JW, Zuidwijk K, Vlug AG, Bajema IM, et al. 2007. Quantiﬁcation of dendritic cell subsets in human renal tissue under normal and pathological conditions. Kidney Int. 71:1001–8 52. Jahnsen FL, Gran E, Haye R, Brandtzaeg P. 2004. Human nasal mucosa contains antigenpresenting cells of strikingly different functional phenotypes. Am. J. Respir. Cell Mol. Biol. 30:31–37 53. De Heer HJ, Hammad H, Soullie T, Hijdra D, Vos N, et al. 2004. Essential role of lung plasmacytoid dendritic cells in preventing asthmatic reactions to harmless inhaled antigen. J. Exp. Med. 200:89–98 54. Wendland M, Czeloth N, Mach N, Malissen B, Kremmer E, et al. 2007. CCR9 is a homing receptor for plasmacytoid dendritic cells to the small intestine. Proc. Natl. Acad. Sci. USA 104:6347–52 www.annualreviews.org • Migration of Dendritic Cell Subsets

311

ARI

25 March 2008

22:6

55. Farkas L, Beiske K, Lund-Johansen F, Brandtzaeg P, Jahnsen FL. 2001. Plasmacytoid dendritic cells (natural interferon-α/β-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am. J. Pathol. 159:237–43 56. Ochando JC, Homma C, Yang Y, Hidalgo A, Garin A, et al. 2006. Alloantigen-presenting plasmacytoid dendritic cells mediate tolerance to vascularized grafts. Nat. Immunol. 7:652– 62 57. Yrlid U, Jenkins CD, MacPherson GG. 2006. Relationships between distinct blood monocyte subsets and migrating intestinal lymph dendritic cells in vivo under steady state conditions. J. Immunol. 176:4155–62 58. Chackerian AA, Alt JM, Perera TV, Dascher CC, Behar SM. 2002. Dissemination of Mycobacterium tuberculosis is inﬂuenced by host factors and precedes the initiation of Tcell immunity. Infect. Immun. 70:4501–9 59. Vazquez-Torres A, Jones-Carson J, Baumler AJ, Falkow S, Valdivia R, et al. 1999. Extraintestinal dissemination of Salmonella by CD18-expressing phagocytes. Nature 401:804–8 60. Cavanagh LL, Bonasio R, Mazo IB, Halin C, Cheng G, et al. 2005. Activation of bone marrow-resident memory T cells by circulating, antigen-bearing dendritic cells. Nat. Immunol. 6:1029–37 61. Angeli V, Ginhoux F, Llodra J, Quemeneur L, Frenette PS, et al. 2006. B cell-driven lymphangiogenesis in inﬂamed lymph nodes enhances dendritic cell mobilization. Immunity 24:203–15 62. Rennert PD, Hochman PS, Flavell RA, Chaplin DD, Jayaraman S, et al. 2001. Essential role of lymph nodes in contact hypersensitivity revealed in lymphotoxin-α-deﬁcient mice. J. Exp. Med. 193:1227–38 63. Enioutina EY, Bareyan D, Daynes RA. 2007. Vitamin D3-mediated alterations to myeloid dendritic cell trafﬁcking in vivo expand the scope of their antigen presenting properties. Vaccine 25:1236–49 64. Liu YJ. 2006. A uniﬁed theory of central tolerance in the thymus. Trends Immunol. 27:215– 21 65. Mathis D, Benoist C. 2004. Back to central tolerance. Immunity 20:509–16 66. Bonasio R, Scimone ML, Schaerli P, Grabie N, Lichtman AH, von Andrian UH. 2006. Clonal deletion of thymocytes by circulating dendritic cells homing to the thymus. Nat. Immunol. 7:1092–100 67. Larsen CP, Morris PJ, Austyn JM. 1990. Migration of dendritic leukocytes from cardiac allografts into host spleens. A novel pathway for initiation of rejection. J. Exp. Med. 171:307–14 68. Saiki T, Ezaki T, Ogawa M, Matsuno K. 2001. Trafﬁcking of host- and donor-derived dendritic cells in rat cardiac transplantation: allosensitization in the spleen and hepatic nodes. Transplantation 71:1806–15 69. Llodra J, Angeli V, Liu J, Trogan E, Fisher EA, Randolph GJ. 2004. Emigration of monocyte-derived cells from atherosclerotic lesions characterizes regressive, but not progressive, plaques. Proc. Natl. Acad. Sci. USA 101:11779–84 70. Ochando J, Krieger NR, Bromberg JS. 2006. Direct vs. indirect allorecognition: visualization of dendritic cell distribution and interactions during rejection and tolerization. Am. J. Transplant. 6:2488–96 71. Mori S, Nakano H, Aritomi K, Wang CR, Gunn MD, Kakiuchi T. 2001. Mice lacking expression of the chemokines ccl21-ser and ccl19 (plt mice) demonstrate delayed but enhanced T cell immune responses. J. Exp. Med. 193:207–18 72. Glass CK, Witztum JL. 2001. Atherosclerosis: the road ahead. Cell 104:503–16

Annu. Rev. Immunol. 2008.26:293-316. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-10

312

Randolph

·

Ochando

·

Partida-S´anchez

Annu. Rev. Immunol. 2008.26:293-316. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-10

ARI

25 March 2008

22:6

73. Gerrity RG. 1981. The role of the monocyte in atherogenesis: II. Migration of foam cells from atherosclerotic lesions. Am. J. Pathol. 103:191–200 74. Huang Y, Rumschitzki D, Chien S, Weinbaum S. 1994. A ﬁber matrix model for the growth of macromolecular leakage spots in the arterial intima. J. Biomech. Eng. 116:430– 45 75. Dal Canto AJ, Swanson PE, O’Guin AK, Speck SH, Virgin HW. 2001. IFN-γ action in the media of the great elastic arteries, a novel immunoprivileged site. J. Clin. Invest. 107:R15–22 76. Deleted in proof 77. Llodra J, Angeli V, Liu J, Trogan E, Fisher EA, Randolph GJ. 2004. Emigration of monocyte-derived cells from atherosclerotic lesions characterizes regressive, but not progressive, plaques. Proc. Natl. Acad. Sci. USA 101:11779–84 78. Van Haastert PJ, Devreotes PN. 2004. Chemotaxis: signalling the way forward. Nat. Rev. Mol. Cell Biol. 5:626–34 79. Sanchez-Sanchez N, Riol-Blanco L, Rodriguez-Fernandez JL. 2006. The multiple personalities of the chemokine receptor CCR7 in dendritic cells. J. Immunol. 176:5153–9 80. Bourne HR. 1997. How receptors talk to trimeric G proteins. Curr. Opin. Cell Biol. 9:134– 42 81. Kuang Y, Wu Y, Jiang H, Wu D. 1996. Selective G protein coupling by C-C chemokine receptors. J. Biol. Chem. 271:3975–78 82. Wu D. 2005. Signaling mechanisms for regulation of chemotaxis. Cell Res. 15:52–56 83. Del Prete A, Vermi W, Dander E, Otero K, Barberis L, et al. 2004. Defective dendritic cell migration and activation of adaptive immunity in PI3Kγ-deﬁcient mice. EMBO J. 23:3505–15 84. Shin EH, Lee HY, Bae YS. 2006. Leukotriene B4 stimulates human monocyte-derived dendritic cell chemotaxis. Biochem. Biophys. Res. Commun. 348:606–11 85. Andrew N, Insall RH. 2007. Chemotaxis in shallow gradients is mediated independently of PtdIns 3-kinase by biased choices between random protrusions. Nat. Cell Biol. 9:193– 200 86. Smith DF, Deem TL, Bruce AC, Reutershan J, Wu D, Ley K. 2006. Leukocyte phosphoinositide-3 kinase γ is required for chemokine-induced, sustained adhesion under ﬂow in vivo. J. Leukoc. Biol. 80:1491–99 87. Riol-Blanco L, Sanchez-Sanchez N, Torres A, Tejedor A, Narumiya S, et al. 2005. The chemokine receptor CCR7 activates in dendritic cells two signaling modules that independently regulate chemotaxis and migratory speed. J. Immunol. 174:4070–80 88. Sanchez-Sanchez N, Riol-Blanco L, de la Rosa G, Puig-Kroger A, Garcia-Bordas J, et al. 2004. Chemokine receptor CCR7 induces intracellular signaling that inhibits apoptosis of mature dendritic cells. Blood 104:619–25 89. Iijima N, Yanagawa Y, Clingan JM, Onoe K. 2005. CCR7-mediated c-Jun N-terminal kinase activation regulates cell migration in mature dendritic cells. Int. Immunol. 17:1201– 12 90. Scandella E, Men Y, Legler DF, Gillessen S, Prikler L, et al. 2004. CCL19/CCL21triggered signal transduction and migration of dendritic cells requires prostaglandin E2. Blood 103:1595–601 91. Luft T, Maraskovsky E, Schnurr M, Knebel K, Kirsch M, et al. 2004. Tuning the volume of the immune response: strength and persistence of stimulation determine migration and cytokine secretion of dendritic cells. Blood 104:1066–74 www.annualreviews.org • Migration of Dendritic Cell Subsets

313

ARI

25 March 2008

22:6

92. Galgani M, De Rosa V, De Simone S, Leonardi A, D’Oro U, et al. 2004. Cyclic AMP modulates the functional plasticity of immature dendritic cells by inhibiting Src-like kinases through protein kinase A-mediated signaling. J. Biol. Chem. 279:32507–14 93. Sato K, Kawasaki H, Nagayama H, Enomoto M, Morimoto C, et al. 2001. Signaling events following chemokine receptor ligation in human dendritic cells at different developmental stages. Int. Immunol. 13:167–79 94. Kitanaka N, Owada Y, Okuyama R, Sakagami H, Nourani MR, et al. 2006. Epidermaltype fatty acid binding protein as a negative regulator of IL-12 production in dendritic cells. Biochem. Biophys. Res. Commun. 345:459–66 95. Nagayama H, Sato K, Kawasaki H, Enomoto M, Morimoto C, et al. 2000. IL-12 responsiveness and expression of IL-12 receptor in human peripheral blood monocyte-derived dendritic cells. J. Immunol. 165:59–66 96. Khader SA, Partida-S´anchez S, Bell G, Jelley-Gibbs DM, Swain S, et al. 2006. Interleukin 12p40 is required for dendritic cell migration and T cell priming after Mycobacterium tuberculosis infection. J. Exp. Med. 203:1805–15 97. Yanagawa Y, Onoe K. 2006. Distinct regulation of CD40-mediated interleukin-6 and interleukin-12 productions via mitogen-activated protein kinase and nuclear factor κBinducing kinase in mature dendritic cells. Immunology 117:526–35 98. Wang S, Hong S, Yang J, Qian J, Zhang X, et al. 2006. Optimizing immunotherapy in multiple myeloma: restoring the function of patients’ monocyte-derived dendritic cells by inhibiting p38 or activating MEK/ERK MAPK and neutralizing interleukin6 in progenitor cells. Blood 108:4071–77 99. Nakagawa S, Ohtani T, Mizuashi M, Mollah ZU, Ito Y, et al. 2004. p38 mitogen-activated protein kinase mediates dual role of UVB radiation in induction of maturation and apoptosis of monocyte-derived dendritic cells. J. Invest. Dermatol. 123:361–70 100. Aiba S, Manome H, Nakagawa S, Mollah ZU, Mizuashi M, et al. 2003. p38 mitogenactivated protein kinase and extracellular signal-regulated kinases play distinct roles in the activation of dendritic cells by two representative haptens, NiCl2 and 2,4dinitrochlorobenzene. J. Invest. Dermatol. 120:390–99 101. Shi GX, Harrison K, Han SB, Moratz C, Kehrl JH. 2004. Toll-like receptor signaling alters the expression of regulator of G protein signaling proteins in dendritic cells: implications for G protein-coupled receptor signaling. J. Immunol. 172:5175–84 102. Oppermann M. 2004. Chemokine receptor CCR5: insights into structure, function, and regulation. Cell. Signal. 16:1201–10 103. Shi G, Partida-Sanchez S, Misra RS, Tighe M, Borchers MT, et al. 2007. Identiﬁcation of an alternative Gαq -dependent chemokine receptor signal transduction pathway in dendritic cells and granulocytes. J. Exp. Med. 204:2705–18 104. Klinker JF, Wenzel-Seifert K, Seifert R. 1996. G-protein-coupled receptors in HL-60 human leukemia cells. Gen. Pharmacol. 27:33–54 105. Riobo NA, Manning DR. 2005. Receptors coupled to heterotrimeric G proteins of the G12 family. Trends Pharmacol. Sci. 26:146–54 106. Schaerli P, Moser B. 2005. Chemokines: control of primary and memory T-cell trafﬁc. Immunol. Res. 31:57–74 107. Weninger W, von Andrian UH. 2003. Chemokine regulation of naive T cell trafﬁc in health and disease. Semin. Immunol. 15:257–70 108. Muller G, Hopken UE, Lipp M. 2003. The impact of CCR7 and CXCR5 on lymphoid organ development and systemic immunity. Immunol. Rev. 195:117–35 109. Muller G, Lipp M. 2003. Shaping up adaptive immunity: the impact of CCR7 and CXCR5 on lymphocyte trafﬁcking. Microcirculation 10:325–34

Annu. Rev. Immunol. 2008.26:293-316. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-10

314

Randolph

·

Ochando

·

Partida-S´anchez

Annu. Rev. Immunol. 2008.26:293-316. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-10

ARI

25 March 2008

22:6

110. Sozzani S. 2005. Dendritic cell trafﬁcking: more than just chemokines. Cytokine Growth Factor Rev. 16:581–92 111. Kim CH. 2005. The greater chemotactic network for lymphocyte trafﬁcking: chemokines and beyond. Curr. Opin. Hematol. 12:298–304 112. Steinman RM, Hemmi H. 2006. Dendritic cells: translating innate to adaptive immunity. Curr. Top. Microbiol. Immunol. 311:17–58 113. Crow MK. 2006. Modiﬁcation of accessory molecule signaling. Springer Semin. Immunopathol. 27:409–24 114. Hemmi H, Akira S. 2005. TLR signalling and the function of dendritic cells. Chem. Immunol. Allergy 86:120–35 115. Ouaaz F, Arron J, Zheng Y, Choi Y, Beg AA. 2002. Dendritic cell development and survival require distinct NF-κB subunits. Immunity 16:257–70 116. Lindner I, Cejas PJ, Carlson LM, Torruellas J, Plano GV, Lee KP. 2007. Signal transduction in DC differentiation: winged messengers and Achilles’ heel. Adv. Exp. Med. Biol. 590:1–29 117. Colonna M. 2003. TREMs in the immune system and beyond. Nat. Rev. Immunol. 3:445– 53 118. Bouchon A, Hernandez-Munain C, Cella M, Colonna M. 2001. A DAP12-mediated pathway regulates expression of CC chemokine receptor 7 and maturation of human dendritic cells. J. Exp. Med. 194:1111–22 119. Lanier LL, Bakker AB. 2000. The ITAM-bearing transmembrane adaptor DAP12 in lymphoid and myeloid cell function. Immunol. Today 21:611–14 120. Bakker AB, Hoek RM, Cerwenka A, Blom B, Lucian L, et al. 2000. DAP12-deﬁcient mice fail to develop autoimmunity due to impaired antigen priming. Immunity 13:345–53 121. Tessarz AS, Weiler S, Zanzinger K, Angelisova P, Horejsi V, Cerwenka A. 2007. Non-T cell activation linker (NTAL) negatively regulates TREM-1/DAP12-induced inﬂammatory cytokine production in myeloid cells. J. Immunol. 178:1991–99 122. Bagley KC, Abdelwahab SF, Tuskan RG, Lewis GK. 2004. Calcium signaling through phospholipase C activates dendritic cells to mature and is necessary for the activation and maturation of dendritic cells induced by diverse agonists. Clin. Diagn. Lab. Immunol. 11:77–82 123. Aliberti J, Valenzuela JG, Carruthers VB, Hieny S, Andersen J, et al. 2003. Molecular mimicry of a CCR5 binding-domain in the microbial activation of dendritic cells. Nat. Immunol. 4:485–90 124. Yang D, Chen Q, Gertz B, He R, Phulsuksombati M, et al. 2002. Human dendritic cells express functional formyl peptide receptor-like-2 (FPRL2) throughout maturation. J. Leukoc. Biol. 72:598–607 125. Idzko M, Dichmann S, Ferrari D, Di Virgilio F, la Sala A, et al. 2002. Nucleotides induce chemotaxis and actin polymerization in immature but not mature human dendritic cells via activation of pertussis toxin-sensitive P2y receptors. Blood 100:925–32 126. Partida-S´anchez S, Rivero-Nava L, Shi G, Lund FE. 2007. CD38: an ecto-enzyme at the crossroads of innate and adaptive immune responses. Adv. Exp. Med. Biol. 590:171–83 127. Lund FE. 2006. Signaling properties of CD38 in the mouse immune system: enzymedependent and -independent roles in immunity. Mol. Med. 12:328–33 128. Partida-S´anchez S, Goodrich S, Kusser K, Oppenheimer N, Randall TD, Lund FE. 2004. Regulation of dendritic cell trafﬁcking by the ADP-ribosyl cyclase CD38: impact on the development of humoral immunity. Immunity 20:279–91 129. Partida-S´anchez S, Randall TD, Lund FE. 2003. Innate immunity is regulated by CD38, an ecto-enzyme with ADP-ribosyl cyclase activity. Microbes Infect. 5:49–58 www.annualreviews.org • Migration of Dendritic Cell Subsets

315

ARI

25 March 2008

22:6

130. Partida-Sanchez S, Gasser A, Fliegert R, Siebrands CC, Dammermann W, et al. 2007. Chemotaxis of mouse bone marrow neutrophils and dendritic cells is controlled by ADPribose, the major product generated by the CD38 enzyme reaction. J. Immunol. 179:7827– 39 131. Fliegert R, Gasser A, Guse AH. 2007. Regulation of calcium signalling by adenine-based second messengers. Biochem. Soc. Trans. 35:109–14 132. Perraud AL, Schmitz C, Scharenberg AM. 2003. TRPM2 Ca2+ permeable cation channels: from gene to biological function. Cell Calcium 33:519–31 133. Massullo P, Sumoza-Toledo A, Bhagat H, Partida-Sanchez S. 2006. TRPM channels, calcium and redox sensors during innate immune responses. Semin. Cell Dev. Biol. 17:654– 66 134. Fonfria E, Murdock PR, Cusdin FS, Benham CD, Kelsell RE, McNulty S. 2006. Tissue distribution proﬁles of the human TRPM cation channel family. J. Recept. Signal. Transduct. Res. 26:159–78 135. Farina C, Theil D, Semlinger B, Hohlfeld R, Meinl E. 2004. Distinct responses of monocytes to Toll-like receptor ligands and inﬂammatory cytokines. Int. Immunol. 16:799–809 136. Iqbal J, Zaidi M. 2007. CD38 is required for priming by TNF-α: a mechanism for extracellular coordination of cell fate. Am. J. Physiol. Renal Physiol. 292:F1283–90 137. Guerrero-Plata A, Casola A, Suarez G, Yu X, Spetch L, et al. 2006. Differential response of dendritic cells to human metapneumovirus and respiratory syncytial virus. Am. J. Respir. Cell Mol. Biol. 34:320–29 138. Rotta G, Edwards EW, Sangaletti S, Bennett C, Ronzoni S, et al. 2003. Lipopolysaccharide or whole bacteria block the conversion of inﬂammatory monocytes into dendritic cells in vivo. J. Exp. Med. 198:1253–63 139. Watts C, Zaru R, Prescott AR, Wallin RP, West MA. 2007. Proximal effects of Toll-like receptor activation in dendritic cells. Curr. Opin. Immunol. 19:73–78 140. Pasare C, Medzhitov R. 2005. Toll-like receptors: linking innate and adaptive immunity. Adv. Exp. Med. Biol. 560:11–18 141. Krutzik SR, Tan B, Li H, Ochoa MT, Liu PT, et al. 2005. TLR activation triggers the rapid differentiation of monocytes into macrophages and dendritic cells. Nat. Med. 11:653–60 142. Angeli V, Staumont D, Charbonnier AS, Hammad H, Gosset P, et al. 2004. Activation of the D prostanoid receptor 1 regulates immune and skin allergic responses. J. Immunol. 172:3822–29 143. Hartiala P, Hytonen J, Pelkonen J, Kimppa K, West A, et al. 2007. Transcriptional response of human dendritic cells to Borrelia garinii–defective CD38 and CCR7 expression detected. J. Leukoc. Biol. 82:33–43 144. Dumitriu IE, Bianchi ME, Bacci M, Manfredi AA, Rovere-Querini P. 2007. The secretion of HMGB1 is required for the migration of maturing dendritic cells. J. Leukoc. Biol. 81:84– 91 145. la Sala A, Ferrari D, Di Virgilio F, Idzko M, Norgauer J, Girolomoni G. 2003. Alerting and tuning the immune response by extracellular nucleotides. J. Leukoc. Biol. 73:339–43 146. Di Virgilio F, Chiozzi P, Ferrari D, Falzoni S, Sanz JM, et al. 2001. Nucleotide receptors: an emerging family of regulatory molecules in blood cells. Blood 97:587–600 147. la Sala A, Sebastiani S, Ferrari D, Di Virgilio F, Idzko M, et al. 2002. Dendritic cells exposed to extracellular adenosine triphosphate acquire the migratory properties of mature cells and show a reduced capacity to attract type 1 T lymphocytes. Blood 99:1715–22 148. Bray M, Geisbert TW. 2005. Ebola virus: the role of macrophages and dendritic cells in the pathogenesis of Ebola hemorrhagic fever. Int. J. Biochem. Cell Biol. 37:1560–66

Annu. Rev. Immunol. 2008.26:293-316. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-10

316

Randolph

·

Ochando

·

Partida-S´anchez

AR338-FM

ARI

12 January 2008

18:11

Annual Review of Immunology

Annu. Rev. Immunol. 2008.26:293-316. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

Contents

Volume 26, 2008

Frontispiece K. Frank Austen p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p x Doing What I Like K. Frank Austen p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p1 Protein Tyrosine Phosphatases in Autoimmunity Torkel Vang, Ana V. Miletic, Yutaka Arimura, Lutz Tautz, Robert C. Rickert, and Tomas Mustelin p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p 29 Interleukin-21: Basic Biology and Implications for Cancer and Autoimmunity Rosanne Spolski and Warren J. Leonard p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p 57 Forward Genetic Dissection of Immunity to Infection in the Mouse S.M. Vidal, D. Malo, J.-F. Marquis, and P. Gros p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p 81 Regulation and Functions of Blimp-1 in T and B Lymphocytes Gislâine Martins and Kathryn Calame p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p133 Evolutionarily Conserved Amino Acids That Control TCR-MHC Interaction Philippa Marrack, James P. Scott-Browne, Shaodong Dai, Laurent Gapin, and John W. Kappler p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p171 T Cell Trafﬁcking in Allergic Asthma: The Ins and Outs Benjamin D. Medoff, Seddon Y. Thomas, and Andrew D. Luster p p p p p p p p p p p p p p p p p p p p p205 The Actin Cytoskeleton in T Cell Activation Janis K. Burkhardt, Esteban Carrizosa, and Meredith H. Shaffer p p p p p p p p p p p p p p p p p p p p233 Mechanism and Regulation of Class Switch Recombination Janet Stavnezer, Jeroen E.J. Guikema, and Carol E. Schrader p p p p p p p p p p p p p p p p p p p p p p p261 Migration of Dendritic Cell Subsets and their Precursors Gwendalyn J. Randolph, Jordi Ochando, and Santiago Partida-Sánchez p p p p p p p p p p p p p293

v

AR338-FM

ARI

12 January 2008

18:11

The APOBEC3 Cytidine Deaminases: An Innate Defensive Network Opposing Exogenous Retroviruses and Endogenous Retroelements Ya-Lin Chiu and Warner C. Greene p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p317 Thymus Organogenesis Hans-Reimer Rodewald p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p355 Death by a Thousand Cuts: Granzyme Pathways of Programmed Cell Death Dipanjan Chowdhury and Judy Lieberman p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p389 Annu. Rev. Immunol. 2008.26:293-316. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

Monocyte-Mediated Defense Against Microbial Pathogens Natalya V. Serbina, Ting Jia, Tobias M. Hohl, and Eric G. Pamer p p p p p p p p p p p p p p p p p p p421 The Biology of Interleukin-2 Thomas R. Malek p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p453 The Biochemistry of Somatic Hypermutation Jonathan U. Peled, Fei Li Kuang, Maria D. Iglesias-Ussel, Sergio Roa, Susan L. Kalis, Myron F. Goodman, and Matthew D. Scharff p p p p p p p p p p p p p p p p p p p p p481 Anti-Inﬂammatory Actions of Intravenous Immunoglobulin Falk Nimmerjahn and Jeffrey V. Ravetch p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p513 The IRF Family Transcription Factors in Immunity and Oncogenesis Tomohiko Tamura, Hideyuki Yanai, David Savitsky, and Tadatsugu Taniguchi p p p p p535 Choreography of Cell Motility and Interaction Dynamics Imaged by Two-Photon Microscopy in Lymphoid Organs Michael D. Cahalan and Ian Parker p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p585 Development of Secondary Lymphoid Organs Troy D. Randall, Damian M. Carragher, and Javier Rangel-Moreno p p p p p p p p p p p p p p p p627 Immunity to Citrullinated Proteins in Rheumatoid Arthritis Lars Klareskog, Johan Rönnelid, Karin Lundberg, Leonid Padyukov, and Lars Alfredsson p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p651 PD-1 and Its Ligands in Tolerance and Immunity Mary E. Keir, Manish J. Butte, Gordon J. Freeman, and Arlene H. Sharpe p p p p p p p p677 The Master Switch: The Role of Mast Cells in Autoimmunity and Tolerance Blayne A. Sayed, Alison Christy, Mary R. Quirion, and Melissa A. Brown p p p p p p p p p p705 T Follicular Helper (TFH ) Cells in Normal and Dysregulated Immune Responses Cecile King, Stuart G. Tangye, and Charles R. Mackay p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p741

vi

Contents

Annu. Rev. Immunol. 2008.26:317-353. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-11

ARI

24 February 2008

9:35

The APOBEC3 Cytidine Deaminases: An Innate Defensive Network Opposing Exogenous Retroviruses and Endogenous Retroelements Ya-Lin Chiu1 and Warner C. Greene1,2 1

Gladstone Institute of Virology and Immunology, San Francisco, California 94158

2

Departments of Medicine and of Microbiology and Immunology, University of California, San Francisco, California 94143; email: [email protected], [email protected]

Annu. Rev. Immunol. 2008. 26:317–53

Key Words

First published online as a Review in Advance on December 3, 2007

Alu, APOBEC3G, HIV-1, LINE-1, retrotransposition, Vif

The Annual Review of Immunology is online at immunol.annualreviews.org This article’s doi: 10.1146/annurev.immunol.26.021607.090350 c 2008 by Annual Reviews. Copyright All rights reserved 0732-0582/08/0423-0317$20.00

Abstract All retroviruses, including HIV-1, display species-speciﬁc patterns of infection. The impaired growth of these retroviruses in foreign and sometimes even in their natural hosts often stems from the action of potent host-encoded “viral restriction factors” that form important protective components of the innate immune system. The discovery of APOBEC3G and related cytidine deaminases as one class of host restriction factors and of the action of HIV-1 Vif as a speciﬁc APOBEC3G antagonist have stimulated intense scientiﬁc interest. This Vif-APOBEC3G axis now forms a very attractive target for development of an entirely new class of anti-HIV drugs. In this review, we summarize current understanding of the mechanism of action of the APOBEC3 family of enzymes, their intriguing regulation within cells, the impact of these enzymes on viral evolution and disease progression, and their roles in controlling not only the replication of exogenous retroviruses but also the retrotransposition of endogenous retroelements.

317

ANRV338-IY26-11

ARI

24 February 2008

9:35

DISCOVERY OF APOBEC3G AS AN ANTI-RETROVIRAL FACTOR

Annu. Rev. Immunol. 2008.26:317-353. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

APOBEC: apolipoprotein B mRNA-editing enzyme, catalytic polypeptide

The HIV-1 Vif Phenotype

APOBEC proteins: a family of DNA or RNA cytidine deaminases, enzymes that have the hallmark deaminase motif (Cys/His)Xaa-Glu-Xaa23∼28 Pro-Cys-Xaa2∼4 -Cys Retroviruses: enveloped RNA viruses with positive-sense single-stranded RNA genomes that undergo reverse transcription and integration as obligatory steps in their life cycle Human immunodeficiency virus (HIV): a retrovirus with two types (1 and 2) belonging to the lentivirus family that causes AIDS Virion infectivity factor (Vif ): an HIV-1 accessory protein essential for efﬁcient viral replication in primary CD4 T cells and macrophages

318

The identiﬁcation of human APOBEC3G (apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G, or hA3G) and related cytidine deaminases as potent innate inhibitors of a wide range of exogenous retroviruses emerged from studies of the HIV-1 protein Vif (virion infectivity factor). HIV-1 is a member of the primate lentivirus family of retroviruses. In contrast to simple retroviruses, which encode only Gag, Pol, and Env, HIV-1 encodes six additional auxiliary proteins (Tat, Rev, Nef, Vif, Vpr, and Vpu) that play pivotal roles in orchestrating the pathogenic interplay of HIV-1 with its human host. Vif itself, a basic 23-kDa phosphoprotein, is expressed late in the retroviral life cycle and is conserved among all of the primate lentiviruses, except for equine infectious anemia virus. Viruses lacking a functional vif gene (vif ) fail to mount a spreading infection in “nonpermissive” cells, which include biologically relevant primary CD4 T cells and macrophages (Figure 1). Vif is required for viral spread in cultures of some T cell leukemia lines, such as H9, HuT78, and MT2. Conversely, many “permissive” T cell lines (e.g., Jurkat and SupT1) and nonhematopoietic cell

lines (e.g., HeLa, 293T, and COS) fully support HIV spread in the absence of Vif (1– 3). Despite the early recognition of permissive and nonpermissive cell types supporting or not supporting the spread of vif HIV-1 respectively, the molecular basis for these cellular differences remained elusive for many years. Similarly, the mechanism by which Vif allowed wild-type HIV-1 to spread readily in cultures of nonpermissive cells was unclear.

Identifying the Vif-Sensitive Anti-HIV Factor Produced by Nonpermissive Cells Of note, nonpermissive cells support the normal production of vif HIV-1 virions, but these virions are unable to productively infect the next target cell (1–3). These ﬁndings suggest that Vif either overcomes the effects of a negative factor produced in nonpermissive cells or, alternatively, that permissive cells express a Vif-like host factor that positively inﬂuences virion infectivity. This issue was resolved in experiments in which heterokaryons formed between permissive and nonpermissive cells were infected with vif HIV-1 (4, 5). Progeny virions from these heterokaryons proved noninfectious, promoting the argument that nonpermissive cells express an inhibitory factor whose function is somehow defeated by Vif (Figure 1). This

−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−→ Figure 1 Nonpermissive cells produce an anti-HIV factor that is neutralized by Vif. (a) The HIV-1 Vif phenotype. Viruses lacking a functional vif gene (vif ) fail to mount a spreading infection in “nonpermissive” cells, which include biologically relevant primary CD4 T cells and macrophages. Conversely, many “permissive” T cell lines (e.g., Jurkat and SupT1) and nonhematopoietic cell lines (e.g., HeLa, 293T, and COS) fully support HIV spread in the absence of Vif. Note that permissive and nonpermissive cells produce the same amount of progeny virions, but virions derived from nonpermissive cells are unable to infect the next target cell. (b) Nonpermissivity is dominant in heterokaryons formed between permissive and nonpermissive cells. Nonpermissive T cells (HuT78 or CEM-SS) were initially infected with HIV-1vifenv viruses pseudotyped with VSV-G. Heterokaryons were formed by incubation of these nonpermissive cells with permissive cells expressing HIV Env. The presence of CD4/CXCR4 receptors on the nonpermissive cells mediated fusion and heterokaryon formation. When progeny virions (HIV-1vif ) were tested for their ability to infect the next target cell, no spread was detected. However, in the presence of Vif, effective spread occurred. These ﬁndings indicated that nonpermissive cells produce an inhibitor of HIV infectious spread and that the action of this inhibitor is circumvented by Vif. This host inhibitory factor was subsequently identiﬁed as APOBEC3G. Chiu

·

Greene

ANRV338-IY26-11

ARI

24 February 2008

9:35

Vif-sensitive inhibitory factor remained uncharacterized until Sheehy et al. used subtractive hybridization techniques with two near-isogenic cell lines, CEM-S (permissive) and CEM-SS (nonpermissive) (6). One clone identiﬁed in this screen was hA3G (initially named CEM15), a known cytidine deami-

nase. Strikingly, permissive cells lacked hA3G expression, and the introduction of hA3G cDNA into permissive cells proved sufﬁcient to convert these cells into nonpermissive hosts. Additionally, virions budding from nonpermissive cells were shown to contain hA3G, providing an explanation for how viral

a Nonpermissive cell

Permissive cell

Annu. Rev. Immunol. 2008.26:317-353. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

HIV-1∆Vif Infectious

Infectious

Noninfectious

Infectious

b Infectious VSVG-pseudotyped HIV-1∆Env∆Vif virus CXCR4 CD4 LTR

HIV-1 Env

LTR

HIV-1∆Env ∆Vif

Nonpermissive cell

LTR

Permissive cell

LTR

Noninfectious HIV-1∆Vif virus HIV-1∆Env ∆Vif

Heterokaryons found to be nonpermissive www.annualreviews.org • The APOBEC3 Cytidine Deaminases

319

ANRV338-IY26-11

ARI

24 February 2008

Cytidine deamination: the conversion of a cytidine to uridine by the hydrolytic substitution of an amine group

9:35

replication might be altered in the next set of target cells. The mechanism by which Vif overcomes the effects of hA3G remained unexplained.

Functional Clues from Related Enzymes: APOBEC1 and Activation-Induced Deaminase

Annu. Rev. Immunol. 2008.26:317-353. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

Human A3G is a member of a much larger family of tissue-restricted cytidine deaminases (7) that exhibit RNA editing and/or DNA mutating activity (8, 9). In humans, the APOBEC family of enzymes includes activation-induced deaminase (AID), APOBEC1, APOBEC2, APOBEC3A–H, and APOBEC4 (7, 10– 12). Their active sites are characterized by the presence of a conserved zinc-binding motif (Cys/His)-Xaa-Glu-Xaa23∼28 -Pro-CysXaa2∼4 -Cys, a key glutamate involved in the proton shuttling that occurs during deamination, and two critical aromatic residues involved in nucleic acid substrate binding (7). These enzymes mediate hydrolytic deamination at the C4 position of the C (or dC) base, converting C to U (or dC to dU). These changes are often referred to as RNA or DNA editing (Figure 2). Two well-studied members of this enzyme family are APOBEC1 and AID, which are located in tandem on human chromosome 12 (13, 14). Initially identiﬁed in 1993, APOBEC1 is primarily expressed in gastrointestinal tissue (8), where it is the central component of

an RNA editosome complex mediating the deamination of cytosine-6666 in apolipoprotein B mRNA (15). This action of APOBEC1 converts a glutamine at this position to an inframe stop codon, resulting in the expression of a truncated version of the apoB protein (8). These two forms of apoB protein serve different functions. The longer apoB100 protein mediates the transport of endogenously produced cholesterol and triglycerides, while the shorter apoB48 regulates the absorption and transport of exogenous dietary lipids. Of note, forced expression of APOBEC1 as a transgene in the livers of mice consistently leads to hepatic dysplasia and hepatocellular carcinoma, possibly owing to promiscuous RNA editing of tumor suppressors or oncogenes (16). Such activity likely reﬂects the formation of nonphysiological RNA editosomes whose normally exquisite substrate speciﬁcity is lost. APOBEC1 appears to be the only member of the APOBEC superfamily of enzymes whose principal nucleic acid substrate is RNA rather than DNA. In contrast to APOBEC1’s role in lipid metabolism, AID is required for the normal evolution of the humoral immune response. AID is selectively expressed in germinal center B cells (17), where it catalyzes dC-to-dU deamination at the DNA level and thus promotes immunoglobulin-gene diversiﬁcation via somatic hypermutation and class switch recombination (18). These events are critically required for the natural maturation of

−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−→ Figure 2 A family of APOBEC3 cytidine deaminases. The APOBEC3 gene locus containing seven related but distinct APOBEC3 genes is located on chromosome 22 in humans. This multigene family stands in sharp contrast to the single APOBEC3 gene present on syntenic chromosome 15 in mice. This genetic expansion reﬂects tandem duplication and unequal crossover resulting in a head to tail arrangement of the human APOBEC3 genes. Four genes (hA3B, hA3DE, hA3F, and hA3G) exhibit additional duplications of the cytidine deaminase domain (CD), as well as the intervening linker and pseudoactive domains. The length of these double domain enzymes varies somewhat as indicated, although each of the CDs are similar in size. The active sites of these enzymes catalyze hydrolytic deamination at the C4 position of 2 -deoxycytidine requiring the presence of cysteine (Cys) residues coordinating a single zinc ion and a key glutamate involved in proton shuttling. In this reaction, 2 -deoxycytidine is converted to 2 -deoxyuridine as a result of the removal of an amine group in the presence of water. 320

Chiu

·

Greene

ANRV338-IY26-11

ARI

24 February 2008

9:35

Mouse chromosome 15 mA3

Annu. Rev. Immunol. 2008.26:317-353. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

Human chromosome 22 A3B

A3A

A3C

1

aa: 1

1

A3DE

1

A3F

A3G

A3H

1

1

1

Catalytic domain

182

190

199

366

382

373

384

Deaminase Active Site Consensus

-Pr -Glu-Xaa23–28 o-Cys-Xaa2– -C -Xaa 4 ys s i H NH2 N O

O

O

P

O H

O H

NH3

O HN

Deamination

N

P

O

O H H

O– H

2'-deoxycytidine

N

O

O O

O H H

O–

H2O

H

O H

H

2'-deoxyuridine

www.annualreviews.org • The APOBEC3 Cytidine Deaminases

321

ANRV338-IY26-11

ARI

24 February 2008

Annu. Rev. Immunol. 2008.26:317-353. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

Reverse transcription: the process of copying RNA into DNA, mediated by a reverse transcriptase enzyme

9:35

the antibody response. Uracil DNA glycosylase, a DNA repair enzyme that removes uracil from single- and double-stranded DNA, is required for all AID-dependent processes (19). Mutations within the AID are linked to the Hyper-IgM syndrome, as well as aberrant activity linked with the development of various large B cell lymphomas and non-Hodgkin’s lymphomas (20). Like transgenic expression of APOBEC1, the constitutive and ubiquitous transgenic expression of AID in mice uniformly results in the development of various cancers, speciﬁcally T cell lymphomas, micro-adenomas, and lung adenocarcinomas (21). This link of APOBEC1 and AID to cancer emphasizes how tight intracellular regulation of these cytidine deaminases is likely required to avoid harmful transforming events within cells. When expressed in Escherichia coli, hA3G, AID, and even APOBEC1 catalyze the deamination of dC residues in single-stranded DNA (9, 22), suggesting that single-stranded DNA is the favored substrate for hA3G. This ﬁnding provides a ready explanation for how viral replication might be blocked in the next target cell via the inherent deaminase activity of hA3G acting on the nascent reverse transcribed cDNAs of the virus.

MULTIFACETED ANTIVIRAL ACTIONS OF APOBEC3G Retroviruses as a Target for the Inherent Deaminase Activity of APOBEC3G In the absence of Vif, hA3G is effectively incorporated into budding HIV-1 virions (23, 24). This encapsidation reaction involves interaction with the nucleocapsid region of the HIV-1 Gag polyprotein (25–27). This interaction is further strengthened by A3G’s propensity to bind single-stranded nucleic acids, particularly viral RNA at the plasma membrane site of virion budding (28–34). The incorporation of only 7 ± 4 molecules of hA3G into vif HIV virions produced from 322

Chiu

·

Greene

human peripheral blood mononuclear cells appears sufﬁcient to inhibit HIV-1 replication during the next round of infection (35). The virion-incorporated hA3G is bound to the viral core (32) and thus is effectively introduced into the target cell as a result of virion fusion. The enzyme then mediates extensive dC-todU mutations of the minus-strand viral DNA formed during reverse transcription (36, 37). These mutated viral minus-strand DNAs containing excessive dUs may then be destroyed by the action of two virion-associated DNA base repair enzymes, uracil DNA glycosylase and apurinic-apyrimidinic endonuclease (38, 39), although uracil DNA glycosylase 2 appears dispensable for this antiviral action of hA3G (40, 41). A few viral minus strands appear to survive this attack and serve as templates for plus-strand synthesis, where the dU promotes dA misincorporation. The resultant dG-to-dA mutations, which can exceed 10% of all dG residues, likely further negate HIV1 replication by altering viral open reading frames and introducing inappropriate translation termination codons (42–45) (Figure 3). HIV reverse transcription is initiated by extension from the tRNALys3 primer that anneals to the primer binding site of the viral genomic RNA generating minus-strand strong-stop DNA. This minus-strand strongstop DNA is translocated to the 3 end of the genome and further extended to complete the minus-strand cDNA. As the minusstrand cDNA is synthesized, the RNA template is degraded by the RNase H activity of the reverse transcriptase, exposing the singlestranded minus-strand DNA. Two RNase H– resistant RNA polypurine tracts (PPT), cPPT and 3 PPT, remain associated with the minusstrand cDNA to serve as initiation sites for subsequent plus-strand cDNA synthesis. As such, hA3G’s single-stranded DNA speciﬁcity (36, 37) accounts for two highly polarized (5 -to-3 ) mutational gradients within the viral genome, each with maxima just 5 to the cPPT and the 3 PPT. These gradients are in remarkable agreement with the time these regions of the minus-strand DNA

Annu. Rev. Immunol. 2008.26:317-353. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-11

ARI

24 February 2008

9:35

Figure 3 Multifaceted antiviral actions of virion-incorporated hA3G. In the absence of Vif, hA3G present in the cytoplasm of virus-producing cells is effectively incorporated into budding virions and thus is carried forward into the next target cells, where it is available to act as a potent inhibitor of HIV-1 replication. These results explain how nonpermissive cells can produce normal levels of progeny virions, but the virions emanating from nonpermissive cells fail to replicate effectively in the next target cells. These inhibitory effects involve both deaminase-independent and deaminase-dependent antiviral actions of hA3G. Human A3G bound to HIV-1 RNA may physically impede reverse transcriptase movement on the viral RNA template, resulting in a deaminase-independent decrease in the production of early reverse transcripts (1). However, this inhibition is frequently incomplete, and minus-strand viral DNA is generated. This single-stranded DNA forms the target for hA3G’s deaminase-dependent antiviral attack. Human A3G mediates extensive deamination of deoxycytidine residues in the minus-stranded viral DNA. This action effectively halts HIV-1 replication either due to the accumulation of dG-to-dA hypermutations in the subsequently synthesized plus-strand DNA of the virus or because the uracil-containing minus-strand DNA is destroyed by the combined actions of uracil DNA glycosylase and apurinic-apyrimidinic endonuclease (2). Additionally, diminished chromosomal integration of the double-stranded viral DNA required for provirus formation may occur owing to defects in tRNALys3 primer cleavage leading to the formation of viral DNA with aberrant ends (3).

remain single-stranded, awaiting the commencement of plus-strand synthesis (36, 46). These gradients could also result from a processive directional attack leveled by hA3G on its single-stranded cDNA substrate (47). Human A3G binds randomly to single-stranded DNA, then jumps and/or slides processively for at least 100 nucleotides to deaminate target motifs. This intrinsic “slide-and-jump” cat-

alytic activity of hA3G exhibits a clear bias favoring 5 dCs over 3 dCs. Thus deamination occurs predominantly 3 to 5 on the minus-strand viral DNA without requiring hydrolysis of a nucleotide cofactor (47). Rarely, hA3G also modiﬁes the viral plusstrand in the 5 U3 region and primer-binding site (36). Of note, the 5 U3 region becomes brieﬂy single-stranded when displaced

www.annualreviews.org • The APOBEC3 Cytidine Deaminases

323

ANRV338-IY26-11

ARI

24 February 2008

Simian immunodeficiency virus (SIV): a collection of related retroviruses belonging to the lentivirus family that infect many nonhuman primates

Annu. Rev. Immunol. 2008.26:317-353. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

MLV: murine leukemia virus HTLV: human T cell leukemia virus Hepatitis B virus (HBV): a DNA virus belonging to the hepadnavirus family that replicates via an RNA intermediate and requires reverse transcription

9:35

from the minus-strand during plus-strand synthesis; the primer-binding site in the plus-strand similarly becomes single-stranded when RNase H degrades the tRNALys3 primer bound at this site. These ﬁndings strongly support the notion that single-stranded DNA is the physiological substrate of hA3G. The editing activity of hA3G exerts broad antiretroviral effects, blocking the replication of HIV-1 and other lentiviruses, including simian immunodeﬁciency virus (SIV) and equine infectious anemia virus, and even distantly related retroviruses, such as murine leukemia virus (MLV) and foamy viruses (23, 42, 44, 48–50). The common use of DNA deamination by hA3G and AID emphasizes an intriguing biological strategy whereby both the innate and adaptive immune defenses commonly exploit DNA editing for defense of the host.

Deaminase-Independent Antiviral Activity of APOBEC3G In contrast to APOBEC1 and AID, which have single catalytic domains, hA3G contains two cytidine deaminase domains (CDs), as well as duplicated intervening linker and pseudoactive domains (7) (Figure 2). Despite their homology, these two CDs display quite distinct functional properties; the N-terminal CD1 mediates RNA binding and virion encapcidation (51–53), whereas the C-terminal CD2 confers deoxycytidine deaminase activity (51–54) and sequence speciﬁcity for modiﬁcation of the single-stranded DNA substrate. A3G preferentially deaminates 5 -CC dinucleotides at the 3 dC (42, 44, 45, 55–57). The ensuing degradation of the dU-containing viral minus-strands and the massive dG-to-dA hypermutation in the surviving viral plusstrand represent important events that centrally contribute to the antiviral properties of hA3G. Additionally, the accumulation of dUs in minus-strand DNA may lead to decreased plus-strand synthesis by HIV-1 reverse transcriptase owing to aberrant initiation at the PPT sites (58).

324

Chiu

·

Greene

Despite this clear link between the deoxycytidine deaminase activity of hA3G and its antiviral activity, emerging evidence suggests that A3G exerts additional antiviral effects independent of its enzymatic activity. Specifically, hA3G analogs containing disabling mutations in the C-terminal CD continue to substantially reduce the infectivity of vif HIV-1 virions. The RNA binding activity of the N-terminal CD appears critically involved in this nonenzymatic form of inhibition, which likely involves physical impairment of reverse transcriptase activity (52, 59). Additionally, the presence of hA3G in vif HIV-1 virions results in a 50% or greater reduction in the ability of tRNALys3 primers to initiate reverse transcription (60). Whether this inhibition reﬂects decreased tRNALys3 annealing to viral RNA or an altered conﬁguration of the tRNALys3 /viral RNA hybrid in the presence of hA3G remains unclear. Finally, hA3G may also cause defects in tRNALys3 cleavage during plus-strand DNA transfer, leading to the formation of aberrant viral DNA ends that could interfere with subsequent chromosomal integration of the double-stranded viral DNA required for provirus formation (41) (Figure 3). Of note, the N-terminal linker region of hA3G has been implicated as a docking site for the C-terminal domain of HIV-1 integrase. The association of hA3G with components of the preintegration complex (PIC) such as integrase might interfere with the structural integrity of the PIC and consequently inhibit nuclear import of the PIC, thereby further impairing the successful integration of the viral DNA (61). Human A3G also mediates deaminaseindependent antiviral activity against human T cell leukemia virus type-1 (HTLV-1), although the effects are more modest than those occurring with HIV-1. Hypermutations are also not abundant in most of the HTLV-1 viral DNA (62, 63). Furthermore, hA3G also blocks the replication of hepatitis B virus (HBV) in a manner that does not require deamination. The HBV life cycle involves an obligatory reverse transcription

Annu. Rev. Immunol. 2008.26:317-353. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-11

ARI

24 February 2008

9:35

step during which pregenomic RNA intermediates within nucleocapsids in the cytoplasm of virus-producer cells are converted to DNA before being packaged into budding virions. Human A3G appears to inhibit viral pregenome packaging, thereby destabilizing the reverse transcription complex and preventing HBV DNA accumulation in virions (64, 65). Only limited dG-to-dA mutations can be detected in HBV DNA, and these effects are only observed in selected hepatoma cell lines (65–67). All these studies support the notion that A3G’s antiviral activity is far more complex than previously thought. However, the precise mechanisms underlying these deaminase-independent antiviral actions of hA3G remain incompletely characterized.

Nuances of Intracellular Regulation of APOBEC3G Reveal a Novel Postentry Antiviral Activity A central question highly relevant to normal cell function is how the potentially promiscuous mutagenic activity of the hA3G enzymes is controlled. One possibility was immediately suggested by subcellular localization studies, which indicated that hA3G is chieﬂy cytoplasmic and does not appear to shuttle like APOBEC1 and AID. Rather hA3G is strongly retained in the cytoplasm (12, 42, 68–71). However, such localization is unlikely to represent the sole mechanism for limiting promiscuous editing of genomic DNA, especially because nuclear and cytoplasmic components are admixed in dividing cells after breakdown of the nuclear membrane. Indeed, subsequent studies revealed that endogenous hA3G expressed in the cytoplasm of H9 T cell lines and mitogen-activated CD4 T cells is assembled in 5–15 MDa high-molecularmass (HMM) ribonucleoprotein (RNP) complexes and that the deoxycytidine deaminase activity of hA3G is greatly inhibited in these complexes. Interestingly, these HMM hA3G complexes can be artiﬁcially converted to an enzymatically active low-molecular-mass (LMM) form by treatment with RNase A, sug-

gesting that RNA components play an important role in the assembly of HMM A3G complexes (72). This discovery of different forms of hA3G ultimately provided pivotal information bearing on the question of why resting CD4 T cells in lymphoid tissue are permissive to HIV1 infection, whereas CD4 T cells circulating in the peripheral blood are not, even though A3G is expressed in both cell types. The answer is that hA3G is expressed in two very different forms in these two populations of CD4 T cells. Circulating resting CD4 T cells are distinguished by the presence of LMM hA3G (72) and are refractory to HIV-1 infection at least in part because of an early postentry block during or soon after the reverse transcription step (73, 74). In sharp contrast, in lymphoid tissue–resident resting CD4 T cells, which display increased permissiveness to HIV-1 infection (75), hA3G is predominantly found in the HMM complexes (76). The formation of these complexes reﬂects, at least in part, the action of various cytokines, including IL-2 and IL-15, that are present in the lymphoid tissue microenvironment. These cytokines induce the assembly of HMM A3G complexes (76) (Figure 4). When RNA interference is used to knock down expression of the LMM hA3G present in peripheral blood– derived resting CD4 T lymphocytes, these cells are rendered permissive to HIV infection. This ﬁnding provides direct evidence that LMM hA3G functions as a potent postentry restriction factor that inhibits the replication of incoming HIV-1 virions (72). LMM hA3G can be converted to an HMM complex when CD4 T cells are activated with various mitogens (anti-CD3/CD28 and phorbol myristate acetate) and cytokines (IL-2, IL-7, and IL-15) (72, 77). The assembly of HMM A3G complexes appears to require entry into the G1b phase of the cell cycle (72), a stage characterized by RNA synthesis (78). These events result in HMM A3G complex assembly thereby removing the LMM hA3G postentry block and creating a favorable environment for productive HIV-1 infection www.annualreviews.org • The APOBEC3 Cytidine Deaminases

HMM: high molecular mass LMM: low molecular mass

325

ANRV338-IY26-11

ARI

24 February 2008

9:35

Peripheral blood

Lymphoid organs IL-2 IL-15 Other cytokines

HIV

HMM APOBEC3G LMM APOBEC3G

Annu. Rev. Immunol. 2008.26:317-353. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

Post-entry block

Resting g CD4 4 T celll

Resting CD4 T cell

Permissive for infection Nonpermissive for infection

Figure 4 APOBEC3G also functions as a potent postentry restriction factor for HIV-1 in resting CD4 T cells present in peripheral blood. Human A3G exists exclusively in LMM forms in peripheral blood–derived resting CD4 T cells. LMM hA3G functions as a postentry restriction factor blocking the replication of incoming HIV-1 viral particles. Of note, this action does not strictly depend on editing but rather appears to involve signiﬁcant delays in the accumulation of viral reverse transcripts. Strikingly and in sharp contrast to their cellular counterparts isolated from peripheral blood, resting CD4 T cells residing in human lymphoid tissues are permissive to HIV-1 infection. In these cells, hA3G is predominantly detected in HMM complexes and as such is unable to exert the postentry restricting activity characteristic of LMM hA3G. Induction of HMM hA3G complex assembly in these tissue-derived resting CD4 T cells appears to reﬂect the action of various cytokines including IL-2 and IL-15, which are present in this lymphoid tissue microenvironment. Additional inductive signals may occur as a result of cell-cell contacts in these tissues. However, though sufﬁcient to induce HMM hA3G complex assembly, these signals do not induce full-ﬂedged lymphocyte activation.

(72, 77). Of note, the action of LMM A3G is not antagonized by Vif because virions contain little or no Vif (79), and the virus has not progressed far enough through its life cycle to produce new Vif. Thus, this postentry restricting activity of LMM A3G is equally effective against wild-type HIV-1 and vif HIV-1 virions. Vif springs into action much later in the viral replication cycle when its synthesis is triggered by Rev, and it prevents hA3G incorporation into progeny virions budding from productively infected cellular hosts. 326

Chiu

·

Greene

The identiﬁcation of LMM forms of hA3G in primary resting CD4 T cells isolated from peripheral blood provided the ﬁrst evidence that hA3G can exert antiviral effects in target cells independently of its prior incorporation into virions. Interestingly, this HIV-1 postentry replication block by cellular LMM hA3G does not depend strictly on editing. Instead, it involves signiﬁcant delays in the accumulation of late reverse transcription products. Over 90% of the reverse transcripts that slowly form in infected blood-derived resting CD4 T cells contain no evidence of

Annu. Rev. Immunol. 2008.26:317-353. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-11

ARI

24 February 2008

9:35

dG-to-dA hypermutation, arguing for an antiviral action of hA3G independent of cytidine deamination (72). However, the possibility that many transcripts are in fact hypermutated, but rapidly degraded, cannot be completely ruled out. The status of HMM hA3G complex formation also correlates well with the susceptibility or resistance of cells within the monocyte lineage to infection with HIV-1 (72, 80– 82). Speciﬁcally, freshly isolated monocytes are highly refractory to infection in vitro (83– 85) and are distinguished by the presence of LMM hA3G (72). Differentiation of these cells into macrophages promotes the HMM hA3G complex assembly (72), a transition that correlates with a sharp increase in permissiveness to HIV-1 infection (83–85). HMM hA3G complexes also are observed in the CD16+ subset of monocytes, which are more permissive than other monocytes. These cells may form a reservoir for viral persistence during antiretroviral therapy (80). Immature dendritic cells contain low levels of hA3G that is assembled into HMM complexes. Maturation of these cells is associated with a sharp increase in hA3G expression and the additional expression of LMM hA3G forms (77, 81). Mature dendritic cells are less permissive than immature dendritic cells to HIV infection (81).

DIVERSE RETROVIRAL STRATEGIES FOR CIRCUMVENTING APOBEC3G ANTIVIRAL ACTIVITY The Vif-APOBEC3G Paradigm Human A3G poses a signiﬁcant threat to the successful replication and spread of HIV-1. One of the nine gene products of HIV1, Vif, is speciﬁcally utilized to counter this threat. Vif binds to hA3G and promotes its accelerated degradation by the 26S proteasome. The resulting depletion of the intracellular stores of hA3G prevents effective virion encapsidation of hA3G and ensures high infectivity of the progeny virions

(Figure 5). Vif uses multiple protein interaction regions to orchestrate proteasomemediated degradation of hA3G. The Nterminal region of Vif binds to the N-terminal region of hA3G (amino acids 54–124) (68, 86–88). The SLQ(Y/F)LA motif (amino acids 144–150) of Vif, which resembles a conserved sequence in the BC-box of the suppressors of cytokine signaling (SOCS) proteins, binds to Elongin C (87, 89–92). Finally, a novel zincbinding motif, His-Xaa5 -Cys-Xaa17−18 -CysX3−5 -His (HCCH, amino acids 108–139), interacts with Cullin5 (93–95). Through these interactions, Vif effectively recruits an active ubiquitin ligase (E3) complex composed of Elongin C, Elongin B, Cullin5, Nedd8, and Rbx1 (89, 92), which mediates polyubiquitylation of hA3G—a posttranslational modiﬁcation that targets proteins for destruction by the proteasome (24, 86, 87, 96). Mutation of the BC-box domain (SLQ motif) or the HCCH motif in Vif or overexpression of Cullin5 mutants that fail to engage Nedd8 or Rbx1 all result in a loss of hA3G polyubiquitylation and the preservation of hA3G’s antiviral activity (89, 91–93). Two additional Vif domains, the central hydrophilic EWRKKR domain (amino acids 88–93) and the prolinerich PPLP domain (amino acids 161–164), are important respectively for enhancing steadystate levels of Vif and for interaction with tyrosine kinases (97, 98). Mutation of these domains also compromises Vif activity. In addition to accelerating proteasomal degradation of hA3G, Vif partially impairs the translation of hA3G mRNA (24), although the mechanism remains undeﬁned. Nevertheless, the combined effects of accelerated degradation and diminished synthesis result in a striking depletion of intracellular hA3G and thus forfeiture of its antiviral activity (23, 24) (Figure 5). Additional mechanistic insights have emerged from interspecies studies. HIV-1 and HIV-2 represent the products of independent cross-species (zoonotic) transmission events of related but distinct lentiviruses (SIVs) that naturally infect nonhuman www.annualreviews.org • The APOBEC3 Cytidine Deaminases

Zoonotic transmissions: The cross-species transfer of an infectious agent from one animal species to another that is not regarded as a natural host for the pathogen

327

ANRV338-IY26-11

ARI

24 February 2008

9:35

Annu. Rev. Immunol. 2008.26:317-353. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

primates in sub-Saharan Africa (99). One lentivirus, SIVcpz, present in chimpanzees (Pan troglodytes) in western equatorial Africa represents the precursor of pandemic HIV-1. Similarly, SIVsm from sooty mangabeys (Cercocebus atys) is the immediate source of HIV-2. Unlike HIV-1, HIV-2 infection remains largely restricted to western Africa.

328

Chiu

·

Greene

Other lentiviruses, such as SIV from African green monkeys (SIVagm), have not been transmitted to humans. Additionally, rhesus macaques strongly resist experimental infection with HIV-1, reﬂecting the action of TRIM5α, a second and distinct type of postentry restriction factor (100). Such species-speciﬁc barriers to infection not only

Annu. Rev. Immunol. 2008.26:317-353. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-11

ARI

24 February 2008

9:35

oppose zoonotic infections but provide an important resource for better understanding virus-host interactions. In contrast to the broad antiviral action of A3G, Vif’s counterattack occurs in a highly species-speciﬁc manner (23). For example, Vif from SIVagm effectively triggers the degradation of African green monkey A3G but fails to neutralize either human or chimpanzee A3G. Similarly, HIV-1 Vif cannot induce degradation of African green monkey or rhesus macaque A3G. These species-speciﬁc limitations in Vif activity likely form an important barrier that minimizes successful zoonotic transmission of many primate lentiviruses. Of note, the fact that the Vif gene products of SIVsm and SIVcpz successfully degrade hA3G (23, 101, 102) provides a compelling explanation for how these viruses were able to spawn the HIV-1 and HIV-2 epidemics in humans. Species speciﬁcity is governed by a single amino acid at position 128 in A3G (aspartic acid in human and lysine in African green monkey) (101, 103–105) and amino acids 14–17 in Vif (106). Introduction of a D128K substitution in hA3G renders this protein sensitive to SIVagm Vif and resistant to HIV-1 Vif (101, 103–105). Corresponding mutations introduced into Vif similarly alter its species-speciﬁc effects. For example, replacement of D14 RMR17 in HIV-

1 Vif with SERQ or SEMQ, the equivalent residues in SIVagm Vif, allows functional interactions of HIV-1 Vif with rhesus macaque A3G and African green monkey A3G, as well as D128K-A3G. This loss of species restriction is likely linked to overall increase in the negative charge of amino acids 14–17 in HIV1 Vif that promotes effective interaction with the positively charged lysine present at residue 128 in African green monkey and rhesus A3G (106). Although Vif-induced degradation of hA3G plays an important role in overcoming the antiviral effects of hA3G, nondegradative mechanisms of Vif action have also been proposed. One study indicates that Vif can enhance virion infectivity even under conditions where it only moderately reduces steadystate levels of hA3G. Further, an S144A mutation in Vif that prevents phosphorylation at this site leads to progeny virions with poor infectivity. Nevertheless, this mutant effectively depletes hA3G (90). Additional complexity in Vif’s mechanism of action is highlighted by a recent report showing that Vif inhibits virion encapsidation and the antiviral activity of a hA3G variant, C97A, which is intrinsically resistant to degradation (107). Possible alternative mechanisms of Vif action include the physical exclusion of hA3G from sites of viral assembly and budding or inhibition of A3G encapsidation by competing for binding

←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−− Figure 5 The interplay of Vif and APOBEC3G. (a) Neutralization of hA3G in virus-producing cells by HIV Vif. Vif defeats the antiviral activity of hA3G principally by both binding to hA3G and recruiting an E3 ligase complex that mediates polyubiquitylation (Ubn) of hA3G. This posttranslational modiﬁcation of hA3G promotes its accelerated degradation in 26S proteasomes (1). Vif also partially impairs the translation of hA3G mRNA (2). These dual effects of Vif effectively deplete hA3G in the virus-producing cells; thus, hA3G is not available for incorporation into virions budding from these cells. Other auxiliary functions of Vif have been proposed, including physical exclusion of hA3G from virion encapsidation in the absence of degradation, perhaps owing to sequestration of hA3G away from the sites of viral assembly/budding (3). (b) Model of the Vif-Cul5-Elongin BC complex. Vif employs multiple protein interaction domains to orchestrate hA3G degradation. The N-terminal region of Vif has been implicated in its binding to an N-terminal region of hA3G (amino acids 54–124). The SLQ(Y/F)LA motif (amino acids 144–150) of Vif mediates binding to the Elongin C component of the E3 ligase complex. Finally, a novel zinc-binding motif (HCCH, amino acids 108–139) within Vif containing two conserved cysteines mediates a second interaction with the Cullin5 component. The Cul5-Vif E3 ubiquitin ligase binds hA3G and brings it into close proximity to the E2 ubiquitin-conjugating enzyme. www.annualreviews.org • The APOBEC3 Cytidine Deaminases

329

ARI

24 February 2008

9:35

to viral components like the nucleocapsid component of Gag or viral genomic RNA, which play central roles in A3G incorporation into virions (23, 107, 108) (Figure 5). Additionally, both Vif and a second viral accessory protein, Vpr, induce G2 cell-cycle arrest, which may play a role in the T cell cytopathicity induced by HIV infection (109, 110). These ﬁndings suggest that Vif may play a larger biological role beyond its function as a hA3G antagonist. Indeed, due to the limited size of the HIV genome, many viral proteins perform multiple functions, thereby achieving remarkable genetic economy.

Annu. Rev. Immunol. 2008.26:317-353. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-11

Viron Exclusion of APOBEC3G as a Common Strategy Although lentiviral Vif efﬁciently fends off A3G’s attack at least in part through proteasome-mediated degradation of the enzyme, other retroviruses have evolved rather different counterstrikes. These different strategies unambiguously highlight the importance of virion exclusion as a way to circumvent the antiviral activity of A3G. Primate foamy viruses and a distantly related feline foamy virus resist the inhibitory effects of hA3G through the action of the accessory protein Bet. Bet binds to hA3G and prevents its packaging into virus particles, but these effects do not involve degradation of hA3G in virionproducing cells (48, 49). HTLV-1 utilizes a very different strategy. Within the C-terminal region of its nucleocapsid domain, HTLV-1 encodes a peptide motif that impairs hA3G from interacting with viral genomic RNA and thus inhibits hA3G packaging into budding virions (111). This motif is highly conserved among the primate T cell leukemia viruses but is absent in all other retroviral nucleocapsid proteins. MLV replicates effectively in murine APOBEC3 (mA3)-expressing cells and survives because its Gag protein has been evolutionarily selected neither to bind nor to package the cognate mA3 enzyme. However, MLV infectivity is effectively restricted by hA3G, which continues to bind to MLV Gag (112– 330

Chiu

·

Greene

114). Similarly, Mason-Pﬁzer monkey virus (MPMV) escapes inhibition by A3G in its natural host, the rhesus macaque, by failing to incorporate rhesus A3G into budding virions. However, this virus is highly susceptible to inhibition by mA3, which efﬁciently forms a complex with MPMV Gag and is effectively encapsidated into virions (115). The ﬁnding that two essentially unrelated retroviruses (MLV and MPMV) employ similar strategies to escape inhibition by APOBEC3 proteins in their normal host species suggests that the selective exclusion of APOBEC3 proteins from virion particles represents a general mechanism employed by simple mammalian retroviruses. Although the speciﬁc virion exclusion of cognate APOBEC3 protein has been attributed to an inability to bind MLV Gag, MLV may also utilize additional strategies to prevent A3G encapsidation. Speciﬁcally, MLV viral RNA also blocks the binding of mA3 to Gag, contributing to the exclusion of mA3 from MLV virions (114). Finally, even if mA3 is successfully packaged, this antiviral enzyme may be inactivated by cleavage by the MLV protease (114).

RIBONUCLEOPROTEIN COMPLEXES INVOLVED IN REGULATING APOBEC3G ANTIVIRAL ACTIVITY Molecular Assemblies Involved in Cellular APOBEC3G Complexes Several laboratories joined in efforts to characterize the protein and RNA components of the HMM hA3G RNP complexes (71, 116, 117). Tandem afﬁnity puriﬁcation and mass spectrometry have led to the identiﬁcation of at least 95 different proteins as participants in HMM hA3G complexes. Numerous cellular RNA binding proteins with diverse roles in RNA function, metabolism, and fate determination are present in these HMM hA3G complexes, but most are present owing to their binding to resident RNAs rather than

Annu. Rev. Immunol. 2008.26:317-353. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-11

ARI

24 February 2008

9:35

their direct assembly with hA3G (71, 116, 117). These complexes actually correspond to three well-characterized multisubunit RNPs present in human cells: (a) Staufencontaining, polysome-associated RNA granules, (b) Ro RNPs, and (c) prespliceosomes plus reservoirs for transcriptional regulators (116). Of note, the protein cofactors in the latter class are multifunctional, and many participate in Staufen-containing RNA granules or function as cytoplasmic regulators of translation. Staufen, a double-stranded RNA-binding protein, is best known for its role in the localization of speciﬁc mRNAs during Drosophila oogenesis. Mammalian homologs of Staufen (Staufen1 and Staufen2) have been implicated in the function of neuronal granules within dendrites of hippocampal neurons. After synaptic stimulation, these granules are transported to the synapse, where their mRNA cargoes are rapidly translated. The resultant protein products contribute to orchestrating changes in synaptic plasticity (118, 119). In general, RNA granules are >10 MDa macromolecular RNP complexes containing more than 100 proteins, including ribosomal subunits, scaffold proteins, translation machinery, RNA-binding proteins, helicases, and various decay enzymes (i.e., Staufen; Purα; Purβ; DbpA and DbpB; nucleolin; RNA binding motif protein 3; NFAR; FMR1; FXR1; FXR2; PABP; CBP80; CBP20; EF1α; Hsp70; Upf1; 60S and 40S ribosomal proteins; DDX1; DDX3; p68 RNA helicases; RNA helicase A; and hnRNP A/B, A0, A, D, and U) (118–121). Ro RNPs are the major RNP autoantigens recognized by sera from patients with various connective tissue diseases, although their normal function remains incompletely understood. In human cells, Ro RNPs contain one of the four human small Y (hY) RNAs (hY1, hY3, hY4, and hY5) and two core proteins (60-kDa Ro and 50-kDa La) (122). Almost all of the proteins mentioned above that participate in the formation of Staufen-containing RNA granules and Ro RNPs are readily de-

tectable in the puriﬁed HMM hA3G RNP complexes. An association of hA3G with stress granules (SGs) and processing bodies (PBs) instead of RNA granules has also been proposed (69, 71, 117). RNA granules, SGs, and PBs are in fact related, dynamic cytoplasmic RNA structures that control the localization, translation, and stability of their resident mRNA cargoes. However, RNA granules harbor highly speciﬁc mRNA sequences, whereas SG and PB are less discriminating. In addition to differing in their mRNA selectivity, RNA granules contain both the 60S and 40S ribosomal subunits, whereas SGs contain only small ribosomal subunits and PBs lack both subunits (118, 119). Staufen proteins are present in all three types of cytoplasmic RNA structures (118, 119). However, the RNA granules that associate with HMM hA3G contain both the 60S and 40S ribosomal subunits and harbor highly speciﬁc mRNA cargos including hA3G mRNA (116, 117); thus, they are more reminiscent of Staufen-containing, polysome-associated RNA granules rather than of SGs or PBs. Further, an association of endogenous proteins that are characteristic components of SGs (i.e., TIA-1) and PBs (i.e., Ago2 and decapping enzymes) has not been demonstrated in HMM hA3G complexes. Nevertheless, exogenously expressed components of SGs and PBs can be copuriﬁed with HMM hA3G complexes (69, 71). Under these conditions of forced expression, confocal microscopy further supports substantial colocalization of hA3G with cytoplasmic SGs and PBs (69, 71). Indeed, hA3G complexes are shifted reversibly between polysomes and dormant pools (likely, SGs) in response to translational inhibitors (117). Stressing the cells also induces the rapid redistribution of hA3G and a number of PB proteins (Ago1 and Ago2) to SGs (71). These ﬁndings imply that the dynamic spatial organizations between RNA granules and related cytoplasmic RNA complexes could affect the status of hA3G complexes, control A3G’s antiviral activity, and www.annualreviews.org • The APOBEC3 Cytidine Deaminases

331

ANRV338-IY26-11

ARI

24 February 2008

Annu. Rev. Immunol. 2008.26:317-353. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

Retroelement: any mobile genetic element that undergoes reverse transcription and then inserts the new DNA copy into the host cell genomes

9:35

regulate translation/decay of mRNAs encoding this innate antiretroviral factor. Intriguingly, delineation of the RNA components in HMM hA3G complexes identiﬁed human Alu (Sx, Sp, Ya5, Ya8, and Yb8 subfamily) and small hY (hY1–5) endogenous retroelement RNA sequences (116). Activation of CD4 T cells with PHA and IL-2 induces high-level expression of these endogenous retroelement RNAs. Conversely, almost all of the protein cofactors that participate in the HMM A3G complexes are constitutively expressed in resting CD4 T cells but are not assembled into complexes (116). These ﬁndings raise the distinct possibility that the induced expression of Alu and hY RNAs forms the driving force for HMM hA3G complex assembly. The hA3G-dependent recruitment and speciﬁc enrichment of Alu and hY RNAs into Staufen-containing RNA granules further suggest a potential physiological function for these complexes (116). Speciﬁcally, endogenous nonautonomous retroelements (i.e., Alu and hY RNAs) (123, 124) likely form the natural cellular targets of hA3G (see below).

Intravirion APOBEC3G Complexes: Unexpected Interplay Between Host and Virus The fact that cellular hA3G principally resides in 5–15-MDa HMM RNP complexes in activated, virus-producing T cells prompted studies to determine which form of hA3G is actually incorporated into budding virions. Three models seemed possible: (a) Although unlikely, the entire HMM hA3G complex might be incorporated into budding virions; (b) hA3G residing in HMM complexes might be selectively extracted via interactions with HIV Gag and genomic RNA; and (c) newly synthesized hA3G not yet assembled into HMM complexes might be preferentially recruited into virions. When virions are examined for proteins that compose the HMM A3G complex, most are undetectable; those that are present do not appear to be recruited 332

Chiu

·

Greene

into virions in an hA3G-dependent manner (32, 117). These ﬁndings argue strongly against model a. In pulse-chase radiolabeling and size fractionation studies, hA3G is rapidly assembled (<30 min) into HMM complexes (32). Thus, only small quantities of newly synthesized LMM A3G are brieﬂy present in cells. However, pulse-chase studies revealed that virion hA3G is mainly recruited from this cellular pool of newly synthesized enzyme (32). Once hA3G becomes incorporated into the HMM complexes, it is no longer available for incorporation into virions. These unexpected ﬁndings also indicate that the small pool of newly synthesized LMM hA3G rather than the HMM A3G complex is the biologically relevant target of Vif. Although Vif promotes proteasome-mediated degradation of hA3G in the HMM complex (72), its mechanism of attack on LMM A3G remains undeﬁned. This attack could involve proteolytic degradation or effects that curtail virion encapsidation in the absence of degradation. What is the fate of the newly synthesized hA3G that is successfully incorporated into HIV virions? Because virion hA3G ultimately mediates high-level deamination of deoxycytidines in nascent minus-strand DNA formed during reverse transcription, it seemed likely that virion hA3G would be enzymatically active. However, interrogation of hA3G incorporated into virions revealed an absence of enzymatic activity (32). Apparently, the interaction of hA3G with HIV genomic RNA in the virion core leads to inhibition of its activity, analogous to the inactivation of cellular hA3G activity when it engages cellular RNAs in the HMM RNA-protein complexes (32, 72). Of note, when virions are produced under conditions of marked overexpression of hA3G, enzymatic activity of hA3G is readily apparent (36). However, under these nonphysiological conditions, excess packaging of the enzyme occurs outside of the core (32). Because this form of the enzyme is not bound to RNA, its enzymatic activity is not inhibited. The unexpected lack of enzymatic activity by virion-incorporated hA3G raised an

Annu. Rev. Immunol. 2008.26:317-353. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-11

ARI

24 February 2008

9:35

important question: How is the enzyme ultimately activated? Intriguingly, the answer appears to involve the action of HIV-1 RNase H. Degradation of the viral genomic RNA by RNase H during reverse transcription not only generates the minus-strand DNA substrate of hA3G but also removes the inhibitory RNA bound to hA3G, thereby activating its deaminase activity (32). These ﬁndings highlight an unusual virus-host interaction where initiation of antiviral enzymatic activity of hA3G is contingent on the prior action of an essential viral enzyme. These studies also imply a dual strategy for restriction of HIV-1 by hA3G that could account for the deaminase-dependent and -independent antiviral activities described above (Figure 3). Initially, the enzymatically latent form of hA3G bound to HIV-1 RNA may impair the generation of minus-strand DNA by physically impeding reverse transcriptase on its viral RNA template. However, this physical block may be incomplete, and minus-strand viral DNA may be occasionally generated. Subsequently, hA3G deaminase activity is restored when RNase H degrades the viral RNA and leaves the singlestranded DNA template intact for plus-strand synthesis, allowing extensive deamination of the minus-strand DNA. The relative effectiveness of these two sequential antiviral actions of hA3G in different cellular environments could explain why HBV replication is inhibited by deaminase-dependent actions of hA3G in HepG2 cells but by deaminaseindependent action in Huh7 cells (64–67).

APOBEC3G AND OTHER MEMBERS OF THE EXTENDED APOBEC3 GENE FAMILY Evolutionary Expansion of APOBEC3 Deaminases The gene encoding hA3G is located on chromosome 22q13.2 within a cluster of highly related APOBEC3 genes (hA3A, hA3B, hA3C, hA3DE, hA3F, and hA3H) arrayed in a head-

to-tail manner (7, 10, 12, 125). In contrast, only a single APOBEC3 gene (mA3) is present in the syntenic chromosome 15 in rodents, suggesting that the APOBEC3 locus expanded after the genetic radiation of mice and humans, likely by tandem duplication and recombination with unequal crossover (Figure 2). Four of the human APOBEC3 proteins (hA3B, hA3DE, hA3F, and hA3G) and mA3 have two CDs, whereas hA3A, hA3C, and hA3H have only a single deaminase motif (7, 10, 12, 125). Phylogenetic analyses suggest that the primordial APOBEC3 likely contained only one CD, which might have evolved from AID or APOBEC2 during the onset of vertebrate speciation (10). The presence of two CDs may increase the antiviral potency of the APOBEC3 proteins by providing a means to separate the RNA binding and catalytic activities of the enzyme. In this regard, the single domain proteins, hA3A and hA3C, are notable for their inactivity or at best weak activity against HIV-1 (126, 127). In hA3G, both CDs are required for full antiviral activity, although they serve quite distinct functions. The N-terminal CD1 has been implicated in viral-RNA binding and virion encapsidation (51–53), whereas Cterminal CD2 confers deaminase activity (51– 54) and sequence speciﬁcity (42, 44, 45, 55– 57). This separation of functional domains is maintained in hA3B and hA3F, except the target-site preference for hypermutation conferred by CD2 differs from hA3G (5 -CC and 5 -TC are the favored dinucleotides for A3G and A3B/A3F deamination, respectively) (55– 57, 127). Conversely, in murine A3, the roles of these two domains are reversed; deamination is mediated by CD1, whereas encapsidation and dimerization are mediated by CD2 (128). Interestingly, the A3F enzymes from artiodactyls (cattle, pigs, and sheep) exhibit an enzymatically active CD1, which displays a broader dinucleotide deamination preference, and CD2, which confers deaminaseindependent antiviral activity (129). Because artiodactyls are positioned between rodents www.annualreviews.org • The APOBEC3 Cytidine Deaminases

333

ANRV338-IY26-11

ARI

24 February 2008

9:35

Annu. Rev. Immunol. 2008.26:317-353. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

and primates in most mammalian phylogenetic trees, artiodactyl A3F proteins likely represent evolutionary intermediates between the rodent and primate APOBEC3 enzymes (129). These ﬁndings highlight fascinating similarities and differences in this family of enzymes, including the emergence of double domain deaminases with specialized domain functions, the “ﬂip-ﬂopping” of these domain functions during evolution, and the development of different target site speciﬁcities characteristic of the various family members.

Tantalizing Insights into the Structure of APOBEC3 Deaminases Little is known about the structure of the APOBEC3 enzymes or how they engage their polynucleotide substrates. Two recent structures provide tantalizing insights. APOBEC2 corresponds to a single domain cytidine deaminase that is principally expressed in cardiac and skeletal muscle. Its function remains unknown. APOBEC2 is the closest known paralog of APOBEC3 for which a high-resolution structure is available (130). APOBEC2 crystallizes as a rod-shaped tetramer that can be viewed as two homodimers joined head to head and held together by extensive salt bridges, hydrogen bonding, and hydrophobic packing. Homodimers of APOBEC2 principally form as a result of hydrophobic beta-sheet interactions (130). The APOBEC2 dimer appears to be analogous to a monomer of APOBEC3, which contains two catalytic domains (131, 132). If a similar structural conﬁguration holds true for the APOBEC3 family members, this could explain how these family members can bind long polynucleotide substrates because their active sites are much more exposed than those of other known deaminases that act on free cytidine or cytosine. Small-angle X-ray scattering analysis of hA3G provides independent evidence for such an extended, symmetric structure (131), which could be a key to understanding the RNA-associated HMM hA3G complexes (72). Consistent with these mod334

Chiu

·

Greene

els of dimer interaction (130, 131), active APOBEC3 proteins, including hA3G, hA3F and hA3DE, have been reported to form homodimers and heterodimers in cells (57, 125). The crystal structure of APOBEC2 provides a template for constructing a model structure for hA3G (132). Mapping of functional and evolutionarily informative residues in hA3G CD1 demonstrates that critical residues cluster in well-deﬁned patches at the surface of the model. For example, amino acids 128–130 of hA3G are critical for its interaction with Vif, while R122 and W127 are required for efﬁcient encapsidation. Placing these ﬁndings in a detailed structural model suggests a surface hot-spot domain that includes R122, W127, and D128 and overlaps with a cluster of residues under positive selective pressure that includes T98, K99, R102, D128, and P129 (132). Strategies combining extensive site-directed mutagenesis and critical residue mapping with this structural model of full-length hA3G could speed rational antiviral drug design in the near future.

Diversified Antiviral Defense by APOBEC3 Family Members Several groups have worked to deﬁne the function and spectrum of antiviral activities of the various members of the human APOBEC3 family (Table 1). Apart from hA3G, several human APOBEC3 family members (e.g., hA3F, hA3B, and hA3DE) can inhibit HIV-1. Compared to hA3G, hA3F displays lethal, but less potent editing activity against vif HIV-1 (55–57) and is slightly less sensitive to the effects of Vif (55), possibly because a different binding interface is used (133, 134). Like hA3G, hA3F probably achieves its restrictive effect through a two-pronged sequential attack: initial impairment of the generation of reverse transcript products followed by mutational inactivation of successfully formed reverse transcripts (59, 135, 136). Human A3B also has moderate activity against HIV-1, but is quite resistant to Vif (56, 137). Although hA3B, hA3F,

Annu. Rev. Immunol. 2008.26:317-353. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-11

ARI

24 February 2008

9:35

and hA3G all block HIV-1 replication when packaged into budding virions, only hA3F and hA3G are coordinately expressed in nonpermissive human T cell lines and tissues, including the primary cellular targets (CD4 T cells and macrophages) of HIV-1 (57); hA3B is barely detectable in human cell lines and tissues but is prevalent in various cancer cell lines (7, 137). Thus, A3G and A3F combine to form the dominant APOBEC3-mediate defense against HIV-1 in vivo. Like hA3G, hA3F also mediates postentry restriction of HIV-1. Although most recovered sequences are wild type, dG-to-dA hypermutations matching the recognized sequence preferences for both hA3G (CC) and hA3F (TC) are detectable in a minor subset of slowly formed reverse transcripts isolated from resting CD4 T cells infected with HIV1 (72). Furthermore, siRNA-mediated downregulation of hA3F expression in dendritic cells increases the permissiveness of these cells to HIV-1 infection (81). Human A3DE is the most recent APOBEC3 protein found to suppress HIV-1 infection (125). It is effectively encapsidated into budding virions and can mutate HIV-1 viral minus-strand DNA, albeit to a lesser extent than hA3G or hA3F. It preferentially deaminates AC, a dinucleotide motif that is distinct from that of other APOBEC3 members, but signatures of this type of mutation are evident in clinical HIV-1 isolates (125). In addition, hA3DE is more highly expressed than hA3F in biologically relevant cell targets such as CD4 T cells and macrophages (125). HIV is not the sole viral target of the APOBEC3 gene products. Indeed, each displays a different pattern of antiviral activity (Table 1). Human A3G actively suppresses the spread of HIV-1, SIV, and MLV; hA3F, hA3B, and hA3DE inhibit the replication of HIV-1 and SIV, but not MLV (56, 125, 137). Human A3C blocks SIV and HIV-1, although the anti-HIV effects are quite modest (127). Within the nucleus, hA3A blocks the replication of adeno-associated virus, which replicates as a single-stranded DNA in the nuclei of

infected cells (126). Strikingly, although failing to block HIV-1 replication when incorporated into vif HIV-1 virions, hA3A seems to be critical, likely acting in concert with hA3G, for restriction of HIV-1 infection in monocytes (82). In close parallel to the postentry restricting function of hA3G and hA3F against HIV-1, the deaminase-independent actions of hA3G, hA3F, hA3B, and hA3C sharply interfere with the HBV replication in cotransfected hepatoma cell lines. Mouse protein mA3 also restricts mouse mammary tumor virus, a betaretrovirus that replicates in lymphocytes, both in vitro and in vivo as highlighted by the increased vulnerability of mA3 knockout mice to MMTV infection (138).

Potential Roles of APOBEC3 Enzymes in HIV-1 Diversification and AIDS Progression Although current antiretroviral drugs are effective against AIDS, this may not be the case in the future. A major obstacle for controlling the spread of HIV/AIDS lies in the diversity and enormous evolutionary potential of the virus itself. Numerous HIV strains are contributing to the AIDS pandemic: two viral types (HIV-1 and HIV-2), 11 groups (M, N, and O for HIV-1 and A–H for HIV-2), and numerous subtypes, subsubtypes, and circulating recombinant forms have been described (99). The notorious genetic variation of HIV-1 has been attributed to a variety of factors, including (a) the high error rate of HIV-1 reverse transcriptase (approximately one nucleotide mistake per genome per replication cycle); (b) genomic recombination owing to the ability of reverse transcriptase to switch between the two virion-packaged viral RNA templates, coupled with the presence of multiple different proviruses in individually infected cells in vivo; and (c) the extensive and monotonous base substitutions of G to A (G-to-A hypermutations) that are evident in many viral genome sequences and account for 21% of the drug-resistance mutations against www.annualreviews.org • The APOBEC3 Cytidine Deaminases

335

ANRV338-IY26-11

Table 1

ARI

24 February 2008

9:35

Summary of restriction patterns by APOBEC proteinsa Other Viruses

Retroviruses

Annu. Rev. Immunol. 2008.26:317-353. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

HIV-1

SIVmac WT

SIVagm

WT

Δvif

APOBEC3A

−

−

APOBEC3B

+

+/−

+

+

+

+

+/−

+/−

APOBEC3C

−

+/−

−

+

−

+

+/−

−

APOBEC3DE

−

+/−

−

+

+

+

APOBEC3F

−

+

−

+

+

+

+/−

APOBEC3G Human

−

+

−

+

+

+

+

Chimpanzee

−

+

−

+

+

+

MAC

+

+

−

+

−

+

AGM

+

+

−

+

−

+

APOBEC3H

−

−

−

−

−

−

−

Mouse APOBEC3

+

+

+

+

+

+

−

Rat APOBEC1

+

+

Δvif

WT

PFV

Δvif

HTLV-1

EIAV

MLV

−

ΔBet

HBV

−

+ +

−

+

+/−

−

−

+

+

−

+

+

+

−

−

+

+

+

−

Subcellular Expression Profile

localization

LTR Retroelements IAP

MusD

Ty1

Non-LTR Retroelements L1

Alu

+

+

+

+

+

+

Keratinocytes, spleen, small intestine, monocytes, macrophages, colorectal adenocarcinoma, Burkitt’s lymphoma, chronic myelogenous leukemia

APOBEC3B

Keratinocytes, colon, small intestine, testis, ovary, stem cells, lung carcinoma, colorectal adenocarcinoma, Burkitt’s lymphoma, chronic myelogenous leukemia

N

+

+

APOBEC3C

Many tissues and a variety of cancer cell lines

N/C

+

+

+

+

APOBEC3DE

Many tissues

N/C

APOBEC3F

Many tissues and probably coexpressed with APOBEC3G

C

+

+

+

+/−

APOBEC3G Human Chimpanzee MAC AGM

Primarily expressed in the lymphoid and myeloid cell lineage, thymus, tonsil, bone marrow; also observed in testis, ovary, uterus, brain, heart, lung, liver, kidney, spleen, and pancreas, colorectal adenocarcinoma, and Burkitt’s lymphoma

C + + + +

+ − − +/−

+

− − − +/−

Chiu

·

Greene

N/C

−

APOBEC3A

336

AAV

+

−

+

ANRV338-IY26-11

Table 1

ARI

24 February 2008

9:35

(Continued )

APOBEC3H

Subcellular

LTR Retroelements

Expression Profile

localization

IAP

Peripheral blood lymphocytes, testis, ovary, fetal liver, skin, cerebellum, colon, small intestine

N/C

Mouse APOBEC3 Rat APOBEC1

C

MusD

Non-LTR Retroelements

Ty1

L1

+

+

−

+

N/C

a

Annu. Rev. Immunol. 2008.26:317-353. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

Alu

−

Abbreviations: +, restricted; −, not restricted; +/−, moderately restricted; blank, not determined. N, nuclear; C, cytoplasm; N/C, nucleo-cytoplasmic shuttling with primary signal retained in the nucleus; MAC/mac, Rhesus Macaque; AGM/agm, African green monkey; HIV, human immunodeﬁciency virus; SIV, simian immunodeﬁciency virus; HTLV-1, human T cell leukemia virus type-1; EIAV, equine infectious anemia virus; MLV, murine leukemia virus; PFV, primate foamy virus; HBV, hepatitis B virus; AAV, adeno-associated virus.

currently available protease and reverse transcriptase inhibitors (139). G-to-A hypermutation was ﬁrst noted in the HIV-1 env gene during propagation of HIV-1 virus in vitro (140). Sporadic G-to-A hypermutation sequences in clinical samples are also readily detected in multiple regions of the viral genome (141–145). These altered sequences seem to follow a speciﬁc pattern whereby hypermutation increases progressively from the 5 end of the genome to the central polypurine tract (PPT), then declines, and increases again in sequences preceding the 3 PPT (144). As shown by sequence analysis of these hypermutated HIV genomes, G-to-A transitions occur preferentially in a GA and GG dinucleotide context (140–145). Initially, this pattern was proposed to reﬂect dislocation mutagenesis in the case of GA mutations (140) and base misincorporation in the GG context, possibly stemming from suboptimal dCTP concentrations (142). The most prominent dinucleotide context (GG and GA) of mutations in the plus strand of the HIV-1 genome is consistent with the site preferences (CC and TC) for hA3G and hA3F, respectively, within the minus strand of proviral DNA. These ﬁndings suggest that G-to-A hypermutations might, in fact, result from the antiviral activity of different APOBEC3 family members (54). However, the signiﬁcance of such APOBEC3-mediated hypermutation in clinical HIV pathogenesis

remains uncertain. Nevertheless, it is striking that up to 60% of the guanines within speciﬁc segments of the HIV-1 genome are mutated. Massively edited genomes are frequently nonviable because they contain many missense and nonsense codon changes. Indeed, in a population-based study of HIV-1 proviral DNA sequences, G-to-A hypermutation conforming to expected hA3G and hA3F sequence preferences appears to be independently associated with at least a 0.7-log reduction in pretreatment viral load (146). Hypermutated viruses are also associated with slower disease progression and become predominant over time in long-term nonprogressive infection (147, 148), implying a protective role for such hypermutation. Genetic variation in APOBEC3 genes or critical cellular regulators (e.g., those involved in polyubiquitination or protein degradation) and natural variations in the expression levels of APOBEC3 proteins may impact HIV1 pathogenesis, as suggested by three recent reports. First, in an analysis of more than 3000 subjects, single nucleotide polymorphisms were identiﬁed in the hA3G gene. One of these codon-changing variants, H186R in exon 4, was polymorphic (∼37%) in African Americans, and the 186R/R genotype was strongly associated with more rapid decline in CD4 T cell numbers and accelerated progression to AIDS in HIV-infected individuals (149). www.annualreviews.org • The APOBEC3 Cytidine Deaminases

337

Annu. Rev. Immunol. 2008.26:317-353. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-11

ARI

24 February 2008

Retrotransposition: an intracellular process utilized by retroelements to replicate through reverse transcription of RNA intermediates and integration of the retroelement DNA into host cell genomes. Long interspersed nuclear element (LINE): an autonomous non-LTR retroelement with coding capacity for the protein machinery required for catalyzing its own retrotransposition Short interspersed nuclear element (SINE): a non-LTR retroelement that is dependent on LINE reverse transcription machinery for its retrotransposition

338

9:35

Second, 12 single nucleotide polymorphisms of the Cullin5 gene were examined in ﬁve longitudinal cohorts of HIV-infected patients and grouped into two clusters of related haplotypes. Six major haplotypes in cluster II were linked with more rapid CD4 T cell loss and HIV-1 disease progression (150). Interestingly, hA3G-186R and Cullin5 haplotypes likely confer independent and additive effects on the rate of CD4 T cell loss (149, 150). Third, a recent study suggests a highly signiﬁcant inverse correlation between hA3G mRNA levels in peripheral blood mononuclear cells and levels of plasma HIV-1 RNA and CD4 T cell counts, both of which are predictors of HIV disease progression in treatment-naive patients. Furthermore, hA3G mRNA levels appear higher in longterm nonprogressors than in HIV-uninfected subjects and lowest in individuals with progressive HIV disease (151). Therefore, it is highly likely that human APOBEC3 proteins, particularly hA3G and hA3F, confer an innate antiviral resistance that is clinically and biologically relevant. These effects of the APOBEC3 proteins likely modify both the efﬁciency of HIV-1 transmission and the tempo of disease progression. Do G-to-A mutations induced by the innate APOBEC3 host-defense system actively contribute to genetic variation in HIV1? Because drug-resistant strains of HIV1 often exhibit G-to-A transitions in their genomic sequences (139), it is certainly conceivable that APOBEC3-mediated hypermutation importantly contributes to the evolution of such drug resistance mutations. The effects of hA3G are likely dose-dependent, because moderately elevated levels of hA3G are associated with occasional G-to-A transitions in the wild-type virus (23). These ﬁndings illustrate how the defensive actions of the APOBEC3, if incomplete, could undermine the effectiveness of current antiretroviral therapies. It is also possible that natural variations in Vif function may result in selective or parChiu

·

Greene

tial neutralization of these APOBEC3 cytidine deaminases, thereby promoting viral sequence diversiﬁcation in HIV-1-infected persons. Indeed, defective vif alleles that cannot neutralize hA3G or hA3F are frequently detected in HIV-1 isolates and in infected patients (88). Concordantly, independently hypermutated proviruses with distinguishable patterns of G-to-A substitution attributable to deamination induced by hA3G, hA3F, or both are detectable in subjects carrying proviruses with completely or partly defective Vif variants (88). These studies suggest that sporadic inactivation of Vif likely occurs rather frequently in vivo. These apparent ﬂaws in the Vif counterstrike may be exploited by HIV-1 to accelerate viral sequence diversiﬁcation and evolution, enabling escape from both speciﬁc immune responses or antiviral drugs.

PARTICIPATION OF APOBEC3 ENZYMES IN THE CONTROL OF ENDOGENOUS RETROELEMENTS Mammalian Endogenous Retroelements The mammalian genome harbors many thousands of mobile genetic elements, including distinct families of DNA transposons and retrotransposons (123). Retrotransposons are mobile DNA sequences that integrate into the genome of host cells. New copies are generated by coupled transcription and reverse transcription followed by insertion of the new DNA into different sites in the genome. This process is termed retrotransposition as it does not involve the release of infectious particles. The major classes of endogenous retroelements in mammalian cells include elements that contain long terminal repeats (LTRs), such as endogenous retroviruses, and non-LTR retroelements, such as long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs) (123). These retroelements are believed to have played an important role in evolution and

Annu. Rev. Immunol. 2008.26:317-353. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-11

ARI

24 February 2008

9:35

speciation. However, mobilization of these elements can also be deleterious to the host cell, resulting in various genetic disorders and cancers. To limit the negative effects of retrotransposition, cells have adopted several strategies to restrict the mobility of transposable elements. Human endogenous retroviruses (HERVs) and many other non-LTR retroelements have been rendered replicationincompetent owing to the accumulation of inactivating mutations, promoter CpG methylation, or small RNA-mediated silencing (123, 152). However, some mammalian species exhibit more active retroelements. For example, although endogenous retroelements are four- to ﬁve-fold more abundant in the human genome than in the mouse genome (42% versus 8%–10%), retrotransposition activity is 100-fold higher in mouse cells (152). In mice, even endogenous retroviruses, including murine intracisternal A-particle (IAP) and MusD sequences, remained highly mobile. The singularly lower levels of retrotransposon activity found in primates intriguingly coincides with the expansion of the APOBEC3 gene cluster from a single gene in mice to seven genes in primates (7). The sequence variability of primate APOBEC3 indicates that this gene cluster has been subjected to strong positive selective pressure for more than 30 million years (153, 154). This selective pressure clearly antedates the appearance of the modern lentiviruses (∼1 Mya), further strengthening the notion that this gene family expanded in order to curtail the genomic instability caused by endogenous retroelements.

APOBEC3 Deaminases as Inhibitors of LTR Retrotransposons APOBEC3 proteins do in fact function as inhibitors of LTR retrotransposons. Human A3B, hA3C, hA3F, hA3G, and mA3 all effectively inhibit mouse IAP and MusD elements (126, 155, 156), whereas hA3C, hA3F, and hA3G inhibit the yeast Ty1 retrotrans-

poson (157, 158). APOBEC3 proteins exert dual inhibitory effects on these endogenous retroviruses, involving both a decrease in the number of transposed cDNA copies and extensive editing of the transposed copies (155, 159). These effects are reminiscent of the dual effects of hA3G in HIV-1 replication. In the mouse genome, many retrotransposon proviruses bear mutations consistent with APOBEC3-mediated deamination (155, 159). Interestingly, hA3A effectively inhibits IAP and MusD retrotransposition through a novel deamination-independent mechanism (156). Although none of the HERVs currently present in the human genome are replication competent, a pseudoancestral HERV-K DNA sequence was recently reconstructed based on the fossil record of ancient endogenous retroviruses. Of note, this reconstituted human retrovirus is effectively restricted by hA3F but not by hA3G (160).

HERV: human endogenous retrovirus

APOBEC3 Deaminases as Inhibitors of Non-LTR Retrotransposons What about the non-LTR retroelements that are continuing to retrotranspose in the human genome? These retroelements can be subdivided into autonomous LINEs (L1 being the most common), nonautonomous SINEs (Alu being the most prevalent), and processed pseudogenes (123). The average human diploid genome contains 80–100 active L1 retroelements, which encode the enzymes needed for their own retrotransposition. Alu elements constitute ∼10% of the human genome. These small retroelements lack protein-coding capacity but retrotranspose by “stealing” the reverse transcriptase/endonuclease enzymes encoded by the L1 open reading frame (ORF) 2 (123, 161). The replication cycle of L1 and Alu involves cytoplasmic RNA intermediates, reverse transcription in the nucleus, and integration of the newly formed DNA at novel chromosomal sites (Figure 6). Human APOBEC3 proteins, including hA3A, hA3B, hA3C, and hA3F, effectively inhibit L1 retroelements (70, 126, www.annualreviews.org • The APOBEC3 Cytidine Deaminases

339

ANRV338-IY26-11

ARI

a

24 February 2008

9:35

b

LINE 1 (L1) (6 kb) 5' UTR ORF1

ORF2

SINE (Alu) (100–300 bp)

3' UTR AAAAAA

A B

AAAAAA

Human genome AAAAAA

Pol II-mediated transcription

AAAAAA

APOBEC3A/3B/3C

Integration

AAAAA

L1 RNA

AAAAAA

Pol II-mediated transcription L1 RNA

Pol III-mediated transcription Alu RNA

AAAA A

AAA AA

ORF2 AA AA A

AAAA

Annu. Rev. Immunol. 2008.26:317-353. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

Export

L1 ORF2-mediated reverse transcription

A

Nuclear pore

AAAA

ORF2 A AAA

A AAA

ORF2

Export

AA

A

Export

Import N U C L EU S

Translation

C YTOPLA YTO PLA SM SM AAAAA

L1 RNA 5'

ORF ORF1

L1 RNA 5'

ORF1

ORF2 L1 RNP A A AA A

assembly

Translation L1 RNA 5'

A A

AAAAA

APOBEC3B

Alu RNA AAA U UU

APOBEC3G

APOBEC3F ORF2 ORF1 ORF2

HMM APOBEC3G

Figure 6 Human APOBEC3 protects cells from the potentially detrimental effects of non-LTR retroelements. (a) Human APOBEC3 proteins, including hA3A, hA3B, hA3C, and hA3F, inhibit human LINE (long interspersed nuclear elements)-1 (L1) retroelements. Functional L1 elements are 6-kb long autonomous retroelements that contain an internal RNA polymerase II (Pol II) promoter within their 5 UTR, two open reading frames (ORF1 and ORF2), and a 3 UTR. L1 retroelements are characterized by ﬂanking target site duplications (short black arrows) that vary in length (usually 9–20 nucleotides) and by the presence of a poly(A)-rich tail. L1 retrotransposition involves the initial production of cytoplasmic RNA intermediates that in turn are reverse transcribed by ORF2 in the nucleus, and integration occurs at new genetic sites to complete the retrotransposition cycle. A number of human APOBEC3 proteins, including hA3A, hA3B, and hA3C, have been reported to inhibit retrotransposition of human L1 retroelements, reﬂecting their ability to enter the nucleus, where L1 reverse transcription and integration occur. Interactions of hA3B and hA3F with the L1 ORF2 protein have been suggested. (b) Human A3G proteins inhibit L1-dependent Alu retrotransposition through a novel nonenzymatic inhibitory mechanism directly targeting Alu RNA transcripts. Short interspersed nuclear elements (SINEs), including the most prominent and active member Alu, correspond to short RNA polymerase III (Pol III)-transcribed retroelements that contain an internal promoter but no protein coding capacity. Successful retrotransposition of Alu elements depends on their ability to “steal” the reverse transcriptase/endonuclease enzymes encoded by L1 ORF2. Human A3G impairs the retrotransposition of Alu by sequestering Alu RNA transcripts in the cytoplasmic HMM complexes, especially Staufen-containing RNA granules, away from the nuclear L1 machinery, thereby interdicting the retrotransposition cycle. Human A3A, hA3B, and, to a lesser extent, hA3C also inhibit Alu retrotransposition, although in this case the A3 proteins target the L1 machinery required for Alu retrotransposition (see panel a).

156, 162); hA3A, hA3B, and to a lesser extent hA3C also inhibit L1-mediated Alu retrotransposition (156). This ﬁnding could reﬂect the ability of these deaminases to en340

Chiu

·

Greene

ter the nucleus (126, 156), where L1 reverse transcription occurs. Human A3B and A3F may also directly interact with the L1 ORF2 protein through a highly homologous region

Annu. Rev. Immunol. 2008.26:317-353. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-11

ARI

24 February 2008

9:35

present in these two deaminases. Of note, this domain is not present in hA3G (162) (Figure 6). Notably, hA3G does not affect the retrotransposition of L1 (70, 126, 155, 156, 162, 163), but it greatly inhibits L1-dependent retrotransposition of Alu retroelements (116, 164) (Figure 6). Catalytically inactive mutants of hA3G also effectively inhibit Alu retrotransposition, suggesting an enzymeindependent mechanism for hA3G action (116, 164). Experimentally, hA3G sequesters Alu RNAs in cytoplasmic HMM complexes, particularly Staufen-containing RNA granules, denying these retroelements access to the nuclear L1 machinery. These effects appear to explain how hA3G interdicts the Alu retrotransposition cycle (116). This inhibitory mechanism does not involve editing of the Alu RNA and also differs from hA3A- and hA3B-mediated inhibition of Alu retrotransposition, where the APOBEC3 proteins alter the activity of the L1 machinery in the nucleus. The lack of inhibitory effect of hA3G on autonomous L1 may reﬂect efﬁcient assembly of retrotransposing L1 RNA with its catalytic machinery encoded by the same RNA, a phenomenon termed cis preference, which minimizes hA3G’s opportunity to act. Although retrotransposition events occasionally occur in speciﬁc somatic cell types, L1 and Alu retrotransposition are most active in germ cells and during early embryogenesis, where extensive genome demethylation prevails and retroelements are thought to be transcribed and expressed (123, 152). Novel heritable insertions of L1 and Alu occur in ∼1 in 50 and ∼1 in 250 live human births, respectively (123, 152). Such retrotransposition events may also contribute to spontaneous abortions. The relatively high-level expression of APOBEC3 proteins in human testis and ovary (hA3G, hA3F, and hA3C) (7, 12) and embryonic stem cells (hA3B) (156) points to a physiologically relevant role for these DNA deaminases in the protection of these cells from the potentially deleterious effects of endogenous retroelement retrotransposi-

tion. The APOBEC3 family likely evolved in uniquely different ways to defend the integrity of the human genome against the attack leveled by various classes of endogenous retroelements.

THERAPEUTIC PERSPECTIVES AND FUTURE DIRECTIONS Vif Antagonists as Novel Therapeutics Advances in APOBEC3 biology provide a number of attractive targets for the development of novel anti-HIV-1 drugs. Enhancing hA3G/hA3F activities and inhibiting Vif function are attractive therapeutic strategies. Progress in deciphering how Vif counteracts hA3G action suggests various possibilities for developing a new class of anti-HIV drugs. Many HIV researchers regard the Vif-hA3G axis as the most attractive new drug target to emerge since the identiﬁcation of the HIV coreceptors. The ﬁrst and perhaps most attractive approach would be to identify smallmolecule inhibitors that selectively disrupt the binding of HIV-1 Vif to hA3G proteins. Such inhibitors would prevent Vif-mediated degradation of hA3G, promoting its effective encapsidation. Although these inhibitors would necessarily have to interfere with a proteinprotein interface, the fact that the D128K mutation completely blocks HIV-1 Vif binding is encouraging. Another point of attack might include blocking Vif recruitment of the E3 ligase complex by interfering with the binding of Cullin5 or Elongin C to Vif. However, a potential drawback to this approach is that Vif would still bind to hA3G and might be coencapsidated, with uncertain effects on A3G antiviral activity.

Potential Strategies to Boost the Expression of APOBEC3 Deaminases Identifying the signaling pathways that lead to APOBEC3 expression might be www.annualreviews.org • The APOBEC3 Cytidine Deaminases

341

ARI

24 February 2008

9:35

therapeutically valuable if APOBEC3 levels could be safely boosted beyond the capacity of Vif to deplete the enzyme. For example, hA3G is present at low levels in resting T cells but is strongly induced when these cells are activated by phytohemagglutinin and IL2 (24). PMA stimulation of H9 T cells activates hA3G gene transcription via the MAP kinase signaling pathway (165). It might be possible to use cytokines (IL-2, IL-7, and IL15) to elevate the levels of hA3G/hA3F beyond the capacity of Vif to deplete the intracellular stores of these deaminases (77). Of note, interferon-α (IFN-α) treatment of macrophages markedly upregulates hA3G and A3A expression, and the induction of hA3G appears to be a major component of the IFN-α-induced anti-HIV response in these cells (82, 166). However, an appreciation of the respective contributions of these potential beneﬁcial effects must be weighed against the possible role of APOBEC3 enzymes in promoting viral diversity and drug resistance as well a mutation of the host genome. Additional information concerning the factors that regulate the levels of APOBEC3 expression might also provide a means to counteract Vif-mediated degradation. The speciﬁc enrichment of hA3G/hA3F mRNA in HMM hA3G complexes, particularly Staufen-containing RNA granules (116), along with translation initiation and elongation factors, provides an attractive mechanism to explain how destruction of the HMM complex by Vif (72) might impair de novo synthesis of hA3G (23, 24). Together with the proposed association of hA3G with SGs and PBs in response to the addition of translational inhibitors and agents that induce cellular stress (69, 71, 117), these ﬁndings suggest that the intracellular signals and molecular interactions governing the inducible formation, dynamic spatial localization, and controlled disassembly of RNA granules and related cytoplasmic RNA structures could serve as major regulatory switches controlling the expression and antiviral activity of hA3G/hA3F in human cells.

Annu. Rev. Immunol. 2008.26:317-353. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-11

342

Chiu

·

Greene

The signiﬁcant upregulation of APOBEC3 (hA3G, hA3F, and hA3B) protein expression that occurs in primary hepatocytes in response to IFN-α provides a possible mechanism for interferon-mediated noncytolytic clearance of HBV (67). A better understanding of the potential participation of APOBEC3 proteins in this response could facilitate the identiﬁcation of new therapeutic strategies for HBV. Furthermore, population genetic analyses indicate that the hA3B gene is inﬂuenced by a 29.5-kb deletion polymorphism in the human genome and that the frequency varies signiﬁcantly among major ethnic groups (167). Because expression of hA3B in primary hepatocytes can be induced by IFN-α treatment, it will be interesting to determine whether the hA3B polymorphism correlates with the susceptibility of different human populations to infection with HBV or other hepadnaviruses.

Enforcing the Postentry Antiviral Activity of APOBEC3G The discovery of LMM hA3G as a postentry restriction factor in resting CD4 T cells and in cells within the monocyte lineage suggests it might be possible to recapitulate this activity or prevent its inactivation in cells normally permissive of HIV-1 infection (72, 80, 81, 166). A hA3G mutant constitutively residing in the LMM form, even after T cell activation or monocyte differentiation, could provide early intracellular resistance against incoming viruses. To avoid promiscuous editing of host genomic DNA, it will be important to determine whether catalytically inactive LMM hA3G can also mediate this postentry block. The conversion of LMM to HMM complexes after T cell activation merits careful assessment in terms of the signals and molecular pathways that induce this response. For example, cytokine stimulation appears to promote the assembly of hA3G into enzymatically inactive HMM complexes and thus creates a permissive state for HIV-1 in resting T cells in the absence of full-ﬂedged cellular

ANRV338-IY26-11

ARI

24 February 2008

9:35

Annu. Rev. Immunol. 2008.26:317-353. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

activation and proliferation (76, 77). Similarly, it has been proposed that IFN-α locks hA3G in an LMM complex in activated CD4 T cells and confers anti-HIV-1 activity (168). Insights into the protein and RNA cofactors in HMM hA3G and the factors that govern complex assembly will undoubtedly be important for developing strategies to block HMM hA3G complex formation without compromising the ability of these HMM hA3G complexes to restrict endogenous retroelements retrotransposition.

Other Questions Meriting Further Investigation In summary, APOBEC3 proteins inhibit a range of exogenous viruses and endogenous mobile retroelements by multiple mechanisms. Many basic questions remain to be explored. The antiviral mechanisms of the APOBEC3 family appear to involve their intrinsic RNA binding and deaminase activities, yet uncertainty persists regarding the relative role and effectiveness of each. It is also unclear whether the mechanism employed by Vif

to counteract hA3G/hA3F activity solely involves protein degradation and virion exclusion. Neither is it known whether different APOBEC genotypes correlate with susceptibility to HIV infection and progression to AIDS or whether endogenous retroelements such as Alu and hY RNAs are the nucleating factors for HMM hA3G complex assembly and, if they are, whether downregulation of these endogenous retroelements would help to preserve hA3G in LMM form, thereby conferring potent postentry restricting activity even in activated CD4 T cells. Finally, the mobility of L1 and Alu elements often results in both insertional and postinsertional mutagenesis, which is commonly associated with cancer and leukemia development. It remains unclear whether, when, or how APOBEC3 proteins curtail such events in vivo and whether these proteins really function as inhibitors of tumorigenesis. Studies addressing these topics are urgently needed to derive clear insights into the exact relevance of the APOBEC3 family in retroviral pathogenesis in vivo and its potential role in maintaining host genomic stability.

DISCLOSURE STATEMENT The authors are not aware of any biases that might be perceived as affecting the objectivity of this review.

ACKNOWLEDGMENTS We wish to acknowledge the outstanding contributions from various laboratories in the APOBEC ﬁeld that we were unable to cite owing to space limitations. Research in our laboratory is supported by funding from the National Institutes of Health Grants R01 AI065329–01 (to W.C.G.) and RR18928–01; the San Francisco Women’s HIV Interdisciplinary Network (National Institutes of Health Grant P01 HD40543 to W.C.G.); American Foundation for AIDS Research Grant 10652535-RFHF (to Y.-L.C.); and University of California San Francisco–Gladstone Institute of Virology and Immunology Center for AIDS Research Grant AI0277635P30GY. We thank John Carroll for assistance with graphics, Gary Howard and Stephen Ordway for editorial assistance, and Mr. Robin Givens for administrative support.

LITERATURE CITED 1. Gabuzda DH, Lawrence K, Langhoff E, Terwilliger E, Dorfman T, et al. 1992. Role of vif in replication of human immunodeﬁciency virus type 1 in CD4+ T lymphocytes. J. Virol. 66:6489–95 www.annualreviews.org • The APOBEC3 Cytidine Deaminases

343

ARI

24 February 2008

9:35

2. Sova P, Volsky DJ. 1993. Efﬁciency of viral DNA synthesis during infection of permissive and nonpermissive cells with vif-negative human immunodeﬁciency virus type 1. J. Virol. 67:6322–26 3. von Schwedler U, Song J, Aiken C, Trono D. 1993. Vif is crucial for human immunodeﬁciency virus type 1 proviral DNA synthesis in infected cells. J. Virol. 67:4945–55 4. Madani N, Kabat D. 1998. An endogenous inhibitor of human immunodeﬁciency virus in human lymphocytes is overcome by the viral Vif protein. J. Virol. 72:10251–55 5. Simon JH, Gaddis NC, Fouchier RA, Malim MH. 1998. Evidence for a newly discovered cellular anti-HIV-1 phenotype. Nat. Med. 4:1397–400 6. Sheehy AM, Gaddis NC, Choi JD, Malim MH. 2002. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418:646–50 7. Jarmuz A, Chester A, Bayliss J, Gisbourne J, Dunham I, et al. 2002. An anthropoid-speciﬁc locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics 79:285–96 8. Teng B, Burant CF, Davidson NO. 1993. Molecular cloning of an apolipoprotein B messenger RNA editing protein. Science 260:1816–19 9. Harris RS, Petersen-Mahrt SK, Neuberger MS. 2002. RNA editing enzyme APOBEC1 and some of its homologs can act as DNA mutators. Mol. Cell 10:1247–53 10. Conticello SG, Thomas CJ, Petersen-Mahrt SK, Neuberger MS. 2005. Evolution of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases. Mol. Biol. Evol. 22:367–77 11. Rogozin IB, Basu MK, Jordan IK, Pavlov YI, Koonin EV. 2005. APOBEC4, a new member of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases predicted by computational analysis. Cell Cycle 4:1281–85 12. OhAinle M, Kerns JA, Malik HS, Emerman M. 2006. Adaptive evolution and antiviral activity of the conserved mammalian cytidine deaminase APOBEC3H. J. Virol. 80:3853– 62 13. Espinosa R III, Funahashi T, Hadjiagapiou C, Le Beau MM, Davidson NO. 1994. Assignment of the gene encoding the human apolipoprotein B mRNA editing enzyme (APOBEC1) to chromosome 12p13.1. Genomics 24:414–15 14. Muto T, Muramatsu M, Taniwaki M, Kinoshita K, Honjo T. 2000. Isolation, tissue distribution, and chromosomal localization of the human activation-induced cytidine deaminase (AID) gene. Genomics 68:85–88 15. Mehta A, Kinter MT, Sherman NE, Driscoll DM. 2000. Molecular cloning of apobec1 complementation factor, a novel RNA-binding protein involved in the editing of apolipoprotein B mRNA. Mol. Cell Biol. 20:1846–54 16. Yamanaka S, Balestra ME, Ferrell LD, Fan J, Arnold KS, et al. 1995. Apolipoprotein B mRNA-editing protein induces hepatocellular carcinoma and dysplasia in transgenic animals. Proc. Natl. Acad. Sci. USA 92:8483–87 17. Muramatsu M, Sankaranand VS, Anant S, Sugai M, Kinoshita K, et al. 1999. Speciﬁc expression of activation-induced cytidine deaminase (AID), a novel member of the RNAediting deaminase family in germinal center B cells. J. Biol. Chem. 274:18470–76 18. Muramatsu M, Kinoshita K, Fagarasan S, Yamada S, Shinkai Y, Honjo T. 2000. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 102:553–63 19. Rada C, Williams GT, Nilsen H, Barnes DE, Lindahl T, Neuberger MS. 2002. Immunoglobulin isotype switching is inhibited and somatic hypermutation perturbed in UNG-deﬁcient mice. Curr. Biol. 12:1748–55

Annu. Rev. Immunol. 2008.26:317-353. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-11

344

Chiu

·

Greene

Annu. Rev. Immunol. 2008.26:317-353. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-11

ARI

24 February 2008

9:35

20. Revy P, Muto T, Levy Y, Geissmann F, Plebani A, et al. 2000. Activation-induced cytidine deaminase (AID) deﬁciency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2). Cell 102:565–75 21. Okazaki IM, Hiai H, Kakazu N, Yamada S, Muramatsu M, et al. 2003. Constitutive expression of AID leads to tumorigenesis. J. Exp. Med. 197:1173–81 22. Beale RC, Petersen-Mahrt SK, Watt IN, Harris RS, Rada C, Neuberger MS. 2004. Comparison of the differential context-dependence of DNA deamination by APOBEC enzymes: correlation with mutation spectra in vivo. J. Mol. Biol. 337:585–96 23. Mariani R, Chen D, Schrofelbauer B, Navarro F, Konig R, et al. 2003. Species-speciﬁc exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 114:21–31 24. Stopak K, de Noronha C, Yonemoto W, Greene WC. 2003. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol. Cell 12:591–601 25. Cen S, Guo F, Niu M, Saadatmand J, Deﬂassieux J, Kleiman L. 2004. The interaction between HIV-1 Gag and APOBEC3G. J. Biol. Chem. 279:33177–84 26. Luo K, Liu B, Xiao Z, Yu Y, Yu X, et al. 2004. Amino-terminal region of the human immunodeﬁciency virus type 1 nucleocapsid is required for human APOBEC3G packaging. J. Virol. 78:11841–52 27. Alce TM, Popik W. 2004. APOBEC3G is incorporated into virus-like particles by a direct interaction with HIV-1 Gag nucleocapsid protein. J. Biol. Chem. 279:34083–86 28. Svarovskaia ES, Xu H, Mbisa JL, Barr R, Gorelick RJ, et al. 2004. Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs. J. Biol. Chem. 279:35822–28 29. Schafer A, Bogerd HP, Cullen BR. 2004. Speciﬁc packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor. Virology 328:163–68 30. Zennou V, Perez-Caballero D, Gottlinger H, Bieniasz PD. 2004. APOBEC3G incorporation into human immunodeﬁciency virus type 1 particles. J. Virol. 78:12058–61 31. Khan MA, Kao S, Miyagi E, Takeuchi H, Goila-Gaur R, et al. 2005. Viral RNA is required for the association of APOBEC3G with human immunodeﬁciency virus type 1 nucleoprotein complexes. J. Virol. 79:5870–74 32. Soros VB, Yonemoto W, Greene WC. 2007. Newly synthesized APOBEC3G is incorporated into HIV virions, inhibited by HIV RNA, and subsequently activated by RNase H. PLoS Pathog. 3:e15 33. Burnett A, Spearman P. 2007. APOBEC3G multimers are recruited to the plasma membrane for packaging into human immunodeﬁciency virus type 1 virus-like particles in an RNA-dependent process requiring the NC basic linker. J. Virol. 81:5000–13 34. Khan MA, Goila-Gaur R, Opi S, Miyagi E, Takeuchi H, et al. 2007. Analysis of the contribution of cellular and viral RNA to the packaging of APOBEC3G into HIV-1 virions. Retrovirology 4:48 35. Xu H, Chertova E, Chen J, Ott DE, Roser JD, et al. 2007. Stoichiometry of the antiviral protein APOBEC3G in HIV-1 virions. Virology 360:247–56 36. Yu Q, Konig R, Pillai S, Chiles K, Kearney M, et al. 2004. Single-strand speciﬁcity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat. Struct. Mol. Biol. 11:435–42 37. Suspene R, Sommer P, Henry M, Ferris S, Guetard D, et al. 2004. APOBEC3G is a single-stranded DNA cytidine deaminase and functions independently of HIV reverse transcriptase. Nucleic Acids Res. 32:2421–29 www.annualreviews.org • The APOBEC3 Cytidine Deaminases

345

ARI

24 February 2008

9:35

38. Schrofelbauer B, Yu Q, Zeitlin SG, Landau NR. 2005. Human immunodeﬁciency virus type 1 Vpr induces the degradation of the UNG and SMUG uracil-DNA glycosylases. J. Virol. 79:10978–87 39. Yang B, Chen K, Zhang C, Huang S, Zhang H. 2007. Virion-associated uracil DNA glycosylase-2 and apurinic/apyrimidinic endonuclease are involved in the degradation of APOBEC3G-edited nascent HIV-1 DNA. J. Biol. Chem. 282:11667–75 40. Kaiser SM, Emerman M. 2006. Uracil DNA glycosylase is dispensable for human immunodeﬁciency virus type 1 replication and does not contribute to the antiviral effects of the cytidine deaminase Apobec3G. J. Virol. 80:875–82 41. Mbisa JL, Barr R, Thomas JA, Vandegraaff N, Dorweiler IJ, et al. 2007. HIV-1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration. J. Virol. 81:7099–110 42. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D. 2003. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424:99–103 43. Lecossier D, Bouchonnet F, Clavel F, Hance AJ. 2003. Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science 300:1112 44. Harris RS, Bishop KN, Sheehy AM, Craig HM, Petersen-Mahrt SK, et al. 2003. DNA deamination mediates innate immunity to retroviral infection. Cell 113:803–9 45. Zhang H, Yang B, Pomerantz RJ, Zhang C, Arunachalam SC, Gao L. 2003. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 424:94–98 46. Suspene R, Rusniok C, Vartanian JP, Wain-Hobson S. 2006. Twin gradients in APOBEC3 edited HIV-1 DNA reﬂect the dynamics of lentiviral replication. Nucleic Acids Res. 34:4677–84 47. Chelico L, Pham P, Calabrese P, Goodman MF. 2006. APOBEC3G DNA deaminase acts processively 3 → 5 on single-stranded DNA. Nat. Struct. Mol. Biol. 13:392–99 48. Lochelt M, Romen F, Bastone P, Muckenfuss H, Kirchner N, et al. 2005. The antiretroviral activity of APOBEC3 is inhibited by the foamy virus accessory Bet protein. Proc. Natl. Acad. Sci. USA 102:7982–87 49. Russell RA, Wiegand HL, Moore MD, Schafer A, McClure MO, Cullen BR. 2005. Foamy virus Bet proteins function as novel inhibitors of the APOBEC3 family of innate antiretroviral defense factors. J. Virol. 79:8724–31 50. Delebecque F, Suspene R, Calattini S, Casartelli N, Saib A, et al. 2006. Restriction of foamy viruses by APOBEC cytidine deaminases. J. Virol. 80:605–14 51. Navarro F, Bollman B, Chen H, Konig R, Yu Q, et al. 2005. Complementary function of the two catalytic domains of APOBEC3G. Virology 333:374–86 52. Newman EN, Holmes RK, Craig HM, Klein KC, Lingappa JR, et al. 2005. Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Curr. Biol. 15:166–70 53. Iwatani Y, Takeuchi H, Strebel K, Levin JG. 2006. Biochemical activities of highly puriﬁed, catalytically active human APOBEC3G: correlation with antiviral effect. J. Virol. 80:5992–6002 54. Hache G, Liddament MT, Harris RS. 2005. The retroviral hypermutation speciﬁcity of APOBEC3F and APOBEC3G is governed by the C-terminal DNA cytosine deaminase domain. J. Biol. Chem. 280:10920–24 55. Liddament MT, Brown WL, Schumacher AJ, Harris RS. 2004. APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Curr. Biol. 14:1385–91

Annu. Rev. Immunol. 2008.26:317-353. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-11

346

Chiu

·

Greene

Annu. Rev. Immunol. 2008.26:317-353. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-11

ARI

24 February 2008

9:35

56. Bishop KN, Holmes RK, Sheehy AM, Davidson NO, Cho SJ, Malim MH. 2004. Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr. Biol. 14:1392–96 57. Wiegand HL, Doehle BP, Bogerd HP, Cullen BR. 2004. A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. EMBO J. 23:2451–58 58. Klarmann GJ, Chen X, North TW, Preston BD. 2003. Incorporation of uracil into minus strand DNA affects the speciﬁcity of plus strand synthesis initiation during lentiviral reverse transcription. J. Biol. Chem. 278:7902–9 59. Bishop KN, Holmes RK, Malim MH. 2006. Antiviral potency of APOBEC proteins does not correlate with cytidine deamination. J. Virol. 80:8450–58 60. Guo F, Cen S, Niu M, Saadatmand J, Kleiman L. 2006. Inhibition of formula-primed reverse transcription by human APOBEC3G during human immunodeﬁciency virus type 1 replication. J. Virol. 80:11710–22 61. Luo K, Wang T, Liu B, Tian C, Xiao Z, et al. 2007. Cytidine deaminases APOBEC3G and APOBEC3F interact with HIV-1 integrase and inhibit proviral DNA formation. J. Virol. 81:7238–48 62. Sasada A, Takaori-Kondo A, Shirakawa K, Kobayashi M, Abudu A, et al. 2005. APOBEC3G targets human T-cell leukemia virus type 1. Retrovirology 2:32 63. Mahieux R, Suspene R, Delebecque F, Henry M, Schwartz O, et al. 2005. Extensive editing of a small fraction of human T-cell leukemia virus type 1 genomes by four APOBEC3 cytidine deaminases. J. Gen. Virol. 86:2489–94 64. Turelli P, Mangeat B, Jost S, Vianin S, Trono D. 2004. Inhibition of hepatitis B virus replication by APOBEC3G. Science 303:1829 65. Rosler C, Kock J, Malim MH, Blum HE, von Weizsacker F. 2004. Comment on “Inhibition of hepatitis B virus replication by APOBEC3G.” Science 305:1403 66. Suspene R, Guetard D, Henry M, Sommer P, Wain-Hobson S, Vartanian JP. 2005. Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivo. Proc. Natl. Acad. Sci. USA 102:8321–26 67. Bonvin M, Achermann F, Greeve I, Stroka D, Keogh A, et al. 2006. Interferon-inducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication. Hepatology 43:1364–74 68. Wichroski MJ, Ichiyama K, Rana TM. 2005. Analysis of HIV-1 viral infectivity factormediated proteasome-dependent depletion of APOBEC3G: correlating function and subcellular localization. J. Biol. Chem. 280:8387–96 69. Wichroski MJ, Robb GB, Rana TM. 2006. Human retroviral host restriction factors APOBEC3G and APOBEC3F localize to mRNA processing bodies. PLoS Pathog. 2:e41 70. Muckenfuss H, Hamdorf M, Held U, Perkovic M, Lower J, et al. 2006. APOBEC3 proteins inhibit human LINE-1 retrotransposition. J. Biol. Chem. 281:22161–72 71. Gallois-Montbrun S, Kramer B, Swanson CM, Byers H, Lynham S, et al. 2007. Antiviral protein APOBEC3G localizes to ribonucleoprotein complexes found in P bodies and stress granules. J. Virol. 81:2165–78 72. Chiu YL, Soros VB, Kreisberg JF, Stopak K, Yonemoto W, Greene WC. 2005. Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells. Nature 435:108–14 73. Zack JA, Arrigo SJ, Weitsman SR, Go AS, Haislip A, Chen IS. 1990. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell 61:213–22 74. Stevenson M, Stanwick TL, Dempsey MP, Lamonica CA. 1990. HIV-1 replication is controlled at the level of T cell activation and proviral integration. EMBO J. 9:1551–60 www.annualreviews.org • The APOBEC3 Cytidine Deaminases

347

ARI

24 February 2008

9:35

75. Eckstein DA, Penn ML, Korin YD, Scripture-Adams DD, Zack JA, et al. 2001. HIV1 actively replicates in naive CD4+ T cells residing within human lymphoid tissues. Immunity 15:671–82 76. Kreisberg JF, Yonemoto W, Greene WC. 2006. Endogenous factors enhance HIV infection of tissue naive CD4 T cells by stimulating high molecular mass APOBEC3G complex formation. J. Exp. Med. 203:865–70 77. Stopak KS, Chiu YL, Kropp J, Grant RM, Greene WC. 2007. Distinct patterns of cytokine regulation of APOBEC3G expression and activity in primary lymphocytes, macrophages, and dendritic cells. J. Biol. Chem. 282:3539–46 78. Korin YD, Zack JA. 1998. Progression to the G1b phase of the cell cycle is required for completion of human immunodeﬁciency virus type 1 reverse transcription in T cells. J. Virol. 72:3161–68 79. Camaur D, Trono D. 1996. Characterization of human immunodeﬁciency virus type 1 Vif particle incorporation. J. Virol. 70:6106–11 80. Ellery PJ, Tippett E, Chiu YL, Paukovics G, Cameron PU, et al. 2007. The CD16+ monocyte subset is more permissive to infection and preferentially harbors HIV-1 in vivo. J. Immunol. 178:6581–89 81. Pion M, Granelli-Piperno A, Mangeat B, Stalder R, Correa R, et al. 2006. APOBEC3G/3F mediates intrinsic resistance of monocyte-derived dendritic cells to HIV-1 infection. J. Exp. Med. 203:2887–93 82. Peng G, Greenwell-Wild T, Nares S, Jin W, Lei KJ, et al. 2007. Myeloid differentiation and susceptibility to HIV-1 are linked to APOBEC3 expression. Blood 110:393–400 83. Sonza S, Maerz A, Deacon N, Meanger J, Mills J, Crowe S. 1996. Human immunodeﬁciency virus type 1 replication is blocked prior to reverse transcription and integration in freshly isolated peripheral blood monocytes. J. Virol. 70:3863–69 84. Neil S, Martin F, Ikeda Y, Collins M. 2001. Postentry restriction to human immunodeﬁciency virus-based vector transduction in human monocytes. J. Virol. 75:5448–56 85. Triques K, Stevenson M. 2004. Characterization of restrictions to human immunodeﬁciency virus type 1 infection of monocytes. J. Virol. 78:5523–27 86. Conticello SG, Harris RS, Neuberger MS. 2003. The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr. Biol. 13:2009–13 87. Marin M, Rose KM, Kozak SL, Kabat D. 2003. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat. Med. 9:1398–403 88. Simon V, Zennou V, Murray D, Huang Y, Ho DD, Bieniasz PD. 2005. Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversiﬁcation. PLoS Pathog. 1:e6 89. Yu X, Yu Y, Liu B, Luo K, Kong W, et al. 2003. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302:1056–60 90. Mehle A, Strack B, Ancuta P, Zhang C, McPike M, Gabuzda D. 2004. Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitinproteasome pathway. J. Biol. Chem. 279:7792–98 91. Mehle A, Goncalves J, Santa-Marta M, McPike M, Gabuzda D. 2004. Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation. Genes Dev. 18:2861–66 92. Yu Y, Xiao Z, Ehrlich ES, Yu X, Yu XF. 2004. Selective assembly of HIV-1 Vif-Cul5ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines. Genes Dev. 18:2867–72 93. Mehle A, Thomas ER, Rajendran KS, Gabuzda D. 2006. A zinc-binding region in Vif binds Cul5 and determines cullin selection. J. Biol. Chem. 281:17259–65

Annu. Rev. Immunol. 2008.26:317-353. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-11

348

Chiu

·

Greene

Annu. Rev. Immunol. 2008.26:317-353. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-11

ARI

24 February 2008

9:35

94. Xiao Z, Ehrlich E, Yu Y, Luo K, Wang T, et al. 2006. Assembly of HIV-1 Vif-Cul5 E3 ubiquitin ligase through a novel zinc-binding domain-stabilized hydrophobic interface in Vif. Virology 349:290–99 95. Luo K, Xiao Z, Ehrlich E, Yu Y, Liu B, et al. 2005. Primate lentiviral virion infectivity factors are substrate receptors that assemble with cullin 5-E3 ligase through a HCCH motif to suppress APOBEC3G. Proc. Natl. Acad. Sci. USA 102:11444–49 96. Sheehy AM, Gaddis NC, Malim MH. 2003. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat. Med. 9:1404–7 97. Douaisi M, Dussart S, Courcoul M, Bessou G, Lerner EC, et al. 2005. The tyrosine kinases Fyn and Hck favor the recruitment of tyrosine-phosphorylated APOBEC3G into vif-defective HIV-1 particles. Biochem. Biophys. Res. Commun. 329:917–24 98. Fujita M, Sakurai A, Yoshida A, Miyaura M, Koyama AH, et al. 2003. Amino acid residues 88 and 89 in the central hydrophilic region of human immunodeﬁciency virus type 1 Vif are critical for viral infectivity by enhancing the steady-state expression of Vif. J. Virol. 77:1626–32 99. Sharp PM, Bailes E, Chaudhuri RR, Rodenburg CM, Santiago MO, Hahn BH. 2001. The origins of acquired immune deﬁciency syndrome viruses: where and when? Philos. Trans. R. Soc. London B Biol. Sci. 356:867–76 100. Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, Sodroski J. 2004. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 427:848–53 101. Xu H, Svarovskaia ES, Barr R, Zhang Y, Khan MA, et al. 2004. A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion. Proc. Natl. Acad. Sci. USA 101:5652–57 102. Gaddis NC, Sheehy AM, Ahmad KM, Swanson CM, Bishop KN, et al. 2004. Further investigation of simian immunodeﬁciency virus Vif function in human cells. J. Virol. 78:12041–46 103. Bogerd HP, Doehle BP, Wiegand HL, Cullen BR. 2004. A single amino acid difference in the host APOBEC3G protein controls the primate species speciﬁcity of HIV type 1 virion infectivity factor. Proc. Natl. Acad. Sci. USA 101:3770–74 104. Mangeat B, Turelli P, Liao S, Trono D. 2004. A single amino acid determinant governs the species-speciﬁc sensitivity of APOBEC3G to Vif action. J. Biol. Chem. 279:14481– 83 105. Schrofelbauer B, Chen D, Landau NR. 2004. A single amino acid of APOBEC3G controls its species-speciﬁc interaction with virion infectivity factor (Vif ). Proc. Natl. Acad. Sci. USA 101:3927–32 106. Schrofelbauer B, Senger T, Manning G, Landau NR. 2006. Mutational alteration of human immunodeﬁciency virus type 1 Vif allows for functional interaction with nonhuman primate APOBEC3G. J. Virol. 80:5984–91 107. Opi S, Kao S, Goila-Gaur R, Khan MA, Miyagi E, et al. 2007. Human immunodeﬁciency virus type 1 Vif inhibits packaging and antiviral activity of a degradation-resistant APOBEC3G variant. J. Virol. 81:8236–46 108. Kao S, Miyagi E, Khan MA, Takeuchi H, Opi S, Goila-Gaur R, Strebel K. 2004. Production of infectious human immunodeﬁciency virus type 1 does not require depletion of APOBEC3G from virus-producing cells. Retrovirology 1:27 109. Sakai K, Dimas J, Lenardo MJ. 2006. The Vif and Vpr accessory proteins independently cause HIV-1-induced T cell cytopathicity and cell cycle arrest. Proc. Natl. Acad. Sci. USA 103:3369–74 www.annualreviews.org • The APOBEC3 Cytidine Deaminases

349

ARI

24 February 2008

9:35

110. Wang J, Shackelford JM, Casella CR, Shivers DK, Rapaport EL, et al. 2007. The Vif accessory protein alters the cell cycle of human immunodeﬁciency virus type 1 infected cells. Virology 359:243–52 111. Derse D, Hill SA, Princler G, Lloyd P, Heidecker G. 2007. Resistance of human T cell leukemia virus type 1 to APOBEC3G restriction is mediated by elements in nucleocapsid. Proc. Natl. Acad. Sci. USA 104:2915–20 112. Kobayashi M, Takaori-Kondo A, Shindo K, Abudu A, Fukunaga K, Uchiyama T. 2004. APOBEC3G targets speciﬁc virus species. J. Virol. 78:8238–44 113. Doehle BP, Schafer A, Wiegand HL, Bogerd HP, Cullen BR. 2005. Differential sensitivity of murine leukemia virus to APOBEC3-mediated inhibition is governed by virion exclusion. J. Virol. 79:8201–7 114. Abudu A, Takaori-Kondo A, Izumi T, Shirakawa K, Kobayashi M, et al. 2006. Murine retrovirus escapes from murine APOBEC3 via two distinct novel mechanisms. Curr. Biol. 16:1565–70 115. Doehle BP, Bogerd HP, Wiegand HL, Jouvenet N, Bieniasz PD, et al. 2006. The betaretrovirus Mason-Pﬁzer monkey virus selectively excludes simian APOBEC3G from virion particles. J. Virol. 80:12102–8 116. Chiu YL, Witkowska HE, Hall SC, Santiago M, Soros VB, et al. 2006. High-molecularmass APOBEC3G complexes restrict Alu retrotransposition. Proc. Natl. Acad. Sci. USA 103:15588–93 117. Kozak SL, Marin M, Rose KM, Bystrom C, Kabat D. 2006. The anti-HIV-1 editing enzyme APOBEC3G binds HIV-1 RNA and messenger RNAs that shuttle between polysomes and stress granules. J. Biol. Chem. 281:29105–19 118. Kiebler MA, Bassell GJ. 2006. Neuronal RNA granules: movers and makers. Neuron 51:685–90 119. Anderson P, Kedersha N. 2006. RNA granules. J. Cell Biol. 172:803–8 120. Kanai Y, Dohmae N, Hirokawa N. 2004. Kinesin transports RNA: isolation and characterization of an RNA-transporting granule. Neuron 43:513–25 121. Villace P, Marion RM, Ortin J. 2004. The composition of Staufen-containing RNA granules from human cells indicates their role in the regulated transport and translation of messenger RNAs. Nucleic Acids Res. 32:2411–20 122. Fabini G, Rutjes SA, Zimmermann C, Pruijn GJ, Steiner G. 2000. Analysis of the molecular composition of Ro ribonucleoprotein complexes. Identiﬁcation of novel Y RNAbinding proteins. Eur. J. Biochem. 267:2778–89 123. Kazazian HHJ. 2004. Mobile elements: drivers of genome evolution. Science 303:1626–32 124. Perreault J, Noel JF, Briere F, Cousineau B, Lucier JF, et al. 2005. Retropseudogenes derived from the human Ro/SS-A autoantigen-associated hY RNAs. Nucleic Acids Res. 33:2032–41 125. Dang Y, Wang X, Esselman WJ, Zheng YH. 2006. Identiﬁcation of APOBEC3DE as another antiretroviral factor from the human APOBEC family. J. Virol. 80:10522–33 126. Chen H, Lilley CE, Yu Q, Lee DV, Chou J, et al. 2006. APOBEC3A is a potent inhibitor of Adeno-associated virus and retrotransposons. Curr. Biol. 16:480–85 127. Yu Q, Chen D, Konig R, Mariani R, Unutmaz D, Landau NR. 2004. APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeﬁciency virus replication. J. Biol. Chem. 279:53379–86 128. Hakata Y, Landau NR. 2006. Reversed functional organization of mouse and human APOBEC3 cytidine deaminase domains. J. Biol. Chem. 281:36624–31

Annu. Rev. Immunol. 2008.26:317-353. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-11

350

Chiu

·

Greene

Annu. Rev. Immunol. 2008.26:317-353. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-11

ARI

24 February 2008

9:35

129. Jonsson SR, Hache G, Stenglein MD, Fahrenkrug SC, Andresdottir V, Harris RS. 2006. Evolutionarily conserved and nonconserved retrovirus restriction activities of artiodactyl APOBEC3F proteins. Nucleic Acids Res. 34:5683–94 130. Prochnow C, Bransteitter R, Klein MG, Goodman MF, Chen XS. 2007. The APOBEC-2 crystal structure and functional implications for the deaminase AID. Nature 445:447–51 131. Wedekind JE, Gillilan R, Janda A, Krucinska J, Salter JD, et al. 2006. Nanostructures of APOBEC3G support a hierarchical assembly model of high molecular mass ribonucleoprotein particles from dimeric subunits. J. Biol. Chem. 281:38122–26 132. Zhang KL, Mangeat B, Ortiz M, Zoete V, Trono D, et al. 2007. Model structure of human APOBEC3G. PLoS ONE 2:e378 133. Tian C, Yu X, Zhang W, Wang T, Xu R, Yu XF. 2006. Differential requirement for conserved tryptophans in human immunodeﬁciency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F. J. Virol. 80:3112–15 134. Russell RA, Pathak VK. 2007. Identiﬁcation of two distinct HIV-1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F. J. Virol. 81:8201–10 135. Holmes RK, Koning FA, Bishop KN, Malim MH. 2007. APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G. J. Biol. Chem. 282:2587–95 136. Yang Y, Guo F, Cen S, Kleiman L. 2007. Inhibition of initiation of reverse transcription in HIV-1 by human APOBEC3F. Virology 365:92–100 137. Doehle BP, Schafer A, Cullen BR. 2005. Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif. Virology 339:281–88 138. Okeoma CM, Lovsin N, Peterlin BM, Ross SR. 2007. APOBEC3 inhibits mouse mammary tumour virus replication in vivo. Nature 445:927–30 139. Berkhout B, De Ronde A. 2004. APOBEC3G vs reverse transcriptase in the generation of HIV-1 drug-resistance mutations. AIDS 18:1861–63 140. Vartanian JP, Meyerhans A, Asjo B, Wain-Hobson S. 1991. Selection, recombination, and G–>A hypermutation of human immunodeﬁciency virus type 1 genomes. J. Virol. 65:1779–88 141. Fitzgibbon JE, Mazar S, Dubin DT. 1993. A new type of G–>A hypermutation affecting human immunodeﬁciency virus. AIDS Res. Hum. Retroviruses 9:833–38 142. Vartanian JP, Meyerhans A, Sala M, Wain-Hobson S. 1994. G–>A hypermutation of the human immunodeﬁciency virus type 1 genome: evidence for dCTP pool imbalance during reverse transcription. Proc. Natl. Acad. Sci. USA 91:3092–96 143. Borman AM, Quillent C, Charneau P, Kean KM, Clavel F. 1995. A highly defective HIV-1 group O provirus: evidence for the role of local sequence determinants in G–>A hypermutation during negative-strand viral DNA synthesis. Virology 208:601–9 144. Janini M, Rogers M, Birx DR, McCutchan FE. 2001. Human immunodeﬁciency virus type 1 DNA sequences genetically damaged by hypermutation are often abundant in patient peripheral blood mononuclear cells and may be generated during near-simultaneous infection and activation of CD4+ T cells. J. Virol. 75:7973–86 145. Kieffer TL, Kwon P, Nettles RE, Han Y, Ray SC, Siliciano RF. 2005. G–>A hypermutation in protease and reverse transcriptase regions of human immunodeﬁciency virus type 1 residing in resting CD4+ T cells in vivo. J. Virol. 79:1975–80 146. Pace C, Keller J, Nolan D, James I, Gaudieri S, et al. 2006. Population level analysis of human immunodeﬁciency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation. J. Virol. 80:9259–69 www.annualreviews.org • The APOBEC3 Cytidine Deaminases

351

ARI

24 February 2008

9:35

147. Wang B, Mikhail M, Dyer WB, Zaunders JJ, Kelleher AD, Saksena NK. 2003. First demonstration of a lack of viral sequence evolution in a nonprogressor, deﬁning replication-incompetent HIV-1 infection. Virology 312:135–50 148. Wei M, Xing H, Hong K, Huang H, Tang H, et al. 2004. Biased G-to-A hypermutation in HIV-1 proviral DNA from a long-term nonprogressor. AIDS 18:1863–65 149. An P, Bleiber G, Duggal P, Nelson G, May M, et al. 2004. APOBEC3G genetic variants and their inﬂuence on the progression to AIDS. J. Virol. 78:11070–76 150. An P, Duggal P, Wang LH, O’Brien SJ, Donﬁeld S, et al. 2007. Polymorphisms of CUL5 are associated with CD4+ T cell loss in HIV-1 infected individuals. PLoS Genet. 3:e19 151. Jin X, Wu H, Smith H. 2007. APOBEC3G levels predict rates of progression to AIDS. Retrovirology 4:20 152. Maksakova IA, Romanish MT, Gagnier L, Dunn CA, van de Lagemaat LN, Mager DL. 2006. Retroviral elements and their hosts: insertional mutagenesis in the mouse germ line. PLoS Genet. 2:e2 153. Sawyer SL, Emerman M, Malik HS. 2004. Ancient adaptive evolution of the primate antiviral DNA-editing enzyme APOBEC3G. PLoS Biol. 2:e275 154. Zhang J, Webb DM. 2004. Rapid evolution of primate antiviral enzyme APOBEC3G. Hum. Mol. Genet. 13:1785–91 155. Esnault C, Heidmann O, Delebecque F, Dewannieux M, Ribet D, et al. 2005. APOBEC3G cytidine deaminase inhibits retrotransposition of endogenous retroviruses. Nature 433:430–33 156. Bogerd HP, Wiegand HL, Doehle BP, Lueders KK, Cullen BR. 2006. APOBEC3A and APOBEC3B are potent inhibitors of LTR-retrotransposon function in human cells. Nucleic Acids Res. 34:89–95 157. Dutko JA, Schafer A, Kenny AE, Cullen BR, Curcio MJ. 2005. Inhibition of a yeast LTR retrotransposon by human APOBEC3 cytidine deaminases. Curr. Biol. 15:661–66 158. Schumacher AJ, Nissley DV, Harris RS. 2005. APOBEC3G hypermutates genomic DNA and inhibits Ty1 retrotransposition in yeast. Proc. Natl. Acad. Sci. USA 102:9854–59 159. Esnault C, Millet J, Schwartz O, Heidmann T. 2006. Dual inhibitory effects of APOBEC family proteins on retrotransposition of mammalian endogenous retroviruses. Nucleic Acids Res. 34:1522–31 160. Lee YN, Bieniasz PD. 2007. Reconstitution of an infectious human endogenous retrovirus. PLoS Pathog. 3:e10 161. Dewannieux M, Esnault C, Heidmann T. 2003. LINE-mediated retrotransposition of marked Alu sequences. Nat. Genet. 35:41–48 162. Stenglein MD, Harris RS. 2006. APOBEC3B and APOBEC3F inhibit L1 retrotransposition by a DNA deamination-independent mechanism. J. Biol. Chem. 281:16837–41 163. Turelli P, Vianin S, Trono D. 2004. The innate antiretroviral factor APOBEC3G does not affect human LINE-1 retrotransposition in a cell culture assay. J. Biol. Chem. 279:43371– 73 164. Hulme AE, Bogerd HP, Cullen BR, Moran JV. 2007. Selective inhibition of Alu retrotransposition by APOBEC3G. Gene 390:199–205 165. Rose KM, Marin M, Kozak SL, Kabat D. 2004. Transcriptional regulation of APOBEC3G, a cytidine deaminase that hypermutates human immunodeﬁciency virus. J. Biol. Chem. 279:41744–79 166. Peng G, Lei KJ, Jin W, Greenwell-Wild T, Wahl SM. 2006. Induction of APOBEC3 family proteins, a defensive maneuver underlying interferon-induced anti-HIV-1 activity. J. Exp. Med. 203:41–46

Annu. Rev. Immunol. 2008.26:317-353. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-11

352

Chiu

·

Greene

ANRV338-IY26-11

ARI

24 February 2008

9:35

Annu. Rev. Immunol. 2008.26:317-353. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

167. Kidd JM, Newman TL, Tuzun E, Kaul R, Eichler EE. 2007. Population stratiﬁcation of a common APOBEC gene deletion polymorphism. PLoS Genet. 3:e63 168. Chen K, Huang J, Zhang C, Huang S, Nunnari G, et al. 2006. Alpha interferon potently enhances the antihuman immunodeﬁciency virus type 1 activity of APOBEC3G in resting primary CD4 T cells. J. Virol. 80:7645–57

www.annualreviews.org • The APOBEC3 Cytidine Deaminases

353

AR338-FM

ARI

12 January 2008

18:11

Annual Review of Immunology

Annu. Rev. Immunol. 2008.26:317-353. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

Contents

Volume 26, 2008

Frontispiece K. Frank Austen p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p x Doing What I Like K. Frank Austen p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p1 Protein Tyrosine Phosphatases in Autoimmunity Torkel Vang, Ana V. Miletic, Yutaka Arimura, Lutz Tautz, Robert C. Rickert, and Tomas Mustelin p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p 29 Interleukin-21: Basic Biology and Implications for Cancer and Autoimmunity Rosanne Spolski and Warren J. Leonard p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p 57 Forward Genetic Dissection of Immunity to Infection in the Mouse S.M. Vidal, D. Malo, J.-F. Marquis, and P. Gros p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p 81 Regulation and Functions of Blimp-1 in T and B Lymphocytes Gislâine Martins and Kathryn Calame p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p133 Evolutionarily Conserved Amino Acids That Control TCR-MHC Interaction Philippa Marrack, James P. Scott-Browne, Shaodong Dai, Laurent Gapin, and John W. Kappler p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p171 T Cell Trafﬁcking in Allergic Asthma: The Ins and Outs Benjamin D. Medoff, Seddon Y. Thomas, and Andrew D. Luster p p p p p p p p p p p p p p p p p p p p p205 The Actin Cytoskeleton in T Cell Activation Janis K. Burkhardt, Esteban Carrizosa, and Meredith H. Shaffer p p p p p p p p p p p p p p p p p p p p233 Mechanism and Regulation of Class Switch Recombination Janet Stavnezer, Jeroen E.J. Guikema, and Carol E. Schrader p p p p p p p p p p p p p p p p p p p p p p p261 Migration of Dendritic Cell Subsets and their Precursors Gwendalyn J. Randolph, Jordi Ochando, and Santiago Partida-Sánchez p p p p p p p p p p p p p293

v

AR338-FM

ARI

12 January 2008

18:11

The APOBEC3 Cytidine Deaminases: An Innate Defensive Network Opposing Exogenous Retroviruses and Endogenous Retroelements Ya-Lin Chiu and Warner C. Greene p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p317 Thymus Organogenesis Hans-Reimer Rodewald p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p355 Death by a Thousand Cuts: Granzyme Pathways of Programmed Cell Death Dipanjan Chowdhury and Judy Lieberman p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p389 Annu. Rev. Immunol. 2008.26:317-353. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

Monocyte-Mediated Defense Against Microbial Pathogens Natalya V. Serbina, Ting Jia, Tobias M. Hohl, and Eric G. Pamer p p p p p p p p p p p p p p p p p p p421 The Biology of Interleukin-2 Thomas R. Malek p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p453 The Biochemistry of Somatic Hypermutation Jonathan U. Peled, Fei Li Kuang, Maria D. Iglesias-Ussel, Sergio Roa, Susan L. Kalis, Myron F. Goodman, and Matthew D. Scharff p p p p p p p p p p p p p p p p p p p p p481 Anti-Inﬂammatory Actions of Intravenous Immunoglobulin Falk Nimmerjahn and Jeffrey V. Ravetch p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p513 The IRF Family Transcription Factors in Immunity and Oncogenesis Tomohiko Tamura, Hideyuki Yanai, David Savitsky, and Tadatsugu Taniguchi p p p p p535 Choreography of Cell Motility and Interaction Dynamics Imaged by Two-Photon Microscopy in Lymphoid Organs Michael D. Cahalan and Ian Parker p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p585 Development of Secondary Lymphoid Organs Troy D. Randall, Damian M. Carragher, and Javier Rangel-Moreno p p p p p p p p p p p p p p p p627 Immunity to Citrullinated Proteins in Rheumatoid Arthritis Lars Klareskog, Johan Rönnelid, Karin Lundberg, Leonid Padyukov, and Lars Alfredsson p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p651 PD-1 and Its Ligands in Tolerance and Immunity Mary E. Keir, Manish J. Butte, Gordon J. Freeman, and Arlene H. Sharpe p p p p p p p p677 The Master Switch: The Role of Mast Cells in Autoimmunity and Tolerance Blayne A. Sayed, Alison Christy, Mary R. Quirion, and Melissa A. Brown p p p p p p p p p p705 T Follicular Helper (TFH ) Cells in Normal and Dysregulated Immune Responses Cecile King, Stuart G. Tangye, and Charles R. Mackay p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p741

vi

Contents

ANRV338-IY26-12

ARI

16 February 2008

12:33

Thymus Organogenesis Annu. Rev. Immunol. 2008.26:355-388. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

Hans-Reimer Rodewald Institute for Immunology, University of Ulm, D-89070 Ulm, Germany; email: [email protected]

Annu. Rev. Immunol. 2008. 26:355–88

Key Words

First published online as a Review in Advance on November 30, 2007

thymus medulla, thymus cortex, germ layers, thymus epithelial stem and progenitor cells, transcription factors, cervical thymus, reaggregate organ cultures, Cre recombinase, fate mapping, nude blastocyst complementation

The Annual Review of Immunology is online at immunol.annualreviews.org This article’s doi: 10.1146/annurev.immunol.26.021607.090408 c 2008 by Annual Reviews. Copyright All rights reserved 0732-0582/08/0423-0355$20.00

Abstract The epithelial architecture of the thymus fosters growth, differentiation, and T cell receptor repertoire selection of large numbers of immature T cells that continuously feed the mature peripheral T cell pool. Failure to build or to maintain a proper thymus structure can lead to defects ranging from immunodeﬁciency to autoimmunity. There has been long-standing interest in unraveling the cellular and molecular basis of thymus organogenesis. Earlier studies gave important morphological clues on thymus development. More recent cell biological and genetic approaches yielded new and conclusive insights regarding the germ layer origin of the epithelium and the composition of the medulla as a mosaic of clonally derived islets. The existence of epithelial progenitors common for cortex and medulla with the capacity for forming functional thymus after birth has been uncovered. In addition to the thymus in the chest, mice can have a cervical thymus that is small, but functional, and produces T cells only after birth. It will be important to elucidate the pathways from putative thymus stem cells to mature thymus epithelial cells, and the properties and regulation of these pathways from ontogeny to thymus involution.

355

ANRV338-IY26-12

ARI

16 February 2008

12:33

INTRODUCTION

Annu. Rev. Immunol. 2008.26:355-388. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

The classical embryological view of thymus development that had been perpetuated for decades has undergone major revisions within the past few years. Advancing the understanding of thymus organ development has been slow by comparison to the progress in research addressing cellular pathways and underlying molecular mechanisms of developing T cells. Why are experiments addressing the development of the thymus interesting? The unique function of the thymus in establishment and maintenance of the T cell arm of the immune system is intimately linked to specialized functions of thymus stromal cells and the thymus architecture (1, 2). These cells are of major immunological relevance for the intrathymic selection of a selftolerant and self-MHC-restricted T cell antigen receptor (TCR) repertoire (3–6). It is broadly recognized that thymus structure is key to these speciﬁc immunological properties of the thymus. This, combined with the realization that thymus structure and its development are, in large part, still uncharted territory, has spurred increased interest in thymus organogenesis. Novel experimental access has been facilitated by the development of experimental tools such as, to name a few, stromal cell isolation by phenotype-based cell sorting (e.g., 7– 9), dissociation and reaggregation of stromal cell subsets to probe their functional capacity in vitro (10, 11) and in vivo (e.g., 12–15), or global gene expression analyses to determine the pattern of self-antigen expression in thymus epithelial cell (TEC) subsets (5). Key questions in thymus organogenesis surround the fundamental cellular and molecular mechanisms that lead to the formation of a normal thymus. Areas of interest include the transient or permanent germ layer contribution to thymus structure, that is, origin of TEC, and other stromal elements; the quest for thymusbuilding and/or maintaining stem or progenitor cells; an understanding of the turnover of thymus stromal elements in the steady-state

356

Rodewald

thymus; and the role of thymus stromal cells in thymus involution or pathology-associated transient thymus malfunctions (16). In particular, quantitative answers to many of these questions would be useful. For instance, the number of cells with TEC-forming potential (TEC progenitors) needs to be determined, as well as their clonogenic potential, steps of commitment, life span, etc. Thymus stroma can be viewed as all nonhematopoietic components of the thymus that are functionally deﬁned as those elements, regardless of their origin and lineage, that constitute the thymus structure, and hence provide the matrix on which thymocytes develop (Figure 1). A simple, but useful classiﬁcation of stroma lacking the pan-hematopoietic marker CD45 is based on keratin expression, in that keratin+ cells represent thymus epithelium, and keratin− cells are a mixture of mesenchymal cells. Keratin+ cells are composed of two major subsets referred to as cortical TEC (cTEC) and medullary TEC (mTEC). Keratin− cells—by default collectively considered as mesenchymal cells—include ﬁbroblasts (17), nonﬁbroblastic mesenchymal cells (9), capsule- and septae-forming connective tissue cells, and endothelial cells forming the typical thymus vasculature (9, 18, 19). Finally, dendritic cells and macrophages that are CD45+ hematopoietic cells are also important elements of thymus stroma. Stroma is not only heterogeneous at a given time point, but its composition also varies considerably over time (20). Such restructuring can reach extreme forms under thymus-ablating conditions (steroid treatment, irradiation, cachectic conditions) or with age-associated thymus involution, events that seriously impair thymus function (16). The cellular heterogeneity of thymus structure, as is true for most organs, poses intrinsic difﬁculties to analyze the development or function of given cell types in the physiological context and their transient or permanent contribution to the thymus structure and function. Moreover, direct from indirect

ANRV338-IY26-12

ARI

16 February 2008

12:33

Phenotypes

Cell types

Medullary TEC +

Keratin

Cortical TEC

Origins

Third pharyngeal pouch endoderm TEC progenitors; Foxn1-dependent

Annu. Rev. Immunol. 2008.26:355-388. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

CD45–

Capsule Septae Keratin–

Endothelium Fibrobasts Nonfibroblastmesenchyme

Neural crest mesenchyme early in ontogeny with minor contribution to adult thymus?; replenished from “local” mesenchyme? Foxn1-independent

Thymus

Thymocytes Dendritic cells CD45+

Macrophages

Hematopoietic stem cells; continuous colonization

B cells Figure 1 Major cell types in the thymus and their developmental origin. The thymus can be divided into hematopoietic cells (CD45+ ) that are transient passengers and resident stromal cells (CD45− ). CD45− cells include two lineages: Thymus epithelial cells (TEC, Keratin+ ) that originate from pharyngeal pouch endoderm (third pouch in the mouse) and mesenchymal cells (Keratin− ), which are a mixture of cell types that contribute to various structures of the thymus such as capsule or vasculature. The origin of the mesenchyme appears heterogeneous. The ratio of CD45+ to CD45− cells is about 50 to 1, but most of the depicted cell types can be isolated based on phenotype from thymus cell suspensions following enzymatic digestion of the thymus.

phenotypes are not easily distinguishable because defects in one cell type may cause alterations in other cell types as well. This limitation also holds true for conclusions drawn about the relationship between overall organ architecture and T cell development, and vice versa, or, in short, the concept of crosstalk (21).

Until about 2001, the prevailing view of thymus organogenesis was, at least in part, based on early morphological studies that had to rely on extrapolation from standing pictures to moving cells (22). Anatomical but also functional data were obtained by grafting experiments in developing birds (23, 24). Collectively, these studies led to the view that www.annualreviews.org • Thymus Organogenesis

357

ARI

16 February 2008

12:33

epithelial cells of endodermal and ectodermal origin (22) and mesenchymal cells of neuroectodermal (neural crest) origin (23, 24) all contributed directly or indirectly to the thymus. Directly means that cells and their progeny constitute thymus structure, as is the case for pharyngeal pouch–derived epithelium, and indirectly means that cells provide inductive signals in trans. Neural crest (NC)derived mesenchyme is thought to fall in this latter category. To what extent it also contributes to thymus structure has not been fully resolved. The mechanism that establishes the separation into the inner, morphologically lighter zone, the medulla, and the outer, morphologically darker zone, the cortex, had apparently been settled many years ago. A look at the evolution of the immune system strongly suggests that medulla-cortex organization is functionally important because, as soon as there was a thymus, this architectural hallmark of the thymus was present (25). According to an earlier model of cortex and medulla development (22), a layer of pharyngeal pouch epithelium (endoderm) was the source of medullary epithelium, whereas its surrounding cortex was derived from a layer of ectodermal epithelium. The latter was donated by the cervical vesicle, ectodermal epithelium that comes closely into the proximity of the endodermal pouch at one point in ontogeny (embryonic day 10.5 in the mouse). Hence, medulla-cortex organization was supposed to be established from two cell layers by a mechanism involving invagination and circumferential growth. The model implying cell layer movements was revised by the ﬁnding that the medullary epithelium is composed of single epithelial cell–derived islets that coalesce to form larger medullary areas in the adult thymus (13, 26). Hence, the medulla develops from few progenitors, and the extent of progenitor proliferation establishes the boundaries between medulla and cortex. The remarkable capacity of cell suspensions of puriﬁed fetal thymus epithelial cells to reaggregate in vitro (11) and to form a functional thymus when grafted under the kid-

Annu. Rev. Immunol. 2008.26:355-388. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-12

358

Rodewald

ney capsule (12) paved the way to examine the potential of fetal epithelial cells, or subsets thereof. Based on this approach, a TEC stem/progenitor phenotype was proposed a few years ago (14, 15), but the exclusivity of this phenotype was questioned recently (27). Hence, the search to identify, enumerate, and functionally characterize true thymic stem or progenitor cells is only beginning. In fact, it is not clear whether self-renewing thymic epithelial stem cells exist, and if so, to what extent they are involved in the generation, or regeneration, of the thymus. Grafting techniques were further reﬁned by mixing in single, genetically marked cells into a donor thymus, followed by grafting of this tagged tissue, and subsequent visualization of single cell–derived medullary and cortical TEC progeny (26, 28, 29). Moreover, genetic activation of single thymic epithelial cells in athymic nude mice showed that one TEC progenitor could form small yet functional thymus units, again composed of medulla and cortex. This can happen, at least experimentally, early after birth in the thorax and hence later than normal and away from its normal physiological place, the third pouch (26; discussed in 29). On the basis of dyemarking and embryo culture techniques and in line with earlier studies on thymus development in birds (23), researchers abandoned the dual germ layer origin model of mouse thymus epithelium in favor of a single endodermal origin model (30, 31). By deﬁnition, the identiﬁcation of clonal common medulla and cortex progenitors also calls for a common germ layer origin (26, 28). The structural components of the thymus have been only poorly accessible for a long time, mostly owing to difﬁculties or inefﬁciency in retrieving these cells from the solid organ. This, however, is a prerequisite, for instance, to probe the stromal cell subsets functionally (10) or phenotypically (8). Monoclonal antibodies and other reagents that speciﬁcally recognize subtypes of stromal cells have been instrumental in dissecting the thymus structure (8, 32–36). Mutations

Annu. Rev. Immunol. 2008.26:355-388. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-12

ARI

16 February 2008

12:33

can now be introduced into thymus epithelium by tissue-speciﬁc gene targeting (37) that has been applied to thymus stromal cells (38, 39), or by nude mouse [ forkhead box N1 gene (Foxn1nu/nu )] blastocyst complementation (9). Mice expressing Cre recombinase speciﬁcally in ancestors and/or their progeny of thymus epithelial cells (Foxn1Cre ) (39, 40) will prove useful not only for studying gene function in thymus organogenesis but also for clarifying the origin and lineage relationship of stromal cell subsets (fate mapping). Strategies for gene targeting in, and fate mapping of, thymus epithelial cells are depicted in Figure 2. Visualization of thymus epithelium by expression of markers such as enhanced green ﬂuorescent protein (Egfp) (Foxn1Egfp ) (41) or enzymes (Foxn1LacZ ) (39, 40) under the control of TEC-speciﬁc genes should also shed new light onto the development and maintenance of TEC and reveal temporal and special changes in expression patterns of TEC genes. Finally, genetic screens in vertebrates other than mice, e.g., zebraﬁsh, are ongoing and aim at the identiﬁcation of new genes that control thymus organogenesis (42, 43). Rather than attempting a comprehensive coverage of all current knowledge of thymus organogenesis, this review focuses on signiﬁcant recent advances in the ﬁeld, starting with a brief primer on the embryological origin of the thymus in phylogeny and concluding with the recently identiﬁed functional second thymus in mice, located in the neck.

PHYLOGENY OF THYMUS ORGANOGENESIS The appearance of the thymus in evolution is linked to the appearance of lymphocytes expressing highly diverse antigen-recognition receptors based on DNA recombination of variable (V), diversity (D), and joining ( J) gene elements. This diversity, combined with stringent selection processes forced onto developing lymphocytes, allowed for self-nonself discrimination that is a condition of cellmediated adaptive immunity (44–47). The

thymus evolved as the primary lymphoid organ to fulﬁll these functions, that is, generation of a large and selected T cell repertoire. In light of recent ideas on anatomical microcompartments that serve as specialized hematopoietic and stem cell niches, it is noteworthy that T cells required an entire organ, and not merely a niche. The thymus is an autonomous organ, physically separated from the general primary hematopoietic sites such as the bone marrow. The destructive potential of T cells, once released into the body following incomplete or faulty selection in an only poorly separated niche, could have necessitated the emergence of an entirely separate organ. No thymus is known in species more primitive than vertebrates. Among vertebrates, only jawed, and not jawless (agnatha such as lamprey), species have a thymus (44–46). The precise embryological origin of the thymus, the number of thymus organs per animal, and the ﬁnal anatomical positions of thymus lobes all differ markedly in different species (Figure 3) (reviewed in 48). The common theme is that the thymus always originates from pharyngeal pouches that arise as specialized pockets of the foregut endodermal tube. Pharyngeal pouches harbor primordia for organs and tissues later found in chest, neck, or head regions, including the thymus, and the parathyroid gland (49). The origin of the thymus in the inner layer of an embryonic gut ancestor is reminiscent of GALT (gut-associated lymphoid tissue), which is a key lymphoid structure in species prior to the appearance of a thymus. Thus, the thymus may have evolved as a GALT derivative (45). The most primitive thymus-bearing species are cartilaginous ﬁsh (e.g., sharks and rays). In sharks, thymus anlagen are located in the second to sixth pouch, whereas they are found in the second pouch in frogs, in the second and third in reptiles, and in the third and/or fourth in bony ﬁsh, birds, and mammals (Figure 3). Thus, species are ﬂexible in positioning of the thymus anlage somewhere along the pharyngeal foregut endoderm. Numbers and positions of the www.annualreviews.org • Thymus Organogenesis

359

ANRV338-IY26-12

ARI

16 February 2008

12:33

ﬁnal thymus, or thymi, can also be variable. Chickens have seven, sharks ﬁve, and urodele (e.g., salamander) amphibians three thymus pairs, while many teleost ﬁsh species, anuran amphibians (e.g., frogs), and many mammals have only one thymus composed of two bilat-

eral lobes. The position of thymus in the neck and/or in the chest in different mammals is discussed in the context of the cervical thymus in the mouse. In some species, each thymus has a private anlage. For instance, in sharks, ﬁve thymus

Strategies for gene targeting in and fate mapping of thymus epithelium

Annu. Rev. Immunol. 2008.26:355-388. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

a

Nude blastocyst complementation

b

Foxn1+/+ ES cells with homozygous mutation in gene of interest

Conditional knockout or marker switch driven by Foxn1Cre, KeratinCre , or other loci Mouse with floxed genes of interest or floxed stopper preventing marker gene expression in the absence of Cre

Foxn1Cre mouse KeratinCre mouse Others

X Foxn1nu/nu blastocyst Cre-dependent deletion of floxed genes in TEC or Cre-dependent activation of marker genes in TEC

Principle The Foxn1 gene acts in cis in TEC. Hence Foxn1nu/nu cells cannot be rescued by Foxn1+/+ cells in trans. In Foxn1+/+ ES into Foxn1nu/nu blastocyst chimeric mice, TEC originate from Foxn1+/+ ES cells. Hence, TEC in such mice bear the homozygous mutations from the ES cells. Advantage

Nude blastocyst complementation is arguably a technique forcing most, if not all, TEC to carry the desired mutation.

Disadvantage Nude blastocyst complementation is laborious because it requires generating chimeras by repeated blastocyst injections. In addition, homozygous null ES cells are required, and the method is constitutive and not conditional. 360

Rodewald

Foxn1Cre drives Cre expression in all or the vast majority of Foxn1-expressing cells at any time in ontogeny, leading to homozygous deletion in floxed alleles in mTEC and cTEC. This also works using KeratinCre mice, or Cre mice that drive expression of Cre in all or subsets of TEC.

Tissue-specific gene targeting of TEC is a versatile approach that could be applied to all floxed genes of interest. Incomplete or late deletion via Foxn1Cre (or KeratinCre) may lead to a mosaic in TEC. The spatial distribution of deleted versus nondeleted TEC is a challenge to analyze.

Annu. Rev. Immunol. 2008.26:355-388. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-12

ARI

16 February 2008

12:33

primordia each give rise to one thymus lobe positioned along each side of the body. Thus, multiple thymi arise in a one-anlage-to-onethymus ratio (Figure 3). In contrast, in the chicken, the anlagen in the third and fourth pouches give rise to one immature thymus that subdivides secondarily into multiple individual thymus lobes positioned along the neck (Figure 3) (50). As we begin to think in terms of organ progenitor cells, it is likely that the original pharyngeal anlage in the chicken harbors a certain number of progenitor TEC that are partitioned into separate cell clusters, each of which gives rise to one ﬁnal thymus lobe.

CELLULAR BASIS OF THYMUS ORGANOGENESIS: ENDODERMAL EPITHELIUM AND THE GERM LAYER ORIGIN OF THE THYMUS In analogy to general organ development, thymus organogenesis has been divided into several consecutive steps: (a) positioning; (b) budding and outgrowth of the thymus anlage from the third pouch; (c) detachment of the primitive thymus from its endodermal basis; and (d ) patterning, differentiation, and migration of the thymus toward its ﬁnal anatomical position (51, 52). Positioning refers to pouch formation at the prospective site where epithelial cells will later undergo commitment toward

thymus and parathyroid fates. Morphological three-dimensional reconstructions (22) indicate that, on embryonic day 9 (developmental timing is from analyses of the mouse), the pharyngeal pouch constitutes a double-layered membrane composed of an ectodermal and an endodermal cell sheet. On day 9.5, these layers blend together, and it is likely that the precise germ layer origin of these epithelial cells in the third pouch can no longer be assigned with certainty solely based on morphology. Later, on day 10.5, parts of the ectodermal cervical vesicle come into close contact with the endoderm of the third pouch. It was thought that these ectodermal cells rapidly proliferate and ﬁnally surround the endodermal tissue. These and earlier (53) observations formed the basis for the long-held textbook view (54– 56) of a double germ layer origin of the thymus with endodermal and ectodermal origins of medullary and cortical epithelium, respectively. In contrast, on the basis of grafting experiments in birds, researchers concluded that thymus epithelium is derived from a single germ layer, the endoderm (23, 24), that required the presence of NC mesenchyme (see below). More recently, the question of the germ layer origin of thymus epithelium was readdressed, this time in the mouse (30). Examination of the histiogenesis of the thymus during the critical period (E10.5 to E12) conﬁrmed that third pouch endoderm and third cleft

←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−− Figure 2 Strategies for gene targeting and fate mapping of thymus epithelium. (a) Mutations can be targeted to the thymus epithelium, and gene function can be analyzed in TEC by the generation of chimeric mice made by injection of Foxn1+/+ embryonic stem (ES) cells into nude (Foxn1nu/nu ) blastocysts, termed nude blastocyst complementation (9). This strategy takes advantage of the fact that all thymic epithelial cells in such chimeras (9), as well as in aggregation chimeras of Foxn1+/+ and Foxn1nu/nu embryos (149, 150), are derived from the Foxn1+ origin because the nude gene acts in cis and cannot be rescued in trans (149). The use of Foxn1+/+ ES cells bearing homozygous null alleles in a gene of interest will result in a thymus in which TEC lack the gene that is deleted in the ES cell. Nude complementation has been used to study the role of vascular endothelial growth factor (Vegf )-A in thymus epithelium, a gene that is heterozygous lethal if mutated in all cells of an embryo. (b) Thymus epithelium can be genetically modiﬁed using TEC-speciﬁc Cre recombinase deleter mice such as Foxn1Cre (40), or various KeratinCre (e.g., 26) mice. These lines can be used to delete ﬂoxed genes or to activate Cre-dependent reporter loci (fate mapping). The ﬁdelity and inclusiveness of the Cre activity determines how speciﬁc and how quantitative the experiment will be. Advantages and disadvantages are listed. www.annualreviews.org • Thymus Organogenesis

361

ANRV338-IY26-12

ARI

16 February 2008

12:33

Pharyngeal pouches

Thymi

a pp1

Shark

pp2 pp3 pp4 pp5

Annu. Rev. Immunol. 2008.26:355-388. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

pp6

b pp1 pp2 pp3

Chicken

pp4 pp5 pp6

c pp1

Cervical thymus

pp2

Mouse

pp3

?

pp4

Thoracic thymus

Figure 3 Origin of the thymus in phylogeny: a variation of the theme. A phylogenetic comparison of the origins of the thymus in shark (a), chicken (b), and mouse (c) demonstrates that thymus anlagen can be found in different pharyngeal pouches (pp) and that the ratio of mature thymus lobes per pharyngeal pouches can differ. In the shark, each thymus lobe has its own anlage (a), whereas the chicken splits one thymus, from two pouches, into seven lobes (b). In the mouse, the thoracic thymus originates from the third pouch. It remains to be determined whether the cervical thymus in mice develops akin to the chicken or the shark thymus. 362

Rodewald

ectoderm indeed make contact. Evidently, this contact does not result in a compound structure incorporating cells of both germ layer origins. Instead, there are signs of apoptosis at the contact site, suggesting a cell loss, presumably on the ectodermal side (30). Moreover, when the outer pharyngeal surface of E10.5 embryos was dye-labeled in vitro and these ectodermally tagged embryos were cultured for 30 h, there were no labeled cells found in the thymus. This indicates, again, that ectodermal epithelium does not contribute to the thymus proper. In addition to these experiments involving in vitro dye labeling and embryo culture techniques (57), endoderm-only third pouch tissue was dissected from E9 embryos and grafted into nude recipients. These grafts developed into functional thymi with medulla-cortex architecture (30). There is also genetic evidence for a common germ layer origin of cortical and medullary epithelium from tetraparental chimeric mice generated by injection of ES cells into MHC-mismatched blastocysts (13). There was no clear relationship between the origin of mTEC islets, discussed later in the context of TEC progenitors, and the origin of the cortex immediately surrounding a medullary islet (13). In other words, a medullary islet of ES cell origin could be localized in cortical epithelium of its own (ES), but also of the opposite (blastocyst) origin. Hence, there was no sign that a common origin translates into local units composed of adjacent mTEC and cTEC. However, a common germ layer origin of mTEC and cTEC, and a late developmental split into mTEC and cTEC, might imply that, overall, the origins of mTEC and cTEC are proportional. The relative contribution of the ES cell and the blastocyst to the tested organs (thymus, skin, liver, heart) was random, suggesting that these organs developed independently (Figure 4). In contrast, comparison of the overall contribution of ES cell or blastocyst to medullary and cortical epithelium revealed a straight line pointing at a common origin and close

12:33

CONTRIBUTION OF NEURAL CREST (NC) MESENCHYME TO THYMUS ORGANOGENESIS: TRANSIENT OR LONG LASTING? NC-derived mesenchyme is crucial for thymus organogenesis and thymus function (reviewed and further references in 1, 51, 58, 65, 66). In the original description of this phenomenon in bird embryos, it was demonstrated that NC-derived mesenchyme colonizes the branchial arches, surrounds the

b

Heart

a

Thymus

Thymus

d

Cortex

c

Medulla

Thymus

e

f

Heart

relationship of cells forming medulla and cortex in ontogeny (58). These data also imply that the common origin holds true for the entire thymus epithelium. Collectively, independent experimental approaches have now provided compelling evidence that thymus epithelium is derived from the endodermal layer of the third pharyngeal pouch only (reviewed in 52, 59). Budding and outgrowth of the thymus anlage from the third pouch coincides with onset of expression of the Foxn1 gene (60). Foxn1 expression is ﬁrst detected in a subset of epithelial cells in the third pouch on embryonic day 11.5 in mouse development (61–63). Doublestaining for expression of Foxn1 versus glial cells missing 2 [Gcm2], a transcription factor gene required for parathyroid organogenesis (64), reveals adjacently located epithelial cell clusters whereby Foxn1+ cells are located in the ventral part of the third pouch while Gcm2 marks the dorsal aspects of the same pouch (62). Because Foxn1 and Gcm2 are essential for thymus (60, 61) and parathyroid (64) development, respectively, these cell clusters likely represent the anlagen for each or the two third pouch–derived organs. However, a direct and exclusive precursor-product relationship between Foxn1- or Gcm2-expressing cells in the pouch and the mature organs has not been established. This would require the puriﬁcation of cells based on their expression of these transcription factors and a prospective test of their potential.

Skin

16 February 2008

Liver

ARI

Liver

Annu. Rev. Immunol. 2008.26:355-388. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-12

Skin

Skin 0

50

100

100

50

0

Blastocyst origin (%)

ES cell origin (%)

Figure 4 Common origin of medullary and cortical TEC in tetraparental (chimeric) mice. Mice generated as described by injecting embryonic stem (ES) cells into MHC-mismatched blastocysts (13) were analyzed for ES cell versus blastocyst contributions to skin, heart, liver, and thymus utilizing microsatellite differences in ES cell and blastocyst genomic DNA. The contributions of ES cell and blastocyst to thymus medulla and cortex were determined by histological analysis of the MHC class II haplotypes indicative of ES cell or blastocyst origin. None of the organs showed any linkage of the origins except for thymus cortex and medulla.

www.annualreviews.org • Thymus Organogenesis

363

ARI

16 February 2008

12:33

thymic epithelium, and forms perivascular mesenchyme (23). Ablation of cephalic NC in birds prevented any contribution to or induction of thymus epithelium by NC-derived mesenchyme, and this resulted in small thymi with delayed development and poor function (24). These early reports were conﬁrmed in principle and extended by many subsequent experiments that showed an important role for NC in thymus development in vivo (reviewed in 51, 52) and in organ culture systems (10, 67, 68; reviewed in 1). Examples of genetic pathways involved in mesenchymethymus epithelium interactions are provided below. Given that mesenchymal-epithelial contact takes place early in development and that mesenchymal cells are abundant in the adult thymus, as speciﬁed in the introduction, it has been debated whether or not embryonic NCderived mesenchyme and adult thymus mesenchyme share a precursor-product relationship (reviewed in 66). Several reports address this point in mice generated with the aim to express Cre recombinase speciﬁcally in the NC lineage. In combination with appropriate Cre activity–dependent reporter mice, NCderived cells and their progeny should be permanently labeled in this system. Mesenchyme marked by Wnt1Cre surrounds the E13.5 thymus as a massively stained, thick layer. However, labeled cells become rare as soon as the thymus grows, owing to the rapid proliferation of thymocytes. In the adult thymus, the overall contribution of Wnt1Cre -marked cells appears too low to account for major mesenchymal components such as the capsule, the septae, or intrathymic ﬁbroblast (66, 69). Some cells of unknown character are, however, present in the adult thymus (66). A similar result of transient but not permanent participation was obtained using a different NC-speciﬁc marker gene, myelin protein zero (P0). By ﬂow cytometry on thymus cells from E13.5, as many as 30% of all stromal cells are labeled by P0Cre (70), which is the ﬁrst quantitative estimate of the contribution of NC to the developing thymus. Again, few marked

Annu. Rev. Immunol. 2008.26:355-388. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-12

364

Rodewald

cells persist at later stages. In vitro, P0Cre marked cells from the fetal thymus could be developed into melanocyte and glial cell lineages, further supporting their NC origin. The idea that the thymus contains cells related to neuronal/glial lineages is not new (71), but there is currently no evidence to deﬁne functions for such cells in the thymus. Finally, a cautionary note may be warranted here because, as in other fate mapping experiments, the result will ultimately depend on the strategy used. Random transgenic integration may yield more mouse-to-mouse variability than targeted knockin approaches, and the result, here low or no contribution of NC cells to the adult thymus, depends on the properties of any particular Cre driver mouse and the sensitivity of the reporter detection. A possible molecular link between NCderived mesenchyme and thymus epithelium is provided via ﬁbroblast growth factors (Fgfs, also termed keratinocyte growth factor [KGF]) and their receptors (FgfR). Fgf7 and Fgf10 are expressed by the mesenchyme surrounding the embryonic thymus epithelium, and the latter expresses FgfR2IIIb. Defects in this signaling pathway perturb thymus development (72), demonstrating a growth-promoting role for mesenchyme toward thymic epithelium. Signals via Fgfs also induce TEC proliferation (73, 74) and protect thymus epithelium from injury by irradiation (75) or by conditions of graftversus-host disease (76). Another role of thymus mesenchyme could be the presentation of growth factors such as IL-7 or c-kit ligand to thymocytes, but currently no data support this idea.

GENES AFFECTING THYMUS DEVELOPMENT PRIOR TO THYMUS SPECIFICATION Mutations in a number of genes, including Hoxa3 (77), Eya1 (78, 79), Six1 (79, 80), Pax1 (81–84), Pax3 (85), Pax9 (86, 87), and Tbx1 (88), lead to thymus aplasia, or hypoplasia, or failure of the thymus lobes to migrate

Annu. Rev. Immunol. 2008.26:355-388. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-12

ARI

16 February 2008

12:33

toward the chest (reviewed and further references in 51, 52, 89). These genes are expressed in multiple cell lineages during development, and hence their loss of function causes pleiotropic defects in embryonic development. It is, therefore, often difﬁcult to distinguish the primary function of these genes in thymus organogenesis, e.g., in TEC progenitors, from an upstream function, e.g., in formation or patterning of pharyngeal structures or in NC migration. It is obvious that the thymus cannot develop normally if the third pouch is absent as a scaffold in which TEC progenitors arise. The effects of such mutations are therefore upstream of thymus organogenesis itself. Moreover, it is also possible that some of these genes are required both upstream of organogenesis and later in the thymus epithelium itself. Along this line, Hoxa3 (90), Pax1 (82), and Pax9 (91) are expressed in thymus epithelial cells. Because this was mostly measured by RT-PCR in cell populations, frequencies and phenotypes of TEC expressing these genes are unknown. TECspeciﬁc deletion of such ubiquitous pathway genes will be required to resolve their function in thymus development beyond the general defects that may be nonspeciﬁc for the thymus. An example of TEC targeting was blocking of Bmp signaling in TEC by expression of Noggin under the control of the Foxn1 promoter. Whereas blocking of Bmp signaling in premigratory NC by transgenic expression of Noggin in NC affected thymus development indirectly (92), Foxn1-driven inhibition of the Bmp pathway demonstrated, in addition to the NC defect, a role for Bmp signaling intrinsic in TEC (93). This is compatible with expression of Bmp family members in the thymus epithelial anlage (94). Another interesting gene that belongs to this gene category, and that is related to DiGeorge syndrome (95–98), is the T box gene Tbx1. DiGeorge syndrome is caused genetically by heterozygous deletions within chromosome 22q11 and clinically by malformations of pharyngeal arch arteries (cardiac

outﬂow tract) and heart, parathyroid hypoplasia, and absence or ectopic location of the thymus (96, 99). Hallmarks of this phenotype are recapitulated in mice lacking Tbx1 (88, 100), a gene that is located in the deleted region in humans (88, 100). Tbx1−/− mice display agenesis of pharyngeal pouches 2–4 and concomitant loss, or malformation, of pharyngeal pouch–derived organs and tissues (thymus, parathyroid gland, cardiac outﬂow tract) (88, 100). Tbx1 is expressed in the pharyngeal pouch endoderm but also in the core mesoderm of the pharyngeal apparatus and the pharyngeal ectoderm but not in NC-derived mesenchyme (101). Thus, Tbx1 expression may play distinct roles in different anatomical sites (e.g., endoderm versus mesoderm) during development. Pharyngeal pouches fail to develop in mice in which the Tbx1 deﬁciency is restricted to the endoderm by means of preferential deletion in pharyngeal endoderm using another Fox family gene locus expressing Cre, Foxg1Cre . Hence, this mutant recapitulates the defects known from the constitutive null mice, including absence of the thymus (102). This demonstrates that Tbx1 expression in the pharyngeal endoderm is required for thymus development. However, mice that lack Tbx1 expression selectively in the pharyngeal mesoderm, but not the endoderm, also have a hypoplastic pharynx with impaired pharyngeal endoderm and lack a thymus (103). Conditional reversion from a defective to a functional Tbx1 allele in pharyngeal mesoderm, but not endoderm, is sufﬁcient to rescue major defects known from the Tbx1 null phenotype (pharyngeal patterning, cardiovascular defects) but does not restore thymus development (103). In conclusion, expression of Tbx1 both in the pharyngeal core mesoderm and in the pharyngeal endoderm is a prerequisite for thymus development. Within the third pouch, Tbx1 expression coincides rather with the parathyroid than the thymus anlage (104), and it remains to be determined if Tbx1 is expressed in TEC and whether it plays a role in their development.

www.annualreviews.org • Thymus Organogenesis

365

ANRV338-IY26-12

ARI

16 February 2008

12:33

EPITHELIAL PATTERNING AND DIFFERENTIATION, AND CROSSTALK BETWEEN THYMOCYTES AND EPITHELIUM

Annu. Rev. Immunol. 2008.26:355-388. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

Coinciding with hematopoietic colonization that initially occurs around E12 and prior to vascularization, the immature thymus undergoes further patterning and differentiation (reviewed in 51, 105, 106). Morphologically, this stage leads to the ﬁrst signs of medullacortex separation. This compartmentalization is associated with changes in keratin expression patterns in the epithelium. During ontogeny, and in the adult thymus, TEC subsets express different members of the keratin family. Major populations of adult mTEC and cTEC have been distinguished by their keratin (K) 5+ K8− and K5− K8+ phenotypes, respectively (107, 108 and references therein). This dichotomy is, however, not absolute because K5 is also expressed in some cTEC, and K8 is also found in some mTEC (107). Regarding the onset and pattern of K5 and K8 expression in ontogeny, third pouch epithelium at E11.5 was reported as K5− K8+ (15, 108), whereas others found coexpression of K5 and K8 already at this stage, even with high expression of K5 (14). A prominent TEC population coexpresses K5 and K8 on days 12 and 13 (14, 15, 108). Using these and other markers, so-called double-positive TEC are thought of as progenitors of mature singlepositive K5+ K8− medullary and K5− K8+ cortical TEC phenotypes (108–110). This idea was based on the fact that K5+ K8+ cells precede the appearance of mature K5+ K8− and K5− K8+ TEC in ontogeny. Moreover, large clusters of K5+ K8+ TEC are maintained in mutants with massive early blockade in T cell development such as compound KitW /W and common γ chain (γ c− ) (111), or RAG2−/− γ c− mice (thymus stromal phenotypes reviewed in 105). Thirdly, and further discussed in the context of TEC progenitors, MTS24+ TEC, a controversial TEC progenitor phenotype (27), also coexpresses K5 and K8 (14, 15). In

366

Rodewald

any case, the initial patterning of the embryonic thymus is dependent on expression of Foxn1 in the epithelium but is independent of hematopoietic colonization. The transition from immature TEC phenotypes, such as abundant K5+ K8+ cells, to the full medulla-cortex organization is perturbed in mice in which T cell development is blocked at immature stages. That the TEC architecture is somehow inﬂuenced by the presence or absence of particular stages of thymocytes development has been viewed as an interdependence between thymocytes and stroma (36, 107, 112) and has been referred to as crosstalk (21). In the original case, it was suggested that the thymus stroma was permanently damaged unless it had proper contact with developing pro-T cells (CD44+ CD25− ) and that this contact needed to take place at fetal stages of TEC development (112). The transgenic mouse (hCD3ε26tg) on which these conclusions were based expressed 40– 60 copies of a human CD3ε transgene (113, 114). T cell development in this mouse was blocked at an early CD4− CD8− (doublenegative) stage prior to expression of CD25, and numbers of residual thymocytes were very low. This paucity of thymocytes and the severe block in thymocyte development were suspected as the cause of aberrant adult TEC structure characterized by poorly discernable cortex and an abundance of cells coexpressing K5 and K8 (107, 112). Subsequent studies found, however, that the hCD3ε26tg thymus was not simply devoid of thymocytes, but harbored B cells (114). Hence, it cannot be excluded that it is not the absence of developing thymocytes that perturbs thymus organogenesis but the aberrant B cells or their development that contributes to the adult stromal cell phenotype. This interpretation would question the speciﬁcity of crosstalk between pro-T cells and TEC. Another concern regarding models of crosstalk in thymus organogenesis has been the inability to distinguish alterations in the epithelial compartment owing to lack of

Annu. Rev. Immunol. 2008.26:355-388. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-12

ARI

16 February 2008

12:33

signals from developing thymocytes to TEC from epithelial reactions to a state of inactivity. The latter scenario could lead indirectly to defects in the maintenance of the epithelial cells. Along this line, a recent reevaluation of the developing thymus in hCD3ε26tg mice found normal proportions of immature K5+ K8+ , as well as single-positive K5+ K8− and K5− K8+ TEC when compared to wildtype thymus (115). These data imply that thymus organogenesis may be quite normal in hCD3ε26tg mice and that the architectural alterations seen in this mutant are secondary to regular TEC development, a conclusion that would support the argument against a role of pro-T cell–mediated signaling for the development of thymic epithelial cells (115). The suggestion that the thymus stromal cell architecture is damaged at long-term unless proT cells contact the epithelium at the proper time in ontogeny is also contradicted by experiments made in KitW /W γ c− mice, a mutant in which thymocyte development was completely abrogated (116). The severely dysmorphic thymus structure of this mutant could be reverted to a structurally normal and functional thymus when grafted postnatally into a recipient that provided wild-type hematopoietic stem cells (111). Finally, the fact that the human thymus of severe combined immunodeﬁciency (SCID) patients can be reconstituted by transplantation of normal bone marrow stem cells (117) further supports the argument against continuous stroma defects caused by a block in T cell development. Collectively, much speculation has surrounded the interesting crosstalk concept. A crosstalk mechanism should involve cell surface molecules such as receptor-ligand pairs that can transmit signals in both directions, and the absence of such signals might cause a speciﬁc phenotype on the nonreceiving end. Some molecularly deﬁned cases for bidirectional crosstalk between thymocytes and thymus epithelium exist. One documented example of a crosstalk mechanism from thymocytes into epithelial cells is the defect

in the mTEC compartment in mice lacking components of the TNF-TNF receptor family. Expression of the lymphotoxin-β receptor (LTβR) on thymocytes and of a LTβR ligand on mTEC are required for normal cellularity and architecture of mTEC. Mutations that interrupt this signaling pathway lead to structural defects associated with faulty selection and autoimmunity (118). Moreover, the recent ﬁnding that expression of RANK ligand on a CD4+ CD3− inducer cell population promotes the maturation of RANK-expressing CD80− Aire− mTEC progenitors into CD80+ Aire+ mTECs (119) can also be viewed as a form of crosstalk, albeit between a highly specialized and rare lymphoid cell and a speciﬁc stage of TEC. There are other candidate molecules that could mediate signaling from stroma to thymocytes and back. For instance, the receptor tyrosine kinase Kit is expressed on proand pre-T cells, and the membrane-bound ligand [Kit ligand (KL), or stem cell factor (Scf )] is expressed on stromal cells (120). Kit signaling into thymocytes via expression of KL in TEC is crucial for T cell development (121), and KL can indeed signal into epithelial cells (122). However, T cell development was permissive in a KL mutant (Sl17H ) (H.-R. Rodewald, unpublished data) in which the cytoplasmic tail of KL is nonfunctional (123). Hence, there is currently no evidence for KL-mediated crosstalk in the thymus. Further potential examples are Notch and Notch ligand pairs. Notch-1 is expressed on proand pre-T cells, and Notch ligands, including Delta-like (Dll)1 and Dll4, are expressed in thymus epithelium (reviewed in 124, 125). Dll1 or Dll4 could signal into the epithelium and induce changes in the microenvironment that could ultimately be involved in the thymus phenotype of Notch-1 mutants, including an abundance of B cells instead of T cells in the thymus (124, 125). However, it is not known whether Notch-Notch ligand–driven mechanisms play a role in crosstalk or in TEC development, as has been speculated (28).

www.annualreviews.org • Thymus Organogenesis

367

ANRV338-IY26-12

ARI

16 February 2008

12:33

POTENTIAL, FREQUENCIES, AND PHENOTYPES OF THYMUS EPITHELIAL STEM/PROGENITOR CELLS Progenitors for mTEC

Annu. Rev. Immunol. 2008.26:355-388. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

Measurements of stem or progenitor cell activity, and the prospective isolation by phenotype and subsequent analysis of progenitor potential, ultimately require clonal assays. Although single cell–based assays to study TEC development in vitro are still lacking, cellular and genetic strategies have been developed to follow the fate of single TEC progenitors or their activity in vivo (13, 26, 28). Clonal progenitor activity for TEC was initially identiﬁed for the medullary lineage in chimeric mice and in grafts of reaggregate fetal thymus organ cultures (RFTOC) (13) and has recently been conﬁrmed independently by genetic means (26). The former approach was based on techniques that allow disassembly of embryonic or fetal thymus by enzymatic digestion, puriﬁcation of stromal cells or subsets thereof, and reassembly into thymus reaggregates in vitro (10). These RFTOC are functional in that they support T cell development in vitro, but the TEC architecture of RFTOC in vitro is quite different from that of a normal thymus in vivo. In RFTOC assembled from puriﬁed TEC in the absence of thymocytes, distinct mTEC or cTEC phenotypes were present, but these cells did not form medulla-cortex structures. In contrast, RFTOC grafted into recipient mice not only supported steady-state T cell development, but also achieved proper thymus architecture, including regular medullacortex organization (12, 126). This remarkable capacity of TEC to build functional thymus architecture from reaggregated cell suspensions suggested that mTEC and cTEC, randomly arranged in the reaggregates in vitro, could migrate within the graft to segregate into cortex and medulla. Such sorting out would have required active migration, or at least directed movement, and recognition

368

Rodewald

of the neighboring cells as mTEC or cTEC. However, experiments using RFTOC assembled from two distinct donor strains, followed by transplantation of these mixed RFTOC, revealed an alternative mechanism and provided evidence for clonal events during epithelial organogenesis of the thymus (13; reviewed in 106). Cellular products of mTEC progenitor activity were visible in the form of epithelial medullary islets, the majority of which were either of one or the other, but not of mixed, origin (13). Medullary epithelial islet formation also occurred during normal thymus organogenesis in vivo, as shown in chimeric mice made by injection of ES cells into MHC-mismatched blastocysts. Here, individual epithelial islets stemmed from either ES cell or blastocyst origin. Hence, medullary islets arise from single progenitors. With age, the islet-like character of mTEC is harder to recognize, as many mTEC islets coalesce to form conﬂuent regions of medullary epithelium. The existence of clonal medullary islets was recently conﬁrmed genetically (26) (see below), and the principle of islet formation in chimeric thymus grafts has been used as an assay to assess the potential of phenotypically deﬁned embryonic mTEC subsets (127) or the role of MHC class II expression for the selection of Foxp3+ regulatory T cells on medullary epithelium (128). Serial sectioning showed that one thymus lobe of a mouse at two weeks postnatal contained ∼300 medullary areas (according to this deﬁnition, a medullary area is larger than a medullary islet). These medullary areas were composed of one to three islets. Hence, up to ∼900 mTEC progenitors are sufﬁcient to generate the entire medulla in one thymus lobe of a mouse (13). This estimate is in a strikingly similar order of magnitude as the estimated 1500 TEC in the E13.5 thymus that express the tight junction proteins claudin (Cld)-3 and 4 (Cld3,4) (127). Already on E10.5 in development, Cld3,4+ cells were found in the apical epithelial layer in the third pouch thymus anlage. Subsequently, Cld3,4+

Annu. Rev. Immunol. 2008.26:355-388. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-12

ARI

16 February 2008

12:33

cells showed a clustered arrangement that partially overlapped with general mTEC markers such as MTS10 or UEA-1. In the adult thymus, Cld3,4 expression marked a subset of mTEC expressing the autoimmune regulator gene Aire (127). Cld3,4+ Aire+ cells are presumably fully mature mTEC that are busy in promiscuous expression of tissue-restricted self-antigens (TRA) (reviewed in 5). By ﬂow cytometry, several TEC subpopulations were identiﬁed and separated based on Cld3,4+ and UEA-1 expression. Interestingly, Cld3,4+ cells, irrespective of UEA-1 expression, gave rise to only mTEC and not cTEC when mixed into RFTOC and grafted into nude mice, whereas Cld3,4low UEA-1− cells gave rise to both mTEC and cTEC. These data suggest that commitment to the mTEC lineage can take place already by E13.5, at least in cells deﬁned by Cld3,4 expression. Collectively, the very early and restricted expression of the tight junction proteins of Cld3,4 marks an mTEC pathway. Because the medullary clusters that arise from Cld3,4+ progenitors are very similar in size and frequency to the medullary islets described earlier, it is possible that Cld3,4 expression marks the entire mTEC pathway at some point in the differentiation tree of TEC. It is not clear whether mTEC progenitors are only active during ontogeny, or whether they continue to generate mTEC de novo in the adult thymus. Clonogenic, mTEC-isletsforming mTEC progenitors, or their activity, have not been detected in the adult thymus. For a long time, TEC were considered postmitotic cells that constitute an epithelial network that is constructed in ontogeny and later maintained. However, several reports recently found TEC proliferation indicating rapid epithelial turnover in the steady-state thymus (5, 20, 129). There are considerable differences in the reported proliferation rates, ranging from as many as 23% of MHC class II+ CD45− TEC (the majority of which are mTEC) incorporating BrdU after three days of continuous labeling (20) to as few as 8% of mTEC incorporating BrdU after one week of label-

ing (129). This would translate into half-lives of about six days in one case versus four weeks in the other case; the latter is similar to a third estimate of six weeks (5). It is obvious from the above considerations that there are large gaps in our understanding of the sequence of events during mTEC differentiation from mTEC progenitors to mature mTEC. Speciﬁcally, the relationship of mTEC differentiation stages to mTEC function (TRA expression and presentation; full maturation as antigen-presenting cells) and mTEC turnover (proliferation versus cell death) are only poorly understood. On the one hand, islets of mTEC vary in diameter from a minimum of 60 × 40 to a maximum of 170 × 170 μm and harbor between 5 and 45 epithelial cells in a two-dimensional lattice (13). On the other hand, numbers of cells expressing a particular TRA in the medulla appear even lower than the cells per islet (129, 130; reviewed in 5). Because an mTEC islet is originally made by a single progenitor, cells within an islet might be further diversiﬁed into subclones (131). It is not known whether this diversiﬁcation is stable or whether individual mTEC change their expressed TRA pattern over time. It will be necessary to better deﬁne stages of mTEC differentiation from mTEC progenitors via immature to mature mTEC and to shed light on the signals that regulate this developmental progression as well as on the capacity of TEC at each stage to present antigens and ultimately guide TCR repertoire selection on thymocyte populations (5, 119, 129, 131, 132).

Common mTEC and cTEC Progenitors It was speculated early on that mTEC and cTEC share a common progenitor (109, 110). The idea was based on coexpression of markers such as keratins on TEC early in thymus organogenesis, as discussed above in the context of the germ layer origin. More recently, the generation of a complete and functional thymus environment in RFTOC grafts was www.annualreviews.org • Thymus Organogenesis

369

ARI

16 February 2008

12:33

also taken as evidence of a common progenitor for both mTEC and cTEC. Transplantation of RFTOC assembled from embryonic day 12.5 (14) or fetal day 15.5 (15) TEC led to the formation of a thymus composed of both medulla and cortex (discussed in 133). Gill et al. (15) interpreted their data as direct evidence of thymic progenitor cells giving rise to both cortical and medullary epithelial lineages, and Bennett et al. (14) argued strongly in the same direction. These polyclonal (bulk) experiments in fact demonstrate that the populations of cells used to assemble the grafts contained all the cells required for a functionally and structurally normal thymus. What they could not answer was whether or not a common progenitor for mTEC and cTEC existed and, if so, whether it was responsible for the generation of both mTEC and cTEC in the grafts. This key property of a common progenitor, clonogenicity, has only recently been addressed (26, 28; reviewed in 29). Single epithelial cells isolated from yellow ﬂuorescent protein (YFP) expressing embryonic E12.5 thymus were injected into a nonﬂuorescent host thymus, and such single cell–tagged thymi were transplanted into recipient mice to allow for full thymus development. Immunohistological analysis showed that, in each case of positive reconstitution, the single embryonic epithelial cell had produced both mTEC and cTEC. Because the donor cells were puriﬁed via expression of a pan-TEC marker [EpCAM1; antibody G8.8 (34)], no particular TEC subset was selected, implying that a large proportion of epithelial cells in the day 12 thymus has dual potential for mTEC and cTEC and that their progeny persists in the adult thymus (28). A different approach addressing progenitor activity in thymus organogenesis was based on epithelial cell tracing using genetic in situ labeling (26). Cre recombinase under the control of the human Keratin 14 promoter (K14Cre ) effectively acted as a random and very rare switch that turned on YFP expression in TEC. Although no labeled cells were

Annu. Rev. Immunol. 2008.26:355-388. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-12

370

Rodewald

found in the thymus at birth, numbers of mice with labeled cells and numbers of YFP+ TEC per thymus increased with age after birth. At all times analyzed, labeled progeny remained very rare, consistent with Cre-mediated YFP expression only in single or in very few TEC progenitors. Three patterns of progeny were noted: (a) mTEC clusters only, reminiscent of medullary islets; (b) cTEC clusters only; or (c) mTEC plus cTEC progeny (26). These results strongly suggest that K14Cre randomly marked TEC progenitors and their progeny and that this labeling event could occur over developmental stages that covered common to committed TEC progenitors. If the genetic hit occurred at an early postnatal age, TEC progenitors, endowed with the listed potentialities, persist at least until that age in a normal thymus. After the putative mTEC versus cTEC branch in TEC differentiation, cells probably migrate considerable distances. This is evident from the space that was observed between mTEC and cTEC progeny of common origin in the adult medullary and cortical zones, respectively (26). The notion of TEC migration, or perhaps passive movement, during development would also ﬁt the topological dissociation of mTEC versus cTEC of the same origin in chimeric mice (13). Collectively, based on cellular (13, 28) and genetic (26) evidence, the thymus harbors TEC progenitors that, at the single cell level, contribute to the formation of thymus epithelial structure. Except for an estimate on total numbers of mTEC progenitors required (see above), there is currently no information on the total number of common mTEC and cTEC progenitors that normally engage in the building of a thymus. The marking of common TEC progenitors left unanswered whether or not single TEC progenitors are capable of forming functional thymus units. This was addressed again in the K14Cre mouse, but in this case the Cre recombinase was used to revert a nonfunctional Foxn1 allele to a functional Foxn1 allele akin to correcting the nude mutation in the thymus in vivo. The Foxn1nu/nu thymus is

Annu. Rev. Immunol. 2008.26:355-388. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-12

ARI

16 February 2008

12:33

composed of epithelial cysts that do not support T cell development. When crossed to a Cre-dependent LacZ reporter, K14Cre marked rare TEC that, in this case, were located in the wall of the nude thymus cysts. When Cre reverted the loss-of-function Foxn1 allele back to a functional Foxn1 allele, an event that occurred again randomly in single postnatal epithelial cell precursors, small units of thymus tissue developed (26). These neo-thymi showed all tested hallmarks of a normal thymus, including medullary and cortical organization and expression of Aire. Mice bearing such thymi had elevated numbers of immunocompetent T cells that, unlike the few T cells found in nude mice, expressed a diverse TCR repertoire. These experiments demonstrate that the block that occurs in TEC development in the nude mouse does not lead to a complete loss of TEC progenitors. Rather, TEC progenitors may enter a stage of dormancy or may be continuously generated de novo in nude mice. Once genetically reverted to wild type, they can recapitulate normal ontogeny and complete their differentiation into functional TEC. It is noteworthy that this development can take place outside of the physiological location, the third pouch, because the cystic thymus rudiments in the nude mouse are at this age in the chest. For anatomical and kinetic reasons, it is unlikely that the inductive signals that are provided to the thymus during normal ontogeny, e.g., by NC-derived cells, are available to those thymi that use their second chance (29). This lack of proper context could at least in part be responsible for their small size (26).

TEC Progenitor Phenotypes In the aforementioned single cell experiments, TEC progenitor cells have not been physically puriﬁed except by the panepithelial marker EpCAM1 (28). Are there cell surface markers known that identify TEC progenitors? This would be an important prerequisite for analyses of the prospective potential of these cells. Previous experiments

have suggested that MTS24 is a marker for embryonic TEC progenitors, a proposal that met with some interest (133, 134). As noted before, RFTOC assembled from embryonic (14) or fetal (13, 15) TEC developed into functional thymi in vivo. Although earlier studies showed thymus development in RFTOC grafts made from several hundred thousand fetal TEC deﬁned as MHC class II+ CD45− cells (12, 13), others reported thymus formation using much lower numbers of cells using the MTS24 marker for positive puriﬁcation. Twelve thousand ﬁve hundred TEC from E12.5 (14), or 2,500 from day 15.5 fetal (15), contained all the cells required for a thymus. Even when only 500 cells were transplanted, nude recipients showed signs of transiently functional thymus (14). In analogy to other progenitor systems, it can be assumed that the frequency of progenitors is low among all TEC. Are MTS24+ TEC rare cells, as has been suggested (133)? On E10.5, MTS24 is broadly expressed in the endodermal pharyngeal pouches (15) (including those that do not give rise to a thymus). By histology, most (14, 15), if not all (27), epithelial cells on day 11.5 and 12.5 express MTS24. By ﬂow cytometry, essentially all thymus epithelial cells, gated as pan-cytokeratin+ or EpCAM1+ cells on E12.5 and 13.5, are MTS24+ (27), suggesting that at this stage of development, MTS24− cells are nonepithelial cells. Consistent with these data, and not surprisingly, only MTS24+ (that is, epithelial) and not MTS24− (that is, nonepithelial) cells from E12.5 have thymus-forming capacity (14). Is MTS24 a progenitor marker at later stages of thymus development? On day 15.5, about half of all TEC still express MTS24 before the frequency of MTS24+ cells declines to a few percent at later fetal and adult stages (14, 15, 27, 135). One report found thymus potential exclusively in MTS24+ and not MTS24− epithelial from day 15.5 thymus (15). However, a recent reassessment of TEC progenitor activity using MTS24 expressionbased puriﬁcation did not reproduce these ﬁndings using larger cell numbers from www.annualreviews.org • Thymus Organogenesis

371

ARI

16 February 2008

12:33

14- or 16-day-old thymi and concluded that both MTS24+ and MTS24− epithelial cells were similarly potent in forming a functional thymus (27). The available evidence suggests the following order of events: MTS24 is initially a nonthymus-speciﬁc marker of pharyngeal endoderm cells; it then marks all TEC around day 12.5 and is expressed on day 15.5 on a major subset of TEC. At this stage, thymus potential is included in both MTS24+ and MTS24− epithelial cells. From the adult thymus, MTS24+ cells can be retrieved, but their function remains to be determined (135). If MTS24 is perhaps not “the” TEC progenitor marker, is there any evidence for stemness among TEC? Interestingly, TEC express genes such as Nanog, Oct4, and Sox2, which are commonly found in stem cells, and the expression of these hallmark genes is reduced in TEC from Aire-deﬁcient mice (91). Because gene expression was detected by reverse transcriptase polymerase chain reaction (RT-PCR) in populations of TEC, it will be important to determine the frequencies of TEC and their maturation stages that express Nanog, Oct4, and Sox2. Perhaps TEC stem or progenitors will be found within these cells or among cells expressing p63 (136) (see below).

Annu. Rev. Immunol. 2008.26:355-388. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-12

GENES AFFECTING THYMUS DEVELOPMENT AFTER THYMUS SPECIFICATION Foxn1, the Gene Mutated in the Nude Mouse There is no deﬁnitive marker that indicates epithelial cell commitment toward thymus fate prior to expression of Foxn1. Functionally speaking, Foxn1 is the single most important gene known to be essential speciﬁcally for thymus epithelial development (60, 61). Therefore, it is worthwhile to take a closer look at properties of Foxn1 such as expression, regulation, and function. Foxn1 is a protein belonging to the family of forkhead box transcription factors (137–139). In addition to Foxn1, other members of this gene family also 372

Rodewald

play important roles in the immune system, such as Foxp3, which determines the development and function of regulatory T cells, and Foxo factors, which are involved in apoptosis and proliferation, and hence leukocyte homeostasis (138, 139). Foxn1 is characterized by a winged-helix/forkhead DNA-binding domain and a transcriptional activation domain (42, 140). In the original nude mouse allele (Foxn1nu ), a single base pair deletion in exon 3 causes a frame shift leading to a truncated Foxn1 protein lacking both the DNA-binding and the activation domain (60). Homozygous Foxn1nu/nu mice had the same thymus and skin phenotypes as compound heterozygous mice bearing one engineered null allele of Foxn1 (Foxn1− ) and one natural mutant allele of Foxn1 (Foxn1nu ), formally showing that Foxn1 is allelic to the nude gene (61). In mice homozygous for a Foxn1 allele lacking exon 3 (Foxn1/ ), thymus epithelium developed beyond the block in Foxn1nu/nu mice. Foxn1 encodes a Foxn1 protein with a large deletion in the N-terminal part of Foxn1 (141). The phenotype of Foxn1/ mice overall resembled that of a hypomorphic mutant in which TEC phenotype and organization suggest an arrest at a K5+ K8+ stage. In contrast to the cystic Foxn1nu/nu thymus, the Foxn1/ thymus had a more continuous structure permissive to support T cell development, albeit only poorly and with a delay in fetal thymocyte development. It is not clear whether this TEC phenotype results from a speciﬁc requirement for the N-terminally deleted amino acids at later stages of TEC development, perhaps beyond the K5+ K8+ stage, or whether the Foxn1 allele encodes a Foxn1 protein with an overall reduced functional activity. The stability of the Foxn1 protein encoded by this particular allele has not been determined. Little is known about upstream factors that regulate Foxn1 expression. Through transgenic work, DNA fragments and promoter elements that permit gene expression under the control of Foxn1 have been described (41, 93, 142). It has been proposed that Foxn1 expression is regulated through members of the Wnt

Annu. Rev. Immunol. 2008.26:355-388. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-12

ARI

16 February 2008

12:33

family (143). Given that no single or compound Wnt mutant mouse has been reported that resembles a nude thymus phenotype, further clariﬁcation of the role of Wnt family members directly upstream of Foxn1 would be helpful. In brief, there is very little information on how Foxn1 transcription is initiated in development or maintained in the adult thymus. On the basis of a Foxn1lacZ knockin allele, in situ hybridization, and antibody staining, investigators have found that Foxn1 expression in thymic epithelium is ﬁrst detectable on E11.5 (61–63), a stage preceding colonization of the thymus by hematopoietic progenitors. Analysis of a Foxn1lacZ allele demonstrates that Foxn1 is expressed in most, if not all, thymic epithelial cells both at embryonic stages and in the adult (61). However, a more recent study that used an anti-Foxn1 antibody suggests that both Foxn1+ keratin+ and Foxn1− keratin+ thymic epithelial cells exist in the embryonic thymus (E13) and that the percentage of Foxn1− keratin+ TEC is even as high as 80% in the adult thymus (63). If subsets of adult TEC differ, in fact, in expression of Foxn1, it would be interesting to deﬁne how those Foxn1+ and Foxn1− subsets differ with regard to the relative stages of maturation, cellular age, turnover, or their functional capacities to promote T cell development. Although the extent to which adult TEC actively express Foxn1 is controversial, fate mapping of TEC using a Foxn1Cre allele convincingly showed that most, if not all, TEC arise from Foxn1+ progenitors, or at least transit through a stage of ubiquitous Foxn1 expression (39, 40). As mentioned earlier, genetic activation of Foxn1 in single TEC led to the appearance of units of productive thymi in an otherwise nude thymus. This underscores the idea that Foxn1 is expressed in thymus-forming progenitors (26). Foxn1-dependent cells in the thymus can be visualized in nude blastocyst complementation (Figure 2) (9) by injection of Gfp+ Foxn1+ ES cells into Gfp− Foxn1nu/nu blastocysts (Figure 5). On thymus tissue sec-

c

a ES cells Gfp + Foxn1 +/+

Estimation of number and location of Foxn1-dependent TEC by visualization of Gfp+ nuclei DAPI = all nuclei Gfp= Foxn1-dependent TEC

b

Blastocysts Gfp – Foxn1nu/nu

Figure 5 Visualization of Foxn1-dependent thymus epithelium. The rare representation of TEC among all thymus cells is demonstrated in chimeric mice generated by injection of Gfp+ Foxn1+/+ embryonic stem (ES) cells (a) into Gfp− Foxn1nu/nu blastocysts (b). Percentages, phenotypes and tissue distribution of Gfp+ cells can be determined by ﬂow cytometry (not shown) and by histology (c). The thymus section is from a chimera with very low (<5%) ES cell contribution to thymocytes or thymic mesenchyme, and hence the Gfp+ cells represent mostly Foxn1-dependent thymus epithelium. Note the abundance of mTEC (inner area) and, by comparison, the paucity of cTEC (outer area), which implies that the density of the two TEC types is different.

tions, Gfp expression is conﬁned to the cell’s nucleus by nuclear localization and indicates the position of cells from ES cell origin. In the example shown in Figure 5, there was minimal contribution (<5%) of the ES cell to hematopoietic cells (thymocytes) and to nonepithelial stromal cells, and hence the vast majority of Gfp+ cells in the thymus represent cells that are dependent in development or maintenance on Foxn1 expression, that is, they are TEC. Overall, the density of these Foxn1-dependent TEC is much higher in the medulla than in the cortex. This is perhaps surprising given that the cortex space is completely ﬁlled with keratin+ cells, but the distribution of Gfp+ cells indicates that mTEC www.annualreviews.org • Thymus Organogenesis

373

ARI

16 February 2008

12:33

and cTEC appear to cover different thymus volumes per cell. The conclusion that mTEC outnumber cTEC in situ is certainly compatible with the observation made by many laboratories that proportionally more mTEC than cTEC are routinely retrieved from stromal cell preparations. Lack of Foxn1 expression in nude mice becomes phenotypically evident as early as E12.5 or 13.5 when the Foxn1-deﬁcient thymus anlage fails to grow adequately when compared to wild-type thymus (22, 42, 144, 145). The nude thymus rudiment is also characterized by a near absence of hematopoietic cells (22, 42, 146), possibly related to loss of expression of the chemokines CCL25 (ligand of CCR9) and CXCL12 (ligand of CXCR4) in the embryonic nude thymus (147). Interestingly, embryonic nude thymic epithelial cells are also deﬁcient in expression of the Notch ligands Dll1 and Dll4 (145). Although the question whether Notch-Notch ligand interactions and concomitant T cell commitment take place before or after entry into the thymus is still debated (see 148 for a recent discussion), lack of Notch ligands in the nude thymus may be prohibitive for T cell development and, as such, may contribute to the alymphoid nude thymus phenotype. Virtually all medullary and cortical TEC in chimeras constructed from Foxn1+/+ plus Foxn1nu/nu embryos (149, 150) or from Foxn1+/+ ES cells plus Foxn1nu/nu blastocysts (9) were from the Foxn1+ but not Foxn1nu origin. This demonstrates that Foxn1 acts in a cell-autonomous manner in thymic epithelial cells. The action of the Foxn1 gene in cis, with no rescue in trans, implies that the essential target genes of the Foxn1 transcription factor do not include a gene encoding a soluble factor such as a growth factor or a cytokine, or at least none that plays a substantial role in the nude thymus phenotype. Although genes have been identiﬁed that are differentially expressed between Foxn1+ and Foxn1nu TECs (144), functionally crucial target genes are unknown. This may appear surprising given that Foxn1 has been known for some time. It

Annu. Rev. Immunol. 2008.26:355-388. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-12

374

Rodewald

should be noted, however, that it has been impossible to study the true function of Foxn1 either in the development or in the maintenance of thymus epithelium in cell lines in vitro. This necessitates analyses of primary thymic epithelial cells that are rare cells (on the order of a few percent of total thymus cells) in a normal thymus and are even rarer in a nude thymus. Hence, although cell numbers of primary wild-type and mutant TEC are permissive for genome-wide expression analyses, low cell numbers have precluded biochemical studies, including the identiﬁcation of relevant DNA binding sites or protein cofactors that regulate the transcription factor activity of Foxn1 in primary TEC. As a consequence, the molecular function of Foxn1 in thymic epithelium remains enigmatic. Likewise, it will be of interest to determine the role of Foxn1 beyond the developmental block in nude mice, that is, in differentiated thymus epithelium and perhaps during thymus involution.

Traf6 and RelB TEC differentiation is completely blocked in Foxn1nu/nu mice at a stage precluding any support of T cell development. In contrast, thymus development is permissive in mice deﬁcient in the NF-κB component RelB or the TNF receptor-associated factor Traf6. Nevertheless, both of these mutants show major defects in TEC structure and function that may indicate faulty TEC differentiation or maintenance. Traf6 is a signal transducer in the NFκB pathway that activates IκB kinase (IKK) in response to proinﬂammatory cytokines. IKK converts the RelB/p100 dimer to RelB/p52, which activates target genes in the nucleus (reviewed in 151). Based on an NF-κB activity reporter mouse, the NF-κB pathway is used in the developing thymus in cells with a medullary location (152). In the absence of Traf6 (153), the thymus architecture is disorganized and the medulla-cortex separation is blurry. Medullary TEC populations are either missing or lack expression of certain cell surface markers (UEA-1− but K5+ phenotype).

Annu. Rev. Immunol. 2008.26:355-388. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-12

ARI

16 February 2008

12:33

These mutants suffer from autoimmunity that correlates strongly with lack of Aire+ TEC, concomitantly reduced expression of tissuerestricted self-antigens on the TEC side, and an absence of Foxp3+ regulatory T cells in the thymus. These defects are indeed stromal cell–intrinsic, as shown by transfer of autoimmune symptoms by thymus grafting. RelB expression was markedly reduced in thymus stroma ex vivo and in TEC cell lines and could be restored by reintroduction of Traf6. The diminished expression of RelB is a plausible molecular mechanism because earlier work has shown that RelB-deﬁcient mice also have severe medullary defects that render mice autoimmune (154–156). The phenotype of the Traf6-deﬁcient thymus has been proposed to be independent of LTβR ligand signaling on mTEC (118) because LTβR-induced activation of NF-κB was unaffected by lack of Traf6 (153). Overall, the importance of different NF-κB pathways in thymus epithelium is not entirely clear because Traf6-independent NFκB activity was noted in the aforementioned reporter mouse (152). The molecular defects in mice lacking RelB or Traf6 give novel insights into the genetic requirements for a key thymus function, tolerance induction. However, further interpretations of these and other studies into TEC defects are complicated by the ambiguity of whether the gene defects cause ablation of a cell type (e.g., Aire-expressing mTEC) or alter the gene expression (e.g., Aire in otherwise normal TEC).

p63 Expression of p63, a homolog of the tumor suppressor p53, is required for the normal development and maintenance of many epithelial tissues. The widespread epithelial defects in mice lacking p63 are consistent with a crucial function of this gene in epithelial stem cells. p63−/− mice possess very small thymi that were recently analyzed in detail (136, 157). p63 was expressed in all K8+ thymic epithelial cells on E12 and continues to be

expressed later in ontogeny in some but not all medullary and cortical TEC. Numbers of thymocytes were very low, but T cell development was normal in p63−/− thymi. Hence, mutant TEC are, in principle, functional (136, 157). This also holds true for hematopoietic progenitors, as shown by T cell development from p63−/− fetal liver stem cells transferred into Rag-2-deﬁcient mice. Further experiments show that TEC from p63−/− thymi have reduced expansion potential in a general epithelial cell colony assay (136). Using single cell suspensions from rat thymus, Senoo et al. (136) also developed an interesting assay for continuous culture of thymus epithelium that was considered a thymus epithelial stem cell assay. Cells that expanded in this assay expressed p63, and knock-down of p63 strongly impaired the colony size, directly supporting the argument for an important role of p63 in TEC or TEC stem cell maintenance. Because support of T cell development is the ultimate functional test for TEC, it would be interesting to know whether TEC that arise in this stem cell assay are functional. An additional mechanism for the abnormally small p63−/− thymus may be the reduced expression of p63 target genes, some of which are familiar as they play a role in thymus organogenesis. Notably, FgfR2-IIIb, which was mentioned earlier as a crucial receptor involved in mesenchymal-epithelial interactions (72), as well as Jag2 were downregulated (157). Collectively, these recent ﬁndings on the role of p63 in TEC development, and possibly TEC stem cell maintenance, may open new experimental access to the identity of thymus stem cells and their molecular regulation.

FUNCTIONAL CERVICAL THYMUS IN MICE Incidence Recently, evidence has been provided that mice have a cervical thymus that is indeed www.annualreviews.org • Thymus Organogenesis

375

Annu. Rev. Immunol. 2008.26:355-388. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-12

ARI

16 February 2008

12:33

functional in its ability to be colonized by bone marrow–derived progenitors, to generate thymocytes that are TCR repertoire selected according to the laws of positive and negative selection, and to export mature immunocompetent T cells. Terszowski et al. (41) found cervical thymus in chimeras generated as controls for mutant chimeras initially made to test the function of Tbx1 in thymus organogenesis. Dooley and colleagues (158) searched for ectopic thymus in the neck based on the similarity of thymus epithelium with nonthymic epithelium such as respiratory epithelium (90) and on the observation that samples of human parathyroid showed inclusions of ectopic thymus (158). Both reports provided evidence for a strain-dependent incidence of cervical thymi ranging from ∼50% (158) to ∼90% (41) in BALB/c mice and the lower but still signiﬁcant frequency of ∼30%

a

b Foxn1:: Egfp

C57BL/6

Neck Neck

Thoracic and Cervical Thymus in Other Mammals Chest

Chest

2.6 mm

3 mm Figure 6

Functional cervical thymi in mice. (a) Visualization of bilateral cervical (neck) thymi in a Foxn1::Egfp reporter mouse, and (b) histological ¨ comparison of May-Grunwald-Giemsa-stained tissue sections from the thoracic thymus and one cervical thymus lobe in a C57BL/6 mouse. The functional properties of neck thymus have recently been described (41, 158). 376

Rodewald

(158) to ∼50% (41) in C57BL/6 mice. These differences might be explained by the different counting of either all detectable (41) or only medially located thymi (158). As other tools of visualization of thymus become available (39, 40, 41), frequencies of cervical thymus in mice can be measured more precisely. Examples of cervical thymi are shown in a mouse line (FVB × C56BL/6 backcross) transgenic for a Foxn1Egfp reporter gene in which Foxn1-expressing cells are visualized speciﬁcally by green ﬂuorescence (41) (Figure 6a), and in a normal C57BL/6 mouse in which two thoracic and one cervical lobe are ¨ displayed as May-Grunwald-Giemsa-stained tissue sections (Figure 6b). Hence, although cervical thymi are not detectable in every single mouse in the strains analyzed so far, two of the most commonly used laboratory strains (BALB/c and C57BL/6) frequently have cervical thymi. Although the neck region of nude mice has, to my knowledge, not formally been examined for cervical thymi, the known lack of functional T cells in this mutant and the expression of Foxn1 in TEC in the neck thymus (41, 158) support the argument for a common defect in the generation of thoracic and cervical thymi in the nude mouse.

The cervical thymus in mice is not without precedent, because neck thymus is known from other mammals. Primitive mammals such as marsupials (pouched mammals) provide interesting examples. Most marsupials have only thoracic thymus, whereas others, interestingly, have both thoracic and cervical thymi (kangaroo or possum), and yet others have only a cervical thymus (koala) (159). In some of these species, cervical thymus tissue can be mingled with parathyroid tissue. In sheep, cattle, and pigs, the thymus has cervical and thoracic parts belonging to one thymus and therefore they are connected to each other (160). In humans, case reports of diseaseassociated cervical thymi (161–163) suggest

Annu. Rev. Immunol. 2008.26:355-388. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-12

ARI

16 February 2008

12:33

that cervical thymus is rare (see references in 41, 158) and is caused by failure of the thymus to properly descend to its ﬁnal mediastinal location. However, others have estimated that the cervical thymus in humans may be quite frequent, with an incidence of 50% in adults (further references in 158) and 60% in children (164). Collectively, precise ﬁgures on the normal incidence of neck thymus in human are difﬁcult to extract from the literature (for further references and considerations, see also 162), and a deﬁnitive answer to this question may require further and more systematic imaging data.

Origin of the Cervical Thymus in Mice and the Relationship of Thymus and Parathyroid The following possibilities can be considered for the origin of the second thymus. 1. The cervical thymus originates from the third pouch as the thoracic thymus does, but it takes the parathyroid route of migration. This could occur as a result of imprecise separation of the parathyroid and thymus domains (62) within the third pouch epithelium, leading to the partition of thymus progenitors into the parathyroid anlage and vice versa (see below). This would be reminiscent of the model of secondary splitting of the thymus anlagen in chicken (Figure 3). In this regard, it is noteworthy that thymus and parathyroid organs do not only develop from the same pharyngeal pouch but also share, at least in mice, some functional similarities. Some 70% of Gcm2-deﬁcient mice survive despite a complete absence of parathyroids (64). In mice, but not in humans (165), the thymus was identiﬁed as the auxiliary source of parathyroid hormone (PTH) (64). However, though expression of Gcm2 is restricted to the parathyroid and is required for the development of precursors for this organ

(104), the PTH-producing cells in the thymus colocalize with Gcm1, a gene homologous to Gcm2, that is expressed in clusters of cells in the thymus (166). The lineage of these Gcm1-expressing cells in the thymus is unknown. 2. The anlage for the cervical thymus arises independently in a different pouch, and, up to now, these few TEC progenitors may have escaped detection. An origin in a separate pharyngeal pouch would be akin to the multiple thymus anlagen in the shark (Figure 3) and could be considered an atavism. 3. There could be a delayed epithelial speciﬁcation toward the cervical thymus fate at an unknown location in the neck. In this case, a search for cells expressing Foxn1 between days 14 and 18 outside the thoracic thymus may provide a clue. This latter idea is supported by the notion that the development of the cervical thymus is delayed by about one week compared to the thoracic thymus (41) (see below).

Developmental Kinetics of the Cervical Thymus The identiﬁcation of the primitive anlage for the cervical thymus in the neck of newborn mice also led to the surprising result that thoracic and cervical thymi do not develop in parallel but asynchronously (41). Cells in the cervical thymus anlage in the neck of newborn mice express Foxn1 and MHC class II, indicative of their thymus identity, but, at this stage, the overall TEC structure is still primitive, with many cells coexpressing K5 and K18 and poor epithelial cell compartmentalization. In addition, there are only few and only immature thymocytes present in the neck thymus at this stage (41). TCR DJβ and V(D)Jβ rearrangements are undetectable in the neck on fetal day 18.5, further supporting the lack of thymic function in the neck before birth. Based on the kinetics and a maturational comparison of cervical and thoracic thymus, the www.annualreviews.org • Thymus Organogenesis

377

ARI

16 February 2008

12:33

cervical thymus appears at birth as immature as the major thymus one week earlier, that is, on days 12 or 13 in embryonic development. The developmental delay between the thoracic and the cervical thymus is also evident by a burst of CD4+ CD8+ cells as late as one week after birth in the neck thymus, as opposed to the same burst, on a larger scale, in the thorax thymus on fetal day 18. The presumed onset of thymopoiesis in the neck only after birth could make the cervical thymus miss the wave of production of Vγ5-expressing thymocytes (G. Terszowski & H.-R. Rodewald, unpublished) that are the precursors of the canonical TCR-expressing dendritic epidermal T cells (167). Along these lines, asynchronous functioning of thoracic and cervical thymus within individual mice may give clues as to which properties of the thymus are organautonomous and which are regulated at the level of the organism or at the level of the bone marrow that is producing thymus-bound progenitors.

Annu. Rev. Immunol. 2008.26:355-388. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-12

Anatomy Cervical thymi in the mouse are often single unilateral lobes, but two bilateral (Figure 6) or even two unilateral lobes can also be found. Cervical thymi are usually located medially, that is, on the inside of the large cervical vessels, and along the ventral region between the thyroid or even more cranially toward the submandibular glands and caudally toward the lower part of the neck. However, in no instance could we ﬁnd open connections to the chest or a continuous chest-neck-thymus in mice. The position of the cervical thymus is usually superﬁcial, but cervical thymus lobes are also present between or under muscle strings (for anatomical positions, see 41, 158). Overall, the distribution of cervical thymus is much wider than previously suggested on the basis of previous anatomical reports of thymus tissue located within or next to the thyroid (168, 169). Likewise, the view that mice, similar to sheep or cattle, have a cervical part of

378

Rodewald

their thymus (170) is not supported by recent studies (41, 158). Many of these discrepancies, and the fact that cervical thymus in mice has by and large been overlooked in immunology, could be explained by the fact that cervical thymus lobes may have been considered cervical lymph nodes. Cervical thymi can easily be distinguished from lymph nodes by histology or ﬂow cytometry using thymus-speciﬁc markers (41, 158).

Function of the Cervical Thymus and Implications Several differences have been noted comparing cervical and thoracic thymus. Cervical thymi are mostly single small lobes composed of medulla and cortex, whereas thoracic thymi are, of course, composed of multiple medulla and cortex structures (41, 158) (Figure 6). Thymic ﬁbroblasts are found more locally restricted in the neck than the chest thymus (158). The cortex in the cervical thymus contains clusters of CD4+ CD8− cells that are unusual among normal cortical CD4+ CD8+ cells (41). The cervical thymus has between 105 and 2 × 105 cells but these cell numbers can also be smaller or be as large as 106 . This cellularity is low when compared to the thoracic thymus (∼108 cells) but large when compared to, say, single gut cryptopatches, intestinal areas harboring ∼103 lymphoid progenitors (171, 172). When tested in model systems for positive and negative TCR repertoire selection, thoracic and cervical thymus obey the same wellknown rules (41, 158). Moreover, the cervical thymus can export functional T cells when grafted into nude mice (41, 158), and these T cells mount T cell help required for an antibody response, including class switching (41). The contribution of the cervical thymi to the overall T cell pool in a mouse that has both thoracic and cervical thymi is unknown, and it may be proportional to the size differences. Likewise, the contribution of cervical thymi to peripheral T cells in a

Annu. Rev. Immunol. 2008.26:355-388. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-12

ARI

16 February 2008

12:33

mouse that underwent thoracic thymectomy remains to be determined. The cervical thymus contains Foxp3+ thymocytes in their normal medullary location, suggesting that the neck thymus provides both effector and regulatory T cells to the periphery (158). This raises some interesting questions regarding the possible role of the cervical thymus in models of autoimmunity that are driven by thoracic thymectomy shortly after birth (173). Because cervical thymi have not been removed in these experiments, it remains to be determined whether T cells produced by the cervical thymus postnatally contribute to this phenomenon or not, and if so, why they cannot be controlled by regulatory cells that can also be generated in the cervical thymus. Hints that mice have a thymus in their neck date back to 1964. A histological section from the parathyroid region of a BALB/c mouse neck included thymus tissue (168; discussed in 174, 175). Moreover, cervical thymus embedded in the thyroid gland in 80% of female diabetes-prone NOD but not in normal control mice had been reported (169). Cervical thymi in lieu of normal thoracic thymi were identiﬁed in Pax9-deﬁcient mice, providing a case for ectopic thymus as a result of failed migration toward the thorax (87). Anatomical drawings, on the other hand, suggested that

mice, similar to sheep (160), have a cervical part of the thymus (170), a view not supported by the recent analyses (41, 158). In any case, the function of the cervical thymus in mice was clearly unknown. Moreover, as far as we know, neither the proper anatomical location (as opposed to cervical lymph nodes) nor the incidence had been reported. It is clear now that the cervical thymus, though not detectable in every individual mouse, is not restricted to the BALB/c strain, and it is also not restricted anatomically to the thyroid/parathyroid area, nor is it part of the thoracic thymus. Arguments surrounding early hints of a cervical thymus, and the fact that it had been ignored in subsequent experimentation, have recently been exchanged (for a discussion and further references, see 174– 176). Because the cervical thymus is capable of generating and releasing functional T cells that render athymic mice immunocompetent, at least toward antigens tested so far, it may have confounded thoracic thymectomy experiments. Determining to what degree this is the case requires further work. Finally, comparative analyses of thoracic and cervical thymi may yield insights into the regulation of thymus organogenesis, the location dependency of thymus functions, and possibly thymus aging.

DISCLOSURE STATEMENT The author is not aware of any biases that might be perceived as affecting the objectivity of this review.

ACKNOWLEDGMENTS I thank past and present members of my laboratory, in particular Carmen Blum, Verena ¨ ¨ Buhrmann, Susanna Muller, Sabine Paul, Greg Terszowski (Ulm), and Corinne Haller (Basel), for their contributions to our studies addressing thymus development. I am grateful to Graham ¨ Fehling, Reinhard Pabst, and Nick Anderson, Thomas Boehm, Louis Du Pasquier, Hans Jorg Trede for advice and discussions, Louis Du Pasquier for drawings incorporated into Figure 3, Virginia Papaioannou for providing Gfp-marked ES cells (Figure 5), and Thomas Boehm for collaborating on the Foxn1::Egfp reporter mouse (Figure 6). Thymus research in my laboratory is supported by grants from the Deutsche Forschungsgemeinschaft (SFB 497-B5 and Klinische Forschergruppe 142-P8).

www.annualreviews.org • Thymus Organogenesis

379

ANRV338-IY26-12

ARI

16 February 2008

12:33

LITERATURE CITED

Annu. Rev. Immunol. 2008.26:355-388. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

1. Anderson G, Jenkinson EJ. 2001. Lymphostromal interactions in thymic development and function. Nat. Rev. Immunol. 1:31–40 2. Petrie HT, Zuniga-Pﬂucker JC. 2007. Zoned out: functional mapping of stromal signaling microenvironments in the thymus. Annu. Rev. Immunol. 25:649–79 3. Anderson MS, Venanzi ES, Klein L, Chen Z, Berzins SP, et al. 2002. Projection of an immunological self shadow within the thymus by the aire protein. Science 298:1395–401 4. von Boehmer H. 2004. Selection of the T-cell repertoire: receptor-controlled checkpoints in T-cell development. Adv. Immunol. 84:201–38 5. Kyewski B, Klein L. 2006. A central role for central tolerance. Annu. Rev. Immunol. 24:571–606 6. Martinic MM, van den Broek MF, Rulicke T, Huber C, Odermatt B, et al. 2006. Functional CD8+ but not CD4+ T cell responses develop independent of thymic epithelial MHC. Proc. Natl. Acad. Sci. USA 103:14435–40 7. Klein L, Kyewski B. 2000. Self-antigen presentation by thymic stromal cells: a subtle division of labor. Curr. Opin. Immunol. 12:179–86 8. Gray DH, Chidgey AP, Boyd RL. 2002. Analysis of thymic stromal cell populations using ﬂow cytometry. J. Immunol. Methods 260:15–28 9. Muller SM, Terszowski G, Blum C, Haller C, Anquez V, et al. 2005. Gene targeting of VEGF-A in thymus epithelium disrupts thymus blood vessel architecture. Proc. Natl. Acad. Sci. USA 102:10587–92 10. Anderson G, Jenkinson EJ, Moore NC, Owen JJ. 1993. MHC class II-positive epithelium and mesenchyme cells are both required for T-cell development in the thymus. Nature 362:70–73 11. Jenkinson EJ, Anderson G. 1994. Fetal thymic organ cultures. Curr. Opin. Immunol. 6:293–97 12. Rodewald HR. 2000. Thymus epithelial cell reaggregate grafts. Curr. Top. Microbiol. Immunol. 251:101–8 13. Rodewald HR, Paul S, Haller C, Bluethmann H, Blum C. 2001. Thymus medulla consisting of epithelial islets each derived from a single progenitor. Nature 414:763–68 14. Bennett AR, Farley A, Blair NF, Gordon J, Sharp L, Blackburn CC. 2002. Identiﬁcation and characterization of thymic epithelial progenitor cells. Immunity 16:803–14 15. Gill J, Malin M, Hollander GA, Boyd R. 2002. Generation of a complete thymic microenvironment by MTS24+ thymic epithelial cells. Nat. Immunol. 3:635–42 16. Sutherland JS, Goldberg GL, Hammett MV, Uldrich AP, Berzins SP, et al. 2005. Activation of thymic regeneration in mice and humans following androgen blockade. J. Immunol. 175:2741–53 17. Gray DH, Tull D, Ueno T, Seach N, Classon BJ, et al. 2007. A unique thymic ﬁbroblast population revealed by the monoclonal antibody MTS-15. J. Immunol. 178:4956–65 18. Raviola E, Karnovsky MJ. 1972. Evidence for a blood-thymus barrier using electronopaque tracers. J. Exp. Med. 136:466–98 19. Anderson M, Anderson SK, Farr AG. 2000. Thymic vasculature: organizer of the medullary epithelial compartment? Int. Immunol. 12:1105–10 20. Gray DH, Seach N, Ueno T, Milton MK, Liston A, et al. 2006. Developmental kinetics, turnover, and stimulatory capacity of thymic epithelial cells. Blood 108:3777–85 21. van Ewijk W, Shores EW, Singer A. 1994. Crosstalk in the mouse thymus. Immunol. Today 15:214–17 380

Rodewald

Annu. Rev. Immunol. 2008.26:355-388. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-12

ARI

16 February 2008

12:33

22. Cordier AC, Haumont SM. 1980. Development of thymus, parathyroids, and ultimobranchial bodies in NMRI and nude mice. Am. J. Anat. 157:227–63 23. Le Douarin NM, Jotereau FV. 1975. Tracing of cells of the avian thymus through embryonic life in interspeciﬁc chimeras. J. Exp. Med. 142:17–40 24. Bockman DE, Kirby ML. 1984. Dependence of thymus development on derivatives of the neural crest. Science 223:498–500 25. Wyffels JT, Walsh CJ, Luer CA, Bodine AB. 2005. In vivo exposure of clearnose skates, Raja eglanteria, to ionizing X-radiation: acute effects on the thymus. Dev. Comp. Immunol. 29:315–31 26. Bleul CC, Corbeaux T, Reuter A, Fisch P, Monting JS, Boehm T. 2006. Formation of a functional thymus initiated by a postnatal epithelial progenitor cell. Nature 441:992–96 27. Rossi SW, Chidgey AP, Parnell SM, Boyd R, Jenkinson EJ, Anderson G. 2007. Redeﬁning epithelial progenitor potential in the developing thymus. Eur. J. Immunol. 37:2411–18 28. Rossi SW, Jenkinson WE, Anderson G, Jenkinson EJ. 2006. Clonal analysis reveals a common progenitor for thymic cortical and medullary epithelium. Nature 441:988–91 29. Rodewald HR. 2006. Immunology: a second chance for the thymus. Nature 441:942–43 30. Gordon J, Wilson VA, Blair NF, Sheridan J, Farley A, et al. 2004. Functional evidence for a single endodermal origin for the thymic epithelium. Nat. Immunol. 5:546–53 31. Manley NR, Blackburn CC. 2004. Thymus and parathyroid organogenesis. In Handbook of Stem Cells, ed. R Lanza, pp. 391–406. Amsterdam: Elsevier Acad. 32. Farr AG, Anderson SK. 1985. Epithelial heterogeneity in the murine thymus: fucosespeciﬁc lectins bind medullary epithelial cells. J. Immunol. 134:2971–77 33. Kampinga J, Berges S, Boyd RL, Brekelmans P, Colic M, et al. 1989. Thymic epithelial antibodies: immunohistological analysis and introduction of nomenclature. Thymus 13:165–73 34. Farr A, Nelson A, Truex J, Hosier S. 1991. Epithelial heterogeneity in the murine thymus: a cell surface glycoprotein expressed by subcapsular and medullary epithelium. J. Histochem. Cytochem. 39:645–53 35. Boyd RL, Tucek CL, Godfrey DI, Izon DJ, Wilson TJ, et al. 1993. The thymic microenvironment. Immunol. Today 14:445–59 36. van Ewijk W, Hollander G, Terhorst C, Wang B. 2000. Stepwise development of thymic microenvironments in vivo is regulated by thymocyte subsets. Development 127:1583–91 37. Rajewsky K, Gu H, Kuhn R, Betz UA, Muller W, et al. 1996. Conditional gene targeting. J. Clin. Invest. 98:600–3 38. Hozumi K, Negishi N, Suzuki D, Abe N, Sotomaru Y, et al. 2004. Delta-like 1 is necessary for the generation of marginal zone B cells but not T cells in vivo. Nat. Immunol. 6:638–44 39. Liston A, Farr AG, Chen Z, Benoist C, Mathis D, et al. 2007. Lack of Foxp3 function and expression in the thymic epithelium. J. Exp. Med. 204:475–80 40. Gordon J, Xiao S, Hughes B 3rd, Su DM, Navarre SP, et al. 2007. Speciﬁc expression of lacZ and cre recombinase in fetal thymic epithelial cells by multiplex gene targeting at the Foxn1 locus. BMC Dev. Biol. 7:69–78 41. Terszowski G, Muller SM, Bleul CC, Blum C, Schirmbeck R, et al. 2006. Evidence for a functional second thymus in mice. Science 312:284–87 42. Boehm T, Bleul CC, Schorpp M. 2003. Genetic dissection of thymus development in mouse and zebraﬁsh. Immunol. Rev. 195:15–27 43. Trede NS, Medenbach J, Damianov A, Hung LH, Weber GJ, et al. 2007. Network of coregulated spliceosome components revealed by zebraﬁsh mutant in recycling factor p110. Proc. Natl. Acad. Sci. USA 104:6608–13 www.annualreviews.org • Thymus Organogenesis

381

ARI

16 February 2008

12:33

44. Cohen N. 1975. Phylogeny of lymphocyte structure and function. Amer. Zool. 15:119–33 45. Du Pasquier L. 1993. Evolution of the immune system. In Fundamental Immunology, ed. W Paul, pp. 221–26. Philadelphia/New York: Raven 46. Boehm T, Bleul CC. 2007. The evolutionary history of lymphoid organs. Nat. Immunol. 8:131–35 47. Litman GW, Cooper MD. 2007. Why study the evolution of immunity? Nat. Immunol. 8:547–48 48. Du Pasquier L. 1995. Syst`eme immunitaire. In Respiration Circulation Syst`eme Immunitaire, ed. A Beaumont, JP Truchot, L Du Pasquier, pp. 217–55. Paris: Dunod 49. Manley NR, Capecchi MR. 1995. The role of Hoxa-3 in mouse thymus and thyroid development. Development 121:1989–2003 50. Nickel R, Schummer A, Seiferle E. 1973. Anatomie der Hausv¨ogel, pp. 108–9. Berlin/Hamburg: Paul Parey 51. Manley NR. 2000. Thymus organogenesis and molecular mechanisms of thymic epithelial cell differentiation. Semin. Immunol. 12:421–28 52. Blackburn CC, Manley NR. 2004. Developing a new paradigm for thymus organogenesis. Nat. Rev. Immunol. 4:278–89 53. Norris EH. 1938. The morphogenesis and histogenesis of the thymus gland in man: in which the origin of the Hassall’s corpuscles of the human thymus is discovered. Contrib. Embryol. 166:191–221 54. Janeway CA, Travers P. 1997. Immunobiology. The Immune System in Health and Disease. London/San Francisco/New York: Current Biology Ltd., Garland. 3rd ed. 55. Picker LJ, Siegelman MH. 1999. Lymphoid tissues and organs. In Fundamental Immunology, ed. W Paul, pp. 479–531. Philadelphia/New York: Lippincott-Raven 56. Chaplin DD. 2003. Lymphoid tissues and organs. In Fundamental Immunology, ed. WE Paul, pp. 419–453. Philadelphia: Lippincott Williams & Wilkins 57. Gordon J, Wilson VA, Moore-Scott BA, Manley NR, Blackburn CC. 2005. In vivo and in vitro assays of thymic organogenesis. Meth. Mol. Med. 105:303–10 58. Rodewald HR. 2004. Islets of thymic epithelium: telltale signs of epithelial stemprogenitor cell activity in thymus organogenesis. In Handbook of Stem Cells, ed. R Lanza, pp. 555–64. Amsterdam: Elsevier Acad. 59. Boehm T, Bleul CC. 2006. Thymus-homing precursors and the thymic microenvironment. Trends Immunol. 27:477–84 60. Nehls M, Pfeifer D, Schorpp M, Hedrich H, Boehm T. 1994. New member of the winged-helix protein family disrupted in mouse and rat nude mutations. Nature 372:103– 7 61. Nehls M, Kyewski B, Messerle M, Waldschutz R, Schuddekopf K, et al. 1996. Two genetically separable steps in the differentiation of thymic epithelium. Science 272:886– 89 62. Gordon J, Bennett AR, Blackburn CC, Manley NR. 2001. Gcm2 and Foxn1 mark early parathyroid- and thymus-speciﬁc domains in the developing third pharyngeal pouch. Mech. Dev. 103:141–43 63. Itoi M, Tsukamoto N, Amagai T. 2007. Expression of Dll4 and CCL25 in Foxn1-negative epithelial cells in the postnatal thymus. Int. Immunol. 19:127–32 64. Gunther T, Chen ZF, Kim J, Priemel M, Rueger JM, et al. 2000. Genetic ablation of parathyroid glands reveals another source of parathyroid hormone. Nature 406:199–203 65. Owen JJ, McLoughlin DE, Suniara RK, Jenkinson EJ. 2000. The role of mesenchyme in thymus development. Curr. Top. Microbiol. Immunol. 251:133–37

Annu. Rev. Immunol. 2008.26:355-388. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-12

382

Rodewald

Annu. Rev. Immunol. 2008.26:355-388. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-12

ARI

16 February 2008

12:33

66. Petrie HT. 2002. Role of thymic organ structure and stromal composition in steady-state postnatal T-cell production. Immunol. Rev. 189:8–19 67. Shinohara T, Honjo T. 1996. Epidermal growth factor can replace thymic mesenchyme in induction of embryonic thymus morphogenesis in vitro. Eur. J. Immunol. 26:747–52 68. Suniara RK, Jenkinson EJ, Owen JJ. 2000. An essential role for thymic mesenchyme in early T cell development. J. Exp. Med. 191:1051–56 69. Jiang X, Rowitch DH, Soriano P, McMahon AP, Sucov HM. 2000. Fate of the mammalian cardiac neural crest. Development 127:1607–16 70. Yamazaki H, Sakata E, Yamane T, Yanagisawa A, Abe K, et al. 2005. Presence and distribution of neural crest-derived cells in the murine developing thymus and their potential for differentiation. Int. Immunol. 17:549–58 71. Kranz A, Kendall MD, von Gaudecker B. 1997. Studies on rat and human thymus to demonstrate immunoreactivity of calcitonin gene-related peptide, tyrosine hydroxylase and neuropeptide Y. J. Anat. 191:441–50 72. Revest JM, Suniara RK, Kerr K, Owen JJ, Dickson C. 2001. Development of the thymus requires signaling through the ﬁbroblast growth factor receptor R2-IIIb. J. Immunol. 167:1954–61 73. Erickson M, Morkowski S, Lehar S, Gillard G, Beers C, et al. 2002. Regulation of thymic epithelium by keratinocyte growth factor. Blood 100:3269–78 74. Rossi SW, Jeker LT, Ueno T, Kuse S, Keller MP, et al. 2007. Keratinocyte growth factor (KGF) enhances postnatal T-cell development via enhancements in proliferation and function of thymic epithelial cells. Blood 109:3803–11 75. Min D, Taylor PA, Panoskaltsis-Mortari A, Chung B, Danilenko DM, et al. 2002. Protection from thymic epithelial cell injury by keratinocyte growth factor: a new approach to improve thymic and peripheral T-cell reconstitution after bone marrow transplantation. Blood 99:4592–600 76. Rossi S, Blazar BR, Farrell CL, Danilenko DM, Lacey DL, et al. 2002. Keratinocyte growth factor preserves normal thymopoiesis and thymic microenvironment during experimental graft-vs-host disease. Blood 100:682–91 77. Manley NR, Capecchi MR. 1998. Hox group 3 paralogs regulate the development and migration of the thymus, thyroid, and parathyroid glands. Dev. Biol. 195:1–15 78. Xu PX, Zheng W, Laclef C, Maire P, Maas RL, et al. 2002. Eya1 is required for the morphogenesis of mammalian thymus, parathyroid and thyroid. Development 129:3033– 44 79. Zou D, Silvius D, Davenport J, Grifone R, Maire P, Xu PX. 2006. Patterning of the third pharyngeal pouch into thymus/parathyroid by Six and Eya1. Dev. Biol. 293:499–512 80. Laclef C, Souil E, Demignon J, Maire P. 2003. Thymus, kidney and craniofacial abnormalities in Six1 deﬁcient mice. Mech. Dev. 120:669–79 81. Dietrich S, Gruss P. 1995. Undulated phenotypes suggest a role of Pax-1 for the development of vertebral and extravertebral structures. Dev. Biol. 167:529–48 82. Wallin J, Eibel H, Neubuser A, Wilting J, Koseki H, Balling R. 1996. Pax1 is expressed during development of the thymus epithelium and is required for normal T-cell maturation. Development 122:23–30 83. Su DM, Manley NR. 2000. Hoxa3 and Pax1 transcription factors regulate the ability of fetal thymic epithelial cells to promote thymocyte development. J. Immunol. 164:5753–60 84. Su D, Ellis S, Napier A, Lee K, Manley NR. 2001. Hoxa3 and pax1 regulate epithelial cell death and proliferation during thymus and parathyroid organogenesis. Dev. Biol. 236:316–29 www.annualreviews.org • Thymus Organogenesis

383

ARI

16 February 2008

12:33

85. Conway SJ, Henderson DJ, Copp AJ. 1997. Pax3 is required for cardiac neural crest migration in the mouse: evidence from the splotch (Sp2H) mutant. Development 124:505– 14 86. Peters H, Neubuser A, Kratochwil K, Balling R. 1998. Pax9-deﬁcient mice lack pharyngeal pouch derivatives and teeth and exhibit craniofacial and limb abnormalities. Genes Dev. 12:2735–47 87. Hetzer-Egger C, Schorpp M, Haas-Assenbaum A, Balling R, Peters H, Boehm T. 2002. Thymopoiesis requires Pax9 function in thymic epithelial cells. Eur. J. Immunol. 32:1175– 81 88. Jerome LA, Papaioannou VE. 2001. DiGeorge syndrome phenotype in mice mutant for the T-box gene, Tbx1. Nat. Genet. 27:286–91 89. Hollander G, Gill J, Zuklys S, Iwanami N, Liu C, Takahama Y. 2006. Cellular and molecular events during early thymus development. Immunol. Rev. 209:28–46 90. Dooley J, Erickson M, Farr AG. 2005. An organized medullary epithelial structure in the normal thymus expresses molecules of respiratory epithelium and resembles the epithelial thymic rudiment of nude mice. J. Immunol. 175:4331–37 91. Gillard GO, Dooley J, Erickson M, Peltonen L, Farr AG. 2007. Aire-dependent alterations in medullary thymic epithelium indicate a role for Aire in thymic epithelial differentiation. J. Immunol. 178:3007–15 92. Ohnemus S, Kanzler B, Jerome-Majewska LA, Papaioannou VE, Boehm T, Mallo M. 2002. Aortic arch and pharyngeal phenotype in the absence of BMP-dependent neural crest in the mouse. Mech. Dev. 119:127–35 93. Bleul CC, Boehm T. 2005. BMP signaling is required for normal thymus development. J. Immunol. 175:5213–21 94. Patel SR, Gordon J, Mahbub F, Blackburn CC, Manley NR. 2006. Bmp4 and Noggin expression during early thymus and parathyroid organogenesis. Gene. Expr. Patterns 6:794–99 95. Greenberg F. 1993. DiGeorge syndrome: an historical review of clinical and cytogenetic features. J. Med. Genet. 30:803–6 96. Naiche LA, Harrelson Z, Kelly RG, Papaioannou VE. 2005. T-box genes in vertebrate development. Annu. Rev. Genet. 39:219–39 97. Perez E, Sullivan KE. 2002. Chromosome 22q11.2 deletion syndrome (DiGeorge and velocardiofacial syndromes). Curr. Opin. Pediatr. 14:678–83 98. Packham EA, Brook JD. 2003. T-box genes in human disorders. Hum. Mol. Genet. 12:37– 44 99. Scambler PJ. 2000. The 22q11 deletion syndromes. Hum. Mol. Genet. 9:2421–26 100. Lindsay EA, Vitelli F, Su H, Morishima M, Huynh T, et al. 2001. Tbx1 haploinsufﬁciency in the DiGeorge syndrome region causes aortic arch defects in mice. Nature 410:97–101 101. Chapman DL, Garvey N, Hancock S, Alexiou M, Agulnik SI, et al. 1996. Expression of the T-box family genes, Tbx1-Tbx5, during early mouse development. Dev. Dyn. 206:379–90 102. Arnold JS, Werling U, Braunstein EM, Liao J, Nowotschin S, et al. 2006. Inactivation of Tbx1 in the pharyngeal endoderm results in 22q11DS malformations. Development 133:977–87 103. Zhang Z, Huynh T, Baldini A. 2006. Mesodermal expression of Tbx1 is necessary and sufﬁcient for pharyngeal arch and cardiac outﬂow tract development. Development 133:3587– 95 104. Liu Z, Yu S, Manley NR. 2007. Gcm2 is required for the differentiation and survival of parathyroid precursor cells in the parathyroid/thymus primordia. Dev. Biol. 305:333–46

Annu. Rev. Immunol. 2008.26:355-388. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-12

384

Rodewald

Annu. Rev. Immunol. 2008.26:355-388. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-12

ARI

16 February 2008

12:33

105. Gill J, Malin M, Sutherland J, Gray D, Hollander G, Boyd R. 2003. Thymic generation and regeneration. Immunol. Rev. 195:28–50 106. Rodewald HR. 2004. Epithelial stem/progenitor cells in thymus organogenesis. In Adult Stem Cells, ed. S Sell, pp. 83–100. Totowa, NJ: Humana 107. Klug DB, Carter C, Crouch E, Roop D, Conti CJ, Richie ER. 1998. Interdependence of cortical thymic epithelial cell differentiation and T-lineage commitment. Proc. Natl. Acad. Sci. USA 95:11822–27 108. Klug DB, Carter C, Gimenez-Conti IB, Richie ER. 2002. Cutting edge: thymocyteindependent and thymocyte-dependent phases of epithelial patterning in the fetal thymus. J. Immunol. 169:2842–45 109. Ritter MA, Boyd RL. 1993. Development in the thymus: it takes two to tango. Immunol. Today 14:462–69 110. Ropke C, van Soest P, Platenburg PP, van Ewijk W. 1995. A common stem cell for murine cortical and medullary thymic epithelial cells? Dev. Immunol. 4:149–56 111. Rodewald H-R, Fehling HJ. 1998. Molecular and cellular events in early thymocyte development. Adv. Immunol. 69:1–112 112. Hollander GA, Wang B, Nichogiannopoulou A, Platenburg PP, van Ewijk W, et al. 1995. Developmental control point in induction of thymic cortex regulated by a subpopulation of prothymocytes. Nature 373:350–53 113. Wang B, Biron C, She J, Higgins K, Sunshine MJ, et al. 1994. A block in both early T lymphocyte and natural killer cell development in transgenic mice with high-copy numbers of the human CD3E gene. Proc. Natl. Acad. Sci. USA 91:9402–6 114. Tokoro Y, Sugawara T, Yaginuma H, Nakauchi H, Terhorst C, et al. 1998. A mouse carrying genetic defect in the choice between T and B lymphocytes. J. Immunol. 161:4591– 98 115. Jenkinson WE, Rossi SW, Jenkinson EJ, Anderson G. 2005. Development of functional thymic epithelial cells occurs independently of lymphostromal interactions. Mech. Dev. 122:1294–99 116. Rodewald HR, Ogawa M, Haller C, Waskow C, DiSanto JP. 1997. Pro-thymocyte expansion by c-kit and the common cytokine receptor gamma chain is essential for repertoire formation. Immunity 6:265–72 117. Hong R, Horowitz S, Moen R, Trigg M, Sondel P, et al. 1987. Thymus and B cell reconstitution in severe combined immunodeﬁciency after transplantation of monoclonal antibody depleted parental mismatched bone marrow. Bone Marrow Transplant 1:405–9 118. Boehm T, Scheu S, Pfeffer K, Bleul CC. 2003. Thymic medullary epithelial cell differentiation, thymocyte emigration, and the control of autoimmunity require lympho-epithelial cross talk via LTbR. J. Exp. Med. 198:757–69 119. Rossi SW, Kim MY, Leibbrandt A, Parnell SM, Jenkinson WE, et al. 2007. RANK signals from CD4+ 3− inducer cells regulate development of Aire-expressing epithelial cells in the thymic medulla. J. Exp. Med. 204:1267–72 120. Di Santo JP, Rodewald HR. 1998. In vivo roles of receptor tyrosine kinases and cytokine receptors in early thymocyte development. Curr. Opin. Immunol. 10:196–207 121. Rodewald HR, Kretzschmar K, Swat W, Takeda S. 1995. Intrathymically expressed c-kit ligand (stem cell factor) is a major factor driving expansion of very immature thymocytes in vivo. Immunity 3:313–19 122. Wehrle-Haller B, Imhof BA. 2001. Stem cell factor presentation to c-Kit. Identiﬁcation of a basolateral targeting domain. J. Biol. Chem. 276:12667–74 www.annualreviews.org • Thymus Organogenesis

385

ARI

16 February 2008

12:33

123. Tajima Y, Huang EJ, Vosseller K, Ono M, Moore MA, Besmer P. 1998. Role of dimerization of the membrane-associated growth factor kit ligand in juxtacrine signaling: the Sl17H mutation affects dimerization and stability-phenotypes in hematopoiesis. J. Exp. Med. 187:1451–61 124. Radtke F, Wilson A, MacDonald H. 2004. Notch signaling in T- and B-cell development. Curr. Opin. Immunol. 16:174–79 125. Maillard I, Fang T, Pear WS. 2005. Regulation of lymphoid development, differentiation, and function by the Notch pathway. Annu. Rev. Immunol. 23:945–74 126. Rodewald HR. 1996. Reconstitution of selective hematopoietic lineages and hematopoietic environments in vivo. In Human Disease—From Genetic Causes to Biochemical Effects. Proceedings of the Symposium “The Genetic Basis of Human Disease,” ed. J Drews, S Ryser, pp. 51–57. Berlin: Blackwell Sci. 127. Hamazaki Y, Fujita H, Kobayashi T, Choi Y, Scott HS, et al. 2007. Medullary thymic epithelial cells expressing Aire represent a unique lineage derived from cells expressing claudin. Nat. Immunol. 8:304–11 128. Aschenbrenner K, D’Cruz LM, Vollmann EH, Hinterberger M, Emmerich J, et al. 2007. Selection of Foxp3+ regulatory T cells speciﬁc for self antigen expressed and presented by Aire+ medullary thymic epithelial cells. Nat. Immunol. 8:351–58 129. Gillard GO, Farr AG. 2006. Features of medullary thymic epithelium implicate postnatal development in maintaining epithelial heterogeneity and tissue-restricted antigen expression. J. Immunol. 176:5815–24 130. Derbinski J, Schulte A, Kyewski B, Klein L. 2001. Promiscuous gene expression in medullary thymic epithelial cells mirrors the peripheral self. Nat. Immunol. 2:1032–39 131. Gillard GO, Farr AG. 2005. Contrasting models of promiscuous gene expression by thymic epithelium. J. Exp. Med. 202:15–19 132. Farr AG, Dooley JL, Erickson M. 2002. Organization of thymic medullary epithelial heterogeneity: implications for mechanisms of epithelial differentiation. Immunol. Rev. 189:20–27 133. Petrie HT, Van Ewijk W. 2002. Thymus by numbers. Nat. Immunol. 3:604–5 134. Couzin J. 2002. Immunology. Plant a few cells, sprout a thymus. Science 296:2120–21 135. Barthlott T, Keller MP, Krenger W, Hollander GA. 2006. A short primer on early molecular and cellular events in thymus organogenesis and replacement. Swiss Med. Wkly. 136:365–69 136. Senoo M, Pinto F, Crum CP, McKeon F. 2007. p63 is essential for the proliferative potential of stem cells in stratiﬁed epithelia. Cell 129:523–36 137. Kaestner KH, Knochel W, Martinez DE. 2000. Uniﬁed nomenclature for the winged helix/forkhead transcription factors. Genes Dev. 14:142–46 138. Coffer PJ, Burgering BM. 2004. Forkhead-box transcription factors and their role in the immune system. Nat. Rev. Immunol. 4:889–99 139. Jonsson H, Peng SL. 2005. Forkhead transcription factors in immunology. Cell. Mol. Life Sci. 62:397–409 140. Schuddekopf K, Schorpp M, Boehm T. 1996. The whn transcription factor encoded by the nude locus contains an evolutionarily conserved and functionally indispensable activation domain. Proc. Natl. Acad. Sci. USA 93:9661–64 141. Su DM, Navarre S, Oh WJ, Condie BG, Manley NR. 2003. A domain of Foxn1 required for crosstalk-dependent thymic epithelial cell differentiation. Nat. Immunol. 4:1128–35 142. Cunliffe VT, Furley AJ, Keenan D. 2002. Complete rescue of the nude mutant phenotype by a wild-type Foxn1 transgene. Mamm. Genome 13:245–52

Annu. Rev. Immunol. 2008.26:355-388. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-12

386

Rodewald

Annu. Rev. Immunol. 2008.26:355-388. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-12

ARI

16 February 2008

12:33

143. Balciunaite G, Keller MP, Balciunaite E, Piali L, Zuklys S, et al. 2002. Wnt glycoproteins regulate the expression of FoxN1, the gene defective in nude mice. Nat. Immunol. 3:1102– 8 144. Bleul CC, Boehm T. 2001. Laser capture microdissection-based expression proﬁling identiﬁes PD1-ligand as a target of the nude locus gene product. Eur. J. Immunol. 31:2497– 503 145. Tsukamoto N, Itoi M, Nishikawa M, Amagai T. 2005. Lack of Delta like 1 and 4 expressions in nude thymus anlages. Cell. Immunol. 234:77–80 146. Itoi M, Kawamoto H, Katsura Y, Amagai T. 2001. Two distinct steps of immigration of hematopoietic progenitors into the early thymus anlage. Int. Immunol. 13:1203–11 147. Bleul CC, Boehm T. 2000. Chemokines deﬁne distinct microenvironments in the developing thymus. Eur. J. Immunol. 30:3371–79 148. Jenkinson EJ, Jenkinson WE, Rossi SW, Anderson G. 2006. The thymus and T-cell commitment: the right niche for Notch? Nat. Rev. Immunol. 6:551–55 149. Blackburn CC, Augustine CL, Li R, Harvey RP, Malin MA, et al. 1996. The nu gene acts cell-autonomously and is required for differentiation of thymic epithelial progenitors. Proc. Natl. Acad. Sci. USA 93:5742–46 150. Martinic MM, Rulicke T, Althage A, Odermatt B, Hochli M, et al. 2003. Efﬁcient T cell repertoire selection in tetraparental chimeric mice independent of thymic epithelial MHC. Proc. Natl. Acad. Sci. USA 100:1861–66 151. Karin M, Lin A. 2002. NF-κB at the crossroads of life and death. Nat. Immunol. 3:221–27 152. Dickson KM, Bhakar AL, Barker PA. 2004. TRAF6-dependent NF-κB transcriptional activity during mouse development. Dev. Dyn. 231:122–27 153. Akiyama T, Maeda S, Yamane S, Ogino K, Kasai M, et al. 2005. Dependence of selftolerance on TRAF6-directed development of thymic stroma. Science 308:248–51 154. Burkly L, Hession C, Ogata L, Reilly C, Marconi LA, et al. 1995. Expression of relB is required for the development of thymic medulla and dendritic cells. Nature 373:531–36 155. Weih F, Carrasco D, Durham SK, Barton DS, Rizzo CA, et al. 1995. Multiorgan inﬂammation and hematopoietic abnormalities in mice with a targeted disruption of RelB, a member of the NF-κB/Rel family. Cell 80:331–40 156. Zuklys S, Balciunaite G, Agarwal A, Fasler-Kan E, Palmer E, Hollander GA. 2000. Normal thymic architecture and negative selection are associated with Aire expression, the gene defective in the autoimmune-polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED). J. Immunol. 165:1976–83 157. Candi E, Ruﬁni A, Terrinoni A, Giamboi-Miraglia A, Lena AM, et al. 2007. Np63 regulates thymic development through enhanced expression of FgfR2 and Jag2. Proc. Natl. Acad. Sci. USA 104:11999–2004 158. Dooley J, Erickson M, Gillard GO, Farr AG. 2006. Cervical thymus in the mouse. J. Immunol. 176:6484–90 159. Haynes JI. 2003. The marsupial and monotreme thymus, revisited. J. Zool. London 253:167–73 160. Yamashita A, Miyasaka M, Trnka Z. 1985. Early post-thymic T cells: studies on lymphocytes in the lymph from the thymus of sheep. In Immunology of the Sheep, ed. B Morris, M Miyasaka, pp. 165–86. Basel: Editiones Roche 161. Tovi F, Mares AJ. 1978. The aberrant cervical thymus. Embryology, pathology, and clinical implications. Am. J. Surg. 136:631–37 162. Millman B, Pransky S, Castillo J III, Zipfel TE, Wood WE. 1999. Cervical thymic anomalies. Int. J. Pediatr. Otorhinolaryngol. 47:29–39 www.annualreviews.org • Thymus Organogenesis

387

ARI

16 February 2008

12:33

163. Shah SS, Lai SY, Ruchelli E, Kazahaya K, Mahboubi S. 2001. Retropharyngeal aberrant thymus. Pediatrics 108:E94 164. Chu WC, Metreweli C. 2002. Ectopic thymic tissue in the paediatric age group. Acta Radiol. 43:144–46 165. Maret A, Bourdeau I, Ding C, Kadkol SS, Westra WH, Levine MA. 2004. Expression of GCMB by intrathymic parathyroid hormone-secreting adenomas indicates their parathyroid cell origin. J. Clin. Endocrinol. Metab. 89:8–12 166. Hashemolhosseini S, Hadjihannas M, Stolt CC, Haas CS, Amann K, Wegner M. 2002. Restricted expression of mouse GCMa/Gcm1 in kidney and thymus. Mech. Dev. 118:175– 78 167. Hayday AC, Pennington DJ. 2007. Key factors in the organized chaos of early T cell development. Nat. Immunol. 8:137–44 168. Law LW, Dunn TB, Trainin N, Levy RH, eds. 1964. Studies of Thymic Function, Vol. 2, pp. 105–20. Philadelphia: Wistar Inst. Press 169. Many MC, Drexhage HA, Denef JF. 1993. High frequency of thymic ectopy in thyroids from autoimmune prone nonobese diabetic female mice. Lab. Invest. 69:364–67 170. Popesko P, Rajtova V, Horak J. 1992. A Colour Atlas of the Anatomy of Small Laboratory Animals, Vol. 2. Bratislava: Wolfe 171. Kanamori Y, Ishimaru K, Nanno M, Maki K, Ikuta K, et al. 1996. Identiﬁcation of novel lymphoid tissues in murine intestinal mucosa where clusters of c-kit+ IL-7R+ Thy1+ lympho-hemopoietic progenitors develop. J. Exp. Med. 184:1449–59 172. Rocha B. 2007. The extrathymic T-cell differentiation in the murine gut. Immunol. Rev. 215:166–77 173. Asano M, Toda M, Sakaguchi N, Sakaguchi S. 1996. Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J. Exp. Med. 184:387–96 174. Miller JF. 2006. Investigating a second thymus in mice. Science 312:1597–98 175. Rodewald HR. 2006. Investigating a second thymus in mice (response). Science 312:1598 176. von Boehmer H. 2006. Immunology. Thoracic thymus, exclusive no longer. Science 312:206–7

Annu. Rev. Immunol. 2008.26:355-388. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

ANRV338-IY26-12

388

Rodewald

AR338-FM

ARI

12 January 2008

18:11

Annual Review of Immunology

Annu. Rev. Immunol. 2008.26:355-388. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

Contents

Volume 26, 2008

Frontispiece K. Frank Austen p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p x Doing What I Like K. Frank Austen p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p1 Protein Tyrosine Phosphatases in Autoimmunity Torkel Vang, Ana V. Miletic, Yutaka Arimura, Lutz Tautz, Robert C. Rickert, and Tomas Mustelin p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p 29 Interleukin-21: Basic Biology and Implications for Cancer and Autoimmunity Rosanne Spolski and Warren J. Leonard p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p 57 Forward Genetic Dissection of Immunity to Infection in the Mouse S.M. Vidal, D. Malo, J.-F. Marquis, and P. Gros p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p 81 Regulation and Functions of Blimp-1 in T and B Lymphocytes Gislâine Martins and Kathryn Calame p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p133 Evolutionarily Conserved Amino Acids That Control TCR-MHC Interaction Philippa Marrack, James P. Scott-Browne, Shaodong Dai, Laurent Gapin, and John W. Kappler p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p171 T Cell Trafﬁcking in Allergic Asthma: The Ins and Outs Benjamin D. Medoff, Seddon Y. Thomas, and Andrew D. Luster p p p p p p p p p p p p p p p p p p p p p205 The Actin Cytoskeleton in T Cell Activation Janis K. Burkhardt, Esteban Carrizosa, and Meredith H. Shaffer p p p p p p p p p p p p p p p p p p p p233 Mechanism and Regulation of Class Switch Recombination Janet Stavnezer, Jeroen E.J. Guikema, and Carol E. Schrader p p p p p p p p p p p p p p p p p p p p p p p261 Migration of Dendritic Cell Subsets and their Precursors Gwendalyn J. Randolph, Jordi Ochando, and Santiago Partida-Sánchez p p p p p p p p p p p p p293

v

AR338-FM

ARI

12 January 2008

18:11

The APOBEC3 Cytidine Deaminases: An Innate Defensive Network Opposing Exogenous Retroviruses and Endogenous Retroelements Ya-Lin Chiu and Warner C. Greene p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p317 Thymus Organogenesis Hans-Reimer Rodewald p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p355 Death by a Thousand Cuts: Granzyme Pathways of Programmed Cell Death Dipanjan Chowdhury and Judy Lieberman p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p389 Annu. Rev. Immunol. 2008.26:355-388. Downloaded from arjournals.annualreviews.org by Shanghai Information Center for Life Sciences on 04/28/08. For personal use only.

Monocyte-Mediated Defense Against Microbial Pathogens Natalya V. Serbina, Ting Jia, Tobias M. Hohl, and Eric G. Pamer p p p p p p p p p p p p p p p p p p p421 The Biology of Interleukin-2 Thomas R. Malek p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p453 The Biochemistry of Somatic Hypermutation Jonathan U. Peled, Fei Li Kuang, Maria D. Iglesias-Ussel, Sergio Roa, Susan L. Kalis, Myron F. Goodman, and Matthew D. Scharff p p p p p p p p p p p p p p p p p p p p p481 Anti-Inﬂammatory Actions of Intravenous Immunoglobulin Falk Nimmerjahn and Jeffrey V. Ravetch p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p513 The IRF Family Transcription Factors in Immunity and Oncogenesis Tomohiko Tamura, Hideyuki Yanai, David Savitsky, and Tadatsugu Taniguchi p p p p p535 Choreography of Cell Motility and Interaction Dynamics Imaged by Two-Photon Microscopy in Lymphoid Organs Michael D. Cahalan and Ian Parker p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p585 Development of Secondary Lymphoid Organs Troy D. Randall, Damian M. Carragher, and Javier Rangel-Moreno p p p p p p p p p p p p p p p p627 Immunity to Citrullinated Proteins in Rheumatoid Arthritis Lars Klareskog, Johan Rönnelid, Karin Lundberg, Leonid Padyukov, and Lars Alfredsson p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p651 PD-1 and Its Ligands in Tolerance and Immunity Mary E. Keir, Manish J. Butte, Gordon J. Freeman, and Arlene H. Sharpe p p p p p p p p677 The Master Switch: The Role of Mast Cells in Autoimmunity and Tolerance Blayne A. Sayed, Alison Christy, Mary R. Quirion, and Melissa A. Brown p p p p p p p p p p7